Page last updated: 2024-10-18

dalteparin and Hemorrhage

dalteparin has been researched along with Hemorrhage in 754 studies

Dalteparin: A low-molecular-weight fragment of heparin, prepared by nitrous acid depolymerization of porcine mucosal heparin. The mean molecular weight is 4000-6000 daltons. It is used therapeutically as an antithrombotic agent. (From Merck Index, 11th ed)

Hemorrhage: Bleeding or escape of blood from a vessel.

Research Excerpts

ExcerptRelevanceReference
" We evaluated the rates of VTE recurrence and major bleeding and the relative efficacy and safety of 6-month treatment with oral apixaban or subcutaneous dalteparin in patients with different cancer sites randomized in the Caravaggio study."9.51Apixaban and Dalteparin for the Treatment of Venous Thromboembolism in Patients with Different Sites of Cancer. ( Agnelli, G; Bauersachs, R; Becattini, C; Brenner, B; Connors, JM; Franco, L; Gussoni, G; Hamulyak, EN; Lambert, C; Mahé, I; Muñoz, A; Suero, MR; Torbicki, A, 2022)
" We conducted a prospective, multicenter, open-label trial (NCT00952380) on dose-finding, safety, and efficacy (measured by 90-day risks of clinically relevant bleeding [CRB] and symptomatic recurrent VTE [srVTE]) of twice-daily subcutaneous dalteparin for acute VTE treatment in patients ≤18 years old."9.51A phase 2 pharmacodynamic dose-finding, safety, and efficacy study of dalteparin for pediatric venous thromboembolism treatment in children with and without cancer. ( Goldenberg, NA; Hartman, LR; Jani, D; Nurmeev, I; Sherman, N; Svirin, P; Wolter, KD; Yan, JL, 2022)
"Of 138 randomized patients, 100 patients with active malignancy presenting with acute deep venous thrombosis and still treated with chemotherapy were assigned to either oral apixaban therapy or subcutaneous low-molecular weight heparin (enoxaparin) through randomized clinical study in 1:1 ratio."9.41Efficacy and safety of apixaban in patients with active malignancy and acute deep venous thrombosis. ( Algaby, AZ; Hassan, A; Mokadem, ME, 2021)
" Major bleeding occurred in 22 of 576 patients on apixaban (3."9.41Bleeding with Apixaban and Dalteparin in Patients with Cancer-Associated Venous Thromboembolism: Results from the Caravaggio Study. ( Ageno, W; Agnelli, G; Bauersachs, R; Becattini, C; Cohen, A; Gussoni, G; Huisman, M; Vedovati, MC, 2021)
"We evaluated the effects of concomitant administration of anticancer agents on recurrent VTE, major bleeding and death in patients with cancer-associated VTE randomised to receive apixaban or dalteparin in the Caravaggio study."9.41Effects of concomitant administration of anticancer agents and apixaban or dalteparin on recurrence and bleeding in patients with cancer-associated venous thromboembolism. ( Agnelli, G; Bauersachs, R; Becattini, C; Huisman, MV; Mandalà, M; Munoz, A; Verso, M; Vescovo, G, 2021)
"Emerging evidence suggests aspirin may be an effective venous thromboembolism (VTE) prophylaxis for orthopaedic trauma patients, with fewer bleeding complications."9.34Aspirin versus low-molecular-weight heparin for venous thromboembolism prophylaxis in orthopaedic trauma patients: A patient-centered randomized controlled trial. ( Castillo, RC; Haac, BE; Manson, TT; O'Hara, NN; O'Toole, RV; Slobogean, GP; Stein, DM, 2020)
"Oral apixaban was noninferior to subcutaneous dalteparin for the treatment of cancer-associated venous thromboembolism without an increased risk of major bleeding."9.34Apixaban for the Treatment of Venous Thromboembolism Associated with Cancer. ( Agnelli, G; Bauersachs, R; Becattini, C; Brenner, B; Campanini, M; Cohen, A; Connors, JM; Fontanella, A; Gussoni, G; Huisman, MV; Lambert, C; Meyer, G; Muñoz, A; Sueiro, MR; Torbicki, A; Verso, M; Vescovo, G, 2020)
"Extended-duration thromboprophylaxis with betrixaban reduces the risk of venous thromboembolism (VTE) without increasing major bleeding rates in acutely ill medical patients as compared to standard duration enoxaparin."9.30Net-clinical benefit of extended prophylaxis of venous thromboembolism with betrixaban in medically ill patients aged 80 or more. ( Ageno, W; Cohen, AT; Gibson, CM; Goldhaber, SZ; Hernandez, A; Hull, RD; Lopes, RD; Yee, MK, 2019)
"To provide direct comparison between apixaban and rivaroxaban in patients with acute cancer-associated venous thromboembolism (Ca-VTE), consecutive patients treated with apixaban, rivaroxaban, or enoxaparin at Mayo Thrombophilia Clinic (March 1, 2013 to January 31, 2018)) were followed prospectively."9.30Comparison of apixaban to rivaroxaban and enoxaparin in acute cancer-associated venous thromboembolism. ( Bott-Kitslaar, DM; Casanegra, AI; Froehling, DA; Hodge, DO; Houghton, DE; Mcbane, RD; Peterson, LG; Vlazny, DT; Wysokinski, WE, 2019)
"In patients with active cancer and acute venous thromboembolism (VTE), the low-molecular-weight-heparin (LMWH) dalteparin is more effective than vitamin K antagonist (VKA) in reducing the risk of recurrent venous thromboembolism (rVTE) without increasing the risk of bleeding."9.30Low-molecular-weight-heparin versus a coumarin for the prevention of recurrent venous thromboembolism in high- and low-risk patients with active cancer: a post hoc analysis of the CLOT Study. ( Abreu, P; Carrier, M; Feugère, G; Heissler, J; Lee, AYY; Woodruff, S, 2019)
"Oral edoxaban was noninferior to subcutaneous dalteparin with respect to the composite outcome of recurrent venous thromboembolism or major bleeding."9.27Edoxaban for the Treatment of Cancer-Associated Venous Thromboembolism. ( Büller, HR; Carrier, M; Di Nisio, M; Garcia, D; Grosso, MA; Kakkar, AK; Kovacs, MJ; Mercuri, MF; Meyer, G; Raskob, GE; Segers, A; Shi, M; van Es, N; Verhamme, P; Wang, TF; Weitz, JI; Yeo, E; Zhang, G; Zwicker, JI, 2018)
"The 80-mg betrixaban dose achieves higher plasma concentrations than the 40-mg dose and, in contrast to the 40-mg dose, is associated with improved efficacy across all cohorts relative to standard-dose enoxaparin without an excess risk of major bleeding in the management of medically ill subjects."9.24The safety and efficacy of full- versus reduced-dose betrixaban in the Acute Medically Ill VTE (Venous Thromboembolism) Prevention With Extended-Duration Betrixaban (APEX) trial. ( Arbetter, DF; Bandman, O; Cohen, AT; Daaboul, Y; Gibson, CM; Gold, A; Goldhaber, SZ; Halaby, R; Harrington, RA; Hernandez, AF; Hull, R; Korjian, S; Leeds, JM; Lu, SP; Yee, MK, 2017)
"The study aim was to identify predictive factors for major bleeding in patients receiving the novel oral factor Xa inhibitor rivaroxaban or enoxaparin-vitamin K antagonists (VKAs) for the treatment of acute symptomatic venous thromboembolism."9.22Risk of major bleeding in patients with venous thromboembolism treated with rivaroxaban or with heparin and vitamin K antagonists. ( Ageno, W; Büller, HR; Di Nisio, M; Pap, AF; Rutjes, AW, 2016)
"Apixaban, a direct acting oral anticoagulant (DOAC), was found to be non-inferior to and safer as enoxaparin followed by warfarin for treatment of venous thromboembolism (VTE) in the AMPLIFY trial."9.22Clinical presentation and course of bleeding events in patients with venous thromboembolism, treated with apixaban or enoxaparin and warfarin. Results from the AMPLIFY trial. ( Agnelli, G; Bleker, SM; Büller, HR; Cohen, AT; Curto, M; Gallus, AS; Middeldorp, S; Raskob, GE; Sisson, M; Weitz, JI, 2016)
"Edoxaban, an oral factor Xa inhibitor, is non-inferior for prevention of stroke and systemic embolism in patients with atrial fibrillation and is associated with less bleeding than well controlled warfarin therapy."9.22Edoxaban versus enoxaparin-warfarin in patients undergoing cardioversion of atrial fibrillation (ENSURE-AF): a randomised, open-label, phase 3b trial. ( Al-Saady, N; Batushkin, V; de Groot, JR; Ezekowitz, MD; Fernandez, V; Goette, A; Grosso, MA; Jin, J; Kushnir, M; Lip, GY; Melino, M; Mercuri, MF; Merino, JL; Merkely, B; Pelekh, N; Spinar, J; Zamoryakhin, D; Zenin, S, 2016)
"In this French cohort of NSTEMI patients, predominantly managed invasively, there was no evidence that fondaparinux was superior to enoxaparin as regards bleeding events or 1-year mortality (FAST-MI 2010; NCT01237418)."9.20Impact of fondaparinux versus enoxaparin on in-hospital bleeding and 1-year death in non-ST-segment elevation myocardial infarction. FAST-MI (French Registry of Acute ST-elevation and non-ST-elevation Myocardial Infarction) 2010. ( Bonnefoy-Cudraz, E; Collet, JP; Coste, P; Danchin, N; Ennezat, PV; Puymirat, E; Richard, P; Roul, G; Schiele, F; Simon, T, 2015)
"To evaluate the effect of prestudy heparin on the efficacy and safety of rivaroxaban relative to enoxaparin/VKA, the 3-month incidence of recurrent VTE, and the 14-day incidence of major and nonmajor clinically relevant bleeding were compared in patients who did and did not receive prestudy heparin."9.20Use of prestudy heparin did not influence the efficacy and safety of rivaroxaban in patients treated for symptomatic venous thromboem-bolism in the EINSTEIN DVT and EINSTEIN PE studies. ( Cohen, AT; Lensing, AW; Müller, K; Pap, ÁF; Prandoni, P; Prins, MH; Tewes, MC, 2015)
"The AMPLIFY trial compared apixaban with enoxaparin followed by warfarin for the treatment of acute venous thromboembolism (VTE)."9.20Oral apixaban for the treatment of venous thromboembolism in cancer patients: results from the AMPLIFY trial. ( Agnelli, G; Buller, HR; Cohen, A; Gallus, AS; Lee, TC; Pak, R; Raskob, GE; Weitz, JI; Yamabe, T, 2015)
"Major bleeding was less frequent during dalteparin therapy beyond 6 months."9.20Treatment of venous thromboembolism in cancer patients with dalteparin for up to 12 months: the DALTECAN Study. ( Bergqvist, D; Francis, CW; Goldhaber, SZ; Huisman, MV; Kakkar, AK; Kessler, CM; Kovacs, MJ; Monreal, M; Ortel, TL; Pabinger, I; Spyropoulos, AC; Turpie, AG, 2015)
"Among patients with active cancer and acute symptomatic VTE, the use of full-dose tinzaparin (175 IU/kg) daily compared with warfarin for 6 months did not significantly reduce the composite measure of recurrent VTE and was not associated with reductions in overall mortality or major bleeding, but was associated with a lower rate of clinically relevant nonmajor bleeding."9.20Tinzaparin vs Warfarin for Treatment of Acute Venous Thromboembolism in Patients With Active Cancer: A Randomized Clinical Trial. ( Bauersachs, R; Janas, MS; Jarner, MF; Kamphuisen, PW; Khorana, AA; Lee, AYY; Meyer, G, 2015)
"Antepartum prophylactic dalteparin does not reduce the occurrence of venous thromboembolism, pregnancy loss, or placenta-mediated pregnancy complications in pregnant women with thrombophilia at high risk of these complications and is associated with an increased risk of minor bleeding."9.19Antepartum dalteparin versus no antepartum dalteparin for the prevention of pregnancy complications in pregnant women with thrombophilia (TIPPS): a multinational open-label randomised trial. ( Chan, WS; Clement, AM; Coat, S; Demers, C; Dwyer, J; Greer, IA; Hague, WM; Hinshaw, K; Kahn, SR; Karovitch, A; Keely, E; Khandelwal, M; Khurana, R; Kingdom, J; Kovacs, MJ; Le Gal, G; McDonald, S; McLeod, A; Newstead-Angel, J; Rey, E; Robinson, S; Rodger, MA; Rosene-Montella, K; Said, J; Sermer, M; Silver, RM; Smith, G; Solymoss, S; Walker, M; Wells, PS, 2014)
"A fixed-dose regimen of apixaban alone was noninferior to conventional therapy for the treatment of acute venous thromboembolism and was associated with significantly less bleeding (Funded by Pfizer and Bristol-Myers Squibb; ClinicalTrials."9.17Oral apixaban for the treatment of acute venous thromboembolism. ( Agnelli, G; Buller, HR; Cohen, A; Curto, M; Gallus, AS; Johnson, M; Masiukiewicz, U; Pak, R; Raskob, GE; Thompson, J; Weitz, JI, 2013)
"Whether the oral factor Xa inhibitor edoxaban can be an alternative to warfarin in patients with venous thromboembolism is unclear."9.17Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. ( Büller, HR; Décousus, H; Grosso, MA; Mercuri, M; Middeldorp, S; Prins, MH; Raskob, GE; Schellong, SM; Schwocho, L; Segers, A; Shi, M; Verhamme, P; Wells, P, 2013)
"To compare extended prophylaxis with aspirin and dalteparin for prevention of symptomatic venous thromboembolism (VTE) after THA."9.17Aspirin versus low-molecular-weight heparin for extended venous thromboembolism prophylaxis after total hip arthroplasty: a randomized trial. ( Anderson, DR; Andreou, P; Belzile, E; Bohm, ER; Carrier, M; Crowther, M; Davis, N; Dunbar, MJ; Fisher, W; Gofton, W; Gross, P; Kahn, SR; Kim, P; Kovacs, M; MacDonald, S; Pelet, S; Pleasance, S; Ramsay, T; Rodger, MA; Vendittoli, PA; Wells, P; Zukor, D, 2013)
"In a randomized, open-label, event-driven, noninferiority trial involving 4832 patients who had acute symptomatic pulmonary embolism with or without deep-vein thrombosis, we compared rivaroxaban (15 mg twice daily for 3 weeks, followed by 20 mg once daily) with standard therapy with enoxaparin followed by an adjusted-dose vitamin K antagonist for 3, 6, or 12 months."9.16Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. ( Agnelli, G; Berkowitz, SD; Bounameaux, H; Büller, HR; Chlumsky, J; Cohen, A; Davidson, BL; Decousus, H; Gallus, AS; Jacobson, BF; Lensin, AW; Minar, E; Misselwitz, F; Prins, MH; Raskob, GE; Schellong, S; Segers, A; Verhamme, P; Wells, P, 2012)
"Dalteparin is superior to the NSAID ibuprofen in preventing extension of superficial thrombophlebitis during the 14-day treatment period with similar relief of pain and no increase in bleeding."9.16A randomized trial of dalteparin compared with ibuprofen for the treatment of superficial thrombophlebitis. ( Aston, CE; Rathbun, SW; Whitsett, TL, 2012)
" In this randomized, open-label, multicenter trial, we compared aspirin (ASA) or fixed low-dose warfarin (WAR) versus low molecular weight heparin (LMWH) for preventing thromboembolism in patients with myeloma treated with thalidomide-based regimens."9.15Aspirin, warfarin, or enoxaparin thromboprophylaxis in patients with multiple myeloma treated with thalidomide: a phase III, open-label, randomized trial. ( Baldini, L; Benevolo, G; Boccadoro, M; Bringhen, S; Callea, V; Caravita, T; Carella, AM; Cavo, M; Cellini, C; Crippa, C; Elice, F; Evangelista, A; Galli, M; Gentilini, F; Magarotto, V; Marasca, R; Montefusco, V; Morabito, F; Nozzoli, C; Offidani, M; Palumbo, A; Patriarca, F; Pescosta, N; Polloni, C; Pulini, S; Ria, R; Romano, A; Rossi, D; Tacchetti, P; Tosi, P; Zamagni, E; Zambello, R, 2011)
"The OASIS-5 (Organization to Assess Strategies in Ischemic Syndromes-5) trial demonstrated that fondaparinux was noninferior to enoxaparin while reducing the risk of bleeding by 50%."9.14Fondaparinux compared to enoxaparin in patients with acute coronary syndromes without ST-segment elevation: outcomes and treatment effect across different levels of risk. ( Afzal, R; Bassand, JP; Budaj, A; Chrolavicius, S; Flather, M; Fox, KA; Franzosi, MG; Granger, CB; Joyner, CD; Mehta, SR; Peters, RJ; Yusuf, S, 2009)
"Ambulatory treatment with enoxaparin plus warfarin seems to be effective in symptomatic healing and in clinical improvement by reducing thrombus formation and organization at all levels of lower extremity venous system with DVT, without a significant major bleeding risk."9.14Long-term efficacy and safety of once-daily enoxaparin plus warfarin for the outpatient ambulatory treatment of lower-limb deep vein thrombosis in the TROMBOTEK trial. ( Akcalı, Y; Filizcan, U; Hasan, E; Karabay, O; Koksoy, C; Kurtoglu, M, 2010)
"Rivaroxaban offers a simple, single-drug approach to the short-term and continued treatment of venous thrombosis that may improve the benefit-to-risk profile of anticoagulation."9.14Oral rivaroxaban for symptomatic venous thromboembolism. ( Agnelli, G; Bauersachs, R; Berkowitz, SD; Bounameaux, H; Brenner, B; Buller, HR; Cohen, A; Davidson, BL; Decousus, H; Gallus, AS; Lensing, AW; Misselwitz, F; Piovella, F; Prins, MH; Raskob, GE; Schellong, S; Segers, A; Verhamme, P; Wells, P, 2010)
"Compared with a heparin-based strategy, fondaparinux reduced mortality, ischemic events, and major bleeding across the full spectrum of acute coronary syndromes and was associated with a more favorable net clinical outcome in patients undergoing either an invasive or a conservative management strategy."9.13Antithrombotic therapy with fondaparinux in relation to interventional management strategy in patients with ST- and non-ST-segment elevation acute coronary syndromes: an individual patient-level combined analysis of the Fifth and Sixth Organization to Ass ( Afzal, R; Avezum, A; Bassand, JP; Boden, WE; Budaj, A; Chrolavicius, S; Eikelboom, JW; Faxon, DP; Flather, M; Fox, KA; Granger, CB; Jolly, S; Mehta, SR; Piegas, LS; Rupprecht, HJ; Steg, PG; Widimsky, P; Yusuf, S, 2008)
"Switching from enoxaparin to bivalirudin for patients with ACS undergoing PCI appears to be clinically safe without increased risk of major bleeding complications, regardless of the time of enoxaparin administration, and is safe enough to warrant testing it in larger numbers."9.12Switching from Enoxaparin to Bivalirudin in Patients with Acute Coronary Syndromes without ST-segment Elevation who Undergo Percutaneous Coronary Intervention. Results from SWITCH--a multicenter clinical trial. ( Kent, KM; Okubagzi, P; Satler, LF; Suddath, WO; Torguson, RL; Waksman, R; Wolfram, RM; Xue, Z, 2006)
"The current recommended doses of fondaparinux and heparins for the treatment of venous thromboembolism appear to provide similar protection against recurrence and major bleeding to one another and to obese and non-obese patients."9.12Effect of obesity on outcomes after fondaparinux, enoxaparin, or heparin treatment for acute venous thromboembolism in the Matisse trials. ( Büller, HR; Davidson, BL; Decousus, H; Gallus, A; Gent, M; Lensing, AW; Piovella, F; Prins, MH; Raskob, GE; Segers, AE, 2007)
"A recent randomized, controlled trial, the Fifth Organization to Assess Strategies in Acute Ischemic Syndromes (OASIS 5) trial, reported that major bleeding was 2-fold less frequent with fondaparinux than with enoxaparin in acute coronary syndromes (ACS)."9.12Influence of renal function on the efficacy and safety of fondaparinux relative to enoxaparin in non ST-segment elevation acute coronary syndromes. ( Afzal, R; Bassand, JP; Chrolavicius, S; Fox, KA; Mehta, SR; Moccetti, T; Piegas, LS; Theroux, P; Valentin, V; Wallentin, L; Yusuf, S, 2007)
"Oral dabigatran etexilate was as effective as enoxaparin in reducing the risk of venous thromboembolism after total hip replacement surgery, with a similar safety profile."9.12Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial. ( Büller, HR; Dahl, OE; Eriksson, BI; Frostick, SP; Hantel, S; Hettiarachchi, R; Kurth, AA; Prins, MH; Rosencher, N; Schnee, J; van Dijk, CN, 2007)
"The aim of this prospective cohort study was to determine the incidence of dalteparin bioaccumulation (measured using anti-Xa levels), and bleeding during thromboprophylaxis in elderly patients with renal failure who were admitted to hospital with an acute medical illness."9.12Safety of dalteparin for the prophylaxis of venous thromboembolism in elderly medical patients with renal insufficiency: a pilot study. ( Bondi, M; Casolari, B; Cenci, AM; Crowther, MA; Mannucci, C; Prisco, D; Tincani, E; Turrini, F, 2006)
"Once-daily subcutaneous fondaparinux was at least as effective (not inferior) and safe as twice-daily, body weight-adjusted enoxaparin in the initial treatment of patients with symptomatic deep venous thrombosis."9.11Fondaparinux or enoxaparin for the initial treatment of symptomatic deep venous thrombosis: a randomized trial. ( Büller, HR; Cariou, R; Davidson, BL; Decousus, H; Gallus, A; Gent, M; Leeuwenkamp, O; Lensing, AW; Piovella, F; Prins, MH; Raskob, G; Segers, AE, 2004)
"In this dose-finding study, we sought to compare fondaparinux with enoxaparin in patients with acute coronary syndromes (ACS)."9.11A dose-finding study of fondaparinux in patients with non-ST-segment elevation acute coronary syndromes: the Pentasaccharide in Unstable Angina (PENTUA) Study. ( Bobbink, IW; Boland, J; Gardien, M; Klootwijk, P; Lensing, AW; Ruzyllo, W; Simoons, ML; Umans, VA; Vahanian, A; Van De Werf, F; Zeymer, U, 2004)
"Dalteparin 5000 IU once daily halved the rate of venous thromboembolism with a low risk of bleeding."9.11Randomized, placebo-controlled trial of dalteparin for the prevention of venous thromboembolism in acutely ill medical patients. ( Cohen, AT; Goldhaber, SZ; Leizorovicz, A; Olsson, CG; Turpie, AG; Vaitkus, PT, 2004)
"Similar compliance, health status, deep venous thrombosis, and bleeding rates were found between dalteparin and enoxaparin."9.10Comparison of dalteparin and enoxaparin for deep venous thrombosis prophylaxis in patients with spinal cord injury. ( Chan, KT; Chiou-Tan, FY; Donovan, WH; Garza, H; Graves, DE; Holmes, SA; Parsons, KC; Rintala, DH; Robertson, CS, 2003)
"The FRISC II trial demonstrated that, for patients with unstable coronary artery disease, an early invasive strategy following acute treatment with dalteparin and aspirin, was superior to a more conservative approach."9.10Benefits of extended treatment with dalteparin in patients with unstable coronary artery disease eligible for revascularization. ( Husted, SE; Kontny, F; Lagerqvist, B; Ståhle, E; Swahn, E; Wallentin, L, 2002)
"In patients undergoing surgery for hip fracture, fondaparinux was more effective than enoxaparin in preventing venous thromboembolism and equally safe."9.09Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after hip-fracture surgery. ( Bauer, KA; Eriksson, BI; Lassen, MR; Turpie, AG, 2001)
" The fondaparinux group had a significantly lower incidence of venous thromboembolism by day 11 (12."9.09Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after elective major knee surgery. ( Bauer, KA; Eriksson, BI; Lassen, MR; Turpie, AG, 2001)
"This was a prospective cohort study of eligible patients with pulmonary embolism managed as outpatients using dalteparin (200 U/kg s/c daily) for a minimum of five days and warfarin for 3 months."9.09Outpatient treatment of pulmonary embolism with dalteparin. ( Anderson, D; Gray, L; Kovacs, MJ; Morrow, B; Touchie, D; Wells, PS, 2000)
"To compare the effectiveness and safety of fixed-dose enoxaparin and adjusted dose warfarin in preventing venous thromboembolism after knee arthroplasty."9.08Prevention of venous thromboembolism after knee arthroplasty. A randomized, double-blind trial comparing enoxaparin with warfarin. ( Cruickshank, M; Delorme, F; Demers, C; Desjardins, L; Geerts, WH; Kassis, J; L'Espérance, B; Laflamme, GH; Leclerc, JR; Whitman, L, 1996)
"The present trial investigated the efficacy and safety of dalteparin in the prevention of arterial thromboembolism after an acute anterior myocardial infarction (MI)."9.08Randomized trial of low molecular weight heparin (dalteparin) in prevention of left ventricular thrombus formation and arterial embolism after acute anterior myocardial infarction: the Fragmin in Acute Myocardial Infarction (FRAMI) Study. ( Abildgaard, U; Dale, J; Kontny, F; Pedersen, TR, 1997)
" with coumarin) is still the most widely used treatment for deep venous thromboembolism."9.07Comparison of subcutaneous unfractionated heparin with a low molecular weight heparin (Fragmin) in patients with venous thromboembolism and contraindications to coumarin. ( del Rio, L; Lafoz, E; Monreal, M; Olive, A; Vedia, C, 1994)
"In the EINSTEIN-Pulmonary Embolism (PE) trial, subjects randomized to rivaroxaban versus enoxaparin bridging to vitamin K antagonist (VKA) therapy experienced a reduced index hospital length of stay (LOS)."8.95Association between rivaroxaban use and length of hospital stay, treatment costs and early outcomes in patients with pulmonary embolism: a systematic review of real-world studies. ( Ashton, V; Baugh, CW; Coleman, CI; Crivera, C; Fermann, GJ; Kohn, CG; Peacock, WF; Schein, JR; Wells, PS; Wildgoose, P, 2017)
"In conclusion, our results confirmed that direct Xa inhibitors (rivaroxaban and apixaban) were more effective for prevention of VTE after total knee replacement as compared with enoxaparin, without increasing major bleeding risk."8.91Direct factor Xa inhibitors (rivaroxaban and apixaban) versus enoxaparin for the prevention of venous thromboembolism after total knee replacement: A meta-analysis of 6 randomized clinical trials. ( Ma, G; Wang, D; Wu, X; Ying, K; Zhang, R, 2015)
"Oral dabigatran was as effective as subcutaneous enoxaparin in reducing the risk of major VTE and VTE-related mortality after hip or knee arthroplasty and has a similar bleeding profile."8.86Dabigatran versus enoxaparin for prevention of venous thromboembolism after hip or knee arthroplasty: a pooled analysis of three trials. ( Caprini, JA; Clemens, A; Dahl, OE; Eriksson, BI; Francis, CW; Friedman, RJ; Hantel, S; Kurth, AA; Rosencher, N; Schnee, JM, 2010)
"Dabigatran etexilate has been investigated in three phase III trials for the prevention of venous thromboembolism (VTE)."8.85Efficacy and safety of dabigatran etexilate for the prevention of venous thromboembolism following total hip or knee arthroplasty. A meta-analysis. ( Caprini, JA; Eriksson, BI; Plumb, JM; Roskell, NS; Wolowacz, SE, 2009)
"A 70-year-old man on enoxaparin and warfarin sodium therapy due to pulmonary embolism was admitted for evaluation of a sudden, sharp pain in the left inguinal region."8.82Surgical management of enoxaparin- and/or warfarin-induced massive retroperitoneal bleeding: report of a case and review of the literature. ( Anadol, AZ; Gök, A; Topgül, K; Uzun, O, 2005)
"In 8246 patients included in the EINSTEIN-VTE studies for acute VTE, we evaluated the effect of polypharmacy on bleeding and on the relative differences between rivaroxaban and enoxaparin/vitamin K antagonist (VKA)."8.12Effect of polypharmacy on bleeding with rivaroxaban versus vitamin K antagonist for treatment of venous thromboembolism. ( Bavalia, R; Bistervels, IM; Coppens, M; Gebel, M; Lensing, AWA; Middeldorp, S; Prins, MH, 2022)
"Apixaban has a higher rate of major bleeding in patients with luminal GI cancer compared with patients with non-GI cancer and compared with enoxaparin in patients with luminal GI cancer."8.02Bleeding in Patients With Gastrointestinal Cancer Compared With Nongastrointestinal Cancer Treated With Apixaban, Rivaroxaban, or Enoxaparin for Acute Venous Thromboembolism. ( Brunton, N; Casanegra, AI; Froehling, DA; Hodge, DO; Houghton, DE; McBane, RD; Meverden, RA; Peterson, LG; Vlazny, DT; Wysokinski, WE, 2021)
"In this study, although there were no significant differences in effectiveness or safety between the rivaroxaban and dalteparin groups, rivaroxaban use was associated with a higher rate of clinically relevant bleeding than dalteparin."7.96Comparison of rivaroxaban and dalteparin for the long-term treatment of venous thromboembolism in patients with gynecologic cancers. ( Huh, JW; Jo, KW; Lee, JH; Lee, JS; Oh, YM, 2020)
"Purpose Although low-molecular-weight heparin (LMWH) remains the standard of care, factor Xa inhibitors such as rivaroxaban may serve as an alternative treatment for venous thromboembolism (VTE) in patients with active malignancy."7.88Recurrence of malignancy-associated venous thromboembolism among patients treated with rivaroxaban compared to enoxaparin. ( Kettle, JK; Ludwig, SL; Nicklaus, MD, 2018)
" The aim of this study was to determine the efficacy and safety, using the incidence of recurrent symptomatic VTE and major bleeding, respectively, throughout the treatment with rivaroxaban."7.85Oral Rivaroxaban for the Treatment of Symptomatic Venous Thromboembolism in 400 Patients With Active Cancer: A Single-Center Experience. ( Bomfim, GAZ; Cavalcante, RN; Centofanti, G; Fonseca, IYI; Krutman, M; Nishinari, K; Pignataro, BS; Ramacciotti, E; Sanches, SM; Teivelis, MP; Wolosker, N; Yazbek, G, 2017)
"Recent studies have shown fondaparinux's superiority over enoxaparin in patients with non-ST elevation acute coronary syndrome (ACS), especially in relation to bleeding reduction."7.83Fondaparinux versus Enoxaparin - Which is the Best Anticoagulant for Acute Coronary Syndrome? - Brazilian Registry Data. ( Bossa, AS; César, MC; Leal, TC; Okada, MY; Oliveira, MT; Pedroti, FC; Roque, EA; Silva, PG; Simões, SA; Soeiro, AM, 2016)
"We compared the incidence of clinically significant bleeding in patients with CKD receiving therapeutic doses of dalteparin to that of patients with CKD receiving therapeutic doses of UFH."7.83Treatment with Dalteparin is Associated with a Lower Risk of Bleeding Compared to Treatment with Unfractionated Heparin in Patients with Renal Insufficiency. ( Billett, HH; Calvo, M; Kushnir, M; Park, D; Sinnet, M; Solorzano, C; Southern, W, 2016)
"The reduction in inpatient utilization, recurrences, and major bleeding resulting from a 25% shift from standard therapy to rivaroxaban following acute VTE would conserve ∼$860,475 for every 1 million commercial health plan enrollees."7.81The economic implications of switching to rivaroxaban from enoxaparin plus vitamin K antagonist in the treatment of venous thromboembolism. ( Bookhart, B; Mody, SH; Ogden, K; Patel, AA, 2015)
"The oral Factor Xa inhibitor rivaroxaban (Xarelto) has been the pharmacologic agent used for venous thromboembolism (VTE) prophylaxis after primary hip and knee arthroplasty (THA/TKA) at our institution since February 2012."7.81Rivaroxaban Versus Enoxaparin for Venous Thromboembolism Prophylaxis after Hip and Knee Arthroplasty. ( Charters, MA; Dobson, C; Frisch, NB; Les, CM; Silverton, CD; Wessell, NM, 2015)
" The primary analysis compared the temporal course of event rates and rate differences between rivaroxaban and enoxaparin prophylaxis for symptomatic venous thromboembolism plus all-cause mortality (efficacy events) versus nonfatal major bleeding (safety events)."7.80Benefit-risk assessment of rivaroxaban versus enoxaparin for the prevention of venous thromboembolism after total hip or knee arthroplasty. ( Berkowitz, SD; Berlin, JA; DiBattiste, PM; Friedman, RJ; Homering, M; Levitan, B; Turpie, AG; Weinstein, RB; Yuan, Z, 2014)
"Combined anticoagulant and aspirin therapy is associated with increased bleeding risk in patients with atrial fibrillation, but the bleeding risk of combined use of anticoagulant and nonsteroidal anti-inflammatory drugs (NSAIDs) is poorly documented."7.80Bleeding risk of patients with acute venous thromboembolism taking nonsteroidal anti-inflammatory drugs or aspirin. ( Brighton, TA; Davidson, BL; Gebel, M; Lensing, AW; Lyons, RM; Prins, MH; Rehm, J; Verheijen, S, 2014)
"Cost considered: the drugs for the prevention of VTE (apixaban, dabigatran, enoxaparin, fondaparinux, other heparins, rivaroxaban and warfarin) and the complications of VTE in the short term and in 5 years (deep vein thrombosis, pulmonary embolism, bleedings and the post-thrombotic syndrome)."7.78[Budgetary impact for the National Health System of apixaban prophylaxis of venous thromboembolism in patients undergoing total knee or hip replacement]. ( Betegón Nicolás, L; de Salas-Cansado, M; Gómez Arrayas, I; Gómez Cerezo, JF; Rubio-Terrés, C; Suárez Fernández, C, 2012)
"Oral dabigatran etexilate is indicated for the prevention of venous thromboembolism (VTE) in patients undergoing total knee replacement or total hip replacement."7.76Economic evaluation of dabigatran etexilate for the prevention of venous thromboembolism in patients aged over 75 years or with moderate renal impairment undergoing total knee or hip replacement. ( Brenkel, IJ; Clemens, A; Dolan, G; Noack, H; Plumb, JM; Robinson, PA; Roskell, NS; Wolowacz, SE, 2010)
"Rates of VTE and bleeding events did not differ significantly between dabigatran etexilate and enoxaparin."7.75Economic evaluation of dabigatran etexilate for the prevention of venous thromboembolism after total knee and hip replacement surgery. ( Beard, SM; Brenkel, IJ; Dolan, G; Maciver, F; Plumb, JM; Robinson, PA; Roskell, NS; Wolowacz, SE, 2009)
"Dysfibrinogenemia is caused by a variety of structural abnormalities in the fibrinogen molecule, which results in a tendency for bleeding and thrombosis as well as obstetric complications."7.75Treatment of patients with dysfibrinogenemia and a history of abortions during pregnancy. ( Galanakis, D; Miesbach, W; Scharrer, I, 2009)
"Deep vein thrombosis (DVT) remains a major burden and fondaparinux represents a new option for DVT therapy."7.74Minimizing costs for treating deep vein thrombosis: the role for fondaparinux. ( Jackson, WL; Moores, LK; Shorr, AF; Warkentin, TE, 2007)
"In ICU patients with renal insufficiency, the incidence of DVT and major bleeding are considerable but appear related to patient comorbidities rather than to an inadequate or excessive anticoagulant from thromboprophylaxis with dalteparin."7.74Venous thromboembolism and bleeding in critically ill patients with severe renal insufficiency receiving dalteparin thromboprophylaxis: prevalence, incidence and risk factors. ( Albert, M; Cook, D; Crowther, M; Douketis, J; Fowler, R; Freitag, A; Friedrich, J; Geerts, W; Granton, J; Guyatt, G; Hebert, P; Heels-Ansdell, D; Karachi, T; Meade, M; Pagliarello, G; Rabbat, C; Skrobik, Y; Zytaruk, N, 2008)
"The primary safety end point was bleeding events, as defined by the International Society on Thrombosis and Haemostasis, and the primary efficacy end point was major adverse cardiovascular events (MACEs), including cardiac death, myocardial infarction, rerevascularization, or stroke during the 6-month follow-up."7.30Effect of Rivaroxaban vs Enoxaparin on Major Cardiac Adverse Events and Bleeding Risk in the Acute Phase of Acute Coronary Syndrome: The H-REPLACE Randomized Equivalence and Noninferiority Trial. ( Chen, F; Fu, G; Ge, L; Huang, L; Jiang, W; Liu, C; Liu, Q; Ouyang, Z; Pan, G; Pan, H; Shen, Q; Xiao, Y; Zeng, G; Zhang, Y; Zheng, Z; Zhou, C; Zhou, S; Zhu, C, 2023)
"Rivaroxaban is a novel oral anticoagulant with potent anti-Xa activity, which might be an attractive alternative drug to enoxaparin."7.11Rationale and Design of the H-REPLACE Study: Safety and Efficacy of LMWH Versus Rivaroxaban in ChinEse Patients HospitaLized with Acute Coronary SyndromE. ( Fang, Z; Hu, X; Liu, Q; Tang, L; Xiao, Y; Zhou, S, 2022)
"Advanced or metastatic cancer was the only independent predictor of major bleeding (HR=2."7.11Renal function and clinical outcome of patients with cancer-associated venous thromboembolism randomized to receive apixaban or dalteparin. Results from the Caravaggio trial ( Agnelli, G; Bauersachs, R; Becattini, C; Bertoletti, L; Brenner, B; Cohen, A; Connors, JM; Manfellotto, D; Maraziti, G; Sanchez, A, 2022)
"Patients with active cancer and venous thromboembolism (VTE) are at high risk of recurrence."6.90Extended treatment with edoxaban in cancer patients with venous thromboembolism: A post-hoc analysis of the Hokusai-VTE Cancer study. ( Buller, H; Carrier, M; Di Nisio, M; Garcia, D; Raskob, G; Segers, A; van Es, N; Wang, TF; Weitz, J, 2019)
"Major bleeding was similar (N=1) in each arm but clinically relevant bleeding was higher in dalteparin arm (N=7 versus 1 on observation) (HR=7."6.84Dalteparin thromboprophylaxis in cancer patients at high risk for venous thromboembolism: A randomized trial. ( Baran, A; Carrier, M; Francis, CW; Hobbs, S; Iyer, R; Kaproth-Joslin, K; Khorana, AA; Kuderer, NM; Lyman, GH; Ortel, TL; Peterson, D; Rubens, D; Wun, T, 2017)
"Risks of recurrence and bleeding are highest during the first weeks of anticoagulant therapy for venous thromboembolism (VTE)."6.82Early time courses of recurrent thromboembolism and bleeding during apixaban or enoxaparin/warfarin therapy. A sub-analysis of the AMPLIFY trial. ( Agnelli, G; Buller, HR; Cohen, AT; Gallus, AS; Ramacciotti, E; Raskob, GE; Sanders, P; Thompson, JR; Weitz, JI, 2016)
"This double-blind, double-dummy, randomised, phase IIb study (NCT00902928) evaluated different dosing regimens of darexaban compared with enoxaparin (randomised 1:1:1:1:1 to 15 mg twice daily [bid], 30 mg once daily [qd], 30 mg bid or 60 mg qd or enoxaparin 40 mg qd) in patients undergoing elective total hip arthroplasty."6.79Darexaban (YM150) versus enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a randomised phase IIb dose confirmation study (ONYX-3). ( Agnelli, G; Eriksson, BI; Gallus, AS; Kashiwa, M; Lassen, MR; Prins, MH; Renfurm, RW; Turpie, AG, 2014)
" There were no related serious adverse events, no clinically relevant bleeding events, and no symptomatic recurrent VTEs."6.79Multicenter dose-finding and efficacy and safety outcomes in neonates and children treated with dalteparin for acute venous thromboembolism. ( Burr, S; Goldenberg, NA; Hamblin, F; Kulkarni, R; O'Brien, SH; Wallace, A, 2014)
"Apixaban is a potent, selective direct inhibitor of the coagulation factor Xa, recently approved in Europe for the prevention of venous thromboembolism (VTE) in adult patients after total hip replacement (THR) or total knee replacement (TKR) surgery."6.77Therapeutic potential of apixaban in the prevention of venous thromboembolism in patients undergoing total knee replacement surgery. ( Gallerani, M; Imberti, D; Manfredini, R, 2012)
"Melagatran 2 mg was started immediately before surgery; 3 mg was then administered postoperatively, followed by 24 mg of oral ximelagatran b."6.71The direct thrombin inhibitor melagatran followed by oral ximelagatran compared with enoxaparin for the prevention of venous thromboembolism after total hip or knee replacement: the EXPRESS study. ( Agnelli, G; Andersson, M; Cohen, AT; Dahl, OE; Eriksson, BI; Eskilson, C; Freij, A; Kälebo, P; Lassen, MR; Mouret, P; Panfilov, S; Rosencher, N, 2003)
"Warfarin dosing with a target international normalized ratio (INR) range of 1."6.71Low-dose warfarin for prevention of symptomatic thromboembolism after orthopedic surgery. ( Enyart, JJ; Jones, RJ, 2005)
" dalteparin is associated with a low risk of major side effects and is as safe as the combination of abciximab and UFH."6.70Safety and efficacy of abciximab combined with dalteparin in treatment of acute coronary syndromes. ( Armstrong, P; Califf, R; Husted, S; James, S; Kontny, F; Niemminen, M; Pfisterer, M; Simoons, ML; Wallentin, L, 2002)
"Betrixaban is a novel factor Xa inhibitor with unique pharmacokinetic properties, including low renal clearance, long half-life, and low peak-to-trough ratio."6.61Betrixaban for Extended Venous Thromboembolism Prophylaxis in High-Risk Hospitalized Patients: Putting the APEX Results into Practice. ( Brenner, MJ; Miller, KM, 2019)
"Dabigatran was not superior to enoxaparin for prevention of VTE (RR 1."6.47Dabigatran and rivaroxaban for prevention of venous thromboembolism--systematic review and adjusted indirect comparison. ( Kwok, CS; Loke, YK, 2011)
"Dalteparin was not stopped in any women."5.91Prophylactic Dose of Dalteparin in Pregnant Women With History of Venous Thromboembolisms and/or Thrombophilia: Real-World Data. ( Kozak, M; Novak, A; Novak, P; Šabović, M, 2023)
"Apixaban is a direct factor Xa inhibitor that may be intended as an ideal alternative for the management of HIT."5.72An Open-Label, Single-Arm, Pilot Intervention Study to Assess the Efficacy and Safety of Apixaban in Heparin-Induced Thrombocytopenia. ( Ansarinejad, N; Balouchzehi, S; Farasatinasab, M; Moghaddam, OM; Mohammadi, M; Nasiripour, S, 2022)
"In this randomized, open-label, prospective superiority trial involving hospitalized patients with confirmed mild or moderate COVID-19 disease without known thromboembolism, we assigned 230 patients to receive either once-daily oral rivaroxaban (10mg or 15mg) or once-daily subcutaneous enoxaparin (40mg or 60mg) for a median duration of 8 days."5.51Oral Rivaroxaban in the Prophylaxis of COVID-19 Induced Coagulopathy. ( Chandralekha, S; Kaimaparambil, V; Kumar, D; Lalchandani, J, 2022)
" We evaluated the rates of VTE recurrence and major bleeding and the relative efficacy and safety of 6-month treatment with oral apixaban or subcutaneous dalteparin in patients with different cancer sites randomized in the Caravaggio study."5.51Apixaban and Dalteparin for the Treatment of Venous Thromboembolism in Patients with Different Sites of Cancer. ( Agnelli, G; Bauersachs, R; Becattini, C; Brenner, B; Connors, JM; Franco, L; Gussoni, G; Hamulyak, EN; Lambert, C; Mahé, I; Muñoz, A; Suero, MR; Torbicki, A, 2022)
"In a randomized open-label noninferiority trial, patients with active cancer who had proximal DVT, pulmonary embolism (PE), or both were assigned randomly to therapeutic doses of rivaroxaban or dalteparin for 3 months."5.51Rivaroxaban vs Dalteparin in Cancer-Associated Thromboembolism: A Randomized Trial. ( Aquilanti, S; Bertoletti, L; Brebion, N; Brisot, D; Bura-Rivière, A; Burnod, A; Charles-Nelson, A; Chatellier, G; Constans, J; Couturaud, F; Elias, A; Falvo, N; Girard, P; Grange, C; Laporte, S; Mahé, I; Meyer, G; Mismetti, P; Pernod, G; Planquette, B; Ray, V; Roy, PM; Sanchez, O; Sevestre, MA; Timar-David, M, 2022)
" We conducted a prospective, multicenter, open-label trial (NCT00952380) on dose-finding, safety, and efficacy (measured by 90-day risks of clinically relevant bleeding [CRB] and symptomatic recurrent VTE [srVTE]) of twice-daily subcutaneous dalteparin for acute VTE treatment in patients ≤18 years old."5.51A phase 2 pharmacodynamic dose-finding, safety, and efficacy study of dalteparin for pediatric venous thromboembolism treatment in children with and without cancer. ( Goldenberg, NA; Hartman, LR; Jani, D; Nurmeev, I; Sherman, N; Svirin, P; Wolter, KD; Yan, JL, 2022)
"The three most common cancer diagnoses were lung (21%), colorectal (14%), and breast (14%)."5.48Retrospective comparison of low molecular weight heparin vs. warfarin vs. oral Xa inhibitors for the prevention of recurrent venous thromboembolism in oncology patients: The Re-CLOT study. ( Alzghari, SK; Baty, KA; Evans, MF; Garza, JE; Hashimie, YF; Herrington, JD; Seago, SE; Shaver, C, 2018)
"Tranexamic acid (TXA) is an antifibrinolytic that reduces blood loss after THA and TKA."5.43Balancing Thromboprophylaxis and Bleeding in Total Joint Arthroplasty: Impact of Eliminating Enoxaparin and Predonation and Implementing Pneumatic Compression and Tranexamic Acid. ( Campbell, JC; Mirocha, JM; Sharfman, ZT; Spitzer, AI, 2016)
"Apixaban is a new oral anticoagulant with the potential to overcome these limitations."5.43Apixaban versus enoxaparin in the prevention of venous thromboembolism following total knee arthroplasty: a single-centre, single-surgeon, retrospective analysis. ( Dickison, DM; King, DA; Pow, RE; Vale, PR, 2016)
" Of the eight papers comparing chemical prophylaxis medications in patients with hip or lower limb injuries, fondaparinux and enoxaparin were found to be significantly superior to placebo in respect of prevention of DVT, with no increased risk of bleeding."5.41The effectiveness of venous thromboembolism prophylaxis interventions in trauma patients: A systematic review and network meta-analysis. ( Jin, J; MacCormick, AD; Peng, S; Zhang, M, 2023)
"Of 138 randomized patients, 100 patients with active malignancy presenting with acute deep venous thrombosis and still treated with chemotherapy were assigned to either oral apixaban therapy or subcutaneous low-molecular weight heparin (enoxaparin) through randomized clinical study in 1:1 ratio."5.41Efficacy and safety of apixaban in patients with active malignancy and acute deep venous thrombosis. ( Algaby, AZ; Hassan, A; Mokadem, ME, 2021)
"In patients hospitalised with COVID-19 and elevated D-dimer concentration, in-hospital therapeutic anticoagulation with rivaroxaban or enoxaparin followed by rivaroxaban to day 30 did not improve clinical outcomes and increased bleeding compared with prophylactic anticoagulation."5.41Therapeutic versus prophylactic anticoagulation for patients admitted to hospital with COVID-19 and elevated D-dimer concentration (ACTION): an open-label, multicentre, randomised, controlled trial. ( Alexander, JH; Armaganijan, L; Avezum, A; Azevedo, LCP; Barbosa, LM; Berwanger, O; Bronhara, B; Canesin, MF; Cavalcanti, AB; Conceição-Souza, GE; Damiani, LP; de Alcântara Chaud, MS; de Aquino Martins, P; de Aveiro Morata, J; de Barros E Silva, PGM; de Faria, LM; de Matos Soeiro, A; de Oliveira Twardowsky, A; de Oliveira, AL; de Souza Dantas, VC; Diaz, DRA; Dracoulakis, MDA; Feitosa-Filho, GS; Fernandes, ACS; Figueiredo, EL; Furtado, RHM; Gazzana, MB; Gebara, OCE; Guimarães, PO; Hernandes, ME; Lima, RGSD; Liporace, IL; Lopes, RD; Macedo, AVS; Machado, FR; Maia, LN; Melro, LMG; Neuenschwander, FC; Nunes, VS; Queiroz, DAR; Ramacciotti, E; Ritt, LEF; Rocha, AT; Rosa, RG; Santos, SV; Tramujas, L; Veiga, VC; Viana, LS, 2021)
" Major bleeding occurred in 22 of 576 patients on apixaban (3."5.41Bleeding with Apixaban and Dalteparin in Patients with Cancer-Associated Venous Thromboembolism: Results from the Caravaggio Study. ( Ageno, W; Agnelli, G; Bauersachs, R; Becattini, C; Cohen, A; Gussoni, G; Huisman, M; Vedovati, MC, 2021)
"We evaluated the effects of concomitant administration of anticancer agents on recurrent VTE, major bleeding and death in patients with cancer-associated VTE randomised to receive apixaban or dalteparin in the Caravaggio study."5.41Effects of concomitant administration of anticancer agents and apixaban or dalteparin on recurrence and bleeding in patients with cancer-associated venous thromboembolism. ( Agnelli, G; Bauersachs, R; Becattini, C; Huisman, MV; Mandalà, M; Munoz, A; Verso, M; Vescovo, G, 2021)
"A model-based approach was used to integrate data from a phase II study in order to provide a quantitative rationale for selecting the apixaban dosage regimen for a phase III trial."5.36Quantification of apixaban's therapeutic utility in prevention of venous thromboembolism: selection of phase III trial dose. ( Feng, Y; Leil, TA; Mohan, P; Paccaly, A; Pfister, M; Zhang, L, 2010)
"In this international, parallel-group, randomized, double-blind, noninferiority trial, we randomly assigned adult patients undergoing lower-limb nonmajor orthopedic surgery who were considered to be at risk for venous thromboembolism on the basis of the investigator's judgment to receive either rivaroxaban or enoxaparin."5.34Rivaroxaban or Enoxaparin in Nonmajor Orthopedic Surgery. ( Cucherat, M; Deygas, B; Duverger, D; Fisher, W; Girard, P; Laporte, S; Llau, J; Martínez-Martín, J; Mismetti, P; Mouret, P; Presles, E; Rosencher, N; Samama, CM, 2020)
"Emerging evidence suggests aspirin may be an effective venous thromboembolism (VTE) prophylaxis for orthopaedic trauma patients, with fewer bleeding complications."5.34Aspirin versus low-molecular-weight heparin for venous thromboembolism prophylaxis in orthopaedic trauma patients: A patient-centered randomized controlled trial. ( Castillo, RC; Haac, BE; Manson, TT; O'Hara, NN; O'Toole, RV; Slobogean, GP; Stein, DM, 2020)
" However, further studies are needed to validate the dose-response relationship and further support the clinical utility of factor VIIa in this life-threatening situation."5.34Recombinant activated factor VII treatment of retroperitoneal hematoma in a patient with renal failure receiving enoxaparin and clopidogrel. ( Al Askar, A; Al Shimemeri, A; Arabi, Y; Cherfan, A, 2007)
"Oral apixaban was noninferior to subcutaneous dalteparin for the treatment of cancer-associated venous thromboembolism without an increased risk of major bleeding."5.34Apixaban for the Treatment of Venous Thromboembolism Associated with Cancer. ( Agnelli, G; Bauersachs, R; Becattini, C; Brenner, B; Campanini, M; Cohen, A; Connors, JM; Fontanella, A; Gussoni, G; Huisman, MV; Lambert, C; Meyer, G; Muñoz, A; Sueiro, MR; Torbicki, A; Verso, M; Vescovo, G, 2020)
"Extended-duration thromboprophylaxis with betrixaban reduces the risk of venous thromboembolism (VTE) without increasing major bleeding rates in acutely ill medical patients as compared to standard duration enoxaparin."5.30Net-clinical benefit of extended prophylaxis of venous thromboembolism with betrixaban in medically ill patients aged 80 or more. ( Ageno, W; Cohen, AT; Gibson, CM; Goldhaber, SZ; Hernandez, A; Hull, RD; Lopes, RD; Yee, MK, 2019)
"To provide direct comparison between apixaban and rivaroxaban in patients with acute cancer-associated venous thromboembolism (Ca-VTE), consecutive patients treated with apixaban, rivaroxaban, or enoxaparin at Mayo Thrombophilia Clinic (March 1, 2013 to January 31, 2018)) were followed prospectively."5.30Comparison of apixaban to rivaroxaban and enoxaparin in acute cancer-associated venous thromboembolism. ( Bott-Kitslaar, DM; Casanegra, AI; Froehling, DA; Hodge, DO; Houghton, DE; Mcbane, RD; Peterson, LG; Vlazny, DT; Wysokinski, WE, 2019)
"In patients with active cancer and acute venous thromboembolism (VTE), the low-molecular-weight-heparin (LMWH) dalteparin is more effective than vitamin K antagonist (VKA) in reducing the risk of recurrent venous thromboembolism (rVTE) without increasing the risk of bleeding."5.30Low-molecular-weight-heparin versus a coumarin for the prevention of recurrent venous thromboembolism in high- and low-risk patients with active cancer: a post hoc analysis of the CLOT Study. ( Abreu, P; Carrier, M; Feugère, G; Heissler, J; Lee, AYY; Woodruff, S, 2019)
"Oral edoxaban was noninferior to subcutaneous dalteparin with respect to the composite outcome of recurrent venous thromboembolism or major bleeding."5.27Edoxaban for the Treatment of Cancer-Associated Venous Thromboembolism. ( Büller, HR; Carrier, M; Di Nisio, M; Garcia, D; Grosso, MA; Kakkar, AK; Kovacs, MJ; Mercuri, MF; Meyer, G; Raskob, GE; Segers, A; Shi, M; van Es, N; Verhamme, P; Wang, TF; Weitz, JI; Yeo, E; Zhang, G; Zwicker, JI, 2018)
"In the Hokusai VTE Cancer study, edoxaban was non-inferior to dalteparin for the composite outcome of recurrent venous thromboembolism (VTE) and major bleeding in 1,050 patients with cancer-associated VTE."5.27Clinical Impact of Bleeding in Cancer-Associated Venous Thromboembolism: Results from the Hokusai VTE Cancer Study. ( Beyer-Westendorf, J; Büller, HR; Carrier, M; Di Nisio, M; Garcia, D; Grosso, M; Hernandez, CR; Kakkar, AK; Kraaijpoel, N; Mercuri, MF; Middeldorp, S; Mulder, FI; Raskob, GE; Santamaria, A; Schwocho, L; Segers, A; van Es, N; Verhamme, P; Wang, TF; Weitz, JI; Zhang, G; Zwicker, JI, 2018)
"Among hospitalized medically ill patients, extended-duration betrixaban demonstrated an ≈30% reduction in fatal or irreversible ischemic or bleeding events compared with standard-duration enoxaparin."5.24Comparison of Fatal or Irreversible Events With Extended-Duration Betrixaban Versus Standard Dose Enoxaparin in Acutely Ill Medical Patients: An APEX Trial Substudy. ( Arbetter, D; Chi, G; Cohen, AT; Daaboul, Y; Gibson, CM; Gold, A; Goldhaber, SZ; Harrington, RA; Hernandez, AF; Hull, R; Jain, P; Korjian, S; Lopes, RD, 2017)
"The 80-mg betrixaban dose achieves higher plasma concentrations than the 40-mg dose and, in contrast to the 40-mg dose, is associated with improved efficacy across all cohorts relative to standard-dose enoxaparin without an excess risk of major bleeding in the management of medically ill subjects."5.24The safety and efficacy of full- versus reduced-dose betrixaban in the Acute Medically Ill VTE (Venous Thromboembolism) Prevention With Extended-Duration Betrixaban (APEX) trial. ( Arbetter, DF; Bandman, O; Cohen, AT; Daaboul, Y; Gibson, CM; Gold, A; Goldhaber, SZ; Halaby, R; Harrington, RA; Hernandez, AF; Hull, R; Korjian, S; Leeds, JM; Lu, SP; Yee, MK, 2017)
"In patients with NSTE-ACS undergoing an early invasive strategy, treatment with bivalirudin alone significantly reduced major bleeding and improved net clinical outcomes during the upstream medical management phase with comparable rates of MACE."5.22Impact of anticoagulation regimen prior to revascularization in patients with non-ST-segment elevation acute coronary syndromes: The ACUITY trial. ( Bernstein, D; Bertrand, ME; Cequier, AR; Deliargyris, EN; Desmet, W; Droppa, M; Gawaz, M; Geisler, T; Hoekstra, JW; Lincoff, AM; Mehran, R; Rasmussen, LH; Steinhubl, SR; Stone, GW, 2016)
"The study aim was to identify predictive factors for major bleeding in patients receiving the novel oral factor Xa inhibitor rivaroxaban or enoxaparin-vitamin K antagonists (VKAs) for the treatment of acute symptomatic venous thromboembolism."5.22Risk of major bleeding in patients with venous thromboembolism treated with rivaroxaban or with heparin and vitamin K antagonists. ( Ageno, W; Büller, HR; Di Nisio, M; Pap, AF; Rutjes, AW, 2016)
"Apixaban, a direct acting oral anticoagulant (DOAC), was found to be non-inferior to and safer as enoxaparin followed by warfarin for treatment of venous thromboembolism (VTE) in the AMPLIFY trial."5.22Clinical presentation and course of bleeding events in patients with venous thromboembolism, treated with apixaban or enoxaparin and warfarin. Results from the AMPLIFY trial. ( Agnelli, G; Bleker, SM; Büller, HR; Cohen, AT; Curto, M; Gallus, AS; Middeldorp, S; Raskob, GE; Sisson, M; Weitz, JI, 2016)
"Edoxaban, an oral factor Xa inhibitor, is non-inferior for prevention of stroke and systemic embolism in patients with atrial fibrillation and is associated with less bleeding than well controlled warfarin therapy."5.22Edoxaban versus enoxaparin-warfarin in patients undergoing cardioversion of atrial fibrillation (ENSURE-AF): a randomised, open-label, phase 3b trial. ( Al-Saady, N; Batushkin, V; de Groot, JR; Ezekowitz, MD; Fernandez, V; Goette, A; Grosso, MA; Jin, J; Kushnir, M; Lip, GY; Melino, M; Mercuri, MF; Merino, JL; Merkely, B; Pelekh, N; Spinar, J; Zamoryakhin, D; Zenin, S, 2016)
" Direct comparisons show that DOACs significantly decrease recurrent venous thromboembolism (VTE) events compared with dalteparin (odds ratio [OR], 0."5.22Direct Oral Anticoagulants Compared With Dalteparin for Treatment of Cancer-Associated Thrombosis: A Living, Interactive Systematic Review and Network Meta-analysis. ( Badgett, RG; Bryce, AH; Fuentes, HE; He, H; Liu, H; Marshall, AL; McBane, RD; Montori, V; Murad, MH; Naqvi, SAA; Padranos, L; Riaz, IB; Sipra, QR; Tafur, AJ; Vandvik, PO; Wysokinski, WE, 2022)
"In this French cohort of NSTEMI patients, predominantly managed invasively, there was no evidence that fondaparinux was superior to enoxaparin as regards bleeding events or 1-year mortality (FAST-MI 2010; NCT01237418)."5.20Impact of fondaparinux versus enoxaparin on in-hospital bleeding and 1-year death in non-ST-segment elevation myocardial infarction. FAST-MI (French Registry of Acute ST-elevation and non-ST-elevation Myocardial Infarction) 2010. ( Bonnefoy-Cudraz, E; Collet, JP; Coste, P; Danchin, N; Ennezat, PV; Puymirat, E; Richard, P; Roul, G; Schiele, F; Simon, T, 2015)
"To evaluate the effect of prestudy heparin on the efficacy and safety of rivaroxaban relative to enoxaparin/VKA, the 3-month incidence of recurrent VTE, and the 14-day incidence of major and nonmajor clinically relevant bleeding were compared in patients who did and did not receive prestudy heparin."5.20Use of prestudy heparin did not influence the efficacy and safety of rivaroxaban in patients treated for symptomatic venous thromboem-bolism in the EINSTEIN DVT and EINSTEIN PE studies. ( Cohen, AT; Lensing, AW; Müller, K; Pap, ÁF; Prandoni, P; Prins, MH; Tewes, MC, 2015)
"The AMPLIFY trial compared apixaban with enoxaparin followed by warfarin for the treatment of acute venous thromboembolism (VTE)."5.20Oral apixaban for the treatment of venous thromboembolism in cancer patients: results from the AMPLIFY trial. ( Agnelli, G; Buller, HR; Cohen, A; Gallus, AS; Lee, TC; Pak, R; Raskob, GE; Weitz, JI; Yamabe, T, 2015)
"Major bleeding was less frequent during dalteparin therapy beyond 6 months."5.20Treatment of venous thromboembolism in cancer patients with dalteparin for up to 12 months: the DALTECAN Study. ( Bergqvist, D; Francis, CW; Goldhaber, SZ; Huisman, MV; Kakkar, AK; Kessler, CM; Kovacs, MJ; Monreal, M; Ortel, TL; Pabinger, I; Spyropoulos, AC; Turpie, AG, 2015)
"Among patients with active cancer and acute symptomatic VTE, the use of full-dose tinzaparin (175 IU/kg) daily compared with warfarin for 6 months did not significantly reduce the composite measure of recurrent VTE and was not associated with reductions in overall mortality or major bleeding, but was associated with a lower rate of clinically relevant nonmajor bleeding."5.20Tinzaparin vs Warfarin for Treatment of Acute Venous Thromboembolism in Patients With Active Cancer: A Randomized Clinical Trial. ( Bauersachs, R; Janas, MS; Jarner, MF; Kamphuisen, PW; Khorana, AA; Lee, AYY; Meyer, G, 2015)
"Rivaroxaban demonstrated superior efficacy and a similar safety profile to enoxaparin for the prevention of venous thromboembolism in the phase III RECORD programme in patients undergoing elective hip or knee replacement surgery."5.19A non-interventional comparison of rivaroxaban with standard of care for thromboprophylaxis after major orthopaedic surgery in 17,701 patients with propensity score adjustment. ( Haas, S; Holberg, G; Jamal, W; Kreutz, R; Lassen, MR; Mantovani, LG; Pattanayak, CW; Schmidt, A; Turpie, AG; van Eickels, M, 2014)
"Antepartum prophylactic dalteparin does not reduce the occurrence of venous thromboembolism, pregnancy loss, or placenta-mediated pregnancy complications in pregnant women with thrombophilia at high risk of these complications and is associated with an increased risk of minor bleeding."5.19Antepartum dalteparin versus no antepartum dalteparin for the prevention of pregnancy complications in pregnant women with thrombophilia (TIPPS): a multinational open-label randomised trial. ( Chan, WS; Clement, AM; Coat, S; Demers, C; Dwyer, J; Greer, IA; Hague, WM; Hinshaw, K; Kahn, SR; Karovitch, A; Keely, E; Khandelwal, M; Khurana, R; Kingdom, J; Kovacs, MJ; Le Gal, G; McDonald, S; McLeod, A; Newstead-Angel, J; Rey, E; Robinson, S; Rodger, MA; Rosene-Montella, K; Said, J; Sermer, M; Silver, RM; Smith, G; Solymoss, S; Walker, M; Wells, PS, 2014)
"A fixed-dose regimen of apixaban alone was noninferior to conventional therapy for the treatment of acute venous thromboembolism and was associated with significantly less bleeding (Funded by Pfizer and Bristol-Myers Squibb; ClinicalTrials."5.17Oral apixaban for the treatment of acute venous thromboembolism. ( Agnelli, G; Buller, HR; Cohen, A; Curto, M; Gallus, AS; Johnson, M; Masiukiewicz, U; Pak, R; Raskob, GE; Thompson, J; Weitz, JI, 2013)
"Whether the oral factor Xa inhibitor edoxaban can be an alternative to warfarin in patients with venous thromboembolism is unclear."5.17Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. ( Büller, HR; Décousus, H; Grosso, MA; Mercuri, M; Middeldorp, S; Prins, MH; Raskob, GE; Schellong, SM; Schwocho, L; Segers, A; Shi, M; Verhamme, P; Wells, P, 2013)
"To compare extended prophylaxis with aspirin and dalteparin for prevention of symptomatic venous thromboembolism (VTE) after THA."5.17Aspirin versus low-molecular-weight heparin for extended venous thromboembolism prophylaxis after total hip arthroplasty: a randomized trial. ( Anderson, DR; Andreou, P; Belzile, E; Bohm, ER; Carrier, M; Crowther, M; Davis, N; Dunbar, MJ; Fisher, W; Gofton, W; Gross, P; Kahn, SR; Kim, P; Kovacs, M; MacDonald, S; Pelet, S; Pleasance, S; Ramsay, T; Rodger, MA; Vendittoli, PA; Wells, P; Zukor, D, 2013)
"Co-medication use with rivaroxaban or enoxaparin resulted in non-significant increases in bleeding events."5.16Concomitant use of medication with antiplatelet effects in patients receiving either rivaroxaban or enoxaparin after total hip or knee arthroplasty. ( Dahl, OE; Eriksson, BI; Friedman, RJ; Homering, M; Rosencher, N, 2012)
"In a randomized, open-label, event-driven, noninferiority trial involving 4832 patients who had acute symptomatic pulmonary embolism with or without deep-vein thrombosis, we compared rivaroxaban (15 mg twice daily for 3 weeks, followed by 20 mg once daily) with standard therapy with enoxaparin followed by an adjusted-dose vitamin K antagonist for 3, 6, or 12 months."5.16Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. ( Agnelli, G; Berkowitz, SD; Bounameaux, H; Büller, HR; Chlumsky, J; Cohen, A; Davidson, BL; Decousus, H; Gallus, AS; Jacobson, BF; Lensin, AW; Minar, E; Misselwitz, F; Prins, MH; Raskob, GE; Schellong, S; Segers, A; Verhamme, P; Wells, P, 2012)
"Edoxaban inhibited venous thrombosis comparably to warfarin and enoxaparin, and the attendant bleeding risk of edoxaban was lower than that of warfarin and enoxaparin in rats."5.16Comparison of antithrombotic and haemorrhagic effects of edoxaban, an oral direct factor Xa inhibitor, with warfarin and enoxaparin in rats. ( Edo, N; Honda, Y; Kamisato, C; Kita, A; Morishima, Y; Shibano, T; Tsuji, N, 2012)
"Dalteparin is superior to the NSAID ibuprofen in preventing extension of superficial thrombophlebitis during the 14-day treatment period with similar relief of pain and no increase in bleeding."5.16A randomized trial of dalteparin compared with ibuprofen for the treatment of superficial thrombophlebitis. ( Aston, CE; Rathbun, SW; Whitsett, TL, 2012)
"To determine whether low molecular weight heparin (LMWH) plus low-dose aspirin (LDA) is comparable in efficacy and safety to unfractionated heparin (UFH) plus LDA in the management of pregnant women with a history of recurrent spontaneous abortion secondary to antiphospholipid syndrome (APS)."5.15Enoxaparin versus unfractionated heparin in the management of recurrent abortion secondary to antiphospholipid syndrome. ( Abdou, AM; Fouda, IM; Fouda, UM; Ramadan, DI; Sayed, AM; Zaki, MM, 2011)
" In this randomized, open-label, multicenter trial, we compared aspirin (ASA) or fixed low-dose warfarin (WAR) versus low molecular weight heparin (LMWH) for preventing thromboembolism in patients with myeloma treated with thalidomide-based regimens."5.15Aspirin, warfarin, or enoxaparin thromboprophylaxis in patients with multiple myeloma treated with thalidomide: a phase III, open-label, randomized trial. ( Baldini, L; Benevolo, G; Boccadoro, M; Bringhen, S; Callea, V; Caravita, T; Carella, AM; Cavo, M; Cellini, C; Crippa, C; Elice, F; Evangelista, A; Galli, M; Gentilini, F; Magarotto, V; Marasca, R; Montefusco, V; Morabito, F; Nozzoli, C; Offidani, M; Palumbo, A; Patriarca, F; Pescosta, N; Polloni, C; Pulini, S; Ria, R; Romano, A; Rossi, D; Tacchetti, P; Tosi, P; Zamagni, E; Zambello, R, 2011)
"In this double-blind, double-dummy, placebo-controlled trial, we randomly assigned acutely ill patients who had congestive heart failure or respiratory failure or other medical disorders and at least one additional risk factor for venous thromboembolism and who were hospitalized with an expected stay of at least 3 days to receive apixaban, administered orally at a dose of 2."5.15Apixaban versus enoxaparin for thromboprophylaxis in medically ill patients. ( Goldhaber, SZ; Haas, SK; Kakkar, AK; Knabb, RM; Leizorovicz, A; Merli, G; Weitz, JI, 2011)
" We examined the incidence and outcomes after bleeding in 20 078 patients with acute coronary syndromes (ACS) enrolled in the OASIS-5 trial who were treated with fondaparinux or the low-molecular weight heparin, enoxaparin."5.14Improving clinical outcomes by reducing bleeding in patients with non-ST-elevation acute coronary syndromes. ( Afzal, R; Bassand, JP; Budaj, A; Chrolavicius, S; Eikelboom, JW; Fox, KA; Granger, CB; Joyner, CD; Mehta, SR; Peters, RJ; Wallentin, L; Yusuf, S, 2009)
"The OASIS-5 (Organization to Assess Strategies in Ischemic Syndromes-5) trial demonstrated that fondaparinux was noninferior to enoxaparin while reducing the risk of bleeding by 50%."5.14Fondaparinux compared to enoxaparin in patients with acute coronary syndromes without ST-segment elevation: outcomes and treatment effect across different levels of risk. ( Afzal, R; Bassand, JP; Budaj, A; Chrolavicius, S; Flather, M; Fox, KA; Franzosi, MG; Granger, CB; Joyner, CD; Mehta, SR; Peters, RJ; Yusuf, S, 2009)
" Patients age > or =75 years treated with bivalirudin alone had similar ischemic outcomes, but significantly lower rates of bleeding compared with those treated with heparin and glycoprotein IIb/IIIa inhibitors overall and in the PCI subset."5.14Advanced age, antithrombotic strategy, and bleeding in non-ST-segment elevation acute coronary syndromes: results from the ACUITY (Acute Catheterization and Urgent Intervention Triage Strategy) trial. ( Alexander, KP; Bertrand, ME; Feit, F; Gersh, BJ; Hoekstra, J; Lopes, RD; Manoukian, SV; Ohman, EM; Pollack, CV; Stone, GW; White, HD, 2009)
"Enoxaparin was superior to unfractionated heparin (UFH), regardless of fibrinolytic agent in ST-elevation myocardial infarction (STEMI) patients receiving fibrinolytic therapy in ExTRACT-TIMI 25 (Enoxaparin and Thrombolysis Reperfusion for Acute Myocardial Infarction Treatment - Thrombolysis in Myocardial Infarction 25) trial."5.14Streptokinase and enoxaparin as an alternative to fibrin-specific lytic-based regimens: an ExTRACT-TIMI 25 analysis. ( Antman, EM; Giraldez, RR; Giugliano, RP; Mohanavelu, S; Morrow, DA; Nicolau, JC; Wiviott, SD, 2009)
" Apixaban, a specific factor Xa inhibitor, may provide effective thromboprophylaxis with a low risk of bleeding and improved ease of use."5.14Apixaban or enoxaparin for thromboprophylaxis after knee replacement. ( Chen, D; Gallus, A; Lassen, MR; Pineo, G; Portman, RJ; Raskob, GE, 2009)
"In the OASIS-5 trial, fondaparinux reduced major bleeding with similar short-term efficacy as enoxaparin but lowered death and stroke during long-term follow-up."5.14Comparison of the anticoagulant intensities of fondaparinux and enoxaparin in the Organization to Assess Strategies in Acute Ischemic Syndromes (OASIS)-5 trial. ( Afzal, R; Anderson, JA; Budaj, A; Eikelboom, JW; Fox, KA; Hirsh, J; Johnston, M; Mehta, SR; Yusuf, S, 2010)
"Ambulatory treatment with enoxaparin plus warfarin seems to be effective in symptomatic healing and in clinical improvement by reducing thrombus formation and organization at all levels of lower extremity venous system with DVT, without a significant major bleeding risk."5.14Long-term efficacy and safety of once-daily enoxaparin plus warfarin for the outpatient ambulatory treatment of lower-limb deep vein thrombosis in the TROMBOTEK trial. ( Akcalı, Y; Filizcan, U; Hasan, E; Karabay, O; Koksoy, C; Kurtoglu, M, 2010)
"In patients undergoing hip or knee arthroplasty, enoxaparin and dabigatran showed similar rates of efficacy and bleeding."5.14Enoxaparin versus dabigatran or rivaroxaban for thromboprophylaxis after hip or knee arthroplasty: Results of separate pooled analyses of phase III multicenter randomized trials. ( Dahl, OE; Huisman, MV; Quinlan, DJ; Schulman, S, 2010)
"Rivaroxaban offers a simple, single-drug approach to the short-term and continued treatment of venous thrombosis that may improve the benefit-to-risk profile of anticoagulation."5.14Oral rivaroxaban for symptomatic venous thromboembolism. ( Agnelli, G; Bauersachs, R; Berkowitz, SD; Bounameaux, H; Brenner, B; Buller, HR; Cohen, A; Davidson, BL; Decousus, H; Gallus, AS; Lensing, AW; Misselwitz, F; Piovella, F; Prins, MH; Raskob, GE; Schellong, S; Segers, A; Verhamme, P; Wells, P, 2010)
" Orally active, specific factor Xa inhibitors such as apixaban may provide effective thromboprophylaxis with a lower risk of bleeding and improved ease of use."5.14Apixaban versus enoxaparin for thromboprophylaxis after hip replacement. ( Chen, D; Gallus, A; Lassen, MR; Pineo, G; Ramirez, LM; Raskob, GE, 2010)
"Compared with a heparin-based strategy, fondaparinux reduced mortality, ischemic events, and major bleeding across the full spectrum of acute coronary syndromes and was associated with a more favorable net clinical outcome in patients undergoing either an invasive or a conservative management strategy."5.13Antithrombotic therapy with fondaparinux in relation to interventional management strategy in patients with ST- and non-ST-segment elevation acute coronary syndromes: an individual patient-level combined analysis of the Fifth and Sixth Organization to Ass ( Afzal, R; Avezum, A; Bassand, JP; Boden, WE; Budaj, A; Chrolavicius, S; Eikelboom, JW; Faxon, DP; Flather, M; Fox, KA; Granger, CB; Jolly, S; Mehta, SR; Piegas, LS; Rupprecht, HJ; Steg, PG; Widimsky, P; Yusuf, S, 2008)
"According to the available data, Apixaban, Edoxaban, and Darexaban are better than any anticoagulants in the prevention of VTE and bleeding during total knee or total hip arthroplasty."5.12Ranking the efficacy of anticoagulants for the prevention of venous thromboembolism after total hip or knee arthroplasty: A systematic review and a network meta-analysis. ( Feng, W; Huang, D; Lu, A; Wang, X, 2021)
"In the THRIVE Treatment study, no patient suffered from a recurrent VTE, but 1 patient randomised to enoxaparin/warfarin experienced major bleeding."5.12Incidence of recurrent venous thromboembolism of patients after termination of treatment with ximelagatran. ( Harenberg, J; Jörg, I; Weiss, C, 2006)
"Fondaparinux is similar to enoxaparin in reducing the risk of ischemic events at nine days, but it substantially reduces major bleeding and improves long term mortality and morbidity."5.12Comparison of fondaparinux and enoxaparin in acute coronary syndromes. ( Afzal, R; Bassand, JP; Budaj, A; Chrolavicius, S; Fox, KA; Granger, CB; Joyner, C; Mehta, SR; Peters, RJ; Pogue, J; Wallentin, L; Yusuf, S, 2006)
"Switching from enoxaparin to bivalirudin for patients with ACS undergoing PCI appears to be clinically safe without increased risk of major bleeding complications, regardless of the time of enoxaparin administration, and is safe enough to warrant testing it in larger numbers."5.12Switching from Enoxaparin to Bivalirudin in Patients with Acute Coronary Syndromes without ST-segment Elevation who Undergo Percutaneous Coronary Intervention. Results from SWITCH--a multicenter clinical trial. ( Kent, KM; Okubagzi, P; Satler, LF; Suddath, WO; Torguson, RL; Waksman, R; Wolfram, RM; Xue, Z, 2006)
"In patients with moderate- or high-risk acute coronary syndromes who were undergoing invasive treatment with glycoprotein IIb/IIIa inhibitors, bivalirudin was associated with rates of ischemia and bleeding that were similar to those with heparin."5.12Bivalirudin for patients with acute coronary syndromes. ( Aylward, PE; Bertrand, ME; Cequier, AR; Colombo, A; Cox, DA; Darius, H; Desmet, W; Ebrahimi, R; Feit, F; Hamon, M; Hoekstra, J; Lincoff, AM; McLaurin, BT; Mehran, R; Moses, JW; Ohman, EM; Pocock, SJ; Rasmussen, LH; Rupprecht, HJ; Stone, GW; Ware, JH; White, HD, 2006)
"This study aimed to determine whether a weight-adjusted dose of subcutaneous enoxaparin is as effective and safe as oral acenocoumarol for the secondary prophylaxis of pulmonary embolism."5.12Monotherapy with enoxaparin for the prevention of recurrent venous thromboembolism. ( Castro, DJ; Díaz, G; Escobar, C; García-Rull, S; Martí, D; Ortega, J; Picher, J; Sueiro, A, 2007)
"The current recommended doses of fondaparinux and heparins for the treatment of venous thromboembolism appear to provide similar protection against recurrence and major bleeding to one another and to obese and non-obese patients."5.12Effect of obesity on outcomes after fondaparinux, enoxaparin, or heparin treatment for acute venous thromboembolism in the Matisse trials. ( Büller, HR; Davidson, BL; Decousus, H; Gallus, A; Gent, M; Lensing, AW; Piovella, F; Prins, MH; Raskob, GE; Segers, AE, 2007)
"A recent randomized, controlled trial, the Fifth Organization to Assess Strategies in Acute Ischemic Syndromes (OASIS 5) trial, reported that major bleeding was 2-fold less frequent with fondaparinux than with enoxaparin in acute coronary syndromes (ACS)."5.12Influence of renal function on the efficacy and safety of fondaparinux relative to enoxaparin in non ST-segment elevation acute coronary syndromes. ( Afzal, R; Bassand, JP; Chrolavicius, S; Fox, KA; Mehta, SR; Moccetti, T; Piegas, LS; Theroux, P; Valentin, V; Wallentin, L; Yusuf, S, 2007)
"Heparins and warfarin are currently used as venous thromboembolism (VTE) prophylaxis in surgery."5.12The efficacy and safety of apixaban, an oral, direct factor Xa inhibitor, as thromboprophylaxis in patients following total knee replacement. ( Ansell, J; Davidson, BL; Deitchman, D; Gallus, A; Lassen, MR; Pineo, G, 2007)
"Oral dabigatran etexilate was as effective as enoxaparin in reducing the risk of venous thromboembolism after total hip replacement surgery, with a similar safety profile."5.12Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial. ( Büller, HR; Dahl, OE; Eriksson, BI; Frostick, SP; Hantel, S; Hettiarachchi, R; Kurth, AA; Prins, MH; Rosencher, N; Schnee, J; van Dijk, CN, 2007)
"The aim of this prospective cohort study was to determine the incidence of dalteparin bioaccumulation (measured using anti-Xa levels), and bleeding during thromboprophylaxis in elderly patients with renal failure who were admitted to hospital with an acute medical illness."5.12Safety of dalteparin for the prophylaxis of venous thromboembolism in elderly medical patients with renal insufficiency: a pilot study. ( Bondi, M; Casolari, B; Cenci, AM; Crowther, MA; Mannucci, C; Prisco, D; Tincani, E; Turrini, F, 2006)
"Enoxaparin is noninferior to UFH+phenprocoumon for prevention of ischemic and embolic events, bleeding complications, and death in TEE-guided cardioversion of atrial fibrillation."5.11Safety and efficacy of enoxaparin compared with unfractionated heparin and oral anticoagulants for prevention of thromboembolic complications in cardioversion of nonvalvular atrial fibrillation: the Anticoagulation in Cardioversion using Enoxaparin (ACE) ( Daniel, WG; Geller, C; Hanrath, P; Hofmann, T; Lehmacher, W; Mügge, A; Nixdorff, U; Schmidt-Lucke, C; Schmidt-Lucke, JA; Sehnert, W; Stellbrink, C, 2004)
"Once-daily subcutaneous fondaparinux was at least as effective (not inferior) and safe as twice-daily, body weight-adjusted enoxaparin in the initial treatment of patients with symptomatic deep venous thrombosis."5.11Fondaparinux or enoxaparin for the initial treatment of symptomatic deep venous thrombosis: a randomized trial. ( Büller, HR; Cariou, R; Davidson, BL; Decousus, H; Gallus, A; Gent, M; Leeuwenkamp, O; Lensing, AW; Piovella, F; Prins, MH; Raskob, G; Segers, AE, 2004)
"In this dose-finding study, we sought to compare fondaparinux with enoxaparin in patients with acute coronary syndromes (ACS)."5.11A dose-finding study of fondaparinux in patients with non-ST-segment elevation acute coronary syndromes: the Pentasaccharide in Unstable Angina (PENTUA) Study. ( Bobbink, IW; Boland, J; Gardien, M; Klootwijk, P; Lensing, AW; Ruzyllo, W; Simoons, ML; Umans, VA; Vahanian, A; Van De Werf, F; Zeymer, U, 2004)
"Dalteparin 5000 IU once daily halved the rate of venous thromboembolism with a low risk of bleeding."5.11Randomized, placebo-controlled trial of dalteparin for the prevention of venous thromboembolism in acutely ill medical patients. ( Cohen, AT; Goldhaber, SZ; Leizorovicz, A; Olsson, CG; Turpie, AG; Vaitkus, PT, 2004)
"Tirofiban combined with dalteparin was associated with relatively more bleeding complications in the short term, but was effective in reducing the incidence of MACE during long-term clinical follow-up in patients with ACS."5.11Long-term clinical outcomes of platelet glycoprotein IIb/IIIa inhibitor combined with low molecular weight heparin in patients with acute coronary syndrome. ( Ahn, YK; Cho, JG; Hong, SN; Hong, YJ; Jeong, MH; Kang, DK; Kang, JC; Kim, JH; Kim, KH; Kim, W; Lee, SH; Lee, YS; Lim, JH; Lim, SY; Moon, Y; Park, HW; Park, JC; Rhew, JY; Yun, KH, 2005)
"Our objective was to provide estimates of the frequency of bleeding complications, as defined by means of the Thrombolysis In Myocardial Infarction(TIMI) group, and collect data on clinical efficacy of the combination of tirofiban with enoxaparin plus ASA."5.10Randomized double-blind safety study of enoxaparin versus unfractionated heparin in patients with non-ST-segment elevation acute coronary syndromes treated with tirofiban and aspirin: the ACUTE II study. The Antithrombotic Combination Using Tirofiban and ( Bigonzi, F; Borzak, S; Cohen, M; Frey, MJ; Harris, K; Lis, J; Mukherjee, R; Senatore, F; Théroux, P; Van Mieghem, W; White, HD, 2002)
"This study was designed to assess whether use of enoxaparin during percutaneous coronary intervention (PCI) increased bleeding compared with unfractionated heparin, in addition to background therapy with eptifibatide."5.10Safety of concomitant therapy with eptifibatide and enoxaparin in patients undergoing percutaneous coronary intervention: results of the Coronary Revascularization Using Integrilin and Single bolus Enoxaparin Study. ( Bhatt, DL; Breall, JA; Casterella, PJ; Cohen, M; Corrigan, VE; Eaton, GM; Lee, BI; Lincoff, AM; Moses, JW; Pulsipher, M; Rogers, M; Ryan, TJ; Sklar, MA, 2003)
"Similar compliance, health status, deep venous thrombosis, and bleeding rates were found between dalteparin and enoxaparin."5.10Comparison of dalteparin and enoxaparin for deep venous thrombosis prophylaxis in patients with spinal cord injury. ( Chan, KT; Chiou-Tan, FY; Donovan, WH; Garza, H; Graves, DE; Holmes, SA; Parsons, KC; Rintala, DH; Robertson, CS, 2003)
"The FRISC II trial demonstrated that, for patients with unstable coronary artery disease, an early invasive strategy following acute treatment with dalteparin and aspirin, was superior to a more conservative approach."5.10Benefits of extended treatment with dalteparin in patients with unstable coronary artery disease eligible for revascularization. ( Husted, SE; Kontny, F; Lagerqvist, B; Ståhle, E; Swahn, E; Wallentin, L, 2002)
"In patients with cancer and acute venous thromboembolism, dalteparin was more effective than an oral anticoagulant in reducing the risk of recurrent thromboembolism without increasing the risk of bleeding."5.10Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. ( Baker, RI; Bowden, C; Gent, M; Haley, S; Julian, JA; Kakkar, AK; Kovacs, MJ; Lee, AY; Levine, MN; Prins, M; Rickles, FR, 2003)
"In patients undergoing surgery for hip fracture, fondaparinux was more effective than enoxaparin in preventing venous thromboembolism and equally safe."5.09Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after hip-fracture surgery. ( Bauer, KA; Eriksson, BI; Lassen, MR; Turpie, AG, 2001)
" The fondaparinux group had a significantly lower incidence of venous thromboembolism by day 11 (12."5.09Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after elective major knee surgery. ( Bauer, KA; Eriksson, BI; Lassen, MR; Turpie, AG, 2001)
"This was a prospective cohort study of eligible patients with pulmonary embolism managed as outpatients using dalteparin (200 U/kg s/c daily) for a minimum of five days and warfarin for 3 months."5.09Outpatient treatment of pulmonary embolism with dalteparin. ( Anderson, D; Gray, L; Kovacs, MJ; Morrow, B; Touchie, D; Wells, PS, 2000)
"To compare the effectiveness and safety of fixed-dose enoxaparin and adjusted dose warfarin in preventing venous thromboembolism after knee arthroplasty."5.08Prevention of venous thromboembolism after knee arthroplasty. A randomized, double-blind trial comparing enoxaparin with warfarin. ( Cruickshank, M; Delorme, F; Demers, C; Desjardins, L; Geerts, WH; Kassis, J; L'Espérance, B; Laflamme, GH; Leclerc, JR; Whitman, L, 1996)
"Antithrombotic therapy with enoxaparin plus aspirin was more effective than unfractionated heparin plus aspirin in reducing the incidence of ischemic events in patients with unstable angina or non-Q-wave myocardial infarction in the early phase."5.08A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-Wave Coronary Events Study Group. ( Bigonzi, F; Califf, RM; Cohen, M; Demers, C; Fox, KA; Fromell, GJ; Goodman, S; Gurfinkel, EP; Langer, A; Premmereur, J; Turpie, AG, 1997)
"The present trial investigated the efficacy and safety of dalteparin in the prevention of arterial thromboembolism after an acute anterior myocardial infarction (MI)."5.08Randomized trial of low molecular weight heparin (dalteparin) in prevention of left ventricular thrombus formation and arterial embolism after acute anterior myocardial infarction: the Fragmin in Acute Myocardial Infarction (FRAMI) Study. ( Abildgaard, U; Dale, J; Kontny, F; Pedersen, TR, 1997)
" with coumarin) is still the most widely used treatment for deep venous thromboembolism."5.07Comparison of subcutaneous unfractionated heparin with a low molecular weight heparin (Fragmin) in patients with venous thromboembolism and contraindications to coumarin. ( del Rio, L; Lafoz, E; Monreal, M; Olive, A; Vedia, C, 1994)
"Literature on the efficacy and safety of enoxaparin for thromboembolism and thromboprophylaxis remains scanty, and therefore efficacy was not assessed; in terms of safety, when including other indications for enoxaparin in pregnancy, we found that enoxaparin was associated with significantly lower complications than aspirin."5.05Safety and Efficacy of Enoxaparin in Pregnancy: A Systematic Review and Meta-Analysis. ( Jacobson, B; Leisegang, R; Naidoo, P; Paek, D; Rambiritch, V; Sayre, T; Shan, J, 2020)
" Initial studies of extended thromboprophylaxis in acutely ill medical patients with enoxaparin, rivaroxaban and apixaban showed little to no benefit towards VTE reduction that was consistently outweighed by increased bleeding."4.98Extended thromboprophylaxis in the acutely ill medical patient after hospitalization - a paradigm shift in post-discharge thromboprophylaxis. ( Burnett, AE; Fletcher, ML; Mahan, CE; Spyropoulos, AC, 2018)
"In the EINSTEIN-Pulmonary Embolism (PE) trial, subjects randomized to rivaroxaban versus enoxaparin bridging to vitamin K antagonist (VKA) therapy experienced a reduced index hospital length of stay (LOS)."4.95Association between rivaroxaban use and length of hospital stay, treatment costs and early outcomes in patients with pulmonary embolism: a systematic review of real-world studies. ( Ashton, V; Baugh, CW; Coleman, CI; Crivera, C; Fermann, GJ; Kohn, CG; Peacock, WF; Schein, JR; Wells, PS; Wildgoose, P, 2017)
" The RR of major/clinically relevant bleeding was lowest for apixaban 2."4.95Safety and Efficacy of New Anticoagulants for the Prevention of Venous Thromboembolism After Hip and Knee Arthroplasty: A Meta-Analysis. ( Gage, BF; Ganti, BR; Lee, ED; Lin, H; Nunley, RM; Venker, BT, 2017)
" The cluster ranking of major outcomes indicated that FXI-ASO, ardeparin, aspirin, and apixaban were ideal for preventing all-cause VTE and avoiding all bleeding events."4.95Effectiveness and Tolerability of Anticoagulants for Thromboprophylaxis after Major Joint Surgery: a Network Meta-Analysis. ( Chen, X; Jin, Y; Wang, Z; Xiang, Y; Zhao, Y; Zheng, J, 2017)
"In conclusion, our results confirmed that direct Xa inhibitors (rivaroxaban and apixaban) were more effective for prevention of VTE after total knee replacement as compared with enoxaparin, without increasing major bleeding risk."4.91Direct factor Xa inhibitors (rivaroxaban and apixaban) versus enoxaparin for the prevention of venous thromboembolism after total knee replacement: A meta-analysis of 6 randomized clinical trials. ( Ma, G; Wang, D; Wu, X; Ying, K; Zhang, R, 2015)
"Studies reporting vein re-opening, inflammation expressed as Gadolinium enhancement and coagulation parameters were searched in the literature and pooled into a meta-analysis using an inverse variance with random effects."4.86P-selectin/ PSGL-1 inhibitors versus enoxaparin in the resolution of venous thrombosis: a meta-analysis. ( Deatrick, KB; Henke, PK; Londy, FJ; Myers, DD; Ramacciotti, E; Rectenwald, JE; Schaub, RG; Wakefield, TW; Wrobleski, SK, 2010)
"Primary efficacy (any VTE+all-cause mortality) and safety (major bleeding) outcomes in enoxaparin arms largely differed across similarly designed rivaroxaban and dabigatran trials (differences in venography adjudication and bleeding events definitions)."4.86Rivaroxaban vs dabigatran for thromboprophylaxis after joint-replacement surgery: exploratory indirect comparison based on meta-analysis of pivotal clinical trials. ( Kolundzic, R; Trkulja, V, 2010)
"Oral dabigatran was as effective as subcutaneous enoxaparin in reducing the risk of major VTE and VTE-related mortality after hip or knee arthroplasty and has a similar bleeding profile."4.86Dabigatran versus enoxaparin for prevention of venous thromboembolism after hip or knee arthroplasty: a pooled analysis of three trials. ( Caprini, JA; Clemens, A; Dahl, OE; Eriksson, BI; Francis, CW; Friedman, RJ; Hantel, S; Kurth, AA; Rosencher, N; Schnee, JM, 2010)
" Newer agents, such as bivalirudin or fondaparinux, reduce bleeding complications, with no improvement in anti-ischemic efficacy."4.86Pharmacologic therapy for non ST-segment elevation acute coronary syndromes: focus on antithrombotic therapy. ( Aïssaoui, N; Danchin, N, 2010)
"Dabigatran etexilate has been investigated in three phase III trials for the prevention of venous thromboembolism (VTE)."4.85Efficacy and safety of dabigatran etexilate for the prevention of venous thromboembolism following total hip or knee arthroplasty. A meta-analysis. ( Caprini, JA; Eriksson, BI; Plumb, JM; Roskell, NS; Wolowacz, SE, 2009)
" High-dose atorvastatin reduces recurrent stroke in patients with recent stroke, but probably slightly increases central nervous system hemorrhage (SPARCL)."4.84What's new in stroke? The top 10 studies of 2006-2008. Part II. ( Hart, RG, 2008)
" We explore the role of glycoprotein IIb-IIIa inhibitors and the direct thrombin inhibitor bivalirudin in ACS patients, and consider the difficulties involved in reducing ischemic events while limiting bleeding risks."4.84Current update on glycoprotein IIb-IIIa and direct thrombin inhibition in percutaneous coronary intervention for non-ST elevation acute coronary syndromes: balancing bleeding risk and antiplatelet efficacy. ( Kwa, AT; Rogers, JH, 2008)
"A 70-year-old man on enoxaparin and warfarin sodium therapy due to pulmonary embolism was admitted for evaluation of a sudden, sharp pain in the left inguinal region."4.82Surgical management of enoxaparin- and/or warfarin-induced massive retroperitoneal bleeding: report of a case and review of the literature. ( Anadol, AZ; Gök, A; Topgül, K; Uzun, O, 2005)
"Rivaroxaban chemoprophylaxis following TKA and THA was associated with an increased risk of bleeding and prothrombotic complications compared to aspirin and enoxaparin."4.31Safety and Efficacy of Rivaroxaban in Primary Total Hip and Knee Arthroplasty. ( Christ, AB; Heckmann, ND; Kang, HP; Lieberman, JR; Mayfield, CK; Mills, ES; Piple, AS; Wang, JC, 2023)
" Of the 7 readmissions in the enoxaparin group, one was due to bleeding requiring transfusion; there were no readmissions for bleeding in the apixaban group."4.31Apixaban for extended postoperative thromboprophylaxis in gynecologic oncology patients undergoing laparotomy. ( Covens, A; Geerts, W; Gien, LT; Kupets, R; Lin, Y; Spénard, E; Vicus, D, 2023)
"In 8246 patients included in the EINSTEIN-VTE studies for acute VTE, we evaluated the effect of polypharmacy on bleeding and on the relative differences between rivaroxaban and enoxaparin/vitamin K antagonist (VKA)."4.12Effect of polypharmacy on bleeding with rivaroxaban versus vitamin K antagonist for treatment of venous thromboembolism. ( Bavalia, R; Bistervels, IM; Coppens, M; Gebel, M; Lensing, AWA; Middeldorp, S; Prins, MH, 2022)
" The MAGELLAN (Multicenter, Randomized, Parallel Group Efficacy and Safety Study for the Prevention of Venous Thromboembolism in Hospitalized Medically Ill Patients Comparing Rivaroxaban With Enoxaparin) and MARINER (Medically Ill Patient Assessment of Rivaroxaban Versus Placebo in Reducing Post-Discharge Venous Thrombo-Embolism Risk) trials evaluated whether rivaroxaban compared with enoxaparin or placebo could prevent venous thromboembolism without increased bleeding."4.12Association of Bleeding Severity With Mortality in Extended Thromboprophylaxis of Medically Ill Patients in the MAGELLAN and MARINER Trials. ( Ageno, W; Albers, GW; Barnathan, ES; Cohen, AT; Elliott, CG; Halperin, JL; Hiatt, WR; Lipardi, C; Lu, W; Maynard, G; Raskob, GE; Spiro, TE; Spyropoulos, AC; Steg, PG; Sugarmann, C; Weitz, JI, 2022)
"We evaluated the risks of VTE recurrence and treatment-related major bleeding according to the cancer stage in patients with VTE and solid cancer randomised to apixaban or dalteparin in the Caravaggio study."4.12Recurrent venous thromboembolism and major bleeding in patients with localised, locally advanced or metastatic cancer: an analysis of the Caravaggio study. ( Agnelli, G; Becattini, C; Brenner, B; Cohen, AT; Connors, JM; Gussoni, G; Huisman, M; Munoz, A; Sanchez, O; Verso, M, 2022)
"Apixaban has a higher rate of major bleeding in patients with luminal GI cancer compared with patients with non-GI cancer and compared with enoxaparin in patients with luminal GI cancer."4.02Bleeding in Patients With Gastrointestinal Cancer Compared With Nongastrointestinal Cancer Treated With Apixaban, Rivaroxaban, or Enoxaparin for Acute Venous Thromboembolism. ( Brunton, N; Casanegra, AI; Froehling, DA; Hodge, DO; Houghton, DE; McBane, RD; Meverden, RA; Peterson, LG; Vlazny, DT; Wysokinski, WE, 2021)
" The aim of our study was to evaluate the clinical impact of venous thromboembolism prophylaxis with fondaparinux versus enoxaparin among 100 hospitalized COVID-19 patients."3.96Fondaparinux Use in Patients With COVID-19: A Preliminary Multicenter Real-World Experience. ( Agrusta, F; Amitrano, M; Bellizzi, A; Cardillo, G; Cavalli, A; Di Micco, P; Fontanella, A; Iannuzzo, M; Lodigiani, C; Mangiacapra, S; Russo, V; Sacco, C; Viggiano, GV, 2020)
"This study aims to validate the application of a multicriteria decision analysis in a real-world problem, the use of rivaroxaban and enoxaparin to prevent deep venous thrombosis."3.96Multi-Criteria Model for Evaluating Drugs to Prevent Deep Venous Thrombosis Associated With Orthopedic Surgery: A Hospital-Based Case Study. ( Morais, QCD; Santos, MS, 2020)
"In this study, although there were no significant differences in effectiveness or safety between the rivaroxaban and dalteparin groups, rivaroxaban use was associated with a higher rate of clinically relevant bleeding than dalteparin."3.96Comparison of rivaroxaban and dalteparin for the long-term treatment of venous thromboembolism in patients with gynecologic cancers. ( Huh, JW; Jo, KW; Lee, JH; Lee, JS; Oh, YM, 2020)
"This study was a retrospective pilot analysis of adult patients with gynecologic malignancies who received either rivaroxaban, warfarin or low molecular weight heparin for treatment of venous thromboembolism at Augusta University Medical Center from 1 July 2013 to 30 June 2015."3.91Evaluation of rivaroxaban use in patients with gynecologic malignancies at an academic medical center: A pilot study. ( Gandhi, AS; Signorelli, JR, 2019)
"Purpose Although low-molecular-weight heparin (LMWH) remains the standard of care, factor Xa inhibitors such as rivaroxaban may serve as an alternative treatment for venous thromboembolism (VTE) in patients with active malignancy."3.88Recurrence of malignancy-associated venous thromboembolism among patients treated with rivaroxaban compared to enoxaparin. ( Kettle, JK; Ludwig, SL; Nicklaus, MD, 2018)
" Objectives To estimate the incidence of VTE and bleeding outcomes, comparing prolonged prophylaxis with rivaroxaban 10 mg daily for 35 days with enoxaparin 40 mg daily for 10 days."3.88Rivaroxaban for thromboprophylaxis among patients recently hospitalized for acute infectious diseases: a subgroup analysis of the MAGELLAN study. ( Cohoon, KP; De Sanctis, Y; Haskell, L; McBane, RD; Spiro, TE, 2018)
"There was no evidence that fondaparinux, enoxaparin, or warfarin were superior to aspirin in the prevention of pulmonary embolism, deep vein thrombosis, or venous thromboembolism or that aspirin was safer than these alternatives."3.85Comparative Effectiveness and Safety of Drug Prophylaxis for Prevention of Venous Thromboembolism After Total Knee Arthroplasty. ( Bini, SA; Cafri, G; Cheetham, CT; Chen, Y; Gould, MK; Khatod, M; Paxton, EW; Sluggett, J, 2017)
" The aim of this study was to determine the efficacy and safety, using the incidence of recurrent symptomatic VTE and major bleeding, respectively, throughout the treatment with rivaroxaban."3.85Oral Rivaroxaban for the Treatment of Symptomatic Venous Thromboembolism in 400 Patients With Active Cancer: A Single-Center Experience. ( Bomfim, GAZ; Cavalcante, RN; Centofanti, G; Fonseca, IYI; Krutman, M; Nishinari, K; Pignataro, BS; Ramacciotti, E; Sanches, SM; Teivelis, MP; Wolosker, N; Yazbek, G, 2017)
"To evaluate the occurrence of bleeding and venous thromboembolic (VTE) events in patients receiving rivaroxaban, warfarin, or warfarin with the addition of enoxaparin during the immediate postoperative period following major orthopedic surgery."3.85Retrospective Evaluation of Postoperative Adverse Drug Events in Patients Receiving Rivaroxaban After Major Orthopedic Surgery Compared with Standard Therapy in a Community Hospital. ( Cieri, NE; Hassan, AK; Kusmierski, K; Lackie, C; Van Opdorp, A, 2017)
"Recent studies have shown fondaparinux's superiority over enoxaparin in patients with non-ST elevation acute coronary syndrome (ACS), especially in relation to bleeding reduction."3.83Fondaparinux versus Enoxaparin - Which is the Best Anticoagulant for Acute Coronary Syndrome? - Brazilian Registry Data. ( Bossa, AS; César, MC; Leal, TC; Okada, MY; Oliveira, MT; Pedroti, FC; Roque, EA; Silva, PG; Simões, SA; Soeiro, AM, 2016)
"We compared the incidence of clinically significant bleeding in patients with CKD receiving therapeutic doses of dalteparin to that of patients with CKD receiving therapeutic doses of UFH."3.83Treatment with Dalteparin is Associated with a Lower Risk of Bleeding Compared to Treatment with Unfractionated Heparin in Patients with Renal Insufficiency. ( Billett, HH; Calvo, M; Kushnir, M; Park, D; Sinnet, M; Solorzano, C; Southern, W, 2016)
"The reduction in inpatient utilization, recurrences, and major bleeding resulting from a 25% shift from standard therapy to rivaroxaban following acute VTE would conserve ∼$860,475 for every 1 million commercial health plan enrollees."3.81The economic implications of switching to rivaroxaban from enoxaparin plus vitamin K antagonist in the treatment of venous thromboembolism. ( Bookhart, B; Mody, SH; Ogden, K; Patel, AA, 2015)
"The oral Factor Xa inhibitor rivaroxaban (Xarelto) has been the pharmacologic agent used for venous thromboembolism (VTE) prophylaxis after primary hip and knee arthroplasty (THA/TKA) at our institution since February 2012."3.81Rivaroxaban Versus Enoxaparin for Venous Thromboembolism Prophylaxis after Hip and Knee Arthroplasty. ( Charters, MA; Dobson, C; Frisch, NB; Les, CM; Silverton, CD; Wessell, NM, 2015)
" She is currently on warfarin, with which she has been adequately controlled most of the time, presenting with only one haemorrhagic event consisting of haematuria and prolonged international normalised ratio (INR) without bleeding."3.81Variability in the international normalised ratio (INR) in patients with antiphospholipid syndrome and positive lupus anticoagulant: should the INR targets be higher? ( Baquero-Salamanca, M; Calderon-Ospina, C; Téllez-Arévalo, AM, 2015)
" The primary analysis compared the temporal course of event rates and rate differences between rivaroxaban and enoxaparin prophylaxis for symptomatic venous thromboembolism plus all-cause mortality (efficacy events) versus nonfatal major bleeding (safety events)."3.80Benefit-risk assessment of rivaroxaban versus enoxaparin for the prevention of venous thromboembolism after total hip or knee arthroplasty. ( Berkowitz, SD; Berlin, JA; DiBattiste, PM; Friedman, RJ; Homering, M; Levitan, B; Turpie, AG; Weinstein, RB; Yuan, Z, 2014)
"Combined anticoagulant and aspirin therapy is associated with increased bleeding risk in patients with atrial fibrillation, but the bleeding risk of combined use of anticoagulant and nonsteroidal anti-inflammatory drugs (NSAIDs) is poorly documented."3.80Bleeding risk of patients with acute venous thromboembolism taking nonsteroidal anti-inflammatory drugs or aspirin. ( Brighton, TA; Davidson, BL; Gebel, M; Lensing, AW; Lyons, RM; Prins, MH; Rehm, J; Verheijen, S, 2014)
"Our experience with rivaroxaban in elective hip and knee arthroplasty showed no significant difference in the incidence of VTE or major bleeding."3.79Elective hip and knee arthroplasty and the effect of rivaroxaban and enoxaparin thromboprophylaxis on wound healing. ( Jeer, P; Rose, B; Saran, D; Shrivastava, R; Sindali, K; Soueid, H, 2013)
"To evaluate the consistency of the antithrombotic efficacy and bleeding risk of apixaban 2."3.79Apixaban after hip or knee arthroplasty versus enoxaparin: efficacy and safety in key clinical subgroups. ( Chen, D; Gallus, AS; Lassen, MR; Pineo, GF; Ramacciotti, E; Ramirez, LM; Raskob, GE; Wang, L, 2013)
" In this analysis of pooled data from four large, randomised, phase III clinical trials that compared the oral, direct Factor Xa inhibitor rivaroxaban with subcutaneous enoxaparin for the prevention of venous thromboembolism after total hip or knee replacement (n = 12,729), the incidence of complications, including bleeding and adverse events related to surgery (such as wound infection, wound dehiscence and haemarthrosis) are reported."3.78The effects of rivaroxaban on the complications of surgery after total hip or knee replacement: results from the RECORD programme. ( Berkowitz, SD; Eriksson, BI; Gent, M; Homering, M; Kakkar, AK; Lassen, MR; Turpie, AG, 2012)
"Cost considered: the drugs for the prevention of VTE (apixaban, dabigatran, enoxaparin, fondaparinux, other heparins, rivaroxaban and warfarin) and the complications of VTE in the short term and in 5 years (deep vein thrombosis, pulmonary embolism, bleedings and the post-thrombotic syndrome)."3.78[Budgetary impact for the National Health System of apixaban prophylaxis of venous thromboembolism in patients undergoing total knee or hip replacement]. ( Betegón Nicolás, L; de Salas-Cansado, M; Gómez Arrayas, I; Gómez Cerezo, JF; Rubio-Terrés, C; Suárez Fernández, C, 2012)
"Oral dabigatran etexilate is indicated for the prevention of venous thromboembolism (VTE) in patients undergoing total knee replacement or total hip replacement."3.76Economic evaluation of dabigatran etexilate for the prevention of venous thromboembolism in patients aged over 75 years or with moderate renal impairment undergoing total knee or hip replacement. ( Brenkel, IJ; Clemens, A; Dolan, G; Noack, H; Plumb, JM; Robinson, PA; Roskell, NS; Wolowacz, SE, 2010)
"Non-steroidal anti-inflammatory drugs (NSAIDs) may be prothrombotic, may worsen hypertension or congestive heart failure and obstruct access to the binding site of aspirin to cyclooxygenase-1 and thereby interfere with aspirin's mechanism of action in reducing death and recurrent myocardial infarction (MI)."3.75Association of non-steroidal anti-inflammatory drugs with outcomes in patients with ST-segment elevation myocardial infarction treated with fibrinolytic therapy: an ExTRACT-TIMI 25 analysis. ( Antman, EM; Aylward, PE; Bergovec, M; Buros, JL; Col, JJ; Gibson, CM; Goodman, SG; Gulba, D; Kunadian, V; Murphy, SA; Pride, YB; Zorkun, C, 2009)
"Rates of VTE and bleeding events did not differ significantly between dabigatran etexilate and enoxaparin."3.75Economic evaluation of dabigatran etexilate for the prevention of venous thromboembolism after total knee and hip replacement surgery. ( Beard, SM; Brenkel, IJ; Dolan, G; Maciver, F; Plumb, JM; Robinson, PA; Roskell, NS; Wolowacz, SE, 2009)
"In the initial treatment of venous thromboembolism (VTE) fondaparinux, a pentasaccharide, is a good alternative to heparin."3.75Treatment of venous thromboembolism in patients with cancer: subgroup analysis of the Matisse clinical trials. ( Büller, HR; Davidson, BL; Decousus, H; Gallus, A; Lensing, AW; Piovella, F; Prins, MH; Raskob, GE; van Doormaal, FF, 2009)
"Dysfibrinogenemia is caused by a variety of structural abnormalities in the fibrinogen molecule, which results in a tendency for bleeding and thrombosis as well as obstetric complications."3.75Treatment of patients with dysfibrinogenemia and a history of abortions during pregnancy. ( Galanakis, D; Miesbach, W; Scharrer, I, 2009)
"Deep vein thrombosis (DVT) remains a major burden and fondaparinux represents a new option for DVT therapy."3.74Minimizing costs for treating deep vein thrombosis: the role for fondaparinux. ( Jackson, WL; Moores, LK; Shorr, AF; Warkentin, TE, 2007)
"In ICU patients with renal insufficiency, the incidence of DVT and major bleeding are considerable but appear related to patient comorbidities rather than to an inadequate or excessive anticoagulant from thromboprophylaxis with dalteparin."3.74Venous thromboembolism and bleeding in critically ill patients with severe renal insufficiency receiving dalteparin thromboprophylaxis: prevalence, incidence and risk factors. ( Albert, M; Cook, D; Crowther, M; Douketis, J; Fowler, R; Freitag, A; Friedrich, J; Geerts, W; Granton, J; Guyatt, G; Hebert, P; Heels-Ansdell, D; Karachi, T; Meade, M; Pagliarello, G; Rabbat, C; Skrobik, Y; Zytaruk, N, 2008)
"Over 2 million patients in North America are on warfarin anticoagulation therapy for prevention of thromboembolism."3.73Low-molecular-weight-heparins as periprocedural anticoagulation for patients on long-term warfarin therapy: a standardized bridging therapy protocol. ( Ahmed, M; Bragg, L; Brotman, DJ; Jaffer, AK; Klein, A; Qadeer, MA; Seshadri, N, 2005)
"To determine the rate of bleeding and thromboembolic events within 1 month of outpatient dalteparin therapy in veterans with mechanical heart valves, to evaluate potential risk factors associated with these events, and to examine the prescribing patterns of dalteparin in this patient population."3.73Safety of outpatient dalteparin therapy in veterans with mechanical heart valves. ( Copeland, LA; Flanagan, PS; O'Neill, JL; Zaleon, CR, 2005)
"The safety outcome was any on-treatment bleeding event."3.30Rivaroxaban versus nadroparin for thromboprophylaxis following thoracic surgery for lung cancer: A randomized, noninferiority trial. ( Bao, Y; Chen, C; Chen, L; Chen, Q; Jiang, C; Jiang, G; Li, J; Liu, X; She, Y; Shen, L; Xu, L; Yang, Y; Zhao, M, 2023)
"The primary safety end point was bleeding events, as defined by the International Society on Thrombosis and Haemostasis, and the primary efficacy end point was major adverse cardiovascular events (MACEs), including cardiac death, myocardial infarction, rerevascularization, or stroke during the 6-month follow-up."3.30Effect of Rivaroxaban vs Enoxaparin on Major Cardiac Adverse Events and Bleeding Risk in the Acute Phase of Acute Coronary Syndrome: The H-REPLACE Randomized Equivalence and Noninferiority Trial. ( Chen, F; Fu, G; Ge, L; Huang, L; Jiang, W; Liu, C; Liu, Q; Ouyang, Z; Pan, G; Pan, H; Shen, Q; Xiao, Y; Zeng, G; Zhang, Y; Zheng, Z; Zhou, C; Zhou, S; Zhu, C, 2023)
"Bleeding was predominantly intracranial (n=331 [69%]) or gastrointestinal (n=109 [23%])."3.30Final Study Report of Andexanet Alfa for Major Bleeding With Factor Xa Inhibitors. ( Albaladejo, P; Beyer-Westendorf, J; Cohen, AT; Connolly, SJ; Coppens, M; Crowther, M; Demchuk, A; Eikelboom, JW; Gibson, CM; Koch, B; Lopez-Sendon, J; Middeldorp, S; Milling, TJ; Schmidt, J; Shoamanesh, A; Verhamme, P; Xu, L, 2023)
"The study INHIXACOVID19 was registred on ClinicalTrials."3.30Intermediate dose enoxaparin in hospitalized patients with moderate-severe COVID-19: a pilot phase II single-arm study, INHIXACOVID19. ( Bignami, EG; Brambilla, P; Castagna, A; Cosmi, B; Cristini, F; De Stefano, G; Di Perri, G; Drago, F; Fornaro, G; Frattima, S; Giannella, M; Grandone, E; Lupi, M; Mazzaferri, F; Montineri, A; Pan, A; Patacca, A; Romagnoli, A; Rozzini, R; Salvetti, M; Stella, A; Testa, S; Viale, P, 2023)
"No DVT developed in COVID-19 patients hospitalized in general wards, independently of enoxaparin dosing used for thromboprophylaxis."3.11Enoxaparin for thromboprophylaxis in hospitalized COVID-19 patients: The X-COVID-19 Randomized Trial. ( Agostinis, M; Antolini, L; Barberis, D; Birocchi, S; Bonacchini, L; Carioti, G; Cattaneo, M; Gazzaniga, G; Grazia Valsecchi, M; Massaini, G; Merli, M; Morici, N; Podda, G; Saverio Serino, F; Trezzi, M, 2022)
"This study aimed to compare initiating warfarin at the recommended dosing regimen versus empirically lowered doses intended to account for the variation in warfarin sensitivity."3.11Comparison of Warfarin Initiation at 3 mg Versus 5 mg for Anticoagulation of Patients with Mechanical Mitral Valve Replacement Surgery: A Prospective Randomized Trial. ( Ahmed, MA; El Wakeel, LM; Sabry, S; Saleh, A, 2022)
"Rivaroxaban is a novel oral anticoagulant with potent anti-Xa activity, which might be an attractive alternative drug to enoxaparin."3.11Rationale and Design of the H-REPLACE Study: Safety and Efficacy of LMWH Versus Rivaroxaban in ChinEse Patients HospitaLized with Acute Coronary SyndromE. ( Fang, Z; Hu, X; Liu, Q; Tang, L; Xiao, Y; Zhou, S, 2022)
"Advanced or metastatic cancer was the only independent predictor of major bleeding (HR=2."3.11Renal function and clinical outcome of patients with cancer-associated venous thromboembolism randomized to receive apixaban or dalteparin. Results from the Caravaggio trial ( Agnelli, G; Bauersachs, R; Becattini, C; Bertoletti, L; Brenner, B; Cohen, A; Connors, JM; Manfellotto, D; Maraziti, G; Sanchez, A, 2022)
"Compared to cancer patients with symptomatic VTE, those with incidental VTE have different clinical features at presentation, with a numerically lower incidence of recurrent VTE and a numerically higher incidence of major bleeding."3.01Clinical characteristics and outcomes of incidental venous thromboembolism in cancer patients: Insights from the Caravaggio study. ( Agnelli, G; Bauersachs, R; Becattini, C; Cohen, AT; Connors, JM; Dentali, F; Falvo, N; Giustozzi, M; Huisman, M; Ruperez Blanco, AB; Szmit, S, 2021)
"Proximal deep vein thrombosis and/or pulmonary embolism occurred in seven patients (3·4 per cent) in the IPC group and one patient (0·5 per cent) in the IPC with enoxaparin group (P = 0·050)."2.94Intermittent pneumatic compression versus additional prophylaxis with enoxaparin for prevention of venous thromboembolism after laparoscopic surgery for gastric and colorectal malignancies: multicentre randomized clinical trial. ( Amano, T; Funakoshi, T; Homma, S; Ichikawa, N; Kamachi, H; Kawamura, H; Maeda, Y; Ohno, Y; Takahashi, N; Taketomi, A; Yokota, R; Yoshida, T, 2020)
"Thromboprophylaxis dosing strategies using enoxaparin in elderly patients with renal disease are limited, while dose adjustments or monitoring of anti-Xa levels are recommended."2.90Evaluation of prophylactic dosages of Enoxaparin in non-surgical elderly patients with renal impairment. ( Chamoun, N; Dimassi, H; Ghanem, G; Ghanem, H; Hachem, A; Hariri, E; Lteif, C; Mansour, H; Zalloum, R, 2019)
"This study aimed to assess whether low-molecular-weight heparin (LMWH) is effective and safe in preventing postoperative venous thromboembolism (VTE) in patients undergoing esophageal cancer surgery."2.90Efficacy and Safety of Enoxaparin for Prophylaxis of Postoperative Venous Thromboembolism After Esophagectomy: A Single-center Prospective Randomized Controlled Phase II Study. ( Hirata, S; Matsuhashi, N; Sakuratani, T; Shimokawa, T; Tanaka, H; Tanaka, Y; Yamada, A; Yamaguchi, K; Yoshida, K, 2019)
"Patients with active cancer and venous thromboembolism (VTE) are at high risk of recurrence."2.90Extended treatment with edoxaban in cancer patients with venous thromboembolism: A post-hoc analysis of the Hokusai-VTE Cancer study. ( Buller, H; Carrier, M; Di Nisio, M; Garcia, D; Raskob, G; Segers, A; van Es, N; Wang, TF; Weitz, J, 2019)
"Essentials Cancer patients receiving anticoagulants for venous thromboembolism have an elevated bleeding risk."2.87Clinically relevant bleeding in cancer patients treated for venous thromboembolism from the CATCH study. ( Bauersachs, R; Janas, MS; Jarner, MF; Kamphuisen, PW; Khorana, AA; Lee, AYY; Meyer, G, 2018)
"RI in patients with cancer-associated thrombosis on anticoagulation was associated with a statistically significant increase in recurrent VTE and major bleeding, but no significant increase in CRB or mortality."2.87Renal Impairment, Recurrent Venous Thromboembolism and Bleeding in Cancer Patients with Acute Venous Thromboembolism-Analysis of the CATCH Study. ( Bauersachs, R; Janas, MS; Jarner, MF; Kamphuisen, PW; Khorana, AA; Lee, AYY; Meyer, G, 2018)
"No episodes of transfusion, pulmonary embolism, or major bleeding occurred in either group."2.84Comparison of Enoxaparin and Rivaroxaban in Balance of Anti-Fibrinolysis and Anticoagulation Following Primary Total Knee Replacement: A Pilot Study. ( Huang, Q; Ma, J; Pei, F; Xie, J; Yue, C, 2017)
"Major bleeding was similar (N=1) in each arm but clinically relevant bleeding was higher in dalteparin arm (N=7 versus 1 on observation) (HR=7."2.84Dalteparin thromboprophylaxis in cancer patients at high risk for venous thromboembolism: A randomized trial. ( Baran, A; Carrier, M; Francis, CW; Hobbs, S; Iyer, R; Kaproth-Joslin, K; Khorana, AA; Kuderer, NM; Lyman, GH; Ortel, TL; Peterson, D; Rubens, D; Wun, T, 2017)
"The results show that the treatment with heparin and nadroparin is safe and effective."2.82The safety and efficacy of Heparin and Nadroparin compared to placebo in acute ischemic stroke - pilot study. ( Dluha, J; Dusenka, R; Kalmarova, K; Kantorova, E; Kurca, E; Nosal, V; Sivak, S; Turcanova Koprusakova, M, 2016)
"Trauma patients are at high risk of developing venous thromboembolism (VTE), and standard dosing enoxaparin regimens may be inadequate for prophylaxis."2.82The efficacy of weight-based enoxaparin dosing for venous thromboembolism prophylaxis in trauma patients: A systematic review and meta-analysis. ( Cole, E; Ebeid, A; Stallwood-Hall, C, 2022)
"To compare two enoxaparin dosing strategies at achieving prophylactic anti-Xa levels in women with a body mass index (BMI) ⩾35 (kg m(-2)) postcesarean delivery."2.82A randomized controlled trial of differing doses of postcesarean enoxaparin thromboprophylaxis in obese women. ( Caballero, DC; McNulty, J; Neeper, JM; Serra, AE; Stephenson, ML, 2016)
"Risks of recurrence and bleeding are highest during the first weeks of anticoagulant therapy for venous thromboembolism (VTE)."2.82Early time courses of recurrent thromboembolism and bleeding during apixaban or enoxaparin/warfarin therapy. A sub-analysis of the AMPLIFY trial. ( Agnelli, G; Buller, HR; Cohen, AT; Gallus, AS; Ramacciotti, E; Raskob, GE; Sanders, P; Thompson, JR; Weitz, JI, 2016)
"Bleeding was predominantly gastrointestinal or intracranial."2.82Andexanet Alfa for Acute Major Bleeding Associated with Factor Xa Inhibitors. ( Albaladejo, P; Beyer-Westendorf, J; Bronson, MD; Cohen, AT; Conley, PB; Connolly, SJ; Crowther, M; Curnutte, JT; Eikelboom, JW; Gibson, CM; Gold, A; Goodman, S; Leeds, J; Lim, WT; Lopez-Sendon, J; Lu, G; Meeks, B; Middeldorp, S; Milling, TJ; Nakamya, J; Schmidt, J; Siegal, DM; Verhamme, P; Wiens, BL; Zotova, E, 2016)
"Prevention of deep venous thrombosis (DVT) and associated pulmonary embolism following major orthopedic surgeries is challenging, and there is an increased interest in developing new treatment strategies."2.80Comparison of switch-therapy modalities (enoxaparin to rivaroxaban/dabigatran) and enoxaparin monotherapy after hip and knee replacement. ( Altıntaş, F; Önal, A; Özler, T; Uluçay, Ç, 2015)
"The Hokusai VTE-cancer study is a randomised, open-label, clinical trial to evaluate whether edoxaban, an oral factor Xa inhibitor, is non-inferior to LMWH for treatment of VTE in patients with cancer."2.80Edoxaban for treatment of venous thromboembolism in patients with cancer. Rationale and design of the Hokusai VTE-cancer study. ( Beyer-Westendorf, J; Bleker, SM; Boda, Z; Büller, HR; Carrier, M; Chlumsky, J; Décousus, H; Di Nisio, M; Garcia, D; Gibbs, H; Grosso, MA; Kakkar, A; Kamphuisen, PW; Mercuri, MF; Monreal, M; Ockelford, P; Pabinger, I; Raskob, GE; Schwocho, L; Segers, A; van Es, N; Verhamme, P; Weitz, JI, 2015)
"We conclude that low-molecular-weight heparin either in a low-dose or high-dose regime during a peripheral EVR is safe concerning bleeding complications and acute reobstructions."2.79Safety and efficacy of periprocedural anticoagulation with enoxaparin in patients undergoing peripheral endovascular revascularization. ( Brodmann, M; Deutschmann, H; Dorr, A; Froehlich, H; Gary, T; Hafner, F; Kvas, E; Pilger, E, 2014)
"This double-blind, double-dummy, randomised, phase IIb study (NCT00902928) evaluated different dosing regimens of darexaban compared with enoxaparin (randomised 1:1:1:1:1 to 15 mg twice daily [bid], 30 mg once daily [qd], 30 mg bid or 60 mg qd or enoxaparin 40 mg qd) in patients undergoing elective total hip arthroplasty."2.79Darexaban (YM150) versus enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a randomised phase IIb dose confirmation study (ONYX-3). ( Agnelli, G; Eriksson, BI; Gallus, AS; Kashiwa, M; Lassen, MR; Prins, MH; Renfurm, RW; Turpie, AG, 2014)
" There were no related serious adverse events, no clinically relevant bleeding events, and no symptomatic recurrent VTEs."2.79Multicenter dose-finding and efficacy and safety outcomes in neonates and children treated with dalteparin for acute venous thromboembolism. ( Burr, S; Goldenberg, NA; Hamblin, F; Kulkarni, R; O'Brien, SH; Wallace, A, 2014)
"Apixaban is a potent, selective direct inhibitor of the coagulation factor Xa, recently approved in Europe for the prevention of venous thromboembolism (VTE) in adult patients after total hip replacement (THR) or total knee replacement (TKR) surgery."2.77Therapeutic potential of apixaban in the prevention of venous thromboembolism in patients undergoing total knee replacement surgery. ( Gallerani, M; Imberti, D; Manfredini, R, 2012)
"Patients receiving chemotherapy for cancer are at increased risk for venous thromboembolism."2.77Semuloparin for thromboprophylaxis in patients receiving chemotherapy for cancer. ( Agnelli, G; Chaudhari, U; Fisher, W; George, DJ; Kakkar, AK; Lassen, MR; Lawson, F; Mismetti, P; Mouret, P; Turpie, AG, 2012)
"Traditionally, patients with pulmonary embolism (PE) are initially treated in the hospital with low molecular weight heparin (LMWH)."2.76Outpatient treatment in patients with acute pulmonary embolism: the Hestia Study. ( Creemers-Schild, D; de Vreede, MJ; Dekkers, OM; Dolsma, J; Eijsvogel, M; Faber, LM; Hofstee, HM; Hoogerbrugge, AD; Hovens, MM; Huisman, MV; Jonkers, GJ; Kruip, MJ; Mos, IC; van Kralingen, KW; Vlasveld, T; Zondag, W, 2011)
"Our purpose was to describe anti-Xa levels, dosage requirements, and complications associated with enoxaparin treatment doses in patients with morbid obesity."2.76Evaluation of therapeutic anticoagulation with enoxaparin and associated anti-Xa monitoring in patients with morbid obesity: a case series. ( Deal, EN; Hollands, JM; Reichley, RM; Riney, JN; Skrupky, LP; Smith, JR, 2011)
"In selected low-risk patients with pulmonary embolism, outpatient care can safely and effectively be used in place of inpatient care."2.76Outpatient versus inpatient treatment for patients with acute pulmonary embolism: an international, open-label, randomised, non-inferiority trial. ( Aujesky, D; Beer, HJ; Cornuz, J; Egloff, M; Fine, MJ; Hugli, O; Legall, C; N'gako, A; Osterwalder, J; Perrier, A; Pugh, NA; Renaud, B; Righini, M; Roy, PM; Sanchez, O; Stone, RA; Verhamme, P; Verschuren, F; Yealy, DM, 2011)
"Major bleeding was comparable and minor bleedings (0."2.76Heparin based prophylaxis to prevent venous thromboembolic events and death in patients with cancer - a subgroup analysis of CERTIFY. ( Abletshauser, C; Bauersachs, R; Bramlage, P; Gerlach, HE; Haas, S; Melzer, N; Riess, H; Schellong, SM; Sieder, C; Tebbe, U, 2011)
"Major bleeding was not significantly different between enoxaparin and placebo in either group."2.75Does ambulation modify venous thromboembolism risk in acutely ill medical patients? ( Amin, AN; Girard, F; Samama, MM, 2010)
"In acutely ill medical patients of at least 40 years of age, thromboprophylaxis with certoparin 3000 IU daily is effective and safe in comparison with 7500 IU twice daily UFH."2.75An open-label comparison of the efficacy and safety of certoparin versus unfractionated heparin for the prevention of thromboembolic complications in acutely ill medical patients: CERTAIN. ( Abletshauser, C; Bramlage, P; Greinacher, A; Haas, S; Riess, H; Schellong, SM; Schwanebeck, U; Sieder, C, 2010)
"Edoxaban is a new oral direct factor Xa inhibitor."2.75Oral direct factor Xa inhibition with edoxaban for thromboprophylaxis after elective total hip replacement. A randomised double-blind dose-response study. ( Bocanegra, T; Cohen, AT; Eriksson, BI; Puskas, D; Raskob, G; Shi, M; Weitz, JI, 2010)
" The betrixaban dosage was blinded, but enoxaparin was not."2.74A randomized evaluation of betrixaban, an oral factor Xa inhibitor, for prevention of thromboembolic events after total knee replacement (EXPERT). ( Bauer, KA; Davidson, BL; Fisher, WD; Gent, M; Gretler, DD; Huo, MH; Sinha, U; Turpie, AG, 2009)
" Consecutive patients receiving enoxaparin at a dosage of 1 mg/kg body weight/12 hours for temporary interruption of phenprocoumon were prospectively enrolled to the study."2.74How useful is determination of anti-factor Xa activity to guide bridging therapy with enoxaparin? A pilot study. ( Hammerstingl, C; Omran, H; Poetzsch, B; Tripp, C, 2009)
" In the ABW dosing group, mean patient age was 76 years, mean weight 80 kg, mean serum creatinine 1."2.74Enoxaparin dosing in the elderly using adjusted body weight. ( Dzielak, E; Glavich, W; Guzek, J; Leri, F; Scialla, S; Smego, RA; Voyce, SJ, 2009)
"Data were obtained from a randomized controlled trial (n = 118) that compared conventional dosing of enoxaparin (product label) with an individualized dosing regimen."2.74Modelling the occurrence and severity of enoxaparin-induced bleeding and bruising events. ( Atherton, JJ; Barras, MA; Duffull, SB; Green, B, 2009)
" We evaluated three dosage regimens of postoperative enoxaparin in Japanese patients undergoing elective total hip or knee arthroplasty."2.73Prevention of postoperative venous thromboembolism in Japanese patients undergoing total hip or knee arthroplasty: two randomized, double-blind, placebo-controlled studies with three dosage regimens of enoxaparin. ( Fuji, T; Fujita, S; Niwa, S; Ochi, T, 2008)
"Bleeding is associated with adverse outcome in acute coronary syndromes."2.73Bleeding and outcome in acute coronary syndrome: insights from continuous electrocardiogram monitoring in the Integrilin and Enoxaparin Randomized Assessment of Acute Coronary Syndrome Treatment (INTERACT) Trial. ( DeYoung, P; Fitchett, DH; Goodman, SG; Huynh, T; Langer, A; Weeks, A; Yan, AT; Yan, RT, 2008)
"Major bleeding was observed in nine of 260 patients (3."2.73Bridging therapy in patients on long-term oral anticoagulants who require surgery: the Prospective Peri-operative Enoxaparin Cohort Trial (PROSPECT). ( Dunn, AS; Spyropoulos, AC; Turpie, AG, 2007)
"The aim of this study was to compare an individualized dosing regimen for enoxaparin to conventional dosing."2.73Individualized compared with conventional dosing of enoxaparin. ( Atherton, JJ; Barras, MA; Duffull, SB; Green, B, 2008)
"Minor bleeding was defined as hematoma that did not require intervention."2.73Atrial fibrillation ablation in patients with therapeutic international normalized ratio: comparison of strategies of anticoagulation management in the periprocedural period. ( Arruda, M; Barrett, C; Beheiry, S; Cummings, J; Di Biase, L; Fahmy, T; Hao, S; Kanj, M; Martin, DO; Natale, A; Patel, D; Saliba, W; Schweikert, R; Wazni, OM, 2007)
"In high risk critically ill patients citrate based anticoagulation for CVVH is safe in terms of bleeding complications and transfusion requirements."2.72Safety of citrate based hemofiltration in critically ill patients at high risk for bleeding: a comparison with nadroparin. ( Boerma, EC; Kingma, WP; Postma, SR; Van der Voort, PH; Van Roon, EN, 2006)
" The primary efficacy analysis did not demonstrate any significant trend in dose-response relationship for BAY 59-7939."2.72Oral, direct Factor Xa inhibition with BAY 59-7939 for the prevention of venous thromboembolism after total hip replacement. ( Borris, L; Dahl, OE; Eriksson, BI; Haas, S; Huisman, MV; Kakkar, AK; Kälebo, P; Misselwitz, F, 2006)
"Studies in cancer patients with venous thromboembolism suggested that low molecular weight heparin may prolong survival."2.71The effect of low molecular weight heparin on survival in patients with advanced malignancy. ( Bos, MM; Büller, HR; Klerk, CP; Lensing, AW; Otten, HM; Piovella, F; Prandoni, P; Prins, MH; Richel, DJ; Smorenburg, SM; van Tienhoven, G, 2005)
" This trial shows that bemiparin started postoperatively is as effective and safe as enoxaparin started preoperatively in the prevention of venous thromboembolism in patients undergoing total knee replacement."2.71Efficacy and safety of bemiparin compared with enoxaparin in the prevention of venous thromboembolism after total knee arthroplasty: a randomized, double-blind clinical trial. ( Castellet, E; Navarro-Quilis, A; Paz-Jiménez, J; Planès, A; Rocha, E, 2003)
"Minor bleeding was more frequent in the enoxaparin group (30."2.71Randomized evaluation of the safety and efficacy of enoxaparin versus unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes receiving the glycoprotein IIb/IIIa inhibitor eptifibatide. ( Armstrong, PW; Fitchett, D; Goodman, SG; Langer, A; Tan, M, 2003)
"Ximelagatran was to be initiated within the first two postoperative days."2.71Direct thrombin inhibitor melagatran followed by oral ximelagatran in comparison with enoxaparin for prevention of venous thromboembolism after total hip or knee replacement. ( Agnelli, G; Cohen, AT; Dahl, OE; Eriksson, BI; Eskilson, C; Frison, L; Mouret, P; Nylander, I; Ogren, M; Rosencher, N, 2003)
" Three enoxaparin dosing strategies had been prescribed: therapeutic, prophylactic, or adjusted."2.71Prescribing patterns and outcomes of enoxaparin for anticoagulation of atrial fibrillation. ( Adamson, R; Khazan, M; Mathis, AS; Scheuering, S, 2003)
"We randomized 60 symptomatic pulmonary embolism patients in a 2:1 ratio to 90 days of enoxaparin as monotherapy without warfarin (N=40) or to intravenous unfractionated heparin as a "bridge" to warfarin, target INR 2."2.71Enoxaparin monotherapy without oral anticoagulation to treat acute symptomatic pulmonary embolism. ( Beckman, JA; Dunn, K; Goldhaber, SZ; Sasahara, AA, 2003)
"The risk of venous thromboembolism is high after spinal cord injury (SCI)."2.71Prevention of venous thromboembolism in the acute treatment phase after spinal cord injury: a randomized, multicenter trial comparing low-dose heparin plus intermittent pneumatic compression with enoxaparin. ( , 2003)
"Incidences of recurrence of thromboembolism and of severe bleeding were assessed at the end of this period."2.71[Multicenter, prospective study comparing enoxaparin with unfractionated heparin in the treatment of submassive pulmonary thromboembolism]. ( Baloira Villar, A; Golpe Gómez, R; Pajuelo Fernández, F; Pérez de Llano, LA; Veiga, F; Veres Racamonde, A, 2003)
" A population pharmacokinetic analysis was conducted and individual estimates of enoxaparin clearance and area under the curve were tested as prognostic factors for the occurrence of haemorrhagic episodes."2.71Population pharmacokinetics and pharmacodynamics of enoxaparin in unstable angina and non-ST-segment elevation myocardial infarction. ( Antman, EM; Baille, P; Becker, R; Bruno, R; Retout, S; Sanderink, GJ; Veyrat-Follet, C; Vivier, N, 2003)
"Melagatran 2 mg was started immediately before surgery; 3 mg was then administered postoperatively, followed by 24 mg of oral ximelagatran b."2.71The direct thrombin inhibitor melagatran followed by oral ximelagatran compared with enoxaparin for the prevention of venous thromboembolism after total hip or knee replacement: the EXPRESS study. ( Agnelli, G; Andersson, M; Cohen, AT; Dahl, OE; Eriksson, BI; Eskilson, C; Freij, A; Kälebo, P; Lassen, MR; Mouret, P; Panfilov, S; Rosencher, N, 2003)
" It is not clear if combining enoxaparin with glycoprotein IIb/IIIa inhibitors is as safe or as effective as the current standard combination of unfractionated heparin with glycoprotein IIb/IIIa inhibitors."2.71Safety and efficacy of enoxaparin vs unfractionated heparin in patients with non-ST-segment elevation acute coronary syndromes who receive tirofiban and aspirin: a randomized controlled trial. ( Ardissino, D; Bilheimer, DW; Blazing, MA; Braunwald, E; Califf, RM; de Lemos, JA; DiBattiste, PM; Fox, KA; Gardner, LH; Hasselblad, V; Lewis, EF; Palmisano, J; Pfeffer, MA; Ramsey, KE; Snapinn, SM; Verheugt, FW; White, HD, 2004)
"More bleeding was observed with enoxaparin, with a statistically significant increase in TIMI (Thrombolysis in Myocardial Infarction) major bleeding (9."2.71Enoxaparin vs unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes managed with an intended early invasive strategy: primary results of the SYNERGY randomized trial. ( Antman, EM; Armstrong, PW; Avezum, A; Aylward, P; Becker, RC; Biasucci, L; Borzak, S; Califf, RM; Cohen, M; Col, J; Ferguson, JJ; Frey, MJ; Fry, E; Goodman, S; Grines, CL; Gulba, DC; Guneri, S; Gurfinkel, E; Harrington, R; Hochman, JS; Kereiakes, DJ; Kleiman, NS; Langer, A; Leon, MB; Lopez-Sendon, JL; Mahaffey, KW; Nessel, CC; Pepine, CJ; Ruzyllo, W; Steinhubl, SR; Teirstein, PS; Toro-Figueroa, L; White, H, 2004)
" The primary efficacy endpoint was recurrent DVT (confirmed by venography or ultrasonography), and safety endpoints included bleeding and serious adverse events."2.71An open-label, comparative study of the efficacy and safety of once-daily dose of enoxaparin versus unfractionated heparin in the treatment of proximal lower limb deep-vein thrombosis. ( Araújo, GR; Dietrich-Neto, F; Karaoglan de Moura, L; Lastoria, S; Maffei, FH; Michaelis, W; Ramacciotti, E; Sandri, JL, 2004)
"When there was a suspicion of pulmonary embolism (PE), patients were evaluated with spiral computed tomography."2.71Venous thromboembolism prophylaxis after head and spinal trauma: intermittent pneumatic compression devices versus low molecular weight heparin. ( Bilsel, Y; Buyukkurt, D; Granit, V; Guloglu, R; Kizilirmak, S; Kurtoglu, M; Yanar, H, 2004)
"Warfarin dosing with a target international normalized ratio (INR) range of 1."2.71Low-dose warfarin for prevention of symptomatic thromboembolism after orthopedic surgery. ( Enyart, JJ; Jones, RJ, 2005)
" Dosage adjustments were made for patients developing renal failure."2.71Low molecular weight heparin for the prevention of hepatic veno-occlusive disease (VOD) after hematopoietic stem cell transplantation: a prospective phase II study. ( Couban, SH; Dorcas, VG; Forrest, DL; Pierce, R; Thompson, K, 2003)
"Venous thromboembolism is a frequent complication of total hip replacement."2.70A synthetic pentasaccharide for the prevention of deep-vein thrombosis after total hip replacement. ( Gallus, AS; Hoek, JA; Turpie, AG, 2001)
"Patients with unstable angina pectoris (UAP) or non-ST-segment elevation acute myocardial infarction (AMI) are at risk of death or recurrent ischemic events, despite receiving aspirin and unfractionated heparin (UFH)."2.70Prospective comparison of hemorrhagic complications after treatment with enoxaparin versus unfractionated heparin for unstable angina pectoris or non-ST-segment elevation acute myocardial infarction. ( Berkowitz, SD; Bigonzi, F; Cohen, M; Fromell, GJ; Stinnett, S, 2001)
" The general use and correct dosage of low-molecular-weight heparin, however, are still under debate."2.70Low-molecular-weight heparin in arterial reconstructive surgery: a double-blind, randomized dose-finding trial. ( Eckmann, C; Kujath, P; Misselwitz, F, 2002)
"Low-molecular-weight heparins are frequently used to treat venous thromboembolism, but optimal dosing regimens and clinical outcomes need further definition."2.70Effects of a low-molecular-weight heparin on thrombus regression and recurrent thromboembolism in patients with deep-vein thrombosis. ( Breddin, HK; Hach-Wunderle, V; Kakkar, VV; Nakov, R, 2001)
" dalteparin is associated with a low risk of major side effects and is as safe as the combination of abciximab and UFH."2.70Safety and efficacy of abciximab combined with dalteparin in treatment of acute coronary syndromes. ( Armstrong, P; Califf, R; Husted, S; James, S; Kontny, F; Niemminen, M; Pfisterer, M; Simoons, ML; Wallentin, L, 2002)
" SC weight-based dosing on off-dialysis days is a feasible regimen for further clinical thromboprophylaxis efficacy studies in hemodialysis patients."2.70Intravenous and subcutaneous weight-based dosing of the low molecular weight heparin tinzaparin (Innohep) in end-stage renal disease patients undergoing chronic hemodialysis. ( Assaid, CA; Barrett, JS; Cox, DS; Fossler, MJ; Hainer, JW; Hua, TA; Pittenger, AL; Sherrard, DJ; Stephenson, CA; Swan, SK; Williams, RM, 2002)
"This pharmacodynamic study examined weight-based dosing of the low molecular weight heparin (LMWH), tinzaparin, in heavyweight/obese subjects."2.70Dosing in heavy-weight/obese patients with the LMWH, tinzaparin: a pharmacodynamic study. ( Assaid, CA; Barrett, JS; Cox, DS; Fossler, MJ; Hainer, JW; Leathers, T; Leese, PT, 2002)
"Bleedings were all minor, mostly during hospital stay."2.69Comparison of low-molecular-weight heparin, administered primarily at home, with unfractionated heparin, administered in hospital, and subcutaneous heparin, administered at home for deep-vein thrombosis. ( Barsotti, A; Belcaro, G; Cesarone, MR; Christopoulos, D; Corsi, M; De Sanctis, MT; Incandela, L; Laurora, G; Lennox, A; Malouf, M; Nicolaides, AN; Vasdekis, S, 1999)
"The incidence of deep vein thrombosis in group 1 was 14% (14 patients, 5 proximal vein thromboses and 9 distal vein thromboses) while in group 2, no patients developed deep vein thrombosis."2.69Use of low molecular weight heparin for prevention of deep vein thrombosis in total knee arthroplasty--a study of its efficacy in an Asian population. ( Fong, YK; Lee, BP; Lo, NN; Ng, SC; Ruban, P; Seow, KH; Yeo, SJ, 2000)
" However, body weight-adjusted dosage of low-molecular-weight heparin may be cumbersome and could lead possibly to incorrect dosing."2.69Fixed-dose, body weight-independent subcutaneous LMW heparin versus adjusted dose unfractionated intravenous heparin in the initial treatment of proximal venous thrombosis. EASTERN Investigators. ( Büller, HR; Harenberg, J; Huisman, MV; Koppenhagen, K; Schmidt, JA; Tolle, A, 2000)
"Dalteparin-treated patients received a commencement bolus of 20 units/kg and a maintenance infusion at 10 units/kg/hr."2.69A controlled trial of low-molecular-weight heparin (dalteparin) versus unfractionated heparin as anticoagulant during continuous venovenous hemodialysis with filtration. ( Cumming, AR; Gallagher, L; O'Brien, JL; Reeves, JH; Santamaria, JD, 1999)
" Therefore, tinzaparin administered in a dosage of 75 U anti-Xa/kg BW 12 hours before surgery is significantly more protective against proximal DVT and safer than the standard regimen of 50 U anti-Xa/kg BW started 2 hours before surgery in patients undergoing primary elective hip arthroplasty."2.69Dose relation in the prevention of proximal vein thrombosis with a low molecular weight heparin (tinzaparin) in elective hip arthroplasty. ( Andersen, BS; Borris, LC; Ejstrud, P; Jensen, HP; Lassen, MR; Poulsen, KA, 2000)
" This study was designed to test the hypothesis that 3 months of subcutaneous dosing of ardeparin would reduce angiographic restenosis after coronary balloon angioplasty."2.69Usefulness of subcutaneous low molecular weight heparin (ardeparin) for reduction of restenosis after percutaneous transluminal coronary angioplasty. ( Gimple, LW; Herrmann, HC; Mammen, E; Winniford, M, 1999)
"Bleeding was determined according to pre-defined objective criteria for major and minor episodes."2.68Low molecular weight heparin and compression stockings in the prevention of venous thromboembolism in neurosurgery. ( Büller, HR; d'Azemar, P; Gent, M; Haley, S; Henkens, CM; Hoek, JA; Koopman, MM; Nurmohamed, MT; Que, GT; Sicurella, A; ten Cate, JW; Turpie, AG; van der Heul, C; van der Meer, J; van Riel, AM, 1996)
" This study showed that Enoxaparin administered postoperatively 30 mg every 12 hours is more effective and as safe as unfractionated heparin prophylaxis to prevent deep venous thrombosis in patients having elective total knee arthroplasty."2.68Efficacy and safety of enoxaparin versus unfractionated heparin for prevention of deep venous thrombosis after elective knee arthroplasty. Enoxaparin Clinical Trial Group. ( Colwell, CW; Gardiner, GA; Ritter, MA; Spiro, TE; Stephens, JW; Trowbridge, AA, 1995)
" However, the longer plasma half-life, better bioavailability after subcutaneous administration, and more predictable anticoagulant response of low-molecular-weight heparins make them attractive for possible home use."2.68A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis. ( Anderson, D; Demers, C; Gent, M; Ginsberg, J; Hirsh, J; Kovacs, M; Leclerc, J; Levine, M; Turpie, AG; Weitz, J, 1996)
" Safety outcomes were defined as the occurrence of major and minor haemorrhage, other adverse events and changes in laboratory parameters."2.68Efficacy and safety of postdischarge administration of enoxaparin in the prevention of deep venous thrombosis after total hip replacement. A prospective randomised double-blind placebo-controlled trial. ( Bellaud, M; Compan, D; Darmon, JY; Fagola, M; Huet, Y; Planes, A; Saliba, E; Vochelle, N; Weisslinger, N, 1996)
"However, its application to pulmonary embolism or previous episodes of thromboembolism has not been studied."2.68Low-molecular-weight heparin in the treatment of patients with venous thromboembolism. ( Baildon, R; Büller, HR; Gallus, AS; Gent, M; Ginsberg, J; Prins, MH, 1997)
"Bleeding was assessed on the basis of intraoperative blood loss, transfusion requirements, a decrease in hematocrit, and clinically identified bleeding complications."2.68Prevention of deep-vein thrombosis after total hip arthroplasty. Comparison of warfarin and dalteparin. ( Ayers, DC; Boyd, AD; Francis, CW; Johanson, NA; Kessler, C; Liebert, KM; Marder, VJ; Pellegrini, VD; Rosenberg, A; Stulberg, BN; Totterman, S, 1997)
"Of these 14 late recurrences, just one occurred in patients with postoperative DVT."2.67Low molecular weight heparin versus warfarin in the prevention of recurrences after deep vein thrombosis. ( Aiello, S; Dettori, AG; Manotti, C; Pattacini, C; Pini, M; Poli, T; Quintavalla, R; Tagliaferri, A, 1994)
"The incidence of DVT and of pulmonary embolism was 4."2.67An international multicentre study: Clivarin in the prevention of venous thromboembolism in patients undergoing general surgery. Report of the International Clivarin Assessment Group. ( Boneu, B, 1993)
"In THA patients, the rate of deep vein thrombosis (DVT) was lower with factor Xa inhibitors than LMWH."2.61Factor Xa Inhibitors and Direct Thrombin Inhibitors Versus Low-Molecular-Weight Heparin for Thromboprophylaxis After Total Hip or Total Knee Arthroplasty: A Systematic Review and Meta-Analysis. ( Cheng, K; Jia, J; Liang, Q; Sun, G; Wang, Q; Wang, Z; Wu, J, 2019)
"Betrixaban is a novel factor Xa inhibitor with unique pharmacokinetic properties, including low renal clearance, long half-life, and low peak-to-trough ratio."2.61Betrixaban for Extended Venous Thromboembolism Prophylaxis in High-Risk Hospitalized Patients: Putting the APEX Results into Practice. ( Brenner, MJ; Miller, KM, 2019)
"No significant increase in major intracranial hemorrhage (p = 0."2.58Chemical venous thromboembolism prophylaxis in neurosurgical patients: an updated systematic review and meta-analysis. ( Khan, NR; Lee, SL; Patel, PG; Sharpe, JP; Sorenson, J, 2018)
"Venous thromboembolism, specifically pulmonary embolism, is a rare complication following elective pediatric orthopedic surgery."2.58Symptomatic bilateral pulmonary embolism without deep venous thrombosis in an adolescent following arthroscopic anterior cruciate ligament reconstruction: a case report and review of the literature. ( Bourget-Murray, J; Clarke, MA; Gorzitza, S; Phillips, LA, 2018)
"Compared with people without cancer, people with cancer who receive anticoagulant treatment for venous thromboembolism (VTE) are more likely to develop recurrent VTE."2.58Anticoagulation for the initial treatment of venous thromboembolism in people with cancer. ( Akl, EA; Barba, M; Hakoum, MB; Kahale, LA; Matar, CF; Schünemann, H; Sperati, F; Terrenato, I; Tsolakian, IG; Yosuico, VE, 2018)
"Patients with cancer are at increased risk of recurrent venous thromboembolism (VTE) and bleeding."2.58Tinzaparin for Long-Term Treatment of Venous Thromboembolism in Patients With Cancer: A Systematic Review and Meta-Analysis. ( Bauersachs, R; Martínez-Zapata, MJ; Mathioudakis, AG; Mousa, SA, 2018)
"We carried out a dose-response model-based meta-analysis to assess venous thromboembolism (VTE) and bleeding with factor Xa (FXa) inhibitors (apixaban, edoxaban, rivaroxaban) and a thrombin inhibitor (dabigatran) compared with European (EU) (40 mg q."2.55Direct Oral Anticoagulants Vs. Enoxaparin for Prevention of Venous Thromboembolism Following Orthopedic Surgery: A Dose-Response Meta-analysis. ( Boyd, RA; DiCarlo, L; Mandema, JW, 2017)
"To review the evidence regarding increased enoxaparin dosing for venous thromboembolism (VTE) prophylaxis in the general trauma patient population."2.55Increased Enoxaparin Dosing for Venous Thromboembolism Prophylaxis in General Trauma Patients. ( Gales, MA; Horyna, TJ; Sandmann, EA; Walker, CK, 2017)
" With regard to dosage, for in-hospital treatment the higher dosage of 40 mg twice daily as opposed to 30 mg seems to significantly reduce the incidence of VTE without significantly affecting bleeding rate."2.52Enoxaparin venous thromboembolism prophylaxis in bariatric surgery: A best evidence topic. ( Khan, OA; Knight, WR; McGlone, ER; Parker, SG; Sufi, P, 2015)
"No major bleeding was observed in the patients treated with LMWH or warfarin and in less than 1% of those treated with aspirin."2.50Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy. ( Di Nisio, M; Otten, HM; Porreca, E; Rutjes, AW, 2014)
"Dabigatran was not superior to enoxaparin for prevention of VTE (RR 1."2.47Dabigatran and rivaroxaban for prevention of venous thromboembolism--systematic review and adjusted indirect comparison. ( Kwok, CS; Loke, YK, 2011)
"Rivaroxaban is a newly developed oral medicine that direct inhibits factor Xa for the prevention and treatment of thromboembolic disorders."2.46Rivaroxaban versus enoxaparin for thromboprophylaxis after total hip or knee arthroplasty: a meta-analysis of randomized controlled trials. ( Cao, YB; Jiang, YY; Shen, H; Zhang, JD, 2010)
" Selection of the appropriate dosage is strongly recommended."2.45Safety evaluation of enoxaparin in currently approved indications. ( Meneveau, N, 2009)
" Furthermore, there is no difference according to liver enzymes elevation and cardio-vascular adverse events."2.44[Rivaroxaban (Xarelto): efficacy and safety]. ( Arnaout, L; Bellamy, L; Chabbouh, T; Rosencher, N, 2008)
"Rivaroxaban (BAY 59-7939) is an oral, direct factor Xa inhibitor in clinical development for the prevention and treatment of venous thromboembolism (VTE)."2.44Rivaroxaban for thromboprophylaxis after orthopaedic surgery: pooled analysis of two studies. ( Bauer, KA; Borris, L; Dahl, OE; Eriksson, BI; Fisher, WD; Gent, M; Haas, S; Homering, M; Huisman, MV; Kakkar, AK; Kälebo, P; Kwong, LM; Misselwitz, F; Turpie, AG, 2007)
"Fondaparinux has been shown to be as effective as enoxaparin in the prevention of thrombosis in patients undergoing orthopedic surgery and showed similar results compared to enoxaparin or UFH in patients with deep-vein-thrombosis or pulmonary embolism."2.44Factor Xa inactivation in acute coronary syndrome. ( Barantke, M; Bonnemeier, H, 2008)
" The dosage of LMWH was performed by body weight adjustment without dose-finding studies."2.42[Treatment of thrombosis with low-molecular-weight heparin. Comparison of body weight-adjusted and fixed dosage]. ( Harenberg, J, 2003)
" Future issues that need to be addressed include refinement of indications for administration and patient selection, comparison between existing agents, evaluation of newer agents, and optimization of dosing to maximize benefit and safety in the use of these powerful new classes of drugs."2.41Glycoprotein IIb/IIIa antagonists and low-molecular weight heparin in acute coronary syndromes. ( Vernon, SM, 2001)
" As prophylaxis, reviparin 1,750 anti-XaIU once daily was as effective as unfractionated heparin 5,000IU twice daily in 1,311 patients undergoing abdominal surgery and, in a once daily dosage of 4,200 anti-XaIU, was as effective as subcutaneous enoxaparin sodium 40 mg/day or acenocoumarol in patients undergoing hip replacement surgery."2.41Reviparin: a review of its efficacy in the prevention and treatment of venous thromboembolism. ( Jarvis, B; McClellan, K; Wellington, K, 2001)
" In comparative clinical trials, this dosage demonstrated either improved efficacy and a similar haemorrhagic profile, or a similar degree of efficacy with a lower rate of haemorrhagic events, compared with unfractionated heparin 5000IU 3 times daily."2.39Enoxaparin. A reappraisal of its pharmacology and clinical applications in the prevention and treatment of thromboembolic disease. ( Goa, KL; Noble, S; Peters, DH, 1995)
" The enhanced bioavailability of these drugs, in conjunction with their prolonged half-life, makes subcutaneous therapy, in one to two daily doses, possible."2.39Low molecular weight heparins and their use in obstetrics and gynecology. ( Fejgin, MD; Lourwood, DL, 1994)
" This agent also showed sustained activity and better bioavailability characteristics than heparin."2.38Pharmacological profile of reviparin-sodium. ( Fareed, J; Hoppensteadt, D; Jeske, W, 1993)
" 27 patients (n = 68 samples) were evaluated and combined with published data (n = 319 samples from 35 patients) using population pharmacokinetic (popPK) modelling."1.91The effect of renal impairment and obesity on anti-Xa peak and trough levels in patients receiving therapeutic doses of nadroparin: a comparison with control patients. ( Hackeng, CM; Knibbe, CAJ; Mast, L; Peeters, MYM; Söhne, M; van den Broek, MPH, 2023)
"This single-center study suggests that DOACs are both safe and efficacious for the treatment of VTE in children with cancer."1.91Safety and Efficacy of Direct Oral Anticoagulants for Treatment of Venous Thromboembolism in Pediatric Oncology Patients. ( Branchford, B; Liegl, M; Malec, L; Scheuermann, A; Simpson, P, 2023)
" capped (< 1 mg/kg) enoxaparin dosing regimen."1.91Management of venous thromboembolism in morbidly obese patients: a 10-year review. ( Donarelli, C; Ho, P; Khattak, Z; Kwok, A; Lai, J; Lim, HY; Lui, B; Wee, B, 2023)
" There is concern whether body mass index (BMI)-based enoxaparin dosing consistently achieves prophylactic targets in patients with severe obesity."1.91Effectiveness of Body Mass Index-Based Prophylactic Enoxaparin Dosing in Bariatric Surgery Patients. ( Chang, CK; Herrmann, DJ; Higgins, RM; Kindel, T; Peppard, WJ; Rein, L, 2023)
"Dalteparin was not stopped in any women."1.91Prophylactic Dose of Dalteparin in Pregnant Women With History of Venous Thromboembolisms and/or Thrombophilia: Real-World Data. ( Kozak, M; Novak, A; Novak, P; Šabović, M, 2023)
" After observing higher than expected VTE rates within our center's Trauma Quality Improvement Program data, we instituted a change in our VTE prophylaxis protocol, moving to enoxaparin dosing titrated by anti-Xa levels."1.72Enoxaparin titrated by anti-Xa levels reduces venous thromboembolism in trauma patients. ( Collier, BR; Faulks, ER; Gates, RS; Gillen, JR; Lollar, DI; Smith, J, 2022)
"Anti-Xa-guided enoxaparin dosing for VTE prophylaxis in neurosurgical patients may help prevent major bleeding."1.72Supraprophylactic Anti-Factor Xa Levels Are Associated with Major Bleeding in Neurosurgery Patients Receiving Prophylactic Enoxaparin. ( Cua, S; May, CC; Powers, CJ; Smetana, KS, 2022)
" Weight-based enoxaparin dosing was administered using a pharmacy-driven protocol, which later included a low molecular weight, anti-Xa level directed-dose adjustment strategy."1.72Outcomes of Prophylactic Enoxaparin Against Venous Thromboembolism in Hospitalized Children. ( Bennett, E; Delgado-Corcoran, C; Faustino, EV; Heyrend, C; Pannucci, CJ; Wilcox, R, 2022)
"Apixaban is a direct factor Xa inhibitor that may be intended as an ideal alternative for the management of HIT."1.72An Open-Label, Single-Arm, Pilot Intervention Study to Assess the Efficacy and Safety of Apixaban in Heparin-Induced Thrombocytopenia. ( Ansarinejad, N; Balouchzehi, S; Farasatinasab, M; Moghaddam, OM; Mohammadi, M; Nasiripour, S, 2022)
" Standard trauma prophylaxis dosing with enoxaparin 30 mg twice daily may be inadequate to prevent VTEs."1.72Impact of Increased Enoxaparin Dosing on Anti-Xa Levels for Venous Thromboembolism Prophylaxis in Trauma Patients. ( Bellfi, LT; Boudreau, R; Greiffenstein, P; Hunt, JP; Marr, A; Mosier, W; Rueb, N; Schoen, J; Smith, A; Stuke, L; Zimmerman, SA, 2022)
"Risk of bleeding was assessed with the Academic Research Consortium for High Bleeding Risk (ARC-HBR) scale, and risk of major bleeding in patients with NSTEMI was additionally assessed with the CRUSADE scale."1.72Features of Parenteral Anticoagulant Therapy in Patients With Myocardial Infarction According to the Russian Register of Acute Myocardial Infarction - REGION-IM. ( Boytsov, SA; Erlikh, AD; Gulyan, RG; Pevsner, DV; Shakhnovich, RM; Tereschenko, SN, 2022)
" There is no guideline regarding enoxaparin bridging in LVAD patients and a dosing strategy to ensure efficacy and safety is uncertain."1.72Enoxaparin Use and Adverse Events in Outpatients With a Continuous Flow Left Ventricular Assist Device at a Single Institution. ( Alvarez, PA; Bernard, AM; Bream-Rouwenhorst, HR; Briasoulis, A; Czerniak, LC; Horner, KE, 2022)
"Central venous catheter (CVC) related venous thrombosis (VT) after pediatric cardiac surgery increases morbidity and mortality."1.72Enoxaparin Reduces Catheter-associated Venous Thrombosis After Infant Cardiac Surgery. ( Alfieris, GM; Cholette, JM; Hutchinson, DJ; Stauber, SD; Swartz, MF; Taillie, ER, 2022)
" The only registered antidote for ENX, protamine sulfate (PS), has 60% efficacy and can cause severe adverse side effects."1.62Reversal Activity and Toxicity of Heparin-Binding Copolymer after Subcutaneous Administration of Enoxaparin in Mice. ( Kalaska, B; Miklosz, J; Mogielnicki, A; Pawlak, D; Swieton, J; Szczubialka, K; Yusa, SI, 2021)
" Enoxaparin dosing and corresponding anti-factor Xa levels were collected."1.62Evaluation of the Efficacy of Enoxaparin in the Neonatal Intensive Care Unit. ( Abdel-Rasoul, M; Magers, J; Prusakov, P; Song, D, 2021)
" Enoxaparin dosing was nearly double the recommended starting doses for secondary thromboprophylaxis."1.62Thromboprophylaxis in congenital nephrotic syndrome: 15-year experience from a national cohort. ( Dobbie, LJ; Eskell, L; Lamb, A; Ramage, IJ; Reynolds, BC, 2021)
"Major bleeding was defined by INTERMACS criteria."1.62Comparison of Outcomes of Enoxaparin Bridge Therapy in HeartMate II versus HeartWare HVAD Recipients. ( Ahuja, T; Arnouk, S; Gidea, C; Lewis, TC; Moazami, N; Papadopoulos, J; Patel, M; Reyentovich, A; Smith, DE, 2021)
"The use of initial weight-based enoxaparin dosing in trauma patients routinely achieved the prespecified target anti-Xa goal."1.62Achievement of goal anti-Xa activity with weight-based enoxaparin dosing for venous thromboembolism prophylaxis in trauma patients. ( Huang, E; Martinez-Quinones, P; Robinson, T; Taylor, A; Waller, J; White, C, 2021)
"Patients with oesophageal cancer undergoing neoadjuvant chemoradiotherapy and surgery are at substantial risk of thromboembolic and bleeding events throughout all stages of treatment."1.56Thromboembolic and bleeding complications in patients with oesophageal cancer. ( Büller, HR; Hovenkamp, A; Hulshof, MCCM; Kamphuisen, PW; Middeldorp, S; Mulder, FI; van Berge Henegouwen, MI; van Es, N; van Laarhoven, HWM, 2020)
" Various prophylaxis dosing strategies have been investigated."1.56Safety and Efficacy of High-Dose Unfractionated Heparin Versus High-Dose Enoxaparin for Venous Thromboembolism Prevention in Morbidly Obese Hospitalized Patients. ( Barber, A; Chen, SL; Jones, E; Mason, SW; Moll, S; Northam, K, 2020)
" Concomitant administration of single-dose DS-1040 with multiple-dose aspirin, multiple-dose clopidogrel, or single-dose enoxaparin, consistent with clinically relevant dose regimens, was safe and well tolerated with no serious treatment-emergent adverse events (TEAEs), TEAEs leading to discontinuation, bleeding-related TEAEs, and no significant changes in coagulation parameters."1.56Safety and Pharmacokinetics of DS-1040 Drug-Drug Interactions With Aspirin, Clopidogrel, and Enoxaparin. ( Dishy, V; Kobayashi, F; Kochan, J; Limsakun, T; McPhillips, P; Mendell, J; Orihashi, Y; Pav, J; Pizzagalli, F; Rambaran, C; Vandell, AG; Warren, V; Zhou, J, 2020)
" Given the favourable safety profile of NOACs (especially if a reduced dosage of Apixaban or Rivaroxaban is initiated after at least six months of therapeutic anticoagulation), extended oral anticoagulation of indefinite duration should be considered for all patients with intermediate risk of recurrence."1.56[Antithrombotic Treatment of Pulmonary Embolism]. ( Ebner, M; Lankeit, M, 2020)
"In patients with renal failure, enoxaparin 20 mg SC daily resulted in a 5."1.51Enoxaparin 20 mg for thromboprophylaxis in severe renal impairment. ( Chamoun, N; Karaoui, LR; Salameh, P; Tawil, S, 2019)
"Geographic region, patient age, gender, deep vein thrombosis prophylaxis strategy, and complications were obtained."1.51Utilization Patterns, Efficacy, and Complications of Venous Thromboembolism Prophylaxis Strategies in Primary Hip and Knee Arthroplasty as Reported by American Board of Orthopedic Surgery Part II Candidates. ( Gottschalk, MB; Pour, AE; Roberson, JR; Runner, RP; Staley, CA, 2019)
"Current treatment dose of enoxaparin is based on total body weight (TBW), however dosage in obesity remains unclear."1.51Evaluation of weight based enoxaparin dosing on anti-Xa concentrations in patients with obesity. ( Barras, M; van Oosterom, N; Winckel, K, 2019)
" One patient required a switch to fondaparinux due to an adverse reaction."1.51Safety and Efficacy of Tinzaparin Anticoagulation during Nocturnal Hemodialysis. ( Akbari, A; Brown, PA; Bugeja, A; Harris, S; Krepelka, T; Liberty, C; McCormick, B; St-Cyr, G, 2019)
"The three most common cancer diagnoses were lung (21%), colorectal (14%), and breast (14%)."1.48Retrospective comparison of low molecular weight heparin vs. warfarin vs. oral Xa inhibitors for the prevention of recurrent venous thromboembolism in oncology patients: The Re-CLOT study. ( Alzghari, SK; Baty, KA; Evans, MF; Garza, JE; Hashimie, YF; Herrington, JD; Seago, SE; Shaver, C, 2018)
" The risk of under dosing seems less predictable; therefore, anti-Xa assay may be useful in severe clinical situations that require higher anticoagulant activity."1.48Can we reliably predict the level of anticoagulation after enoxaparin injection in elderly patients with renal failure? ( Corrà, L; Di Francesco, V; Facchinetti, R; Fantin, F; Fontana, G; Pellizzari, L; Sepe, A; Zamboni, M, 2018)
"Adults with active cancer and an acute VTE were included."1.48Once-Daily Versus Twice-Daily Enoxaparin for the Treatment of Acute Venous Thromboembolism in Cancer Patients. ( Anselmo, L; Borrego, ME; Burnett, A; Fuller, K; Jakeman, B; Malecki, S, 2018)
"Cancer is a known hypercoagulable state that leads to an increased risk of venous thromboembolism (VTE)."1.48Anticoagulation prescribing patterns in patients with cancer. ( Ahuja, T; Cirrone, F; Green, D; Papadopoulos, J; Raco, V; Xiang, E, 2018)
"Dabigatran etexilate is an oral anticoagulant recognized as noninferior to LMWH."1.48Incidence of symptomatic venous thromboembolism in 2372 knee and hip replacement patients after discharge: data from a thromboprophylaxis registry in Montreal, Canada. ( Banica, A; Benoit, B; Delisle, J; Fernandes, JC; Laflamme, GY; Malo, M; Nguyen, H; Ranger, P; Senay, A; Trottier, M, 2018)
"Standard low-molecular-weight heparin dosing may be suboptimal for venous thromboembolism prophylaxis."1.48Inability to predict subprophylactic anti-factor Xa levels in trauma patients receiving early low-molecular-weight heparin. ( Clark, AT; Cripps, MW; Cunningham, HB; Eastman, AL; Huang, E; Imran, JB; Kacir, CD; Koshy, JP; Madni, TD; Minshall, CT; Rizk, P; Taveras, LR, 2018)
"Funded studies reported less pulmonary embolisms, fewer events of major bleeding, and significantly less 90-day mortality compared with nonfunded studies."1.48Differences in Reported Outcomes in Industry-Funded vs Nonfunded Studies Assessing Thromboprophylaxis After Total Joint Arthroplasty. ( Azboy, I; Groff, H; Parvizi, J, 2018)
": Lupus anticoagulant hypoprothrombinemia syndrome (LAHS) is a rare disorder characterized by development of lupus anticoagulant and antiprothrombin antibodies."1.48Fatal pulmonary embolism and pulmonary hemorrhage in lupus anticoagulant hypoprothrombinemia syndrome: a case report and review of literature. ( Chen, X; Cunningham, MT; Nedved, D; Plapp, FV, 2018)
"Dalteparin is a safe and effective anticoagulant when used for paediatric home HD."1.48Dalteparin anticoagulation in paediatric home haemodialysis. ( Hothi, DK; Lutkin, M; Stronach, L; Yadav, P, 2018)
"In the Hokusai VTE Cancer study, 1050 patients with cancer and acute VTE were randomized to oral edoxaban or subcutaneous dalteparin for at least 6 months and up to 12 months."1.48[Treatment of cancer-associated venous thromboembolism]. ( Di Nisio, M, 2018)
" Once-daily dosing was associated with a lower bleeding risk as compared with twice-daily."1.46Major bleeding risks of different low-molecular-weight heparin agents: a cohort study in 12 934 patients treated for acute venous thrombosis. ( Biedermann, JS; Cannegieter, SC; Kruip, MJHA; Lijfering, WM; Reitsma, PH; van der Meer, FJM; van Rein, N; Vermaas, HW; Wiersma, N, 2017)
"The rate of VTE recurrences was similar in both subgroups."1.46Once versus twice daily enoxaparin for the initial treatment of acute venous thromboembolism. ( Bascuñana, J; Bergmann, JF; Bortoluzzi, C; Ferrazzi, P; Giorgi-Pierfranceschi, M; López-Reyes, R; López-Sáez, JB; Monreal, M; Suriñach, JM; Trujillo-Santos, J, 2017)
" The changes in anti-factor Xa activity due to plasmapheresis altered the final enoxaparin dosage required to remain in the therapeutic range of 0."1.46Effect of Plasmapheresis on the Anti-Factor Xa Activity of Enoxaparin in an Obese Adolescent Patient. ( Higgins, KL; Noda, C; Rahawi, KW; Stultz, JS, 2017)
"In 2011, Memorial Sloan Kettering Cancer Center (MSKCC) implemented the following guidelines in this setting: administer full dose enoxaparin for a platelet count > 50,000/mcL, half-dose enoxaparin for a platelet count of 25,000-50,000/mcL, and hold anticoagulation for a platelet count < 25,000/mcL."1.46Enoxaparin dose reduction for thrombocytopenia in patients with cancer: a quality assessment study. ( Mantha, S; Miao, Y; Parameswaran, R; Soff, GA; Wills, J, 2017)
"Adherence to FDA-approved dosing for the direct oral anticoagulants (DOACs) based on renal function, hepatic function, and concomitant medications in a real-world setting has not been evaluated."1.46Appropriateness of direct oral anticoagulant dosing for venous thromboembolism treatment. ( Bohm, N; Duckett, A; Fisher, S; Tran, E, 2017)
"Tranexamic acid (TXA) is an antifibrinolytic that reduces blood loss after THA and TKA."1.43Balancing Thromboprophylaxis and Bleeding in Total Joint Arthroplasty: Impact of Eliminating Enoxaparin and Predonation and Implementing Pneumatic Compression and Tranexamic Acid. ( Campbell, JC; Mirocha, JM; Sharfman, ZT; Spitzer, AI, 2016)
"Apixaban is a new oral anticoagulant with the potential to overcome these limitations."1.43Apixaban versus enoxaparin in the prevention of venous thromboembolism following total knee arthroplasty: a single-centre, single-surgeon, retrospective analysis. ( Dickison, DM; King, DA; Pow, RE; Vale, PR, 2016)
" Standard FDA-approved enoxaparin dosing in this population results in a high incidence of above-goal anti-Xa levels, but its association with bleeding remains unclear."1.43Evaluation of Enoxaparin Dosing as a Risk Factor for Bleeding in Lung Transplant Recipients. ( Bain, KB; Deal, EN; Hachem, RR; Iuppa, JA; Sofjan, AK; Witt, CA; Yusen, RD, 2016)
" The VTE rate when enoxaparin sodium is dosed by anti-factor Xa (anti-Xa) trough level is not well described."1.43Association Between Enoxaparin Dosage Adjusted by Anti-Factor Xa Trough Level and Clinically Evident Venous Thromboembolism After Trauma. ( Barmparas, G; Chung, K; Dhillon, N; Gewertz, BL; Harada, MY; Ko, A; Ley, EJ; Margulies, DR; Mason, R; Yim, DA, 2016)
" The usage of enoxaparin for venous thromboembolism prophylaxis is safe for Japanese patients after gastrectomy."1.43Safety and Effectiveness of Enoxaparin as Venous Thromboembolism Prophylaxis after Gastric Cancer Surgery in Japanese Patients. ( Kusanagi, H; Yanagita, T, 2016)
"Early enoxaparin-based anticoagulation may be a safe option in trauma patients with blunt solid organ injury."1.42Early thromboembolic prophylaxis in patients with blunt solid abdominal organ injuries undergoing nonoperative management: is it safe? ( Friese, RS; Green, DJ; Gries, L; Harrison, C; Joseph, B; Kulvatunyou, N; Lubin, D; O'Keeffe, T; Pandit, V; Rhee, P; Tang, A; Zangbar, B, 2015)
"Active bleeding was documented by contrast enhanced-multidetector row computed tomography (CE-MDCT)."1.42Role of percutaneous transcatheter embolization (PTE) in the treatment of spontaneous bleeding associated with anticoagulant therapy. ( Carrafiello, G; Floridi, C; Golia, E; Grassi, R; Iadevito, I; Ierardi, AM; Pellegrino, C; Perillo, A; Petrillo, M; Pinto, A; Rotondo, A, 2015)
"Ninety-nine morbidly obese patients (body mass index [BMI] higher than 40 kg/m(2) or total body weight more than 150 kg) who received at least three doses of the standard treatment dosage of enoxaparin and had steady-state antifactor Xa peak levels between April 2009 and January 2014."1.42Monitoring Enoxaparin with Antifactor Xa Levels in Obese Patients. ( Ballew, A; Duong, HN; Lee, YR; Vega, JA, 2015)
"Intrahepatic bleeding is exceptional and only very few cases have been described."1.40Fatal intrahepatic hemorrhage after nadroparin use for total hip arthroplasty. ( Bonsignore, A; De Stefano, F; Palmiere, C; Pizzorno, E; Ventura, F, 2014)
"Obesity increases the risk for venous thromboembolism (VTE), but whether high-dose thromboprophylaxis is safe and effective in morbidly obese inpatients is unknown."1.40Efficacy and safety of high-dose thromboprophylaxis in morbidly obese inpatients. ( Deal, EN; Gage, BF; Milligan, PE; Thoelke, MS; Wang, TF; Wong, CA, 2014)
"Age, critical illness, and timing of AT3 had no effect on time to therapeutic anti-Xa levels."1.40Retrospective evaluation of antithrombin III supplementation in neonates and infants receiving enoxaparin for treatment of thrombosis. ( Corder, A; Held, K; Oschman, A, 2014)
"Dalteparin 5000 U/day was used in both groups."1.40The value of extended preoperative thromboprophylaxis with dalteparin in patients with ovarian cancer qualified to surgical treatment. ( Dzieciuchowicz, L; Krasińska, B; Krasiński, Z; Pawlaczyk, K; Staniszewski, R; Szpurek, D; Urbanek, T; Wójcicka, K, 2014)
"Venous thromboembolism and subsequent pulmonary embolism are frequent and sometimes fatal complications in patients after surgical interventions."1.39[Compliance of patients undergoing thromboprophylaxis with enoxaparin: the COMFORT study]. ( Guschmann, M; Kaiser, J; Rübenacker, S, 2013)
" In most patients with end-stage renal disease (ESRD), prophylactic dosage of enoxaparin does not appear to be associated with an increased bleeding risk and can be used without the need for monitoring and adjustment of regimens."1.39Use of enoxaparin in end-stage renal disease. ( Coppola, B; Lai, S, 2013)
"Enoxaparin dosing for patients with morbid obesity is uncertain, and therefore, an elevated incidence of bleeding may exist in this group."1.39Assessment of bleeding events associated with short-duration therapeutic enoxaparin use in the morbidly obese. ( Deal, EN; Hagopian, JC; Hollands, JM; Riney, JN, 2013)
" The aim of this retrospective study was to measure the therapeutic response to standard dosing with LMWH (using anti-Xa) in patients after ablative and reconstructive surgery for head and neck cancer, and to review the associated risk of bleeding."1.39Low molecular weight heparin in patients undergoing free tissue transfer following head and neck ablative surgery: review of efficacy and associated complications. ( Eley, KA; Parker, RJ; Watt-Smith, SR, 2013)
"As major bleeding has modifiable risk factors and is associated with in-hospital mortality, strategies to mitigate these factors should be evaluated in critically ill patients."1.39Risk factors and impact of major bleeding in critically ill patients receiving heparin thromboprophylaxis. ( Albert, M; Arnold, DM; Ashley, BJ; Cook, D; Crowther, M; Dodek, P; Finfer, S; Fowler, R; Heels-Ansdell, D; Karachi, T; Khwaja, K; Lauzier, F; Lopes, RD; McIntyre, L; Nates, JL; Ostermann, M; Rabbat, C; Skrobik, Y; Zarychanski, R; Zytaruk, N, 2013)
"However, bleeding was more prominent in the fondaparinux group compared with the enoxaparin group at an equipotent dose for anti-Xa activity."1.38Enoxaparin and fondaparinux attenuates endothelial damage in endotoxemic rats. ( Aihara, K; Iba, T; Kayhanian, H; Ohike, T; Okamoto, K; Tajirika, T; Watanabe, S, 2012)
"Among patients with cancer-related VTE, 59."1.38Management and adherence to VTE treatment guidelines in a national prospective cohort study in the Canadian outpatient setting. The Recovery Study. ( Blostein, M; Faucher, JP; Gamble, G; Game, M; Gordon, W; Kagoma, PK; Kahn, SR; Komari, N; Laverdière, D; Martineau, J; McLeod, A; Mills, A; Miron, MJ; Schulman, S; Springmann, V; Stewart, JA; Strulovitch, C, 2012)
" Inappropriate dosing of LMWH suggested by subtherapeutic and supratherapeutic antifactor Xa levels were very high in patients with different levels of kidney dysfunction."1.38Are low-molecular-weight heparins appropriately dosed in patients with CKD stage 3 to 5? ( Altun, B; Arici, M; Buyukasik, Y; Erdem, Y; Kocak, T; Yildirim, T; Yilmaz, R, 2012)
" The aim of this prospective study was to determine the lowest single bolus dose of low-molecular-weight heparin nadroparin for safe and effective HD in patients with a bleeding risk."1.37The individually optimized bolus dose of nadroparin is safe and effective in diabetic and nondiabetic patients with bleeding risk on hemodialysis. ( Jelicic, I; Kovacic, V; Ljutic, D; Radic, J; Sain, M, 2011)
"In short-term (up to 2 weeks) treatment, bleeding and VTE were more frequent than in long-term treatment."1.37Prolonged thromboprophylaxis with enoxaparin in early neurological rehabilitation. ( Kienitz, C; Lang, A; Rollnik, JD; Wetzel, P, 2011)
"Primary end point was amount of valve thrombus at 30 days."1.37Effectiveness of dabigatran etexilate for thromboprophylaxis of mechanical heart valves. ( Abel, S; Camp, CL; Ereth, MH; McKellar, SH; Schaff, HV; Suri, RM, 2011)
" Few standards exist for delineating the optimal dosing strategy for VTE prevention in obese patients, especially in the setting of major surgery or trauma."1.37Implementation of an enoxaparin protocol for venous thromboembolism prophylaxis in obese surgical intensive care unit patients. ( Barton, RG; Kimball, EJ; Ludwig, KP; Mone, M; Simons, HJ, 2011)
" Enoxaparin was dosed as 1 mg/kg regardless of body weight without maximum."1.36Obesity in patients with non-ST-segment elevation acute coronary syndromes: results from the SYNERGY trial. ( Antman, EM; Aylward, PE; Becker, RC; Califf, RM; Col, JJ; Ducas, J; Ferguson, JJ; Gallo, R; Goodman, SG; Langer, A; Levine, GN; Mahaffey, KW; Spinler, SA; Tonev, ST; White, HD, 2010)
"Hospitalized cancer patients are at an increased risk for venous thromboembolism (VTE) and it is recommended they receive pharmacologic prophylaxis unless otherwise contraindicated."1.36Retrospective evaluation of venous thromboembolism prophylaxis in the adult cancer population. ( Liu, CY; Reeves, D, 2010)
"A model-based approach was used to integrate data from a phase II study in order to provide a quantitative rationale for selecting the apixaban dosage regimen for a phase III trial."1.36Quantification of apixaban's therapeutic utility in prevention of venous thromboembolism: selection of phase III trial dose. ( Feng, Y; Leil, TA; Mohan, P; Paccaly, A; Pfister, M; Zhang, L, 2010)
"In patients receiving oral anticoagulant therapy with a target INR of 2,0-3,0 and at an intermediate risk of thromboembolic events who require interruption of oral anticoagulant therapy a half therapeutic dose of enoxaparin seems to be safe and effective for bridging."1.36Bridging with enoxaparin using a half-therapeutic dose regimen: safety and efficacy. ( Essers, E; Gottstein, S; Klamroth, R; Landgraf, H, 2010)
"Dalteparin was used as a reference compound."1.36Evaluation of AR-H067637, the active metabolite of the new direct thrombin inhibitor AZD0837, in models of venous and arterial thrombosis and bleeding in anaesthetised rats. ( Elg, M; Johansson, K; Kjaer, M; Pehrsson, S, 2010)
" They analyzed rates of documented symptomatic venous thromboembolism (VTE) (deep vein thrombosis and pulmonary embolism) confirmed by objective methods, major bleeding, death, thrombocytopenia, and other adverse events."1.35Evaluation of the effectiveness and safety of bemiparin in a large population of orthopedic patients in a normal clinical practice. ( Fontcuberta, J; Gómez-Outes, A; Martínez-González, J; Otero-Fernández, R; Rocha, E, 2008)
"Despite a lack of clear recommendations to guide decision-making, reductions in enoxaparin sodium dosage in the elderly and in patients with mild and moderate renal dysfunction are common in patients with acute coronary syndrome."1.35Factors associated with bleeding in elderly hospitalized patients treated with enoxaparin sodium : a prospective, open-label, observational study. ( Beckerman, P; Ben-Artzi, M; Ben-Yehuda, A; Haber, G; Levin, A; Muszkat, M; Varon, D, 2009)
"The fibrinogen level was maintained at significantly better levels, and the elevation of alanine aminotransferase was significantly suppressed in enoxaparin group (P < 0."1.35Enoxaparin attenuates endothelial damage with less bleeding compared with unfractionated heparin in endotoxemic rats. ( Iba, T; Takayama, T, 2009)
" Therefore, we believe that intravenous enoxaparin is a safe alternative to unfractionated heparin in both settings."1.35Safety of enoxaparin versus unfractionated heparin during percutaneous coronary intervention. ( Cheong, BY; Díez, JG; Ferguson, JJ; Medina, HM; O'Meallie, L, 2009)
"To evaluate how enoxaparin is dosed in contemporary clinical practice as a function of patients' total body weight (TBW) and body mass index (BMI), and to determine any association between dose and major bleeding."1.35Weight-based dosing of enoxaparin in obese patients with non-ST-segment elevation acute coronary syndromes: results from the CRUSADE initiative. ( Alexander, KP; Gibler, WB; Ohman, EM; Ou, FS; Peterson, ED; Pollack, CV; Roe, MT; Spinler, SA, 2009)
" While patients with renal impairment have a higher risk of bleeding and dosing of heparins is more difficult, there are no specific recommendations for bridging the latter patients."1.35Bridging of oral anticoagulation with low-molecular-weight heparin: experience in 373 patients with renal insufficiency undergoing invasive procedures. ( Hammerstingl, C; Omran, H, 2009)
"But dabigatran was associated with surgical wound seepage in 7% of patients, versus 4."1.35Dabigatran: new drug. Continue to use heparin, a better-known option. ( , 2009)
"Major bleedings were reported as secondary endpoints in only two hospitalized patients."1.35[Prophylaxis of deep vein thrombosis with enoxaparin 40 mg in outpatients compared to hospitalized medically ill patients]. ( Kröger, K, 2009)
"Important CKD disagreements occur in approximately 20% of acute coronary syndrome patients, affecting dosing adjustments in those already susceptible to bleeding."1.35Cockcroft-Gault versus modification of diet in renal disease: importance of glomerular filtration rate formula for classification of chronic kidney disease in patients with non-ST-segment elevation acute coronary syndromes. ( Alexander, KP; Chen, AY; Gibler, WB; Harrington, RA; Melloni, C; Newby, LK; Ohman, EM; Peterson, ED; Roe, MT; Spinler, SA; Szczech, LA, 2008)
"Oral rivaroxaban (BAY 597939) is a new, highly selective and potent direct factor-Xa (FXa) inhibitor with a predictable pharmacodynamic and pharmacokinetic profile and could therefore be an attractive antithrombotic drug."1.34Prevention and treatment of experimental thrombosis in rabbits with rivaroxaban (BAY 597939)--an oral, direct factor Xa inhibitor. ( Biemond, BJ; Buetehorn, U; Büller, HR; Friederich, PW; Levi, M; Perzborn, E, 2007)
" However, further studies are needed to validate the dose-response relationship and further support the clinical utility of factor VIIa in this life-threatening situation."1.34Recombinant activated factor VII treatment of retroperitoneal hematoma in a patient with renal failure receiving enoxaparin and clopidogrel. ( Al Askar, A; Al Shimemeri, A; Arabi, Y; Cherfan, A, 2007)
" In 35 patients (34%) with renal impairment (creatinine clearance <50 ml/min), LMWH dosage was halved."1.34Periprocedural bridging therapy with low-molecular-weight heparin in chronically anticoagulated patients with prosthetic mechanical heart valves: experience in 116 patients from the prospective BRAVE registry. ( Hammerstingl, C; Omran, H; Schmidt, H; Tripp, C; von der Recke, G, 2007)
" The extent to which bleeding risk is attributable to excess dosing of enoxaparin is unclear."1.34Enoxaparin dosing and associated risk of in-hospital bleeding and death in patients with non ST-segment elevation acute coronary syndromes. ( Alexander, KP; Chen, AY; Gibler, BW; LaPointe, NM; Lytle, BL; Ohman, ME; Peterson, ED; Pollack, CV; Roe, MT, 2007)
" An initial dosage of 1."1.34Enoxaparin use in the neonatal intensive care unit: experience over 8 years. ( Chan, AK; Knoppert, DC; Lee, DS; Malowany, JI; Pepelassis, D, 2007)
"Discontinuing LMWH more than 12 hours before delivery is safe in relation to maternal hemorrhagic complications."1.33The safety of low molecular weight heparin therapy during labor. ( Kupferminc, MJ; Landsberg, JA; Lessing, JB; Many, A; Maslovitz, S; Varon, D, 2005)
"Hemorrhage was documented in a total of 94 patients (17."1.33Hemorrhagic complications in patients treated with anticoagulant doses of a low molecular weight heparin (enoxaparin) in routine hospital practice. ( Elis, A; Ellis, MH; Hadari, R; Kovlenko, I; Kozmiakova, M; Shapira, S; Tchuvrero, N; Zissin, R, 2006)
"12 patients (2,6%) had pulmonary embolism and 8 of them (1,7%) had died."1.32[Venous thromboembolism prophylaxis with low molecular weight heparins in polytraumatized patients in intensive care unit (extended serie)]. ( Akar, U; Büyükkurt, CD; Dural, CA; Güloğlu, R; Kurtoğlu, M, 2003)
"To describe dosing practices and to identify risk factors for bleeding in patients with an acute coronary syndrome (ACS) who received treatment with enoxaparin."1.32Dosing practices and risk factors for bleeding in patients receiving enoxaparin for the treatment of an acute coronary syndrome. ( Douketis, JD; Forbes, L; Foster, GA; Macie, C, 2004)
"Outpatient treatment of deep venous thrombosis (DVT) with low molecular weight heparin (LMWH) seems as safe and effective as inpatient treatment with unfractionated heparin (UFH)."1.31Home treatment of deep venous thrombosis with low molecular weight heparin: Long-term incidence of recurrent venous thromboembolism. ( Ferrer, R; Grau, E; Medrano, J; Pastor, E; Real, E; Selfa, S; Tenias, JM, 2001)
"Home treatment of deep vein thrombosis (DVT) has been shown to be safe and effective."1.31Eligibility for home treatment of deep vein thrombosis: a prospective study in 202 consecutive patients. ( Beyer, J; Schellong, SM; Schmidt, B; Schröder, HE; Schwarz, T, 2001)
" Prospective studies need to be conducted to define the drug's role and dosage adjustments in these patients."1.31Enoxaparin and bleeding complications: a review in patients with and without renal insufficiency. ( Barnes, JF; Gerlach, AT; Pickworth, KK; Seth, SK; Tanna, SB, 2000)
"Major bleeding was defined as a postoperative drop of > or = 5 g/dL) of hemoglobin."1.31Plasma tissue factor pathway inhibitor levels as a marker for postoperative bleeding after enoxaparin use in deep vein thrombosis prophylaxis in orthopedics and general surgery. ( Abdullah, H; Camblin, J; Fareed, J; Hakki, SI; Hamadeh, O; Hoppensteadt, DA; Nasseri, AF; Wright, T, 2000)
"The observed recurrence rate of 0."1.31Should patients with deep vein thrombosis alone be treated as those with concomitant asymptomatic pulmonary embolism? A prospective study. ( Bonet, M; Büller, H; Fraile, M; Lensing, AW; Monreal, M; Muchart, J; Roncales, J, 2002)
"Three patients (0."1.30The incidence of symptomatic venous thromboembolism during and after prophylaxis with enoxaparin: a multi-institutional cohort study of patients who underwent hip or knee arthroplasty. Canadian Collaborative Group. ( Geerts, WH; Gent, M; Ginsberg, JS; Hirsh, J; Leclerc, JR, 1998)
" LMWH allows for consistent dosing in postoperative patients without the need for laboratory monitoring."1.30Intrahepatic hemorrhage after use of low-molecular-weight heparin for total hip arthroplasty. ( Houde, JP; Steinberg, G, 1999)
" This agent also showed sustained activity and better bioavailability characteristics than heparin."1.29Biochemical and pharmacologic profile of low molecular weight heparin (LU 47311, Clivarin). ( Ahsan, A; Fareed, J; Hoppensteadt, D; Jeske, W; Lojewski, B; Walenga, JM, 1993)
"During all low-dose treatments, marked thrombus formation occurred in the extracorporeal circuit, and in 2, the circuit clotted within the study period."1.29Anticoagulation with low molecular weight heparin (Fragmin) during continuous hemodialysis in the intensive care unit. ( Davison, AM; Douglas, JT; Jeffrey, RF; Khan, AA; Will, EJ, 1993)

Research

Studies (754)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's63 (8.36)18.2507
2000's285 (37.80)29.6817
2010's301 (39.92)24.3611
2020's105 (13.93)2.80

Authors

AuthorsStudies
Zhao, M1
Bao, Y1
Jiang, C1
Chen, L1
Xu, L2
Liu, X1
Li, J2
Yang, Y1
Jiang, G1
She, Y1
Chen, Q1
Shen, L1
Chen, C2
Mast, L1
Peeters, MYM1
Söhne, M2
Hackeng, CM1
Knibbe, CAJ1
van den Broek, MPH1
Mulder, FI2
Hovenkamp, A1
van Laarhoven, HWM1
Büller, HR29
Kamphuisen, PW5
Hulshof, MCCM1
van Berge Henegouwen, MI1
Middeldorp, S7
van Es, N5
Atamanova, EA1
Andryukhin, MI1
Vasilenko, IA1
Makarov, OV1
van Rein, N1
Biedermann, JS1
van der Meer, FJM1
Cannegieter, SC1
Wiersma, N1
Vermaas, HW1
Reitsma, PH1
Kruip, MJHA1
Lijfering, WM1
Ventura, F1
Bonsignore, A1
De Stefano, F1
Pizzorno, E1
Palmiere, C1
Duzhyĭ, ID1
Kravets', OV1
Hres'ko, IIa1
Iurchenko, AV1
Dluha, J1
Sivak, S1
Kurca, E1
Dusenka, R1
Kalmarova, K1
Turcanova Koprusakova, M1
Kantorova, E1
Nosal, V1
Righini, M2
Galanaud, JP1
Guenneguez, H1
Brisot, D2
Diard, A1
Faisse, P1
Barrellier, MT1
Hamel-Desnos, C1
Jurus, C1
Pichot, O1
Martin, M1
Mazzolai, L1
Choquenet, C1
Accassat, S1
Robert-Ebadi, H1
Carrier, M10
Le Gal, G2
Mermilllod, B1
Laroche, JP1
Bounameaux, H4
Perrier, A2
Kahn, SR4
Quere, I1
Ofosu, FA1
Kistler, U1
Kramers-de Quervain, I1
Munzinger, U1
Kucher, N1
Oudemans-van Straaten, HM1
Bosman, RJ1
Koopmans, M1
van der Voort, PH3
Wester, JP1
van der Spoel, JI1
Dijksman, LM1
Zandstra, DF1
Camporese, G3
Bernardi, E1
Noventa, F1
Sain, M1
Ljutic, D1
Kovacic, V1
Radic, J1
Jelicic, I1
van Doormaal, FF2
Di Nisio, M8
Otten, HM3
Richel, DJ2
Prins, M2
Zondag, W1
Mos, IC1
Creemers-Schild, D1
Hoogerbrugge, AD1
Dekkers, OM1
Dolsma, J1
Eijsvogel, M1
Faber, LM1
Hofstee, HM1
Hovens, MM1
Jonkers, GJ1
van Kralingen, KW1
Kruip, MJ1
Vlasveld, T1
de Vreede, MJ1
Huisman, MV10
Zhang, W1
Chen, X3
Chen, Y3
Chen, N1
Bassand, JP9
Berthe, C1
Bethencourt, A1
Bolognese, L1
Wójcik, J1
Gerlach, R1
Raabe, A1
Beck, J1
Woszczyk, A1
Seifert, V1
Klerk, CP1
Smorenburg, SM1
Lensing, AW10
Prins, MH14
Piovella, F6
Prandoni, P6
Bos, MM1
van Tienhoven, G1
Postma, SR2
Kingma, WP2
Boerma, EC2
Van Roon, EN1
Biemond, BJ1
Perzborn, E1
Friederich, PW1
Levi, M2
Buetehorn, U1
Wong, KS2
Ng, PW1
Tsoi, TH1
Li, HL1
Fong, WC1
Yeung, J1
Wong, CK2
Yip, KK1
Gao, H1
Wong, HB1
de Heide, LJ1
Bakker, AJ1
Forette, B1
Wolmark, Y1
Peyrou, V1
Lormeau, JC1
Caranobe, C1
Gabaig, AM1
Crepon, B1
Saivin, S1
Houin, G1
Sié, P2
Boneu, B3
Pistorius, MA1
Said, L1
Planchon, B1
Koopman, MM2
Ockelford, PA1
Brandjes, DP1
van der Meer, J2
Gallus, AS11
Simonneau, G3
Chesterman, CH1
Cyrkowicz, A1
Rytwińska, E1
Nytko, J1
Słowińska-Zabówka, M1
Nurmohamed, MT1
van Riel, AM1
Henkens, CM1
Que, GT1
d'Azemar, P2
ten Cate, JW1
Hoek, JA2
van der Heul, C1
Turpie, AG26
Haley, S2
Sicurella, A1
Gent, M14
Hirsh, J7
Lablanche, JM2
McFadden, EP1
Meneveau, N2
Lusson, JR1
Bertrand, B1
Metzger, JP1
Legrand, V1
Grollier, G1
Macaya, C3
de Bruyne, B1
Vahanian, A2
Grentzinger, A1
Masquet, C1
Wolf, JE1
Tobelem, G1
Fontecave, S1
Vacheron, A1
Bertrand, ME5
Martineau, P1
Tawil, N1
Martyin, T1
Jakucs, J1
Iványi, J1
Kis, E1
Varga, I1
Mellár, E1
Tam, WH1
Yuen, PM1
Leung, TN1
Li, CY1
Zed, PJ1
Tisdale, JE1
Borzak, S3
Belcaro, G1
Nicolaides, AN1
Cesarone, MR1
Laurora, G1
De Sanctis, MT1
Incandela, L1
Barsotti, A1
Corsi, M1
Vasdekis, S1
Christopoulos, D1
Lennox, A1
Malouf, M1
Breddin, HK3
Fong, YK1
Ruban, P1
Yeo, SJ1
Lee, BP1
Lo, NN1
Seow, KH1
Ng, SC1
López-Beret , P1
Orgaz, A1
Fontcuberta, J2
Doblas, M1
Martinez, A1
Lozano, G1
Romero, A1
Grau, E1
Tenias, JM1
Real, E1
Medrano, J1
Ferrer, R1
Pastor, E1
Selfa, S1
Vernon, SM1
Couturaud, F3
Julian, JA2
Kearon, C2
Schwarz, T1
Schmidt, B1
Beyer, J1
Schröder, HE1
Schellong, SM8
Bugamelli, S1
Zangheri, E1
Montebugnoli, M1
Guerra, L1
Ageno, W6
Cattaneo, R1
Manfredi, E1
Chelazzi, P1
Venco, L1
Ghirarduzzi, A2
Cimino, L1
Filippucci, E1
Ricci, AL1
Romanelli, D1
Incorvaia, C1
D'Angelo, S1
Campana, F1
Molfino, F1
Scannapieco, G1
Rubbi, F1
Imberti, D3
Cosmi, B2
Filippini, M1
Tonti, D1
Avruscio, G1
Bucherini, E1
Palareti, G2
Wang, XK1
Zhang, Y2
Yang, CM1
Wang, Y1
Liu, GY1
Galeano-Valle, F1
Pérez-Rus, G1
Demelo-Rodríguez, P1
Ordieres-Ortega, L1
Ortega-Morán, L1
Muñoz-Martín, AJ1
Medina-Molina, S1
Alvarez-Sala-Walther, LA1
Del-Toro-Cervera, J1
Lecumberri, R1
López Vivanco, G1
Font, A1
González Billalabeitia, E1
Gúrpide, A1
Gómez Codina, J1
Isla, D1
Galán, A1
Bover, I1
Domine, M1
Vicente, V1
Rosell, R1
Rocha, E3
Rodríguez-Mañas, L1
Gómez-Huelgas, R1
Veiga-Fernández, F1
Ruiz, GM1
González, JM1
Del Peso, G1
Bajo, MA1
Fontán, MP1
Martínez, J1
Marrón, B1
Selgas, R1
Navarro-Quilis, A1
Castellet, E1
Paz-Jiménez, J1
Planès, A5
Otero-Fernández, R1
Gómez-Outes, A2
Martínez-González, J1
Oldham, M1
Palkimas, S1
Hedrick, A1
Gates, RS1
Lollar, DI1
Collier, BR1
Smith, J1
Faulks, ER1
Gillen, JR1
May, CC1
Cua, S1
Smetana, KS1
Powers, CJ1
Swieton, J1
Miklosz, J1
Yusa, SI1
Szczubialka, K1
Pawlak, D1
Mogielnicki, A1
Kalaska, B1
Raskob, GE21
Spyropoulos, AC11
Spiro, TE12
Lu, W3
Yuan, Z2
Levitan, B2
Suh, E2
Barnathan, ES3
Morici, N1
Podda, G1
Birocchi, S1
Bonacchini, L1
Merli, M1
Trezzi, M1
Massaini, G1
Agostinis, M1
Carioti, G1
Saverio Serino, F1
Gazzaniga, G1
Barberis, D1
Antolini, L1
Grazia Valsecchi, M1
Cattaneo, M1
Di Micco, P2
Imbalzano, E1
Russo, V2
Attena, E1
Mandaliti, V1
Orlando, L1
Lombardi, M1
Di Micco, G1
Annunziata, S1
Piccinocchi, G1
Pacelli, W1
Del Guercio, M1
Baumann Kreuziger, L1
Feng, M1
Bartosic, A1
Simpson, P2
Wang, TF6
Bistervels, IM1
Bavalia, R1
Gebel, M3
Lensing, AWA1
Coppens, M2
Sabry, S1
El Wakeel, LM1
Saleh, A1
Ahmed, MA1
Bouget, J1
Balusson, F1
Kerbrat, S1
Roy, PM3
Viglino, D1
Lacut, K1
Pavageau, L1
Oger, E1
Cohen, AT22
Weitz, JI16
Lipardi, C2
Albers, GW1
Elliott, CG2
Halperin, JL1
Hiatt, WR1
Maynard, G1
Steg, PG6
Sugarmann, C1
Kumar, D1
Kaimaparambil, V1
Chandralekha, S1
Lalchandani, J1
Sochet, AA1
Morrison, JM1
Jaffray, J1
Godiwala, N1
Wilson, HP1
Thornburg, CD1
Bhat, RV1
Zia, A1
Lawrence, C1
Kudchadkar, SR1
Hamblin, F2
Russell, CJ1
Streiff, MB2
Amankwah, EK1
Goldenberg, NA3
Bennett, E1
Delgado-Corcoran, C1
Pannucci, CJ2
Wilcox, R1
Heyrend, C1
Faustino, EV1
Ebeid, A1
Cole, E1
Stallwood-Hall, C1
Farasatinasab, M1
Balouchzehi, S1
Moghaddam, OM1
Ansarinejad, N1
Mohammadi, M1
Nasiripour, S1
Cools, F1
Virdone, S1
Sawhney, J1
Lopes, RD8
Jacobson, B2
Arcelus, JI1
Hobbs, FDR1
Gibbs, H2
Himmelreich, JCL1
MacCallum, P1
Schellong, S5
Haas, S11
Turpie, AGG2
Rocha, AT2
Kayani, G1
Pieper, K1
Kakkar, AK11
Stitzel, HJ1
Hue, JJ1
Elshami, M1
McCaulley, L1
Hoehn, RS1
Rothermel, LD1
Ammori, JB1
Hardacre, JM1
Winter, JM1
Ocuin, LM1
Abatzis-Papadopoulos, M1
Tigkiropoulos, K1
Nikas, S1
Papoutsis, I1
Kostopoulou, O1
Stavridis, K1
Karamanos, D1
Lazaridis, I1
Saratzis, N1
Bellfi, LT1
Zimmerman, SA1
Boudreau, R1
Mosier, W1
Smith, A1
Rueb, N1
Hunt, JP1
Stuke, L1
Greiffenstein, P1
Schoen, J1
Marr, A1
Scheuermann, A1
Liegl, M1
Branchford, B1
Malec, L1
Kandula, V1
Shah, PV1
Thirunavu, VM1
Yerneni, K1
Karras, C1
Abecassis, ZA1
Hopkins, B1
Bloch, O1
Potts, MB1
Jahromi, BS1
Tate, MC1
Boytsov, SA3
Shakhnovich, RM3
Tereschenko, SN3
Erlikh, AD3
Pevsner, DV3
Gulyan, RG3
Albisinni, R2
Vitrone, M2
Ursi, MP2
Spiezia, S2
Salemme, A2
Florio, LL2
Boccia, F2
Iossa, D2
Zampino, R2
Atripaldi, L2
Squillante, F2
Maturo, N2
Fraganza, F2
Severino, S2
Punzi, R2
Fiorentino, G2
Verhoeff, K2
Connell, M2
Shapiro, AJ2
Strickland, M2
Bigam, DL2
Anantha, RV2
Wee, B2
Lui, B2
Lai, J2
Khattak, Z2
Kwok, A2
Donarelli, C2
Ho, P2
Lim, HY2
Elmi, G1
Allegri, D1
Aluigi, L1
Antignani, PL1
Aspide, R1
Camaggi, V1
DI Giulio, R1
Domanico, A1
Rinaldi, ER1
Martignani, A1
Zhou, S2
Xiao, Y2
Zhou, C1
Zheng, Z1
Jiang, W1
Shen, Q1
Zhu, C1
Pan, H1
Liu, C1
Zeng, G1
Ge, L1
Ouyang, Z1
Fu, G1
Pan, G1
Chen, F1
Huang, L1
Liu, Q2
Milling, TJ2
Koch, B1
Demchuk, A1
Eikelboom, JW10
Verhamme, P13
Beyer-Westendorf, J5
Gibson, CM10
Lopez-Sendon, J2
Crowther, M6
Shoamanesh, A1
Schmidt, J2
Albaladejo, P3
Connolly, SJ2
Piple, AS1
Wang, JC1
Kang, HP1
Mills, ES1
Mayfield, CK1
Lieberman, JR2
Christ, AB1
Heckmann, ND1
Spénard, E1
Geerts, W3
Lin, Y1
Gien, LT1
Kupets, R1
Covens, A1
Vicus, D1
Chang, CK1
Higgins, RM1
Rein, L1
Peppard, WJ1
Herrmann, DJ1
Kindel, T1
Durila, M1
Berousek, J1
Vlasakova, V1
Vymazal, T1
Weerasaksanti, A1
Siwamogsatham, S1
Kunlamas, Y1
Bunditanukul, K1
Grubic, N1
Canney, M1
Delluc, A1
Hundemer, GL1
Knoll, G1
Lazo-Langner, A1
Massicotte-Azarniouch, D1
Tanuseputro, P1
Sood, MM1
Rajput, RV1
Sharron, MP1
Pavuluri, P1
Hansen, H1
Ansusinha, E1
DeBiasi, R1
Majumdar, S1
Diab, Y1
Alexander, M1
Harris, S2
Underhill, C1
Torres, J1
Sharma, S1
Lee, N1
Wong, H1
Eek, R1
Michael, M1
Tie, J1
Rogers, J1
Heriot, AG1
Ball, D1
MacManus, M1
Wolfe, R1
Solomon, BJ1
Burbury, K1
Peng, S1
Zhang, M2
Jin, J2
MacCormick, AD1
Giannella, M1
Fornaro, G1
Cristini, F1
Patacca, A1
Castagna, A1
Mazzaferri, F1
Testa, S1
Pan, A1
Lupi, M1
Brambilla, P1
Montineri, A1
Frattima, S1
Bignami, EG1
Salvetti, M1
De Stefano, G1
Grandone, E1
Di Perri, G1
Rozzini, R1
Stella, A1
Romagnoli, A1
Drago, F1
Viale, P1
Yee, MK3
Hernandez, A1
Hull, RD7
Goldhaber, SZ13
Lobo, Y1
Robertson, I1
Stewart, A1
Rowe, C1
Song, D1
Magers, J1
Abdel-Rasoul, M1
Prusakov, P1
Rambiritch, V1
Paek, D1
Sayre, T1
Naidoo, P1
Shan, J1
Leisegang, R1
Gersch, K1
Spencer, TR1
Torres-Navarro, I1
de Unamuno-Bustos, B1
Pujol-Marco, C1
Mason, SW1
Barber, A1
Jones, E1
Chen, SL1
Moll, S1
Northam, K1
Roy, SF1
Watson, P1
Bouffard, D1
Bauersachs, R15
Becker, B1
Berkowitz, SD8
Freitas, MCS1
Lassen, MR16
Metzig, C1
De Sanctis, Y3
Xu, J1
Argenti, D1
Yang, H1
Albanese, J1
Limsakun, T1
Dishy, V1
Mendell, J1
Pizzagalli, F1
Pav, J1
Kochan, J1
Vandell, AG1
Rambaran, C1
Kobayashi, F1
Orihashi, Y1
Warren, V1
McPhillips, P1
Zhou, J1
Samama, CM2
Laporte, S4
Rosencher, N9
Girard, P4
Llau, J1
Mouret, P5
Fisher, W5
Martínez-Martín, J1
Duverger, D1
Deygas, B1
Presles, E1
Cucherat, M1
Mismetti, P5
Kubicek, P1
Boughalem, E1
Frere, C1
Kamachi, H1
Homma, S1
Kawamura, H1
Yoshida, T1
Ohno, Y1
Ichikawa, N1
Yokota, R1
Funakoshi, T1
Maeda, Y1
Takahashi, N1
Amano, T1
Taketomi, A1
Haac, BE1
O'Hara, NN1
Manson, TT1
Slobogean, GP1
Castillo, RC1
O'Toole, RV1
Stein, DM1
Chen, PF1
Yi, JL1
Pei, JY1
Tang, L2
Fang, ZF1
Zhou, SH1
Hu, XQ1
Hu, X1
Fang, Z1
Cattelan, AM1
Carrozzi, L1
Leone, L1
Filippi, L1
De Gaudenzi, E1
Villalta, S1
Pesavento, R1
Cardillo, G1
Viggiano, GV1
Mangiacapra, S1
Cavalli, A1
Fontanella, A2
Agrusta, F1
Bellizzi, A1
Amitrano, M1
Iannuzzo, M1
Sacco, C1
Lodigiani, C1
Oh, TH1
Jung, H1
Lee, Y1
Dobbie, LJ1
Lamb, A1
Eskell, L1
Ramage, IJ1
Reynolds, BC1
Mokadem, ME1
Hassan, A1
Algaby, AZ1
Morais, QCD1
Santos, MS1
Veeranki, SP1
Xiao, Z1
Levorsen, A1
Sinha, M1
Shah, BR1
Feng, W1
Wang, X1
Huang, D1
Lu, A1
Rentsch, CT1
Beckman, JA2
Tomlinson, L1
Gellad, WF1
Alcorn, C1
Kidwai-Khan, F1
Skanderson, M1
Brittain, E1
King, JT1
Ho, YL1
Eden, S1
Kundu, S1
Lann, MF1
Greevy, RA1
Ho, PM2
Heidenreich, PA1
Jacobson, DA1
Douglas, IJ1
Tate, JP1
Evans, SJW1
Atkins, D1
Justice, AC1
Freiberg, MS1
Snoga, JL1
Benitez, RM1
Kim, S1
Creager, O1
Lusk, KA1
Stillson, JE1
Bunch, CM1
Gillespie, L1
Khan, R1
Wierman, M1
Pulvirenti, J1
Phyu, H1
Anderson, S1
Al-Fadhl, M1
Thomas, AV1
Kwaan, HC2
Moore, E1
Moore, H1
Walsh, MM1
Lv, Y1
Bai, W1
Li, K1
Wang, Z3
Guo, W1
Luo, B1
Wang, J1
Wang, Q2
Wang, E1
Xia, D1
Li, X1
Yuan, J1
Han, N1
Niu, J1
Yin, Z1
Fan, D1
Han, G1
DeBiase, C1
Giuliano, CA1
Doshi, M1
Ganoff, M1
Alexander Paxton, R1
Bernard, AM1
Alvarez, PA1
Bream-Rouwenhorst, HR1
Horner, KE1
Briasoulis, A1
Czerniak, LC1
Sadeghipour, P4
Talasaz, AH2
Rashidi, F2
Sharif-Kashani, B2
Beigmohammadi, MT2
Farrokhpour, M2
Sezavar, SH2
Payandemehr, P2
Dabbagh, A2
Moghadam, KG2
Jamalkhani, S2
Khalili, H2
Yadollahzadeh, M2
Riahi, T2
Rezaeifar, P2
Tahamtan, O2
Matin, S2
Abedini, A2
Lookzadeh, S2
Rahmani, H2
Zoghi, E2
Mohammadi, K2
Abri, H2
Tabrizi, S2
Mousavian, SM2
Shahmirzaei, S2
Bakhshandeh, H2
Amin, A2
Rafiee, F2
Baghizadeh, E2
Mohebbi, B2
Parhizgar, SE2
Aliannejad, R2
Eslami, V2
Kashefizadeh, A2
Kakavand, H2
Hosseini, SH2
Shafaghi, S2
Ghazi, SF2
Najafi, A2
Jimenez, D2
Gupta, A2
Madhavan, MV2
Sethi, SS2
Parikh, SA2
Monreal, M9
Hadavand, N2
Hajighasemi, A2
Maleki, M2
Sadeghian, S2
Piazza, G2
Kirtane, AJ2
Van Tassell, BW2
Dobesh, PP2
Stone, GW6
Lip, GYH2
Krumholz, HM2
Bikdeli, B2
Patel, M1
Ahuja, T2
Arnouk, S1
Gidea, C1
Reyentovich, A1
Smith, DE1
Moazami, N1
Papadopoulos, J2
Lewis, TC1
Taylor, A1
Huang, E2
Waller, J1
White, C1
Martinez-Quinones, P1
Robinson, T1
de Barros E Silva, PGM2
Furtado, RHM2
Macedo, AVS2
Ramacciotti, E7
Damini, LP1
Bronhara, B2
Cavalcanti, AB2
Rosa, RG2
Azevedo, LCP2
Veiga, VC2
Machado, FR2
Ritt, LE1
Martins, PA1
Alexander, JH3
Avezum, A4
Berwanger, O3
Rodríguez-Villa Lario, A1
Piteiro-Bermejo, AB1
Bèa-Ardébol, S1
Swartz, MF1
Hutchinson, DJ1
Stauber, SD1
Taillie, ER1
Alfieris, GM1
Cholette, JM1
Damiani, LP1
Barbosa, LM1
de Aveiro Morata, J1
de Aquino Martins, P1
de Oliveira, AL1
Nunes, VS1
Ritt, LEF1
Tramujas, L1
Santos, SV1
Diaz, DRA1
Viana, LS1
Melro, LMG1
de Alcântara Chaud, MS1
Figueiredo, EL1
Neuenschwander, FC1
Dracoulakis, MDA1
Lima, RGSD1
de Souza Dantas, VC1
Fernandes, ACS1
Gebara, OCE1
Hernandes, ME1
Queiroz, DAR1
Canesin, MF1
de Faria, LM1
Feitosa-Filho, GS1
Gazzana, MB1
Liporace, IL1
de Oliveira Twardowsky, A1
Maia, LN1
de Matos Soeiro, A1
Conceição-Souza, GE1
Armaganijan, L1
Guimarães, PO1
Ortiz, RM1
Golijanin, B1
O'Rourke, TK1
Sobel, DW1
Pillsbury, L1
T Tucci, C1
Caffery, P1
Golijanin, D1
Yi, BA1
Segers, A9
Salter, J1
Bloomfield, D1
Houghton, DE2
Vlazny, DT2
Casanegra, AI2
Brunton, N1
Froehling, DA2
Meverden, RA1
Hodge, DO2
Peterson, LG2
McBane, RD4
Wysokinski, WE4
Boyd, RA1
DiCarlo, L1
Mandema, JW1
Shavadia, J1
Welsh, R1
Gershlick, A1
Zheng, Y1
Huber, K3
Halvorsen, S1
Van de Werf, F5
Armstrong, PW5
Tang, Y1
Wang, K1
Shi, Z1
Yang, P1
Dang, X1
Cafri, G1
Paxton, EW1
Cheetham, CT1
Gould, MK1
Sluggett, J1
Bini, SA1
Khatod, M1
Kohn, CG1
Fermann, GJ1
Peacock, WF1
Wells, PS3
Baugh, CW1
Ashton, V1
Crivera, C1
Schein, JR1
Wildgoose, P1
Coleman, CI1
Korjian, S2
Chi, G3
Daaboul, Y2
Jain, P1
Arbetter, D1
Hull, R5
Hernandez, AF3
Gold, A4
Harrington, RA12
Alzghari, SK1
Seago, SE1
Garza, JE1
Hashimie, YF1
Baty, KA1
Evans, MF1
Shaver, C1
Herrington, JD1
Cimminiello, C2
Agnelli, G19
Di Minno, G1
Polo Friz, H1
Scaglione, F1
Boracchi, P1
Marano, G1
Harenberg, J10
Kittelson, JM1
Curnutte, JT2
De la Torre Hernández, JM1
Sadaba Sagredo, M1
Telleria Arrieta, M1
Gimeno de Carlos, F1
Sanchez Lacuesta, E1
Bullones Ramírez, JA1
Pineda Rocamora, J1
Martin Yuste, V1
Garcia Camarero, T1
Larman, M1
Rumoroso, JR1
Pellizzari, L1
Facchinetti, R1
Corrà, L1
Sepe, A1
Fantin, F1
Fontana, G1
Zamboni, M1
Di Francesco, V1
Nam, KW1
Kim, CK1
Kim, TJ1
An, SJ1
Oh, K1
Ko, SB1
Yoon, BW1
Fuller, K1
Malecki, S1
Anselmo, L1
Borrego, ME1
Jakeman, B1
Burnett, A1
Xiang, E1
Raco, V1
Cirrone, F1
Green, D1
Hamilton, CE1
King, BA1
Cowper, SE1
Hochster, H1
Leventhal, JS1
Ek, L1
Gezelius, E1
Bergman, B1
Bendahl, PO1
Anderson, H1
Sundberg, J1
Wallberg, M1
Falkmer, U1
Verma, S1
Belting, M1
Signorelli, JR1
Gandhi, AS1
Mahan, CE1
Burnett, AE1
Fletcher, ML1
Khan, NR1
Patel, PG1
Sharpe, JP1
Lee, SL1
Sorenson, J1
Nicklaus, MD1
Ludwig, SL1
Kettle, JK1
Yang, LS1
Alukaidey, S1
Croucher, K1
Dowling, D1
Peetermans, M1
Liesenborghs, L1
Peerlinck, K1
Wijngaerden, EV1
Gheysens, O1
Goffin, KE1
Hoylaerts, MF1
Jacquemin, M1
Verhaegen, J1
Peetermans, WE1
Vanassche, T1
Cohoon, KP1
Haskell, L4
Gill-Schuster, D1
Bergold, M1
Holzer, L1
Senay, A1
Trottier, M1
Delisle, J1
Banica, A1
Benoit, B1
Laflamme, GY1
Malo, M1
Nguyen, H1
Ranger, P1
Fernandes, JC1
Bourget-Murray, J1
Clarke, MA1
Gorzitza, S1
Phillips, LA1
Imran, JB1
Madni, TD1
Clark, AT1
Rizk, P1
Minshall, CT1
Taveras, LR1
Cunningham, HB1
Eastman, AL1
Koshy, JP1
Kacir, CD1
Cripps, MW1
Groff, H1
Azboy, I1
Parvizi, J1
Karaoui, LR1
Tawil, S1
Salameh, P1
Chamoun, N2
Levin, G1
Badrieh, A1
Attari, R1
Sabag, L1
Safrai, M1
Rottenstreich, A1
Nafee, T1
Alkhalfan, F1
Travis, R1
Mir, M1
Kalayci, A1
Jafarizade, M1
Ganti, A1
Kazmi, SH1
Ghaffarpasand, E1
Pitliya, A1
Datta, S1
Sharfaei, S1
Alihashemi, M1
Elsaiey, A1
Qamar, I1
Jahansouz, M1
Talib, U1
Kahe, F1
Habibi, S1
Abdelwahed, M1
Tariq, F1
Kaur, M1
Younes, A1
Walia, SS1
Singh, A1
Dildar, SM1
Afzal, MK1
Kerneis, M2
Nedved, D1
Plapp, FV1
Cunningham, MT1
Yu, Z1
Shan, P1
Yang, X1
Lou, XJ1
Runner, RP1
Gottschalk, MB1
Staley, CA1
Pour, AE1
Roberson, JR1
Sun, G2
Wu, J1
Liang, Q1
Jia, J1
Cheng, K1
Miller, KM1
Brenner, MJ1
Amos, LE1
Silvey, M1
Hall, M1
Witmer, CM1
Carpenter, SL1
Yoo, HH1
Nunes-Nogueira, VS1
Fortes Villas Boas, PJ1
Broderick, C1
van Oosterom, N1
Winckel, K1
Barras, M1
Ghanem, H1
Hachem, A1
Hariri, E1
Lteif, C1
Mansour, H1
Dimassi, H1
Zalloum, R1
Ghanem, G1
Tanaka, Y1
Yamada, A1
Hirata, S1
Tanaka, H1
Sakuratani, T1
Matsuhashi, N1
Yamaguchi, K1
Shimokawa, T1
Yoshida, K1
Stepien, K1
Nowak, K1
Zalewski, J1
Pac, A1
Undas, A1
Wilsey, HA1
Pandya, K1
Beavers, C1
Xiaoshu, L1
Ather, A1
Bott-Kitslaar, DM1
Rübenacker, S1
Kaiser, J1
Guschmann, M1
Sindali, K1
Rose, B1
Soueid, H1
Jeer, P1
Saran, D1
Shrivastava, R1
Lu, G2
DeGuzman, FR1
Hollenbach, SJ1
Karbarz, MJ1
Abe, K1
Lee, G1
Luan, P1
Hutchaleelaha, A1
Inagaki, M1
Conley, PB2
Phillips, DR1
Sinha, U2
Zeidan, AM1
Lau, BD1
Ahmed, SR1
Kraus, PS1
Hobson, DB1
Carolan, H1
Lambrianidi, C1
Horn, PB1
Shermock, KM1
Tinoco, G1
Siddiqui, S1
Haut, ER2
Alameddine, R1
Husari, A1
Derksen, RJ1
Mulder, WM1
Mulder, JW1
Vink, R1
Peña, ZG1
Suszko, JW1
Morrison, LH1
Chan, KE1
Thadhani, RI1
Maddux, FW1
Brodmann, M1
Dorr, A1
Hafner, F1
Gary, T1
Froehlich, H1
Kvas, E1
Deutschmann, H1
Pilger, E1
Cohen, A7
Curto, M2
Johnson, M1
Masiukiewicz, U1
Pak, R2
Thompson, J1
Vavalle, JP1
Clare, R1
Chiswell, K2
Rao, SV2
Petersen, JL4
Kleiman, NS6
Mahaffey, KW12
Wang, TY1
Lucania, G1
Camiolo, E1
Carmina, MG1
Fiandaca, T1
Indovina, A1
Malato, A1
Messina, R1
Fabbiano, F1
Marcenò, R1
Lai, S1
Coppola, B1
Décousus, H8
Grosso, MA4
Mercuri, M1
Schwocho, L3
Shi, M3
Wells, P4
Yusen, RD4
Tapson, VF4
Samama, MM4
Chen, M1
Deslandes, B1
Pelzer, U1
Sinn, M1
Stieler, J1
Riess, H7
Ginsberg, JS3
Chan, N1
Guyatt, G3
Milligan, PE1
Wong, CA1
Deal, EN4
Thoelke, MS1
Gage, BF2
Eriksson, BI16
Renfurm, RW1
Kashiwa, M1
Kreutz, R1
Mantovani, LG1
Pattanayak, CW1
Holberg, G1
Jamal, W1
Schmidt, A1
van Eickels, M1
Hagopian, JC1
Riney, JN2
Hollands, JM2
Corder, A1
Held, K1
Oschman, A1
Desanctis, YH1
Homering, M5
Hu, D3
Mebazaa, A3
Merli, G5
Burton, P1
Loidi Pascual, L1
Valcayo Peñalba, A1
Yerani Ruiz de Azúa Ciria, A1
Yanguas Bayona, I1
Hayashi, H1
Morikawa, T1
Yoshida, H1
Motoi, F1
Okada, T1
Nakagawa, K1
Mizuma, M1
Naitoh, T1
Katayose, Y1
Unno, M1
Friedman, RJ4
Berlin, JA1
Weinstein, RB1
DiBattiste, PM2
Davidson, BL11
Verheijen, S1
Brighton, TA2
Lyons, RM1
Rehm, J1
Yeung, V1
Formal, C1
Robinson, S2
Zincuk, A1
Larsen, UL1
Ekstrøm, C1
Toft, P1
Joseph, B1
Pandit, V1
Harrison, C1
Lubin, D1
Kulvatunyou, N1
Zangbar, B1
Tang, A1
O'Keeffe, T1
Green, DJ1
Gries, L1
Friese, RS1
Rhee, P1
Jinatongthai, P1
Khaisombut, N1
Likittanasombat, K1
Chaiyakunapruk, N1
Watcharathanakij, S1
Nathisuwan, S1
Schellong, SW1
Figueiró-Filho, EA1
Aydos, RD1
Senefonte, FR1
Ferreira, CM1
Pereira, EF1
Oliveira, VM1
Menezes, GP1
Bósio, MA1
Puymirat, E1
Schiele, F1
Ennezat, PV1
Coste, P1
Collet, JP7
Bonnefoy-Cudraz, E1
Roul, G1
Richard, P1
Simon, T1
Danchin, N2
Saheb Sharif-Askari, F1
Syed Sulaiman, SA1
Saheb Sharif-Askari, N1
Al Sayed Hussain, A1
Railey, MJ1
Oliveira, SN2
Santos, GR1
Glauser, BF3
Capillé, NV1
Queiroz, IN1
Pereira, MS3
Pomin, VH1
Mourão, PA3
Bahl, V1
Shuman, AG1
Hu, HM1
Jackson, CR1
Alaniz, C1
Chepeha, DB1
Bradford, CR1
Revigliono, JI1
Cornavaca, T1
Becerra, F1
Albertini, R1
Contreras, AE1
Tabares, A1
Ierardi, AM1
Floridi, C1
Pellegrino, C1
Petrillo, M1
Pinto, A1
Iadevito, I1
Golia, E1
Perillo, A1
Grassi, R1
Rotondo, A1
Carrafiello, G1
Bethune, C1
Bhanot, S1
Gailani, D2
Monia, BP2
Concha-Garzon, M1
Sotomayor-Lopez, E1
Solano-Lopez, G1
Fraga, J1
De Argila, D1
Patel, AA1
Ogden, K1
Mody, SH1
Bookhart, B1
Müller, K1
Pap, ÁF2
Tewes, MC1
Charters, MA1
Frisch, NB1
Wessell, NM1
Dobson, C1
Les, CM1
Silverton, CD1
Ma, G1
Zhang, R1
Wu, X1
Wang, D1
Ying, K1
Vazquez, FJ1
Paulin, P1
Rodriguez, P1
Lubertino, M1
Gándara, E1
Aydin, U1
Asik, MB1
Gokgoz, MC1
Karakoc, O1
Cui, SB1
Shu, RH1
Yan, SP1
Wu, H1
Wang, L2
Zhu, Q1
Baquero-Salamanca, M1
Téllez-Arévalo, AM1
Calderon-Ospina, C1
Gouveia, AI1
Lopes, L1
Soares-Almeida, L1
Filipe, P1
Dang, JD1
Davis, LE1
Kathmann, W1
Gulati, A1
Faed, JM1
Isbister, GK1
Duffull, SB3
Ong, WL1
Koh, TL1
Fletcher, J1
Gruen, R1
Royce, P1
Özler, T1
Uluçay, Ç1
Önal, A1
Altıntaş, F1
Kooistra, HA1
Sahin, K1
Meijer, K1
Geisler, T1
Droppa, M1
Gawaz, M1
Steinhubl, SR6
Lincoff, AM3
Cequier, AR2
Desmet, W2
Rasmussen, LH4
Hoekstra, JW1
Bernstein, D1
Deliargyris, EN1
Mehran, R3
Parker, SG1
McGlone, ER1
Knight, WR1
Sufi, P1
Khan, OA1
Lee, TC1
Yamabe, T1
Triscott, J1
Mercer, S1
Tian, PG1
Dobbs, B1
Rutjes, AW2
Lee, YR1
Vega, JA1
Duong, HN1
Ballew, A1
Adams, CB1
Vollman, KE1
Leventhal, EL1
Acquisto, NM1
Stephenson, ML1
Serra, AE1
Neeper, JM1
Caballero, DC1
McNulty, J1
Sanders, P1
Thompson, JR1
Ross Terres, JA1
Lozano-Ortega, G1
Kendall, R1
Sculpher, MJ1
Rostagno, C1
Mehta, AY1
Mohammed, BM1
Martin, EJ1
Brophy, DF2
Desai, UR1
Quon, P1
Le, HH1
Raymond, V1
Mtibaa, M1
Moshyk, A1
Sharfman, ZT2
Campbell, JC2
Mirocha, JM1
Spitzer, AI2
Kim, SM1
Moon, YW1
Lim, SJ1
Kim, DW1
Park, YS1
Campbell, PM1
Ippoliti, C1
Parmar, S1
Liu, Z1
Silvain, J4
Barthélémy, O3
Payot, L2
Choussat, R5
Sabouret, P1
Cohen, M19
Pollack, CV4
Goldstein, P3
Zeymer, U6
Vicaut, E3
Montalescot, G12
Ning, GZ1
Kan, SL1
Chen, LX1
Shangguan, L1
Feng, SQ1
Zhou, Y1
Desai, A2
Calixte, R1
Aparnath, M1
Hindenburg, A1
Salzman, S1
Mathew, JP1
King, DA1
Pow, RE1
Dickison, DM1
Vale, PR1
Krueger, K1
Schmutz, A1
Zieger, B1
Kalbhenn, J1
Sofjan, AK1
Iuppa, JA1
Bain, KB1
Witt, CA1
Hachem, RR1
Ko, A1
Harada, MY1
Barmparas, G1
Chung, K1
Mason, R1
Yim, DA1
Dhillon, N1
Margulies, DR1
Gewertz, BL1
Ley, EJ1
Bonilla, GA1
Gutierrez, C1
Bautista, MP1
Llinas, AM1
Monsalvo, DJ1
Bronson, MD1
Goodman, S3
Leeds, J1
Wiens, BL1
Siegal, DM2
Zotova, E1
Meeks, B1
Nakamya, J1
Lim, WT1
Soeiro, AM1
Silva, PG1
Roque, EA1
Bossa, AS1
César, MC1
Simões, SA1
Okada, MY1
Leal, TC1
Pedroti, FC1
Oliveira, MT1
Bleker, SM2
Sisson, M1
Goette, A2
Merino, JL1
Ezekowitz, MD1
Zamoryakhin, D1
Melino, M1
Mercuri, MF4
Fernandez, V1
Al-Saady, N1
Pelekh, N1
Merkely, B1
Zenin, S1
Kushnir, M2
Spinar, J1
Batushkin, V1
de Groot, JR1
Lip, GY2
Greig, SL1
Garnock-Jones, KP1
Venker, BT1
Ganti, BR1
Lin, H1
Lee, ED1
Nunley, RM1
Samuel, NG1
Seifert, CF1
Tao, DL1
Bien, JY1
DeLoughery, TG1
Shatzel, JJ1
Pignataro, BS1
Nishinari, K1
Cavalcante, RN1
Centofanti, G1
Yazbek, G1
Krutman, M1
Bomfim, GAZ1
Fonseca, IYI1
Teivelis, MP1
Wolosker, N1
Sanches, SM1
Cieri, NE1
Kusmierski, K1
Lackie, C1
Van Opdorp, A1
Hassan, AK1
Trujillo-Santos, J1
Bergmann, JF2
Bortoluzzi, C1
López-Reyes, R1
Giorgi-Pierfranceschi, M1
López-Sáez, JB1
Ferrazzi, P1
Bascuñana, J1
Suriñach, JM1
Rahawi, KW1
Higgins, KL1
Noda, C1
Stultz, JS1
Xie, J1
Ma, J1
Huang, Q1
Yue, C1
Pei, F1
Mantha, S1
Miao, Y1
Wills, J1
Parameswaran, R1
Soff, GA1
Walker, CK1
Sandmann, EA1
Horyna, TJ1
Gales, MA1
Yanagita, T1
Kusanagi, H1
Halaby, R1
Arbetter, DF1
Lu, SP1
Bandman, O1
Leeds, JM1
Tran, E1
Duckett, A1
Fisher, S1
Bohm, N1
Alexander, KP6
Marcucci, G1
White, HD19
Spinler, S1
Col, J2
Aylward, PE9
Califf, RM11
Khoobiar, S1
Mejevoi, N1
Kaid, K1
Boiangiu, C1
Setty, S1
Tanwir, A1
Khalid, K1
Pride, YB1
Col, JJ3
Goodman, SG8
Gulba, D1
Bergovec, M1
Kunadian, V1
Zorkun, C1
Buros, JL1
Murphy, SA7
Antman, EM19
Budaj, A8
Mehta, SR8
Afzal, R7
Chrolavicius, S6
Fox, KA12
Wallentin, L7
Peters, RJ3
Granger, CB6
Joyner, CD3
Yusuf, S8
Díez, JG2
Fuji, T1
Ochi, T1
Niwa, S1
Fujita, S1
Yan, AT1
Yan, RT1
Huynh, T1
DeYoung, P1
Weeks, A1
Fitchett, DH1
Langer, A8
Boden, WE1
Flather, M2
Piegas, LS2
Faxon, DP1
Widimsky, P1
Rupprecht, HJ3
Jolly, S1
Deitelzweig, SB1
Becker, R2
Lin, J2
Benner, J1
Lotke, PA3
Tonev, ST1
Spinler, SA3
Levine, GN1
Gallo, R6
Ducas, J2
Becker, RC2
Ferguson, JJ11
Al-Sallami, H1
Ferguson, R1
Wilkins, G1
Gray, A1
Medlicott, NJ1
Bode, C3
Steinhubl, S1
Heer, T3
Juenger, C1
Gitt, AK1
Bauer, T3
Towae, F1
Zahn, R3
Senges, J3
Levin, A1
Ben-Artzi, M1
Beckerman, P1
Haber, G1
Varon, D2
Ben-Yehuda, A1
Muszkat, M1
Eikelboom, JE1
Bauer, KA6
Fisher, WD4
Huo, MH2
Gretler, DD1
Wolowacz, SE3
Roskell, NS3
Plumb, JM3
Caprini, JA2
Heidenreich, C1
Hohmann, V1
Bramlage, P6
Hacobian, M1
Shetty, R1
Niles, CM1
Gerhard-Herman, M1
Vallurupalli, N1
Baroletti, S1
McKean, SC1
Sonis, J1
Parasuraman, S1
Kosowsky, JM1
Arnaout, L1
Chabbouh, T1
Bellamy, L1
Hammerstingl, C6
Omran, H6
Tripp, C2
Poetzsch, B1
Arellano-Rodrigo, E2
Gironella, M1
Nicolau, I3
Vila, M1
Hart, RG1
Maciver, F1
Beard, SM1
Robinson, PA2
Dolan, G2
Brenkel, IJ2
Brener, SJ2
Bhatt, DL2
Franzosi, MG1
Leri, F1
Voyce, SJ1
Scialla, S1
Glavich, W1
Dzielak, E1
Smego, RA1
Guzek, J1
Gitt, A2
Jünger, C2
Koeth, O2
Iba, T2
Takayama, T1
Karthikeyan, G2
Manoukian, SV2
Feit, F2
Hoekstra, J2
Gersh, BJ2
Ohman, EM4
Gallus, A6
Miesbach, W1
Galanakis, D1
Scharrer, I1
Reeves, D1
Liu, CY1
Kwong, LM3
Cushner, FD1
Bandel, TJ1
Benson, A1
Misselwitz, F7
Medina, HM1
Cheong, BY1
O'Meallie, L1
Ou, FS1
Roe, MT5
Gibler, WB2
Peterson, ED4
Hamon, M3
Cequier, A1
Lincoff, MA1
Mann, T1
Kuczka, K1
Baum, K1
Picard-Willems, B1
Harder, S1
Giraldez, RR2
Wiviott, SD2
Nicolau, JC2
Mohanavelu, S3
Morrow, DA6
Giugliano, RP2
Pineo, G3
Chen, D3
Portman, RJ1
Kosar, A1
Cipil, HS1
Kaya, A1
Uz, B1
Haznedaroglu, IC1
Goker, H1
Ozdemir, O1
Ercetin, S1
Kirazli, S1
Firat, HC1
Kröger, K1
Suárez-Gea, ML1
Blázquez-Pérez, A1
Pozo-Hernández, C1
Vargas-Castrillón, E1
Famularo, G1
Gasbarrone, L1
Minisola, G1
De Simone, C1
Eikelboom, J1
Peters, R1
Mehta, S1
De, A1
Roy, P1
Garg, VK1
Pandey, NK1
Bui, HT1
Krisnaswami, A1
Le, CU1
Chan, J1
Shenoy, BN1
Dobrev, D1
Ravens, U1
Schmitz, A1
Fimmers, R1
Barras, MA2
Atherton, JJ2
Green, B2
Sakon, M1
Kobayashi, T1
Shimazui, T1
Chiariello, M2
King, SB2
Desmet, WJ2
Amin, AN2
Johnson, BH1
Schulman, KL1
Anderson, JA1
Johnston, M1
Myers, DD1
Wrobleski, SK1
Deatrick, KB1
Londy, FJ1
Rectenwald, JE1
Henke, PK2
Schaub, RG1
Wakefield, TW1
Tsai, TT1
Maddox, TM1
Dai, D1
Messenger, JC1
Nallamothu, BK1
Rumsfeld, JS1
Rajamanickam, A1
Patel, P1
Anbazhagan, P1
Harte, B1
Clemens, A2
Noack, H1
Raja, Y1
Lo, TS1
Townend, JN1
Motte, S1
Claes, N1
Verhaeghe, R2
Hermans, C1
Giugliano, R1
McCabe, CH4
Braunwald, E10
Trkulja, V1
Kolundzic, R1
Dahl, OE12
Kurth, AA4
Francis, CW5
Hantel, S4
Schnee, JM2
Sinnaeve, P1
Liang, J1
Brant, R1
Lang, A1
Kienitz, C1
Wetzel, P1
Rollnik, JD1
Brieger, D1
Landivier, A1
Beygui, F4
Bellemain-Appaix, A1
Mercadier, A1
Vignolles, N3
Costagliola, D1
Quinlan, DJ2
Bergqvist, D2
Nicol, P1
Leil, TA1
Feng, Y1
Zhang, L1
Paccaly, A1
Mohan, P1
Pfister, M1
Aïssaoui, N1
Kurtoglu, M4
Koksoy, C1
Hasan, E1
Akcalı, Y1
Karabay, O1
Filizcan, U1
Klamroth, R1
Gottstein, S1
Essers, E1
Landgraf, H2
Tsiatis, AA1
Davidian, M1
Pieper, KS3
Zhang, H1
Löwenberg, EC1
Crosby, JR1
MacLeod, AR1
Zhao, C1
Gao, D1
Black, C1
Revenko, AS1
Meijers, JC1
Stroes, ES1
Cao, YB1
Zhang, JD1
Shen, H1
Jiang, YY1
Girard, F1
Cao, C1
Kupfer, S1
Raskob, G5
Spaeder, J1
Zufferey, PJ1
Schulman, S2
Huang, J1
Cao, Y1
Liao, C1
Wu, L1
Gao, F1
Bottaro, FJ1
Ceresetto, JM1
Dentali, F3
Gianni, M1
Squizzato, A1
Carson, MP1
Kuo, YH1
Brenner, B6
Ramirez, LM2
Loke, YK1
Kwok, CS1
Hermansson, K1
Liotier, J1
Bertoletti, L3
Kleber, FX2
Pineo, GF3
Chapelle, C1
Moulin, N1
Fouda, UM1
Sayed, AM1
Abdou, AM1
Ramadan, DI1
Fouda, IM1
Zaki, MM1
Palumbo, A1
Cavo, M1
Bringhen, S1
Zamagni, E1
Romano, A1
Patriarca, F1
Rossi, D1
Gentilini, F1
Crippa, C1
Galli, M1
Nozzoli, C1
Ria, R1
Marasca, R1
Montefusco, V1
Baldini, L1
Elice, F1
Callea, V1
Pulini, S1
Carella, AM1
Zambello, R1
Benevolo, G1
Magarotto, V1
Tacchetti, P1
Pescosta, N1
Cellini, C1
Polloni, C1
Evangelista, A1
Caravita, T1
Morabito, F1
Offidani, M1
Tosi, P1
Boccadoro, M1
Moliterno, DJ1
Lokhnygina, Y3
Hochman, JS2
Jameson, SS1
Sanders, RD1
Reed, MR1
Landman, GW1
Gans, RO1
McKellar, SH1
Abel, S1
Camp, CL1
Suri, RM1
Ereth, MH1
Schaff, HV1
Skrupky, LP1
Smith, JR1
Reichley, RM1
Vairo, BC2
Oliveira, CP1
Cinelli, LP2
Stark, JE1
Smith, WJ1
Rosenberger, LH1
Smith, PW1
Sawyer, RG1
Quirke, M1
O'Donnell, JJ1
Aujesky, D1
Verschuren, F1
Osterwalder, J1
Egloff, M1
Renaud, B1
Stone, RA1
Legall, C1
Sanchez, O4
Pugh, NA1
N'gako, A1
Cornuz, J1
Hugli, O1
Beer, HJ1
Fine, MJ1
Yealy, DM1
Rahman, MS1
Soo, L1
Qasim, A1
Montero Ruiz, E1
Baldominos Utrilla, G1
López Álvarez, J1
Santolaya Perrin, R1
Duschek, N1
Vafaie, M1
Skrinjar, E1
Hirsch, K1
Waldhör, T1
Hübl, W1
Bergmayr, W1
Knoebl, P1
Assadian, A1
Ludwig, KP1
Simons, HJ1
Mone, M1
Barton, RG1
Kimball, EJ1
Leizorovicz, A3
Haas, SK1
Knabb, RM1
Hoffmann, P1
Keller, F2
Parakh, R1
Wang, C1
Pollack, C1
Cayla, G1
Okamoto, K1
Ohike, T1
Tajirika, T1
Aihara, K1
Watanabe, S1
Kayhanian, H1
Villanueva, CA1
Nájera, L1
Espinosa, P1
Borbujo, J1
Elsaid, KA1
Collins, CM1
Nieto, JA1
Espada, NG1
Merino, RG1
González, TC1
George, D1
Kakkar, A2
Lensin, AW1
Jacobson, BF1
Minar, E1
Chlumsky, J2
Gallerani, M1
Manfredini, R1
Morishima, Y1
Honda, Y1
Kamisato, C1
Tsuji, N1
Kita, A1
Edo, N1
Shibano, T1
Springmann, V1
Martineau, J1
Stewart, JA1
Komari, N1
McLeod, A2
Strulovitch, C1
Blostein, M1
Faucher, JP1
Gamble, G1
Gordon, W1
Kagoma, PK1
Miron, MJ1
Laverdière, D1
Game, M1
Mills, A1
Dufour, B1
Toussaint-Hacquard, M1
Kearney-Schwartz, A1
Manckoundia, MD1
Laurain, MC1
Joly, L1
Deibener, J1
Wahl, D1
Lecompte, T2
Benetos, A1
Perret-Guillaume, C1
Albertsen, IE1
Larsen, TB1
Overvad, TF1
Marx, S1
Marder, VJ3
Schulze, A1
Wehling, M1
Weiss, C2
Yildirim, T1
Kocak, T1
Buyukasik, Y1
Yilmaz, R1
Altun, B1
Erdem, Y1
Arici, M1
Byrne, M1
Zumberg, M1
Gómez Arrayas, I1
Suárez Fernández, C1
Gómez Cerezo, JF1
Betegón Nicolás, L1
de Salas-Cansado, M1
Rubio-Terrés, C1
Yoshida, Rde A1
Yoshida, WB1
Maffei, FH2
El Dib, R1
Nunes, R1
Rollo, HA1
Tapson, V1
Bigonzi, F5
Théroux, P3
Frey, MJ2
Van Mieghem, W1
Senatore, F1
Lis, J1
Mukherjee, R1
Harris, K1
Morris, E1
Vormfelde, SV1
Hughes, SJ1
Fitchett, D1
Tan, M1
Fine, E1
Golmard, JL2
Dalby, M1
Ankri, A3
Dumaine, R2
Lesty, C1
Thomas, D3
Lee, BI1
Casterella, PJ1
Pulsipher, M1
Rogers, M1
Corrigan, VE1
Ryan, TJ1
Breall, JA1
Moses, JW2
Eaton, GM1
Sklar, MA1
Eskilson, C2
Nylander, I1
Frison, L1
Ogren, M1
Cestac, P1
Bagheri, H1
Lapeyre-Mestre, M1
Fouladi, A1
Maupas, E1
Léger, P1
Fontan, B1
Massip, P1
Montastruc, JL1
Büyükkurt, CD1
Dural, CA1
Güloğlu, R2
Akar, U1
Alikhan, R1
Witt, C1
Vogel, G1
Koppenhagen, K4
Schomaker, U1
Flosbach, CW2
Ferreira, I1
Dos, L1
Tornos, P2
Permanyer-Miralda, G2
Soler-Soler, J2
Khazan, M1
Scheuering, S1
Adamson, R1
Mathis, AS1
Pless, T1
Loertzer, H1
Brandt, S1
Radke, J1
Fornara, P1
Soukup, J1
Dunn, K1
Sasahara, AA1
Adgey, AA1
Arntz, HR1
Bogaerts, K1
Danays, T1
Lindahl, B2
Mäkijärvi, M1
Verheugt, F1
Pérez de Llano, LA1
Baloira Villar, A1
Veres Racamonde, A1
Veiga, F2
Golpe Gómez, R1
Pajuelo Fernández, F1
Carroll, DN1
Hudson, EB1
Streif, W1
Goebel, G1
Chan, AK2
Massicotte, MP1
Gómez de la Torre, R1
Milla Crespo, A1
Cadenas, F1
Fernández Bustamante, J1
Vázquez Castañón, M1
Chiou-Tan, FY1
Garza, H1
Chan, KT1
Parsons, KC1
Donovan, WH1
Robertson, CS1
Holmes, SA1
Graves, DE1
Rintala, DH1
Bruno, R1
Baille, P1
Retout, S1
Vivier, N1
Veyrat-Follet, C1
Sanderink, GJ1
Colwell, CW3
Neubauer, J1
McElhattan, JL1
Peters, GR1
Nader, F1
Bates, ER1
Every, NR1
Pepine, CJ2
Kälebo, P5
Panfilov, S1
Andersson, M1
Freij, A1
Stellbrink, C1
Nixdorff, U1
Hofmann, T1
Lehmacher, W1
Daniel, WG1
Hanrath, P1
Geller, C1
Mügge, A1
Sehnert, W1
Schmidt-Lucke, C1
Schmidt-Lucke, JA1
Thorevska, N1
Amoateng-Adjepong, Y1
Sabahi, R1
Schiopescu, I1
Salloum, A1
Muralidharan, V1
Manthous, CA1
Woessner, R1
Grauer, M1
Bianchi, O1
Mueller, M1
Moersdorf, S1
Berlit, P1
Goertler, M1
Grotemeyer, KH1
Sliwka, U1
Stoll, M1
Treib, J1
Kavanagh, D1
Hill, AD1
Martin, S1
Power, C1
McDermott, EW1
O'Higgins, N1
Murphy, K2
Tanguy, ML2
Drobinski, G1
Ellis, SG1
Armstrong, P2
Betriu, A1
Brodie, B1
Herrmann, H1
Neumann, FJ1
Smith, JJ1
Topol, E1
Macie, C1
Forbes, L1
Foster, GA1
Douketis, JD2
Segers, AE2
Cariou, R1
Leeuwenkamp, O1
Hu, Q1
Brady, JO1
Simoons, ML2
Bobbink, IW1
Boland, J1
Gardien, M1
Klootwijk, P1
Ruzyllo, W2
Umans, VA1
Blazing, MA2
de Lemos, JA2
Verheugt, FW1
Ardissino, D1
Palmisano, J1
Bilheimer, DW1
Snapinn, SM1
Ramsey, KE1
Gardner, LH1
Hasselblad, V3
Pfeffer, MA1
Lewis, EF1
Grines, CL1
Kereiakes, DJ1
Nessel, CC3
Aylward, P1
Biasucci, L1
Fry, E1
Gulba, DC3
Guneri, S3
Gurfinkel, E1
Harrington, R1
Leon, MB1
Lopez-Sendon, JL2
Teirstein, PS1
Toro-Figueroa, L1
White, H1
Le-Moigne-Amrani, A1
Gallois, V1
Araújo, GR1
Lastoria, S1
Karaoglan de Moura, L1
Michaelis, W1
Sandri, JL1
Dietrich-Neto, F1
Michaels, LA1
Gurian, M1
Hegyi, T1
Drachtman, RA1
Herishanu, Y1
Misgav, M1
Kirgner, I1
Ben-Tal, O1
Eldor, A2
Naparstek, E1
Yanar, H1
Bilsel, Y1
Kizilirmak, S1
Buyukkurt, D1
Granit, V1
Lynd, LD2
O'brien, BJ2
Hoffman, R1
Carp, H1
Dulitsky, M1
Younis, J1
Davutoglu, V1
Kervancioglu, S1
Sezen, Y1
Topgül, K1
Uzun, O1
Anadol, AZ1
Gök, A1
Quiles, J1
Avanzas, P1
Bueno, H1
Maslovitz, S1
Many, A2
Landsberg, JA1
Lessing, JB1
Kupferminc, MJ1
Ibrahim, RB1
Peres, E1
Dansey, R1
Abidi, MH1
Abella, EM1
Gumma, MM1
Milan, N1
Smith, DW1
Heilbrun, LK1
Klein, J1
Huxtable, LM1
Tafreshi, MJ1
Ondreyco, SM1
Nessel, CO1
Enyart, JJ1
Jones, RJ1
Siddiqui, MA1
Wagstaff, AJ1
Weinsheimer, RL1
Libby, E1
Howdieshell, TR1
Chong, BH1
Baker, RI2
Thurlow, P1
Lee, CH1
Jaffer, AK1
Ahmed, M1
Brotman, DJ1
Bragg, L1
Seshadri, N1
Qadeer, MA1
Klein, A1
Irwin, MW1
Borris, L2
Jörg, I1
Zalc, S1
Lemos, PA1
Esteves, A1
Ribeiro, EE1
Horta, P1
Ramires, JA1
Martinez, EE1
Pogue, J1
Joyner, C1
Gibbons, RJ1
Fuster, V1
Ruda, M2
Sadowski, Z1
Jiang, F1
Lim, W1
Crowther, MA6
Ellis, MH1
Hadari, R1
Tchuvrero, N1
Shapira, S1
Kovlenko, I1
Kozmiakova, M1
Zissin, R1
Elis, A1
Schädlich, PK1
Kentsch, M1
Weber, M1
Kämmerer, W1
Brecht, JG1
Nadipelli, V1
Huppertz, E1
Majure, DT1
Aberegg, SK1
DeCarolis, DD1
Sleight, P1
Waksman, R1
Wolfram, RM1
Torguson, RL1
Okubagzi, P1
Xue, Z1
Suddath, WO1
Satler, LF1
Kent, KM1
O'Neill, WW1
Bickler, P1
Brandes, J1
Lee, M1
Bozic, K1
Chesbro, B1
Claassen, J1
Klein, AL1
Jasper, SE1
Katz, WE1
Malouf, JF1
Pape, LA1
Stoddard, MF1
Apperson-Hansen, C1
Lieber, EA1
Dharmarajan, TS1
Sohagia, A1
McLaurin, BT1
Cox, DA1
Pocock, SJ1
Ware, JH1
Colombo, A1
Darius, H1
Ebrahimi, R1
Shorr, AF1
Jackson, WL1
Moores, LK1
Warkentin, TE2
Frezza, EE1
Wachtel, MS1
Cantor, WJ1
Huang, Z1
Das, P1
Glezer, S1
Chisholm, RJ1
Schobess, R1
Düring, C1
Bidlingmaier, C1
Heinecke, A1
Merkel, N1
Nowak-Göttl, U1
Chew, DP1
Berdan, LG2
Bhala, N1
Schuler, J1
Altenberger, J1
Heigert, M1
Pasceri, V1
Riddell, JW1
Gardner, MJ1
Flik, KR1
Dreese, JC1
Athanasian, EA1
Lyden, JP1
O'Donnell, MJ1
Johnson, J1
Robinson, M1
Zondag, M1
Turpie, I1
Castro, DJ1
Díaz, G1
Martí, D1
Escobar, C1
Ortega, J1
García-Rull, S1
Picher, J1
Sueiro, A1
Crooke, B1
Callaway, LK1
Ben-David, B1
Chelly, JE1
Bleckner, LL1
Buckenmaier, CC1
Jacob, AJ2
Gotcheva, N1
Polonetsky, L1
Cherfan, A1
Arabi, Y1
Al Askar, A1
Al Shimemeri, A1
Rivas-Gándara, N1
Ferreira-González, I1
Torrents, A1
Vallejo, N1
Igual, A1
Kamal, MK1
Reilly, PM1
Stavropoulos, SW1
Schmidt, H1
von der Recke, G1
Marlovits, S1
Striessnig, G1
Schuster, R1
Stocker, R1
Luxl, M1
Trattnig, S1
Vécsei, V1
LaPointe, NM1
Chen, AY2
Lytle, BL1
Ohman, ME1
Gibler, BW1
Goeree, R1
Dunn, AS1
Malowany, JI1
Knoppert, DC1
Pepelassis, D1
Lee, DS1
Despotovic, N2
Erceg, P1
Nikolic-Despotovic, M2
Milosevic, DP1
Davidovic, M1
van Dijk, CN2
Frostick, SP2
Christiansen, AV1
Hettiarachchi, R2
Schnee, J2
Valentin, V1
Moccetti, T1
Ansell, J1
Deitchman, D1
Paar, WD1
Sica, DA1
Ruff, CT1
Wazni, OM1
Beheiry, S1
Fahmy, T1
Barrett, C1
Hao, S1
Patel, D1
Di Biase, L1
Martin, DO1
Kanj, M1
Arruda, M1
Cummings, J1
Schweikert, R1
Saliba, W1
Natale, A1
Tricoci, P1
Newby, LK2
Qin, J1
Loncar, G1
Ilicć, M1
Dimković, S1
Dixon, D1
Peek, B1
Reeve, R1
Normand, SL1
Rubboli, A1
Capecchi, A1
Di Pasquale, G1
Wienbergen, H1
Kwa, AT1
Rogers, JH1
Melloni, C1
Szczech, LA1
Barantke, M1
Bonnemeier, H1
Trowbridge, AA5
Stephens, JW1
Gardiner, GA2
Ritter, MA1
Bang, CJ1
Talstad, I1
Berstad, A1
Noble, S2
Peters, DH1
Goa, KL1
Pini, M1
Aiello, S1
Manotti, C1
Pattacini, C1
Quintavalla, R1
Poli, T1
Tagliaferri, A1
Dettori, AG1
Fejgin, MD1
Lourwood, DL1
Morris, BA1
Blaha, JD1
Comerota, AJ1
Skoutakis, VA1
Levine, M1
Leclerc, J1
Anderson, D2
Weitz, J3
Ginsberg, J2
Demers, C4
Kovacs, M2
Leclerc, JR2
Geerts, WH2
Desjardins, L1
Laflamme, GH1
L'Espérance, B1
Kassis, J1
Cruickshank, M1
Whitman, L1
Delorme, F1
Vochelle, N2
Darmon, JY1
Fagola, M2
Bellaud, M2
Compan, D1
Saliba, E1
Weisslinger, N1
Huet, Y2
Borris, LC2
Nelson-Piercy, C1
Letsky, EA1
de Swiet, M1
Gurfinkel, EP2
Fromell, GJ2
Premmereur, J2
Manktelow, AR1
Haddad, FS1
Powles, DP1
Leadley, RJ1
Kasiewski, CJ1
Bostwick, JS1
Bentley, R1
McVey, MJ1
White, FJ1
Perrone, MH1
Dunwiddie, CT1
Parent, F1
Page, Y2
Tardy, B1
Faivre, R1
Charbonnier, B2
Barral, FG1
Connolly, ES1
Mocco, J1
Andreassen, G1
Houde, JP1
Steinberg, G1
Bernink, PJ1
Salein, D1
Bayes De Luna, A1
Fox, K1
Radley, D1
Saltissi, D1
Morgan, C1
Westhuyzen, J1
Healy, H1
Sosis, MB1
Calderon, EJ1
Varela, JM1
Gonzalez de la Puente, MA1
Dolenska, S1
Gerlach, AT1
Pickworth, KK1
Seth, SK1
Tanna, SB1
Barnes, JF1
Lindqvist, PG1
Dahlbäck, B1
Hakki, SI1
Fareed, J3
Hoppensteadt, DA1
Abdullah, H1
Camblin, J1
Nasseri, AF1
Hamadeh, O1
Wright, T1
Escribá, A1
Maluenda, MP1
López Rubio, M1
Margalet, I1
Lezana, A1
Gallego, J1
Ribera, JM1
Olsson, CG2
Abildgaard, U2
Elias, D1
Grigg, A1
Musset, D1
Rodgers, GM2
Zawilska, K1
Busby, LT1
Weyman, A1
Fitzgerald, RH1
Whitsett, TL3
O'Connell, MB1
Ohar, JA1
Young, TR1
Lile, J1
Stinnett, S1
Cook, C1
Callaway, M1
Pauzner, R1
Dulitzki, M1
Langevitz, P1
Livneh, A1
Kenett, R1
Stepinska, J1
Banaszewski, M1
Konopka, A1
Szajewski, T1
Louwerenburg, HW1
Baars, HF1
Wesdorp, JC1
Hamer, B1
Pisapia, G1
Heidbuchel, H1
Baird, SH1
Menown, IB1
Mcbride, SJ1
Trouton, TG1
Wilson, C1
Sarasin, FP1
Hillbom, M1
Erilä, T1
Sotaniemi, K1
Tatlisumak, T1
Sarna, S1
Kaste, M1
Kujath, P1
Eckmann, C1
Xie, C1
Ahmed, RJ1
Xavier, D1
Pais, P1
Zhu, J1
Liu, L1
De Giorgi, A1
Giannarelli, C1
De Negri, F1
Carmassi, F1
Hoppensteadt, D2
Jeske, W2
Andrassy, K1
Lojewski, B1
Walenga, JM1
Ahsan, A1
Baumbach, A1
Oberhoff, M1
Rübsamen, K1
Jochims, K1
Herdeg, C1
Kranzhöfer, A1
Safer, A1
Karsch, KR2
Preisack, MB1
Baildon, R2
Eschenfelder, V1
Foley, D1
Garcia, EJ1
Kaltenbach, M1
Meisner, C1
Selbmann, HK1
Serruys, PW1
Shiu, MF1
Sujatta, M1
Bonan, R1
Kakkar, VV2
Boeckl, O1
Bordenave, L1
Brehm, OA1
Brücke, P1
Coccheri, S1
Galland, F1
Jarrige, J1
LeQuerrec, A1
Parraguette, E1
Roder, JD1
Roos, M1
Rüschemeyer, C1
Siewert, JR1
Vinazzer, H1
Wenzel, E1
Hach-Wunderle, V1
Nakov, R1
Wellington, K1
McClellan, K1
Jarvis, B1
Greinacher, A1
Schwanebeck, U1
Sieder, C5
Abletshauser, C4
Tebbe, U3
Gerlach, HE3
Melzer, N4
Dorsch, O1
Krieter, DH1
Lemke, HD1
Fischer, S1
Tolle, A2
Kemkes-Matthes, B2
Gräve, M2
Patek, F1
Drexler, M1
Siemens, HJ1
Weidinger, G3
Brom, J3
Diener, HC2
Schmidt, JA1
Ringelstein, EB1
von Kummer, R1
Langohr, HD1
Bewermeyer, H1
Hennerici, M1
Welzel, D1
Tolle, AR1
Kirchmaier, CM1
Muñoz, A4
Franco, L1
Mahé, I3
Connors, JM5
Gussoni, G4
Hamulyak, EN1
Lambert, C2
Suero, MR1
Torbicki, A2
Becattini, C7
Planquette, B1
Charles-Nelson, A1
Grange, C1
Pernod, G1
Elias, A1
Falvo, N2
Sevestre, MA1
Ray, V1
Burnod, A1
Brebion, N1
Timar-David, M1
Aquilanti, S1
Constans, J1
Bura-Rivière, A1
Chatellier, G2
Meyer, G9
Lu, C1
Mithoowani, S1
Verso, M3
Huisman, M3
Hartman, LR1
Nurmeev, I1
Svirin, P1
Wolter, KD1
Yan, JL1
Jani, D1
Sherman, N1
Novak, P1
Novak, A1
Šabović, M1
Kozak, M1
Arce-Huamani, MA1
Barboza, JJ1
Martínez-Herrera, JF1
Torres-Roman, JS1
Maguiña, JL1
Lee, JH2
Jo, KW1
Huh, JW1
Oh, YM1
Lee, JS1
Sueiro, MR1
Campanini, M1
Vescovo, G2
Ebner, M1
Lankeit, M1
Miranda, S1
Levesque, H1
Li Fraine, S1
Coman, D1
Vallée Guignard, V1
Costa, JP1
Riaz, IB2
Marshall, AL2
Badgett, RG2
Vedovati, MC1
Mandalà, M1
Fuentes, HE1
Naqvi, SAA1
He, H1
Sipra, QR1
Tafur, AJ1
Padranos, L1
Vandvik, PO1
Montori, V1
Bryce, AH1
Liu, H1
Murad, MH1
Giustozzi, M1
Ruperez Blanco, AB1
Szmit, S1
Maraziti, G1
Manfellotto, D1
Sanchez, A1
McBane Ii, R1
Loprinzi, CL1
Ashrani, A1
Perez-Botero, J1
Leon Ferre, RA1
Henkin, S1
Lenz, CJ1
Le-Rademacher, JG1
Garcia, D4
Kovacs, MJ6
Yeo, E1
Zhang, G3
Zwicker, JI2
Hakoum, MB1
Kahale, LA1
Tsolakian, IG1
Matar, CF1
Yosuico, VE1
Terrenato, I1
Sperati, F1
Barba, M1
Schünemann, H1
Akl, EA1
Khorana, AA5
Lee, AYY5
Soff, G1
O'Connell, C1
Kraaijpoel, N1
Grosso, M1
Hernandez, CR1
Santamaria, A1
Lutkin, M1
Stronach, L1
Yadav, P1
Hothi, DK1
Woodruff, S1
Feugère, G1
Abreu, P1
Heissler, J1
Buller, H2
Eley, KA1
Parker, RJ1
Watt-Smith, SR1
Anderson, DR1
Dunbar, MJ1
Bohm, ER1
Belzile, E1
Zukor, D1
Gofton, W1
Gross, P1
Pelet, S1
MacDonald, S1
Kim, P1
Pleasance, S1
Davis, N1
Andreou, P1
Rodger, MA2
Ramsay, T1
Vendittoli, PA1
Lauzier, F1
Arnold, DM1
Rabbat, C2
Heels-Ansdell, D3
Zarychanski, R1
Dodek, P1
Ashley, BJ1
Albert, M2
Khwaja, K1
Ostermann, M1
Skrobik, Y2
Fowler, R2
McIntyre, L1
Nates, JL1
Karachi, T2
Zytaruk, N3
Finfer, S1
Cook, D3
Cui, W1
Li, Y1
Gao, X1
Wei, Q1
Cao, X1
Xiao, W1
Jiang, P1
Lyu, X1
Liu, F1
Gu, G1
Liu, J1
Krasiński, Z1
Szpurek, D1
Staniszewski, R1
Dzieciuchowicz, L1
Pawlaczyk, K1
Krasińska, B1
Wójcicka, K1
Urbanek, T1
Hague, WM1
Kingdom, J1
Karovitch, A1
Sermer, M1
Clement, AM1
Coat, S1
Chan, WS1
Said, J1
Rey, E1
Khurana, R1
Solymoss, S2
Hinshaw, K1
Dwyer, J1
Smith, G1
McDonald, S1
Newstead-Angel, J1
Khandelwal, M1
Silver, RM1
Greer, IA1
Keely, E1
Rosene-Montella, K1
Walker, M1
O'Brien, SH1
Kulkarni, R1
Wallace, A1
Burr, S1
Kessler, CM1
Ortel, TL2
Pabinger, I2
Park, D1
Southern, W1
Calvo, M1
Solorzano, C1
Sinnet, M1
Billett, HH1
Boda, Z1
Ockelford, P1
Kuderer, NM1
Wun, T1
Rubens, D1
Hobbs, S1
Iyer, R1
Peterson, D1
Baran, A1
Kaproth-Joslin, K1
Lyman, GH1
McMahon, GS1
Webster, SE1
Hayes, PD1
Jones, CI1
Goodall, AH1
Naylor, AR1
Puskas, D1
Bocanegra, T1
Pehrsson, S1
Johansson, K1
Kjaer, M1
Elg, M1
Meade, M2
Walter, S1
Cooper, DJ1
Vallance, S1
Qushmaq, I1
Rocha, M1
Vlahakis, NE1
Rathbun, SW2
Stoner, JA1
Aston, CE1
Husted, SE1
Lagerqvist, B1
Kontny, F3
Ståhle, E2
Swahn, E1
Ulander, VM1
Stenqvist, P1
Kaaja, R2
James, S1
Califf, R1
Husted, S1
Niemminen, M1
Pfisterer, M1
Bonet, M1
Roncales, J1
Muchart, J1
Fraile, M1
Mah, AF2
Forrest, DL1
Thompson, K1
Dorcas, VG1
Couban, SH1
Pierce, R1
Lee, AY1
Levine, MN2
Bowden, C1
Rickles, FR1
Vaitkus, PT1
Kim, JH1
Jeong, MH1
Rhew, JY1
Lim, JH1
Yun, KH1
Kim, KH1
Kang, DK1
Hong, SN1
Lim, SY1
Lee, SH1
Lee, YS1
Hong, YJ1
Park, HW1
Kim, W1
Ahn, YK1
Moon, Y1
Cho, JG1
Park, JC1
Kang, JC1
O'Neill, JL1
Flanagan, PS1
Zaleon, CR1
Copeland, LA1
Rabbat, CG1
Cook, DJ1
McDonald, E1
Clarke, F1
Meade, MO1
Lee, KA1
Cook, RJ1
Tincani, E1
Mannucci, C1
Casolari, B1
Turrini, F1
Prisco, D1
Cenci, AM1
Bondi, M1
Krafft, A1
Bauersachs, RM1
Dudenhausen, J1
Faridi, A1
Fischer, T1
Fung, S1
Geisen, U1
Herchenhan, E1
Schinzel, H1
Spannagl, M1
Thaler, CJ1
Douketis, J1
Granton, J1
Hebert, P1
Pagliarello, G1
Friedrich, J1
Freitag, A1
Sakuragawa, N1
Hasegawa, H1
Maki, M1
Nakagawa, M1
Nakashima, M1
Lafoz, E1
Olive, A1
del Rio, L1
Vedia, C1
Jeffrey, RF1
Khan, AA1
Douglas, JT1
Will, EJ1
Davison, AM1
Pellegrini, VD1
Totterman, S1
Boyd, AD1
Liebert, KM1
Stulberg, BN1
Ayers, DC1
Rosenberg, A1
Kessler, C1
Johanson, NA1
Dale, J1
Pedersen, TR1
Pan, M1
Suárez de Lezo, J1
Medina, A1
Romero, M1
Hernández, E1
Segura, J1
Melian, F1
Wangüemert, F1
Landin, M1
Benítez, F1
Amat, M1
Velasco, F1
Torres, A1
Reeves, JH1
Cumming, AR1
Gallagher, L1
O'Brien, JL1
Santamaria, JD1
Pettilä, V1
Leinonen, P1
Ekblad, U1
Kataja, M1
Ikkala, E1
Massel, D1
Morrow, B1
Gray, L1
Touchie, D1
Carrascosa Porras, M1
del Riego Martín, M1
González Ruiz, M1
Tinmouth, AH1
Morrow, BH1
Cruickshank, MK1
Moore, PM1
Cho, JH1
Yun, CH1
Seo, HS1
Koga, T1
Dan, T1
Koo, BA1
Kim, HY1
Bugeja, A1
McCormick, B1
Brown, PA1
Liberty, C1
Krepelka, T1
St-Cyr, G1
Akbari, A1
Helfer, H1
Siguret, V2
Dimakakos, EP1
Vathiotis, I1
Syrigos, K1
Janas, MS3
Jarner, MF3
Novo-Veleiro, I1
Alvela-Suárez, L1
Costa-Grille, A1
Suárez-Dono, J1
Ferrón-Vidan, F1
Pose-Reino, A1
Wu, IQ1
Tan, CW1
Wong, WH1
Ng, HJ1
Tseng, EK1
Kolesar, E1
Handa, P1
Anvari, M1
Tiboni, M1
Khalifeh, A1
Grantham, J1
Byrne, J1
McAuliffe, F1
Byrne, B1
Noel-Savina, E1
Descourt, R2
André, M1
Leroyer, C1
Martínez-Zapata, MJ1
Mathioudakis, AG1
Mousa, SA2
Kakkar, R1
Ellis, M1
Fearon, PV1
Besse, B1
Friard, S1
Corbi, P1
Azarian, R2
Monnet, I1
Alifano, M1
Chouaid, C1
Dennewald, G1
Taillade, L1
De Luca, K1
Giraud, F1
Pichon, E1
Stegmayr, BG1
Jonsson, P1
Mahmood, D1
Hainer, JW2
Sherrard, DJ1
Swan, SK1
Barrett, JS2
Assaid, CA2
Fossler, MJ2
Cox, DS2
Williams, RM1
Pittenger, AL1
Stephenson, CA1
Hua, TA1
de Maistre, E1
Allart, C1
Bollaert, PE1
Chan, S1
Kong, M1
Minning, DM1
Hedner, U2
Brant, RF1
Burke, N1
Dear, R1
Wong, T1
Cook, R1
Poon, MC1
Daskalopoulos, ME1
Daskalopoulou, SS1
Liapis, CD1
Qari, MH1
Aljaouni, SK1
Alardawi, MS1
Fatani, H1
Alsayes, FM1
Zografos, P1
Alsaigh, M1
Alalfi, A1
Alamin, M1
Gadi, A1
Lauritzen, B1
Johansen, PB1
Tranholm, M1
Ezban, M1
Sors, H1
Laaban, JP1
Laurent, M2
Hirsch, JL1
Ferrari, E1
Bosson, JL1
Mottier, D1
Beau, B1
Jensen, HP1
Poulsen, KA1
Ejstrud, P1
Andersen, BS1
Pautas, E1
Février, M1
Wipff, C1
Durand-Gasselin, B1
Andreux, JP1
d'Urso, M1
Gaussem, P1
Rose, P1
Bell, D1
Green, ES1
Davenport, A1
Fegan, C1
Grech, H1
O'Shaughnessy, D1
Voke, J1
Leathers, T1
Leese, PT1
Zheng, J1
Zhao, Y1
Xiang, Y1
Jin, Y1
Powers, P1
Neemeh, J1
Willan, A1
Skingley, P1
Morrison, RB1
Diran, LL1
Creager, MA1
Lee, TH1
Gimple, LW1
Herrmann, HC1
Winniford, M1
Mammen, E1
Heit, JA1
Morrey, BF1
Heller, S1
Krause, M1
Porreca, E1
George, DJ1
Chaudhari, U1
Lawson, F1

Clinical Trials (143)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Monitoring the Efficacy and Safety of Heparin and Nadroparin in the Acute Phase of Ischemic Stroke[NCT01862978]Phase 4150 participants (Anticipated)Interventional2013-05-31Recruiting
Contention Alone Versus Anticoagulation for Symptomatic Calf Vein Thrombosis Diagnosed by Ultrasonography[NCT00421538]Phase 3260 participants (Actual)Interventional2008-01-31Completed
The API-CALF Study: Apixaban to Treat Calf Vein Thrombosis[NCT04981327]Phase 31,300 participants (Anticipated)Interventional2022-09-01Not yet recruiting
Safety and Efficacy of the Use of Regional Anticoagulation With Citrate in Continuous Venovenous Hemofiltration, a Randomized Controlled Trial Comparing Anticoagulation With Citrate to the Low Molecular Weight Heparin Nadroparin[NCT00286273]Phase 4215 participants (Actual)Interventional2003-03-31Completed
Simplified Regional Citrate Anticoagulation Protocols for CVVH, CVVHDF and SLED Focused on the Prevention of RRT-related Hypophosphatemia and Optimization of Acid-base Balance: a Pilot Study[NCT03976440]30 participants (Anticipated)Observational2019-06-01Active, not recruiting
A Randomized, Controlled Trial to Evaluate the Effects of Nadroparin on Survival and Disease Progression in Patients With Advanced Malignancies of the Lung, Pancreas, or Prostate[NCT00312013]Phase 3503 participants (Actual)Interventional2006-05-31Completed
Criteria for Hospitalization or Outpatient Management of Patients With Pulmonary Embolism, Hestia Rule Versus Simplified PESI Score : an Open-label Controlled Randomized International Trial (HOME-PE)[NCT02811237]1,975 participants (Actual)Interventional2017-01-31Completed
A Double Blind Randomized Control Trial of Post-Operative Low Molecular Weight Heparin Bridging Therapy Versus Placebo Bridging Therapy for Patients Who Are at High Risk for Arterial Thromboembolism (PERIOP 2)[NCT00432796]Phase 31,473 participants (Actual)Interventional2006-12-31Active, not recruiting
A Randomized Trial of the Effect of Low-Molecular-Weight Heparin Versus Warfarin Sodium on the Mortality in the Long-Term Treatment of Proximal Deep Vein Thrombosis (Main LITE Study)[NCT00203580]Phase 4910 participants Interventional1994-12-31Completed
LITE Study, Appendix A (HOME-LITE), Amendment 6[NCT00203658]Phase 4400 participants Interventional1997-04-30Completed
Rapid Risk Stratification for Outpatient Treatment of Low-risk Pulmonary Embolism[NCT02355548]200 participants (Anticipated)Observational2012-12-31Completed
Parnaparin Versus Aspirin in the Treatment of Retinal Vein Occlusion. A Randomized, Double Blind, Controlled Study[NCT00732927]Phase 367 participants (Actual)Interventional2002-07-31Terminated (stopped due to slow recruitment rate)
Multicenter, Randomized, Open and Sequential Study to Evaluate the Efficacy and Safety of Bemiparin Administration on the Response to Treatment in Patients Diagnosed With Limited Small Cell Lung Cancer[NCT00324558]Phase 239 participants (Actual)Interventional2005-06-30Terminated (stopped due to Sponsor stopped due to difficulties to recruit 130 patients required by protocol)
Bemiparin Versus Enoxaparin in the Prevention of Venous Thromboembolism Among ICU Patients[NCT02795065]100 participants (Actual)Interventional2014-03-31Completed
Multicenter, Randomized, Parallel-group Efficacy and Safety Study for the Prevention of Venous Thromboembolism in Hospitalized Medically Ill Patients Comparing Rivaroxaban With Enoxaparin. The MAGELLAN Study[NCT00571649]Phase 38,101 participants (Actual)Interventional2007-12-31Completed
Medically Ill Patient Assessment of Rivaroxaban Versus Placebo in Reducing Post-Discharge Venous Thrombo-Embolism Risk[NCT02111564]Phase 312,024 participants (Actual)Interventional2014-01-07Completed
Evaluation of Warfarin Initiation at 3mg Versus 5mg for Anticoagulation of Mechanical Mitral Valve Replacement Patients[NCT04235569]Phase 450 participants (Actual)Interventional2018-03-01Completed
Major Bleeding Risk Associated With Antithrombotics : The SACHA (Surveillance Des Accidents Hémorragiques Graves Sous Antithrombotiques) Study[NCT02886533]6,484 participants (Actual)Observational2013-01-01Completed
COVID-19 Anticoagulation in Children - Thromboprophlaxis (COVAC-TP) Trial[NCT04354155]Phase 240 participants (Actual)Interventional2020-06-02Completed
Early Thromboprophylaxis in COVID-19 (ETHIC Trial): an Open Label, Randomized Phase IIIb Trial of Community-based (LMWH) Versus Standard of Care (no Enoxaparin) in COVID-19 Positive Patients[NCT04492254]Phase 3219 participants (Actual)Interventional2020-10-27Terminated (stopped due to Average event rate (end point) was much lower than expected. A larger sample size would have been required to maintain same statistical power, which was not achievable in a feasible time scale. No safety concerns were identified with bleeding.)
A Randomized, Active-comparator-controlled, Multicenter Study to Assess the Safety and Efficacy of Different Doses of BAY1213790 for the Prevention of Venous Thromboembolism in Patients Undergoing Elective Primary Total Knee Arthroplasty, Open-label to Tr[NCT03276143]Phase 2813 participants (Actual)Interventional2017-09-21Completed
A Phase 1, Open-label, 2-period, Fixed-sequence Study to Evaluate the Safety and Tolerability of DS-1040b IV Infusion Coadministered With Clopidogrel in Healthy Subjects[NCT02560688]Phase 122 participants (Actual)Interventional2015-12-31Completed
A PHASE 1, OPEN LABEL, SINGLE DOSE STUDY, TO ASSESS THE SAFETY AND TOLERABILITY OF A SINGLE IV DOSE OF DS-1040B AFTER 5 DAYS OF ASPIRIN TREATMENT IN HEALTHY SUBJECTS[NCT02071004]Phase 118 participants (Actual)Interventional2014-01-31Completed
A Multicentre, Randomised, Double-blind, Controlled, Phase IIIb Study to Assess the Efficacy and Safety of Rivaroxaban 10mg od Versus Enoxaparin 4000 UI for VTE PROphylaxis in NOn Major Orthopaedic Surgery[NCT02401594]Phase 33,608 participants (Actual)Interventional2015-12-08Terminated (stopped due to Remaining outdated treatments and additional costs too high for new manufacturing)
Safety and Efficacy of Low Molecular Weight Heparin Versus Rivaroxaban in Chinese Patients Hospitalized With Acute Coronary Syndrome(H-REPLACE): a Prospective, Randomized, Open-label, Active-controlled, Multicenter Trial[NCT03363035]Phase 42,055 participants (Actual)Interventional2018-01-15Completed
Efficacy and Safety of Apixaban in Patients With Active Malignancy and Acute Deep Venous Thrombosis.[NCT04462003]Phase 3100 participants (Anticipated)Interventional2019-07-03Recruiting
Intermediate-dose Versus Standard Prophylactic Anticoagulation In cRitically-ill pATIents With COVID-19: An opeN Label Randomized Controlled Trial---A Randomized Trial of Atorvastatin vs. Placebo In Critically-ill Patients With COVID-19[NCT04486508]Phase 3600 participants (Actual)Interventional2020-07-30Completed
Evaluation of the Effect of Exogenous Surfactant Through Nebulizer Mask on Clinical Outcomes in Covid-19 Patients[NCT04847375]60 participants (Anticipated)Interventional2021-04-20Not yet recruiting
Randomized Clinical Trial to Evaluate a Routine Full Anticoagulation Strategy in Patients With Coronavirus (COVID-19) - COALIZAO ACTION Trial[NCT04394377]Phase 4615 participants (Actual)Interventional2020-06-21Completed
Standardized, Guidelines Directed But Patients Oriented Clinical Practice Prospectively Registered[NCT03504007]10,000 participants (Anticipated)Observational2013-03-01Recruiting
STREAM (Strategic Reperfusion Early After Myocardial Infarction). Comparison of the Efficacy and Safety of a Strategy of Early Fibrinolytic Treatment With Tenecteplase and Additional Antiplatelet and Antithrombin Therapy Followed by Catheterisation Within[NCT00623623]Phase 31,899 participants (Actual)Interventional2008-03-01Completed
(Apex) Multicenter, Randomized, Active-Controlled Efficacy And Safety Study Comparing Extended Duration Betrixaban With Standard Of Care Enoxaparin For The Prevention Of Venous Thromboembolism In Acute Medically Ill Patients[NCT01583218]Phase 37,513 participants (Actual)Interventional2012-03-31Completed
A Double-Blind, Placebo-Controlled, Parallel, Multicenter Study on Extended VTE Prophylaxis in Acutely Ill Medical Patients With Prolonged Immobilization[NCT00077753]Phase 44,726 participants Interventional2002-02-28Completed
A Phase 3 Randomized, Double-Blind, Parallel-group, Multi-center Study of the Safety and Efficacy of Apixaban for Prophylaxis of Venous Thromboembolism in Acutely Ill Medical Subjects During and Following Hospitalization.[NCT00457002]Phase 36,758 participants (Actual)Interventional2007-06-30Completed
A Randomized Phase III Study of Standard Treatment +/- Enoxaparin in Small Cell Lung Cancer[NCT00717938]Phase 3390 participants (Actual)Interventional2008-06-30Completed
Evaluation of Non-Surgical Venous Thromboembolism Prophylaxis Dosing Strategies: Enoxaparin 20mg Versus 30mg Subcutaneously Once Daily in Elderly Patients With Impaired Renal Function[NCT03158792]Phase 432 participants (Actual)Interventional2015-10-24Completed
Title: EHR Embedded Risk Calculator vs. Standard VTE Prophylaxis for Medical Patients[NCT03243708]90,537 participants (Actual)Interventional2017-12-04Completed
A Safety and Efficacy Trial Evaluating the Use of Apixaban in the Treatment of Symptomatic Deep Vein Thrombosis and Pulmonary Embolism[NCT00643201]Phase 35,614 participants (Actual)Interventional2008-07-31Completed
Standard-dose Apixaban AFtEr Very Low-dose ThromboLYSis for Acute Intermediate-high Risk Acute Pulmonary Embolism[NCT03988842]Phase 44 participants (Actual)Interventional2019-07-25Terminated (stopped due to COVID-19 pandemic)
Efficacy and Safety of Apixaban in Reducing Restenosis and Limb Loss in Subjects With Symptomatic Peripheral Artery Disease (PAD) Undergoing Infrapopliteal Endovascular Peripheral Revascularization Procedures in Patients With Critical Limb[NCT04229264]Phase 3200 participants (Anticipated)Interventional2020-01-09Recruiting
Randomized Trial to Test the Effect of Rivaroxaban or Apixaban on Menstrual Blood Loss in Women[NCT02829957]Phase 2/Phase 319 participants (Actual)Interventional2016-09-30Completed
Apixaban for the Secondary Prevention of Thromboembolism: a Prospective Randomized Outcome Pilot Study Among Patients With the AntiphosPholipid Syndrome[NCT02295475]Phase 448 participants (Actual)Interventional2014-12-10Completed
A Prospective, Randomized, Open-Label, Blinded Endpoint Evaluation (PROBE) Parallel Group Study Comparing Edoxaban vs. VKA in Subjects Undergoing Catheter Ablation of Non-valvular Atrial Fibrillation (ELIMINATE-AF)[NCT02942576]Phase 3632 participants (Actual)Interventional2017-03-21Completed
Non-Interventional Study on Edoxaban Treatment in Routine Clinical Practice in Patients With Venous Thromboembolism (VTE) in Korea and Taiwan[NCT02952599]352 participants (Actual)Observational2017-03-27Completed
The Portuguese Survey on Anticoagulated Patients Register (START-Portugal-Register)[NCT03977363]25 participants (Actual)Observational [Patient Registry]2020-01-27Terminated (stopped due to Halted Prematurely)
Non-Interventional Study on Edoxaban Treatment in Routine Clinical Practice in Patients With Venous Thromboembolism in Europe[NCT02943993]2,809 participants (Actual)Observational2016-04-06Completed
A Phase 3, Open-label, Randomized, Multi-center, Controlled Trial to Evaluate the Pharmacokinetics and Pharmacodynamics of Edoxaban and to Compare the Efficacy and Safety of Edoxaban With Standard of Care Anticoagulant Therapy in Pediatric Subjects From B[NCT02798471]Phase 3290 participants (Actual)Interventional2017-03-27Completed
Effects of Edoxaban on Platelet Aggregation in Patients With Stable Coronary Artery Disease[NCT05122455]Phase 2/Phase 370 participants (Anticipated)Interventional2021-09-14Recruiting
A Phase 3, Randomized, Parallel-Group, Multi-Center, Multi-National Study for the Evaluation of Efficacy and Safety of (LMW) Heparin/Edoxaban Versus (LMW) Heparin/Warfarin in Subjects With Symptomatic Deep-Vein Thrombosis (DVT) and or Pulmonary Embolism ([NCT00986154]Phase 38,292 participants (Actual)Interventional2009-10-31Completed
A Randomized, Double-Blind, Double-Dummy, Parallel Group Study to Compare YM150 Bid and qd Doses and Enoxaparin for Prevention of Venous Thromboembolism in Subjects Undergoing Elective Hip Replacement Surgery[NCT00902928]Phase 2/Phase 31,992 participants (Actual)Interventional2009-04-30Completed
Xarelto in the Prophylaxis of Post Surgical Venous Thromboembolism After Elective Major Orthopedic Surgery of Hip or Knee[NCT00831714]19,076 participants (Actual)Observational2009-02-28Completed
Diagnostic and Prognostic Value of Cardiac Biomarkers and Echocardiography for Patients Hospitalized Due to Acute Dyspnea: Prospective Observational Multicenter Cohort Study[NCT03048032]1,566 participants (Actual)Observational2015-04-30Completed
French Registry of Acute Coronary Syndrome With or Without ST Elevation 2010[NCT01237418]3,700 participants (Anticipated)Observational2010-10-31Active, not recruiting
An Open-label, Randomized, Active Comparator-Controlled, Adaptive Parallel-group Phase 2 Study to Assess the Safety and Efficacy of Multiple Doses of ISIS 416858 Administered Subcutaneously to Patients Undergoing Total Knee Arthroplasty[NCT01713361]Phase 2315 participants (Actual)Interventional2012-10-31Completed
Comparing Anti-XA Levels in Post-Cesarean Patients With BMI >35 Undergoing Enoxaparin Thromboprophylaxis With Weight Based Dosing Twice Daily Versus Fixed Dose 40 Milligrams Daily[NCT02070237]Phase 190 participants (Actual)Interventional2013-08-31Completed
Strategies for Anticoagulation During Venovenous ECMO: The SAFE-ECMO Pilot Trial[NCT04997265]30 participants (Anticipated)Interventional2022-05-12Recruiting
Anticoagulation-free VV ECMO for Acute Respiratory Failure: A Pilot Safety and Feasibility Randomized Clinical Trial[NCT04273607]Phase 2/Phase 340 participants (Anticipated)Interventional2022-09-01Recruiting
Optimal Delay Time to Initiate Anticoagulation After Ischemic Stroke in Atrial Fibrillation[NCT03021928]Phase 3200 participants (Actual)Interventional2017-06-14Active, not recruiting
Prospective, Open-Label Study of Andexanet Alfa in Patients Receiving a Factor Xa Inhibitor Who Have Acute Major Bleeding (ANNEXA-4)[NCT02329327]Phase 3479 participants (Actual)Interventional2015-04-10Completed
A Prospective, Randomized, Open-Label Blinded Endpoint Evaluation (PROBE) Parallel Group Study Comparing Edoxaban (DU-176b) With Enoxaparin/Warfarin Followed by Warfarin Alone in Subjects Undergoing Planned Electrical Cardioversion of Nonvalvular Atrial F[NCT02072434]Phase 32,199 participants (Actual)Interventional2014-03-25Completed
The Blood Saving Effect and Wound-related Complications of Tranexamic Acid in Mininally Invasive Total Knee Arthroplasty With Rivaroxaban as Thromboprophylaxis[NCT02458729]Phase 4294 participants (Actual)Interventional2012-08-31Completed
An International Phase 2-3, Stratified, Randomized, Open-label, Parallel-group Clinical Trial to Evaluate the Safety and Efficacy of a Single Intravenous Bolus of Enoxaparin Versus Intravenous Unfractionated Heparin in Patients Undergoing Non-emergent Per[NCT00077844]Phase 2/Phase 33,532 participants (Anticipated)Interventional2004-01-31Completed
The ACUITY Trial: A Randomized Comparison of Angiomax (Bivalirudin) Versus Heparin (Unfractionated Heparin or Enoxaparin) in Patients Undergoing Early Invasive Management for Acute Coronary Syndromes Without ST-Segment Elevation[NCT00093158]Phase 313,800 participants Interventional2003-08-31Completed
An Efficacy and Safety Study of Rivaroxaban for the Prevention of Deep Vein Thrombosis in Patients With Left Iliac Vein Compression Treated With Stent Implantation (PLICTS):A Prospective Randomized Controlled Trial[NCT04067505]Phase 3224 participants (Anticipated)Interventional2020-05-18Recruiting
RECORD 4 Study: REgulation of Coagulation in ORthopedic Surgery to Prevent DVT and PE; a Controlled, Double-blind, Randomized Study of BAY59-7939 in the Prevention of VTE in Subjects Undergoing Elective Total Knee Replacement[NCT00362232]Phase 33,148 participants (Actual)Interventional2006-06-30Completed
An Efficacy and Safety Study of New Oral Anticoagulants and Vitamin K Antagonists for the Anticoagulation for the Implantation of Vena Cava Filters: A Prospective Randomized Controlled Trial[NCT04066764]Phase 3200 participants (Anticipated)Interventional2020-05-08Recruiting
Comparison of Topical and Infusion Tranexamic Acid on Blood Loss and Risk of Deep Vein Thrombosis After Total Knee Arthroplasty[NCT02453802]Phase 490 participants (Anticipated)Interventional2015-06-30Not yet recruiting
A Phase 3 Randomized, Double-Blind Active-Controlled (Enoxaparin), Parallel-Group, Multi-Center Study to Evaluate the Safety and Efficacy of Oral Apixaban in Subjects Undergoing Elective Total Knee Replacement Surgery[NCT00371683]Phase 33,608 participants (Actual)Interventional2006-11-30Completed
An International, Randomized, Double-blind Study Evaluating the Efficacy and Safety of Fondaparinux Versus Enoxaparin in the Acute Treatment of Unstable Angina/Non ST-segment Elevation MI Acute Coronary Syndromes[NCT00139815]Phase 320,078 participants (Actual)Interventional2003-04-30Completed
Influence of the Compression Method After Transradial Catheterization in Radial Artery[NCT02697526]274 participants (Actual)Interventional2007-01-31Completed
XENITH: Rivaroxaban for Pulmonary Embolism Managed With Catheter Directed Thrombolysis[NCT02506985]Phase 410 participants (Actual)Interventional2015-07-31Terminated
A Randomized, Double-Blind, Double-Dummy , Parallel Group, Multinational, Clinical Study to Evaluate the Efficacy and Safety of Enoxaparin Versus Unfractionated Heparin in Patients With Acute ST-Segment Elevation Myocardial Infarction Receiving Fibrinolyt[NCT00077792]Phase 320,506 participants (Actual)Interventional2002-10-31Completed
Incidence and Characteristics of Pulmonary Embolism in COVID-19 Patients Hospitalized for Acute Respiratory Syndrome[NCT04420312]1,024 participants (Actual)Observational2020-03-01Completed
A Phase 2, Randomized, Active Comparator-Controlled, Dose-Ranging Study to Evaluate the Efficacy and Safety of TAK-442 in Subjects Undergoing Total Knee Replacement[NCT00641732]Phase 21,045 participants (Actual)Interventional2007-10-31Completed
Oral Direct Factor Xa Inhibitor Rivaroxaban in Patients With Acute Symptomatic Deep-Vein Thrombosis or Pulmonary Embolism[NCT00440193]Phase 33,449 participants (Actual)Interventional2007-03-31Completed
Once-daily Oral Direct Factor Xa Inhibitor Rivaroxaban in the Long-term Prevention of Recurrent Symptomatic Venous Thromboembolism in Patients With Symptomatic Deep-vein Thrombosis or Pulmonary Embolism. The Einstein-Extension Study[NCT00439725]Phase 31,197 participants (Actual)Interventional2007-02-28Completed
Comparison of the Efficacy of Rivroxaban to Coumadin( Warfarin ) in Cerebral Venous Thrombosis[NCT03191305]50 participants (Anticipated)Interventional2017-08-31Not yet recruiting
A Phase 3 Randomized, Double-blind, Active-controlled, Parallel-group, Multi-center Study to Evaluate the Safety and Efficacy of Apixaban in Subjects Undergoing Elective Total Hip Replacement Surgery (The Advance-3 Study Apixaban Dosed Orally Versus Antic[NCT00423319]Phase 35,407 participants (Actual)Interventional2007-03-31Completed
A Phase III Randomised, Parallel Group, Double-blind, Active Controlled Study to Investigate the Efficacy and Safety of Orally Administered 220 mg Dabigatran Etexilate Capsules (110 mg Administered on the Day of Surgery Followed by 220 mg Once Daily) Comp[NCT00657150]Phase 32,055 participants (Actual)Interventional2008-03-31Completed
Low-molecular-weight Heparin Versus Unfractionated Heparin in Pregnant Women With History of Recurrent Abortion Secondary to Antiphospholipid Syndrome. A Randomized Controlled Trial[NCT01051778]Phase 260 participants (Actual)Interventional2006-06-30Completed
Thrombosis in Newly Diagnosed Multiple Myeloma Patients: a Clinical Audit of Intermediate Dose Low Molecular Weight Heparin[NCT05541978]140 participants (Actual)Observational2022-09-01Completed
Evaluation of the Use of an Oral Direct Anti-Xa Anticoagulant, Apixaban, in Prevention of Venous Thromboembolic Disease in Patients Treated With IMiDs During Myeloma : a Pilot Study[NCT02066454]Phase 3105 participants (Anticipated)Interventional2014-04-30Recruiting
A Prospective, Randomized, Open-Label, Multicenter Study in Patients Presenting With Acute Coronary Syndromes (ACS)[NCT00043784]Phase 38,000 participants Interventional2001-08-31Completed
Outpatient Treatment of Low-risk Patients With Pulmonary Embolism: a Randomized-controlled Trial[NCT00425542]Phase 3343 participants (Actual)Interventional2007-01-31Completed
International, Multi-center, Randomized, Double Blind Study to Compare the Overall Mortality in Acutely Ill Medical Patients Treated With Enoxaparin Versus Placebo in Addition to Graduated Elastic Stockings[NCT00622648]Phase 48,329 participants (Actual)Interventional2008-01-31Completed
Prospective Study of the Assessment of the Dental Protocol for Tooth Extraction in Patients With Atrial Fibrillation in Continuous Use of New Oral Anticoagulants: A Pilot Study[NCT03181386]Phase 360 participants (Actual)Interventional2017-05-03Completed
Optimizing the Anticoagulation Regimen of Enoxaparin During Percutaneous Coronary Intervention[NCT03145675]Phase 4378 participants (Actual)Interventional2017-05-12Completed
A Multinational, Multicenter, Randomized, Double-Blind Study Comparing the Efficacy and Safety of AVE5026 With Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Elective Total Hip Replacement Surgery[NCT00697099]Phase 32,326 participants (Actual)Interventional2008-06-30Completed
A Multinational, Multicenter, Randomized, Double-Blind Study Comparing the Efficacy and Safety of AVE5026 With Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Hip Fracture Surgery[NCT00721760]Phase 31,003 participants (Actual)Interventional2008-07-31Completed
A Multinational, Multicenter, Randomized, Double-blind Study Comparing the Efficacy and Safety of Semuloparin (AVE5026) With Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Elective Knee Replacement Surgery[NCT00718224]Phase 31,150 participants (Actual)Interventional2008-07-31Completed
Rivaroxaban Post-Transradial Access for the Prevention of Radial Artery Occlusion[NCT03630055]Phase 31,800 participants (Anticipated)Interventional2018-10-03Recruiting
Oral Direct Factor Xa Inhibitor Rivaroxaban in Patients With Acute Symptomatic Deep-Vein Thrombosis or Pulmonary Embolism[NCT00439777]Phase 34,833 participants (Actual)Interventional2007-03-31Completed
Multi-center、Randomize、Open、Non-inferiority Study of Prophylactic Effect of Rivaroxaban on Venous Thromboembolism in AECOPD[NCT03277001]438 participants (Anticipated)Interventional2017-10-01Not yet recruiting
Thromboprophylaxis in Patients Undergoing Orthopedic Surgeries; Focus on Cost-effective Analysis and Safety Comparison Between Rivaroxaban and Enoxaparin[NCT03299296]Phase 3100 participants (Actual)Interventional2017-01-01Enrolling by invitation
A Phase 3, Randomized, Double-blind, Active-controlled (Enoxaparin 40 mg QD), Parallel-group, Multi-center Study to Evaluate the Safety and Efficacy of Apixaban in Subjects Undergoing Elective Total Knee Replacement Surgery (The ADVANCE - 2 Study)[NCT00452530]Phase 33,221 participants (Actual)Interventional2007-06-30Completed
Once Daily Enoxaparin for Outpatient Treatment of Acute Deep Venous Thrombosis and/or Pulmonary Embolism[NCT00413374]40 participants (Actual)Interventional2006-05-31Completed
Multicenter Open Label Randomized Comparative Study of Efficacy and Safety of Single Bolus Injection of Recombinant Nonimmunogenic Staphylokinase (Fortelyzin) and Bolus Infusion Alteplase (Actilyse) in Patients With Acute Ischemic Stroke[NCT03151993]Phase 3336 participants (Actual)Interventional2017-03-18Completed
Multicenter Open Lable Randomized Comparative Study of Efficacy and Safety of Single Bolus Injection of Recombinant Nonimmunogenic Staphylokinase (Fortelyzin) and Tenecteplase (Metalyse) in STEMI Patients[NCT02301910]Phase 3392 participants (Anticipated)Interventional2014-10-31Recruiting
Pharmacodynamics Study of Enoxalow, Produced by Blau Farmacêutica S/A, Compared to Clexane, Produced by Sanofi-Aventis Farmacêutica Ltda, in Healthy Subjects After Intravenous Administration.[NCT01692171]Phase 132 participants (Actual)Interventional2013-02-28Completed
A Muticenter, Randomized, Double-blind, Placebo Controlled Trial Comparing the Efficacy and Safety of Reteplease and Abciximab Combination Therapy With Abciximab Alone Administered Early or Just Prior to Primary Primary Percutaneous Coronary Intervention [NCT00046228]Phase 32,461 participants (Actual)Interventional2002-08-31Completed
Fondaparinux as Monotherapy for Deep Vein Thrombosis and/or Pulmonary Embolism (Pilot Study)[NCT00413504]30 participants (Actual)Interventional2006-04-30Completed
Trousseau Studie, Mortaliteit Door Maligniteit Bij patiënten Met Idiopatische Veneuze Tromboembolie[NCT01088334]630 participants (Actual)Observational2002-12-31Terminated (stopped due to Terminated because of futility to continue, after planned interim analysis.)
Effect of Low Molecular Weight Heparin vs Unfractionated Heparin on Bleeding After Cardiac Surgery[NCT00420667]43 participants (Actual)Interventional2004-11-30Completed
Anti-Xa Assay Correlation to the Efficacy and Safety of Enoxaparin in the Treatment of Pulmonary Embolism[NCT02977013]42 participants (Actual)Observational2013-08-31Completed
Study of the Bioaccumulation of Tinzaparin in Renally Impaired Patients When Given at Prophylactic Doses[NCT02719418]28 participants (Actual)Observational2016-02-01Completed
The Safety and Efficacy of Fondaparinux 1,5 mg for the Prevention of Venous Thromboembolism in Medical Patients With Renal Insufficiency[NCT00927602]Phase 4206 participants (Actual)Interventional2009-04-30Terminated (stopped due to study was stopped after enrolment of about 200 patients for slow recruitment)
Comparative Feasibility and Efficacy of a Five Compartment Technique Using 0.25% Bupivacaine vs a Mixture of 0.25% Bupivacaine and 1.3 % Liposomal Bupivacaine in Patients Undergoing Tka; a Single Blinded Randomized Controlled Study[NCT03303794]Phase 325 participants (Actual)Interventional2017-10-25Terminated (stopped due to Interim Analysis showed no significance)
A Phase III Randomised, Parallel Group, Double-blind, Active Controlled Study to Investigate the Efficacy and Safety of Two Different Dose Regimens of Orally Administered Dabigatran Etexilate Capsules [150 or 220 mg Once Daily Starting With Half Dose (75 [NCT00168818]Phase 33,494 participants (Actual)Interventional2004-11-30Completed
A Hemodynamic Comparison of Stationary and Portable Pneumatic Compression Devices[NCT02345642]20 participants (Actual)Interventional2015-02-28Completed
Study of the Efficacy, Safety and Tolerability of Low Molecular Weight Heparin vs. Unfractionated Heparin as Bridging Therapy in Patients With Embolic Stroke Due to Atrial Fibrillation[NCT02159287]Phase 280 participants (Anticipated)Interventional2014-01-31Recruiting
PREPIC 2 : Interruption of Inferior Vena Cava by a Retrievable Filter for the Prevention of Recurrent Pulmonary Embolism : a Randomised, Open Label Study[NCT00457158]Phase 4399 participants (Actual)Interventional2006-07-31Completed
Retrievable Inferior Vena Cava Filter for Primary Pulmonary Embolism Prophylaxis in At-Risk Trauma Patients: RIPT Feasibility Trial[NCT03070834]42 participants (Actual)Interventional2017-07-01Completed
The Use of Fondaparinux in Preventing Thromboembolism in High Risk Trauma Patients[NCT00531843]Phase 2/Phase 3105 participants (Actual)Interventional2007-12-31Completed
An Open-label Comparison of the Efficacy and Safety of the Low-molecular-weight Heparin (3000 U Anti-Xa Once Daily) With Unfractionated Heparin for the Prevention of Thromboembolic Complications in Acutely Ill Non-surgical Patients[NCT00311753]Phase 3342 participants (Actual)Interventional2006-02-28Completed
A Randomized, Double-blind, Multi-center Comparison of the Efficacy and Safety of Certoparin (3000 U Anti-Xa o.d.) With Unfractionated Heparin (5000 IU t.i.d.) in the Prophylaxis of Thromboembolic Events in Acutely Ill Medical Patients[NCT00451412]Phase 33,254 participants (Actual)Interventional2007-01-31Completed
A Multi-center, Prospective, Open-label, 8-weeks Study to Investigate the Efficacy, Safety and Pharmacokinetics of Certoparin (3000 IU Anti-Xa Bolus, With the Option to Titrate Dose)in the Prophylaxis of Clotting in the Extracorporeal Circuit in Patients [NCT01179620]Phase 3109 participants (Actual)Interventional2010-11-30Completed
Efficacy and Safety of Oral Rivaroxaban for the Treatment of Venous Thromboembolism in Patients With Active Cancer. A Pilot Study.[NCT02746185]Phase 3159 participants (Actual)Interventional2016-09-30Completed
A THREE MONTH PROSPECTIVE OPEN LABEL STUDY OF THERAPY WITH FRAGMIN(REGISTERED) (DALTEPARIN SODIUM INJECTION) IN CHILDREN WITH VENOUS THROMBOEMBOLISM WITH OR WITHOUT MALIGNANCIES[NCT00952380]Phase 238 participants (Actual)Interventional2009-08-31Completed
Apixaban for the Treatment of Venous Thromboembolism in Patients With Cancer: A Prospective Randomized Open Blinded End-Point (Probe) Study[NCT03045406]Phase 31,168 participants (Actual)Interventional2017-04-13Active, not recruiting
CONKO_011/ AIO-SUP-0115/Ass.: Rivaroxaban in the Treatment of Venous Thromboembolism (VTE) in Cancer Patients - a Randomized Phase III Study[NCT02583191]Phase 3246 participants (Actual)Interventional2016-03-23Terminated (stopped due to Recruitment was not as expected.)
Direct Oral Anticoagulants (DOACs) Versus LMWH +/- Warfarin for VTE in Cancer: A Randomized Effectiveness Trial (CANVAS Trial)[NCT02744092]811 participants (Actual)Interventional2016-12-13Completed
A Randomized Phase II Open Label Study to Compare the Safety and Efficacy of Subcutaneous Dalteparin Versus Direct Oral Anticoagulants for Cancer-associated Venous Thromboembolism in Patients With Advanced Upper Gastrointestinal, Hepatobiliary and Pancrea[NCT03139487]Phase 2176 participants (Anticipated)Interventional2017-08-07Recruiting
A Phase III, Randomized, Open Label Study Evaluating the Safety of Apixaban in Subjects With Cancer Related Venous Thromboembolism[NCT02585713]Phase 3300 participants (Actual)Interventional2015-11-20Completed
Safety and Efficacy of Switching From Direct Oral Anticoagulants to Low Molecular Weight Heparin in Cancer Patients With Atrial Fibrillation During Antineoplastic Therapy[NCT04508855]240 participants (Anticipated)Observational2020-08-01Recruiting
A Phase 3b, Prospective, Randomized, Open-label, Blind Evaluator (PROBE) Study Evaluating the Efficacy and Safety of (LMW) Heparin/Edoxaban Versus Dalteparin in Venous Thromboembolism Associated With Cancer[NCT02073682]Phase 31,046 participants (Actual)Interventional2015-07-16Completed
A Different Approach to Preventing Thrombosis (ADAPT): A Randomized Controlled Trial Comparing Low Molecular Weight Heparin to Acetylsalicylic Acid in Orthopedic Trauma Patients[NCT02774265]Phase 3329 participants (Actual)Interventional2016-01-31Completed
PROphylaxis for ThromboEmbolism in Critical Care Trial (PROTECT)[NCT00182143]Phase 33,659 participants (Actual)Interventional2006-05-31Completed
TIPPS - Thrombophilia in Pregnancy Prophylaxis Study: A Multicentre, Multinational, Randomized Control Trial of Prophylaxis Low Molecular Weight Heparin (LMWH) in High-risk Thrombophilic Women.[NCT00967382]Phase 3292 participants (Actual)Interventional2000-07-31Completed
A Prospective Randomized Multicenter Study of Dalteparin Prophylaxis in High-Risk Ambulatory Cancer Patients[NCT00876915]Phase 3218 participants (Actual)Interventional2009-07-31Terminated (stopped due to slow enrollment and lack of continuing funds)
Management of Superficial Thrombophlebitis[NCT00264381]Phase 472 participants (Actual)Interventional2002-10-31Completed
Analysis of Pro-coagulant and Thrombin-generation Markers for the Prediction of Therapeutic Failure in Cancer Patients at Risk for Recurrence of Venous Thromboembolism: A Pilot Study[NCT01602445]700 participants (Anticipated)Observational2012-07-31Completed
Randomized, Phase III-b, Multi-centre, Open-label, Parallel Study of Enoxaparin (Low Molecular Weight Heparin) Given Concomitantly With Chemotherapy vs Chemotherapy Alone in Patients With Inoperable Gastric and Gastro-oesophageal Cancer[NCT00718354]Phase 3740 participants (Actual)Interventional2008-07-31Completed
Anti Xa Activity in Cancer Patients Receiving Low-molecular-weight Heparin for Venous Thromboembolism[NCT02898051]370 participants (Actual)Observational2011-08-31Active, not recruiting
Long-term Treatment for Cancer Patients With Deep Venous Thrombosis or Pulmonary Embolism[NCT01164046]Phase 356 participants (Actual)Interventional2010-08-31Terminated (stopped due to Due to slow inclusion of patients)
Implementing a Tool to Identify Risk for Venous Thromboembolism in Cancer Patients[NCT01602432]0 participants (Actual)Observational2012-11-30Withdrawn (stopped due to Project did not meet criteria of a research study and was confirmed as a Quality Initiative Project)
Weight Based Enoxaparin for Venous Thromboembolism Prophylaxis in Trauma Patients[NCT01916707]Phase 41,200 participants (Anticipated)Interventional2013-07-31Active, not recruiting
Norwegian Intensive Care Unit Dalteparin Effect Study[NCT01721928]70 participants (Actual)Observational2012-12-03Completed
Dalteparin's Influence on Renally Compromised: Anti-Ten-A Study (DIRECT)[NCT00138099]140 participants (Actual)Observational2004-07-31Completed
Efficacy and Safety of Long-Term (6 Months) Innohep® Treatment Versus Anticoagulation With a Vitamin K Antagonist (Warfarin) for the Treatment of Acute Venous Thromboembolism in Cancer Patients / IN 0901 INT[NCT01130025]Phase 3900 participants (Actual)Interventional2010-08-31Completed
A Prospective, Randomized, Double-blind, Placebo Controlled, Multi-national Study of Therapeutic Anticoagulation Strategy for Acute Chest Syndrome in Adults[NCT02580773]Phase 3200 participants (Anticipated)Interventional2016-12-16Recruiting
EXercise Training for the Prevention of Cancer Thrombosis (EXPECT) Pilot Trial[NCT01853202]40 participants (Actual)Interventional2013-03-31Completed
Risk Factors for Thromboembolic and Infectious Complications Related to Percutaneous Central Venous Catheters in Cancer - Prospective Multicenter Study[NCT02025894]3,032 participants (Actual)Observational2010-06-30Completed
A Multinational, Randomized, Double Blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of AVE5026 in the Prevention of Venous Thromboembolism (VTE) in Cancer Patients at High Risk for VTE and Who Are Undergoing Chemotherapy[NCT00694382]Phase 33,212 participants (Actual)Interventional2008-06-30Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Percentage of Participants With Composite Endpoint of Venous Thromboembolism [VTE] (Any Deep Vein Thrombosis [DVT], Non Fatal Pulmonary Embolism [PE]) and VTE-related Death up to Day 35 + 6 Days

A composite endpoint of: asymptomatic proximal DVT in lower extremity detected by mandatory bilateral lower extremity venous ultrasonography; symptomatic DVT in lower extremity, proximal or distal; symptomatic, non-fatal PE; and VTE-related death. (NCT00571649)
Timeframe: Up to Day 35 + 6 days

InterventionPercentage of participants (Number)
Rivaroxaban (Xarelto, BAY59-7939)4.4
Enoxaparin5.7

Percentage of Participants With Composite Endpoint of VTE (Any DVT, Non Fatal PE) and All-cause Mortality up to Day 35 + 6 Days

A composite endpoint of: asymptomatic proximal DVT in lower extremity detected by mandatory bilateral lower extremity venous ultrasonography; symptomatic DVT in lower extremity, proximal or distal; symptomatic, non-fatal PE; and death (VTE-related and not VTE-related). (NCT00571649)
Timeframe: Up to Day 35 + 6 days

InterventionPercentage of participants (Number)
Rivaroxaban (Xarelto, BAY59-7939)8.6
Enoxaparin9.2

Percentage of Participants With Composite Endpoint of VTE (Any DVT, Non Fatal PE) and VTE-related Death up to Day 10 + 5 Days

A composite endpoint of: asymptomatic proximal DVT in lower extremity detected by mandatory bilateral lower extremity venous ultrasonography; symptomatic DVT in lower extremity, proximal or distal; symptomatic, non-fatal PE; and VTE-related death. (NCT00571649)
Timeframe: Up to Day 10 + 5 days

InterventionPercentage of participants (Number)
Rivaroxaban (Xarelto, BAY59-7939)2.7
Enoxaparin2.7

Percentage of Participants With Composite Endpoint of VTE (Any DVT, Non Fatal PE) and VTE-related Death up to Day 10 + 5 Days Per mITT Population

A composite endpoint of: asymptomatic proximal DVT in lower extremity detected by mandatory bilateral lower extremity venous ultrasonography; symptomatic DVT in lower extremity, proximal or distal; symptomatic, non-fatal PE; and VTE-related death. (NCT00571649)
Timeframe: Up to Day 10 + 5 days

InterventionPercentage of participants (Number)
Rivaroxaban (Xarelto, BAY59-7939)3.0
Enoxaparin3.1

Percentage of Participants With Net Clinical Benefit (Any DVT, Non-fatal PE, VTE-related Death, Plus Major and Clinically Relevant Non-major Bleeding Events) up to Day 10 + 5 Days

Net clinical benefit is a composite of the primary efficacy endpoint (asymptomatic proximal DVT in lower extremity detected by mandatory bilateral lower extremity venous ultrasonography; symptomatic DVT in lower extremity, proximal or distal; symptomatic, non-fatal PE; and VTE-related death) plus major and clinically relevant non-major bleeding events (NCT00571649)
Timeframe: Up to Day 10 + 5 days

InterventionPercentage of participants (Number)
Rivaroxaban (Xarelto, BAY59-7939)4.5
Enoxaparin3.9

Percentage of Participants With Net Clinical Benefit (Any DVT, Non-fatal PE, VTE-related Death, Plus Major and Clinically Relevant Non-major Bleeding Events) up to Day 35 + 6 Days

Net clinical benefit is a composite of the primary efficacy endpoint (asymptomatic proximal DVT in lower extremity detected by mandatory bilateral lower extremity venous ultrasonography; symptomatic DVT in lower extremity, proximal or distal; symptomatic, non-fatal PE; and VTE-related death) plus major and clinically relevant non-major bleeding events. (NCT00571649)
Timeframe: Up to Day 35 + 6 days

InterventionPercentage of participants (Number)
Rivaroxaban (Xarelto, BAY59-7939)9.4
Enoxaparin7.8

Percentage of Participants With the Composite of Treatment Emergent Major Bleeding Events and Non-major Clinically Relevant Bleeding Events up to 2 Days After Last Application of a Study Medication Syringe (Day 10 + 5 Days)

Major bleeding events were defined as events leading to >=2 g/dL fall in hemoglobin or transfusion of >=2 units of packed RBCs or whole blood or leading to death. Non-major bleeding events were defined as overt bleeding not meeting the criteria of major bleeding. (NCT00571649)
Timeframe: Up to Day 10 + 5 days

InterventionPercentage of participants (Number)
Rivaroxaban (Xarelto, BAY59-7939)2.8
Enoxaparin1.2

Percentage of Participants With the Composite of Treatment Emergent Major Bleeding Events and Non-major Clinically Relevant Bleeding Events up to 2 Days After Last Intake of Any Study Medication (Day 35 + 6 Days)

Major bleeding events were defined as events leading to >=2 g/dL fall in hemoglobin; or transfusion of >= 2 units of packed RBCs (Red blood cells) or whole blood; or leading to death. Non-major bleeding events were defined as overt bleeding not meeting the criteria of major bleeding (NCT00571649)
Timeframe: Up to Day 35 + 6 days

InterventionPercentage of participants (Number)
Rivaroxaban (Xarelto, BAY59-7939)4.1
Enoxaparin1.7

Percentage of Participants With VTE Combined With All-cause Mortality up to Day 10 + 5 Days

A composite endpoint of: asymptomatic proximal DVT in lower extremity detected by mandatory bilateral lower extremity venous ultrasonography; symptomatic DVT in lower extremity, proximal or distal; symptomatic, non-fatal PE; and death (VTE-related and not VTE-related). (NCT00571649)
Timeframe: Up to Day 10 + 5 days

InterventionPercentage of participants (Number)
Rivaroxaban (Xarelto, BAY59-7939)4.8
Enoxaparin4.5

Percentage of Participants With All-cause Mortality up to Day 90 + 7 Days

All deaths, including VTE-related deaths, cardiovascular deaths, and other deaths. (NCT00571649)
Timeframe: Up to Day 90 + 7 days

,
InterventionPercentage of participants (Number)
Any eventDeath (cardiovascular)Death (other)VTE related death
Enoxaparin6.21.43.71.1
Rivaroxaban (Xarelto, BAY59-7939)6.71.44.31.0

Percentage of Participants With Each Component of the Composite Endpoint of VTE (Any DVT, Non Fatal PE) and VTE-related Death up to Day 10 + 5 Days

The components of the composite endpoint include asymptomatic proximal DVT in lower extremity detected by mandatory bilateral lower extremity venous ultrasonography; symptomatic DVT in lower extremity, proximal or distal; symptomatic, non-fatal PE; and VTE-related death. (NCT00571649)
Timeframe: Up to Day 10 + 5 days

,
InterventionPercentage of participants (Number)
Symptomatic non-fatal PESymptomatic DVT in lower extremityAsymptomatic proximal DVT in lower extremityVTE related death
Enoxaparin0.10.22.40.2
Rivaroxaban (Xarelto, BAY59-7939)0.20.22.40.1

Percentage of Participants With Each Component of the Composite Endpoint of VTE (Any DVT, Non Fatal PE) and VTE-related Death up to Day 35 + 6 Days

The components of the composite endpoint include asymptomatic proximal DVT in lower extremity detected by mandatory bilateral lower extremity venous ultrasonography; symptomatic DVT in lower extremity, proximal or distal; symptomatic, non-fatal PE; and VTE-related death. (NCT00571649)
Timeframe: Up to Day 35 + 6 days

,
InterventionPercentage of participants (Number)
Symptomatic non-fatal PESymptomatic DVT in lower extremityAsymptomatic proximal DVT in lower extremityVTE related death
Enoxaparin0.50.54.41.0
Rivaroxaban (Xarelto, BAY59-7939)0.30.43.50.6

Percentage of Participants With Major Vascular Events up to Days 10, 35, and 90

Major vascular events included cardiovascular death, acute myocardial infarction (MI), or acute ischemic stroke. Participants may have had a vascular event in more than one category. (NCT00571649)
Timeframe: At Day 10 + 5 days, at Day 35 + 6 days, and at Day 90 + 7 days

,
InterventionPercentage of participants (Number)
Any event-Day 10Ischemic stroke-Day 10Acute MI-Day 10Death (cardiovascular)-Day 10Any event-Day 35Ischemic stroke-Day 35Acute MI-Day 35Death (cardiovascular)-Day 35Any event-Day 90Ischemic stroke-Day 90Acute MI-Day 90Death (cardiovascular)-Day 90
Enoxaparin1.00.30.40.41.60.50.50.82.81.10.71.4
Rivaroxaban (Xarelto, BAY59-7939)1.00.30.50.41.80.50.60.92.80.80.91.4

Percentage of Participants With Symptomatic VTE, Including and Excluding VTE-related Death up to Days 10, 35, and 90

Symptomatic VTE (non-fatal PE and DVT in lower extremity), including and excluding VTE-related death (PE and PE cannot be excluded) up to Days 10, 35, and 90 (NCT00571649)
Timeframe: At Day 10 + 5 days, at Day 35 + 6 days, and at Day 90 + 7 days

,
InterventionPercentage of participants (Number)
symptomatic VTE (incl. VTE-related death)-Day 10symptomatic VTE (non fatal)-Day 10symptomatic VTE (incl. VTE-related death)-Day 35symptomatic VTE (non fatal)-Day 35symptomatic VTE (incl. VTE-related death)-Day 90symptomatic VTE (non fatal)-Day 90
Enoxaparin0.60.31.40.71.90.9
Rivaroxaban (Xarelto, BAY59-7939)0.70.51.00.61.70.7

Event Rate Based on Time From Randomization to First Occurrence of All-Cause Mortality (ACM) Adjudicated by CEC

Event rate based on time from randomization to first occurrence of ACM (adjudicated by CEC) was assessed. Event rate was defined as number of events per 100 participants in 45 days of follow up. Participants who did not have events were censored on the minimum of last visit before or on death, or Day 45. (NCT02111564)
Timeframe: Up to Day 45

InterventionEvents per 100 participants in 45 days (Number)
Rivaroxaban 10 mg or 7.5 mg1.19
Placebo1.49

Event Rate Based on Time From Randomization to First Occurrence of VTE-Related Death Adjudicated by CEC

Event rate based on time from randomization to first occurrence of VTE-related death (adjudicated by CEC) was assessed. Event rate was defined as number of events per 100 participants in 45 days of follow up. Participants who did not have events were censored on the minimum of last visit before or on death, or Day 45. (NCT02111564)
Timeframe: Up to Day 45

InterventionEvents per 100 participants in 45 days (Number)
Rivaroxaban 10 mg or 7.5 mg0.72
Placebo0.77

Event Rate Based on Time From Randomization to the First Occurrence of a Composite of Symptomatic VTE and All-Cause Mortality (ACM) Adjudicated by CEC

Event rate based on time from randomization to the first occurrence of a composite of symptomatic VTE and ACM (adjudicated by CEC) was assessed. Event rate was defined as number of events per 100 participants in 45 days of follow up. Participants who did not have events were censored on the minimum of last visit before or on death, or Day 45. (NCT02111564)
Timeframe: Up to Day 45

InterventionEvents per 100 participants in 45 days (Number)
Rivaroxaban 10 mg or 7.5 mg1.31
Placebo1.80

Event Rate Based on Time From Randomization to the First Occurrence of a Composite of Symptomatic VTE, Myocardial Infarction (MI), Non-Hemorrhagic Stroke, and Cardiovascular (CV) Death Adjudicated by CEC

Event rate based on time from randomization to the first occurrence of a composite of symptomatic VTE (lower extremity DVT and non-fatal PE), MI, non-hemorrhagic stroke, and CV death (death due to a known CV cause and death in which a CV cause cannot be ruled out; by this definition, a VTE-related death was considered a CV death) as adjudicated by CEC was reported. Event rate was defined as number of events per 100 participants in 45 days of follow up. Participants who did not have events were censored on the minimum of last visit before or on death, or Day 45. (NCT02111564)
Timeframe: Up to Day 45

InterventionEvents per 100 participants in 45 days (Number)
Rivaroxaban 10 mg or 7.5 mg1.58
Placebo2.03

Event Rate Based on Time From Randomization to the First Occurrence of a Symptomatic Venous Thromboembolism Event (VTE) Adjudicated by CEC

Event rate based on time from randomization to the first occurrence of a symptomatic VTE (adjudicated by CEC) was assessed. Symptomatic VTE included lower extremity DVT and non-fatal PE. Event rate was defined as number of events per 100 participants in 45 days of follow up. Participants who did not have events were censored on the minimum of last visit before or on death, or Day 45. (NCT02111564)
Timeframe: Up to Day 45

InterventionEvents per 100 participants in 45 days (Number)
Rivaroxaban 10 mg or 7.5 mg0.19
Placebo0.42

Event Rate Based on Time From Randomization to the First Occurrence of Major Bleeding Adjudicated by CEC

A major bleeding event was defined using validated International Society on Thrombosis and Haemostasis (ISTH) bleeding criteria. A major bleeding event was defined as overt bleeding that was associated with a fall in hemoglobin of 2 gram per deciliter (g/dL) or more, or a transfusion of 2 or more units of packed red blood cells or whole blood, or a critical site defined as intracranial, intraspinal, intraocular, pericardial, intra-articular, intramuscular with compartment syndrome, retroperitoneal, or a fatal outcome. Event rate was defined as number of events per 100 participants in 45 days of follow up. Participants who did not have events were censored on the minimum of last visit before or on death, or last dose + 2 days. (NCT02111564)
Timeframe: From randomization to 2 days after the last dose (Day 45)

InterventionEvents per 100 participants in 45 days (Number)
Rivaroxaban 10 mg or 7.5 mg0.28
Placebo0.15

Time From Randomization to First Occurrence of Composite of All Symptomatic Venous Thromboembolism (VTE) and VTE Related Death Adjudicated by Clinical Event Committee (CEC)

Symptomatic VTE included lower extremity deep vein thrombosis (DVT) and non-fatal pulmonary embolism (PE). Event rate was defined as number of events per 100 participants in 45 days of follow up. Participants who did not have events were censored on the minimum of last visit before or on death, or Day 45. (NCT02111564)
Timeframe: Up to Day 45

InterventionEvents per 100 participants in 45 days (Number)
Rivaroxaban 10 mg or 7.5 mg0.84
Placebo1.11

Efficacy of In-hospital Thromboprophylaxis as Measured by Number of Participants With Confirmed HA-VTE

To investigate, on a preliminary basis, the efficacy of in-hospital thromboprophylaxis with twice-daily enoxaparin in children hospitalized with COVID-19, as measured by number of participants with confirmed HA-VTE. (NCT04354155)
Timeframe: Day 30

InterventionParticipants (Count of Participants)
Thromboprophylaxis2

Safety of In-hospital Thromboprophylaxis as Assessed by Number of Participants With ISTH-defined Clinically-relevant Bleeding Events During Hospitalization

"The safety of in-hospital thromboprophylaxis with twice-daily low-dose enoxaparin thromboprophylaxis will be measured by cumulative incidence (number of participants) of ISTH-defined clinically-relevant bleeding events during hospitalization. Clinically relevant bleeding episodes may include any of the following:~fatal bleeding;~clinically overt bleeding associated with a decline in hemoglobin of ≥2g/dL in a 24h period;~retroperitoneal, pulmonary, or central nervous system bleeding;~bleeding requiring surgical intervention in an operating suite;~bleeding for which a blood product is administered (blood product administration not directly attributable to the patient's underlying condition);~bleeding that requires medical or surgical intervention to restore hemostasis, other than in an operating suite." (NCT04354155)
Timeframe: Day 30

InterventionParticipants (Count of Participants)
Thromboprophylaxis0

Median Twice-daily Enoxaparin Dose Required to Achieve 4-hour Post-dose Anti-factor Xa Between 0.20-0.49 U/mL

The median twice-daily enoxaparin dose, as measured in mg/kg, required to achieve a 4-hour post-dose anti-factor Xa level of 0.20-0.49 anti-Xa U/mL in children hospitalized with COVID-19, and to compare dose-requirements by age group (<12 and those >12 years of age). (NCT04354155)
Timeframe: 4 hours post initial dose

Interventionmg/kg (Median)
Children 12 years or olderChildren less than 12 years
Thromboprophylaxis0.50.52

Number of Patients With All Cause Death and Non-fatal Stroke

This is a key secondary endpoint. The number of observed patients with all cause death and non-fatal stroke within 30 days was reported (NCT00623623)
Timeframe: 30 days

InterventionParticipants (Count of Participants)
Tenecteplase (Group A)50
Primary PCI (Group B)43

Number of Patients With All Cause Death and Shock

This is a key secondary endpoint. The number of observed patients with all cause death and shock within 30 days was reported (NCT00623623)
Timeframe: 30 days

InterventionParticipants (Count of Participants)
Tenecteplase (Group A)59
Primary PCI (Group B)73

Number of Patients With All Cause Death and Shock and CHF

This is a key secondary endpoint. The number of observed patients with all cause death and shock and CHF within 30 days was reported. (NCT00623623)
Timeframe: 30 days

InterventionParticipants (Count of Participants)
Tenecteplase (Group A)100
Primary PCI (Group B)123

Number of Patients With All Cause Death and Shock and CHF and Reinfarction and Disabling Stroke

This is a key secondary endpoint. The number of observed patients with all cause death and shock and CHF and reinfarction and disabling stroke within 30 days was reported (NCT00623623)
Timeframe: 30 days

InterventionParticipants (Count of Participants)
Tenecteplase (Group A)117
Primary PCI (Group B)135

Number of Patients With All Cause Death and Shock and Reinfarction

This is a key secondary endpoint. The number of observed patients with all cause death and shock and reinfarction within 30 days was reported (NCT00623623)
Timeframe: 30 days

InterventionParticipants (Count of Participants)
Tenecteplase (Group A)77
Primary PCI (Group B)85

Number of Patients With All Cause Mortality

This is a key secondary endpoint. The number of observed patients with all cause mortality within 30 days was reported. (NCT00623623)
Timeframe: 30 days

InterventionParticipants (Count of Participants)
Tenecteplase (Group A)43
Primary PCI (Group B)42

Number of Patients With All-cause Mortality, Cardiogenic Shock, Congestive Heart Failure and Recurrent Myocardial Infarction Within 30 Days for FAS.

The number of observed patients with all-cause mortality, cardiogenic shock, congestive heart failure (CHF) and recurrent myocardial infarction within 30 days was reported for full analysis set (FAS). (NCT00623623)
Timeframe: 30 days

InterventionParticipants (Count of Participants)
Tenecteplase (Group A)116
Primary PCI (Group B)135

Number of Patients With Cardiac Mortality

This is a key secondary endpoint. The number of observed patients with cardiac mortality within 30 days was reported. (NCT00623623)
Timeframe: 30 days

InterventionParticipants (Count of Participants)
Tenecteplase (Group A)31
Primary PCI (Group B)32

Number of Patients With Cardiogenic Shock

This is a key secondary endpoint. The number of observed patients with cardiogenic shock within 30 days was reported. (NCT00623623)
Timeframe: 30 days

InterventionParticipants (Count of Participants)
Tenecteplase (Group A)41
Primary PCI (Group B)56

Number of Patients With Congestive Heart Failure (CHF)

This is a key secondary endpoint. The number of observed patients with congestive heart failure (CHF) within 30 days was reported. (NCT00623623)
Timeframe: 30 days

InterventionParticipants (Count of Participants)
Tenecteplase (Group A)57
Primary PCI (Group B)72

Number of Patients With Intracranial Haemorrhage

This is a key secondary endpoint. The number of observed patients with intracranial haemorrhage within 30 days was reported (NCT00623623)
Timeframe: 30 days

InterventionParticipants (Count of Participants)
Tenecteplase (Group A)9
Primary PCI (Group B)2

Number of Patients With Ischaemic Stroke

This is a key secondary endpoint. The number of observed patients with ischaemic stroke within 30 days was reported (NCT00623623)
Timeframe: 30 days

InterventionParticipants (Count of Participants)
Tenecteplase (Group A)6
Primary PCI (Group B)3

Number of Patients With Major Non-intracranial Bleeds Including Blood Transfusions

This is a key secondary endpoint. The number of observed patients with major non-intracranial bleeds including blood transfusions within 30 days was reported (NCT00623623)
Timeframe: 30 days

InterventionParticipants (Count of Participants)
Tenecteplase (Group A)61
Primary PCI (Group B)45

Number of Patients With Minor Non-intracranial Bleeds

This is a key secondary endpoint. The number of observed patients with minor non-intracranial bleeds within 30 days was reported (NCT00623623)
Timeframe: 30 days

InterventionParticipants (Count of Participants)
Tenecteplase (Group A)206
Primary PCI (Group B)191

Number of Patients With Recurrent Myocardial Infarction (Reinfarction)

This is a key secondary endpoint. The number of observed patients with recurrent myocardial infarction (reinfarction) within 30 days was reported (NCT00623623)
Timeframe: 30 days

InterventionParticipants (Count of Participants)
Tenecteplase (Group A)23
Primary PCI (Group B)21

Number of Patients With Rehospitalisation for Cardiac Reasons

This is a key secondary endpoint. The number of observed patients with rehospitalisation for cardiac reasons within 30 days was reported (NCT00623623)
Timeframe: 30 days

InterventionParticipants (Count of Participants)
Tenecteplase (Group A)45
Primary PCI (Group B)41

Number of Patients With Rehospitalisation for Non-cardiac Reasons

This is a key secondary endpoint. The number of observed patients with rehospitalisation for non-cardiac reasons within 30 days was reported (NCT00623623)
Timeframe: 30 days

InterventionParticipants (Count of Participants)
Tenecteplase (Group A)19
Primary PCI (Group B)11

Number of Patients With Serious Repeat Target Vessel Revascularization

This is a key secondary endpoint. The number of observed patients with serious repeat target vessel revascularization within 30 days was reported (NCT00623623)
Timeframe: 30 days

InterventionParticipants (Count of Participants)
Tenecteplase (Group A)1
Primary PCI (Group B)2

Number of Patients With Serious Resuscitated Ventricular Fibrillation

This is a key secondary endpoint. The number of observed patients with serious resuscitated ventricular fibrillation within 30 days was reported (NCT00623623)
Timeframe: 30 days

InterventionParticipants (Count of Participants)
Tenecteplase (Group A)32
Primary PCI (Group B)38

Number of Patients With Serious Resuscitated Ventricular Fibrillation in Association With Invasive Procedures

This is a key secondary endpoint. The number of observed patients with serious resuscitated ventricular fibrillation in association with invasive procedures (occurring at any time during catheterisation or urgent/elective PCI) within 30 days was reported (NCT00623623)
Timeframe: 30 days

InterventionParticipants (Count of Participants)
Tenecteplase (Group A)10
Primary PCI (Group B)29

Number of Patients With Total Disabling Stroke

This is a key secondary endpoint. The number of observed patients with total disabling stroke within 30 days was reported (NCT00623623)
Timeframe: 30 days

InterventionParticipants (Count of Participants)
Tenecteplase (Group A)2
Primary PCI (Group B)0

Number of Patients With Total Fatal Stroke

This is a key secondary endpoint. The number of observed patients with total fatal stroke within 30 days was reported (NCT00623623)
Timeframe: 30 days

InterventionParticipants (Count of Participants)
Tenecteplase (Group A)7
Primary PCI (Group B)4

Number of Patients With Total Non-disabling Stroke

This is a key secondary endpoint. The number of observed patients with total non-disabling stroke within 30 days was reported (NCT00623623)
Timeframe: 30 days

InterventionParticipants (Count of Participants)
Tenecteplase (Group A)8
Primary PCI (Group B)1

Number of Patients With Total Non-intracranial Bleeds

This is a key secondary endpoint. The number of observed patients with total non-intracranial bleeds within 30 days was reported (NCT00623623)
Timeframe: 30 days

InterventionParticipants (Count of Participants)
Tenecteplase (Group A)267
Primary PCI (Group B)236

Number of Patients With Total Stroke (All Types)

This is a key secondary endpoint. The number of observed patients with total stroke (all types) within 30 days was reported (NCT00623623)
Timeframe: 30 days

InterventionParticipants (Count of Participants)
Tenecteplase (Group A)15
Primary PCI (Group B)5

mITT Cohort 1: Percentage of Participants Experiencing the Composite Event of Symptomatic DVT, Non-fatal PE, or VTE-related Death, Through Visit 3

mITT Cohort 1: Percentage of participants experiencing either symptomatic DVT, non-fatal PE, or VTE related death adjudicated by a blinded independent CEC between randomization and on or before Visit 3 or Day 42 if patient did not have a Visit 3. Visit 3 is between day 35-42 after randomization (day 1). (NCT01583218)
Timeframe: mITT Cohort 1: Between randomization and Day 42 (max)

InterventionPercentage of Participants (Number)
Betrixaban1.30
Enoxaparin1.90

mITT Cohort 2: Percentage of Participants Experiencing the Composite Event of Symptomatic DVT, Non-fatal PE, or VTE-related Death, Through Visit 3

mITT Cohort 2: Percentage of participants experiencing either symptomatic DVT, non-fatal PE, or VTE related death adjudicated by a blinded independent CEC between randomization and on or before Visit 3 or Day 42 if patient did not have a Visit 3. Visit 3 is between day 35-42 after randomization (day 1). (NCT01583218)
Timeframe: mITT Cohort 2: Between randomization and Day 42 (max)

InterventionPercentage of Participants (Number)
Betrixaban1.03
Enoxaparin1.45

mITT Cohort 2: Percentage of Participants Experiencing the Composite Event of Symptomatic DVT, Non-fatal PE, VTE-related Death, or Asymptomatic Proximal DVT, Through Visit 3

mITT Cohort 2: Percentage of participants experiencing either symptomatic DVT, non-fatal PE, VTE related death adjudicated by a blinded independent CEC between randomization and on or before Visit 3 or Day 42 if patient did not have a Visit 3, or a blinded ultrasound core laboratory measuring of asymptomatic proximal DVT between randomization and Day 47. Visit 3 is between day 35-42 after randomization (day 1). (NCT01583218)
Timeframe: mITT Cohort 2: Between randomization and Day 47 (max)

InterventionPercentage of Participants (Number)
Betrixaban4.70
Enoxaparin6.02

mITT: Percentage of Participants Experiencing the Composite Event of Symptomatic DVT, Non-fatal PE, or VTE-related Death, Through Visit 3

mITT: Percentage of participants experiencing either symptomatic DVT, non-fatal PE, or VTE related death adjudicated by a blinded independent CEC between randomization and on or before Visit 3 or Day 42 if patient did not have a Visit 3. Visit 3 is between day 35-42 after randomization (day 1). (NCT01583218)
Timeframe: mITT: Between randomization and Day 42 (max)

InterventionPercentage of Participants (Number)
Betrixaban0.94
Enoxaparin1.45

mITT: Percentage of Participants Experiencing the Composite Event of Symptomatic DVT, Non-fatal PE, VTE-related Death, or Asymptomatic Proximal DVT, Through Visit 3

mITT: Percentage of participants experiencing either symptomatic DVT, non-fatal PE, VTE related death adjudicated by a blinded independent CEC between randomization and on or before Visit 3 or Day 42 if patient did not have a Visit 3, or a blinded ultrasound core laboratory measuring of asymptomatic proximal DVT between randomization and Day 47. Visit 3 is between day 35-42 after randomization (day 1). (NCT01583218)
Timeframe: mITT: Between randomization and Day 47 (max)

InterventionPercentage of Participants (Number)
Betrixaban4.43
Enoxaparin5.99

Modified Intent-to-Treat (mITT) Cohort 1: Percentage of Participants Experiencing the Composite Event of Symptomatic Deep Vein Thrombosis (DVT), Non-fatal Pulmonary Emboli (PE), VTE-related Death, or Asymptomatic Proximal DVT, Through Visit 3

mITT Cohort 1: Percentage of participants experiencing either symptomatic DVT, non-fatal PE, venous thromboembolism (VTE) related death adjudicated by a blinded independent Clinical Events Committee (CEC) between randomization and on or before Visit 3 or Day 42 if patient did not have a Visit 3, or a blinded ultrasound core laboratory measuring of asymptomatic proximal DVT between randomization and Day 47. Visit 3 is between day 35-42 after randomization (day 1). (NCT01583218)
Timeframe: mITT Cohort 1: Between randomization and Day 47 (max)

InterventionPercentage of Participants (Number)
Betrixaban5.70
Enoxaparin7.18

Percentage of Participants Experiencing Major Bleeding Through Seven Days After Discontinuation of All Study Medication

Percentage of participants experiencing at least one major bleeding adjudicated by a blinded independent CEC between randomization (day 1) and up to seven days after discontinuation of all study medication. (NCT01583218)
Timeframe: Between randomization and Day 49 (max)

InterventionPercentage of Participants (Number)
Betrixaban0.67
Enoxaparin0.57

Incidence of Adjudicated Asymptomatic Proximal DVT With Onset During the Intended Treatment Period

A bilateral compression ultrasound (CUS) was performed between Days 5 and 14 for detection of asymptomatic proximal DVT unless a symptomatic VTE was confirmed prior. CUS was also performed on Day 30 ± 2 except for those participants who had a confirmed symptomatic VTE or proximal asymptomatic DVT prior to that time. Events adjudicated by ICAC. Intended Treatment Period=period that starts on day of randomization: period ends (for treated) at latter of a) 2 days after last dose of study drug and b) 32 days after first dose of study drug; (for not treated) period ends 32 days after randomization. Incidence determined by Event Rate (%): n/N*100 (n=number with observation; N=total efficacy evaluable participants). (NCT00457002)
Timeframe: Intended Treatment Period

InterventionEvent Rate (%) (Number)
Apixaban 2.5 mg2.36
Enoxaparin 40 mg2.12

Incidence of Adjudicated Non-Fatal PE With Onset During the Intended Treatment Period

Events adjudicated by ICAC. Intended Treatment Period=period that starts on day of randomization: period ends (for treated) at latter of a) 2 days after last dose of study drug and b) 32 days after first dose of study drug; (for not treated) period ends 32 days after randomization. Incidence determined by Event Rate (%): n/N*100 (n=number with observation; N=total efficacy evaluable participants). (NCT00457002)
Timeframe: Intended Treatment Period

InterventionEvent Rate (%) (Number)
Apixaban 2.5 mg0.22
Enoxaparin 40 mg0.24

Incidence of Adjudicated PE With Onset During the Intended Treatment Period

Events adjudicated by ICAC. Intended Treatment Period=period that starts on day of randomization: period ends (for treated) at latter of a) 2 days after last dose of study drug and b) 32 days after first dose of study drug; (for not treated) period ends 32 days after randomization. PE: non-fatal or fatal. Incidence determined by Event Rate (%): n/N*100 (n=number with observation; N=total efficacy evaluable participants). (NCT00457002)
Timeframe: Intended Treatment Period

InterventionEvent Rate (%) (Number)
Apixaban 2.5 mg0.22
Enoxaparin 40 mg0.24

Incidence of Adjudicated Proximal DVT With Onset During the Intended Treatment Period

Events adjudicated by ICAC. Intended Treatment Period=period that starts on day of randomization: period ends (for treated) at latter of a) 2 days after last dose of study drug and b) 32 days after first dose of study drug; (for not treated) period ends 32 days after randomization. A bilateral compression ultrasound (CUS) was performed between Days 5 and 14 for detection of asymptomatic proximal DVT unless a symptomatic VTE was confirmed prior. CUS was also performed on Day 30 ± 2 except for those participants who had a confirmed symptomatic VTE or proximal asymptomatic DVT prior to that time. Incidence determined by Event Rate (%): n/N*100 (n=number with observation; N=total efficacy evaluable participants). (NCT00457002)
Timeframe: Intended Treatment Period

InterventionEvent Rate (%) (Number)
Apixaban 2.5 mg2.40
Enoxaparin 40 mg2.50

Incidence of Adjudicated Proximal DVT, Non-Fatal PE or All-Cause Death With Onset During the Intended Treatment Period

Events adjudicated by ICAC. Intended Treatment Period=period that starts on day of randomization: period ends (for treated) at latter of a) 2 days after last dose of study drug and b) 32 days after first dose of study drug; (for not treated) period ends 32 days after randomization. Incidence determined by Event Rate (%): n/N*100 (n=number with observation; N=total efficacy evaluable participants). (NCT00457002)
Timeframe: Intended Treatment Period

InterventionEvent Rate (%) (Number)
Apixaban 2.5 mg6.44
Enoxaparin 40 mg6.50

Incidence of Adjudicated Proximal DVT, Non-Fatal PE or VTE-Related Death, With Onset During the Intended Treatment Period

Events adjudicated by ICAC. Intended Treatment Period=period that starts on day of randomization: period ends (for treated) at latter of a) 2 days after last dose of study drug and b) 32 days after first dose of study drug; (for not treated) period ends 32 days after randomization. VTE-related death: fatal PE or sudden death for which VTE cannot be excluded as a cause. Incidence determined by Event Rate (%): n/N*100 (n=number with observation; N=total efficacy evaluable participants). (NCT00457002)
Timeframe: Intended Treatment Period

InterventionEvent Rate (%) (Number)
Apixaban 2.5 mg2.71
Enoxaparin 40 mg2.93

Incidence of Adjudicated Symptomatic Distal DVT With Onset During the Intended Treatment Period

Events were adjudicated by ICAC. Intended Treatment Period=period that starts on day of randomization: period ends (for treated) at latter of a) 2 days after last dose of study drug and b) 32 days after first dose of study drug; (for not treated) period ends 32 days after randomization. Incidence determined by Event Rate (%): n/N*100 (n=number with observation; N=total efficacy evaluable participants). (NCT00457002)
Timeframe: Intended Treatment Period

InterventionEvent Rate (%) (Number)
Apixaban 2.5 mg0.00
Enoxaparin 40 mg0.15

Incidence of Adjudicated Symptomatic DVT With Onset During the Intended Treatment Period

Events adjudicated by ICAC. Intended Treatment Period=period that starts on day of randomization: period ends (for treated) at latter of a) 2 days after last dose of study drug and b) 32 days after first dose of study drug; (for not treated) period ends 32 days after randomization. Incidence determined by Event Rate (%): n/N*100 (n=number with observation; N=total efficacy evaluable participants). (NCT00457002)
Timeframe: Intended Treatment Period

InterventionEvent Rate (%) (Number)
Apixaban 2.5 mg0.15
Enoxaparin 40 mg0.49

Incidence of Adjudicated Symptomatic Proximal DVT With Onset During the Intended Treatment Period

Events adjudicated by ICAC. Intended Treatment Period=period that starts on day of randomization: period ends (for treated) at latter of a) 2 days after last dose of study drug and b) 32 days after first dose of study drug; (for not treated) period ends 32 days after randomization. A bilateral compression ultrasound (CUS) was performed between Days 5 and 14 for detection of asymptomatic proximal DVT unless a symptomatic VTE was confirmed prior. CUS was also performed on Day 30 ± 2 except for those participants who had a confirmed symptomatic VTE or proximal asymptomatic DVT prior to that time. Incidence determined by Event Rate (%): n/N*100 (n=number with observation; N=total efficacy evaluable participants). (NCT00457002)
Timeframe: Intended Treatment Period

InterventionEvent Rate (%) (Number)
Apixaban 2.5 mg0.15
Enoxaparin 40 mg0.37

Incidence of Adjudicated Symptomatic VTE or All-Cause Death With Onset During the Intended Treatment Period

Events adjudicated by ICAC. Intended Treatment Period=period that starts on day of randomization: period ends (for treated) at latter of a) 2 days after last dose of study drug and b) 32 days after first dose of study drug; (for not treated) period ends 32 days after randomization. VTE: nonfatal PE, symptomatic DVT, or asymptomatic proximal DVT detected by ultrasound. Incidence determined by Event Rate (%): n/N*100 (n=number with observation; N=total efficacy evaluable participants). (NCT00457002)
Timeframe: Intended Treatment Period

InterventionEvent Rate (%) (Number)
Apixaban 2.5 mg3.11
Enoxaparin 40 mg3.46

Incidence of Adjudicated Total VTE and VTE-Related Death During Parenteral Treatment in Key Secondary Efficacy Evaluable Participants

Parenteral study drug=active or placebo enoxaparin. Parenteral treatment: started on the first dose of parenteral study drug and ended the day after the last dose of parenteral study drug. Key Secondary Efficacy population: all who received at least 1 dose of parenteral study drug and: (those without suspected VTE events during Parenteral Treatment) had an adjudicated evaluable ultrasound performed at the end of Parenteral Treatment; or (those with suspected VTE events during Parenteral Treatment) had those suspected VTE events adjudicated as non-events, and had an adjudicated evaluable ultrasound performed at the end of Parenteral Treatment; or had an adjudicated total VTE during Parenteral Treatment; or had an adjudicated VTE-related death during Parenteral Treatment. Event rate (%): n/N*100 (n=number with observation; N=total secondary efficacy evaluable participants). (NCT00457002)
Timeframe: Day 1 to last dose of parenteral study drug plus 1 day

InterventionEvent rate (%) (Number)
Apixaban 2.5 mg1.73
Enoxaparin 40 mg1.61

Incidence of Adjudicated Total VTE and VTE-Related Death During Parenteral Treatment in Secondary Efficacy Evaluable Participants

Parenteral study drug=active or placebo enoxaparin. Parenteral treatment: started on the first dose of parenteral study drug and ended the day after the last dose of parenteral study drug. Secondary Efficacy Evaluable includes those who had an adjudicated, evaluable ultrasound at end of parenteral treatment and for those with a suspected symptomatic event, the result of the adjudication for the symptomatic event was not inadequate; or those with an adjudicated event that was part of the composite endpoint.. Event rate (%): n/N*100 (n=number with observation; N=total secondary efficacy evaluable participants). (NCT00457002)
Timeframe: Day 1 to last dose of parenteral study drug plus 1 day

InterventionEvent Rate (%) (Number)
Apixaban 2.5 mg1.66
Enoxaparin 40 mg1.51

Incidence of Adjudicated Total VTE or All-Cause Death With Onset During the Intended Treatment Period

Intended Treatment Period=period that starts on day of randomization: period ends (for treated) at latter of a) 2 days after last dose of study drug and b) 32 days after first dose of study drug; (for not treated) period ends 32 days after randomization. VTE: nonfatal (N-F) PE, symptomatic DVT, or asymptomatic proximal DVT detected by ultrasound. VTE-related death: fatal PE or sudden death for which VTE cannot be excluded as a cause. All-Cause Death (A-C Death). Incidence determined by Event Rate (%): n/N*100 (n=number with observation; N=total efficacy evaluable participants). (NCT00457002)
Timeframe: Intended Treatment Period

InterventionEvent Rate (%) (Number)
Apixaban 2.5 mg6.44
Enoxaparin 40 mg6.63

Incidence of Adjudicated VTE-Related Death With Onset During the Intended Treatment Period in Randomized Participants

Events adjudicated by ICAC. Intended Treatment Period=period that starts on day of randomization: period ends (for treated) at latter of a) 2 days after last dose of study drug and b) 32 days after first dose of study drug; (for not treated) period ends 32 days after randomization. VTE-related death: fatal PE or sudden death for which VTE cannot be excluded as a cause. Incidence determined by Event Rate (%): n/N*100 (n=number with observation; N=total efficacy evaluable participants). (NCT00457002)
Timeframe: Intended Treatment Period

InterventionEvent Rate (%) (Number)
Apixaban 2.5 mg0.06
Enoxaparin 40 mg0.09

Incidence of All Bleeding During the Treatment Period in Treated Participants

Bleeding was adjudicated by an ICAC using criteria from the ISTH. Treatment Period=includes measurements or events with onset from first dose of study drug through 2 days after the last dose of study drugs, for bleeding endpoints. Incidence determined by Event Rate (%): n/N*100 (n=number with observation; N=total efficacy evaluable participants). (NCT00457002)
Timeframe: Day 1, first dose of drug to last dose of drug plus 2 days

InterventionEvent Rate (%) (Number)
Apixaban 2.5 mg7.73
Enoxaparin 40 mg6.81

Incidence of All VTE or Major Bleeding or All-Cause Death During the Intended Treatment Period

Events adjudicated by ICAC. Intended Treatment Period=period that starts on day of randomization: period ends (for treated) at latter of a) 2 days after last dose of study drug and b) 32 days after first dose of study drug; (for not treated) period ends 32 days after randomization. VTE: nonfatal PE, symptomatic DVT, or asymptomatic proximal DVT detected by ultrasound. VTE-related death: fatal PE or sudden death for which VTE cannot be excluded as a cause. Incidence determined by Event Rate (%): n/N*100 (n=number with observation; N=total efficacy evaluable participants). (NCT00457002)
Timeframe: Intended Treatment Period

InterventionEvent Rate (%) (Number)
Apixaban 2.5 mg7.16
Enoxaparin 40 mg6.83

Incidence of Clinically Relevant Non-Major (CRNM) Bleeding During the Treatment Period in Treated Participants

Bleeding was adjudicated by an ICAC using criteria from the ISTH. CRNM bleeding: acute clinically overt bleeding compromising hemodynamics; leading to hospitalization; traumatic subcutaneous hematoma; intramuscular hematoma; epistaxis that lasted for more than 5 minutes, was repetitive or led to an intervention; spontaneous gingival bleeding; spontaneous hematuria; macroscopic gastrointestinal hemorrhage (including at least 1 episode of melena or hematemesis, if clinically apparent with positive results on a fecal occult-blood test); rectal blood loss. Treatment Period=includes measurements or events with onset from first dose of study drug through 2 days after the last dose of study drugs for bleeding endpoints. Incidence determined by Event Rate (%): n/N*100 (n=number with observation; N=total efficacy evaluable participants). (NCT00457002)
Timeframe: Day 1, first dose of study drug, to last dose of study drug plus 2 days

InterventionEvent Rate (%): (Number)
Apixaban 2.5 mg2.26
Enoxaparin 40 mg1.90

Incidence of Composite of Adjudicated Total Venous Thromboembolism (VTE) and VTE-related Death During the Intended Treatment Period - Primary Efficacy Population

VTE: nonfatal pulmonary embolism (PE), symptomatic deep vein thrombosis (DVT), or asymptomatic proximal DVT detected by ultrasound. VTE-related death: fatal PE or sudden death for which VTE could not be excluded as a cause. Intended Treatment Period=period that started on day of randomization: period ended (for treated) at latter of a) 2 days after last dose of study drug and b) 32 days after first dose of study drug; period ended (for not treated) 32 days after randomization. A bilateral compression ultrasound (CUS) was performed between Days 5 and 14 for detection of asymptomatic proximal DVT unless a symptomatic VTE was confirmed prior. CUS was also performed on Day 30 ± 2 except for those participants who had a confirmed symptomatic VTE or proximal asymptomatic DVT prior to that time. All efficacy events were adjudicated by the Independent Central Adjudication Committee (ICAC). Event rate (%): n/N*100 (n=number with observation; N=total efficacy evaluable participants). (NCT00457002)
Timeframe: Intended Treatment Period

InterventionEvent rate (%) (Number)
Apixaban 2.5 mg2.71
Enoxaparin 40 mg3.06

Incidence of Composite of Major or Clinically Relevant Non-Major (CRNM) Bleeding During the Treatment Period in Treated Participants

Bleeding was adjudicated by an ICAC using criteria from the ISTH. Major bleeding: acute clinically overt bleeding: associated with a fall in hemoglobin of 2 g/dL or more, or leading to a transfusion of 2 or more units of packed red blood cells or 1000 mL or more of whole blood, or bleeding in a critical site or bleeding which is fatal. CRNM bleeding: acute clinically overt bleeding compromising hemodynamics; leading to hospitalization; traumatic subcutaneous hematoma; intramuscular hematoma; epistaxis that lasted for more than 5 minutes, was repetitive or led to an intervention; spontaneous gingival bleeding; spontaneous hematuria; macroscopic gastrointestinal hemorrhage; rectal blood loss. Treatment Period=onset from first dose of study drug through 2 days after last dose of study drugs. Incidence: Event Rate (%): n/N*100 (n=number with observation; N=total efficacy evaluable participants). (NCT00457002)
Timeframe: Day 1, first dose of study drug, to last dose of study drug plus 2 days

InterventionEvent Rate (%) (Number)
Apixaban 2.5 mg2.67
Enoxaparin 40 mg2.08

Incidence of Major Bleeding During the Treatment Period in Treated Participants

Major bleeding was adjudicated by an ICAC using criteria from the International Society on Thrombosis and Hemostasis (ISTH) and was defined as acute clinically overt bleeding: associated with a fall in hemoglobin of 2 grams per deciliter (g/dL) or more, or leading to a transfusion of 2 or more units of packed red blood cells or 1000 milliliters (mL) or more of whole blood, or bleeding in a critical site or bleeding which is fatal. Incidence determined by Event Rate (%): n/N*100 (n=number with observation; N=total efficacy evaluable participants). (NCT00457002)
Timeframe: Day 1, first dose of study drug, to last dose of study drug plus 2 days

InterventionEvent Rate (%) (Number)
Apixaban 2.5 mg0.47
Enoxaparin 40 mg0.19

Symptomatic Adjudicated VTE or VTE-Related Death With Onset During the Intended Treatment Period

Events adjudicated by ICAC. Intended Treatment Period=period that starts on day of randomization: period ends (for treated) at latter of a) 2 days after last dose of study drug and b) 32 days after first dose of study drug; (for not treated) period ends 32 days after randomization. VTE: nonfatal PE, symptomatic DVT, or asymptomatic proximal DVT detected by ultrasound. VTE-related death: fatal PE or sudden death for which VTE cannot be excluded as a cause. Incidence determined by Event Rate (%): n/N*100 (n=number with observation; N=total efficacy evaluable participants). (NCT00457002)
Timeframe: Intended Treatment Period

InterventionEvent Rate (%) (Number)
Apixaban 2.5 mg0.40
Enoxaparin 40 mg0.80

Incidence of Events of Special Interest of Adjudicated Myocardial Infarction, Stroke, and Thrombocytopenia During the Treatment Period in Treated Participants

Events of Special Interest include: adjudicated thrombocytopenia, adjudicated myocardial infarction (MI), adjudicated stroke, and adjudicated MI or stroke. Incidence determined by Event Rate (%): n/N*100 (n=number with observation; N=total efficacy evaluable participants). Treatment Period includes measurements or events with onset from first dose of study drug through 2 days after the last dose of study drugs. (NCT00457002)
Timeframe: Day 1 to last dose of study drug plus 2 days

,
InterventionEvent Rate (%) (Number)
MI or stoke (N=3183, 3216)MI (N=3184, 3217)Stroke (N=3183, 3216)Thrombocytopenia (N=3184, 3217)
Apixaban 2.5 mg0.380.220.160.19
Enoxaparin 40 mg0.370.120.250.09

Mean Change From Baseline in Diastolic Blood Pressure in Treated Participants During Treatment Period

Diastolic blood pressure was obtained during Screening/Enrollment Visit (Day 1, prior to drug being administered), on the day of hospital discharge, Day 30 (last day of treatment) plus 2 days. Blood pressure was measured in millimeters of mercury (mmHg) and could have been taken with the participant either sitting, standing, or supine. (NCT00457002)
Timeframe: Day 1 to last dose of study drug plus 2 days

,
InterventionmmHg (Mean)
Day of Discharge from Hospital (N=1607, 1625)Day 30 of Treatment + 2 (N=2227,2301)
Apixaban 2.5 mg-1.00.0
Enoxaparin 40 mg-0.4-0.5

Mean Change From Baseline in Heart Rate in Treated Participants

Heart Rate was obtained during Screening/Enrollment Visit (Day 1, prior to drug being administered), on the day of hospital discharge, Day 30 (last day of treatment) plus 2 days. Heart rate was measured in beats per minute (bpm) and could have been taken with participants either sitting, standing, or supine. (NCT00457002)
Timeframe: Day 1 to last dose of study drug plus 2 days

,
Interventionbpm (Mean)
Hospital Discharge (N=1606,1622)Day 30 of treatment (N=2225,2299)
Apixaban 2.5 mg-5.4-4.0
Enoxaparin 40 mg-5.1-4.3

Mean Change From Baseline in Systolic Blood Pressure in Treated Participants During Treatment Period

Systolic blood pressure was obtained during Screening/Enrollment Visit (Day 1, prior to drug being administered), on the day of hospital discharge, Day 30 (last day of treatment) plus 2 days. Blood pressure was measured in millimeters of mercury (mmHg) and could have been taken either sitting, standing, or supine. (NCT00457002)
Timeframe: Day 1 to last dose of study drug plus 2 days

,
InterventionmmHg (Mean)
Discharge from Hospital (N=1607, 1625)Day 30 of Treatment + 2 (N=2227, 2301)
Apixaban 2.5 mg-3.0-2.3
Enoxaparin 40 mg-2.4-2.9

Number of Participants With Adverse Events (AEs), Serious AEs (SAEs), Bleeding AEs, Deaths, and Discontinuations Due to AEs During the Treatment Period in Treated Participants

Treatment Period=includes measurements or events with onset from first dose of study drug through 2 days after the last dose of study drugs for AEs, and 30 days after last dose of study drugs for SAEs and deaths. (NCT00457002)
Timeframe: Day 1, first dose of study drug, to last dose of study drug plus 2 days (AEs), plus 30 days (SAEs, Deaths)

,
Interventionparticipants (Number)
AEsSAEsBleeding AEsDiscontinuations Due to AEDeaths
Apixaban 2.5 mg1871611244290131
Enoxaparin 40 mg1910601221262133

Number of Participants With Events of Special Interest for Liver Function and Neurology During Treatment Period in Treated Participants With Available Measurements

Special interest include: liver function test increases, AEs related to liver function, and neurologic AEs. Treatment Period includes measurements or events with onset from first dose of study drug through 2 days after the last dose of study drug when summarizing AEs and through 30 days after the last dose when summarizing SAEs. (NCT00457002)
Timeframe: Day 1 to last dose of study drug plus 2 days (AEs) and plus 30 days (SAEs)

,
Interventionparticipants (Number)
Neurologic AEsNeurologic SAEsLiver-related AEsLiver-related SAEs
Apixaban 2.5 mg4551279
Enoxaparin 40 mg42114212

Number of Participants With Liver-Related Elevations During the Treatment Period in Treated Participants

Liver function tests: Alanine aminotransferase (ALT) U/L; Aspartate aminotransferase (AST) U/L; Alkaline phosphatase U/L; Total Bilirubin (TBili) mg/dL. Elevations consist of >3*Upper Limit of Normal (ULN) for ALT and AST and elevation of >2*ULN for Bilirubin. (NCT00457002)
Timeframe: Day 1 to last dose of study drug plus 2 days

,
Interventionparticipants (Number)
AST Elevation >3*ULN (N=2831, 2863)ALT Elevation >3*ULN (N=2827, 2861)AST + ALT >3*ULN on same date (N= 2827, 2861)TBili >2*ULN (N= 2853, 2884)ALT or AST >3*ULN + TBili >2*ULN (N=2818,2855)ALT>3*ULN + TBili >2*ULN (N=2817, 2853)
Apixaban 2.5 mg2322141320
Enoxaparin 40 mg2832131422

Number of Participants With Marked Abnormalities in Electrolyte Laboratory Tests During Treatment Period in Treated Participants

Bicarbonate milliequivalents/Liter (mEq/L) Low/High: < 0.75*LLN or > 1.25*ULN, or if PreRx < LLN then use < 0.75* PreRx or > ULN if PreRx > ULN then use > 1.25*PreRx or < LLN; Serum Calcium mg/dL Low/High: < 0.8*LLN or > 1.2*ULN, or if PreRx < LLN then use < 0.75*PreRx or > ULN if PreRx > ULN then use > 1.25*PreRx or < LLN; Serum Chloride mEq/L: < 0.9*LLN or > 1.1*ULN, or if PreRx < LLN then use < 0.9*PreRx or > ULN if PreRx > ULN then use > 1.1*PreRx or < LLN; Serum Potassium mEq/L: < 0.9*LLN or > 1.1*ULN, or if PreRx < LLN then use < 0.9*PreRx or > ULN if PreRx > ULN then use > 1.1*PreRx or < LLN; Serum Sodium mEq/L: < 0.95*LLN or > 1.05*ULN, or if PreRx < LLN then use < 0.95*PreRx or > ULN if PreRx > ULN then use > 1.05*PreRx or < LLN. Samples obtained at Screening/Enrollment Visit (Day 1, prior to drug being administered), on the day of hospital discharge, Day 30 (last day of treatment) plus 2 days. (NCT00457002)
Timeframe: Day 1 to last dose of study drug plus 2 days

,
Interventionparticipants (Number)
Calcium < 0.8*LLN (N=2861, 2893)Calcium > 1.2*ULN (N=2861, 2893)Chloride < 0.9*LLN (N=2861, 2886)Chloride > 1.1*ULN (N=2861, 2886)Bicarbonate < 0.75*LLN (N=2831, 2855)Bicarbonate > 1.25*ULN (N=2831, 2855)Potassium < 0.9*LLN (N=2851, 2878)Potassium > 1.1*ULN (N=2851, 2878)Sodium < 0.95*LLN (N=2862, 2888)Sodium > 1.05*ULN (N=2862, 2888)
Apixaban 2.5 mg632555661140239
Enoxaparin 40 mg832516458137256

Number of Participants With Marked Abnormalities in Glucose, Creatine Kinase, Uric Acid, and Total Protein Laboratory Tests During the Treatment Period in Treated Participants

Creatine kinase High: >5*ULN Units/Liter (U/L); Total Protein High/Low: < 0.9 *LLN or > 1.1*ULN, or if PreRx < LLN then use 0.9* PreRx or > ULN if PreRx > ULN then use 1.1 *PreRx or 1.5* ULN, or if PreRx > ULN then use > 2 *PreRx. Glucose Fasting: <0.9*LLN or > 1.5*ULN or if PreRx < LLN then use < 0.8*PreRx or > ULN, if PreRx > ULN then use >2.0*PreRx. Samples obtained at Screening/Enrollment Visit (Day 1, prior to drug being administered), on the day of hospital discharge, Day 30 (last day of treatment) ± 2days. (NCT00457002)
Timeframe: Day 1 to last dose of study drug plus 2 days

,
Interventionparticipants (Number)
Glucose Fasting <0.9*LLN (N=284,287)Glucose Fasting > 1.5*ULN (N=284,287)Total Protein < 0.9 *LLN (N=2864, 2890)Total Protein > 1.1*ULN (N=2864, 2890)Creatine kinase >5*ULN U/L(N=2856, 2888)Uric acid > 1.5* ULN (N=2862, 2889)
Apixaban 2.5 mg5397816847
Enoxaparin 40 mg3305181044

Number of Participants With Marked Abnormalities in Hematology Laboratory Tests During Treatment Period in Treated Participants

Lower limit of normal (LLN). Upper limit of normal (ULN). Pre-therapy (PreRx). Absolute (Abs) neutrophil count, bands + neutrophils (ANC). Cells per microliter (c/µL). Grams per deciliter (g/dL). Cells per Liter (c/L). Millimeter (MM). Absolute (Abs). Hemoglobin: >2 g/dL decrease compared to PreRx value or value <=8 g/dL; Hematocrit: <0.75*PreRx; Erythrocytes: <0.75*PreRx c/µL; Leukocytes: <0.75*LLN or > 1.25*ULN, if PreRx ULN, if PreRx >ULN then use >1.2*PreRx or < LLN; Platelet count: < 100*10^9 c/L; ANC: < 1.00*10^3 c/µL; Abs eosinophils: > 0.75*10^3 c/µL; Abs Basophils: > 400/MM^3; Abs Monocytes > 2000/MM^3; Abs Lymphocytes: < 0.750*10*3 c/ µL or > 7.5*10^3 c/ µL. Samples were obtained at Screening/Enrollment Visit (Day 1, prior to drug being administered), on the day of hospital discharge, Day 30 (last day of treatment) plus 2 days. (NCT00457002)
Timeframe: Day 1 to last dose of study drug plus 2 days

,
Interventionparticipants (Number)
Hemoglobin >2 g/dL decrease (N=2835, 2871)Hematocrit <0.75*PreRx (N=2688, 2722)Platelet Count < 100*10^9 c/L (N=2761, 2799)Erythrocytes <0.75*PreRx c/µL (N=2697, 2730)Leukocytes <0.75*LLN (N= 2835, 2869)Leukocytes > 1.25*ULN (N=2835, 2869)Abs Eosinophils > 0.75*10^3 c/µL (N=20, 24)Abs Lymphocytes < 0.750*10*3 c/ µL (N=20, 24)Abs Monocytes > 2000/MM^3 (N= 19, 25)
Apixaban 2.5 mg1332392864331141
Enoxaparin 40 mg981771655283120

Number of Participants With Marked Abnormalities in Kidney and Liver Function Laboratory Tests During the Treatment Period in Treated Participants

Blood urea nitrogen (BUN), milligrams/deciliter (mg/dL), units per liter (U/L). BUN mg/dL > 1.5*ULN; Creatinine mg/dL: > 1.5*ULN; Alanine aminotransferase (ALT) U/L: > 3*ULN; Aspartate aminotransferase (AST) U/L: > 3*ULN; Alkaline phosphatase U/L: > 2*ULN; Bilirubin Direct mg/dL: > 1.5*ULN; Bilirubin Total mg/dL: > 2*ULN. Samples for laboratories obtained at Screening/Enrollment Visit (Day 1, prior to drug being administered), on the day of hospital discharge, Day 30 (last day of treatment) plus 2 days. (NCT00457002)
Timeframe: Day 1 to last dose of study drug plus 2 days

,
Interventionparticipants (Number)
Alkaline phosphatase U/L > 2*ULN(N=2866, 2895)ALT U/L > 3*ULN (N=2827, 2861)AST U/L > 3*ULN (N=2831, 2863)Bilirubin Direct mg/dL > 1.5*ULN (N=2782, 2821)Bilirubin Total mg/dL > 2*ULN (N=2853, 2884)BUN mg/dL > 1.5*ULN (N=2864, 2891)Creatinine mg/dL > 1.5*ULN (N=2862, 2892)
Apixaban 2.5 mg35232412317194150
Enoxaparin 40 mg47332910615188156

Incidence of Adjudicated Clinically Relevant Non Major (CRNM) Bleeding During the Treatment Period in Treated Participants

Bleeding defined by International Society on Thrombosis and Haemostasis: CRNM defined as acute clinically overt bleeding: compromising hemodynamics, leading to hospitalization, hematoma, epistasis >5 minutes or repetitive, gingival bleeding, hematuria, macroscopic gastrointestinal hemorrhage, rectal blood loss, hemoptysis. All events were adjudicated by an ICAC blinded to treatment. Event rate (proportion of participants with event): calculated as n/N (n=number of participants with observation; N=Total number of participants in respective treatment group (all participants who received at least one dose of study drug). Participants were categorized to the treatment group to which they were assigned unless incorrect study treatment was received throughout the study, in which case the participant was categorized according to the treatment received. (NCT00643201)
Timeframe: Day 1 to Week 24 + 2 Days or 355 Days (Discontinued Early)

Interventionproportion of participants (Number)
Apixaban0.0385
Enoxaparin + Warfarin0.0800

Incidence of Adjudicated Composite of Recurrent Symptomatic Venous Thromboembolism (VTE) or All-Cause Death

VTE included: nonfatal DVT or nonfatal PE. All events were adjudicated by an ICAC blinded to treatment. DVT was assessed by compression ultrasound and/or venography; PE was assessed by spiral computed tomography scanning, pulmonary angiography, and/or ventilation/perfusion lung scan. Event rate (proportion of participants with event) calculated as n/N (n=number of participants with observation; N=total number of efficacy evaluable participants). Intended treatment period: longer of the dosing period plus 2 days (completed treatment) or 355 days (discontinued early). Composite endpoint included events at any time from randomization until end of the intended treatment period, regardless whether drug treatment was received, ie intent to treat (ITT) principle. Each participant scored as having an event only if they experienced one or more of the elements of the composite. Participants with missing endpoint information excluded. (NCT00643201)
Timeframe: Day 1 up to 24 Weeks + 2 Days or 355 Days (Discontinued Early)

Interventionproportion of participants (Number)
Apixaban0.0322
Enoxaparin + Warfarin0.0395

Incidence of Adjudicated Composite of Recurrent Symptomatic VTE or Cardiovascular (CV)-Related Death

VTE included: nonfatal DVT or nonfatal PE. All events were adjudicated by an ICAC blinded to treatment. DVT was assessed by compression ultrasound and/or venography; PE was assessed by spiral computed tomography scanning, pulmonary angiography, and/or ventilation/perfusion lung scan. Event rate (proportion of participants with event) calculated as n/N (n=number of participants with observation; N=total number of efficacy evaluable participants, participants with missing endpoint information excluded). Intended treatment period: longer of the dosing period plus 2 days (completed treatment) or 355 days (discontinued early). Composite endpoint included events at any time from randomization until end of the intended treatment period, regardless whether drug treatment was received, ie, ITT principle. Each participant scored as having an event only if the participant experienced one or more of the elements of the composite. (NCT00643201)
Timeframe: Day 1 up to 24 Weeks + 2 Days or 355 Days (Discontinued Early)

Interventionproportion of participants (Number)
Apixaban0.0234
Enoxaparin + Warfarin0.0292

Incidence of Adjudicated Composite of Recurrent Symptomatic VTE or VTE-related Death or Major Bleeding

VTE included: nonfatal DVT or nonfatal PE. All events were adjudicated by an ICAC blinded to treatment. DVT assessed by compression ultrasound and/or venography; PE assessed by spiral computed tomography scanning, pulmonary angiography, and/or ventilation/perfusion lung scan. Major bleeding defined by International Society on Thrombosis and Haemostasis: acute, clinically overt bleeding associated with decrease in hemoglobin (Hgb) of 2 g/dL or more or bleeding leading to transfusion or bleeding in a critical site or bleeding that is fatal . Event rate (proportion of participants with event): n/N (n=number of participants with observation; N=Total number of participants, excluding those with missing endpoint and including those not in the efficacy evaluable population with a bleeding event that occurred during treatment period. Events included regardless of whether or not participant received treatment, ie, ITT principle (NCT00643201)
Timeframe: Day 1 up to 24 Weeks + 2 Days or 355 Days (Discontinued Early)

Interventionproportion of participants (Number)
Apixaban0.0280
Enoxaparin + Warfarin0.0448

Incidence of Adjudicated Composite of Recurrent Symptomatic VTE, Myocardial Infarction, Stroke, CV-related Death, Clinically Relevant Non-major (CRNM) Bleeding or Major Bleeding

VTE=Nonfatal DVT or nonfatal PE adjudicated by ICAC blinded to treatment. DVT: compression ultrasound and/or venography; PE: spiral computed tomography scanning, pulmonary angiography, and/or ventilation/perfusion lung scan. Major Bleeding = acute, clinically overt bleeding: decrease in Hgb of 2 g/dL or more or bleeding leading to transfusion or bleeding in a critical site or fatal bleeding. CRNM = acute clinically overt bleeding: compromising hemodynamics, leading to hospitalization, hematoma, epistasis >5 minutes or repetitive, gingival bleeding, hematuria, macroscopic gastrointestinal hemorrhage, rectal blood loss, hemoptysis. n/N (n=number of participants with observation; N=Total number of participants, excluding those with missing endpoint and including those not in the efficacy evaluable population with a bleeding event that occurred during treatment period). Events included regardless of whether or not treatment was received (ITT). (NCT00643201)
Timeframe: Day 1 up to 24 Weeks + 2 Days or 355 Days (Discontinued Early)

Interventionproportion of participants (Number)
Apixaban0.0699
Enoxaparin + Warfarin0.1261

Incidence of Adjudicated Composite of Symptomatic, Recurrent Venous Thromboembolism (VTE) or VTE-Related Death During 6 Months of Treatment

VTE: nonfatal deep vein thrombosis (DVT) or nonfatal pulmonary embolism (PE). All events were adjudicated by an ICAC blinded to treatment. DVT assessed by compression ultrasound and/or venography; PE assessed by spiral computed tomography scanning, pulmonary angiography, and/or ventilation/perfusion lung scan. Event rate (proportion of participants): n/N (n=number of participants with observation; N=total number of efficacy evaluable participants). Intended treatment period: longer of the dosing period plus 2 days (completed treatment) or 355 days (discontinued early). Composite endpoint: events at any time from randomization until end of intended treatment, regardless whether drug treatment was received. All randomized participants with a non-missing primary endpoint were summarized. Missing endpoint = outcomes which could not be documented on or after study Day 154. Participants were categorized to the assigned group regardless of the treatment actually received (intent-to-treat). (NCT00643201)
Timeframe: Day 1 to Week 24 + 2 Days or 355 days (Discontinued Early)

Interventionproportion of participants (Number)
Apixaban0.0226
Enoxaparin + Warfarin0.0269

Incidence of Adjudicated Major Bleeding During the Treatment Period in Treated Participants

All events were adjudicated by an ICAC blinded to treatment. Bleeding defined by International Society on Thrombosis and Haemostasis: Major Bleeding: acute, clinically overt bleeding: decrease in hemoglobin (hgb) of 2 g/dL or more or bleeding leading to transfusion or bleeding in a critical site or fatal bleeding. Event rate (proportion of participants with event): n/N (n=number of participants with observation; N=Total number of participants in respective treatment group (all participants who received at least one dose of study drug). Participants were categorized to the treatment group to which they were assigned unless incorrect study treatment was received throughout the study, in which case the participant was categorized according to the treatment received. (NCT00643201)
Timeframe: Day 1 to Week 24 + 2 Days or 355 Days (Discontinued Early)

Interventionproportion of participants (Number)
Apixaban0.0056
Enoxaparin + Warfarin0.0182

Incidence of Adjudicated Major/CRNM Bleeding During the Treatment Period in Treated Participants

Major Bleeding = acute, clinically overt bleeding: decrease in hemoglobin of 2 g/dL or more, or bleeding leading to transfusion, or bleeding in a critical site, or fatal bleeding. CRNM = acute clinically overt bleeding: compromising hemodynamics, leading to hospitalization, hematoma, epistasis >5 minutes or repetitive, gingival bleeding, hematuria, macroscopic gastrointestinal hemorrhage, rectal blood loss, hemoptysis. Minor =: All acute clinically overt bleeding events not meeting the criteria for either major bleeding or CRNM. All events were adjudicated by an ICAC blinded to treatment. Total bleeding = any of major, or CRNM, or minor bleeding. Event rate (proportion of participants with event): n/N (n=number of participants with observation; N=Total number of treated (received at least 1 dose of study drug). (NCT00643201)
Timeframe: Day 1 to Week 24 + 2 Days or 355 Days (Discontinued Early)

Interventionproportion of participants (Number)
Apixaban0.0430
Enoxaparin + Warfarin0.0971

Incidence of Adjudicated Minor Bleeding During the Treatment Period in Treated Participants

Bleeding defined by International Society on Thrombosis and Haemostasis: Minor bleeding: all acute clinically overt bleeding events not meeting the criteria for either major bleeding or CRNM. All events wre adjudicated by an ICAC blinded to treatment. Event rate (proportion of participants) calculated as n/N (n=number of participants with observation; N=Total number of participants in respective treatment group (all participants who received at least one dose of study drug). Participants were categorized to the treatment group to which they were assigned unless incorrect study treatment was received throughout the study, in which case the participant was categorized according to the treatment received. (NCT00643201)
Timeframe: Day 1 to Week 24 + 2 Days or 355 Days (Discontinued Early)

Interventionproportion of participants (Number)
Apixaban0.1170
Enoxaparin + Warfarin0.1878

Incidence of Adjudicated Symptomatic Nonfatal Deep Vein Thrombosis (DVT) During the Intended Treatment Period

DVT adjudicated by an ICAC blinded to treatment. DVT evaluated by: compression ultrasound and/or venography. Includes events that occurred during the intended treatment period, regardless of whether the participant received study medication, intent to treat principle (ITT). Event rate (proportion of participants with event): n/N (n=number of participants with observation; N=Total number of participants, excluding those with missing endpoint). Intended treatment period: longer of the dosing period plus 2 days (completed treatment) or 355 days (discontinued early). (NCT00643201)
Timeframe: Day 1 up to 24 Weeks + 2 Days or 355 Days (Discontinued Early)

Interventionproportion of participants (Number)
Apixaban0.0084
Enoxaparin + Warfarin0.0133

Incidence of Adjudicated Symptomatic Nonfatal Pulmonary Embolism (PE) During the Intended Treatment Period

PE adjudicated by an ICAC blinded to treatment. PE: spiral computed tomography scanning, pulmonary angiography, and/or ventilation/perfusion lung scan. Includes events that occurred during the intended treatment period, regardless of whether the participant received study medication (ITT principle). Event rate (proportion of participants with event): n/N (n=number of participants with observation; N=Total number of participants, excluding those with missing endpoint). Intended treatment period: longer of the dosing period plus 2 days (completed treatment) or 355 days (discontinued early). (NCT00643201)
Timeframe: Day 1 to Week 24 + + 2 Days or 355 Days (Discontinued Early)

Interventionproportion of participants (Number)
Apixaban0.0104
Enoxaparin + Warfarin0.0095

Incidence of Adjudicated Total Bleeding During the Treatment Period in Treated Participants

Bleeding defined by International Society on Thrombosis and Haemostasis: Total Bleeding defined as any of major, CRNM, or minor bleeding. All events were adjudicated by an ICAC blinded to treatment. Event rate (proportion of participants with event): n/N (n=number of participants with observation; N=Total number of participants in respective treatment group (all participants who received at least one dose of study drug). Participants were categorized to the treatment group to which they were assigned unless incorrect study treatment was received throughout the study, in which case the participant was categorized according to the treatment received. (NCT00643201)
Timeframe: Day 1 to Week 24 + 2 Days or 355 Days (Discontinued Early)

Interventionproportion of participants (Number)
Apixaban0.1502
Enoxaparin + Warfarin0.2514

Incidence of Adjudicated Venous Thromboembolism (VTE)-Related Death During the Intended Treatment Period

VTE-related death included: DVT-related death or PE-related death. All events were adjudicated by an ICAC blinded to treatment. DVT was assessed by compression ultrasound and/or venography; PE was assessed by spiral computed tomography scanning, pulmonary angiography, and/or ventilation/perfusion lung scan. Event rate (proportion of participants with event) calculated as n/N (n=number of participants with observation; N=total number of participants in respective treatment groups excluding participants with missing endpoint information). Intended treatment period: longer of the dosing period plus 2 days (completed treatment) or 355 days (discontinued early). Includes events that occur during the intended treatment period regardless of whether or not the participant received study medication (ITT principle). (NCT00643201)
Timeframe: Day 1 to Week 24 + 2 Days or 355 Days (Discontinued Early)

Interventionproportion of participants (Number)
Apixaban0.0046
Enoxaparin + Warfarin0.0061

Incidence of All-Cause Death During the Intended Treatment Period

Intended treatment period: longer of the dosing period plus 2 days (completed treatment) or 355 days (discontinued early). Includes events that occurred during the intended treatment period, regardless of whether the participant received study medication (ITT principle). Event rate (proportion of participants with event): n/N (n=number of participants with observation; N=Total number of participants, excluding those with missing endpoint information). (NCT00643201)
Timeframe: Day 1 to Week 24 + 2 Days or 355 Days (Discontinued Early)

Interventionproportion of participants (Number)
Apixaban0.0157
Enoxaparin + Warfarin0.0198

Incidence of Cardiovascular (CV)-Related Death Including VTE-related Death During the Intended Treatment Period

VTE-related death included: DVT-related death or PE-related death. All events were adjudicated by an ICAC blinded to treatment. DVT assessed by compression ultrasound and/or venography; PE assessed by spiral computed tomography scanning, pulmonary angiography, and/or ventilation/perfusion lung scan. Event rate (proportion of participants with event) calculated as n/N (n=number of participants with observation; N=total number of participants in respective treatment groups excluding participants with missing endpoint information). Intended treatment period: longer of the dosing period plus 2 days (completed treatment) or 355 days (discontinued early). Includes events that occur during the intended treatment period regardless of whether or not the participant received study medication (ITT principle). (NCT00643201)
Timeframe: Day 1 to Week 24 + 2 Days or 355 Days (Discontinued Early)

Interventionproportion of participants (Number)
Apixaban0.0058
Enoxaparin + Warfarin0.0087

Number of Participants With Adverse Events (AEs), Serious AEs (SAEs), Bleeding AEs, Discontinuations Due to AEs and Death During the Treatment Period in Treated Participants

Treated Participants: all who received at least 1 dose of study drug. Participants categorized to the treatment group to which they were assigned unless incorrect study treatment was received throughout the study, in which case the participant was categorized according to treatment received. Included all SAEs and AEs with onset from first dose to last dose + 2 days (for AEs) or + 30 days (for SAEs); note; bleeding AEs and SAEs from first dose to last dose + 2 days included. Discontinuations due to AE included all AEs/SAEs from first dose until drug was discontinued. AE=any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that may not have a causal relationship with treatment. SAE=a medical event that at any dose results in death, persistent or significant disability/incapacity, or drug dependency/abuse; is life-threatening, an important medical event, or a congenital anomaly/birth defect; or requires or prolongs hospitalization. (NCT00643201)
Timeframe: First dose to last dose of 24 Weeks + 2 days (AEs) or + 30 days (SAEs) or until drug discontinued

,
Interventionparticipants (Number)
AESAEBleeding AE or SAEDiscontinued Due to AE or SAEDeath
Apixaban179541741516237
Enoxaparin + Warfarin192341069519944

Number of Treated Participants With Marked Abnormalities in Creatine Kinase, Uric Acid, and Total Protein Laboratory Tests

Creatine kinase High: >5*ULN Units/Liter (U/L); Total Protein High/Low: < 0.9 *LLN or > 1.1*ULN, or if pre-dose < LLN then use 0.9* pre-dose or > ULN if pre-dose > ULN then use 1.1 *pre-dose or 1.5* ULN, or if pre-dose > ULN then use > 2 *pre-dose. (NCT00643201)
Timeframe: Day 1 to Week 24 + 2 Days or 355 Days (Discontinued Early)

,
Interventionparticipants (Number)
Creatine Kinase High (N=2601, 2596)Uric Acid High (N=2601, 2596)Total Protein Low (N=2601, 2596)Total Protein High (N=2601, 2596)
Apixaban206150
Enoxaparin + Warfarin243160

Number of Treated Participants With Marked Abnormalities in Electrolyte Laboratory Tests

Bicarbonate milliequivalents/Liter (mEq/L) Low/High: < 0.75*LLN or > 1.25*ULN, or if pre-dose < LLN then use < 0.75*pre-dose or > ULN if pre-dose > ULN then use > 1.25*pre-dose or < LLN; Serum Calcium mg/dL Low/High: < 0.8*LLN or > 1.2*ULN, or if pre-dose < LLN then use < 0.75*pre-dose or > ULN if pre-dose > ULN then use > 1.25*pre-dose or < LLN; Serum Chloride mEq/L: < 0.9*LLN or > 1.1*ULN, or if pre-dose < LLN then use < 0.9*pre-dose or > ULN if pre-dose > ULN then use > 1.1*pre-dose or < LLN; Serum Potassium mEq/L: < 0.9*LLN or > 1.1*ULN, or if pre-dose < LLN then use < 0.9*pre-dose or > ULN if pre-dose > ULN then use > 1.1*pre-dose or < LLN; Serum Sodium mEq/L: < 0.95*LLN or > 1.05*ULN, or if pre-dose < LLN then use < 0.95*pre-dose or > ULN if pre-dose > ULN then use > 1.05*pre-dose or < LLN. (NCT00643201)
Timeframe: Day 1 to Week 24 + 2 Days or 355 Days (Discontinued Early)

,
Interventionparticipants (Number)
Bicarbonate Low (N=2600,2593)Bicarbonate High (N=2600,2593)Total Calcium Low (N=2601,2596)Total Calcium High (N=2601,2596)Chloride Low Total Calcium Low (N=2601,2596)Chloride Low Total Calcium High (N=2601,2596)Potassium Low (N=2601,2596)Potassium High (N=2601,2596)Sodium Low (N=2601,2596)
Apixaban4417312502619104
Enoxaparin + Warfarin3111101131222264

Number of Treated Participants With Marked Abnormalities in Hematology Laboratory Tests

Lower limit of normal (LLN). Upper limit of normal (ULN). Pre-therapy (PreRx). Absolute (Abs) neutrophil count, bands + neutrophils (ANC). Cells per microliter (c/µL). Grams per deciliter (g/dL). Cells per Liter (c/L). Millimeter (MM). White blood cells: < 0.75*LLN, > 1.25*ULN; Hemoglobin: <= 11.5 g/dL (males), <= 9.5 g/dL (females); Hematocrit: <= 37% (males), <= 32% (females); Erythrocytes: <0.75*10^6 c/µL*PreRx; Platelet count: < 75*10^9 c/L, > 700*10^9 c/L; ANC: < 1.00*10^3 c/µL; Abs eosinophils: > 0.750*10^3 c/µL; Abs Basophils: > 400/MM^3; Abs Monocytes> 2000/MM^3; Abs Lymphocytes: < 0.750*10*3 c/ µL, > 7.5*10^3 c/ µL. (NCT00643201)
Timeframe: Day 1 to Week 24 + 2 Days or 355 Days (Discontinued Early)

,
Interventionparticipants (Number)
Erthrocytes Low (N=2599, 2593)Hematocrit Low (N=2588, 2587)Hemoglobin Low (N=2599, 2593)Platelet Count Low (N=2594, 2589)Leukocytes Low (N=2528, 2519)Leukocytes High (N=2528, 2519)Absolute Basophils High (N=2594,2589)Absolute Eosinophils High (N=2594,2589)Absolute Lyphocytes Low (N=2594,2589)Absolute Lyphocytes High (N=2594,2589)Absolute Monocytes High (N=2594,2589)Absolute Neutrophils Low (N=2594,2589)
Apixaban23269623412618494419
Enoxaparin + Warfarin1720101134115279763220

Number of Treated Participants With Marked Abnormalities in Kidney and Liver Function Laboratory Tests

Blood urea nitrogen (BUN), milligrams/deciliter (mg/dL), units per liter (U/L). BUN mg/dL High: > 1.5*ULN; Creatinine mg/dL: > 1.5*ULN; Alanine aminotransferase (ALT) U/L: > 3*ULN; Aspartate aminotransferase (AST) U/L: > 3*ULN; Alkaline phosphatase U/L: > 2*ULN; Bilirubin Direct mg/dL: > 1.5*ULN; Bilirubin Total mg/dL: > 2*ULN. (NCT00643201)
Timeframe: Day 1 to Week 24 + 2 Days or 355 Days (Discontinued Early)

,
Interventionparticipants (Number)
BUN High (N=517, 523)Creatinine High (N=2601, 2596)ALT High (N=2601, 2598)ALP High (N=2601, 2598)AST High (N=2601, 2598)Direct Bilirubin High (N=2601, 2593)Total Bilirubin High (N=2601, 2597)
Apixaban247523540288
Enoxaparin + Warfarin7371452740217

Number of Treated Participants With Marked Abnormalities in Urinalysis Laboratory Tests

All tests in urine: Glucose: If missing pre-dose use ≥ 2, or if value ≥ 4, or if pre-dose = 0 or 0.5 use ≥ 2, or if pre-dose = 1 use ≥ 3, or if pre-dose = 2 or 3 use ≥ 4; Protein: If missing pre-dose use ≥ 2, or if value ≥ 4, or if pre-dose = 0 or 0.5 use ≥ 2, or if pre-dose = 1 use ≥ 3, or if pre-dose = 2 or 3 use ≥ 4; Blood: If missing pre-dose use ≥ 2, or if value ≥ 4, or if pre-dose = 0 or 0.5 use ≥ 2, or if pre-dose = 1 use ≥ 3, or if pre-dose = 2 or 3 use ≥ 4; Leukocyte esterase: If missing pre-dose use ≥ 2, or if value ≥ 4, or if pre-dose = 0 or 0.5 use ≥ 2, or if pre-dose = 1 use ≥ 3, or if pre-dose = 2 or 3 use ≥ 4;Red blood cells (RBC): If missing pre-dose use ≥ 2, or if value ≥ 4, or if pre-dose = 0 or 0.5 use ≥ 2, or if pre-dose = 1 use ≥ 3, or if pre-dose = 2 or 3 use ≥ 4; White blood cells (WBC): If missing pre-dose use ≥ 2, or if value ≥ 4, or if pre-dose = 0 or 0.5 use ≥ 2, or if pre-dose = 1 use ≥ 3, or if pre-dose = 2 or 3 use ≥ 4. (NCT00643201)
Timeframe: Day 1 to Week 24 + 2 Days or 355 Days (Discontinued Early)

,
Interventionparticipants (Number)
Blood in Urine High (N=2289, 2273)Glucose in Urine High (N=2289, 2273)Leukocyte Esterase in Urine High (N=2289, 2273)Protein in Urine High (N=2289, 2273)RBC + WBC in Urine High (N=1685, 1719)RBC in Urine High (N=1293, 1389)WBC in Urine High (N=1354, 1361)
Apixaban854610541359111274
Enoxaparin + Warfarin1273110250361140263

Hemoglobin Concentration

Measure Description: Normal hemoglobin range for adult women - 12 - 16 g/dL. Lower levels indicate worse outcomes. (NCT02829957)
Timeframe: 3 months

Interventiong/dl (Median)
Rivaroxaban12.8
Apixaban13.25

Number of Participants Who Crossed Over to Another Anticoagulant

(NCT02829957)
Timeframe: 3 months

InterventionParticipants (Count of Participants)
Rivaroxaban3
Apixaban1

Number of Participants Who Discontinued Planned Drug Administration

(NCT02829957)
Timeframe: 3 months

InterventionParticipants (Count of Participants)
Rivaroxaban4
Apixaban2

Number of Participants With Clinically Relevant Non-major Bleeding

(NCT02829957)
Timeframe: 3 months

InterventionParticipants (Count of Participants)
Rivaroxaban3
Apixaban0

Number of Participants With Major Hemorrhage

(NCT02829957)
Timeframe: 3 months

InterventionParticipants (Count of Participants)
Rivaroxaban0
Apixaban0

Number of Participants With Venous Thromboembolism (VTE)

(NCT02829957)
Timeframe: 3 months

InterventionParticipants (Count of Participants)
Rivaroxaban0
Apixaban0

Number of Patients That Held Drug for Menorrhagia

(NCT02829957)
Timeframe: 1, 2, and 3 months

InterventionParticipants (Count of Participants)
Rivaroxaban0
Apixaban0

PBAC Scores

"Measure Description: A PBAC Score of < 100 indicates a normal menstrual cycle. The lowest possible score would be zero. Higher values indicate worse outcomes. The higher theoretical range value cannot be calculated. The scoring mechanism is as follows;~Towels~1 point for each lightly stained towel~5 points or each moderately soiled towel~20 points if the towel is completely saturated with blood~Tampons~1 point for each lightly stained tampon~5 points for each moderately soiled tampon~10 points if the tampon is completely saturated with blood~Clots~1 point for small clots~5 points for large clots" (NCT02829957)
Timeframe: 3 months

Interventionscore on a scale (Median)
Rivaroxaban292
Apixaban146

Physical Component Summary of Standard From 36

The RAND 36-Item Health Survey (Version 1.0) taps eight health concepts: physical functioning, bodily pain, role limitations due to physical health problems, role limitations due to personal or emotional problems, emotional well-being, social functioning, energy/fatigue, and general health perceptions. All items are scored so that a high score defines a more favorable health state. In addition, each item is scored on a 0 to 100 range so that the lowest and highest possible scores are 0 and 100, respectively. (NCT02829957)
Timeframe: 3 months

InterventionScore (Median)
Rivaroxaban55.5
Apixaban45.6

Number of Participants Who Experienced Major Bleeding (International Society on Thrombosis and Hemostasis [ISTH]) in the Edoxaban Group Compared With VKA Group Among Participants Undergoing Catheter Ablation (Adjudicated Data)

Major bleeding was defined by the International Society on Thrombosis and Hemostasis (ISTH) as fatal bleeding and/or bleeding that is symptomatic and occurs in a critical area or organ and/or extrasurgical site bleeding causing a fall in hemoglobin level of >2 g/dL or leads to blood transfusion, surgical site bleeding that requires a second intervention, causes hemarthrosis that delays mobilization or wound healing, or causes hemodynamic instability. (NCT02942576)
Timeframe: Day 1 to Day 90

InterventionParticipants (Count of Participants)
Edoxaban-based Regimen10
VKA-based Regimen3

Number of Participants Who Experienced the Composite of All-cause Death, Stroke (Alternative), and Major Bleeding (ISTH) in the Edoxaban Group Compared With VKA Group Among Participants Undergoing Catheter Ablation (Adjudicated Data)

"An alternative definition characterized stroke (ischemic, hemorrhagic, or undetermined) as an abrupt onset, over minutes to hours, of a focal neurological deficit in the distribution of a single brain artery that was not due to an identifiable nonvascular cause (ie, brain tumor or trauma), and that either lasted at least 24 hours or resulted in death within 24 hours of onset.~Major bleeding was defined by the International Society on Thrombosis and Hemostasis (ISTH) as fatal bleeding and/or bleeding that is symptomatic and occurs in a critical area or organ and/or extrasurgical site bleeding causing a fall in hemoglobin level of >2 g/dL or leads to blood transfusion, surgical site bleeding that requires a second intervention, causes hemarthrosis that delays mobilization or wound healing, or causes hemodynamic instability." (NCT02942576)
Timeframe: Day 1 to Day 90

InterventionParticipants (Count of Participants)
Edoxaban-based Regimen1
VKA-based Regimen2

Number of Participants Who Experienced the Composite of All-cause Death, Stroke (VARC-2), and Major Bleeding (ISTH) in the Edoxaban Group Compared With Vitamin K Antagonist (VKA) Group in Participants Undergoing Catheter Ablation (Adjudicated Data)

"Stroke (ischemic, hemorrhagic, or undetermined) was defined by Valve Academic Research Consortium-2 (VARC-2) as an acute episode of focal or global neurological dysfunction caused by brain, spinal cord, or retinal vascular injury following hemorrhage or infarction. A stroke event was based on any of the following: duration of neurological dysfunction >24 hours (h), duration of neurological dysfunction <24 h in case of imaging-documented new hemorrhage or infarction, and a neurological dysfunction resulting in death.~Major bleeding was defined by the International Society on Thrombosis and Hemostasis (ISTH) as fatal bleeding and/or bleeding that is symptomatic and occurs in a critical area or organ and/or extrasurgical site bleeding causing a fall in hemoglobin level of >2 g/dL or leads to blood transfusion, surgical site bleeding that requires a second intervention, causes hemarthrosis that delays mobilization or wound healing, or causes hemodynamic instability." (NCT02942576)
Timeframe: Day 1 to Day 90

InterventionParticipants (Count of Participants)
Edoxaban-based Regimen1
VKA-based Regimen2

Number of Participants Who Experienced the Composite of Stroke (VARC-2), Systemic Embolic Events (SEE), and Cardiovascular (CV) Mortality in the Edoxaban Group Compared With VKA Group Among Participants Undergoing Catheter Ablation (Adjudicated Data)

"Stroke (ischemic, hemorrhagic, or undetermined) was defined by Valve Academic Research Consortium-2 (VARC-2) as an acute episode of focal or global neurological dysfunction caused by brain, spinal cord, or retinal vascular injury following hemorrhage or infarction. A stroke event was based on any of the following: duration of neurological dysfunction >24 hours (h), duration of neurological dysfunction <24 h in case of imaging-documented new hemorrhage or infarction, and a neurological dysfunction resulting in death.~SEE was defined as an arterial embolism resulting in clinical ischemia, excluding the central nervous system, coronary, and pulmonary arterial circulation.~CV mortality was defined as cardiac or vascular death according to Academic Research Consortium." (NCT02942576)
Timeframe: Day 1 to Day 90

InterventionParticipants (Count of Participants)
Edoxaban-based Regimen1
VKA-based Regimen0

Number of Participants With At Least 1 Symptomatic Venous Thromboembolism Recurrence - Overall

Descriptive statistics were used to report the number of participants with at least 1 symptomatic VTE recurrence. Recurrent VTE events were based on adjudicated events. (NCT02943993)
Timeframe: Baseline up to end of observation period (18 months)

InterventionParticipants (Count of Participants)
ETNA-VTE100

Duration of Edoxaban Treatment

Descriptive statistics were used to report the duration of edoxaban treatment. (NCT02943993)
Timeframe: Baseline up to end of observational period (18 months)

InterventionParticipants (Count of Participants)
Month 1 ongoingMonth 3 ongoingMonth 6 ongoingMonth 12 ongoingMonth 18 ongoingParticipants off edoxaban treatment at 18 months
ETNA-VTE25272346184212727131910

Duration of Venous Thromboembolism Events (On Edoxaban Treatment)

Descriptive statistics were used to assess the duration of VTE events reported by the patient. (NCT02943993)
Timeframe: Baseline up to end of observation period (18 months)

Interventiondays (Median)
Total number of VTE recurrencesDeep vein thrombosis (DVT) onlyPulmonary embolism with DVTPulmonary embolism only
ETNA-VTE11.09.5015.0

Duration of Venous Thromboembolism Recurrences, by Type - Overall

Descriptive statistics were used to assess the duration of VTE events reported by the patient. (NCT02943993)
Timeframe: Baseline up to end of observation period (18 months)

Interventiondays (Median)
Total number of VTE recurrencesDeep vein thrombosis (DVT) onlyPulmonary embolism with DVTPulmonary embolism only
ETNA-VTE18.044.58.016.0

Number of Participants Experiencing At Least 1 Real World Safety Event - Overall

Descriptive statistics were used to report the number of participants experiencing recurrent VTE and at least 1 real world safety event. VTE recurrence data were reported by recurrent deep vein thrombosis (DVT), recurrent pulmonary embolism (PE) with DVT, and recurrent PE only. Recurrent VTE events were based on adjudicated events. Real world safety events included all-cause death, cardiovascular (CV)-related death, VTE-related death, stroke, systemic embolic event, and hospitalization related to CV. (NCT02943993)
Timeframe: Baseline up to end of observation period (18 months)

InterventionParticipants (Count of Participants)
Recurrent DVT onlyRecurrent PE with DVTRecurrent PE onlyAll-cause deathCardiovascular-related deathVenous thromboembolism-related deathStrokeSystemic embolic eventHospitalization related to CV
ETNA-VTE6173195231262253

Number of Participants With Adverse Drug Reactions by Preferred Term (≥0.2%)

Adverse drug reactions were reported and coded using the Medical Dictionary for Regulatory Activities (MedDRA) version 20.1. (NCT02943993)
Timeframe: Baseline up to end of observational period (18 months)

InterventionParticipants (Count of Participants)
HaemorrhageGastrointestinal haemorrhageMenorrhagiaEpistaxisFatigueNauseaDizzinessRashHeadachePruritus
ETNA-VTE35121211887755

Number of Participants With At Least 1 Symptomatic Venous Thromboembolism Recurrence - On Edoxaban Treatment

Descriptive statistics were used to report the number of participants with overall symptomatic VTE recurrence. VTE recurrence data were further reported by recurrent deep venous thrombosis (DVT), recurrent pulmonary embolism (PE) with deep venous thrombosis (DVT), and recurrent PE only. Recurrent VTE events were based on adjudicated events. (NCT02943993)
Timeframe: Baseline up to end of observation period (18 months)

InterventionParticipants (Count of Participants)
Recurrent VTERecurrent DVT onlyRecurrent PE with DVTRecurrent PE onlyAll-cause deathCV-related deathVTE-related deathStrokeSystemic embolic eventHospitalization-related to cardiovascular
ETNA-VTE37271950111151167

Number of Participants With Bleeding Events (Adjudicated) While On Edoxaban Treatment

Descriptive statistics were used to report the number of participants with bleeding events. (NCT02943993)
Timeframe: Baseline up to end of observation period (18 months)

InterventionParticipants (Count of Participants)
Participants with any bleeding eventsAt least 1 major bleeding eventClinically relevant non-major bleeding eventMinorGastrointestinal bleeding eventEpidural or subdural haematoma bleeding eventIntra-ocular bleeding eventIntra-articular bleeding eventPleural bleeding eventOther bleeding eventSpontaneous bleedingProvoked bleedingUnknown bleeding
ETNA-VTE304388230077453131928711518

Number of Participants With Pre-defined Adverse Drug Reactions

Descriptive statistics were used to report the number of participants with pre-defined adverse drug reactions (ADR). ADRs were coded using the Medical Dictionary for Regulatory Activities (MedDRA) version 20.1. (NCT02943993)
Timeframe: Baseline up to end of observation period (18 months)

InterventionParticipants (Count of Participants)
StrokeBleeding eventsSystemic embolic eventsNon-valvular atrial fibrillationMalignancyOthers
ETNA-VTE2750004

Number of Participants With Risk Factors for Thromboembolic Events at Baseline

Descriptive statistics were used to assess the number of participants with risk factors for thromboembolic events. (NCT02943993)
Timeframe: at Baseline

InterventionParticipants (Count of Participants)
PuerperiumProlonged immobilisation>5 days in bedHistory of major surgery traumaKnown thrombophilic conditions
ETNA-VTE9401218359111

Number of Stroke Events

Descriptive statistics were used to report the number of stroke events. (NCT02943993)
Timeframe: Baseline up to end of observation period (18 months)

Interventionevents (Number)
Overall treatment: Total number of stroke eventsOverall treatment: Ischemic eventsOverall treatment: Haemorrhagic eventsOverall treatment: Unknown eventsOn treatment: Total number of stroke eventsOn treatment: Ischemic eventsOn treatment: Haemorrhagic eventsOn treatment: Unknown events
ETNA-VTE271755161231

Number of Systemic Embolic Events - Overall

Descriptive statistics were used to report the number of systemic embolic events (SEE). (NCT02943993)
Timeframe: Baseline up to end of observation period (18 months)

InterventionSystemic embolic events (Number)
Upper/lower extremityRenal
ETNA-VTE11

Overview of Participants With Adverse Drug Reactions

Descriptive statistics were used to report an overview of participants with adverse drug reactions (ADR). ADRs were coded using the Medical Dictionary for Regulatory Activities (MedDRA) version 20.1. (NCT02943993)
Timeframe: Baseline up to end of observation period (18 months)

InterventionParticipants (Count of Participants)
Death due to ADRParticipants with at least 1 ADRParticipants with at least 1 serious ADRStudy discontinuation due to ADR
ETNA-VTE2142590

Total Number of Venous Thromboembolism Recurrences (On Edoxaban Treatment)

Descriptive statistics were used to assess the number of recurrent VTE events reported by the patient. (NCT02943993)
Timeframe: Baseline up to end of observation period (18 months)

InterventionVTE recurrences (Number)
Total number of VTE recurrencesDeep vein thrombosis (DVT) onlyPulmonary embolism with DVTPulmonary embolism only
ETNA-VTE392819

Total Number of Venous Thromboembolism Recurrences By Type - Overall

Descriptive statistics were used to describe the number of VTE events reported by the patient. (NCT02943993)
Timeframe: Baseline up to end of observation period (18 months)

InterventionVTE recurrences (Number)
Total number of VTE recurrencesDeep vein thrombosis (DVT) onlyPulmonary embolism with DVTPulmonary embolism only
ETNA-VTE10564732

Number of Participants With All Bleeding Events (On Treatment) During the Overall Treatment Period Following Edoxaban or Standard of Care Treatment (Adjudicated Composite)

All bleeding events included major bleeding defined as a composite of any of the following: fatal bleeding; and/or symptomatic bleeding in critical area or organ such as intracranial, intra-spinal, intraocular, retroperitoneal, intra-articular, pulmonary, or pericardial, or intramuscular with compartment syndrome; and/or bleeding that causes a decrease in hemoglobin of at least 2 g/dL or more, or leading to transfusion of the equivalent of two or more units of whole blood or red blood cells (RBCs), clinically relevant non-major bleeding defined as acute or sub-acute clinically overt bleed that does not meet the criteria for a major bleed but prompts a clinical response, in that it leads to at least one of the following: a hospital admission for bleeding; a physician-guided medical or surgical treatment for bleeding or a change in antithrombotic therapy (including interruption or discontinuation of study drug), nuisance bleeding, or a combination of bleeding events. (NCT02798471)
Timeframe: From randomization up to Month 12

InterventionParticipants (Count of Participants)
Edoxaban25
Standard of Care24

Number of Participants With Major and Clinically Relevant Non-Major Bleeding Events (On Treatment) During the Main Treatment Period Following Edoxaban or Standard of Care Treatment (Adjudicated Composite)

Any bleeding event defined as major and clinically relevant non-major bleeding (CRNM) events was reported. Major bleeding was defined as defined as a composite of any of the following: fatal bleeding; and/or symptomatic bleeding in critical area or organ such as intracranial, intra-spinal, intraocular, retroperitoneal, intra-articular, pulmonary, or pericardial, or intramuscular with compartment syndrome; and/or bleeding that causes a decrease in hemoglobin of at least 2 g/dL or more, or leading to transfusion of the equivalent of two or more units of whole blood or red blood cells. CRNM was defined as acute or sub-acute clinically overt bleed that does not meet the criteria for a major bleed but prompts a clinical response, in that it leads to at least one of the following: a hospital admission for bleeding; a physician-guided medical or surgical treatment for bleeding or a change in antithrombotic therapy (including interruption or discontinuation of study drug). (NCT02798471)
Timeframe: Randomization to Month 3

InterventionParticipants (Count of Participants)
Edoxaban3
Standard of Care5

Number of Participants With Major and Clinically Relevant Non-Major Bleeding Events (On Treatment) During the Overall Treatment Period Following Edoxaban or Standard of Care Treatment (Adjudicated Composite)

Any bleeding event defined as major and clinically relevant non-major bleeding (CRNM) events was reported. Major bleeding was defined as defined as a composite of any of the following: fatal bleeding; and/or symptomatic bleeding in critical area or organ such as intracranial, intra-spinal, intraocular, retroperitoneal, intra-articular, pulmonary, or pericardial, or intramuscular with compartment syndrome; and/or bleeding that causes a decrease in hemoglobin of at least 2 g/dL or more, or leading to transfusion of the equivalent of two or more units of whole blood or red blood cells. CRNM was defined as acute or sub-acute clinically overt bleed that does not meet the criteria for a major bleed but prompts a clinical response, in that it leads to at least one of the following: a hospital admission for bleeding; a physician-guided medical or surgical treatment for bleeding or a change in antithrombotic therapy (including interruption or discontinuation of study drug). (NCT02798471)
Timeframe: From randomization up to Month 12

InterventionParticipants (Count of Participants)
Edoxaban8
Standard of Care5

Number of Participants With No Change or Extension of Thrombotic Burden During the Main Treatment Period Following Edoxaban or Standard of Care Treatment (Adjudicated Composite)

No change or extension of thrombotic burden as assessed by quantitative diagnostic imaging of the index qualifying VTE thrombus at baseline and at Month 3. Imaging criteria for VTE included: - Abnormal compression ultrasonography where compression had been normal or, if non-compressible during screening, an increase in diameter of the thrombus during full compression; - An extension of the echogenic intra-luminal thrombus or absence of flow in the central venous system on Doppler ultrasonography. - An extension of an intraluminal filling defect, or a new intraluminal filling defect, or an extension of non-visualization of veins in the presence of a sudden cut-off on venography. - An extension of an intraluminal filling defect, or a new intraluminal filling defect on computed tomography angiogram (CTA). (NCT02798471)
Timeframe: Randomization to Month 3

InterventionParticipants (Count of Participants)
Edoxaban21
Standard of Care29

Number of Participants With No Change or Extension of Thrombotic Burden During the Overall Treatment Period Following Edoxaban or Standard of Care Treatment (Adjudicated Composite)

No change or extension of thrombotic burden as assessed by quantitative diagnostic imaging of the index qualifying VTE thrombus. Imaging criteria for VTE included: - Abnormal compression ultrasonography where compression had been normal or, if non-compressible during screening, an increase in diameter of the thrombus during full compression; - An extension of the echogenic intra-luminal thrombus or absence of flow in the central venous system on Doppler ultrasonography. - An extension of an intraluminal filling defect, or a new intraluminal filling defect, or an extension of non-visualization of veins in the presence of a sudden cut-off on venography. - An extension of an intraluminal filling defect, or a new intraluminal filling defect on computed tomography angiogram (CTA). (NCT02798471)
Timeframe: From randomization up to Month 12

InterventionParticipants (Count of Participants)
Edoxaban35
Standard of Care47

Number of Participants With Symptomatic Recurrent Venous Thromboembolism During the Main Treatment Period Following Edoxaban or Standard of Care Treatment (Adjudicated Composite)

Diagnosis of recurrent venous thromboembolism (VTE) requires the confirmation by diagnostic imaging and at least one of the symptoms of VTE from such areas as lower or upper extremity, catheter related thrombosis, pulmonary embolism, or sinovenous thrombosis. (NCT02798471)
Timeframe: Randomization to Month 3

InterventionParticipants (Count of Participants)
Edoxaban5
Standard of Care2

Number of Participants With Symptomatic Recurrent Venous Thromboembolism During the Overall Treatment Period Following Edoxaban or Standard of Care Treatment (Adjudicated Composite)

Diagnosis of recurrent venous thromboembolism (VTE) requires the confirmation by diagnostic imaging and at least one of the symptoms of VTE from such areas as lower or upper extremity, catheter related thrombosis, pulmonary embolism, or sinovenous thrombosis. (NCT02798471)
Timeframe: From randomization up to Month 12

InterventionParticipants (Count of Participants)
Edoxaban7
Standard of Care2

Number of Participants Reporting Adjudicated All-Cause Mortality During the Overall Treatment Period Following Edoxaban or Standard of Care Treatment (Adjudicated)

All-cause mortality is defined as death due to any cause. Adjudicated data are reported for overall all-cause mortality, all-cause mortality by the primary cause of death, and primary cause of death further described by additional specifications. (NCT02798471)
Timeframe: From randomization up to Month 12

,
InterventionParticipants (Count of Participants)
Participants with adjudicated all-cause mortalityVenous thromboembolism (VTE)-related deathVenous thromboembolism (VTE)-related death: Unexplained death which VTE cannot be ruled outOther known causes of deathOther known causes of death: CancerOther known causes of death: Infectious diseaseOther known causes of death: Other
Edoxaban2111001
Standard of Care3112110

Number of Participants Who Died as a Result of VTE During the Main Treatment Period Following Edoxaban or Standard of Care Treatment (Adjudicated Composite)

Death from venous thromboembolism (VTE) is based on objective diagnostic testing, autopsy or death which cannot be attributed to documented cause for which VTE cannot be ruled out. (NCT02798471)
Timeframe: Randomization to Month 3

,
InterventionParticipants (Count of Participants)
Pulmonary embolism (PE) with or without deep vein thrombosis (DVT)Fatal PENon-fatal PEDeep vein thrombosis (DVT) onlyFatal DVTNon-fatal DVTUnexplained death which VTE cannot be ruled out
Edoxaban0005041
Standard of Care1011001

Number of Participants Who Died as a Result of VTE During the Main Treatment Period Following Edoxaban or Standard of Care Treatment (Adjudicated Individual Component of Primary Efficacy Endpoint)

Death from venous thromboembolism (VTE) is based on objective diagnostic testing, autopsy or death which cannot be attributed to documented cause for which VTE cannot be ruled out. (NCT02798471)
Timeframe: Randomization to Month 3

,
InterventionParticipants (Count of Participants)
Death as a result of VTEUnexplained death which VTE cannot be ruled out
Edoxaban11
Standard of Care11

Number of Participants Who Died as a Result of VTE During the Overall Treatment Period Following Edoxaban or Standard of Care Treatment (Adjudicated Composite)

Death from venous thromboembolism (VTE) is based on objective diagnostic testing, autopsy or death which cannot be attributed to documented cause for which VTE cannot be ruled out. (NCT02798471)
Timeframe: From randomization up to Month 12

,
InterventionParticipants (Count of Participants)
Pulmonary embolism (PE) with or without deep vein thrombosis (DVT)Fatal PENon-fatal PEDeep vein thrombosis (DVT) onlyFatal DVTNon-fatal DVTUnexplained death which VTE cannot be ruled out
Edoxaban1016051
Standard of Care1011001

Number of Participants With Adjudicated Individual Component of Primary Efficacy Endpoints During the Main Treatment Period Following Edoxaban or Standard of Care Treatment

Diagnosis of recurrent VTE requires the confirmation imaging and ≥1 symptom of VTE. Death from VTE is based on diagnostic testing, autopsy or death which cannot be attributed to documented cause for which VTE cannot be ruled out. No change or extension of thrombotic burden (quantitative diagnostic imaging) of the index qualifying VTE thrombus. Imaging criteria for VTE: - Abnormal compression ultrasonography where compression had been normal or, if non-compressible during screening, an increase in diameter of the thrombus during full compression; - An extension of the echogenic intra-luminal thrombus or absence of flow in the central venous system on Doppler ultrasonography. - An extension of an intraluminal filling defect, or a new intraluminal filling defect, or an extension of non-visualization of veins in the presence of a sudden cut-off on venography. - An extension of an intraluminal filling defect, or a new intraluminal filling defect on computed tomography angiogram (CTA). (NCT02798471)
Timeframe: Randomization to Month 3

,
InterventionParticipants (Count of Participants)
Symptomatic recurrent VTEPE with or without DVTDVT onlyDeath as a result of VTEUnexplained death which VTE cannot be ruled outNo change or extension of thrombotic burden
Edoxaban4041121
Standard of Care1101129

Number of Participants With Deep Vein Thrombosis, Catheter-related Thrombosis, Sino-venous Thrombosis, and Pulmonary Embolism During the Main, Extension, and Overall Treatment Periods Following Edoxaban or Standard of Care Treatment

Deep vein thrombosis was assessed by ultrasonography or magnetic resonance venography (MRV), catheter-related thrombosis was assessed by ultrasonography or echocardiography, sino-venous thrombosis was assessed by brain MRI, and pulmonary embolism was assessed by nuclear ventilation/perfusion (V/Q) scanning. (NCT02798471)
Timeframe: From randomization up to Month 12

,
InterventionParticipants (Count of Participants)
Main Treatment: Participants with DVT onlyMain Treatment: Participants with catheter-related thrombosisMain Treatment: Participants with cerebral sino-venous DVT thrombosisMain Treatment: Participants with PE with or without DVTExtension Treatment: Participants with DVTExtension Treatment: Participants with catheter-related thrombosisExtension Treatment: Participants with sino-venous DVT thrombosisExtension Treatment: Participants with PEOverall Treatment: Participants with DVTOverall Treatment: Participants with catheter-related thrombosisOverall Treatment: Participants with sino-venous DVT thrombosisOverall Treatment: Participants with PE
Edoxaban410010115111
Standard of Care000100000001

Number of Participants With Symptomatic Recurrent VTE During the Main Treatment Period Following Edoxaban or Standard of Care Treatment (Adjudicated Individual Component of Primary Efficacy Endpoint)

Diagnosis of recurrent venous thromboembolism (VTE) requires the confirmation by diagnostic imaging and at least one of the symptoms of VTE from such areas as lower or upper extremity, catheter related thrombosis, pulmonary embolism, or sinovenous thrombosis. (NCT02798471)
Timeframe: Randomization to Month 3

,
InterventionParticipants (Count of Participants)
Symptomatic VTEPulmonary embolism (PE) with or without deep vein thrombosis (DVT)Deep vein thrombosis (DVT) only
Edoxaban404
Standard of Care110

Clinically Relevant Bleeding (i.e., Major or Clinically Relevant Non-major Bleeding) Occurring During Treatment

Clinically relevant bleeding (i.e., major or clinically relevant non-major bleeding) occurring during treatment plus 3 days after their last dose for that time period. (NCT00986154)
Timeframe: 12 months from time of randomization

Interventionparticipants with an event (Number)
Heparin/Edoxaban Tosylate349
Heparin/Warfarin423

Symptomatic Recurrent VTE, i.e., the Composite of DVT, Non-fatal PE, and Fatal PE

"Symptomatic recurrent Venous Thromboembolism (VTE), i.e., the composite of deep Vein Thrombosis (DVT), non-fatal Pulmonary Embolism (PE), and fatal PE occurring during the Overall Study Period.~Overall Study Period defined as The time from the reference date (randomization date/initial dose of study drug date) to the last study follow-up visit." (NCT00986154)
Timeframe: 12 months from time of randomization

Interventionnumber or participants with an event (Number)
Heparin/Edoxaban Tosylate130
Heparin/Warfarin146

The Composite Clinical Outcome of Symptomatic Recurrent VTE and All-cause Mortality

(NCT00986154)
Timeframe: 12 months from time of randomization

Interventionnumber of participants with event (Number)
Heparin/Edoxaban Tosylate228
Heparin/Warfarin228

Anti Xa Level

Our primary outcome will be to assess the Anti Xa level drawn 3.5-4 hours after the third dose of Lovenox (enoxaparin) to assess if this is in the prophylactic range. (NCT02070237)
Timeframe: 3.5-4 hours after the third dose of Lovenox (enoxaparin)

InterventionIU/mL (Mean)
Enoxaparin Once Daily0.14
Enoxaparin Twice Daily0.30

Supraprophylactic Range Anti Xa Level

We will assess if any of the subjects has an Anti Xa level that is in the supraprophylactic range (treatment range). (NCT02070237)
Timeframe: 3.5-4 hours after the third dose of Lovenox (enoxaparin)

Interventionparticipants (Number)
Enoxaparin Once Daily0
Enoxaparin Twice Daily0

Percent Change From Baseline In Anti-fXa Activity By FXa Inhibitor

Anti-fXa activity was measured to assess the ability of andexanet to reverse the anticoagulant effect of FXa inhibitors. Baseline was defined as the last value obtained prior to the start of the andexanet bolus. The change from baseline was calculated as the reduction in anti-fXa activity from baseline to the on-treatment nadir (that is, the minimum value between end of bolus and end of infusion). Percent reduction was calculated as the ratio between the maximum change from baseline and the baseline value, multiplied by 100. (NCT02329327)
Timeframe: Baseline, 12 Hours (post infusion)

InterventionPercent Change (Median)
FXa Inhibitor: Apixaban-93.3
FXa Inhibitor: Rivaroxaban-94.1
FXa Inhibitor: Edoxaban-71.3
FXa Inhibitor: Enoxaparin-75.41
FXa Inhibitor: Rivaroxaban - Additional Participants-96.3

Participants Achieving Hemostatic Efficacy

Hemostatic efficacy was achieved when the body had time to produce thrombin and a subsequent clot and was rated by the EAC as: excellent; good; poor/none; not evaluable due to non-administrative reasons; not evaluable due to administrative reasons. These ratings were based on pre-specified criteria that were included in the EAC Charter. The EAC was blinded to anti-fXa activity levels. Participant results were classified as either success or failure based on the hemostatic efficacy rating (success = excellent/good, failure = poor/none). Participants rated by the EAC as non-evaluable due to administrative reasons were excluded from the analysis of hemostatic efficacy. (NCT02329327)
Timeframe: 12 Hours (post infusion)

,,,,,,,,,,,,,
InterventionParticipants (Count of Participants)
Excellent/GoodPoor/None
Andexanet: High Dose5417
Andexanet: High Dose - Additional Participant10
Andexanet: Low Dose21851
Andexanet: Low Dose - Additional Participant10
Bleed Type: Gastrointestinal6113
Bleed Type: Intracranial Hemorrhage19351
Bleed Type: Intracranial Hemorrhage - Additional Participants20
Bleed Type: Other184
FXa Inhibitor: Apixaban13435
FXa Inhibitor: Edoxaban226
FXa Inhibitor: Enoxaparin142
FXa Inhibitor: Rivaroxaban10225
FXa Inhibitor: Rivaroxaban - Additional Participants20
Overall27268

Percent Change From Baseline In Anti-fXa Activity By Hemostatic Efficacy

This outcome measure assessed the relationship between hemostatic efficacy and anti-fXa activity in participants receiving an FXa inhibitor who had acute major bleeding. Anti-fXa activity was measured to assess the ability of andexanet to reverse the anticoagulant effect of FXa inhibitors. Baseline was defined as the last value obtained prior to the start of the andexanet bolus. Hemostatic efficacy was achieved when the body had time to produce thrombin and a subsequent clot and was rated by the EAC as: excellent; good; poor/none; not evaluable due to non-administrative reasons; not evaluable due to administrative reasons. (NCT02329327)
Timeframe: Baseline, 12 Hours (post infusion)

InterventionPercent Change (Median)
Excellent/Good
FXa Inhibitor: Rivaroxaban - Additional Participants-96.3

Percent Change From Baseline In Anti-fXa Activity By Hemostatic Efficacy

This outcome measure assessed the relationship between hemostatic efficacy and anti-fXa activity in participants receiving an FXa inhibitor who had acute major bleeding. Anti-fXa activity was measured to assess the ability of andexanet to reverse the anticoagulant effect of FXa inhibitors. Baseline was defined as the last value obtained prior to the start of the andexanet bolus. Hemostatic efficacy was achieved when the body had time to produce thrombin and a subsequent clot and was rated by the EAC as: excellent; good; poor/none; not evaluable due to non-administrative reasons; not evaluable due to administrative reasons. (NCT02329327)
Timeframe: Baseline, 12 Hours (post infusion)

,,,
InterventionPercent Change (Median)
Excellent/GoodPoor/None
FXa Inhibitor: Apixaban-93.4-93.3
FXa Inhibitor: Edoxaban-75.8-65.2
FXa Inhibitor: Enoxaparin-75.20-78.44
FXa Inhibitor: Rivaroxaban-94.6-92.4

Percentage of Participants With Composite Endpoint of Stroke, Systemic Embolic Stroke (SEE), Myocardial Infarction (MI) and Cardiovascular (CV) Mortality From Randomization to End of Follow up

(NCT02072434)
Timeframe: Randomization to end of follow-up (within 2 years)

InterventionPercentage of participants (Number)
Edoxaban0.5
Warfarin1

Percentage of Participants With Composite Endpoints of Major and Clinically-relevant Non-major (CRNM) Bleeding

(NCT02072434)
Timeframe: During treatment period (within 2 years)

InterventionPercentage of participants (Number)
Edoxaban1.5
Warfarin1

Percentage of Participants With Composite Endpoints of Stroke, SEE, MI, CV Mortality, and Major Bleeding

(NCT02072434)
Timeframe: From randomization to the end of follow-up (within 2 years)

InterventionPercentage of participants (Number)
Edoxaban0.7
Warfarin1.4

Composite Endpoint of Total Venous Thrombo Embolism (VTE) i.e.: Any Deep Vein Thromboembolism (DVT) (Proximal and/or Distal), Non Fatal Pulmonary Embolism (PE), Death of All Causes Per Protocol Population

Blinded, adjudicated assessment of bilateral venography, clinical signs of deep vein thrombosis (DVT) and pulmonary embolism (PE), ultrasound, clinical chemistry and coagulation factors, autopsy report, electrocardiogram (ECG), pulmonary angiography, perfusion/ventilation lung scintigraphy, chest radiography, computed tomography (NCT00362232)
Timeframe: Up to 16 days after surgery

InterventionPercentage of participants (Number)
Rivaroxaban 10 mg Once Daily (OD) (Xarelto, BAY59-7939)6.71
Enoxaparin 30 mg Twice a Day (Bid)9.34

Composite Endpoint of Total VTE i.e.: Any DVT (Proximal and/or Distal), Non Fatal PE, Death of All Causes Per Modified Intent to Treat Population.

Blinded, adjudicated assessment of bilateral venography, clinical signs of deep vein thrombosis (DVT) and pulmonary embolism (PE), ultrasound, clinical chemistry and coagulation factors, autopsy report, electrocardiogram (ECG), pulmonary angiography, perfusion/ventilation lung scintigraphy, chest radiography, computed tomography (NCT00362232)
Timeframe: Up to 16 days after surgery

InterventionPercentage of participants (Number)
Rivaroxaban 10 mg Once Daily (OD) (Xarelto, BAY59-7939)6.94
Enoxaparin 30 mg Twice a Day (Bid)10.11

Incidence of DVT (Proximal, Distal) Per Modified Intent to Treat Population.

Blinded, adjudicated assessment of bilateral venography, clinical signs of DVT and PE, ultrasound, clinical chemistry and coagulation factors, autopsy report, electrocardiogram (ECG), pulmonary angiography, perfusion/ventilation lung scintigraphy, chest radiography, computed tomography (NCT00362232)
Timeframe: Up to 16 days after surgery

Interventionpercentage of participants (Number)
Rivaroxaban 10 mg Once Daily (OD) (Xarelto, BAY59-7939)6.32
Enoxaparin 30 mg Twice a Day (Bid)8.97

Incidence of DVT (Proximal, Distal) Per Protocol Population.

Blinded, adjudicated assessment of bilateral venography, clinical signs of DVT and PE, ultrasound, clinical chemistry and coagulation factors, autopsy report, electrocardiogram (ECG), pulmonary angiography, perfusion/ventilation lung scintigraphy, chest radiography, computed tomography (NCT00362232)
Timeframe: Up to 16 days after surgery

Interventionpercentage of participants (Number)
Rivaroxaban 10 mg Once Daily (OD) (Xarelto, BAY59-7939)6.37
Enoxaparin 30 mg Twice a Day (Bid)8.66

Incidence of Symptomatic VTE (DVT, PE) Per Modified Intent to Treat Population.

Blinded, adjudicated assessment of bilateral venography, clinical signs of DVT and PE, ultrasound, clinical chemistry and coagulation factors, autopsy report, electrocardiogram (ECG), pulmonary angiography, perfusion/ventilation lung scintigraphy, chest radiography, computed tomography (NCT00362232)
Timeframe: Up to 16 days after surgery

Interventionpercentage of participants (Number)
Rivaroxaban 10 mg Once Daily (OD) (Xarelto, BAY59-7939)1.14
Enoxaparin 30 mg Twice a Day (Bid)1.88

Incidence of Symptomatic VTE (DVT, PE) Per Protocol Population.

Blinded, adjudicated assessment of bilateral venography, clinical signs of DVT and PE, ultrasound, clinical chemistry and coagulation factors, autopsy report, electrocardiogram (ECG), pulmonary angiography, perfusion/ventilation lung scintigraphy, chest radiography, computed tomography (NCT00362232)
Timeframe: Up to 16 days after surgery

Interventionpercentage of participants (Number)
Rivaroxaban 10 mg Once Daily (OD) (Xarelto, BAY59-7939)1.04
Enoxaparin 30 mg Twice a Day (Bid)1.48

Incidence of Symptomatic VTE During Follow-up Per Modified Intent to Treat Population.

Blinded, adjudicated assessment of bilateral venography, clinical signs of DVT and PE, ultrasound, clinical chemistry and coagulation factors, autopsy report, electrocardiogram (ECG), pulmonary angiography, perfusion/ventilation lung scintigraphy, chest radiography, computed tomography (NCT00362232)
Timeframe: Up to 47 days after surgery

Interventionpercentage of participants (Number)
Rivaroxaban 10 mg Once Daily (OD) (Xarelto, BAY59-7939)0.31
Enoxaparin 30 mg Twice a Day (Bid)0.21

Incidence of Symptomatic VTE During Follow-up Per Protocol Population.

Blinded, adjudicated assessment of bilateral venography, clinical signs of DVT and PE, ultrasound, clinical chemistry and coagulation factors, autopsy report, electrocardiogram (ECG), pulmonary angiography, perfusion/ventilation lung scintigraphy, chest radiography, computed tomography (NCT00362232)
Timeframe: Up to 47 days after surgery

Interventionpercentage of participants (Number)
Rivaroxaban 10 mg Once Daily (OD) (Xarelto, BAY59-7939)0.35
Enoxaparin 30 mg Twice a Day (Bid)0.11

Incidence of the Composite Endpoint Comprising Proximal DVT, Non-fatal PE and VTE- Related Death (Major VTE) Per Modified Intent to Treat Population of Major VTE.

Blinded, adjudicated assessment of bilateral venography, clinical signs of deep vein thrombosis (DVT) and pulmonary embolism (PE), ultrasound, clinical chemistry and coagulation factors, autopsy report, electrocardiogram (ECG), pulmonary angiography, perfusion/ventilation lung scintigraphy, chest radiography, computed tomography (NCT00362232)
Timeframe: Up to 16 days after surgery

Interventionpercentage of participants (Number)
Rivaroxaban 10 mg Once Daily (OD) (Xarelto, BAY59-7939)1.16
Enoxaparin 30 mg Twice a Day (Bid)1.98

Incidence of the Composite Endpoint Comprising Proximal DVT, Non-fatal PE and VTE- Related Death (Major VTE) Per Protocol Population of Major VTE

Blinded, adjudicated assessment of bilateral venography, clinical signs of deep vein thrombosis (DVT) and pulmonary embolism (PE), ultrasound, clinical chemistry and coagulation factors, autopsy report, electrocardiogram (ECG), pulmonary angiography, perfusion/ventilation lung scintigraphy, chest radiography, computed tomography (NCT00362232)
Timeframe: Up to 16 days after surgery

Interventionpercentage of participants (Number)
Rivaroxaban 10 mg Once Daily (OD) (Xarelto, BAY59-7939)1.09
Enoxaparin 30 mg Twice a Day (Bid)1.47

Incidence of the Composite Endpoint That Results From Major VTE by Substituting All Cause Mortality for VTE-related Death Per Modified Intent to Treat of Major VTE Population.

Blinded, adjudicated assessment of bilateral venography, clinical signs of DVT and PE, ultrasound, clinical chemistry and coagulation factors, autopsy report, electrocardiogram (ECG), pulmonary angiography, perfusion/ventilation lung scintigraphy, chest radiography, computed tomography (NCT00362232)
Timeframe: Up to 16 days after surgery

Interventionpercentage of participants (Number)
Rivaroxaban 10 mg Once Daily (OD) (Xarelto, BAY59-7939)1.25
Enoxaparin 30 mg Twice a Day (Bid)2.25

Incidence of the Composite Endpoint That Results From Major VTE by Substituting All Cause Mortality for VTE-related Death Per Protocol of Major VTE Population.

Blinded, adjudicated assessment of bilateral venography, clinical signs of DVT and PE, ultrasound, clinical chemistry and coagulation factors, autopsy report, electrocardiogram (ECG), pulmonary angiography, perfusion/ventilation lung scintigraphy, chest radiography, computed tomography (NCT00362232)
Timeframe: Up to 16 days after surgery

Interventionpercentage of participants (Number)
Rivaroxaban 10 mg Once Daily (OD) (Xarelto, BAY59-7939)1.09
Enoxaparin 30 mg Twice a Day (Bid)1.67

Incidence of the Composite Endpoint That Results From the Primary Endpoint by Substituting VTE Related Death for All Death Per Modified Intent to Treat Population.

Blinded, adjudicated assessment of bilateral venography, clinical signs of DVT and PE, ultrasound, clinical chemistry and coagulation factors, autopsy report, electrocardiogram (ECG), pulmonary angiography, perfusion/ventilation lung scintigraphy, chest radiography, computed tomography (NCT00362232)
Timeframe: Up to 16 days after surgery

Interventionpercentage of participants (Number)
Rivaroxaban 10 mg Once Daily (OD) (Xarelto, BAY59-7939)6.84
Enoxaparin 30 mg Twice a Day (Bid)9.80

Incidence of the Composite Endpoint That Results From the Primary Endpoint by Substituting VTE Related Death for All Death Per Protocol Population.

Blinded, adjudicated assessment of bilateral venography, clinical signs of DVT and PE, ultrasound, clinical chemistry and coagulation factors, autopsy report, electrocardiogram (ECG), pulmonary angiography, perfusion/ventilation lung scintigraphy, chest radiography, computed tomography (NCT00362232)
Timeframe: Up to 16 days after surgery

Interventionpercentage of participants (Number)
Rivaroxaban 10 mg Once Daily (OD) (Xarelto, BAY59-7939)6.71
Enoxaparin 30 mg Twice a Day (Bid)9.11

The Composite Endpoint Comprising Major VTE and Treatment-emergent Major Bleeding Per Subjects Valid for Analysis of Net Clinical Benefit

Blinded, adjudicated assessment of bilateral venography, clinical signs of DVT and PE, ultrasound, clinical chemistry and coagulation factors, autopsy report, electrocardiogram (ECG), pulmonary angiography, perfusion/ventilation lung scintigraphy, chest radiography, computed tomography, anesthesia and surgery reports, number of transfusions (NCT00362232)
Timeframe: Up to 47 days after surgery

Interventionpercentage of participants (Number)
Rivaroxaban 10 mg Once Daily (OD) (Xarelto, BAY59-7939)2.04
Enoxaparin 30 mg Twice a Day (Bid)2.33

Treatment-emergent Major Bleedings Per Safety Population.

Blinded, adjudicated assessments of all available information (eg, anesthesia and surgery reports, laboratory results, number of transfusions, autopsy report) (NCT00362232)
Timeframe: from start of double-blind study medication to last dose of double-blind study medication plus two days. The average duration of double-blind treatment was 12 days in each treatment group (safety population).

Interventionpercentage of participants (Number)
Rivaroxaban 10 mg Once Daily (OD) (Xarelto, BAY59-7939)0.66
Enoxaparin 30 mg Twice a Day (Bid)0.27

Event Rate for Participants With All-Cause Death During the Intended Treatment Period

Event rate was number of participants with all-cause death divided by the number of participant's analyzed (%). (NCT00371683)
Timeframe: From Day 1 or Day 2 to last dose, plus 2 days or 14 days post randomization

Interventionpercentage of participants (Number)
Apixaban 2.5mg BID0.19
Enoxaparin 30 mg SC Injection q 12 Hours0.19

Event Rate for Participants With Proximal DVT/Non-Fatal PE/ VTE-Related Death With Onset During the Intended Treatment Period

An ICAC adjudicated all venograms, suspected symptomatic DVT and PE, and cause of death. Event rate was number of participants with the endpoint divided by the number of participant's analyzed (%). (NCT00371683)
Timeframe: From Day 1 or Day 2 to last dose, plus 2 days or 14 days post randomization

Interventionpercentage of participants (Number)
Apixaban 2.5mg BID1.97
Enoxaparin 30 mg SC Injection q 12 Hours1.40

Event Rate for Participants With Symptomatic VTE/ All-Cause Death With Onset During the Intended Treatment Period

ICAC adjudicated suspected symptomatic DVT and PE, and cause of death. Event rate was number of participants with the endpoint divided by the number of participant's analyzed (%). (NCT00371683)
Timeframe: From Day 1 or Day 2 to last dose, plus 2 days or 14 days post randomization

Interventionpercentage of participants (Number)
Apixaban 2.5mg BID1.25
Enoxaparin 30 mg SC Injection q 12 Hours1.00

Event Rate for Participants With Symptomatic VTE/ VTE-Related Death With Onset During the Intended Treatment Period

ICAC adjudicated suspected symptomatic DVT and PE, and cause of death. Event rate was number of participants with the endpoint divided by the number of participant's analyzed (%). (NCT00371683)
Timeframe: From Day 1 or Day 2 to last dose, plus 2 days or 14 days post randomization

Interventionpercentage of participants (Number)
Apixaban 2.5mg BID1.19
Enoxaparin 30 mg SC Injection q 12 Hours0.81

Event Rate for Participants With VTE-Related Death With Onset During the Intended Treatment Period

ICAC adjudicated cause of death. Event rate was number of participants with the endpoint divided by the number of participant's analyzed (%). (NCT00371683)
Timeframe: From Day 1 or Day 2 to last dose, plus 2 days or 14 days post randomization

Interventionpercentage of participants (Number)
Apixaban 2.5mg BID0.13
Enoxaparin 30 mg SC Injection q 12 Hours0.00

Event Rate for Participants With VTE/Major Bleeding/All-Cause Death With Onset During the Intended Treatment Period

ICAC adjudicated VTE, acute clinically overt bleeding events, suspected thrombocytopenia, and cause of death. Event rate was number of participants with the composite endpoint divided by the number of participants analyzed (%). (NCT00371683)
Timeframe: From Day 1 or Day 2 to last dose, plus 2 days or 14 days post randomization

Interventionpercentage of participants (Number)
Apixaban 2.5mg BID9.90
Enoxaparin 30 mg SC Injection q 12 Hours10.60

Event Rate for Total Participants With Adjudicated VTE/All-Cause Death With Onset During the Intended Treatment Period

ICAC adjudicated all venograms, suspected symptomatic DVT and PE, and cause of death. Event rate was number of participants with the endpoint divided by the number of participant's analyzed (%). (NCT00371683)
Timeframe: From Day 1 or Day 2 to last dose, plus 2 days or 14 days post randomization

Interventionpercentage of participants (Number)
Apixaban 2.5mg BID2.13
Enoxaparin 30 mg SC Injection q 12 Hours1.97

Event Rate for Total Participants With VTE/ VTE-Related Death With Onset During the Intended Treatment Period

ICAC adjudicated all venograms, suspected symptomatic DVT and PE, and cause of death. VTE includes DVT and PE. Event rate was number of participants with the endpoint divided by the number of participant's analyzed (%). (NCT00371683)
Timeframe: From Day 1 or Day 2 to last dose, plus 2 days or 14 days post randomization

Interventionpercentage of participants (Number)
Apixaban 2.5mg BID2.05
Enoxaparin 30 mg SC Injection q 12 Hours1.73

Event Rate of Adjudicated VTE / VTE-related Death With Onset During the Treatment Period

VTE / VTE-related death was defined as the combination of fatal or non-fatal PE, and symptomatic or asymptomatic DVT. A mandatory bilateral ascending contrast venogram was performed on all participants after 12 days (±2 days) of study treatment. An ICAC adjudicated all venograms, suspected symptomatic DVT and PE, and cause of death. Event rate was number of participants with the endpoint divided by the number of participant's analyzed (%). (NCT00371683)
Timeframe: From Day 1 or Day 2 to last dose, plus 2 days or 14 days post randomization

Interventionpercentage of participants (Number)
Apixaban 2.5mg BID8.91
Enoxaparin 30 mg SC Injection q 12 Hours8.61

Event Rate of Composite of Adjudicated Proximal DVT, Non-Fatal PE and All-Cause Death With Onset During the Intended Treatment Period PE and All-cause Death During the Intended Treatment Period

A mandatory bilateral ascending contrast venogram was performed on all participants after 12 days (±2 days) of study treatment. An ICAC adjudicated all venograms, suspected proximal DVT and non-fatal PE, and all-cause of death. Event rate was number of participants with the composite endpoint divided by the number of participants analyzed and reported as percentage (%). (NCT00371683)
Timeframe: From Day 1 or Day 2 to last dose, plus 2 days or 14 days post randomization

Interventionpercentage of participants (Number)
Apixaban 2.5mg BID2.05
Enoxaparin 30 mg SC Injection q 12 Hours1.64

Event Rate of the Composite of Adjudicated Venous Thromboembolism (VTE) Events and All-Cause Death With Onset During the Intended Treatment Period - Primary Subjects

An Independent Central Adjudication Committee (ICAC) adjudicated all venograms, suspected symptomatic deep vein thrombosis (DVT) and pulmonary embolism (PE), acute clinically overt bleeding events, suspected thrombocytopenia, suspected acute MI, suspected acute stroke, and cause of death. Event rate was number of participants with the composite endpoint divided by the number of participants analyzed and reported as percentage (%). Surgery=Day 1; Randomization/Treatment started on Day of Surgery or the next day (Day 1 or Day 2). A mandatory bilateral ascending contrast venogram was performed on all participants after 12 days (±2 days) of study treatment. Intended Treatment Period=starts on the day of randomization; for treated participants, the period ends at the latter of 2 days after last dose of study drug or 14 days after the first dose of study drug; for randomized participants who were not treated, the period ends 14 days after randomization. (NCT00371683)
Timeframe: From Day 1 or Day 2 to last dose, plus 2 days or 14 days post randomization

Interventionpercentage of participants (Number)
Apixaban 2.5mg BID8.99
Enoxaparin 30 mg SC Injection q 12 Hours8.85

Event Rate for Participants With Adjudicated Myocardial Infarction (MI) Acute Ischemic Stroke and Thromboembolic Events With Onset During the Treatment Period

ICAC adjudicated acute clinically overt bleeding events, suspected thrombocytopenia, suspected acute MI, suspected acute stroke per International Society on Thrombosis and Hemostasis (ISTH) guidelines modified for surgical patients. Event rate was number of participants with the composite endpoint divided by the number of participants analyzed (%). (NCT00371683)
Timeframe: From first dose to last dose, plus 2 days (12 days, plus 2)

,
Interventionpercentage of participants (Number)
MI/StrokeMIStrokeThrombocytopenia
Apixaban 2.5mg BID0.060.060.000.00
Enoxaparin 30 mg SC Injection q 12 Hours0.310.250.130.13

Event Rate for Participants With Major Bleeding, Clinically Relevant (CR) Non-Major (N-M) Bleeding , Major or Clinically Relevant (CR) Non-Major (N-M) Bleeding, Any Bleeding With Onset During the Follow-Up Period

ICAC adjudicated acute clinically overt bleeding events as per International Society on Thrombosis and Hemostasis (ISTH) guidelines modified for surgical patients. Event rate was number of participants with the composite endpoint divided by the number of participants analyzed (%). Follow up Period was from the end of the treatment period (last dose) up to 60 days post last dose, Day 72. (NCT00371683)
Timeframe: Last dose of study drug to Day 72 (60 days)

,
Interventionpercentage of participants (Number)
Major Bleeding (n=1563, 1553)CR N-M Bleeding (n=1563, 1553)Major or CR N-M Bleeding (n=1563, 1553)Any Bleeding (n=1563, 1553)
Apixaban 2.5mg BID0.130.260.380.90
Enoxaparin 30 mg SC Injection q 12 Hours0.130.450.581.29

Event Rate for Participants With Major Bleeding, Clinically Relevant Non-Major Bleeding, Major or Clinically Relevant Non-Major Bleeding, Any Bleeding With Onset During the Treatment Period - Treated Population

ICAC adjudicated acute clinically overt bleeding events as per International Society on Thrombosis and Hemostasis (ISTH) guidelines modified for surgical patients. Event rate was number of participants with the composite endpoint divided by the number of participants analyzed (%). Clinically relevant (CR); Non-Major (N-M) Bleeding. Day 1=Day of surgery. Treatment started (first dose) day of surgery or next day. Treatment continued for 12 days. (NCT00371683)
Timeframe: First dose of study drug to last dose, plus 2 days post last dose

,
Interventionpercentage of participants (Number)
Major Bleeding (n=1596, 1588)CR N-M Bleeding (n=1596, 1588)Major or CR N-M Bleeding(n=1596, 1588)Any Bleeding (n=1596, 1588)
Apixaban 2.5mg BID0.692.192.885.33
Enoxaparin 30 mg SC Injection q 12 Hours1.392.964.286.80

Event Rate for Participants With PE (Fatal or Non-Fatal), DVT (All, Symptomatic Proximal, and Distal, Asymptomatic) With Onset During the Intended Treatment Period

An ICAC adjudicated all venograms, suspected symptomatic deep vein thrombosis (DVT) and pulmonary embolism (PE), acute clinically overt bleeding events, suspected thrombocytopenia, suspected acute MI, suspected acute stroke, and cause of death. Event rate was number of participants with the composite endpoint divided by the number of participants analyzed (%). (NCT00371683)
Timeframe: From Day 1 or Day 2 to last dose, plus 2 days or 14 days post randomization

,
Interventionpercentage of participants (Number)
PE (Fatal or Non-Fatal) (n=1599, 1596)Non-Fatal PE (n=1599, 1596)All DVT n=1142, 1122Symptomatic DVT (n=1599, 1596)Asymptomatic DVT (n=1139,1115)Symptomatic Proximal DVT (n=1599,1596)Symptomatic Distal DVT (n=1599,1596)
Apixaban 2.5mg BID1.000.887.790.197.550.130.06
Enoxaparin 30 mg SC Injection q 12 Hours0.440.448.200.447.620.190.38

Event Rate for Participants With Proximal DVT, Distal DVT, Asymptomatic Proximal DVT, Asymptomatic Distal DVT With Onset During the Intended Treatment Period

ICAC adjudicated all venograms and suspected symptomatic DVT. Event rate was number of participants with the endpoint divided by the number of participant's analyzed (%). (NCT00371683)
Timeframe: From Day 1 or Day 2 to last dose, plus 2 days or 14 days post randomization

,
Interventionpercentage of participants (Number)
Proximal DVT (n=1254, 1207)Distal DVT (n=1146, 1133)Asymptomatic Proximal DVT (n=1252, 1204)Asymptomatic Distal DVT (n=1145, 1127)
Apixaban 2.5mg BID0.727.240.567.16
Enoxaparin 30 mg SC Injection q 12 Hours0.918.030.667.54

Event Rate of Adjudicated MI, Stroke, and Thrombocytopenia Events During the Follow-Up Period

A 60-day follow-up period started after the last dose of study drug and continued until the End of Study Visit on Day 72 (60 days ± 3 days, after the last dose of study drug). Event rate was number of participants with the endpoint divided by the number of participants analyzed (%). ICAC adjudicated acute clinically overt bleeding events, suspected thrombocytopenia, suspected acute MI, suspected acute stroke per ISTH guidelines modified for surgical patients. (NCT00371683)
Timeframe: Post last dose of study drug to Day 72 (60 days)

,
Interventionpercentage of participants (Number)
MI/StrokeMIStrokeThrombocytopenia
Apixaban 2.5mg BID0.060.060.000.00
Enoxaparin 30 mg SC Injection q 12 Hours0.060.060.000.00

Mean Change From Baseline in Heart Rate During the Treatment Period

Treatment Period=the period from first dose of study drug through 2 days after discontinuation of study drug (12 + 2 days). Baseline=measurement prior to first dose of study drug. Heart rate was measured during screening (pre-operative, post-operative) and in the treatment period on Days 1 (day of first dose), 2, 3, 4,12 (end of treatment). Heart rate was measured in beats per minute (bpm). (NCT00371683)
Timeframe: Baseline to last dose of study drug, plus 2 days

,
Interventionbpm (Mean)
Heart Rate Day 1 (n=240,237)Heart Rate Day 2 (n=1575,1574)Heart Rate Day 3 (n=1490,1498)Heart Rate Day 4 (n=127,134)Heart Rate Day 12 (n=1495, 1462)
Apixaban 2.5mg BID2.34.64.57.6-0.3
Enoxaparin 30 mg SC Injection q 12 Hours2.74.55.09.4-0.1

Mean Change From Baseline in Systolic and Diastolic Blood Pressure During the Treatment Period

Treatment Period=the period from first dose of study drug through 2 days after discontinuation of study drug (12 + 2 days). Baseline=measurement prior to first dose of study drug. Blood pressures (BP) were measured during screening (pre-operative, post-operative) and in the treatment period on Days 1 (day of first dose), 2, 3, 4,12 (end of treatment). Systolic and diastolic pressures were measured in millimeters of mercury (mmHg). (NCT00371683)
Timeframe: Baseline to last dose of study drug, plus 2 days

,
InterventionmmHg (Mean)
Diastolic BP Day 1 (n=240, 237)Diastolic BP Day 2 (n=1577, 1574)Diastolic BP Day 3 (n=1489,1498)Diastolic BP Day 4 (n=127,134)Diastolic BP Day 12 (n=1495,1463)Systolic BP Day 1 (n=240,237)Systolic BP Day 2 (n=1577,1574)Systolic BP Day 3 (n=1489,1498)Systolic BP Day 4 (n=127,134)Systolic BP Day 12 (n=1495,1463)
Apixaban 2.5mg BID-0.41.72.30.67.31.55.44.72.89.1
Enoxaparin 30 mg SC Injection q 12 Hours-0.91.52.10.37.5-0.74.24.31.48.9

Number of Participants With Electrolyte Chemistry Laboratory Marked Abnormalities During the Treatment Period

Laboratory Chemistry profile was measured during screening (pre-operative, post-operative) and in the Treatment Period on Days 4, and 12 (end of treatment). Potassium: < 0.9*LLN or > 1.1*ULN, or if pre-dose < LLN then use < 0.9*predose or > ULN if pre-dose > ULN then use > 1.1*predose or < LLN. Calcium: < 0.8*LLN or > 1.2*ULN, or if pre-dose < LLN then use < 0.75*predose or > ULN If pre-dose > ULN then use > 1.25*predose or < LLN. Chloride: < 0.9*LLN or > 1.1*ULN, or if pre-dose < LLN then use < 0.9*predose or > ULN if pre-dose > ULN then use > 1.1*predose or < LLN. Sodium: < 0.95*LLN or > 1.05*ULN, or if pre-dose < LLN then use < 0.95*predose or >ULN if pre-dose > ULN then use > 1.05*predose or < LLN. Bicarbonate: < 0.75*LLN or > 1.25*ULN, or if pre-dose < LLN then use < 0.75*predose or > ULN if pre-dose > ULN then use > 1.25*predose or < LLN. (NCT00371683)
Timeframe: First dose to last dose of study drug (12 days), plus 2 days

,
Interventionparticipants (Number)
Calcium low (n=1569,1562)Calcium high (n=1569,1562)Chloride low (n=1568,1562)Chloride high (n=1568,1562)Bicarbonate low (n=1568,1561)Potassium low(n=1568,1559)Potassium high(n=1568,1559)Sodium low (n=1568,1562)Sodium high (n=1568,1562)
Apixaban 2.5mg BID10110115426232
Enoxaparin 30 mg SC Injection q 12 Hours51171135620390

Number of Participants With Hematology Laboratory Marked Abnormality During the Treatment Period

Treatment Period=the period from first dose of study drug through 2 days after discontinuation of study drug. Hematology profile was measured during screening (pre-operative, post-operative) and in the Treatment Period on Days 2, 3, 4, 12 (end of treatment). Upper limit of normal (ULN); lower limit of normal (LLN). Platelet Count low: < 100,000/mm^3 (or < 100*109 cells/L). Erythrocytes low: < 0.75 *pre-dose. Hemoglobin low: > 2 g/dL decrease compared to pre-dose or Value ≤ 8 g/dL. Hematocrit low: < 0.75*pre-dose . Leukocytes: < 0.75*LLN or > 1.25* ULN, or if pre-dose < LLN then use < 0.8*predose or > ULN if pre-dose > ULN then use > 1.2*predose or < LLN. Lymphocytes (absolute): < 0.750*10^3 cells/µL or > 7.50*10^3 cells/ µL. Eosinophils (absolute) high: > 0.750*10^3 cells/µL. Basophils(absolute) high: > 400/mm^3 (or > 0.4*103 cells/µL). Monocytes (absolute) high: > 2000/mm^3 (or > 2*103 cells/µL). Neutrophils(absolute) high: < 1.0*103 cells/µL. (NCT00371683)
Timeframe: First dose to last dose of study drug (12 days), plus 2 days

,
Interventionparticipants (Number)
Hemoglobin low (n=1561,1549)Hematocrit low (n=1558,1547)Platelet count low (n=1556,1543)Erythrocytes low (n=1557,1547)Leukocytes low(n=1583,1572)Leukocytes high(n=1583,1572)Basophils high (n=1577, 1564)Eosinophils high (n=1577, 1564)Lymphocytes low (n=1577,1564)Lymphocytes high (n=1577,1564)Monocytes high (n=1577,1564)Neutrophils low (n=1577,1564)
Apixaban 2.5mg BID38613561308214032125244
Enoxaparin 30 mg SC Injection q 12 Hours392157914911210213117445

Number of Participants With Liver and Kidney Function Chemistry Laboratory Marked Abnormalities During the Treatment Period

Treatment Period=the period from first dose of study drug through 2 days after discontinuation of study drug. Laboratory Chemistry profile was measured during screening (pre-operative, post-operative) and in the Treatment Period on Days 4, and 12 (end of treatment). Bilirubin (direct) high: > 1.5*ULN. Total bilirubin: : > 2*ULN, Alanine Aminotransferase (ALT) high: > 3*ULN. Alkaline Phosphatase (ALP): > 2*ULN. Aspartate Aminotransferase (AST): > 3*ULN. Creatinine: > 1.5*ULN. (NCT00371683)
Timeframe: First dose to last dose of study drug (12 days), plus 2 days

,
Interventionparticipants (Number)
ALP high (n=1573,1563)ALT high (n=1573,1562)AST high (n=1573,1562)Bilirubin direct high (n=1563,1553)Bilirubin total high(n=1572,1562)Creatinine high (n=1569,1562)
Apixaban 2.5mg BID42332963217
Enoxaparin 30 mg SC Injection q 12 Hours55454054828

Number of Participants With Other Chemistry Laboratory Marked Abnormalities During the Treatment Period

Treatment Period=the period from first dose of study drug through 2 days after discontinuation of study drug. Laboratory Chemistry profile was measured during screening (pre-operative, post-operative) and in the Treatment Period on Days 4, and 12 (end of treatment). Fasting Glucose: if pre-dose < LLN then use < 0.8*predose; or > ULN if pre-dose > ULN then use > 2.0*predose or 1.1*ULN, or if pre-dose < LLN then use 0.9*predose or > ULN if pre-dose > ULN then use 1.1*predose or < LLN. Uric Acid: > 1.5*ULN, or if pre-dose > ULN then use > 2*predose. Creatine Kinase (CK): > 5*ULN. (NCT00371683)
Timeframe: First dose to last dose of study drug (12 days), plus 2 days

,
Interventionparticipants (Number)
Fasting Glucose low (n=611, 579)Fasting Glucose high (n=611, 579)Total Protein low (n=1568,1562)CK high (n=1573,1563)Uric Acid high (n=1567,1562)
Apixaban 2.5mg BID8545275222
Enoxaparin 30 mg SC Injection q 12 Hours5285134512

Number of Participants With Serious Adverse Events (SAEs), Bleeding Adverse Events (AEs), AEs Leading to Discontinuation, and Deaths - Treated Population

AE=any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that may not have a causal relationship with treatment. SAE=a medical event that at any dose results in death, persistent or significant disability/incapacity, or drug dependency/abuse; is life-threatening, an important medical event, or a congenital anomaly/birth defect; or requires or prolongs hospitalization. (NCT00371683)
Timeframe: First dose to last dose, plus 2 days for AEs (12 + 2 days) or plus 30 days for SAEs (12 + 30 days)

,
Interventionparticipants (Number)
SAEBleeding AEAEs leading to discontinuationDeaths
Apixaban 2.5mg BID123110603
Enoxaparin 30 mg SC Injection q 12 Hours123144585

Percentage of Participants With an Event for Net Clinical Benefit 1 During Observational Period

Net clinical benefit 1: composite of recurrent DVT or non-fatal or fatal PE or major bleeding. Major bleeding was overt bleeding associated with 2 g/dL or greater fall in hemoglobin, leading to a transfusion of ≥2 units, occurring in a critical site or contributing to death. Net clinical benefit was considered greater in those participants with fewer composite events. All events were adjudicated and confirmed by a central independent adjudication committee blinded to treatment, based on either compression ultrasound, venography, spiral computed tomography scanning, pulmonary angiography, ventilation/perfusion lung scan, lung scintigraphy, autopsy or unexplained death for which DVT/PE could not be ruled out, results/films/images of confirmatory testing, and/or case summaries. (NCT00440193)
Timeframe: Up to 30 days after the last intake of study medication

InterventionPercentage of participants (Number)
Rivaroxaban (Xarelto, BAY59-7939)1.1
Enoxaparin/VKA1.1

Percentage of Participants With an Event for Net Clinical Benefit 1 Until the Intended End of Study Treatment

Net clinical benefit 1: composite of recurrent DVT or non-fatal or fatal PE, and major bleeding. Major bleeding was overt bleeding associated with 2 g/dL or greater fall in hemoglobin, leading to a transfusion of ≥2 units, occurring in a critical site or contributing to death. Net clinical benefit was considered greater in those participants with fewer composite events. All events were adjudicated and confirmed by a central independent adjudication committee blinded to treatment, based on either compression ultrasound, venography, spiral computed tomography scanning, pulmonary angiography, ventilation/perfusion lung scan, lung scintigraphy, autopsy or unexplained death for which DVT/PE could not be ruled out, results/films/images of confirmatory testing, and/or case summaries. (NCT00440193)
Timeframe: 3-, 6- or 12-month study treatment period

InterventionPercentage of participants (Number)
Rivaroxaban (Xarelto, BAY59-7939)2.9
Enoxaparin/VKA4.2

Percentage of Participants With an Event for Net Clinical Benefit 2 During Observational Period

Net clinical benefit 2: composite of recurrent DVT or non-fatal or fatal PE, major bleeding, cardiovascular death, myocardial infarctions, stroke, or non CNS systemic embolism. Major bleeding was associated with 2 g/dL or greater fall in hemoglobin, leading to a transfusion of ≥2 units, occurring in a critical site or contributing to death. Net clinical benefit was considered greater in those participants with fewer composite events. All events were adjudicated and confirmed by a central independent adjudication committee blinded to treatment, based on either compression ultrasound (DVT), venography (DVT), spiral CT scanning (PE), pulmonary angiography ( PE), ventilation/perfusion lung scan (PE), lung scintigraphy (PE), autopsy or unexplained death for which DVT/PE could not be ruled out, results/films/images of confirmatory testing, and/or case summaries. (NCT00440193)
Timeframe: Up to 30 days after the last intake of study medication

InterventionPercentage of participants (Number)
Rivaroxaban (Xarelto, BAY59-7939)1.2
Enoxaparin/VKA1.3

Percentage of Participants With an Event for Net Clinical Benefit 2 Until the Intended End of Study Treatment

Net clinical benefit 2: composite of recurrent DVT or non-fatal or fatal PE, major bleeding. Major bleeding was overt bleeding associated with 2 g/dL or greater fall in hemoglobin, leading to transfusion of ≥2 units, occurring in a critical site or contributing to death, cardiovascular death, myocardial infarction, stroke, and non CNS (central nervous system) systemic embolism. Net clinical benefit was considered greater in those participants with fewer composite events. All events confirmed by independent committee blinded to treatment, based on compression ultrasound, venography, spiral CT scan, pulmonary angiography, ventilation/perfusion lung scan, lung scintigraphy, autopsy, results/films/images of confirmatory testing and/or case summaries (NCT00440193)
Timeframe: 3-, 6- or 12-month study treatment period

InterventionPercentage of participants (Number)
Rivaroxaban (Xarelto, BAY59-7939)3.6
Enoxaparin/VKA4.7

Percentage of Participants With Clinically Relevant Bleeding, Treatment-emergent (Time Window: Until 2 Days After Last Dose)

All events were adjudicated and confirmed by a central independent adjudication committee blinded to treatment. Clinically relevant bleeding included major bleeding (overt bleeding associated with 2 g/dL or greater fall in hemoglobin, leading to a transfusion of 2 or more units of packed red blood cells or whole blood, occurring in a critical site or contributing to death) and non-major bleeding associated with medical intervention, unscheduled physician contact, (temporary) cessation of study treatment, discomfort for the participants such as pain, or impairment of activities of daily life. (NCT00440193)
Timeframe: 3-, 6- or 12-month study treatment period

InterventionPercentage of participants (Number)
Rivaroxaban (Xarelto, BAY59-7939)8.1
Enoxaparin/VKA8.1

Percentage of Participants With Other Vascular Events, On-treatment (Time Window: Until 1 Day After Last Dose)

All pre-defined vascular events (ST segment elevation myocardial infarction, non ST segment elevation myocardial infarction, unstable angina, ischemic stroke, transient ischemic attack, non-central nervous system systemic embolism or vascular death) were adjudicated and confirmed by a central independent adjudication committee blinded to treatment. Events were assessed based results/films/images of confirmatory testing, and/or case summaries. (NCT00440193)
Timeframe: 3-, 6- or 12-month study treatment period

InterventionPercentage of participants (Number)
Rivaroxaban (Xarelto, BAY59-7939)0.7
Enoxaparin/VKA0.8

Percentage of Participants With Recurrent DVT During Observational Period

All events were adjudicated and confirmed by a central independent adjudication committee blinded to treatment. Events were assessed based on either compression ultrasound, venography, results/films/images of confirmatory testing, and/or case summaries. (NCT00440193)
Timeframe: Up to 30 days after the last intake of study medication

InterventionPercentage of participants (Number)
Rivaroxaban (Xarelto, BAY59-7939)0.6
Enoxaparin/VKA0.3

Percentage of Participants With Recurrent DVT Until the Intended End of Study Treatment

All events were adjudicated and confirmed by a central independent adjudication committee blinded to treatment. Events were assessed based on either compression ultrasound, venography, results/films/images of confirmatory testing, and/or case summaries. (NCT00440193)
Timeframe: 3-, 6- or 12-month study treatment period

InterventionPercentage of participants (Number)
Rivaroxaban (Xarelto, BAY59-7939)0.9
Enoxaparin/VKA1.6

Percentage of Participants With Symptomatic Recurrent Venous Thromboembolism [VTE] (i.e. the Composite of Recurrent Deep Vein Thrombosis [DVT] or Fatal or Non-fatal Pulmonary Embolism [PE]) During Observational Period

All events were adjudicated and confirmed by a central independent adjudication committee blinded to treatment. Events were assessed based on either compression ultrasound (for DVT), venography (for DVT), spiral computed tomography (CT) scanning (for PE), pulmonary angiography (for PE), ventilation/perfusion lung scan (for PE), lung scintigraphy (for PE), autopsy (for fatal PE) or unexplained death for which DVT/PE could not be ruled out (for fatal PE), results/films/images of confirmatory testing, and/or case summaries. (NCT00440193)
Timeframe: Up to 30 days after the last intake of study medication

InterventionPercentage of participants (Number)
Rivaroxaban (Xarelto, BAY59-7939)0.8
Enoxaparin/VKA0.5

Percentage of Participants With Symptomatic Recurrent Venous Thromboembolism [VTE] (i.e. the Composite of Recurrent Deep Vein Thrombosis [DVT] or Fatal or Non-fatal Pulmonary Embolism [PE]) Until the Intended End of Study Treatment

All events were adjudicated and confirmed by a central independent adjudication committee blinded to treatment. Events were assessed based on either compression ultrasound (for DVT), venography (for DVT), spiral computed tomography (CT) scanning (for PE), pulmonary angiography (for PE), ventilation/perfusion lung scan (for PE), lung scintigraphy (for PE), autopsy (for fatal PE) or unexplained death for which DVT/PE could not be ruled out (for fatal PE), and/or case summaries. (NCT00440193)
Timeframe: 3-, 6- or 12-month study treatment period

InterventionPercentage of participants (Number)
Rivaroxaban (Xarelto, BAY59-7939)2.1
Enoxaparin/VKA3.0

Percentage of Participants With the Composite Variable Comprising Recurrent DVT, Non-fatal PE and All Cause Mortality During Observational Period

All events were adjudicated and confirmed by a central independent adjudication committee blinded to treatment. Events were assessed based on either compression ultrasound (for DVT), venography (for DVT), spiral computed tomography (CT) scanning (for PE), pulmonary angiography (for PE), ventilation/perfusion lung scan (for PE), lung scintigraphy (for PE), autopsy (for deaths), results/films/images of confirmatory testing, and/or case summaries. (NCT00440193)
Timeframe: Up to 30 days after the last intake of study medication

InterventionPercentage of participants (Number)
Rivaroxaban (Xarelto, BAY59-7939)2.2
Enoxaparin/VKA1.8

Percentage of Participants With the Composite Variable Comprising Recurrent DVT, Non-fatal PE and All Cause Mortality Until the Intended End of Study Treatment

All events were adjudicated and confirmed by a central independent adjudication committee blinded to treatment. Events were assessed based on either compression ultrasound (for DVT), venography (for DVT), spiral computed tomography (CT) scanning (for PE), pulmonary angiography (for PE), ventilation/perfusion lung scan (for PE), lung scintigraphy (for PE), autopsy (for deaths), results/films/images of confirmatory testing, and/or case summaries. (NCT00440193)
Timeframe: 3-, 6- or 12-month study treatment period

InterventionPercentage of participants (Number)
Rivaroxaban (Xarelto, BAY59-7939)4.0
Enoxaparin/VKA5.1

Percentage of Participants With All Deaths

All events were adjudicated and confirmed by a central independent adjudication committee blinded to treatment. Events were assessed based on either autopsy, results/films/images of confirmatory testing, and/or case summaries. (NCT00440193)
Timeframe: 3-, 6- or 12-month study treatment period

,
InterventionPercentage of participants (Number)
All post-randomizationTreatment-emergent (time window: 2 days)Treatment-emergent (time window: 7 days)
Enoxaparin/VKA3.01.11.5
Rivaroxaban (Xarelto, BAY59-7939)2.41.01.2

Percentage of Participants With the Individual Components of Efficacy Outcomes During Observational Period

All events were adjudicated and confirmed by a central independent adjudication committee blinded to treatment, based on either compression ultrasound, venography, spiral computed tomography scanning, pulmonary angiography, ventilation/perfusion lung scan, lung scintigraphy, autopsy or unexplained death for which DVT/PE could not be ruled out, results/films/images of confirmatory testing, and/or case summaries. Major bleeding was overt bleeding associated with 2 g/dL or greater fall in hemoglobin, leading to a transfusion of ≥2 units, occurring in a critical site or contributing to death. (NCT00440193)
Timeframe: Up to 30 days after the last intake of study medication

,
InterventionPercentage of participants (Number)
Death (PE)Death (PE cannot be excluded)Symptomatic PE and DVTSymptomatic recurrent PE onlySymptomatic recurrent DVT onlyDeath (bleeding)Death (cardiovascular)Death (other)Major bleeding
Enoxaparin/VKA00.0700.10.30.10.30.80.6
Rivaroxaban (Xarelto, BAY59-7939)00.0700.30.60.070.071.30.2

Percentage of Participants With the Individual Components of Efficacy Outcomes Until the Intended End of Study Treatment

All events were adjudicated and confirmed by a central independent adjudication committee blinded to treatment, based on either compression ultrasound, venography, spiral computed tomography scanning, pulmonary angiography, ventilation/perfusion lung scan, lung scintigraphy, autopsy or unexplained death for which DVT/PE could not be ruled out, results/films/images of confirmatory testing, and/or case summaries. Major bleeding was overt bleeding associated with 2 g/dL or greater fall in hemoglobin, leading to a transfusion of ≥2 units, occurring in a critical site or contributing to death. (NCT00440193)
Timeframe: 3-, 6- or 12-month study treatment period

,
InterventionPercentage of participants (Number)
Death (PE)Death (PE cannot be excluded)Symptomatic PE and DVTSymptomatic recurrent PE onlySymptomatic recurrent DVT onlyDeath (bleeding)Death (cardiovascular)Death (other)Major bleeding
Enoxaparin/VKA00.301.01.60.30.22.01.3
Rivaroxaban (Xarelto, BAY59-7939)0.060.20.061.20.80.060.11.80.9

Percentage of Participants With Death (PE Cannot be Excluded) Until the Intended End of Study Treatment

All events were adjudicated and confirmed by a central independent adjudication committee blinded to treatment. Events were assessed based on unexplained death for which DVT/PE could not be ruled out, results/films/images of confirmatory testing, and/or case summaries. (NCT00439725)
Timeframe: 6- or 12-month study treatment period

InterventionPercentage of participants (Number)
Rivaroxaban (Xarelto, BAY59-7939)0.2
Placebo0.0

Percentage of Participants With Death (PE) Until the Intended End of Study Treatment

All events were adjudicated and confirmed by a central independent adjudication committee blinded to treatment. Events were assessed based on either autopsy, results/films/images of confirmatory testing, and/or case summaries. (NCT00439725)
Timeframe: 6- or 12-month study treatment period

InterventionPercentage of participants (Number)
Rivaroxaban (Xarelto, BAY59-7939)0.0
Placebo0.2

Percentage of Participants With Net Clinical Benefit as Composite of Recurrent DVT or Non-fatal or Fatal PE and Major Bleeding Events During Observational Period

Events were adjudicated/confirmed by a central independent adjudication committee blinded to treatment, based on either compression ultrasound, venography, spiral CT scanning, pulmonary angiography, ventilation/perfusion lung scan, lung scintigraphy, autopsy or unexplained death for which DVT/PE could not be ruled out, results/films/images of confirmatory testing, and/or case summaries. Major bleeding was overt bleeding associated with 2 g/dL or greater fall in hemoglobin, leading to a transfusion of 2 or more units, occurring in a critical site or contributing to death. (NCT00439725)
Timeframe: 30 days observational period after last intake of study medication

InterventionPercentage of participants (Number)
Rivaroxaban (Xarelto, BAY59-7939)1.2
Placebo0.9

Percentage of Participants With Net Clinical Benefit as Composite of Recurrent DVT or Non-fatal or Fatal PE and Major Bleeding Events Until the Intended End of Study Treatment

All events were adjudicated and confirmed by a central independent adjudication committee blinded to treatment, based on either compression ultrasound, venography, spiral computed tomography scanning, pulmonary angiography, ventilation/perfusion lung scan, lung scintigraphy, autopsy or unexplained death for which DVT/PE could not be ruled out, results/films/images of confirmatory testing, and/or case summaries. Major bleeding was overt bleeding associated with 2 g/dL or greater fall in hemoglobin, leading to a transfusion of ≥2 units, occurring in a critical site or contributing to death. (NCT00439725)
Timeframe: 6- or 12-month study treatment period

InterventionPercentage of participants (Number)
Rivaroxaban (Xarelto, BAY59-7939)2.0
Placebo7.1

Percentage of Participants With Recurrent DVT During Observational Period

All events were adjudicated and confirmed by a central independent adjudication committee blinded to treatment. Events were assessed based on either compression ultrasound or venography, results/films/images of confirmatory testing, and/or case summaries. (NCT00439725)
Timeframe: 30 days observational period after last intake of study medication

InterventionPercentage of participants (Number)
Rivaroxaban (Xarelto, BAY59-7939)0.9
Placebo0.7

Percentage of Participants With Recurrent DVT Until the Intended End of Study Treatment

All events were adjudicated and confirmed by a central independent adjudication committee blinded to treatment. Events were assessed based on either compression ultrasound, venography, results/films/images of confirmatory testing, and/or case summaries. (NCT00439725)
Timeframe: 6- or 12-month study treatment period

InterventionPercentage of participants (Number)
Rivaroxaban (Xarelto, BAY59-7939)0.8
Placebo5.2

Percentage of Participants With Recurrent VTE (PE or DVT) During Observational Period

All events were adjudicated and confirmed by a central independent adjudication committee blinded to treatment. Events were assessed based on either compression ultrasound (for DVT), venography (for DVT), spiral computed tomography (CT) scanning (for PE), pulmonary angiography (for PE), ventilation/perfusion lung scan (for PE), lung scintigraphy (for PE), results/films/images of confirmatory testing, and/or case summaries. (NCT00439725)
Timeframe: 30 days observational period after last intake of study medication

InterventionPercentage of participants (Number)
Rivaroxaban (Xarelto, BAY59-7939)1.2
Placebo0.9

Percentage of Participants With Recurrent VTE (PE or DVT) Until the Intended End of Study Treatment

All events were adjudicated and confirmed by a central independent adjudication committee blinded to treatment. Events were assessed based on either compression ultrasound (for DVT), venography (for DVT), spiral computed tomography (CT) scanning (for PE), pulmonary angiography (for PE), ventilation/perfusion lung scan (for PE), lung scintigraphy (for PE), results/films/images of confirmatory testing, and/or case summaries. (NCT00439725)
Timeframe: 6- or 12-month study treatment period

InterventionPercentage of participants (Number)
Rivaroxaban (Xarelto, BAY59-7939)1.2
Placebo7.1

Percentage of Participants With Symptomatic Recurrent PE During Observational Period

All events were adjudicated and confirmed by a central independent adjudication committee blinded to treatment. Events were assessed based on either spiral computed tomography (CT) scanning, pulmonary angiography, ventilation/perfusion lung scan, lung scintigraphy, results/films/images of confirmatory testing, and/or case summaries. (NCT00439725)
Timeframe: 30 days observational period after last intake of study medication

InterventionPercentage of participants (Number)
Rivaroxaban (Xarelto, BAY59-7939)0.3
Placebo0.2

Percentage of Participants With Symptomatic Recurrent PE Until the Intended End of Study Treatment

All events were adjudicated and confirmed by a central independent adjudication committee blinded to treatment. Events were assessed based on either spiral computed tomography (CT) scanning, pulmonary angiography, ventilation/perfusion lung scan, lung scintigraphy, results/films/images of confirmatory testing, and/or case summaries. (NCT00439725)
Timeframe: 6- or 12-month study treatment period

InterventionPercentage of participants (Number)
Rivaroxaban (Xarelto, BAY59-7939)0.3
Placebo2.2

Percentage of Participants With Symptomatic Recurrent Venous Thromboembolism [VTE] (i.e. the Composite of Recurrent Deep Vein Thrombosis [DVT] or Fatal or Non-fatal Pulmonary Embolism [PE]) During Observational Period

All events were adjudicated and confirmed by a central independent adjudication committee blinded to treatment. Events were assessed based on either compression ultrasound (for DVT), venography (for DVT), spiral computed tomography (CT) scanning (for PE), pulmonary angiography (for PE), ventilation/perfusion lung scan (for PE), lung scintigraphy (for PE), autopsy (for fatal PE) or unexplained death for which DVT/PE could not be ruled out (for fatal PE), results/films/images of confirmatory testing, and/or case summaries. (NCT00439725)
Timeframe: 30 days observational period after last intake of study medication

InterventionPercentage of participants (Number)
Rivaroxaban (Xarelto, BAY59-7939)1.2
Placebo0.9

Percentage of Participants With Symptomatic Recurrent Venous Thromboembolism [VTE] (i.e. the Composite of Recurrent Deep Vein Thrombosis [DVT] or Fatal or Non-fatal Pulmonary Embolism [PE]) Until the Intended End of Study Treatment

All events were adjudicated and confirmed by a central independent adjudication committee blinded to treatment. Events were assessed based on either compression ultrasound (for DVT), venography (for DVT), spiral computed tomography (CT) scanning (for PE), pulmonary angiography (for PE), ventilation/perfusion lung scan (for PE), lung scintigraphy (for PE), autopsy (for fatal PE) or unexplained death for which DVT/PE could not be ruled out (for fatal PE), and/or case summaries. For definition of DVT/PE, kindly refer to the link in the Protocol section. (NCT00439725)
Timeframe: 6- or 12-month study treatment period

InterventionPercentage of participants (Number)
Rivaroxaban (Xarelto, BAY59-7939)1.3
Placebo7.1

Percentage of Participants With the Composite Variable Comprising Recurrent DVT, Non-fatal PE and All Cause Mortality During Observational Period

All events were adjudicated and confirmed by a central independent adjudication committee blinded to treatment. Events were assessed based on either compression ultrasound (for DVT), venography (for DVT), spiral computed tomography (CT) scanning (for PE), pulmonary angiography (for PE), ventilation/perfusion lung scan (for PE), lung scintigraphy (for PE), autopsy (for deaths), results/films/images of confirmatory testing, and/or case summaries. (NCT00439725)
Timeframe: 30 days observational period after last intake of study medication

InterventionPercentage of participants (Number)
Rivaroxaban (Xarelto, BAY59-7939)1.2
Placebo1.1

Percentage of Participants With the Composite Variable Comprising Recurrent DVT, Non-fatal PE and All Cause Mortality Until the Intended End of Study Treatment

All events were adjudicated and confirmed by a central independent adjudication committee blinded to treatment. Events were assessed based on either compression ultrasound (for DVT), venography (for DVT), spiral computed tomography (CT) scanning (for PE), pulmonary angiography (for PE), ventilation/perfusion lung scan (for PE), or lung scintigraphy (for PE), and/or case summaries. (NCT00439725)
Timeframe: 6- or 12-month study treatment period

InterventionPercentage of participants (Number)
Rivaroxaban (Xarelto, BAY59-7939)1.3
Placebo7.2

Percentage of Participants With the Composite Variable Comprising Recurrent DVT, Non-fatal PE, All Cause Mortality, Strokes and Myocardial Infarctions During Observational Period

All events were adjudicated and confirmed by a central independent adjudication committee blinded to treatment. Events were assessed based on either compression ultrasound (for DVT), venography (for DVT), spiral computed tomography (CT) scanning (for PE), pulmonary angiography (for PE), ventilation/perfusion lung scan (for PE), lung scintigraphy (for PE), autopsy (for fatal PE) or unexplained death for which DVT/PE could not be ruled out (for fatal PE), results/films/images of confirmatory testing, and/or case summaries. (NCT00439725)
Timeframe: 30 days observational period after last intake of study medication

InterventionPercentage of participants (Number)
Rivaroxaban (Xarelto, BAY59-7939)1.4
Placebo1.1

Percentage of Participants With the Composite Variable Comprising Recurrent DVT, Non-fatal PE, All Cause Mortality, Strokes and Myocardial Infarctions Until the Intended End of Study Treatment

All events were adjudicated and confirmed by a central independent adjudication committee blinded to treatment. Events were assessed based on either compression ultrasound (for DVT), venography (for DVT), spiral computed tomography (CT) scanning (for PE), pulmonary angiography (for PE), ventilation/perfusion lung scan (for PE), lung scintigraphy (for PE), results/films/images of confirmatory testing, and/or case summaries. (NCT00439725)
Timeframe: 6- or 12-month study treatment period

InterventionPercentage of participants (Number)
Rivaroxaban (Xarelto, BAY59-7939)1.5
Placebo7.4

Percentage of Participants With All Death

All events were adjudicated and confirmed by a central independent adjudication committee blinded to treatment. Events were assessed based on either autopsy, results/films/images of confirmatory testing, and/or case summaries. Treatment-emergent events and all events post randomization were reported. Treatment-emergent: after intake of first tablet of study medication as randomized but not more than 2 days after stop of study medication (referred to as time window: 2 days) (NCT00439725)
Timeframe: 6- or 12-month study treatment period

,
InterventionPercentage of participants (Number)
Treatment-emergent (time window: 2 days)All post-randomization
Placebo0.20.3
Rivaroxaban (Xarelto, BAY59-7939)0.20.2

Percentage of Participants With Clinically Relevant Bleeding

All events adjudicated/confirmed by CIAC blinded to treatment. Clinically relevant bleeding included major bleeding (definition: see outcome 7) and non-major bleeding associated with medical intervention, unscheduled physician contact, (temporary) cessation of study treatment, discomfort for the participants such as pain, or impairment of daily life activities. Treatment-emergent events (after intake of 1st study medication tablet as randomized up to 2 days after stop of study medication ['time window: 2 days']) and all events post randomization were reported (NCT00439725)
Timeframe: 6- or 12-month study treatment period

,
InterventionPercentage of participants (Number)
Treatment-emergent (time window: 2 days)All post-randomization
Placebo1.21.9
Rivaroxaban (Xarelto, BAY59-7939)6.06.0

Percentage of Participants With Major Bleeding

All events were adjudicated and confirmed by a central independent adjudication committee (CIAC) blinded to treatment. Major bleeding event was overt bleeding associated with a 2 g/dL or greater fall in hemoglobin, leading to a transfusion of 2 or more units of packed red blood cells or whole blood, occurring in a critical site or contributing to death. Treatment-emergent [after intake of first tablet of study medication as randomized but not more than 2 days after stop of study medication (referred to as time window: 2 days)] events and all events post randomization were reported. (NCT00439725)
Timeframe: 6- or 12-month study treatment period

,
InterventionPercentage of participants (Number)
Treatment-emergent (time window: 2 days)All post-randomization
Placebo0.00.2
Rivaroxaban (Xarelto, BAY59-7939)0.70.7

Percentage of Participants With Other Vascular Events

All pre-defined vascular events (acute coronary syndromes, ischemic stroke, transient ischemic attack, non-central nervous system systemic embolism and vascular death) were adjudicated/confirmed by a central independent adjudication committee blinded to treatment, based on results/films/images of confirmatory testing, and/or case summaries. On treatment events and all events post randomization were reported. On treatment: after intake of first tablet of study medication as randomized but not more than 1 day after stop of study medication (referred to as time window: 1 day) (NCT00439725)
Timeframe: 6- or 12-month study treatment period

,
InterventionPercentage of participants (Number)
On treatment (time window: 1 day)All post-randomization
Placebo0.70.7
Rivaroxaban (Xarelto, BAY59-7939)0.50.8

Rate of Composite of Adjudicated Proximal Deep Vein Thrombosis (DVT), Nonfatal Pulmonary Embolism, and Venous Thromboembolic Event-related Death With Onset During Intended Treatment Period

Event rate=Number of events divided by the number of patients evaluated. Each patient was categorized as having no proximal DVT, having proximal DVT, being nonevaluable for proximal DVT, having no distal DVT, having distal DVT, or being nonevaluable for distal DVT. Adjudication criteria were: Normal=All deep veins were visualized, and there was no intraluminal filling defect (ILFD). ILFD=An area of reduced, or absent filling, at least partially surrounded with contrast medium in ≥ 2 projections or a lack of filling in a vessel in which there was a cut-off that had the configuration of a thrombus. Indeterminate=A lack of filling of a region of the deep vein system, proximal or distal, without the presence of an ILFD elsewhere in the same region. Not Done=A venography was not performed. Proximal DVT was found if any of the proximal veins had an ILFD. Pulmonary embolism was radiographically (angiography, V/Q scan, computed tomography) determined. (NCT00423319)
Timeframe: Day 1 (first dose of study drug) to later of 2 days after last dose or 38 days after first dose

InterventionPercentage of events/patients evaluated (Number)
Apixaban, 2.5 mg BID Plus Placebo0.45
Enoxaparin, 40 mg QD Plus Placebo1.14

Rate of Composite of Adjudicated Venous Thromboembolic Event (VTE)-Related (Pulmonary Embolism and Symptomatic and Asymptomatic Deep Vein Thrombosis[DVT]) and All-cause Death During the Intended Treatment Period

Event rate=Number of events divided by the number of patients evaluated. A mandatory bilateral ascending contrast venogram was to be obtained on Day 35 (± 3). Patients with confirmed symptomatic DVT at any time, or asymptomatic DVT upon venography, were to receive treatment for DVT according to the investigator's standard of care. Signs and symptoms suggestive of VTE included, but were not limited to: 1) lower extremity DVT: erythema, warmth, pain, swelling, tenderness; and 2) PE: pleuritic chest pain, dyspnea, cough, hemoptysis, syncope, light-headedness/dizziness, tachypnea, and tachycardia. Intended Treatment Period started on day of randomization and, for patients who received treatment, ended at the later of 2 days after last dose of study drug or 38 days after the first dose (presurgery) of study drug. For randomized patients who did not receive study drug, the period ended 38 days after randomization. (NCT00423319)
Timeframe: Day 1 (first dose of study drug) to later of 2 days after last dose or 38 days after first dose

InterventionPercentage of events/patients evaluated (Number)
Apixaban, 2.5 mg BID Plus Placebo1.39
Enoxaparin, 40 mg QD Plus Placebo3.86

Number of Participants With a Bleeding-related Adverse Event During the Treatment Period

All suspected bleeding events were to be reported by the investigator as either an adverse event or serious adverse event or and adjudicated by the Independent Central Adjudication Committee (ICAC). Definitions of bleeding outcomes: Acute clinically overt bleeding =new onset, visible bleeding, or signs or symptoms suggestive of bleeding with confirmatory imaging techniques that could detect the presence of blood. All acute clinically overt bleeding events were adjudicated by the ICAC as a major bleeding event or a clinically relevant nonmajor bleeding event; suspected minor bleeding events were not sent for adjudication. (NCT00423319)
Timeframe: First dose of study drug (presurgery) through 2 days after the last dose of study drug

,
InterventionParticipants (Number)
Postprocedural hematomaOperative hemorrhageIncision site hematomaIncision site hemorrhagePostprocedural hemorrhagicHematuria traumaticPeriorbital hematomaSubcutaneous hematomaTraumatic hematomaHematomaWound hemorrhageHemorrhageHematuriaHemorrhage urinary tractUrethral hemorrhageEpistaxisHemoptysis
Apixaban, 2.5 mg BID Plus Placebo20191413411103418134110333
Enoxaparin, 40 mg QD Plus Placebo23141019710013815133912251

Number of Participants With a Bleeding-related Adverse Event During the Treatment Period (Continued)

All suspected bleeding events were to be reported by the investigator as either an adverse event or serious adverse event or and adjudicated by the Independent Central Adjudication Committee (ICAC). Definitions of bleeding outcomes: Acute clinically overt bleeding =new onset, visible bleeding, or signs or symptoms suggestive of bleeding with confirmatory imaging techniques that could detect the presence of blood. All acute clinically overt bleeding events were adjudicated by the ICAC as a major bleeding event or a clinically relevant nonmajor bleeding event; suspected minor bleeding events were not sent for adjudication. (NCT00423319)
Timeframe: First dose of study drug (presurgery) through 2 days after the last dose of study drug

,
InterventionParticipants (Number)
Hemorrhagic anemiaEcchymosisPetechiaeHemorrhage subcutaneousIncreased tendency to bruiseVaginal hemorrhageMenorrhagiaUterine hemorrhageConjunctival hemorrhageHematoma infectionSpinal hematoma
Apixiban, 2.5 mg BID Plus Placebo205210210110
Enoxaparin, 40 mg QD Plus Placebo159205001001

Number of Participants With a Bleeding-related Adverse Events During the Treatment Period (Continued)

All suspected bleeding events were to be reported by the investigator as either an adverse event or serious adverse event or and adjudicated by the Independent Central Adjudication Committee (ICAC). Definitions of bleeding outcomes: Acute clinically overt bleeding =new onset, visible bleeding, or signs or symptoms suggestive of bleeding with confirmatory imaging techniques that could detect the presence of blood. All acute clinically overt bleeding events were adjudicated by the ICAC as a major bleeding event or a clinically relevant nonmajor bleeding event; suspected minor bleeding events were not sent for adjudication. (NCT00423319)
Timeframe: First dose of study drug (presurgery) through 2 days after the last dose of study drug

,
InterventionParticipants (Number)
Bloody dischargeCatheter site hemorrhageInjection site hemorrhageInjection site hematomaInfusion site hematomaVessel puncture site hematomaHematocrit decreasedRed blood cell count decreasedBlood urine presentBlood urineOccult blood positiveFibrin D dimer increasedHematocheziaMallory-Weiss SyndromeHematemesisMelaenaRectal hemorrhageGingival bleedingAnal hemorrhageDiarrhea hemorrhagicDiverticulum intestinal hemorrhagicGastrointestinal hemorrhageIntra-abdominal hematomaDuodenal ulcer hemorrhageHemorrhoidal hemorrhageMouth hemorrhage
Apixaban, 2.5 mg BID Plus Placebo16643111814811064333211111000
Enoxaparin, 40 mg QD Plus Placebo1351028002120610120211300010111

Number of Participants With Adverse Events Related to Elevations in Liver Function Test Results With Onset During the Treatment Period

Treatment guidelines were provided for jaundice and elevated results of liver function tests. (NCT00423319)
Timeframe: First dose of study drug (presurgery) through 30 days after the last dose of study drug

,
InterventionParticipants (Number)
Aspartate aminotransferase increasedAlanine aminotransferase increasedGamma-glutamyltransferase increasedBlood bilirubin increasedBilirubin conjugated increasedHepatic enzyme increasedLiver function test results abnormalTransaminases increasedCholelithiasisHepatitis toxicCholecystitis acuteCholestasisHyperbilirubinemiaPostcholecystectomy syndromeCholecystitisHepatic painHepatitisHepatomegalyJaundice cholestaticHypoalbuminemiaHypoproteinemiaYellow skin
Apixaban, 2.5 mg BID Plus Placebo484027171194122111100000000
Enoxaparin, 40 mg QD Plus Placebo676154712169100000011111111

Number of Participants With Marked Abnormalities (MA) in Clinical Laboratory Test Results During the Treatment Period

preRx=predose; LLN=lower limit of normal; ULN=upper limit of normal. MA criteria: Hemoglobin: >2 g/dL decrease from preRx or value ≤ 8 g/dL; hematocrit (%): <0.75*preRx; platelet count (*10^9 cells/L): <100,000/mm^3; erythrocytes (*10^6 cells/μL): <0.75*preRx level; leukocytes (*10^3 cells/μL): < 0.75*LLN or >1.25*ULN, or if preRx LLN use < 0.8*preRx or >ULN if preRx >ULN use >1.2*preRx or 400/mm^3; eosinophils (*10^3 cells/μL): > 0.75*10^3 cells/μL; lymphocytes (*10^3 cells/μL): >0.75*10^3 cells/μL; monocytes (*10^3 cells/μL): >2000/mm^3; neutrophils (*10^3 cells/μL): <1.0; (NCT00423319)
Timeframe: First dose of study drug (presurgery) through 2 days after the last dose of study drug

,
InterventionParticipants (Number)
Hemoglobin, low (n=2605, 2587)Hematocrit, low (n=2554, 2536)Platelet count, low (n=2597, 2576)Erythrocytes, low (n=2558, 2540)Leukocytes, low (n=2632, 2617)Leukocytes, high (n=2632, 2617)Basophils (absolute), high (n=2629, 2613)Eosinophils (absolute), high (n=2629, 2613)Lymphocytes (absolute), low (n=2629, 2613)Lymphocytes (absolute), high (n=2629, 2613)Monocytes (absolute), high (n=2629, 2613)Neutrophils (absolute), low (n=2629, 2613)
Apixaban, 2.5 mg BID Plus Placebo218912746131054385175383395
Enoxaparin, 40 mg QD Plus Placebo2218135091377543603703823114

Number of Participants With Marked Abnormalities (MA) in Clinical Laboratory Test Results During the Treatment Period (Continued)

preRx=predose; LLN=lower limit of normal; ULN=upper limit of normal. Alanine aminotransferase (ALT) (U/L): >3 *ULN: alkaline phosphatase (ALP) (U/L): >2* ULN; aspartate aminotransferase (ASP) (U/L): >3 *ULN; bilirubin, direct (mg/dL): >2*ULN; bilirubin, total (mg/dL): >2*ULN; BUN (mg/dL): >2*ULN; creatinine (mg/dL): >1.5*ULN; calcium (mg/dL): < 0.8*LLN or >1.2 *ULN, or if preRx ULN if preRx >ULN use > 1.25*preRx or 1.1*ULN, or if preRx ULN if preRx >ULN use >1.1* preRx or 1.25*ULN, or if preRx ULN if preRx >ULN use >1.25*preRx or 1.1*ULN, or if preRx ULN if preRx >ULN use >1.1* preRx or < LLN; sodium (mEq/L): <0.95* LLN or >1.05×ULN, or if preRx ULN if preRx >ULN use >1.05 *preRx or < LLN. (NCT00423319)
Timeframe: First dose of study drug (presurgery) through 2 days after the last dose of study drug

,
InterventionParticipants (Number)
Alkaline phosphatase, high (n=2631, 2618)Alanine aminotransferase, high (n=2629, 2616)Aspartate aminotransferase, high (n=2629, 2616)Bilirubin, direct, high (n=2622, 2604)Bilirubin, total, high (n=2630, 2617)Blood urea nitrogen (BUN), high (n=2618, 2598)Creatinine, high (n=2618, 2598)Calcium, total, low (n=2618, 2598)Calcium, total, high (n=2618, 2598)Chloride, serum, low (n=2615, 2594)Bicarbonate, low (n=2615, 2595)Potassium, serum, low (n=2614, 2594)Potassium, serum, high (n=2614, 2594)Sodium, serum, low (n=2615, 2594)Sodium, serum, high (n=2615, 2594)
Apixaban, 2.5 mg BID Plus Placebo55507314524192170687361295
Enoxaparin, 40 mg QD Plus Placebo578373139121725181687347234

Number of Participants With Marked Abnormalities (MA) in Clinical Laboratory Test Results During the Treatment Period (Continued)

preRx=predose; LLN=lower limit of normal; ULN=upper limit of normal. Glucose, fasting (mg/dL): <.8*LLN or >1.5*ULN, or if preRx ULN if preRx >ULN use >2*preRx or 5*ULN; uric acid (mg/dL): >.5* ULN, or if preRx >ULN use >2*preRx; blood, urine: If missing preRx use ≥2, or if value ≥4, or if preRx=0 or 0.5 use ≥2, or if preRx=1 use ≥3, or if preRx =2 or 3 use ≥4; glucose, urine : If missing preRx use ≥2, or if value ≥4, or if preRx=0 or .5 use ≥2, or if preRx=1 use ≥3, or if preRx=2 or 3 use ≥4; RBC, urine (hpf): If missing preRx use ≥2, or if value ≥4, or if preRx=0 or 0.5 use ≥2, or if preRx dose= 1 use ≥3, or if preRx=2 or 3 use ≥4; WBC, urine (h): If missing preRx use ≥2, or if value ≥4, or if preRx =0 or .5 use ≥2, or if preRx =1 use ≥3, or if preRx=2 or 3 use ≥4. (NCT00423319)
Timeframe: First dose of study drug (presurgery) through 2 days after the last dose of study drug

,
InterventionParticipants (Number)
Glucose, fasting serum, high (n=14, 17)Protein, total, low (n=2618, 2596)Protein, total, high (n=2618, 2596)Creatine kinase, high (n=2630, 2616)Uric acid, high (n=2618, 2597)Blood, urine, high (n=2588, 2568)Glucose, urine, high (n=2588, 2568)Leukocyte esterase, urine, high (n=21, 41)Protein, urine (n=2588, 2568)Red blood cells (RBC), urine, high (n=1310, 1230)White blood cells (WBC),urine, high (n=1311, 1228)
Apixaban, 2.5 mg BID Plus Placebo074736152275680169216217
Enoxaparin, 40 mg QD Plus Placebo175216423234764168173229

Number of Participants With Neurologic Adverse Events With Onset During the Treatment Period

Neurologic events were based on Medical Dictionary for Regulatory Activities search categories.For new or worsening events that were not related to the site of surgery, additional information was collected on a specific form. In addition, neurology consultation was to be obtained for these patients. (NCT00423319)
Timeframe: First dose of study drug (presurgery) through 2 days after the last dose of study drug

,
InterventionParticipants (Number)
ParaesthesiaHypoaesthesiaBurning sensationPeroneal nerve palsyHypotoniaDysarthriaParesisCervicobrachial syndromeCoordination abnormalHypertoniaNeuropathy peripheralPeripheral nerve lesionRadiculitisParalysisMuscular weaknessNerve injuryFemoral nerve injurySciatic nerve injuryPeroneal nerve injuryDiplopiaGait disturbance
Apixaban, 2.5 mg BID Plus Placebo32297543211111107211011
Enoxaparin, 40 mg QD Plus Placebo193556411101210111100100

Number of Participants With Serious Adverse Events (SAEs), Bleeding Adverse Events (AEs), and Death as Outcome

AE=any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that may not have a causal relationship with treatment. SAE=a medical event that at any dose results in death, persistent or significant disability/incapacity, or drug dependency/abuse; is life-threatening, an important medical event, or a congenital anomaly/birth defect; or requires or prolongs hospitalization. All suspected bleeding events were to be reported by the investigator as either an AE or SAE and adjudicated by the Independent Central Adjudication Committee (ICAC). Definitions of bleeding outcomes: Acute clinically overt bleeding =new onset, visible bleeding, or signs or symptoms suggestive of bleeding with confirmatory imaging techniques that could detect the presence of blood. (NCT00423319)
Timeframe: First dose of study drug (presurgery) through 30 days after the last dose of study drug

,
InterventionParticipants (Number)
SAEsBleeding AEsDeath
Apixaban, 2.5 mg BID Plus Placebo18152
Enoxaparin, 40 mg QD Plus Placebo18210

Rate of Major Bleeding, Clinically Relevant Nonmajor Bleeding (CRNM), Major or CRNM, and Any Bleeding During the Treatment Period

Event rate=Number of events divided by the number of patients evaluated. Major bleeding event defined as a bleeding event that was 1) Acute clinically overt bleeding accompanied by at least 1 of the following: decrease in hemoglobin of ≥ 2 g/dL over a 24-hour period, transfusion of ≥2 units of packed red blood cells; bleeding that occurred in at least 1 of the following sites: intracranial, intra-spinal, intraocular, pericardial, an operated joint and requires reoperation or intervention, intramuscular with compartment syndrome, or retroperitoneal; 2) Fatal. CRNM was defined as acute clinically overt bleeding that did not satisfy the criteria for a major bleeding event and met at least 1 of the following: epistaxis, gastrointestinal bleed, hematuria, bruising/ecchymosis, or hemoptysis. Minor bleeding was defined as an acute clinically overt bleeding event that did not meet the criteria for major bleeding or a CRNM. Fatal bleeding event was defined as bleeding that was the primary (NCT00423319)
Timeframe: First dose of study drug (presurgery) through 2 days after the last dose of study drug

,
InterventionPercentage of events/patients evaluted (Number)
Major bleedingCRNMMajor or CRNMAny bleeding
Apixaban, 2.5 mg BID Plus Placebo0.824.084.8311.71
Enoxaparin, 40 mg QD Plus Placebo0.684.515.0412.56

Rates of Adjudicated All-cause Death, VTE-related Death, Pulmonary Embolism (PE), Nonfatal PE, Deep Vein Thrombosis (DVT) (Symptomatic and Asymptomatic), Symptomatic and Asymptomatic Proximal and Distal DVT During the Intended Treatment Period

VTE=venous thromboembolic event; VTE-related death=combination of fatal or nonfatal PE and symptomatic or asymptomatic DVT. Event rate=Number of events divided by the number of patients evaluated. (NCT00423319)
Timeframe: Day 1 (first dose of study drug) to later of 2 days after last dose or 38 days after first dose

,
InterventionPercentage of events/patients evaluated (Number)
All-cause deathVTE-related deathPE (fatal or nonfatal)Nonfatal PEAll DVT (n=1944, 1911)Symptomatic DVTAsymptomatic DVT (n=1943, 1907)Proximal DVT (n=2196, 2190)Distal DVT (1951, 1908)Symptomatic proximal DVTAsymptomatic proximal DVT (n=2195, 2187)Symptomatic distal DVTAsymptomatic distal DVT (n=1950, 1907)
Apixaban, 2.5 mg BID Plus Placebo0.110.040.110.071.130.041.080.321.030.040.270.040.97
Enoxaparin, 40 mg QD Plus Placebo0.040.000.190.193.560.193.300.912.990.150.730.042.94

Rates of Adjudicated Myocardial Infarction (MI)/Stroke, MI, Stroke, and Thrombocytopenia During the Intended Treatment Period

Event rate=Number of events divided by the number of patients evaluated. All suspected events were reported by investigator. Acute MI=the presence of a clinical situation (eg, abnormal history, physical examination, new electrocardiogram changes) suggestive of an MI and at least 1 of the following: elevated creatine kinase (CK)-MB or troponin T or troponin I ≥2*upper limit of normal (ULN); if CK-MB or troponin values not available, total CK ≥2*ULN; or new significant (≥0.04 sec) Q waves in ≥2 contiguous leads. Stroke=a new focal neurologic deficit of sudden onset lasting at least 24 hours that was not due to a readily identifiable nonvascular cause. Adjudication classified each reported stroke as primary hemorrhagic, nonhemorrhagic, infarction with hemorrhagic conversion, or unknown type. Thrombocytopenia=after 3 days as drop in platelet count to <100,000/mm^3 for patients with a baseline value >150,000/mm^3 or a >50% decline, if the baseline value was ≤150,000/mm^3. (NCT00423319)
Timeframe: Day 1 (first dose of study drug) to later of 2 days after last dose or 38 days after first dose

,
InterventionPercent of events/patients evaluated (Number)
MI/strokeMIStrokeThrombocytopenia
Apixaban, 2.5 mg BID Plus Placebo0.220.190.040.07
Enoxaparin, 40 mg QD Plus Placebo0.260.110.150.11

Number of Participants Who Died During Treatment Period

All cause death, as adjudicated by the VTE events committee (NCT00657150)
Timeframe: 28-35 days

InterventionParticipants (Number)
Dabigatran 220mg0
Enoxaparin1

Number of Participants With Major Venous Thromboembolic Event and Venous Thromboembolic Event-related Mortality During Treatment Period

Major Venous Thromboembolic Event (VTE) is defined as proximal DVT and PE, as adjudicated by the VTE events committee (NCT00657150)
Timeframe: 28-35 days

InterventionParticipants (Number)
Dabigatran 220mg18
Enoxaparin33

Number of Participants With Proximal Deep Vein Thrombosis During Treatment Period

Proximal Deep Vein Thrombosis as adjudicated by the VTE events committee (NCT00657150)
Timeframe: 28-35 days

InterventionParticipants (Number)
Dabigatran 220mg17
Enoxaparin31

Number of Participants With Pulmonary Embolism During Treatment Period

Pulmonary embolism confirmed by pulmonary V-Q scintigraphy, chest x-ray, pulmonary angiography, spiral CT or autopsy, and as adjudicated by the VTE events committee (NCT00657150)
Timeframe: 28-35 days

InterventionParticipants (Number)
Dabigatran 220mg1
Enoxaparin2

Number of Participants With Symptomatic Deep Vein Thrombosis During Treatment Period

Symptomatic Deep Vein Thrombosis, confirmed by venous duplex, ultrasound, venography or autopsy, and as adjudicated by the VTE events committee (NCT00657150)
Timeframe: 28-35 days

InterventionParticipants (Number)
Dabigatran 220mg0
Enoxaparin4

Number of Participants With Total Deep Vein Thrombosis During Treatment Period

Total Deep Vein Thrombosis as adjudicated by the VTE events committee (NCT00657150)
Timeframe: 28-35 days

InterventionParticipants (Number)
Dabigatran 220mg60
Enoxaparin67

Number of Participants With Total Venous Thromboembolic Event and All-cause Mortality During Treatment Period

"Total Venous Thromboembolic Event (VTE) includes both proximal and distal deep vein thrombosis (DVT) (detected by routine venography), symptomatic DVT (confirmed by venous duplex, ultrasound, venography or autopsy) and pulmonary embolism (PE) (confirmed by pulmonary V-Q scintigraphy, chest x-ray, pulmonary angiography, spiral CT or autopsy).~All of these components and all deaths were centrally adjudicated by the VTE events committee, which was not aware of the treatment allocation of the patients." (NCT00657150)
Timeframe: 28-35 days

InterventionParticipants (Number)
Dabigatran 220mg61
Enoxaparin69

Volume of Blood Loss

Volume of blood loss for treated and operated patients during surgery. (NCT00657150)
Timeframe: Day 1

InterventionmL (Mean)
Dabigatran 220mg404.9
Enoxaparin411.0

Blood Transfusion

Number of treated and operated patients with required blood transfusion on day of surgery. (NCT00657150)
Timeframe: Day 1

,
Interventionparticipants (Number)
Transfusions requiredMissing
Dabigatran 220mg2464
Enoxaparin2377

Laboratory Analyses

Frequency of patients with possible clinically significant abnormalities. (NCT00657150)
Timeframe: First administration to end of study

,
Interventionparticipants (Number)
AST increase N=(964;962)AST decrease N=(964;962)ALT increase N=(966;962)ALT decrease N=(966;962)Bilirubin increase N=(966;962)Bilirubin decrease N=(966;962)
Dabigatran 220mg28034030
Enoxaparin44067010

Number of Participants With Bleeding Events (Defined According to Modified McMaster Criteria) During Treatment Period

"Major bleeding events were defined as~fatal~clinically overt associated with loss of haemoglobin >=20g/L in excess of what was expected~clinically overt leading to the transfusion of >=2 units packed cells or whole blood in excess of what was expected~symptomatic retroperitoneal, intracranial, intraocular or intraspinal~requiring treatment cessation~leading to re-operation~Clinically-relevant was defined as~spontaneous skin hematoma >=25 cm²~wound hematoma >=100 cm²~spontaneous nose bleed >5 min~macroscopic hematuria spontaneous or >24 hours if associated with an intervention~spontaneous rectal bleeding~gingival bleeding >5 min~any other bleeding event considered clinically relevant by the investigator~Any bleeding events were defined as major, clinically-relevant and minor bleeding events. Minor bleeding events were defined as all other bleeding events that did not fulfil the criteria from above." (NCT00657150)
Timeframe: 28-35 days

,
InterventionParticipants (Number)
Major bleeding eventsMajor and clinically relevant bleeding eventsAny bleeding events
Dabigatran 220mg143798
Enoxaparin92983

Number of Participants With Total Venous Thromboembolic Event (VTE) and All-cause Mortality During the Follow-up Period

Total Venous Thromboembolic Event (VTE) includes both proximal and distal deep vein thrombosis (DVT) (detected by routine venography), symptomatic DVT (confirmed by venous duplex, ultrasound, venography or autopsy) and pulmonary embolism (PE) (confirmed by pulmonary V-Q scintigraphy, chest x-ray, pulmonary angiography, spiral CT or autopsy). (NCT00657150)
Timeframe: 3 months

,
InterventionParticipants (Number)
Total VTE and all-cause mortalityasymptomatic Deep Vein Thrombosissymptomatic Deep Vein ThrombosisPulmonary Embolismdeath
Dabigatran 220mg20110
Enoxaparin41021

Live Birth Rate = (Number of Live Births / Total Number of Pregnancies)

Live birth occurs when a fetus (> 24 weeks ) , exits the maternal body and subsequently shows signs of life, such as voluntary movement, heartbeat, or pulsation of the umbilical cord. (NCT01051778)
Timeframe: pregnancy > 24weeks gestation

InterventionPercentage of pregnancies (Number)
Enoxaparin 40 mg /Day Plus Low Dose Aspirin24
Heparin Calcium 5,000 U Twice Daily Plus Low Dose Aspirin20

Percentage of Participants With an Event for Net Clinical Benefit 1 During Observational Period

Net clinical benefit 1: composite of recurrent DVT or non-fatal or fatal PE, and major bleeding. Major bleeding was overt bleeding associated with 2 g/dL or greater fall in hemoglobin, leading to a transfusion of ≥2 units, occurring in a critical site or contributing to death. Net clinical benefit was considered greater in those participants with fewer composite events. All events were adjudicated and confirmed by a central independent adjudication committee blinded to treatment, based on either compression ultrasound, venography, spiral computed tomography scanning, pulmonary angiography, ventilation/perfusion lung scan, lung scintigraphy, autopsy or unexplained death for which DVT/PE could not be ruled out, results/films/images of confirmatory testing, and/or case summaries. (NCT00439777)
Timeframe: Up to 30 days after the last intake of study medication

InterventionPercentage of participants (Number)
Rivaroxaban (Xarelto, BAY59-7939)1.2
Enoxaparin/VKA1.2

Percentage of Participants With an Event for Net Clinical Benefit 1 Until the Intended End of Study Treatment

Net clinical benefit 1: composite of recurrent DVT or non-fatal or fatal PE, and major bleeding. Major bleeding was overt bleeding associated with 2 g/dL or greater fall in hemoglobin, leading to a transfusion of ≥2 units, occurring in a critical site or contributing to death. Net clinical benefit was considered greater in those participants with fewer composite events. All events were adjudicated and confirmed by a central independent adjudication committee blinded to treatment, based on either compression ultrasound, venography, spiral computed tomography scanning, pulmonary angiography, ventilation/perfusion lung scan, lung scintigraphy, autopsy or unexplained death for which DVT/PE could not be ruled out, results/films/images of confirmatory testing, and/or case summaries. (NCT00439777)
Timeframe: 3-, 6-, or 12-month study treatment period

InterventionPercentage of participants (Number)
Rivaroxaban (Xarelto, BAY59-7939)3.4
Enoxaparin/VKA4.0

Percentage of Participants With an Event for Net Clinical Benefit 2 During Observational Period

Net clinical benefit 2: composite of recurrent DVT or non-fatal or fatal PE, major bleeding (associated with 2 g/dL or greater fall in hemoglobin, leading to transfusion of ≥2 units, occurring in a critical site or contributing to death), cardiovascular death, myocardial infarction, stroke, and non CNS (central nervous system) systemic embolism. Net clinical benefit was considered greater in those participants with fewer composite events. All events were adjudicated and confirmed by a central independent adjudication committee blinded to treatment, based on either compression ultrasound (DVT), venography (DVT), spiral CT scanning (PE), pulmonary angiography (PE), ventilation/perfusion lung scan (PE), lung scintigraphy (PE), autopsy or unexplained death for which DVT/PE could not be ruled out, results/films/images of confirmatory testing, and/or case summaries. (NCT00439777)
Timeframe: Up to 30 days after the last intake of study medication

InterventionPercentage of participants (Number)
Rivaroxaban (Xarelto, BAY59-7939)1.5
Enoxaparin/VKA1.4

Percentage of Participants With an Event for Net Clinical Benefit 2 Until the Intended End of Study Treatment

Net clinical benefit 2: composite of recurrent DVT or non-fatal or fatal PE, major bleeding (associated with 2 g/dL or greater fall in hemoglobin, leading to transfusion of ≥2 units, occurring in a critical site or contributing to death), cardiovascular death, myocardial infarction, stroke, and non CNS (central nervous system) systemic embolism. Net clinical benefit was considered greater in those participants with fewer composite events. All events were adjudicated and confirmed by a central independent adjudication committee blinded to treatment, based on either compression ultrasound (DVT), venography (DVT), spiral CT scanning (PE), pulmonary angiography (PE), ventilation/perfusion lung scan (PE), lung scintigraphy (PE), autopsy or unexplained death for which DVT/PE could not be ruled out, results/films/images of confirmatory testing, and/or case summaries. (NCT00439777)
Timeframe: 3-, 6- or 12-month study treatment period

InterventionPercentage of participants (Number)
Rivaroxaban (Xarelto, BAY59-7939)4.5
Enoxaparin/VKA4.8

Percentage of Participants With Clinically Relevant Bleeding, Treatment-emergent (Time Window: Until 2 Days After Last Dose)

All events were adjudicated and confirmed by a central independent adjudication committee blinded to treatment. Clinically relevant bleeding included major bleeding (overt bleeding associated with 2 g/dL or greater fall in hemoglobin, leading to a transfusion of 2 or more units of packed red blood cells or whole blood, occurring in a critical site or contributing to death) and non-major bleeding associated with medical intervention, unscheduled physician contact, (temporary) cessation of study treatment, discomfort for the participants such as pain, or impairment of activities of daily life. (NCT00439777)
Timeframe: 3-, 6- or 12-month study treatment period

InterventionPercentage of participants (Number)
Rivaroxaban (Xarelto, BAY59-7939)10.3
Enoxaparin/VKA11.4

Percentage of Participants With Other Vascular Events, On-treatment (Time Window: Until 1 Day After Last Dose)

All pre-defined vascular events (ST segment elevation myocardial infarction, non ST segment elevation myocardial infarction, unstable angina, ischemic stroke, transient ischemic attack, non-central nervous system systemic embolism or vascular death) were adjudicated and confirmed by a central independent adjudication committee blinded to treatment. Events were assessed based results/films/images of confirmatory testing, and/or case summaries. (NCT00439777)
Timeframe: 3-, 6- or 12-month study treatment period

InterventionPercentage of participants (Number)
Rivaroxaban (Xarelto, BAY59-7939)1.5
Enoxaparin/VKA1.5

Percentage of Participants With Recurrent DVT During Observational Period

All events were adjudicated and confirmed by a central independent adjudication committee blinded to treatment. Events were assessed based on either compression ultrasound, venography, results/films/images of confirmatory testing, and/or case summaries. (NCT00439777)
Timeframe: Up to 30 days after the last intake of study medication

InterventionPercentage of participants (Number)
Rivaroxaban (Xarelto, BAY59-7939)0.3
Enoxaparin/VKA0.1

Percentage of Participants With Recurrent DVT Until the Intended End of Study Treatment

All events were adjudicated and confirmed by a central independent adjudication committee blinded to treatment. Events were assessed based on either compression ultrasound, venography, results/films/images of confirmatory testing, and/or case summaries. (NCT00439777)
Timeframe: 3-, 6- or 12-month study treatment period

InterventionPercentage of participants (Number)
Rivaroxaban (Xarelto, BAY59-7939)0.7
Enoxaparin/VKA0.8

Percentage of Participants With Recurrent PE Until the Intended End of Study Treatment

All events were adjudicated and confirmed by a central independent adjudication committee blinded to treatment. Events were assessed based on spiral computed tomography scanning, pulmonary angiography, ventilation/perfusion lung scan, lung scintigraphy, autopsy or unexplained death for which DVT/PE could not be ruled out, results/films/images of confirmatory testing, and/or case summaries. (NCT00439777)
Timeframe: 3-, 6- or 12-month study treatment period

InterventionPercentage of participants (Number)
Rivaroxaban (Xarelto, BAY59-7939)1.4
Enoxaparin/VKA1.2

Percentage of Participants With Symptomatic Recurrent Venous Thromboembolism [VTE] (i.e. the Composite of Recurrent Deep Vein Thrombosis [DVT] or Fatal or Non-fatal Pulmonary Embolism [PE]) Until the Intended End of Study Treatment

All events were adjudicated and confirmed by a central independent adjudication committee blinded to treatment. Events were assessed based on either compression ultrasound (for DVT), venography (for DVT), spiral computed tomography (CT) scanning (for PE), pulmonary angiography (for PE), ventilation/perfusion lung scan (for PE), lung scintigraphy (for PE), autopsy (for fatal PE) or unexplained death for which DVT/PE could not be ruled out (for fatal PE), and/or case summaries. (NCT00439777)
Timeframe: 3-, 6-, or 12-month study treatment period

InterventionPercentage of participants (Number)
Rivaroxaban (Xarelto, BAY59-7939)2.1
Enoxaparin/VKA1.8

Percentage of Participants With Symptomatic Recurrent VTE (i.e. the Composite of Recurrent DVT or Fatal or Non-fatal PE) During Observational Period

All events were adjudicated and confirmed by a central independent adjudication committee blinded to treatment. Events were assessed based on either compression ultrasound (for DVT), venography (for DVT), spiral computed tomography (CT) scanning (for PE), pulmonary angiography (for PE), ventilation/perfusion lung scan (for PE), lung scintigraphy (for PE), autopsy (for fatal PE) or unexplained death for which DVT/PE could not be ruled out (for fatal PE), and/or case summaries. (NCT00439777)
Timeframe: Up to 30 days after the last intake of study medication

InterventionPercentage of participants (Number)
Rivaroxaban (Xarelto, BAY59-7939)0.9
Enoxaparin/VKA0.7

Percentage of Participants With the Composite Variable Comprising Recurrent DVT, Non-fatal PE and All Cause Mortality During Observational Period

All events were adjudicated and confirmed by a central independent adjudication committee blinded to treatment. Events were assessed based on either compression ultrasound (for DVT), venography (for DVT), spiral computed tomography (CT) scanning (for PE), pulmonary angiography (for PE), ventilation/perfusion lung scan (for PE), lung scintigraphy (for PE), autopsy (for deaths), results/films/images of confirmatory testing, and/or case summaries. (NCT00439777)
Timeframe: Up to 30 days after the last intake of study medication

InterventionPercentage of participants (Number)
Rivaroxaban (Xarelto, BAY59-7939)2.1
Enoxaparin/VKA1.5

Percentage of Participants With the Composite Variable Comprising Recurrent DVT, Non-fatal PE and All Cause Mortality Until the Intended End of Study Treatment

All events were adjudicated and confirmed by a central independent adjudication committee blinded to treatment. Events were assessed based on either compression ultrasound (for DVT), venography (for DVT), spiral computed tomography (CT) scanning (for PE), pulmonary angiography (for PE), ventilation/perfusion lung scan (for PE), lung scintigraphy (for PE), autopsy (for deaths), results/films/images of confirmatory testing, and/or case summaries. (NCT00439777)
Timeframe: 3-, 6-, or 12-month study treatment period

InterventionPercentage of participants (Number)
Rivaroxaban (Xarelto, BAY59-7939)4.0
Enoxaparin/VKA3.4

Percentage of Participants With All Deaths

All events were adjudicated and confirmed by a central independent adjudication committee blinded to treatment. Events were assessed based on either autopsy, results/films/images of confirmatory testing, and/or case summaries. (NCT00439777)
Timeframe: 3-, 6- or 12-month study treatment period

,
InterventionPercentage of participants (Number)
All post-randomizationTreatment-emergent (time window: 2 days)Treatment-emergent (time window: 7 days)
Enoxaparin/VKA2.10.81.1
Rivaroxaban (Xarelto, BAY59-7939)2.61.21.5

Percentage of Participants With the Individual Components of Efficacy Outcomes During Observational Period

All events were adjudicated and confirmed by a central independent adjudication committee blinded to treatment, based on either compression ultrasound, venography, spiral computed tomography scanning, pulmonary angiography, ventilation/perfusion lung scan, lung scintigraphy, autopsy or unexplained death for which DVT/PE could not be ruled out, results/films/images of confirmatory testing, and/or case summaries. Major bleeding was overt bleeding associated with 2 g/dL or greater fall in hemoglobin, leading to a transfusion of ≥2 units, occurring in a critical site or contributing to death. (NCT00439777)
Timeframe: Up to 30 days after the last intake of study medication

,
InterventionPercentage of participants (Number)
Death (PE)Death (PE cannot be excluded)Symptomatic PE and DVTSymptomatic recurrent PE onlySymptomatic recurrent DVT onlyDeath (bleeding)Death (cardiovascular)Death (other)Major bleeding
Enoxaparin/VKA00.0500.50.10.090.050.70.5
Rivaroxaban (Xarelto, BAY59-7939)0.0900.090.50.20.090.30.80.3

Percentage of Participants With the Individual Components of Efficacy Outcomes Until the Intended End of Study Treatment

All events were adjudicated and confirmed by a central independent adjudication committee blinded to treatment, based on either compression ultrasound, venography, spiral computed tomography scanning, pulmonary angiography, ventilation/perfusion lung scan, lung scintigraphy, autopsy or unexplained death for which DVT/PE could not be ruled out, results/films/images of confirmatory testing, and/or case summaries. Major bleeding was overt bleeding associated with 2 g/dL or greater fall in hemoglobin, leading to a transfusion of ≥2 units, occurring in a critical site or contributing to death. (NCT00439777)
Timeframe: 3-, 6- or 12-month study treatment period

,
InterventionPercentage of participants (Number)
Death (PE)Death (PE cannot be excluded)Symptomatic PE and DVTSymptomatic recurrent PE onlySymptomatic recurrent DVT onlyDeath (bleeding)Death (cardiovascular)Death (other)Major bleeding
Enoxaparin/VKA0.040.20.10.80.70.20.11.52.4
Rivaroxaban (Xarelto, BAY59-7939)0.10.30.01.00.70.20.41.31.4

Rate of Adjudicated Proximal Deep Vein Thrombosis (DVT), Nonfatal Pulmonary Embolism, and Venous Thromboembolic Event-related Death With Onset During the Intended Treatment Period

Event rate=Number of events divided by the number of patients evaluated. Intended treatment period starts on the day of randomization, and for those who received study drug, ends at the later of 2 days after last dose or 14 days after the first dose of study drug; for randomized patients who did not receive study drug, the period ends 14 days after randomization; for randomized patients who did not receive study drug, the period ends 14 days after randomization. Venous thromboembolic event (VTE)=nonfatal pulmonary embolism (PE), symptomatic DVT, or asymptomatic proximal DVT detected by ultrasound. VTE-related death=fatal PE or sudden death for which VTE could not be excluded as a cause. (NCT00452530)
Timeframe: Day of randomization to later of 2 days after last dose or 14 days after first dose; 14 days after randomization for those who did not receive study

InterventionPercentage of events/patients evaluated (Number)
Apixaban, 2.5 mg BID + Placebo1.09
Enoxaparin, 40 mg QD + Placebo2.17

Rate of Adjudicated Venous Thromboembolic Event-related and All-cause Deaths With Onset During the Intended-treatment Period

Event rate=Number of events divided by the number of patients evaluated. Intended treatment period starts on the day of randomization, and for those who received study drug, ends at the later of 2 days after last dose or 14 days after the first dose of study drug; for randomized patients who did not receive study drug, the period ends 14 days after randomization.Venous thromboembolic event (VTE)=nonfatal pulmonary embolism (PE), symptomatic deep vein thrombosis (DVT), or asymptomatic proximal DVT detected by ultrasound. VTE-related death=fatal PE or sudden death for which VTE could not be excluded as a cause. (NCT00452530)
Timeframe: Day of randomization to later of 2 days after last dose or 14 days after first dose; 14 days after randomization for those who did not receive study drug

InterventionPercentage of events/patients evaluated (Number)
Apixaban, 2.5 mg BID15.06
Enoxaparin, 40 mg QD24.37

Number of Participants With Serious Adverse Events (SAE), Bleeding Adverse Events (AEs), Discontinuations Due to AEs, and Death as Outcome

AE=any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that may not have a causal relationship with treatment. SAE=a medical event that at any dose results in death, persistent or significant disability/incapacity, or drug dependency/abuse; is life-threatening, an important medical event, or a congenital anomaly/birth defect; or requires or prolongs hospitalization. Bleeding AEs=all serious or nonserious bleeding-related AEs. (NCT00452530)
Timeframe: Days 1 through 12 + 2 days (nonserious AEs, bleeding AES) or 30 days (SAES, deaths) after last dose of study drug

,
InterventionParticipants (Number)
SAEBleeding AEDiscontinuations due to AEsDeaths
Apixaban, 2.5 mg BID + Placebo7290402
Enoxaparin, 40 mg QD + Placebo88112440

Rate of Major Bleeding, Clinically Relevant Nonmajor Bleeding (CRNM), and Major Bleeding or CRNM

Event rate=Number of events divided by number of patients evaluated. Adjusted difference of event rates takes into consideration type of surgery as a stratification factor. Bleeding Criteria: Major bleeding=an event consisting of clinically overt bleeding accompanied by a decrease in hemoglobin of 2 g/dL or more and/or a transfusion of 2 or more units of packed red blood cells; bleeding that occurred in at least 1 of the following critical sites: intracranial, intraspinal, intraocular (within the corpus of the eye; a conjunctival bleed is not an intraocular bleed), pericardial, intra-articular, intramuscular with compartment syndrome, and retroperitoneal; bleeding that was fatal. CRNM bleeding= clinically overt bleeding; that satisfies none of the additional criteria required for the event to be adjudicated as a major bleeding event; that led to either hospital admission for bleeding, physician-guided medical or surgical treatment for bleeding; or a change in antithrombic treatment. (NCT00452530)
Timeframe: Days 1 to 12

,
InterventionPercentage of events/patients evaluated (Number)
Major bleeding (n=9, 14)CRNM (n=44, 58)Major bleeding or CRNM (n=53, 72)Any bleeding
Apixaban, 2.5 mg BID + Placebo0.602.933.536.93
Enoxaparin, 40 mg QD + Placebo0.933.854.778.36

Summary of Laboratory Marked Abnormalities in Electrolyte and Other Clinical Test Results During the Treatment Period (Patients With Available Measurements)

preRX=pretreatment; LLN=lower limit of normal; ULN=upper limit of normal. Calcium, total (mg/dL): <0.8*LLN or >1.2*ULN, or if preRxULN if preRx >ULN use >1.25*preRx or 1.1*ULN, or if preRxULN if preRx>ULN use >1.1*preRx or 1.25*ULN, or if preRx < LLN use <0.75*preRx or >ULN if preRx >ULN use >1.25*preRx or < LLN; potassium, serum (mEq/L): <0.9* LLN or >1.1*ULN, or if preRxULN if preRx>ULN use >1.1*preRx or 1.05*ULN, or if preRx ULN if preRx>ULN use >1.05*preRx or 1.1*ULN, or if preRx ULN if preRx >ULN use 1.1*preRx or 5*ULN; uric acid (mg/dL): >1.5*ULN, or if preRx >ULN use >2*preRx; glucose, fasting serum (mg/dL): <0.8*LLN or >1.5*ULN, or if preRx ULN. (NCT00452530)
Timeframe: Randomization to Days 2, 3, 4, and 12 (±2 days) and at Days 42 and 72 (±5 days) of follow-up

,
InterventionParticipants (Number)
Calcium, total (low) (n=1447, 1457)Chloride, serum (low)(n=1442, 1454)Bicarbonate (low) (n=1435, 1447)Potassium, serum (low) (n=1438, 1453)Potassium, serum (high)(n=1438, 1453)Sodium, serum (low) (n=1442, 1454)Sodium, serum (high) (n=1442, 1454)Glucose, fasting serum (low) (n=715, 713)Glucose, fasting serum (high) (n=715, 713)Protein, total (low) (n=1447, 1457Creatine kinase (CK) (high) (n=1463, 1476)Uric acid (high) (n=1446, 1458)
Apixaban, 2.5 mg BID + Placebo510383451846223661
Enoxaparin, 40 mg QD + Placebo9034140100125243652

Summary of Laboratory Marked Abnormalities in Urinalysis Results During the Treatment Period-Treated Subjects With Available Measurements (Urinalysis)

preRX=pretreatment. Blood, urine: If missing preRx use ≥2, or if value ≥4, or if preRx=0 or 0.5 use ≥2, or if preRx=1 use ≥3, or if preRx=2 or 3 use ≥4; glucose, urine: If missing preRx use ≥2, or if value ≥4, or if preRx=0 or 0.5 use ≥2, or if preRx=1 use ≥3, or if preRx=2 or 3 use ≥4; protein, urine: If missing preRx use ≥ 2, or if value ≥4, or if preRx=0 or 0.5 use ≥2, or if preRx=1 use ≥3, or if preRx=2 or 3 use ≥4; Red blood cells , urine: If missing preRx use ≥2, or if value ≥4, or if preRx=0 or 0.5 use ≥2, or if preRx=1 use ≥3, or if preRx=2 or 3 use ≥4; white blood cells, urine: If missing preRx use ≥2, or if value ≥4, or if preRx=0 or 0.5 use ≥2, or if preRx=1 use ≥3, or if preRx=2 or 3 use ≥4. (NCT00452530)
Timeframe: Randomization to Days 2, 3, 4, and 12 (±2 days) and at Days 42 and 72 (± 5 days) of follow-up

,
InterventionParticipants (Number)
Blood, urine (high) (n=1421, 1430)Glucose, urine (high) (n=1421, 1429)Protein, urine (high) (n=1421, 1430)Red blood cells, urine (high) (n=441, 385)White blood cells, urine (high)(n=441, 386)
Apixaban, 2.5 mg BID + Placebo16916060133101
Enoxaparin, 40 mg QD + Placebo11315489116102

Summary of Laboratory Marked Abnormalities on Hematology and Liver and Kidney Function Test Results During the Treatment Period (Patients With Available Measurements)

preRX=pretreatment; LLN=lower limit of normal; ULN=upper limit of normal; abs=absolute. Hemoglobin (g/dL): >2 decrease from preRx value or value <=8; hematocrit (%): <0.75*preRx; platelets: <100*10^9 cells/L; erythrocytes (*10^6 cells/μL): <0.75*preRx; leukocytes: <0.75*LLN or >1.25*ULN, or if preRx ULN if preRx >ULN use >1.2*preRx or 400/mm^3; abs eosinophils: > 0.750*10^3 cells/µL; abs lymphocytes: <0.750*10*3 cells/ µL or >7.50*10^3 c/ µL; abs monocytes > 2000/mm^3; abs neutrophils: <1.0*10^3 cells/μL; ALP (U/L): >2*ULN; ALT, AST (U/L): >3*ULN; U/L; bilirubin, direct (mg/dL): >1.5*ULN; bilirubin, total (mg/dL): >2*ULN; BUN (mg/dL): >2*ULN; creatinine (mg/dL): >1.5*ULN. (NCT00452530)
Timeframe: Randomization to Days 2, 3, 4, and 12 (±2 days) and at Days 42 and 72 (±5 days) of follow-up

,
InterventionParticipants (Number)
Hemoglobin, low (n=1424, 1442)Hematocrit, low n=(1369, 1396)Platelet count, low (n=1413, 1425)Erythrocytes, low (n=1368, 1396)Leukocytes, low (n=1457, 1471)Leukocytes, high (n=1457, 1471)Basophils (absolute), high (n=1448, 1465)Eosinophils (absolute), high (n=1448, 1465)Lymphocytes (absolute), low (n=1448, 1465)Lymphocytes (absolute), high (n=1448, 1465)Monocytes (absolute), high (n=1448, 1465)Neutrophils (absolute), low (n=1448, 1465)Alkaline phosphatase (ALP), high (n=1465, 1476)Alanine aminotransferase (ALT), high (n=1459,1472)Aspartate aminotransferase (AST) , high (n=1459,14Bilirubin, direct (high) (n=1447,1457)Bilirubin, total (high) (n=1461,1476)Blood urea nitrogen (BUN) (high)(n=1447,1458)Creatinine (high) (n=1447,1458)
Apixaban, 2.5 mg BID + Placebo112766876902719324320315515323487151517
Enoxaparin, 40 mg QD + Placebo11787235735262134602150223126267691723

Death

All-cause mortality (NCT00413374)
Timeframe: 30 Days

InterventionParticipants (Count of Participants)
Enoxaparin 1.5 mg/kg Once Daily0
Enoxaparin 1 mg/kg Twice Daily0

Major Bleeding Complication

Major bleeding complication as defined as spinal, retroperitoneal, or intracranial bleeding; drop in hemoglobin ≥2g/dl or transfusion ≥2U or surgical or medical intervention, death related to bleeding. (NCT00413374)
Timeframe: 30 Days

Interventionparticipants (Number)
Enoxaparin 1.5 mg/kg Daily0
Enoxaparin 1 mg/kg Twice Daily3

Recurrent VTE

Major clotting complication (recurrent VTE) as defined as recurrent acute pulmonary embolism confirmed on chest CT or recurrent deep vein thrombosis in the contralateral extremity confirmed with venous ultrasound or CT scan while on once daily enoxaparin therapy. (NCT00413374)
Timeframe: 30 Days

Interventionparticipants (Number)
Enoxaparin 1.5 mg/kg Daily1
Enoxaparin 1 mg/kg Twice Daily3

All-Cause Mortality Through 1 Year

All-cause mortality through 1 year from randomization. (NCT00046228)
Timeframe: 1 year

Interventionparticipants (Number)
Primary PCI Group56
Abciximab Facilitated PCI Group60
Reteplase/Abciximab Facilitated PCI Group52

All-Cause Mortality Through 90 Days

All cause mortality occurred through 90 days from randomization. (NCT00046228)
Timeframe: 90 days

Interventionparticipants (Number)
Primary PCI Group36
Abciximab Facilitated PCI Group45
Reteplase/Abciximab Facilitated PCI Group43

Complications of MI as Defined in the Primary Outcome Measure Through 90 Days

The complications of myocardial infarction (MI) is defined as any event of rehospitalization or emergency department visit for CHF, cardiogenic shock, or resuscitated ventricular fibrillation occurring > 48 hours after randomization. (NCT00046228)
Timeframe: 90 Days

Interventionparticipants (Number)
Primary PCI Group72
Abciximab Facilitated PCI Group61
Reteplase/Abciximab Facilitated PCI Group61

Subjects With Any Investigator Reported Bleeding Events Through Discharge/Day 7

(NCT00046228)
Timeframe: Discharge/Day 7

Interventionparticipants (Number)
Primary PCI Group139
Abciximab Facilitated PCI Group178
Reteplase/Abciximab Facilitated PCI Group271

Subjects With Intracranial Hemorrhage (Including Hemorrhagic Transformation) Through Discharge/Day 7

All cases of cerebrovascular event were confirmed by a CEC (Clinical Endpoints Committee). (NCT00046228)
Timeframe: Discharge/Day 7

Interventionparticipants (Number)
Primary PCI Group1
Abciximab Facilitated PCI Group0
Reteplase/Abciximab Facilitated PCI Group5

Subjects With Non Intracranial Thrombolysis In Myocardial Infarction (TIMI) Bleeding Events Through Discharge/Day 7

Subjects with nonintracranial TIMI bleeding (either major or minor) through discharge/day 7, originating from vascular instrumentation sites, non-instrument related bleeding, as well as overall, were examined. (NCT00046228)
Timeframe: Discharge/Day 7

Interventionparticipant (Number)
Primary PCI Group55
Abciximab Facilitated PCI Group81
Reteplase/Abciximab Facilitated PCI Group118

Subjects With Pre-Specified Complications of Index Myocardial Infarction Through Discharge/Day 7

Number of subjects with one or more of the following: 2nd or 3rd Degree AVB, Asystole, Sustained V Tach, A Fib/Flutter, EMD/Pulseless Electrical Activity, Heart Failure, Tamponade, Myocardial Rupture, Papillary Muscle Rupture, Ventricular Septal Defect, Pulmonary Embolism, Systemic Arterial Embolism and/or Pericarditis/Pericardial Effusion. (NCT00046228)
Timeframe: Discharge/Day 7

Interventionparticipants (Number)
Primary PCI Group128
Abciximab Facilitated PCI Group122
Reteplase/Abciximab Facilitated PCI Group120

Subjects With Severe Thrombocytopenia Through Discharge/Day 7

Severe thrombocytopenia is defined as platelet count < 50,000 cells/μL. (NCT00046228)
Timeframe: Discharge/Day 7

Interventionparticipants (Number)
Primary PCI Group11
Abciximab Facilitated PCI Group16
Reteplase/Abciximab Facilitated PCI Group16

Subjects With ST-Segment Resolution > 70% From Baseline at 60 to 90 Minutes Following Randomization

(NCT00046228)
Timeframe: 60 to 90 minutes

Interventionparticipants (Number)
Primary PCI Group75
Abciximab Facilitated PCI Group85
Reteplase/Abciximab Facilitated PCI Group108

The Composite of All-Cause Mortality or Complications of MI at 90 Days.

Occurs within 90 days and is composite of all-cause mortality or complications of myocardial infarction (MI) (rehospitalization or emergency department visit for congestive heart failure (CHF), cardiogenic shock, or resuscitated ventricular fibrillation occurring > 48 hours after randomization). (NCT00046228)
Timeframe: 90 days

Interventionparticipants (Number)
Primary PCI Group86
Abciximab Facilitated PCI Group86
Reteplase/Abciximab Facilitated PCI Group81

AM-PAC Score to Measure Patients Fitness for Discharge

AM-PAC (activity measure for post-acute care) will be used to determine if a patient is fit to discharge based on mobility with 6 being unable to mobilize up to 24 being independent. Patients who scored above 20 were considered fit to discharge. (NCT03303794)
Timeframe: Post-Operation Day 1

Interventionscore on scale (Mean)
Bupivicaine23
Bupivicaine + Exparel23

Opioid Consumption During the First 48 Hours After TKA Surgery

Monitor how much opioid patient consumes (NCT03303794)
Timeframe: During the first 48 hours after surgery

Interventionmilligram (Mean)
Bupivicaine90
Bupivicaine + Exparel76

Pain Scores During 48 Hrs Postoperatively

Will use Numeric Pain Rating Scale (NPRS) to measure pain with 0 being no pain and 10 being the worst pain. (NCT03303794)
Timeframe: 48 hours postoperatively

Interventionscore on scale (Mean)
Bupivicaine4
Bupivicaine + Exparel4

Death During Treatment Period

All cause death, as adjudicated by the VTE events committee (NCT00168818)
Timeframe: First administration until 31-38 days

InterventionParticipants (Number)
Dabigatran 220mg3
Dabigatran 150mg3
Enoxaparin0

Major Venous Thromboembolic Event and Venous Thromboembolic Event-related Mortality During Treatment Period

Major Venous Thromboembolic Event (VTE) is defined as proximal DVT and PE, as adjudicated by the VTE events committee (NCT00168818)
Timeframe: First administration until 31-38 days

InterventionParticipants (Number)
Dabigatran 220mg28
Dabigatran 150mg38
Enoxaparin36

Proximal Deep Vein Thrombosis During Treatment Period

Proximal Deep Vein Thrombosis as adjudicated by the VTE events committee (NCT00168818)
Timeframe: First administration until 31-38 days

InterventionParticipants (Number)
Dabigatran 220mg23
Dabigatran 150mg35
Enoxaparin33

Pulmonary Embolism During Treatment Period

Pulmonary embolism confirmed by pulmonary V-Q scintigraphy, chest x-ray, pulmonary angiography, spiral CT or autopsy, and as adjudicated by the VTE events committee (NCT00168818)
Timeframe: First administration until 31-38 days

InterventionParticipants (Number)
Dabigatran 220mg5
Dabigatran 150mg1
Enoxaparin3

Symptomatic Deep Vein Thrombosis During Treatment Period

Symptomatic Deep Vein Thrombosis, confirmed by venous compression ultrasound, venography or autopsy, and as adjudicated by the VTE events committee (NCT00168818)
Timeframe: First administration until 31-38 days

InterventionParticipants (Number)
Dabigatran 220mg6
Dabigatran 150mg9
Enoxaparin1

Total Deep Vein Thrombosis During Treatment Period

Total Deep Vein Thrombosis as adjudicated by the VTE events committee (NCT00168818)
Timeframe: First administration until 31-38 days

InterventionParticipants (Number)
Dabigatran 220mg46
Dabigatran 150mg72
Enoxaparin57

Total Venous Thromboembolic Event and All-cause Mortality During Treatment Period

"Total Venous Thromboembolic Event (VTE) includes both proximal and distal deep vein thrombosis (DVT) (detected by routine bilateral venography), symptomatic DVT (confirmed by venous compression ultrasound, venography or autopsy) and pulmonary embolism (PE) (confirmed by pulmonary V-Q scintigraphy, chest x-ray, pulmonary angiography, spiral CT or autopsy).~All of these components and all deaths were centrally adjudicated by the VTE events committee, which was not aware of the treatment allocation of the patients." (NCT00168818)
Timeframe: First administration until 31-38 days

InterventionParticipants (Number)
Dabigatran 220mg53
Dabigatran 150mg75
Enoxaparin60

Volume of Blood Loss

Volume of blood loss for treated and operated patients during surgery. (NCT00168818)
Timeframe: Day 1

InterventionmL (Mean)
Dabigatran 220mg457
Dabigatran 150mg435
Enoxaparin463

Blood Transfusion

Blood transfusion for treated and operated patients on Day of surgery. (NCT00168818)
Timeframe: Day 1

,,
Interventionparticipants (Number)
Patients with >=1 transfusionsPatients with >=1 non-autologous transfusions
Dabigatran 150mg531266
Dabigatran 220mg517259
Enoxaparin542286

Laboratory Analyses

Frequency of patients with possible clinically significant abnormalities. (NCT00168818)
Timeframe: First administration to end of study

,,
Interventionparticipants (Number)
AST increase N=(1103;1097;1103)AST decrease N=(1103;1097;1103)ALT increase N=(1103;1098;1103)ALT decrease N=(1103;1098;1103)Bilirubin increase N=(1102;1094;1102)Bilirubin decrease N=(1102;1094;1102)
Dabigatran 150mg160290240
Dabigatran 220mg110280250
Enoxaparin290590340

Number of Participants With Bleeding Events (Defined According to Modified McMaster Criteria) During Treatment Period

"Major bleeding events were defined as~fatal~clinically overt associated with loss of haemoglobin >=20g/L in excess of what was expected~clinically overt leading to the transfusion of >=2 units packed cells or whole blood in excess of what was expected~symptomatic retroperitoneal, intracranial, intraocular or intraspinal~requiring treatment cessation~leading to re-operation~Clinically-relevant was defined as~spontaneous skin hematoma greater than or equal to 25 cm²~wound hematoma greater than or equal to 100 cm²~spontaneous nose bleed lasting longer than 5 min~macroscopic hematuria spontaneous or lasting longer than 24 hours if associated with an intervention~spontaneous rectal bleeding (more than a spot on toilet paper)~gingival bleeding lasting longer than 5 min~any other bleeding event considered clinically relevant by the investigator~Minor bleeding events were defined as all other bleeding events that did not fulfil the criteria from above." (NCT00168818)
Timeframe: First administration until 31-38 days

,,
InterventionParticipants (Number)
MajorClinical relevantMinorNone
Dabigatran 150mg1555721021
Dabigatran 220mg2348701005
Enoxaparin1840741022

Total Venous Thromboembolic Event (VTE) and All-cause Mortality During the Follow-up Period

Total Venous Thromboembolic Event (VTE) includes both proximal and distal deep vein thrombosis (DVT) (detected by routine bilateral venography), symptomatic DVT (confirmed by venous compression ultrasound, venography or autopsy) and pulmonary embolism (PE) (confirmed by pulmonary V-Q scintigraphy, chest x-ray, pulmonary angiography, spiral CT or autopsy). (NCT00168818)
Timeframe: end of treatment to day 91±7

,,
InterventionParticipants (Number)
Total VTE and all-cause mortalityasymptotic Deep Vein Thrombosissymptotic Deep Vein ThrombosisPulmonary Embolismdeath
Dabigatran 150mg41102
Dabigatran 220mg10100
Enoxaparin53011

Peak Venous Velocity

Ultrasound of the venous system just below the saphenofemoral junction to assess the venous velocity will be taken before and after application the VenaFlow and the ActiveCare+S.F.T pneumatic compression devices. Change from Baseline in Peak Venous Velocity 30 minutes after Device is applied is recorded. (NCT02345642)
Timeframe: Change from Baseline in Peak Venous Velocity 30 minutes after Device is Applied

,
Interventioncm/s (Mean)
Delta PVV from before to after Venaflow (Standing)Delta PVV from before to after Venaflow (Supine)delta PVV from before to after Activeca (Standing)delta PVV from before to after Activecare (supine)
10 Healthy Patients Without THA127.987.132.640.5
10 Patients With THA on Post-Op Day 2155.786.841.937.8

Increased Bleeding Attributed to Fondaparinux

Coagulopathic bleeding due to fondaparinux was suspected in patients requiring packed red cell transfusions after initiation of fondaparinux therapy only if the change in hematocrit prompting transfusion was not clinically commensurate with the degree of injuries that the patient had sustained (primarily orthopaedic) and/or the hematocrit did not respond appropriately post-transfusion. (NCT00531843)
Timeframe: 3 weeks post injury

Interventionparticipants (Number)
Fondaparinux Sodium0

Normal Trough and Peak Fondaparinux Concentration

Serum samples were collected 30 minutes before (trough) and 2 hours after (peak) the third dose of fondaparinux. Normative data plots comparing study participants with healthy volunteers were supplied by the company outsourced to analyze samples. (NCT00531843)
Timeframe: Day 3

InterventionParticipants (Number)
Trough values outside normative rangePeak values outside normative range
Fondaparinux Sodium00

Presence of Deep Vein Thrombosis (DVT) or Pulmonary Embolus (PE)

Color-flow duplex venous ultrasonography examinations of upper and lower extremities were performed within 48 hours of injury, and then weekly until discharge or 3 weeks. DVT was defined as any clot occurring in the subclavian, iliac, femoral, or popliteal location. Patients were examined daily for clinical signs and symptoms of venous thromboembolism (VTE) and PE. Small, nonocclusive clots discovered in other locations were observed for progression on sequential ultrasonography examinations. (NCT00531843)
Timeframe: within 3 weeks post injury

,
Interventionparticipants (Number)
DVTDVT after fondaparinuxPE
Fondaparinux Sodium210
No Fondaparinux2NA0

Maintenance Dose of Dalteparin Required to Achieve Prespecified Therapeutic Anti- Factor Xa Levels

Prespecified therapeutic anti-factor Xa level was 0.5-1.0 IU/mL. Cumulative data for day 1 to 7 has been reported. (NCT00952380)
Timeframe: 4 hours post-dose at each Day 1 to 7 in dose adjustment phase

InterventionIU/kg (Mean)
Dalteparin Sodium: Group 2 (>=8 Weeks to <2 Years)207.50
Dalteparin Sodium: Group 3 (>=2 Years to <8 Years)141.85
Dalteparin Sodium: Group 4 (>=8 Years to <12 Years)132.40
Dalteparin Sodium: Group 5 (>=12 Years to <19 Years)115.06

Median Dose of Dalteparin Required to Achieve Prespecified Therapeutic Anti- Factor Xa Level

Prespecified therapeutic anti-factor Xa level was 0.5-1.0 international unit per milliliter (IU/mL). Cumulative data of Day 1 to 7 has been reported. (NCT00952380)
Timeframe: 4 hours post-dose at each Day 1 to 7 in dose adjustment phase

InterventionIU/mL (Median)
Dalteparin Sodium: All Participants (>= 0 to < 19 Years)125

Number of Dose Adjustments Required to Achieve Prespecified Therapeutic Anti-Xa Levels

During dose adjustment phase, doses were adjusted according to prespecified therapeutic anti-Xa levels in order to achieve target prespecified therapeutic anti-factor Xa levels (0.5 to 1.0 IU/mL). Number of dose adjustments which were done within the specified time window of up to 4 hours post dose on all days (1 to 7) to achieve the prespecified therapeutic anti-Xa levels are reported. (NCT00952380)
Timeframe: 4 hours post-dose at each Day 1 to 7 in dose adjustment phase

Interventiondose adjustment (Median)
Dalteparin Sodium: Group 2 (>=8 Weeks to <2 Years)3.5
Dalteparin Sodium: Group 3 (>=2 Years to <8 Years)0.5
Dalteparin Sodium: Group 4 (>=8 Years to <12 Years)0.0
Dalteparin Sodium: Group 5 (>=12 Years to <19 Years)0.0

Number of Participants With Laboratory Abnormalities

Criteria:hematology:hemoglobin, hematocrit, erythrocytes less than(<)0.8*lower limit of normal(LLN), platelets <0.5*LLN >1.75*upper limit of normal (ULN),leukocytes <0.6* LLN >1.5* ULN, lymphocytes, lymphocytes/Leukocytes, neutrophils, neutrophils/leukocytes <0.8* LLN >1.2* ULN, basophils, basophils/leukocytes, eosinophils, eosinophils/leukocytes monocytes monocytes/leukocytes >1.2*ULN, activated partial thromboplastin time, prothrombin time, prothrombin international normalized ratio >1.1* ULN. Clinical chemistry: bilirubin >1.5*ULN, aspartate aminotransferase, alanine aminotransferase, lactate dehydrogenase, alkaline phosphatase >3.0*ULN, protein, albumin <0.8* LLN >1.2* ULN, blood urea nitrogen, creatinine >1.3* ULN, sodium <0.95*LLN >1.05*ULN, potassium, chloride, calcium, magnesium <0.9* LLN >1.1* ULN, phosphate <0.8* LLN >1.2* ULN, glucose <0.6*LLN >1.5*ULN, estimated(est) creatinine clearance, est GFR modified and bedside schwartz, >1.0* ULN. Urinalysis: creatinine >1.0*ULN. (NCT00952380)
Timeframe: Baseline up to 104 days

InterventionParticipants (Count of Participants)
Dalteparin Sodium: Group 1 (>=0 to <8 Weeks)1
Dalteparin Sodium: Group 2 (>=8 Weeks to <2 Years)2
Dalteparin Sodium: Group 3 (>=2 Years to <8 Years)8
Dalteparin Sodium: Group 4 (>=8 Years to <12 Years)5
Dalteparin Sodium: Group 5 (>=12 Years to <19 Years)19

Number of Participants With New or Progressive Symptomatic Venous Thromboembolism (VTE)

Symptomatic VTE defined as new or progressive signs and symptoms as judged by the investigator including but not limited to: objective swelling, pain or tenderness, pitting edema, erythema or cyanosis. Progression of VTE: Progression of clot burden in terms of severity of occlusion, or involvement of new venous segments at any time after the initial diagnosis. (NCT00952380)
Timeframe: Baseline up to 28 days after the last dose of study drug (up to Day 132)

InterventionParticipants (Count of Participants)
Dalteparin Sodium: Group 2 (>=8 Weeks to <2 Years)0
Dalteparin Sodium: Group 3 (>=2 Years to <8 Years)0
Dalteparin Sodium: Group 4 (>=8 Years to <12 Years)1
Dalteparin Sodium: Group 5 (>=12 Years to <19 Years)0

Percentage of Participants Who Achieved Prespecified Therapeutic Anti- Factor Xa Levels

Prespecified therapeutic anti-factor Xa level was 0.5-1.0 IU/mL. Percentage of participants who achieved the prespecified level during the dose adjustment phase were reported in this outcome measure. (NCT00952380)
Timeframe: Day 1 to 7 in dose adjustment phase

Interventionpercentage of participants (Number)
Dalteparin Sodium: Group 1 (>=0 to <8 Weeks)0
Dalteparin Sodium: Group 2 (>=8 Weeks to <2 Years)100.0
Dalteparin Sodium: Group 3 (>=2 Years to <8 Years)100.0
Dalteparin Sodium: Group 4 (>=8 Years to <12 Years)100.0
Dalteparin Sodium: Group 5 (>=12 Years to <19 Years)85.0

Time to Achieve Prespecified Therapeutic Anti- Factor Xa Levels

Time to achieve the target range (prespecified therapeutic anti- factor Xa levels) was defined as the number of days from the first dose of study drug to the final dose that achieves the target anti-factor Xa level. Prespecified therapeutic anti-factor Xa level was 0.5-1.0 IU/mL. Cumulative data of Day 1 to 7 is reported. (NCT00952380)
Timeframe: Day 1 to 7 in dose adjustment phase

Interventiondays (Median)
Dalteparin Sodium: Group 2 (>=8 Weeks to <2 Years)4.5
Dalteparin Sodium: Group 3 (>=2 Years to <8 Years)3.0
Dalteparin Sodium: Group 4 (>=8 Years to <12 Years)2.0
Dalteparin Sodium: Group 5 (>=12 Years to <19 Years)2.0

Time to First Occurrence of Major Bleeding Event

Time to first occurrence of major bleeding event was defined as the time interval (in days) between date of first study treatment and date of documentation of first major bleeding event. A bleeding event was considered as major if it was clinically overt and satisfies 1 or more of the following criteria: fatal bleeding, bleeding accompanied by a decrease in hemoglobin of at least 2 grams per deciliter, overt bleeding deemed by the attending physician to necessitate permanent discontinuation of trial medication, overt bleeding deemed by the attending physician to be unrelated to the participant's underlying condition and accompanied by blood product administration, bleeding occurred at a critical site (intraocular, intracranial, retroperitoneal or intraspinal). (NCT00952380)
Timeframe: Baseline up to 28 days after the last dose of study drug (up to Day 132)

Interventiondays (Median)
Dalteparin Sodium: All Participants (>= 0 to < 19 Years)NA

Time to First Occurrence of Symptomatic Recurrent Venous Thromboembolism (VTE)

It was defined as the time interval (in days) between date of first study treatment and date of documentation of first VTE. VTEs included both DVT and PE. DVT is a blood clot in the deep veins of the leg. If a DVT clot breaks off from a vein wall and flows towards the lungs and blocks some or all of the blood supply, it becomes PE. When a blood clot breaks, loose and travels in the blood, this is called VTE. VTE was confirmed by at least one radiographic test and was defined as any new or progressive VTE whose signs and symptoms (identified by the investigator) included: objective swelling or tenderness, pitting edema, erythema or cyanosis. (NCT00952380)
Timeframe: Baseline up to 28 days after the last dose of study drug (up to Day 132)

Interventiondays (Median)
Dalteparin Sodium: All Participants (>= 0 to < 19 Years)NA

Absolute Values of Body Length of Participants

(NCT00952380)
Timeframe: Baseline, Day 1, Day 2, Day 30, Day 60, Day 90

Interventioncentimeter (Median)
BaselineDay 2Day 30Day 60Day 90
Dalteparin Sodium: Group 3 (>=2 Years to <8 Years)100104.7510010397.75

Absolute Values of Body Length of Participants

(NCT00952380)
Timeframe: Baseline, Day 1, Day 2, Day 30, Day 60, Day 90

,,
Interventioncentimeter (Median)
BaselineDay 1Day 2Day 30Day 60Day 90
Dalteparin Sodium: Group 1 (>=0 to <8 Weeks)545456606364
Dalteparin Sodium: Group 2 (>=8 Weeks to <2 Years)555555.3056.606061
Dalteparin Sodium: Group 5 (>=12 Years to <19 Years)172135135135135151.75

Absolute Values of Body Temperature of Participants

(NCT00952380)
Timeframe: Baseline, Day 1, Day 2, Day 30, Day 60, Day 90

,,,,
Interventiondegree celsius (Median)
BaselineDay 1Day 2Day 30Day 60Day 90
Dalteparin Sodium: Group 1 (>=0 to <8 Weeks)36.6036.7036.9036.5036.6036.70
Dalteparin Sodium: Group 2 (>=8 Weeks to <2 Years)36.7036.8536.4036.5036.7037.15
Dalteparin Sodium: Group 3 (>=2 Years to <8 Years)36.5036.8036.7036.6036.8036.75
Dalteparin Sodium: Group 4 (>=8 Years to <12 Years)37.0036.7036.7036.5036.6036.90
Dalteparin Sodium: Group 5 (>=12 Years to <19 Years)36.8036.8036.7036.7036.6036.80

Absolute Values of Heart Rate (HR) and Pulse Rate (PR) of Participants

Heart rate and pulse rate of participants were measured in terms of beats per minute. (NCT00952380)
Timeframe: Baseline, Day 1, Day 2, Day 30, Day 60, Day 90

,
Interventionbeats per minute (bpm) (Median)
HR: BaselineHR: Day 1HR: Day 2HR: Day 30HR: Day 60HR: Day 90PR: BaselinePR: Day 1PR: Day 2PR: Day 30PR: Day 60PR: Day 90
Dalteparin Sodium: Group 3 (>=2 Years to <8 Years)115.00112.00114.00120.50120.00107.0096.50121.00117.0088.0088.00114.00
Dalteparin Sodium: Group 5 (>=12 Years to <19 Years)70.0085.0075.0087.5094.5080.0073.0094.5093.00102.0095.0092.00

Absolute Values of Heart Rate (HR) and Pulse Rate (PR) of Participants

Heart rate and pulse rate of participants were measured in terms of beats per minute. (NCT00952380)
Timeframe: Baseline, Day 1, Day 2, Day 30, Day 60, Day 90

Interventionbeats per minute (bpm) (Median)
HR: BaselineHR: Day 1HR: Day 2HR: Day 30HR: Day 60HR: Day 90
Dalteparin Sodium: Group 1 (>=0 to <8 Weeks)148.00146.00136.00138.00132.00122.00

Absolute Values of Heart Rate (HR) and Pulse Rate (PR) of Participants

Heart rate and pulse rate of participants were measured in terms of beats per minute. (NCT00952380)
Timeframe: Baseline, Day 1, Day 2, Day 30, Day 60, Day 90

Interventionbeats per minute (bpm) (Median)
PR: BaselinePR: Day 1PR: Day 2PR: Day 30PR: Day 60PR: Day 90
Dalteparin Sodium: Group 4 (>=8 Years to <12 Years)114.0087.0098.00101.0093.0096.00

Absolute Values of Heart Rate (HR) and Pulse Rate (PR) of Participants

Heart rate and pulse rate of participants were measured in terms of beats per minute. (NCT00952380)
Timeframe: Baseline, Day 1, Day 2, Day 30, Day 60, Day 90

Interventionbeats per minute (bpm) (Median)
HR: BaselineHR: Day 1HR: Day 2HR: Day 30HR: Day 60HR: Day 90PR: Day 1PR: Day 90
Dalteparin Sodium: Group 2 (>=8 Weeks to <2 Years)146.00142.00130.00130.00184.00134.00108.00140.00

Absolute Values of Height of Participants

(NCT00952380)
Timeframe: Baseline, Day 1, Day 2, Day 30, Day 60, Day 90

Interventioncentimeters (cm) (Median)
BaselineDay 30Day 60Day 90
Dalteparin Sodium: Group 2 (>=8 Weeks to <2 Years)55.0056.6060.0061.00

Absolute Values of Height of Participants

(NCT00952380)
Timeframe: Baseline, Day 1, Day 2, Day 30, Day 60, Day 90

Interventioncentimeters (cm) (Median)
BaselineDay 1Day 30Day 60Day 90
Dalteparin Sodium: Group 1 (>=0 to <8 Weeks)54.0054.0060.0063.0064.00

Absolute Values of Height of Participants

(NCT00952380)
Timeframe: Baseline, Day 1, Day 2, Day 30, Day 60, Day 90

,,
Interventioncentimeters (cm) (Median)
BaselineDay 1Day 2Day 30Day 60Day 90
Dalteparin Sodium: Group 3 (>=2 Years to <8 Years)110.00115.80107.90115.10115.00109.50
Dalteparin Sodium: Group 4 (>=8 Years to <12 Years)133.00134.00142.00140.30139.70140.70
Dalteparin Sodium: Group 5 (>=12 Years to <19 Years)166.00166.00166.90167.75168.50166.65

Absolute Values of Respiratory Rate of Participants

Respiratory rate was defined as the number of breaths per minute. (NCT00952380)
Timeframe: Baseline, Day 1, Day 2, Day 30, Day 60, Day 90

,,,,
Interventionbreaths per minute (Median)
BaselineDay 1Day 2Day 30Day 60Day 90
Dalteparin Sodium: Group 1 (>=0 to <8 Weeks)35.0034.0034.0034.0030.0024.00
Dalteparin Sodium: Group 2 (>=8 Weeks to <2 Years)25.0036.0034.0036.0036.0034.00
Dalteparin Sodium: Group 3 (>=2 Years to <8 Years)24.0021.0020.0022.0020.0022.00
Dalteparin Sodium: Group 4 (>=8 Years to <12 Years)20.0018.0020.0022.0020.0020.00
Dalteparin Sodium: Group 5 (>=12 Years to <19 Years)20.0018.0018.0018.0020.0018.00

Absolute Values of Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DSBP) in Participants

(NCT00952380)
Timeframe: Baseline, Day 1, Day 2, Day 30, Day 60, Day 90

,,,,
Interventionmillimeters of mercury (mmHg) (Median)
SBP: BaselineSBP: Day 1SBP: Day 2SBP: Day 30SBP: Day 60SBP: Day 90DSBP: BaselineDSBP: Day 1DSBP: Day 2DSBP: Day 30DSBP: Day 60DSBP: Day 90
Dalteparin Sodium: Group 1 (>=0 to <8 Weeks)101.0097.0094.0077.074.0076.0060.0061.0048.0053.0051.0053.00
Dalteparin Sodium: Group 2 (>=8 Weeks to <2 Years)50.00105.5075.0077.00102.00105.0041.0057.0053.0061.0057.0055.50
Dalteparin Sodium: Group 3 (>=2 Years to <8 Years)110.50112.0107.00112.00101.0097.5066.0065.5060.5064.0060.0060.50
Dalteparin Sodium: Group 4 (>=8 Years to <12 Years)96.00111.00112.00109.00118.00116.0067.0066.5070.0068.0067.0067.00
Dalteparin Sodium: Group 5 (>=12 Years to <19 Years)117.50113.00119.50118.00117.50116.0065.0064.0065.0069.0067.0069.00

Absolute Values of Weight of Participants

(NCT00952380)
Timeframe: Baseline, Day 1, Day 2, Day 30, Day 60, Day 90

,,,,
Interventionkilograms (Median)
BaselineDay 1Day 2Day 30Day 60Day 90
Dalteparin Sodium: Group 1 (>=0 to <8 Weeks)4.054.174.506.307.157.70
Dalteparin Sodium: Group 2 (>=8 Weeks to <2 Years)3.934.044.154.564.604.70
Dalteparin Sodium: Group 3 (>=2 Years to <8 Years)18.7817.2314.9515.5016.6021.50
Dalteparin Sodium: Group 4 (>=8 Years to <12 Years)36.6037.0039.3539.2038.3039.30
Dalteparin Sodium: Group 5 (>=12 Years to <19 Years)60.0063.4058.0063.8065.8059.60

Number of Participants With Physical Examination Abnormalities of Participants

Physical examinations included head, eyes, ears, nose, throat, neck, heart, chest, lungs, abdomen, extremities, skin, neurological status and general appearance. Abnormality in physical examination was based on investigator's discretion. Only those categories in which at least 1 participant had abnormality were reported. (NCT00952380)
Timeframe: Screening, Visit 2 (Baseline), Visit 3 (Day 1), Visit 4 (Day 2), Visit 5 (Day 30), Visit 6 (Day 60), Visit 7 (Day 90)

InterventionParticipants (Count of Participants)
Abdomen: ScreeningAbdomen: Visit 3Abdomen: Visit 4Abdomen: Visit 5Abdomen: Visit 6Abdomen: Visit 7Chest: ScreeningChest: Visit 3Chest: Visit 4Chest: Visit 5Chest: Visit 6Chest: Visit 7Extremities: ScreeningExtremities: Visit 3Extremities: Visit 4Extremities: Visit 5Extremities: Visit 6Extremities: Visit 7Eyes, ears, nose, throat:ScreeningEyes, ears, nose, throat: Visit 3Eyes, ears, nose, throat: Visit 4Eyes, ears, nose, throat: Visit 5Eyes, ears, nose, throat: Visit 6Eyes, ears, nose, throat: Visit 7General appearance: ScreeningGeneral appearance: Visit 3General appearance: Visit 4General appearance: Visit 5General appearance: Visit 6General appearance: Visit 7Head: ScreeningHead: Visit 3Head: Visit 4Head: Visit 5Head: Visit 6Head: Visit 7Heart: ScreeningHeart: Visit 3Heart: Visit 4Heart: Visit 7Lungs: ScreeningLungs: Visit 4Lungs: Visit 6Lungs: Visit 7Neck: ScreeningNeck: Visit 4Neurological: ScreeningNeurological: Visit 3Neurological: Visit 4Neurological: Visit 5Neurological: Visit 7Skin: ScreeningSkin: Visit 3Skin: Visit 4Skin: Visit 5Skin: Visit 6Skin: Visit 7
Dalteparin Sodium: Group 4 (>=8 Years to <12 Years)001111223112434112000000101002100111100010001000000312223

Number of Participants With Physical Examination Abnormalities of Participants

Physical examinations included head, eyes, ears, nose, throat, neck, heart, chest, lungs, abdomen, extremities, skin, neurological status and general appearance. Abnormality in physical examination was based on investigator's discretion. Only those categories in which at least 1 participant had abnormality were reported. (NCT00952380)
Timeframe: Screening, Visit 2 (Baseline), Visit 3 (Day 1), Visit 4 (Day 2), Visit 5 (Day 30), Visit 6 (Day 60), Visit 7 (Day 90)

InterventionParticipants (Count of Participants)
Abdomen: ScreeningAbdomen: Visit 2Abdomen: Visit 3Abdomen: Visit 4Abdomen: Visit 5Abdomen: Visit 6Abdomen: Visit 7Chest: ScreeningChest: Visit 2Chest: Visit 3Chest: Visit 4Chest: Visit 5Chest: Visit 6Chest: Visit 7Extremities: ScreeningExtremities: Visit 2Extremities: Visit 3Extremities: Visit 4Extremities: Visit 5Extremities: Visit 6Extremities: Visit 7Eyes: ScreeningEyes: Visit 2Eyes: Visit 3Eyes: Visit 4Eyes: Visit 5Eyes: Visit 6Eyes: Visit 7Eyes, ears, nose, throat:ScreeningGeneral appearance: ScreeningGeneral appearance: Visit 2General appearance: Visit 3General appearance: Visit 4General appearance: Visit 5General appearance: Visit 6General appearance: Visit 7Head: ScreeningHead: Visit 3Head: Visit 4Head: Visit 5Head: Visit 6Head: Visit 7Heart: ScreeningHeart: Visit 3Heart: Visit 4Heart: Visit 7Lungs: ScreeningLungs: Visit 4Lungs: Visit 6Lungs: Visit 7Neck: ScreeningNeck: Visit 4Neurological: ScreeningNeurological: Visit 2Neurological: Visit 3Neurological: Visit 4Neurological: Visit 5Neurological: Visit 7Nose: ScreeningNose: Visit 2Skin: ScreeningSkin: Visit 2Skin: Visit 3Skin: Visit 4Skin: Visit 5Skin: Visit 6Skin: Visit 7
Dalteparin Sodium: Group 1 (>=0 to <8 Weeks)0000000000000000000000000000000000000000000000000000000000001110000

Number of Participants With Physical Examination Abnormalities of Participants

Physical examinations included head, eyes, ears, nose, throat, neck, heart, chest, lungs, abdomen, extremities, skin, neurological status and general appearance. Abnormality in physical examination was based on investigator's discretion. Only those categories in which at least 1 participant had abnormality were reported. (NCT00952380)
Timeframe: Screening, Visit 2 (Baseline), Visit 3 (Day 1), Visit 4 (Day 2), Visit 5 (Day 30), Visit 6 (Day 60), Visit 7 (Day 90)

InterventionParticipants (Count of Participants)
Abdomen: ScreeningAbdomen: Visit 2Abdomen: Visit 3Abdomen: Visit 4Abdomen: Visit 5Abdomen: Visit 6Abdomen: Visit 7Chest: ScreeningChest: Visit 2Chest: Visit 3Chest: Visit 4Chest: Visit 5Chest: Visit 6Chest: Visit 7Extremities: ScreeningExtremities: Visit 2Extremities: Visit 3Extremities: Visit 4Extremities: Visit 5Extremities: Visit 6Extremities: Visit 7Eyes: ScreeningEyes: Visit 2Eyes: Visit 3Eyes: Visit 4Eyes: Visit 5Eyes: Visit 6Eyes: Visit 7Eyes, ears, nose, throat:ScreeningEyes, ears, nose, throat: Visit 3Eyes, ears, nose, throat: Visit 4Eyes, ears, nose, throat: Visit 7General appearance: ScreeningGeneral appearance: Visit 2General appearance: Visit 3General appearance: Visit 4General appearance: Visit 5General appearance: Visit 6General appearance: Visit 7Head: ScreeningHead: Visit 3Head: Visit 4Head: Visit 5Head: Visit 6Head: Visit 7Heart: ScreeningHeart: Visit 3Heart: Visit 4Heart: Visit 7Lungs: ScreeningLungs: Visit 4Lungs: Visit 6Lungs: Visit 7Neck: ScreeningNeck: Visit 4Neurological: ScreeningNeurological: Visit 2Neurological: Visit 3Neurological: Visit 4Neurological: Visit 5Neurological: Visit 7Nose: ScreeningNose: Visit 2Skin: ScreeningSkin: Visit 2Skin: Visit 3Skin: Visit 4Skin: Visit 5Skin: Visit 6Skin: Visit 7
Dalteparin Sodium: Group 2 (>=8 Weeks to <2 Years)1010001000000000000000000000100000000100000000111000010000001001011001

Number of Participants With Physical Examination Abnormalities of Participants

Physical examinations included head, eyes, ears, nose, throat, neck, heart, chest, lungs, abdomen, extremities, skin, neurological status and general appearance. Abnormality in physical examination was based on investigator's discretion. Only those categories in which at least 1 participant had abnormality were reported. (NCT00952380)
Timeframe: Screening, Visit 2 (Baseline), Visit 3 (Day 1), Visit 4 (Day 2), Visit 5 (Day 30), Visit 6 (Day 60), Visit 7 (Day 90)

,
InterventionParticipants (Count of Participants)
Abdomen: ScreeningAbdomen: Visit 2Abdomen: Visit 3Abdomen: Visit 4Abdomen: Visit 5Abdomen: Visit 6Abdomen: Visit 7Chest: ScreeningChest: Visit 2Chest: Visit 3Chest: Visit 4Chest: Visit 5Chest: Visit 6Chest: Visit 7Extremities: ScreeningExtremities: Visit 2Extremities: Visit 3Extremities: Visit 4Extremities: Visit 5Extremities: Visit 6Extremities: Visit 7Eyes: ScreeningEyes: Visit 2Eyes: Visit 3Eyes: Visit 4Eyes: Visit 5Eyes: Visit 6Eyes: Visit 7Eyes, ears, nose, throat:ScreeningEyes, ears, nose, throat: Visit 3Eyes, ears, nose, throat: Visit 4Eyes, ears, nose, throat: Visit 5Eyes, ears, nose, throat: Visit 6Eyes, ears, nose, throat: Visit 7General appearance: ScreeningGeneral appearance: Visit 2General appearance: Visit 3General appearance: Visit 4General appearance: Visit 5General appearance: Visit 6General appearance: Visit 7Head: ScreeningHead: Visit 3Head: Visit 4Head: Visit 5Head: Visit 6Head: Visit 7Heart: ScreeningHeart: Visit 3Heart: Visit 4Heart: Visit 7Lungs: ScreeningLungs: Visit 4Lungs: Visit 6Lungs: Visit 7Neck: ScreeningNeck: Visit 4Neurological: ScreeningNeurological: Visit 2Neurological: Visit 3Neurological: Visit 4Neurological: Visit 5Neurological: Visit 7Nose: ScreeningNose: Visit 2Skin: ScreeningSkin: Visit 2Skin: Visit 3Skin: Visit 4Skin: Visit 5Skin: Visit 6Skin: Visit 7
Dalteparin Sodium: Group 3 (>=2 Years to <8 Years)221100012000000110000100000011002121100011111111010000010211000111012201
Dalteparin Sodium: Group 5 (>=12 Years to <19 Years)2023413200100310138322111211121231230122124254350012011121000110005136754

Number of Participants With Treatment Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)

An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent were events between first dose of study drug and up to 28 days after the last dose of study drug (up to Day 132) that were absent before treatment or that worsened relative to pretreatment state. AEs included both SAEs and non-SAEs. (NCT00952380)
Timeframe: Baseline up to 28 days after the last dose of study drug (up to Day 132)

,,,,
InterventionParticipants (Count of Participants)
AEsSAEs
Dalteparin Sodium: Group 1 (>=0 to <8 Weeks)10
Dalteparin Sodium: Group 2 (>=8 Weeks to <2 Years)22
Dalteparin Sodium: Group 3 (>=2 Years to <8 Years)73
Dalteparin Sodium: Group 4 (>=8 Years to <12 Years)73
Dalteparin Sodium: Group 5 (>=12 Years to <19 Years)1913

Percentage of Participants Who Remained Within Prespecified Therapeutic Anti-Factor Xa Levels at Day 30, 60 and 90 in Follow up Phase

Prespecified therapeutic anti-factor Xa level was 0.5-1.0 IU/mL. The percentage of participants who had anti factor-Xa levels within the prespecified therapeutic range at Day 30, 60 and 90 during the follow up phase were reported in this outcome measure. (NCT00952380)
Timeframe: Day 30, Day 60, Day 90 in follow up phase

,,,
Interventionpercentage of participants (Number)
Day 30Day 60Day 90
Dalteparin Sodium: Group 2 (>=8 Weeks to <2 Years)100.0100.0100.0
Dalteparin Sodium: Group 3 (>=2 Years to <8 Years)100.0100.0100.0
Dalteparin Sodium: Group 4 (>=8 Years to <12 Years)33.375.050.0
Dalteparin Sodium: Group 5 (>=12 Years to <19 Years)93.381.872.7

Percentage of Participants With Anti-Factor Xa Levels Outside the Prespecified Range at Day 30, 60 and 90 in Follow up Phase

Prespecified therapeutic anti-factor Xa range was 0.5-1.0 IU/mL. The percentage of participants who had anti-factor Xa levels outside the prespecified therapeutic range at Day 30, 60 and 90 during the follow up phase were reported in this outcome measure. (NCT00952380)
Timeframe: Day 30, Day 60, Day 90 in follow-up phase

,,,
Interventionpercentage of participants (Number)
Day 30Day 60Day 90
Dalteparin Sodium: Group 2 (>=8 Weeks to <2 Years)000
Dalteparin Sodium: Group 3 (>=2 Years to <8 Years)000
Dalteparin Sodium: Group 4 (>=8 Years to <12 Years)66.725.050.0
Dalteparin Sodium: Group 5 (>=12 Years to <19 Years)6.718.227.3

Percentage of Participants With Clinical Response of Progression, Regression, Resolution and No Change in Venous Thromboembolism (VTE)

VTEs included both DVT and PE. DVT is a blood clot in the deep veins of the leg. PE is a blood clot in the lungs. Clinical response of progression was defined as progression of clot burden in terms of severity of occlusion, or involvement of new venous segments at any time after the initial diagnosis. Clinical response of regression: Regressed clot burden utilizing the same imaging modality as the screening visit. Clinical response of resolution: Thrombus resolution of the qualifying event measured by repeat imaging at the end of study (EOS) visit. (NCT00952380)
Timeframe: Baseline up to 28 days after the last dose of study drug (up to Day 132)

,,,
Interventionpercentage of participants (Number)
ProgressionRegressionResolutionNo Change
Dalteparin Sodium: Group 2 (>=8 Weeks to <2 Years)00100.00
Dalteparin Sodium: Group 3 (>=2 Years to <8 Years)012.562.50
Dalteparin Sodium: Group 4 (>=8 Years to <12 Years)014.357.114.3
Dalteparin Sodium: Group 5 (>=12 Years to <19 Years)029.458.85.9

Percentage of Participants With Major and Minor Bleeding Event

A bleeding event was considered as major if it was clinically overt and satisfies 1 or more of the following criteria: fatal bleeding, bleeding accompanied by a decrease in hemoglobin of at least 2 grams per deciliter 24 hours, Overt bleeding deemed by the attending physician to necessitate permanent discontinuation of trial medication, Overt bleeding deemed by the attending physician to be unrelated to the participant's underlying condition and accompanied by blood product administration or bleeding occurred at a critical site (intraocular, intracranial, retroperitoneal). A bleeding event was considered as minor if it was clinically overt but not meeting the criteria for major or clinically relevant no major bleeding (bleeding resulting in any medical or surgical interventions but which did not meet the criteria for major bleeding). (NCT00952380)
Timeframe: Baseline up to 28 days after the last dose of study drug (up to Day 132)

,,,,
Interventionpercentage of participants (Number)
Major BleedingMinor Bleeding
Dalteparin Sodium: Group 1 (>=0 to <8 Weeks)00
Dalteparin Sodium: Group 2 (>=8 Weeks to <2 Years)50.00
Dalteparin Sodium: Group 3 (>=2 Years to <8 Years)050.0
Dalteparin Sodium: Group 4 (>=8 Years to <12 Years)057.1
Dalteparin Sodium: Group 5 (>=12 Years to <19 Years)040.0

Benefit of Anticoagulation Therapy Reported by Participants Via the Anti-Clot Treatment Scale (ACTS) Questionnaire

To compare the benefit of anticoagulation therapy with DOAC vs. with LMWH/warfarin for cancer patients with VTE at 3 months. The benefits scale has 3 items and patients are asked to rate their experiences on a 5-point scale of intensity (1=not at all, 2=a little, 3=moderately, 4=quite a bit, 5=extremely). The ACTS benefits tool is then scored using the totals from each question with a total score from 3 to 15 possible. Higher scores signify greater satisfaction (greater benefits). (NCT02744092)
Timeframe: 3-months

Interventionscore on a scale (Mean)
Randomized Arm 1 (DOACs)11.2
Randomized Arm 2 (LMWH)10.7
Preference Cohort 1 (DOACs)10.3
Preference Cohort 2 (LMWH)10.5

Benefit of Anticoagulation Therapy Reported by Participants Via the Anti-Clot Treatment Scale (ACTS) Questionnaire

To compare the benefit of anticoagulation therapy with DOAC vs. with LMWH/warfarin for cancer patients with VTE at 6 months. The benefits scale has 3 items and patients are asked to rate their experiences on a 5-point scale of intensity (1=not at all, 2=a little, 3=moderately, 4=quite a bit, 5=extremely). The ACTS benefits tool is then scored using the totals from each question with a total score from 3 to 15 possible. Higher scores signify greater satisfaction (greater benefits). (NCT02744092)
Timeframe: 6-months

Interventionscore on a scale (Mean)
Randomized Arm 1 (DOACs)11.6
Randomized Arm 2 (LMWH)11.3
Preference Cohort 1 (DOACs)11.5
Preference Cohort 2 (LMWH)10.1

Burden of Anticoagulation Therapy Reported by Participants Via the Anti-Clot Treatment Scale (ACTS) Questionnaire

To compare the burden of anticoagulation therapy with DOAC vs. with LMWH/warfarin for cancer patients with VTE at 3 months. The burden scale has12 items and patients are asked to rate their experiences on a 5-point scale of intensity (1=not at all, 2=a little, 3=moderately, 4=quite a bit, 5=extremely). The ACTS burden tool is then scored using the totals from each question with a total score from 12 to 60 possible. Higher scores signify greater satisfaction (lower burden). (NCT02744092)
Timeframe: 3 months

Interventionscore on a scale (Mean)
Randomized Arm 1 (DOACs)56.7
Randomized Arm 2 (LMWH)53.3
Preference Cohort 1 (DOACs)55.8
Preference Cohort 2 (LMWH)54.9

Burden of Anticoagulation Therapy Reported by Participants Via the Anti-Clot Treatment Scale (ACTS) Questionnaire

To compare the burden of anticoagulation therapy with DOAC vs. with LMWH/warfarin for cancer patients with VTE at 6 months. The burden scale has12 items and patients are asked to rate their experiences on a 5-point scale of intensity (1=not at all, 2=a little, 3=moderately, 4=quite a bit, 5=extremely). The ACTS burden tool is then scored using the totals from each question with a total score from 12 to 60 possible. Higher scores signify greater satisfaction (lower burden). (NCT02744092)
Timeframe: 6 months

Interventionscore on a scale (Mean)
Randomized Arm 1 (DOACs)56.5
Randomized Arm 2 (LMWH)54.1
Preference Cohort 1 (DOACs)54.9
Preference Cohort 2 (LMWH)53.1

Cumulative Non-Fatal VTE Recurrence at 6 Months (%)

To compare the effectiveness of anticoagulation with a DOAC (intervention) with LMWH/warfarin (comparator) for preventing VTE recurrence in patients with cancer based on cumulative VTE recurrence reported by patients or clinicians at 6 months. Only VTEs that were nonfatal were considered because of the challenges of attributing cause of death in cancer patients to tumor progression vs. VTE. (NCT02744092)
Timeframe: 6 months

Interventionpercentage of patients (Number)
Randomized Arm 1 (DOACs)6.1
Randomized Arm 2 (LMWH)8.8
Preference Cohort 1 (DOACs)7.5
Preference Cohort 2 (LMWH)4.1

Cumulative Rates of Major Bleeding

To compare the harms of DOAC vs. LMWH/warfarin therapy for cancer patients with VTE based on the cumulative rate of major bleeding at 6 months. d. Major bleeding was defined as Grade >=3 on the Common Terminology Criteria for Adverse Events from the National Cancer Institute (NCI CTCAE) criteria version 5.0 (i.e., severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self care activities of daily living). (NCT02744092)
Timeframe: 6 months

Interventionpercentage of patients (Number)
Randomized Arm 1 (DOACs)5.2
Randomized Arm 2 (LMWH)5.6
Preference Cohort 1 (DOACs)11.5
Preference Cohort 2 (LMWH)7.6

Health Related Quality of Life (Mental Health) Reported by Participants Via the Optum SF-12v2 Health Survey Questionnaire at 3-months

Change in mental health at 3 months from baseline. Health-related quality of life was measured using the 12-Item Short Form Health Survey (SF-12) sub-scales for physical and mental health (score range, 0-100; higher scores indicate better physical and mental health functioning). Survey content included minor verbiage changes for clarity. The scores indicate change in score from baseline. (NCT02744092)
Timeframe: 3-months

Interventionunits on a scale (Mean)
Randomized Arm 1 (DOACs)-0.3
Randomized Arm 2 (LMWH)0.7
Preference Cohort 1 (DOACs)0.3
Preference Cohort 2 (LMWH)0.4

Health Related Quality of Life (Mental Health) Reported by Participants Via the Optum SF-12v2 Health Survey Questionnaire at 6-months

Change in mental health at 6 months from baseline. Health-related quality of life was measured using the 12-Item Short Form Health Survey (SF-12) sub-scales for physical and mental health (score range, 0-100; higher scores indicate better physical and mental health functioning). Survey content included minor verbiage changes for clarity. The scores indicate change in score from baseline. (NCT02744092)
Timeframe: 6-months

Interventionunits on a scale (Mean)
Randomized Arm 1 (DOACs)0.3
Randomized Arm 2 (LMWH)0.9
Preference Cohort 1 (DOACs)1.1
Preference Cohort 2 (LMWH)-1.9

Health Related Quality of Life Reported by Participants Via the Optum SF-12v2 Health Survey Questionnaire

Change in physical health at 3 months. Health-related quality of life was measured using the 12-Item Short Form Health Survey (SF-12) sub-scales for physical and mental health (score range, 0-100; higher scores indicate better physical and mental health functioning). Survey content included minor verbiage changes for clarity. The presented scores in this results section indicate the change (difference) in mean scores between the baseline and 3-month follow-up assessment. (NCT02744092)
Timeframe: 3 months

Interventionunits on a scale (Mean)
Randomized Arm 1 (DOACs)1.8
Randomized Arm 2 (LMWH)0.7
Preference Cohort 1 (DOACs)3.4
Preference Cohort 2 (LMWH)-0.3

Health Related Quality of Life Reported by Participants Via the Optum SF-12v2 Health Survey Questionnaire

Change in physical health at 6 months. Health-related quality of life was measured using the 12-Item Short Form Health Survey (SF-12) sub-scales for physical and mental health (score range, 0-100; higher scores indicate better physical and mental health functioning). Survey content included minor verbiage changes for clarity. The presented scores in this results section indicate the change (difference) in mean scores between the baseline and 6-month follow-up assessment. (NCT02744092)
Timeframe: 6 months

Interventionunits on a scale (Mean)
Randomized Arm 1 (DOACs)2.4
Randomized Arm 2 (LMWH)0.7
Preference Cohort 1 (DOACs)2.1
Preference Cohort 2 (LMWH)-2.8

Mortality Reported by Participants' Surrogates (Via Study-specific Questionnaire) or Clinicians (Via Study-specific Case Report Form)

To compare the impact of DOAC vs. LMWH/warfarin therapy on mortality in cancer patients with VTE based on survival at 6 months. Mortality was reported by participants' surrogates (via study-specific questionnaire) or clinicians (via study-specific case report form) (NCT02744092)
Timeframe: 6 months

Interventionpercentage of patients (Number)
Randomized Arm 1 (DOACs)21.5
Randomized Arm 2 (LMWH)18.4
Preference Cohort 1 (DOACs)16.3
Preference Cohort 2 (LMWH)23.8

6 Month Bleeding Rate

The rate (percentage) of patients experiencing major bleeding at 6 months from treatment initiation and its associated 95% confidence interval was estimated separately by treatment arm using a cumulative incidence function, treating death without bleeding as a competing risk. (NCT02585713)
Timeframe: Up to 6 months

Interventionpercentage of patients (Number)
Arm A (Apixaban)0
Arm B (Dalteparin)2.1

Composite Bleeding Rate: Major Bleed or a Clinically Relevant Non-major Bleed

A similar analysis as described for the primary safety analysis will be used. The rate (percentage) of patients experiencing major bleeding or a clinically relevant non-major bleed at 6 months from treatment initiation and its associated 95% confidence interval was estimated separately by treatment arm using a cumulative incidence function, treating death without bleeding as a competing risk. (NCT02585713)
Timeframe: Up to 6 months

Interventionpercentage of patients (Number)
Arm A (Apixaban)7.0
Arm B (Dalteparin)8.1

Time to the First Event of the Composite Deep Vein Thrombosis (DVT)/Pulmonary Embolism (PE)

Analyzed using the same methods described above for the primary endpoint.Time to the first event of the composite deep vein thrombosis (DVT)/pulmonary embolism (PE) is defined as the time from randomization to the date the patient experienced the first event of the composite deep vein thrombosis (DVT)/pulmonary embolism (PE). (NCT02585713)
Timeframe: Up to 3 months post-treatment

Interventionmonths (Median)
Arm A (Apixaban)NA
Arm B (Dalteparin)NA

Number of Participants With Adjudicated Major Bleeding Events While on Treatment

The primary safety endpoint was major bleeding events during the On-Treatment Study Period (defined as on-study drug or up to 3 days after the last dose of study drug). (NCT02073682)
Timeframe: 12 months

InterventionParticipants (Count of Participants)
Edoxaban Group32
Dalteparin Group16

Number of Participants With Adjudicated Recurrent Venous Thromboembolism (VTE) or Major Bleeding Event

(NCT02073682)
Timeframe: 12 months

InterventionParticipants (Count of Participants)
Edoxaban Group67
Dalteparin Group71

Number of Participants With Recurrent Deep Vein Thrombosis (DVT) During the Overall Study Period

(NCT02073682)
Timeframe: 12 months

InterventionParticipants (Count of Participants)
Edoxaban Group19
Dalteparin Group35

Number of Participants With Recurrent Non-Fatal Pulmonary Embolism (PE) During the Overall Study Period

(NCT02073682)
Timeframe: 12 months

InterventionParticipants (Count of Participants)
Edoxaban Group21
Dalteparin Group24

Number of Participants With Recurrent Venous Thromboembolism (VTE) During the Overall Study Period

(NCT02073682)
Timeframe: 12 months

InterventionParticipants (Count of Participants)
Edoxaban Group41
Dalteparin Group59

Number of Participants With Recurrent VTE, Major Bleed or All-Cause Death

(NCT02073682)
Timeframe: 12 months

InterventionParticipants (Count of Participants)
Edoxaban Group235
Dalteparin Group228

Number of Participants With VTE-Related Death

(NCT02073682)
Timeframe: 12 months

InterventionParticipants (Count of Participants)
Edoxaban Group6
Dalteparin Group4

Number of Participants With Deep Venous Thromboembolism

DVT and how the diagnosis was made will be recorded. The number of events in participants in each arm will be compared to evaluate efficacy. (NCT02774265)
Timeframe: 90 days

InterventionParticipants (Count of Participants)
VTE Prophylaxis With Enoxaparin 30mg BID5
VTE Prophylaxis With Aspirin 81mg BID9

Number of Participants With Pulmonary Embolism Events

Bases on imaging obtained for symptoms. (NCT02774265)
Timeframe: 90 days

InterventionParticipants (Count of Participants)
VTE Prophylaxis With Enoxaparin 30mg BID6
VTE Prophylaxis With Aspirin 81mg BID2

Number of Participants With Treatment-related Bleeding Events as Assessed by the Need for Blood Transfusions and Procedures for Bleeding Complications After Initiation of the Study Medication.

Includes a greater than 2g/dL drop in hemoglobin, blood transfusion, hematoma evacuation, re-operation for a deep surgical site infection or minor procedure for bleeding and GI bleed (NCT02774265)
Timeframe: 90 days

InterventionParticipants (Count of Participants)
VTE Prophylaxis With Enoxaparin 30mg BID52
VTE Prophylaxis With Aspirin 81mg BID53

Percentage of Patients Who Experienced Clinically Significant Bleeding Events.

The percentage of patients who experienced a clinically significant bleeding event were recorded (including major and clinically significant non-major bleeding) over 13 weeks (12 weeks of study and an additional week of observation). Major bleeding was defined as being clinically overt and satisfying one of the following: decrease in hemoglobin of 2.0 g/dL, leading to transfusion of 2 or more units of blood or packed red cells, occurring in a critical site (intraocular, spinal/epidural, intracranial, retroperitoneal, or pericardial) or leading to death. Clinically significant non-major bleeding was defined as clinically overt, not meeting criteria for major bleeding and with one of the following characteristics: multiple-source, spontaneous hematoma > 25 cm², epistaxis > 5 mins, macroscopic hematuria not related to instrumentation, spontaneous rectal bleeding, gingival bleeding > 5 mins, hemoptysis, hematemesis or prolonged bleeding (> 5 minutes) after venipuncture. (NCT00876915)
Timeframe: 13 weeks

Interventionpercentage of participants (Number)
Dalteparin Injection14
No Therapy2

Percentage of Patients With Venous Thromboembolisms

The percentage of patients who developed a Venous thromboembolism were recorded within 12 weeks following randomization including all adjudicated occurrences of symptomatic DVT, PE and upper extremity thrombus as well as all asymptomatic DVT and PE detected by lower extremity ultrasonography and chest CT. (NCT00876915)
Timeframe: 12 weeks

Interventionpercentage of participants (Number)
Dalteparin Injection12
No Therapy21

The Value of D-Dimer at Baseline Prior to Chemotherapy in Ambulatory Cancer Patients

Blood samples were obtained to measure the value of D-Dimer at baseline compared between high risk for VTE and low risk for VTE ambulatory cancer patients (NCT00876915)
Timeframe: baseline value of D-Dimer

Interventionug/mL (Mean)
High Risk2.99
Low Risk1.87

The Value of Factor VIIa (FVIIa) at Baseline Prior to Chemotherapy in Ambulatory Cancer Patients

Blood samples were obtained to measure the value of FVIIa at baseline compared between high risk for VTE and low risk for VTE ambulatory cancer patients (NCT00876915)
Timeframe: baseline value of FVIIa

InterventionpM (Mean)
High Risk151.2
Low Risk148.6

The Value of Human F12 at Baseline Prior to Chemotherapy in Ambulatory Cancer Patients

Blood samples were obtained to measure the value of Human F12 at baseline compared between high risk for VTE and low risk for VTE ambulatory cancer patients (NCT00876915)
Timeframe: baseline value of Human F12

Interventionng/mL (Mean)
High Risk484.7
Low Risk306.3

The Value of Thrombin Antithrombin (TAT) at Baseline Prior to Chemotherapy in Ambulatory Cancer Patients

Blood samples were obtained to measure the value of TAT at baseline compared between high risk for VTE and low risk for VTE ambulatory cancer patients (NCT00876915)
Timeframe: baseline value of TAT

Interventionug/L (Mean)
High Risk9.89
Low Risk12.44

The Value of Tissue Factor (TF) at Baseline Prior to Chemotherapy in Ambulatory Cancer Patients

Blood samples were obtained to measure the value of Tissue Factor at baseline compared between high risk for VTE and low risk for VTE ambulatory cancer patients. (NCT00876915)
Timeframe: baseline value of tissue factor

Interventionpg/mL (Mean)
High Risk0.669
Low Risk0.187

The Value of Tissue Factor Pathway Inhibitor (TFPI) at Baseline Prior to Chemotherapy in Ambulatory Cancer Patients

Blood samples were obtained to measure the value of TFPI at baseline compared between high risk for VTE and low risk for VTE ambulatory cancer patients (NCT00876915)
Timeframe: baseline value of TFPI

Interventionpg/mL (Mean)
High Risk813.6
Low Risk738.2

Change From Baseline to Day 14 in Pain Assessment

Change in pain at day 14 as measured by 11-point Box Pain Scale, 0 being the least amount of pain, and 10 the most amount of pain (NCT00264381)
Timeframe: Day 1, Day 14

Interventionunits on a scale (Mean)
Ibuprofen 800 mg Tid-2.28
Dalteparin 200 U/kg Then 10,000 U Daily-2.23

Major and Minor Bleeding Secondary to Dalteparin and Ibuprofen Treatment During the 3 Month Follow up.

Number of participants with bleeding events related to treatment (NCT00264381)
Timeframe: 3 months

Interventionparticipants (Number)
Ibuprofen 800 mg Tid0
Dalteparin 200 U/kg Then 10,000 U Daily0

Thrombosis Progression and Venous Thromboembolism (VTE)

Thrombosis progression and deep vein thrombosis at day 14 by ultrasound testing (NCT00264381)
Timeframe: Day 14

,
Interventionparticipants (Number)
Thrombosis progressionVTE
Dalteparin 200 U/kg Then 10,000 U Daily00
Ibuprofen 800 mg Tid40

Thrombosis Progression or Venous Thromboembolism (VTE) at 3 Months

Symptomatic thrombosis extension (DVT) or pulmonary embolism at 3 months documented by radiologic testing. (NCT00264381)
Timeframe: 3 months

,
Interventionparticipants (Number)
Thrombosis progressionVTE
Dalteparin 200 U/kg Then 10,000 U Daily41
Ibuprofen 800 mg Tid60

Reviews

90 reviews available for dalteparin and Hemorrhage

ArticleYear
[Prevention of deep venous thrombosis after knee arthroscopy. Recent advances].
    Recenti progressi in medicina, 2009, Volume: 100, Issue:5

    Topics: Anticoagulants; Arthroscopy; Combined Modality Therapy; Follow-Up Studies; Hemorrhage; Humans; Incid

2009
Clinical experience with nadroparin in patients undergoing dialysis for renal impairment.
    Hemodialysis international. International Symposium on Home Hemodialysis, 2011, Volume: 15, Issue:3

    Topics: Acute Kidney Injury; Anticoagulants; Female; Hemorrhage; Humans; Male; Nadroparin; Practice Guidelin

2011
Comparison of the relative efficacy and safety of low molecular weight heparin and unfractionated heparin for the treatment of venous thrombosis.
    Haemostasis, 1996, Volume: 26 Suppl 4

    Topics: Adult; Anticoagulants; Double-Blind Method; Enoxaparin; Fibrinolytic Agents; Hemorrhage; Heparin; He

1996
Low-molecular-weight heparins in the treatment of deep-vein thrombosis.
    The Annals of pharmacotherapy, 1998, Volume: 32, Issue:5

    Topics: Blood Platelets; Capillary Permeability; Dalteparin; Enoxaparin; Fibrinolytic Agents; Hemorrhage; He

1998
[Preventive treatment in internal medicine by low-molecular-weight heparin (nadroparine calcium)].
    Orvosi hetilap, 1998, Dec-20, Volume: 139, Issue:51

    Topics: Fibrinolytic Agents; Hemorrhage; Heparin, Low-Molecular-Weight; Humans; Internal Medicine; Nadropari

1998
Low-molecular-weight heparins in the management of acute coronary syndromes.
    Archives of internal medicine, 1999, Sep-13, Volume: 159, Issue:16

    Topics: Angina, Unstable; Canada; Coronary Disease; Dalteparin; Enoxaparin; Fibrinolytic Agents; Hemorrhage;

1999
Low molecular weight heparins in the prevention of deep-vein thrombosis in general surgery.
    Seminars in thrombosis and hemostasis, 1999, Volume: 25 Suppl 3

    Topics: Dalteparin; Hemorrhage; Heparin, Low-Molecular-Weight; Humans; Nadroparin; Surgical Procedures, Oper

1999
Glycoprotein IIb/IIIa antagonists and low-molecular weight heparin in acute coronary syndromes.
    Cardiology clinics, 2001, Volume: 19, Issue:2

    Topics: Abciximab; Angina, Unstable; Antibodies, Monoclonal; Coronary Artery Bypass; Dalteparin; Enoxaparin;

2001
Low molecular weight heparin administered once versus twice daily in patients with venous thromboembolism: a meta-analysis.
    Thrombosis and haemostasis, 2001, Volume: 86, Issue:4

    Topics: Acute Disease; Anticoagulants; Dalteparin; Drug Administration Schedule; Enoxaparin; Hemorrhage; Hep

2001
Clinical use of parnaparin in major and minor orthopedic surgery: a review.
    Vascular health and risk management, 2008, Volume: 4, Issue:5

    Topics: Drug Administration Schedule; Fibrinolytic Agents; Hemorrhage; Heparin, Low-Molecular-Weight; Humans

2008
Heparin and SARS-CoV-2: Multiple Pathophysiological Links.
    Viruses, 2021, 12-11, Volume: 13, Issue:12

    Topics: Anticoagulants; COVID-19; Enoxaparin; Fondaparinux; Hemorrhage; Heparin; Heparin, Low-Molecular-Weig

2021
The efficacy of weight-based enoxaparin dosing for venous thromboembolism prophylaxis in trauma patients: A systematic review and meta-analysis.
    The journal of trauma and acute care surgery, 2022, 08-01, Volume: 93, Issue:2

    Topics: Adult; Anticoagulants; Blood Coagulation Tests; Drug Administration Schedule; Enoxaparin; Hemorrhage

2022
The effectiveness and safety of direct oral anticoagulants compared to conventional pharmacologic thromboprophylaxis in hip fracture patients: A systematic review and meta-analysis of randomized controlled trials.
    Orthopaedics & traumatology, surgery & research : OTSR, 2023, Volume: 109, Issue:2

    Topics: Anticoagulants; Enoxaparin; Hemorrhage; Heparin, Low-Molecular-Weight; Hip Fractures; Humans; Random

2023
The effectiveness of venous thromboembolism prophylaxis interventions in trauma patients: A systematic review and network meta-analysis.
    Injury, 2023, Volume: 54, Issue:12

    Topics: Adult; Anticoagulants; Enoxaparin; Fondaparinux; Hemorrhage; Humans; Multiple Trauma; Network Meta-A

2023
Safety and Efficacy of Enoxaparin in Pregnancy: A Systematic Review and Meta-Analysis.
    Advances in therapy, 2020, Volume: 37, Issue:1

    Topics: Anticoagulants; Aspirin; Enoxaparin; Female; Hemorrhage; Humans; Pregnancy; Pregnancy Complications;

2020
Ranking the efficacy of anticoagulants for the prevention of venous thromboembolism after total hip or knee arthroplasty: A systematic review and a network meta-analysis.
    Pharmacological research, 2021, Volume: 166

    Topics: Anticoagulants; Arthroplasty, Replacement, Knee; Enoxaparin; Hemorrhage; Humans; Pyrazoles; Pyridine

2021
A clinical focus on the use of extended-duration thromboprophylaxis in medically ill patients.
    American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 2021, 06-07, Volume: 78, Issue:12

    Topics: Anticoagulants; Enoxaparin; Hemorrhage; Humans; Rivaroxaban; Venous Thromboembolism

2021
Direct Oral Anticoagulants Vs. Enoxaparin for Prevention of Venous Thromboembolism Following Orthopedic Surgery: A Dose-Response Meta-analysis.
    Clinical and translational science, 2017, Volume: 10, Issue:4

    Topics: Administration, Oral; Anticoagulants; Dose-Response Relationship, Drug; Enoxaparin; Hemorrhage; Huma

2017
Association between rivaroxaban use and length of hospital stay, treatment costs and early outcomes in patients with pulmonary embolism: a systematic review of real-world studies.
    Current medical research and opinion, 2017, Volume: 33, Issue:9

    Topics: Anticoagulants; Enoxaparin; Health Care Costs; Hemorrhage; Humans; Length of Stay; Pulmonary Embolis

2017
Thromboprophylaxis with enoxaparin and direct oral anticoagulants in major orthopedic surgery and acutely ill medical patients: a meta-analysis.
    Internal and emergency medicine, 2017, Volume: 12, Issue:8

    Topics: Administration, Oral; Anticoagulants; Clinical Trials, Phase III as Topic; Drug-Related Side Effects

2017
Extended thromboprophylaxis in the acutely ill medical patient after hospitalization - a paradigm shift in post-discharge thromboprophylaxis.
    Hospital practice (1995), 2018, Volume: 46, Issue:1

    Topics: Age Factors; Anticoagulants; Benzamides; Drug Administration Schedule; Enoxaparin; Hemorrhage; Hospi

2018
Chemical venous thromboembolism prophylaxis in neurosurgical patients: an updated systematic review and meta-analysis.
    Journal of neurosurgery, 2018, Volume: 129, Issue:4

    Topics: Anticoagulants; Enoxaparin; Evidence-Based Medicine; Hemorrhage; Heparin, Low-Molecular-Weight; Intr

2018
Symptomatic bilateral pulmonary embolism without deep venous thrombosis in an adolescent following arthroscopic anterior cruciate ligament reconstruction: a case report and review of the literature.
    Journal of medical case reports, 2018, Jul-06, Volume: 12, Issue:1

    Topics: Adolescent; Anterior Cruciate Ligament Reconstruction; Anticoagulants; Arthroscopy; Elective Surgica

2018
Betrixaban for first-line venous thromboembolism prevention in acute medically ill patients with risk factors for venous thromboembolism.
    Expert review of cardiovascular therapy, 2018, Volume: 16, Issue:11

    Topics: Anticoagulants; Benzamides; Enoxaparin; Factor Xa Inhibitors; Hemorrhage; Humans; Pyridines; Risk Fa

2018
Comparison of efficiency and safety of rivaroxaban, apixaban and enoxaparin for thromboprophylaxis after arthroplastic surgery: a meta-analysis.
    Bioscience reports, 2018, 12-21, Volume: 38, Issue:6

    Topics: Anticoagulants; Arthroplasty; Enoxaparin; Female; Hemorrhage; Humans; Male; Pyrazoles; Pyridones; Ra

2018
Factor Xa Inhibitors and Direct Thrombin Inhibitors Versus Low-Molecular-Weight Heparin for Thromboprophylaxis After Total Hip or Total Knee Arthroplasty: A Systematic Review and Meta-Analysis.
    The Journal of arthroplasty, 2019, Volume: 34, Issue:4

    Topics: Anticoagulants; Antithrombins; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Enox

2019
Betrixaban for Extended Venous Thromboembolism Prophylaxis in High-Risk Hospitalized Patients: Putting the APEX Results into Practice.
    Drugs, 2019, Volume: 79, Issue:3

    Topics: Anticoagulants; Benzamides; Drug Therapy, Combination; Enoxaparin; Factor Xa Inhibitors; Hemorrhage;

2019
Outpatient versus inpatient treatment for acute pulmonary embolism.
    The Cochrane database of systematic reviews, 2019, 03-06, Volume: 3

    Topics: Acute Disease; Adult; Ambulatory Care; Anticoagulants; Confidence Intervals; Enoxaparin; Hemorrhage;

2019
Mandatory contrast-enhanced venography to detect deep-vein thrombosis (DVT) in studies of DVT prophylaxis: upsides and downsides.
    Thrombosis and haemostasis, 2014, Volume: 111, Issue:1

    Topics: Anticoagulants; Cardiology; Clinical Trials as Topic; Contrast Media; Enoxaparin; Fibrinolytic Agent

2014
Direct factor Xa inhibitors (rivaroxaban and apixaban) versus enoxaparin for the prevention of venous thromboembolism after total knee replacement: A meta-analysis of 6 randomized clinical trials.
    Thrombosis research, 2015, Volume: 135, Issue:5

    Topics: Anticoagulants; Arthroplasty, Replacement, Knee; Enoxaparin; Factor Xa Inhibitors; Hemorrhage; Human

2015
The outcome of pulmonary vein thrombosis in non-surgical patients. A systematic review and case report.
    Thrombosis and haemostasis, 2015, Volume: 113, Issue:5

    Topics: Adult; Aged; Aged, 80 and over; Enoxaparin; Fatal Outcome; Female; Hemorrhage; Humans; Male; Middle

2015
Enoxaparin venous thromboembolism prophylaxis in bariatric surgery: A best evidence topic.
    International journal of surgery (London, England), 2015, Volume: 23, Issue:Pt A

    Topics: Anticoagulants; Bariatric Surgery; Clinical Protocols; Cohort Studies; Enoxaparin; Female; Hemorrhag

2015
Retroperitoneal haematoma associated with enoxaparin use in an elderly woman with chronic kidney disease.
    BMJ case reports, 2015, Oct-05, Volume: 2015

    Topics: Aged, 80 and over; Anticoagulants; Aspirin; Enoxaparin; Erythrocyte Transfusion; Female; Hematoma; H

2015
New Oral Anticoagulants in Prophylaxis of Venous Thromboembolic Disease in Major Orthopedic Surgery.
    Cardiovascular & hematological disorders drug targets, 2016, Volume: 15, Issue:3

    Topics: Administration, Oral; Anticoagulants; Dabigatran; Enoxaparin; Fondaparinux; Hemorrhage; Heparin, Low

2016
Rivaroxaban for thromboprophylaxis after total hip or knee arthroplasty: a meta-analysis with trial sequential analysis of randomized controlled trials.
    Scientific reports, 2016, Mar-29, Volume: 6

    Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Enoxaparin; Factor

2016
Apixaban: A Review in Venous Thromboembolism.
    Drugs, 2016, Volume: 76, Issue:15

    Topics: Administration, Oral; Anticoagulants; Clinical Trials, Phase III as Topic; Enoxaparin; Hemorrhage; H

2016
Safety and Efficacy of New Anticoagulants for the Prevention of Venous Thromboembolism After Hip and Knee Arthroplasty: A Meta-Analysis.
    The Journal of arthroplasty, 2017, Volume: 32, Issue:2

    Topics: Anticoagulants; Arthroplasty, Replacement, Knee; Dabigatran; Enoxaparin; Fondaparinux; Hemorrhage; H

2017
Extended thromboprophylaxis with direct oral anticoagulants for medical patients: a systematic review and meta-analysis.
    Blood, 2017, 02-02, Volume: 129, Issue:5

    Topics: Administration, Oral; Anticoagulants; Enoxaparin; Hemorrhage; Humans; Randomized Controlled Trials a

2017
Increased Enoxaparin Dosing for Venous Thromboembolism Prophylaxis in General Trauma Patients.
    The Annals of pharmacotherapy, 2017, Volume: 51, Issue:4

    Topics: Anticoagulants; Body Weight; Dose-Response Relationship, Drug; Drug Administration Schedule; Enoxapa

2017
Practical issues on the use of enoxaparin in elective and emergent percutaneous coronary intervention.
    The Journal of invasive cardiology, 2008, Volume: 20, Issue:9

    Topics: Angioplasty, Balloon, Coronary; Anticoagulants; Enoxaparin; Hemorrhage; Heparin; Humans; Infusions,

2008
Efficacy and safety of dabigatran etexilate for the prevention of venous thromboembolism following total hip or knee arthroplasty. A meta-analysis.
    Thrombosis and haemostasis, 2009, Volume: 101, Issue:1

    Topics: Administration, Oral; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Kne

2009
[Rivaroxaban (Xarelto): efficacy and safety].
    Annales francaises d'anesthesie et de reanimation, 2008, Volume: 27 Suppl 3

    Topics: Administration, Oral; Anticoagulants; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III

2008
What's new in stroke? The top 10 studies of 2006-2008. Part II.
    Polskie Archiwum Medycyny Wewnetrznej, 2008, Volume: 118, Issue:12

    Topics: Anticoagulants; Atorvastatin; Drug Therapy, Combination; Enoxaparin; Evidence-Based Medicine; Fibrin

2008
Safety evaluation of enoxaparin in currently approved indications.
    Expert opinion on drug safety, 2009, Volume: 8, Issue:6

    Topics: Adult; Animals; Anticoagulants; Enoxaparin; Female; Hemorrhage; Humans; Myocardial Infarction; Posto

2009
P-selectin/ PSGL-1 inhibitors versus enoxaparin in the resolution of venous thrombosis: a meta-analysis.
    Thrombosis research, 2010, Volume: 125, Issue:4

    Topics: Animals; Blood Coagulation; Blood Coagulation Tests; Blood Platelets; Enoxaparin; Fibrin Fibrinogen

2010
Rivaroxaban vs dabigatran for thromboprophylaxis after joint-replacement surgery: exploratory indirect comparison based on meta-analysis of pivotal clinical trials.
    Croatian medical journal, 2010, Volume: 51, Issue:2

    Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Benzimidazoles; Dab

2010
Dabigatran versus enoxaparin for prevention of venous thromboembolism after hip or knee arthroplasty: a pooled analysis of three trials.
    Thrombosis research, 2010, Volume: 126, Issue:3

    Topics: Administration, Oral; Aged; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Benzimi

2010
A critical appraisal of bleeding events reported in venous thromboembolism prevention trials of patients undergoing hip and knee arthroplasty.
    Journal of thrombosis and haemostasis : JTH, 2010, Volume: 8, Issue:9

    Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Cardiology; Clinica

2010
Pharmacologic therapy for non ST-segment elevation acute coronary syndromes: focus on antithrombotic therapy.
    Cardiovascular drugs and therapy, 2010, Volume: 24, Issue:4

    Topics: Acute Coronary Syndrome; Adenosine; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Clopido

2010
Rivaroxaban versus enoxaparin for thromboprophylaxis after total hip or knee arthroplasty: a meta-analysis of randomized controlled trials.
    European journal of clinical pharmacology, 2010, Volume: 66, Issue:11

    Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Double-Blind Method

2010
Apixaban versus enoxaparin in patients with total knee arthroplasty. A meta-analysis of randomised trials.
    Thrombosis and haemostasis, 2011, Volume: 105, Issue:2

    Topics: Aged; Anticoagulants; Arthroplasty, Replacement, Knee; Enoxaparin; Evidence-Based Medicine; Female;

2011
Dabigatran and rivaroxaban for prevention of venous thromboembolism--systematic review and adjusted indirect comparison.
    Journal of clinical pharmacy and therapeutics, 2011, Volume: 36, Issue:1

    Topics: Anticoagulants; Antithrombins; Benzimidazoles; beta-Alanine; Dabigatran; Enoxaparin; Factor Xa Inhib

2011
Antithrombotic therapy in ST-segment elevation myocardial infarction.
    Expert opinion on pharmacotherapy, 2011, Volume: 12, Issue:2

    Topics: Angioplasty, Balloon, Coronary; Anticoagulants; Coronary Thrombosis; Electrocardiography; Enoxaparin

2011
Individual patient data meta-analysis of enoxaparin vs. unfractionated heparin for venous thromboembolism prevention in medical patients.
    Journal of thrombosis and haemostasis : JTH, 2011, Volume: 9, Issue:3

    Topics: Aged; Anticoagulants; Double-Blind Method; Enoxaparin; Female; France; Hemorrhage; Heparin; Humans;

2011
Standard or extended-duration prophylaxis in medical patients? A review of the evidence.
    Journal of thrombosis and thrombolysis, 2011, Volume: 32, Issue:3

    Topics: Anticoagulants; Enoxaparin; Female; Hemorrhage; Humans; Male; Pulmonary Embolism; Randomized Control

2011
Increased major bleeding risk in patients with kidney dysfunction receiving enoxaparin: a meta-analysis.
    European journal of clinical pharmacology, 2012, Volume: 68, Issue:5

    Topics: Anticoagulants; Cardiovascular Diseases; Enoxaparin; Glomerular Filtration Rate; Hemorrhage; Humans;

2012
Efficacy and safety of enoxaparin versus unfractionated heparin during percutaneous coronary intervention: systematic review and meta-analysis.
    BMJ (Clinical research ed.), 2012, Feb-03, Volume: 344

    Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Anticoagulants; Enoxaparin; Hemorrhage; Hep

2012
Bullous hemorrhagic dermatosis at distant sites: a report of 2 new cases due to enoxaparin injection and a review of the literature.
    Actas dermo-sifiliograficas, 2012, Volume: 103, Issue:9

    Topics: Aged; Anticoagulants; Drug Eruptions; Enoxaparin; Hemorrhage; Humans; Male; Skin Diseases, Vesiculob

2012
Prevention of venous thromboembolism with new oral anticoagulants versus standard pharmacological treatment in acute medically ill patients: a systematic review and meta-analysis.
    Drugs, 2012, Sep-10, Volume: 72, Issue:13

    Topics: Acute Disease; Administration, Oral; Anticoagulants; Dose-Response Relationship, Drug; Enoxaparin; F

2012
Interpretation of endpoints in a network meta-analysis of new oral anticoagulants following total hip or total knee replacement surgery.
    Thrombosis and haemostasis, 2012, Volume: 108, Issue:5

    Topics: Administration, Oral; Anticoagulants; Antithrombins; Arthroplasty, Replacement, Hip; Arthroplasty, R

2012
Apixaban. After hip or knee replacement: LMWH remains the standard treatment.
    Prescrire international, 2012, Volume: 21, Issue:130

    Topics: Administration, Oral; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Drug Interact

2012
Systematic review of randomized controlled trials of new anticoagulants for venous thromboembolism prophylaxis in major orthopedic surgeries, compared with enoxaparin.
    Annals of vascular surgery, 2013, Volume: 27, Issue:3

    Topics: Aged; Anticoagulants; Clinical Trials, Phase III as Topic; Elective Surgical Procedures; Enoxaparin;

2013
Efficacy and bleeding complications among patients randomized to enoxaparin or unfractionated heparin for antithrombin therapy in non-ST-Segment elevation acute coronary syndromes: a systematic overview.
    JAMA, 2004, Jul-07, Volume: 292, Issue:1

    Topics: Angina Pectoris; Angina, Unstable; Cause of Death; Enoxaparin; Fibrinolytic Agents; Hemorrhage; Hepa

2004
Enoxaparin can be used safely in patients with severe thrombocytopenia due to intensive chemotherapy regimens.
    Leukemia & lymphoma, 2004, Volume: 45, Issue:7

    Topics: Adult; Aged; Anticoagulants; Antineoplastic Combined Chemotherapy Protocols; Catheterization, Centra

2004
Surgical management of enoxaparin- and/or warfarin-induced massive retroperitoneal bleeding: report of a case and review of the literature.
    Southern medical journal, 2005, Volume: 98, Issue:1

    Topics: Aged; Anticoagulants; Enoxaparin; Hemorrhage; Humans; Laparotomy; Male; Pulmonary Embolism; Retroper

2005
Enoxaparin: a review of its use as thromboprophylaxis in acutely ill, nonsurgical patients.
    Drugs, 2005, Volume: 65, Issue:7

    Topics: Acute Disease; Anticoagulants; Antithrombins; Blood Coagulation; Enoxaparin; Hemorrhage; Humans; Thr

2005
Meta-analysis: low-molecular-weight heparin and bleeding in patients with severe renal insufficiency.
    Annals of internal medicine, 2006, May-02, Volume: 144, Issue:9

    Topics: Anticoagulants; Autoantibodies; Creatinine; Drug Monitoring; Enoxaparin; Factor Xa; Hemorrhage; Huma

2006
Meta-analysis: low-molecular-weight heparin and bleeding in patients with severe renal insufficiency.
    Annals of internal medicine, 2006, May-02, Volume: 144, Issue:9

    Topics: Anticoagulants; Autoantibodies; Creatinine; Drug Monitoring; Enoxaparin; Factor Xa; Hemorrhage; Huma

2006
Meta-analysis: low-molecular-weight heparin and bleeding in patients with severe renal insufficiency.
    Annals of internal medicine, 2006, May-02, Volume: 144, Issue:9

    Topics: Anticoagulants; Autoantibodies; Creatinine; Drug Monitoring; Enoxaparin; Factor Xa; Hemorrhage; Huma

2006
Meta-analysis: low-molecular-weight heparin and bleeding in patients with severe renal insufficiency.
    Annals of internal medicine, 2006, May-02, Volume: 144, Issue:9

    Topics: Anticoagulants; Autoantibodies; Creatinine; Drug Monitoring; Enoxaparin; Factor Xa; Hemorrhage; Huma

2006
Rivaroxaban for thromboprophylaxis after orthopaedic surgery: pooled analysis of two studies.
    Thrombosis and haemostasis, 2007, Volume: 97, Issue:6

    Topics: Adult; Aged; Aged, 80 and over; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Dos

2007
Use of enoxaparin in patients with chronic kidney disease: safety considerations.
    Drug safety, 2007, Volume: 30, Issue:11

    Topics: Animals; Anticoagulants; Clinical Trials as Topic; Enoxaparin; Hemorrhage; Humans; Kidney Failure, C

2007
Utilizing enoxaparin in the management of STEMI.
    Vascular health and risk management, 2007, Volume: 3, Issue:5

    Topics: Clinical Trials as Topic; Enoxaparin; Hemorrhage; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibi

2007
Current update on glycoprotein IIb-IIIa and direct thrombin inhibition in percutaneous coronary intervention for non-ST elevation acute coronary syndromes: balancing bleeding risk and antiplatelet efficacy.
    Journal of interventional cardiology, 2008, Volume: 21, Issue:2

    Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Angiotensin-Converting Enzyme Inhibitors; A

2008
Factor Xa inactivation in acute coronary syndrome.
    Current pharmaceutical design, 2008, Volume: 14, Issue:12

    Topics: Acute Coronary Syndrome; Angina, Unstable; Anticoagulants; Enoxaparin; Factor Xa Inhibitors; Fondapa

2008
Prevention of postoperative thromboembolism in general surgery with enoxaparin.
    The European journal of surgery. Supplement. : = Acta chirurgica. Supplement, 1994, Issue:571

    Topics: Adult; Aged; Blood Loss, Surgical; Enoxaparin; Hematologic Tests; Hemorrhage; Heparin; Humans; Middl

1994
Enoxaparin. A reappraisal of its pharmacology and clinical applications in the prevention and treatment of thromboembolic disease.
    Drugs, 1995, Volume: 49, Issue:3

    Topics: Biological Availability; Blood Coagulation; Dose-Response Relationship, Drug; Enoxaparin; Female; He

1995
Low molecular weight heparins and their use in obstetrics and gynecology.
    Obstetrical & gynecological survey, 1994, Volume: 49, Issue:6

    Topics: Clinical Trials as Topic; Enoxaparin; Female; Fetus; Gynecology; Hemorrhage; Heparin, Low-Molecular-

1994
Neuroaxial blocks and LMWH thromboprophylaxis.
    Hospital medicine (London, England : 1998), 1998, Volume: 59, Issue:12

    Topics: Anesthesia, Epidural; Contraindications; Enoxaparin; Fibrinolytic Agents; Hematoma, Epidural, Crania

1998
The role of low-molecular-weight heparins in the management of unstable angina and non-ST-segment elevation myocardial infarction.
    Journal of thrombosis and thrombolysis, 2001, Volume: 11, Issue:2

    Topics: Angina, Unstable; Angioplasty, Balloon, Coronary; Anticoagulants; Cardiac Catheterization; Electroca

2001
Overview of the clinical results of pentasaccharide in major orthopedic surgery.
    Haematologica, 2001, Volume: 86, Issue:11 Suppl 2

    Topics: Clinical Trials, Phase III as Topic; Enoxaparin; Fibrinolytic Agents; Fondaparinux; Hemorrhage; Huma

2001
Pharmacological profile of reviparin-sodium.
    Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis, 1993, Volume: 4 Suppl 1

    Topics: Animals; Biological Availability; Blood Coagulation; Carbohydrate Sequence; Factor Xa Inhibitors; He

1993
Low molecular weight heparin and haemodialysis: neutralization by protaminchloride.
    Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis, 1993, Volume: 4 Suppl 1

    Topics: Biocompatible Materials; Blood Coagulation Tests; Factor Xa Inhibitors; Hemorrhage; Heparin, Low-Mol

1993
Reviparin: a review of its efficacy in the prevention and treatment of venous thromboembolism.
    Drugs, 2001, Volume: 61, Issue:8

    Topics: Adult; Anticoagulants; Catheterization, Central Venous; Child; Female; Hemorrhage; Heparin, Low-Mole

2001
[Treatment of thrombosis with low-molecular-weight heparin. Comparison of body weight-adjusted and fixed dosage].
    Medizinische Klinik (Munich, Germany : 1983), 2003, Sep-15, Volume: 98, Issue:9

    Topics: Adult; Aged; Anticoagulants; Data Interpretation, Statistical; Female; Fibrinolytic Agents; Hemorrha

2003
Efficacy and Safety of Apixaban versus Dalteparin as a Treatment for Cancer-Associated Venous Thromboembolism: A Systematic Review and Meta-Analysis.
    Medicina (Kaunas, Lithuania), 2023, Oct-20, Volume: 59, Issue:10

    Topics: Anticoagulants; Dalteparin; Hemorrhage; Humans; Neoplasms; Venous Thromboembolism

2023
Direct Oral Anticoagulants Compared With Dalteparin for Treatment of Cancer-Associated Thrombosis: A Living, Interactive Systematic Review and Network Meta-analysis.
    Mayo Clinic proceedings, 2022, Volume: 97, Issue:2

    Topics: Administration, Oral; Anticoagulants; Dalteparin; Hemorrhage; Heparin, Low-Molecular-Weight; Humans;

2022
Direct Oral Anticoagulants Compared With Dalteparin for Treatment of Cancer-Associated Thrombosis: A Living, Interactive Systematic Review and Network Meta-analysis.
    Mayo Clinic proceedings, 2022, Volume: 97, Issue:2

    Topics: Administration, Oral; Anticoagulants; Dalteparin; Hemorrhage; Heparin, Low-Molecular-Weight; Humans;

2022
Direct Oral Anticoagulants Compared With Dalteparin for Treatment of Cancer-Associated Thrombosis: A Living, Interactive Systematic Review and Network Meta-analysis.
    Mayo Clinic proceedings, 2022, Volume: 97, Issue:2

    Topics: Administration, Oral; Anticoagulants; Dalteparin; Hemorrhage; Heparin, Low-Molecular-Weight; Humans;

2022
Direct Oral Anticoagulants Compared With Dalteparin for Treatment of Cancer-Associated Thrombosis: A Living, Interactive Systematic Review and Network Meta-analysis.
    Mayo Clinic proceedings, 2022, Volume: 97, Issue:2

    Topics: Administration, Oral; Anticoagulants; Dalteparin; Hemorrhage; Heparin, Low-Molecular-Weight; Humans;

2022
Direct Oral Anticoagulants Compared With Dalteparin for Treatment of Cancer-Associated Thrombosis: A Living, Interactive Systematic Review and Network Meta-analysis.
    Mayo Clinic proceedings, 2022, Volume: 97, Issue:2

    Topics: Administration, Oral; Anticoagulants; Dalteparin; Hemorrhage; Heparin, Low-Molecular-Weight; Humans;

2022
Direct Oral Anticoagulants Compared With Dalteparin for Treatment of Cancer-Associated Thrombosis: A Living, Interactive Systematic Review and Network Meta-analysis.
    Mayo Clinic proceedings, 2022, Volume: 97, Issue:2

    Topics: Administration, Oral; Anticoagulants; Dalteparin; Hemorrhage; Heparin, Low-Molecular-Weight; Humans;

2022
Direct Oral Anticoagulants Compared With Dalteparin for Treatment of Cancer-Associated Thrombosis: A Living, Interactive Systematic Review and Network Meta-analysis.
    Mayo Clinic proceedings, 2022, Volume: 97, Issue:2

    Topics: Administration, Oral; Anticoagulants; Dalteparin; Hemorrhage; Heparin, Low-Molecular-Weight; Humans;

2022
Direct Oral Anticoagulants Compared With Dalteparin for Treatment of Cancer-Associated Thrombosis: A Living, Interactive Systematic Review and Network Meta-analysis.
    Mayo Clinic proceedings, 2022, Volume: 97, Issue:2

    Topics: Administration, Oral; Anticoagulants; Dalteparin; Hemorrhage; Heparin, Low-Molecular-Weight; Humans;

2022
Direct Oral Anticoagulants Compared With Dalteparin for Treatment of Cancer-Associated Thrombosis: A Living, Interactive Systematic Review and Network Meta-analysis.
    Mayo Clinic proceedings, 2022, Volume: 97, Issue:2

    Topics: Administration, Oral; Anticoagulants; Dalteparin; Hemorrhage; Heparin, Low-Molecular-Weight; Humans;

2022
Direct Oral Anticoagulants Compared With Dalteparin for Treatment of Cancer-Associated Thrombosis: A Living, Interactive Systematic Review and Network Meta-analysis.
    Mayo Clinic proceedings, 2022, Volume: 97, Issue:2

    Topics: Administration, Oral; Anticoagulants; Dalteparin; Hemorrhage; Heparin, Low-Molecular-Weight; Humans;

2022
Direct Oral Anticoagulants Compared With Dalteparin for Treatment of Cancer-Associated Thrombosis: A Living, Interactive Systematic Review and Network Meta-analysis.
    Mayo Clinic proceedings, 2022, Volume: 97, Issue:2

    Topics: Administration, Oral; Anticoagulants; Dalteparin; Hemorrhage; Heparin, Low-Molecular-Weight; Humans;

2022
Direct Oral Anticoagulants Compared With Dalteparin for Treatment of Cancer-Associated Thrombosis: A Living, Interactive Systematic Review and Network Meta-analysis.
    Mayo Clinic proceedings, 2022, Volume: 97, Issue:2

    Topics: Administration, Oral; Anticoagulants; Dalteparin; Hemorrhage; Heparin, Low-Molecular-Weight; Humans;

2022
Direct Oral Anticoagulants Compared With Dalteparin for Treatment of Cancer-Associated Thrombosis: A Living, Interactive Systematic Review and Network Meta-analysis.
    Mayo Clinic proceedings, 2022, Volume: 97, Issue:2

    Topics: Administration, Oral; Anticoagulants; Dalteparin; Hemorrhage; Heparin, Low-Molecular-Weight; Humans;

2022
Direct Oral Anticoagulants Compared With Dalteparin for Treatment of Cancer-Associated Thrombosis: A Living, Interactive Systematic Review and Network Meta-analysis.
    Mayo Clinic proceedings, 2022, Volume: 97, Issue:2

    Topics: Administration, Oral; Anticoagulants; Dalteparin; Hemorrhage; Heparin, Low-Molecular-Weight; Humans;

2022
Direct Oral Anticoagulants Compared With Dalteparin for Treatment of Cancer-Associated Thrombosis: A Living, Interactive Systematic Review and Network Meta-analysis.
    Mayo Clinic proceedings, 2022, Volume: 97, Issue:2

    Topics: Administration, Oral; Anticoagulants; Dalteparin; Hemorrhage; Heparin, Low-Molecular-Weight; Humans;

2022
Direct Oral Anticoagulants Compared With Dalteparin for Treatment of Cancer-Associated Thrombosis: A Living, Interactive Systematic Review and Network Meta-analysis.
    Mayo Clinic proceedings, 2022, Volume: 97, Issue:2

    Topics: Administration, Oral; Anticoagulants; Dalteparin; Hemorrhage; Heparin, Low-Molecular-Weight; Humans;

2022
Anticoagulation for the initial treatment of venous thromboembolism in people with cancer.
    The Cochrane database of systematic reviews, 2018, 01-24, Volume: 1

    Topics: Anticoagulants; Dalteparin; Fibrinolytic Agents; Fondaparinux; Hemorrhage; Heparin; Heparin, Low-Mol

2018
Tinzaparin Sodium Pharmacokinetics in Patients with Chronic Kidney Disease: Practical Implications.
    American journal of cardiovascular drugs : drugs, devices, and other interventions, 2020, Volume: 20, Issue:3

    Topics: Fibrinolytic Agents; Hemorrhage; Humans; Renal Elimination; Renal Insufficiency, Chronic; Risk Adjus

2020
The Role of Tinzaparin in Oncology.
    Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis, 2018, Volume: 24, Issue:5

    Topics: Fibrinolytic Agents; Hemorrhage; Heparin, Low-Molecular-Weight; Humans; Neoplasms; Tinzaparin; Treat

2018
Tinzaparin for Long-Term Treatment of Venous Thromboembolism in Patients With Cancer: A Systematic Review and Meta-Analysis.
    Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis, 2018, Volume: 24, Issue:2

    Topics: Fibrinolytic Agents; Hemorrhage; Heparin, Low-Molecular-Weight; Humans; Neoplasms; Randomized Contro

2018
Effectiveness and Tolerability of Anticoagulants for Thromboprophylaxis after Major Joint Surgery: a Network Meta-Analysis.
    Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology, 2017, Volume: 42, Issue:5

    Topics: Anticoagulants; Aspirin; Databases, Factual; Hemorrhage; Heparin, Low-Molecular-Weight; Humans; Join

2017
Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy.
    The Cochrane database of systematic reviews, 2014, Aug-29, Issue:8

    Topics: Adult; Ambulatory Care; Anticoagulants; Antineoplastic Agents; Antithrombins; Child; Hemorrhage; Hep

2014

Trials

291 trials available for dalteparin and Hemorrhage

ArticleYear
Rivaroxaban versus nadroparin for thromboprophylaxis following thoracic surgery for lung cancer: A randomized, noninferiority trial.
    American journal of hematology, 2023, Volume: 98, Issue:8

    Topics: Anticoagulants; Hemorrhage; Humans; Lung Neoplasms; Nadroparin; Rivaroxaban; Thoracic Surgery; Venou

2023
The safety and efficacy of Heparin and Nadroparin compared to placebo in acute ischemic stroke - pilot study.
    Biomedical papers of the Medical Faculty of the University Palacky, Olomouc, Czechoslovakia, 2016, Volume: 160, Issue:4

    Topics: Administration, Cutaneous; Aged; Aged, 80 and over; Anticoagulants; Brain Ischemia; Double-Blind Met

2016
Anticoagulant therapy for symptomatic calf deep vein thrombosis (CACTUS): a randomised, double-blind, placebo-controlled trial.
    The Lancet. Haematology, 2016, Volume: 3, Issue:12

    Topics: Adult; Aged; Anticoagulants; Canada; Double-Blind Method; Early Termination of Clinical Trials; Exan

2016
Anticoagulant therapy for symptomatic calf deep vein thrombosis (CACTUS): a randomised, double-blind, placebo-controlled trial.
    The Lancet. Haematology, 2016, Volume: 3, Issue:12

    Topics: Adult; Aged; Anticoagulants; Canada; Double-Blind Method; Early Termination of Clinical Trials; Exan

2016
Anticoagulant therapy for symptomatic calf deep vein thrombosis (CACTUS): a randomised, double-blind, placebo-controlled trial.
    The Lancet. Haematology, 2016, Volume: 3, Issue:12

    Topics: Adult; Aged; Anticoagulants; Canada; Double-Blind Method; Early Termination of Clinical Trials; Exan

2016
Anticoagulant therapy for symptomatic calf deep vein thrombosis (CACTUS): a randomised, double-blind, placebo-controlled trial.
    The Lancet. Haematology, 2016, Volume: 3, Issue:12

    Topics: Adult; Aged; Anticoagulants; Canada; Double-Blind Method; Early Termination of Clinical Trials; Exan

2016
Citrate anticoagulation for continuous venovenous hemofiltration.
    Critical care medicine, 2009, Volume: 37, Issue:2

    Topics: Acute Kidney Injury; Aged; Anticoagulants; Citric Acid; Critical Illness; Female; Hemofiltration; He

2009
Citrate anticoagulation for continuous venovenous hemofiltration.
    Critical care medicine, 2009, Volume: 37, Issue:2

    Topics: Acute Kidney Injury; Aged; Anticoagulants; Citric Acid; Critical Illness; Female; Hemofiltration; He

2009
Citrate anticoagulation for continuous venovenous hemofiltration.
    Critical care medicine, 2009, Volume: 37, Issue:2

    Topics: Acute Kidney Injury; Aged; Anticoagulants; Citric Acid; Critical Illness; Female; Hemofiltration; He

2009
Citrate anticoagulation for continuous venovenous hemofiltration.
    Critical care medicine, 2009, Volume: 37, Issue:2

    Topics: Acute Kidney Injury; Aged; Anticoagulants; Citric Acid; Critical Illness; Female; Hemofiltration; He

2009
Randomized trial of the effect of the low molecular weight heparin nadroparin on survival in patients with cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2011, May-20, Volume: 29, Issue:15

    Topics: Aged; Anticoagulants; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung

2011
Outpatient treatment in patients with acute pulmonary embolism: the Hestia Study.
    Journal of thrombosis and haemostasis : JTH, 2011, Volume: 9, Issue:8

    Topics: Acute Disease; Adult; Aged; Ambulatory Care; Anticoagulants; Female; Hemorrhage; Humans; Male; Middl

2011
Tolerability of percutaneous coronary interventions in patients receiving nadroparin calcium for unstable angina or non-Q-wave myocardial infarction: the Angiofrax study.
    Current medical research and opinion, 2003, Volume: 19, Issue:2

    Topics: Aged; Angina, Unstable; Angioplasty, Balloon, Coronary; Female; Fibrinolytic Agents; Hemorrhage; Hum

2003
The effect of low molecular weight heparin on survival in patients with advanced malignancy.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2005, Apr-01, Volume: 23, Issue:10

    Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Double-Blind Method; Female; Hemorrhage; Humans; Inj

2005
Safety of citrate based hemofiltration in critically ill patients at high risk for bleeding: a comparison with nadroparin.
    The International journal of artificial organs, 2006, Volume: 29, Issue:6

    Topics: Anticoagulants; Citric Acid; Cohort Studies; Critical Illness; Erythrocyte Transfusion; Hemofiltrati

2006
Low-molecular-weight heparin compared with aspirin for the treatment of acute ischaemic stroke in Asian patients with large artery occlusive disease: a randomised study.
    The Lancet. Neurology, 2007, Volume: 6, Issue:5

    Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Anticoagulants; Arterial Occlusive Diseases; A

2007
An observational study on the effects of nadroparin-based and citrate-based continuous venovenous hemofiltration on calcium metabolism.
    Blood purification, 2007, Volume: 25, Issue:3

    Topics: Acute Kidney Injury; Aged; Anticoagulants; Calcium; Calcium Citrate; Chelating Agents; Citrates; Cri

2007
[Calcium nadroparin in the prevention of thromboembolic disease in elderly subjects. Study of tolerance].
    Presse medicale (Paris, France : 1983), 1995, Mar-25, Volume: 24, Issue:12

    Topics: Aged; Aged, 80 and over; Female; Hemorrhage; Heparin; Humans; Injections, Subcutaneous; Male; Nadrop

1995
Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. The Tasman Study Group.
    The New England journal of medicine, 1996, Mar-14, Volume: 334, Issue:11

    Topics: Aged; Anticoagulants; Female; Hemorrhage; Heparin; Home Nursing; Hospitalization; Humans; Infusions,

1996
Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. The Tasman Study Group.
    The New England journal of medicine, 1996, Mar-14, Volume: 334, Issue:11

    Topics: Aged; Anticoagulants; Female; Hemorrhage; Heparin; Home Nursing; Hospitalization; Humans; Infusions,

1996
Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. The Tasman Study Group.
    The New England journal of medicine, 1996, Mar-14, Volume: 334, Issue:11

    Topics: Aged; Anticoagulants; Female; Hemorrhage; Heparin; Home Nursing; Hospitalization; Humans; Infusions,

1996
Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. The Tasman Study Group.
    The New England journal of medicine, 1996, Mar-14, Volume: 334, Issue:11

    Topics: Aged; Anticoagulants; Female; Hemorrhage; Heparin; Home Nursing; Hospitalization; Humans; Infusions,

1996
Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. The Tasman Study Group.
    The New England journal of medicine, 1996, Mar-14, Volume: 334, Issue:11

    Topics: Aged; Anticoagulants; Female; Hemorrhage; Heparin; Home Nursing; Hospitalization; Humans; Infusions,

1996
Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. The Tasman Study Group.
    The New England journal of medicine, 1996, Mar-14, Volume: 334, Issue:11

    Topics: Aged; Anticoagulants; Female; Hemorrhage; Heparin; Home Nursing; Hospitalization; Humans; Infusions,

1996
Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. The Tasman Study Group.
    The New England journal of medicine, 1996, Mar-14, Volume: 334, Issue:11

    Topics: Aged; Anticoagulants; Female; Hemorrhage; Heparin; Home Nursing; Hospitalization; Humans; Infusions,

1996
Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. The Tasman Study Group.
    The New England journal of medicine, 1996, Mar-14, Volume: 334, Issue:11

    Topics: Aged; Anticoagulants; Female; Hemorrhage; Heparin; Home Nursing; Hospitalization; Humans; Infusions,

1996
Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. The Tasman Study Group.
    The New England journal of medicine, 1996, Mar-14, Volume: 334, Issue:11

    Topics: Aged; Anticoagulants; Female; Hemorrhage; Heparin; Home Nursing; Hospitalization; Humans; Infusions,

1996
Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. The Tasman Study Group.
    The New England journal of medicine, 1996, Mar-14, Volume: 334, Issue:11

    Topics: Aged; Anticoagulants; Female; Hemorrhage; Heparin; Home Nursing; Hospitalization; Humans; Infusions,

1996
Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. The Tasman Study Group.
    The New England journal of medicine, 1996, Mar-14, Volume: 334, Issue:11

    Topics: Aged; Anticoagulants; Female; Hemorrhage; Heparin; Home Nursing; Hospitalization; Humans; Infusions,

1996
Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. The Tasman Study Group.
    The New England journal of medicine, 1996, Mar-14, Volume: 334, Issue:11

    Topics: Aged; Anticoagulants; Female; Hemorrhage; Heparin; Home Nursing; Hospitalization; Humans; Infusions,

1996
Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. The Tasman Study Group.
    The New England journal of medicine, 1996, Mar-14, Volume: 334, Issue:11

    Topics: Aged; Anticoagulants; Female; Hemorrhage; Heparin; Home Nursing; Hospitalization; Humans; Infusions,

1996
Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. The Tasman Study Group.
    The New England journal of medicine, 1996, Mar-14, Volume: 334, Issue:11

    Topics: Aged; Anticoagulants; Female; Hemorrhage; Heparin; Home Nursing; Hospitalization; Humans; Infusions,

1996
Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. The Tasman Study Group.
    The New England journal of medicine, 1996, Mar-14, Volume: 334, Issue:11

    Topics: Aged; Anticoagulants; Female; Hemorrhage; Heparin; Home Nursing; Hospitalization; Humans; Infusions,

1996
Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. The Tasman Study Group.
    The New England journal of medicine, 1996, Mar-14, Volume: 334, Issue:11

    Topics: Aged; Anticoagulants; Female; Hemorrhage; Heparin; Home Nursing; Hospitalization; Humans; Infusions,

1996
[Preparation for delivery in patients with missed labor considering low-dose heparin and prostaglandins].
    Przeglad lekarski, 1996, Volume: 53, Issue:3

    Topics: Adult; Anticoagulants; Delivery, Obstetric; Dinoprostone; Female; Hemorrhage; Humans; Labor, Induced

1996
Low molecular weight heparin and compression stockings in the prevention of venous thromboembolism in neurosurgery.
    Thrombosis and haemostasis, 1996, Volume: 75, Issue:2

    Topics: Anticoagulants; Bandages; Combined Modality Therapy; Double-Blind Method; Hemorrhage; Humans; Nadrop

1996
Effect of nadroparin, a low-molecular-weight heparin, on clinical and angiographic restenosis after coronary balloon angioplasty: the FACT study. Fraxiparine Angioplastie Coronaire Transluminale.
    Circulation, 1997, Nov-18, Volume: 96, Issue:10

    Topics: Adolescent; Adult; Aged; Angioplasty, Balloon, Coronary; Anticoagulants; Coronary Angiography; Coron

1997
Comparison of low-molecular-weight heparin, administered primarily at home, with unfractionated heparin, administered in hospital, and subcutaneous heparin, administered at home for deep-vein thrombosis.
    Angiology, 1999, Volume: 50, Issue:10

    Topics: Ambulatory Care; Anticoagulants; Female; Fibrinolytic Agents; Follow-Up Studies; Health Care Costs;

1999
Use of low molecular weight heparin for prevention of deep vein thrombosis in total knee arthroplasty--a study of its efficacy in an Asian population.
    Annals of the Academy of Medicine, Singapore, 2000, Volume: 29, Issue:4

    Topics: Activities of Daily Living; Aged; Aged, 80 and over; Anticoagulants; Arthroplasty, Replacement, Knee

2000
Low molecular weight heparin versus oral anticoagulants in the long-term treatment of deep venous thrombosis.
    Journal of vascular surgery, 2001, Volume: 33, Issue:1

    Topics: Acenocoumarol; Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Anticoagulants; Blo

2001
Parnaparin versus aspirin in the treatment of retinal vein occlusion. A randomized, double blind, controlled study.
    Thrombosis research, 2010, Volume: 125, Issue:2

    Topics: Aspirin; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female

2010
A randomized double-blind study of low-molecular-weight heparin (parnaparin) for superficial vein thrombosis: STEFLUX (Superficial ThromboEmbolism and Fluxum).
    Journal of thrombosis and haemostasis : JTH, 2012, Volume: 10, Issue:6

    Topics: Aged; Analysis of Variance; Anticoagulants; Chi-Square Distribution; Dose-Response Relationship, Dru

2012
Use of unfractionated heparin and a low-molecular-weight heparin following thrombolytic therapy for acute ST-segment elevation myocardial infarction.
    Clinical drug investigation, 2006, Volume: 26, Issue:6

    Topics: Aged; Aspirin; Blood Coagulation; Drug Administration Schedule; Drug Therapy, Combination; Electroca

2006
Adjuvant therapy with bemiparin in patients with limited-stage small cell lung cancer: results from the ABEL study.
    Thrombosis research, 2013, Volume: 132, Issue:6

    Topics: Anticoagulants; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemotherapy, Adjuvant;

2013
Effect of self-administered intraperitoneal bemiparin on peritoneal transport and ultrafiltration capacity in peritoneal dialysis patients with membrane dysfunction. A randomized, multi-centre open clinical trial.
    Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 2012, Volume: 27, Issue:5

    Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Female; Hemorrhage; Heparin, Low-Molecular-Weight; H

2012
Efficacy and safety of bemiparin compared with enoxaparin in the prevention of venous thromboembolism after total knee arthroplasty: a randomized, double-blind clinical trial.
    Journal of thrombosis and haemostasis : JTH, 2003, Volume: 1, Issue:3

    Topics: Aged; Arthroplasty, Replacement, Knee; Enoxaparin; Female; Fibrinolytic Agents; Hemoglobins; Hemorrh

2003
Benefit-Risk of Rivaroxaban for Extended Thromboprophylaxis After Hospitalization for Medical Illness: Pooled Analysis From MAGELLAN and MARINER.
    Journal of the American Heart Association, 2021, 11-16, Volume: 10, Issue:22

    Topics: Aftercare; Anticoagulants; Enoxaparin; Hemorrhage; Hospitalization; Humans; Patient Discharge; Risk

2021
Benefit-Risk of Rivaroxaban for Extended Thromboprophylaxis After Hospitalization for Medical Illness: Pooled Analysis From MAGELLAN and MARINER.
    Journal of the American Heart Association, 2021, 11-16, Volume: 10, Issue:22

    Topics: Aftercare; Anticoagulants; Enoxaparin; Hemorrhage; Hospitalization; Humans; Patient Discharge; Risk

2021
Benefit-Risk of Rivaroxaban for Extended Thromboprophylaxis After Hospitalization for Medical Illness: Pooled Analysis From MAGELLAN and MARINER.
    Journal of the American Heart Association, 2021, 11-16, Volume: 10, Issue:22

    Topics: Aftercare; Anticoagulants; Enoxaparin; Hemorrhage; Hospitalization; Humans; Patient Discharge; Risk

2021
Benefit-Risk of Rivaroxaban for Extended Thromboprophylaxis After Hospitalization for Medical Illness: Pooled Analysis From MAGELLAN and MARINER.
    Journal of the American Heart Association, 2021, 11-16, Volume: 10, Issue:22

    Topics: Aftercare; Anticoagulants; Enoxaparin; Hemorrhage; Hospitalization; Humans; Patient Discharge; Risk

2021
Enoxaparin for thromboprophylaxis in hospitalized COVID-19 patients: The X-COVID-19 Randomized Trial.
    European journal of clinical investigation, 2022, Volume: 52, Issue:5

    Topics: Anticoagulants; COVID-19; Enoxaparin; Hemorrhage; Humans; Pulmonary Embolism; Venous Thromboembolism

2022
Comparison of Warfarin Initiation at 3 mg Versus 5 mg for Anticoagulation of Patients with Mechanical Mitral Valve Replacement Surgery: A Prospective Randomized Trial.
    Clinical drug investigation, 2022, Volume: 42, Issue:4

    Topics: Anticoagulants; Drug Resistance; Enoxaparin; Hemorrhage; Humans; International Normalized Ratio; Met

2022
Oral Rivaroxaban in the Prophylaxis of COVID-19 Induced Coagulopathy.
    The Journal of the Association of Physicians of India, 2022, Volume: 70, Issue:2

    Topics: Anticoagulants; COVID-19; Enoxaparin; Hemorrhage; Humans; Prospective Studies; Rivaroxaban; Thromboe

2022
Enoxaparin Thromboprophylaxis in Children Hospitalized for COVID-19: A Phase 2 Trial.
    Pediatrics, 2022, 07-01, Volume: 150, Issue:1

    Topics: Anticoagulants; Child; COVID-19; Enoxaparin; Hemorrhage; Humans; Prospective Studies; Systemic Infla

2022
Thromboprophylactic low-molecular-weight heparin versus standard of care in unvaccinated, at-risk outpatients with COVID-19 (ETHIC): an open-label, multicentre, randomised, controlled, phase 3b trial.
    The Lancet. Haematology, 2022, Volume: 9, Issue:8

    Topics: COVID-19; COVID-19 Vaccines; Enoxaparin; Female; Hemorrhage; Heparin, Low-Molecular-Weight; Humans;

2022
Effect of Rivaroxaban vs Enoxaparin on Major Cardiac Adverse Events and Bleeding Risk in the Acute Phase of Acute Coronary Syndrome: The H-REPLACE Randomized Equivalence and Noninferiority Trial.
    JAMA network open, 2023, 02-01, Volume: 6, Issue:2

    Topics: Acute Coronary Syndrome; Aged; Aspirin; Enoxaparin; Female; Hemorrhage; Humans; Male; Platelet Aggre

2023
Final Study Report of Andexanet Alfa for Major Bleeding With Factor Xa Inhibitors.
    Circulation, 2023, 03-28, Volume: 147, Issue:13

    Topics: Aged; Anticoagulants; Cohort Studies; Enoxaparin; Factor Xa; Factor Xa Inhibitors; Female; Hemorrhag

2023
Intermediate dose enoxaparin in hospitalized patients with moderate-severe COVID-19: a pilot phase II single-arm study, INHIXACOVID19.
    BMC infectious diseases, 2023, Oct-24, Volume: 23, Issue:1

    Topics: Anticoagulants; COVID-19; Enoxaparin; Hemorrhage; Heparin; Humans; Prospective Studies; Treatment Ou

2023
Net-clinical benefit of extended prophylaxis of venous thromboembolism with betrixaban in medically ill patients aged 80 or more.
    Journal of thrombosis and haemostasis : JTH, 2019, Volume: 17, Issue:12

    Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Anticoagulants; Benzamides; Blood Coagulation;

2019
Effect of Osocimab in Preventing Venous Thromboembolism Among Patients Undergoing Knee Arthroplasty: The FOXTROT Randomized Clinical Trial.
    JAMA, 2020, 01-14, Volume: 323, Issue:2

    Topics: Aged; Antibodies, Monoclonal, Humanized; Anticoagulants; Arthroplasty, Replacement, Knee; Dose-Respo

2020
Thromboprophylaxis with Rivaroxaban in Acutely Ill Medical Patients with Renal Impairment: Insights from the MAGELLAN and MARINER Trials.
    Thrombosis and haemostasis, 2020, Volume: 120, Issue:3

    Topics: Acute Disease; Aged; Anticoagulants; Double-Blind Method; Enoxaparin; Female; Hemorrhage; Humans; In

2020
Thromboprophylaxis with Rivaroxaban in Acutely Ill Medical Patients with Renal Impairment: Insights from the MAGELLAN and MARINER Trials.
    Thrombosis and haemostasis, 2020, Volume: 120, Issue:3

    Topics: Acute Disease; Aged; Anticoagulants; Double-Blind Method; Enoxaparin; Female; Hemorrhage; Humans; In

2020
Thromboprophylaxis with Rivaroxaban in Acutely Ill Medical Patients with Renal Impairment: Insights from the MAGELLAN and MARINER Trials.
    Thrombosis and haemostasis, 2020, Volume: 120, Issue:3

    Topics: Acute Disease; Aged; Anticoagulants; Double-Blind Method; Enoxaparin; Female; Hemorrhage; Humans; In

2020
Thromboprophylaxis with Rivaroxaban in Acutely Ill Medical Patients with Renal Impairment: Insights from the MAGELLAN and MARINER Trials.
    Thrombosis and haemostasis, 2020, Volume: 120, Issue:3

    Topics: Acute Disease; Aged; Anticoagulants; Double-Blind Method; Enoxaparin; Female; Hemorrhage; Humans; In

2020
Rivaroxaban or Enoxaparin in Nonmajor Orthopedic Surgery.
    The New England journal of medicine, 2020, 05-14, Volume: 382, Issue:20

    Topics: Administration, Oral; Adult; Anticoagulants; Double-Blind Method; Enoxaparin; Female; Hemorrhage; Hu

2020
Intermittent pneumatic compression versus additional prophylaxis with enoxaparin for prevention of venous thromboembolism after laparoscopic surgery for gastric and colorectal malignancies: multicentre randomized clinical trial.
    BJS open, 2020, Volume: 4, Issue:5

    Topics: Aged; Anticoagulants; Colorectal Neoplasms; Enoxaparin; Female; Hemorrhage; Humans; Intermittent Pne

2020
Aspirin versus low-molecular-weight heparin for venous thromboembolism prophylaxis in orthopaedic trauma patients: A patient-centered randomized controlled trial.
    PloS one, 2020, Volume: 15, Issue:8

    Topics: Adult; Aged; Anticoagulants; Aspirin; Enoxaparin; Female; Fibrinolytic Agents; Fractures, Bone; Hemo

2020
Rationale and Design of the H-REPLACE Study: Safety and Efficacy of LMWH Versus Rivaroxaban in ChinEse Patients HospitaLized with Acute Coronary SyndromE.
    Cardiovascular drugs and therapy, 2022, Volume: 36, Issue:1

    Topics: Acute Coronary Syndrome; Anticoagulants; Asian People; Dose-Response Relationship, Drug; Enoxaparin;

2022
Efficacy and safety of apixaban in patients with active malignancy and acute deep venous thrombosis.
    Vascular, 2021, Volume: 29, Issue:5

    Topics: Administration, Oral; Aged; Anticoagulants; Egypt; Enoxaparin; Factor Xa Inhibitors; Female; Hemorrh

2021
Effect of Intermediate-Dose vs Standard-Dose Prophylactic Anticoagulation on Thrombotic Events, Extracorporeal Membrane Oxygenation Treatment, or Mortality Among Patients With COVID-19 Admitted to the Intensive Care Unit: The INSPIRATION Randomized Clinic
    JAMA, 2021, 04-27, Volume: 325, Issue:16

    Topics: Aged; Anticoagulants; COVID-19; Drug Administration Schedule; Enoxaparin; Extracorporeal Membrane Ox

2021
Effect of Intermediate-Dose vs Standard-Dose Prophylactic Anticoagulation on Thrombotic Events, Extracorporeal Membrane Oxygenation Treatment, or Mortality Among Patients With COVID-19 Admitted to the Intensive Care Unit: The INSPIRATION Randomized Clinic
    JAMA, 2021, 04-27, Volume: 325, Issue:16

    Topics: Aged; Anticoagulants; COVID-19; Drug Administration Schedule; Enoxaparin; Extracorporeal Membrane Ox

2021
Effect of Intermediate-Dose vs Standard-Dose Prophylactic Anticoagulation on Thrombotic Events, Extracorporeal Membrane Oxygenation Treatment, or Mortality Among Patients With COVID-19 Admitted to the Intensive Care Unit: The INSPIRATION Randomized Clinic
    JAMA, 2021, 04-27, Volume: 325, Issue:16

    Topics: Aged; Anticoagulants; COVID-19; Drug Administration Schedule; Enoxaparin; Extracorporeal Membrane Ox

2021
Effect of Intermediate-Dose vs Standard-Dose Prophylactic Anticoagulation on Thrombotic Events, Extracorporeal Membrane Oxygenation Treatment, or Mortality Among Patients With COVID-19 Admitted to the Intensive Care Unit: The INSPIRATION Randomized Clinic
    JAMA, 2021, 04-27, Volume: 325, Issue:16

    Topics: Aged; Anticoagulants; COVID-19; Drug Administration Schedule; Enoxaparin; Extracorporeal Membrane Ox

2021
Intermediate-Dose versus Standard-Dose Prophylactic Anticoagulation in Patients with COVID-19 Admitted to the Intensive Care Unit: 90-Day Results from the INSPIRATION Randomized Trial.
    Thrombosis and haemostasis, 2022, Volume: 122, Issue:1

    Topics: Aged; Anticoagulants; Cohort Studies; COVID-19; COVID-19 Drug Treatment; Critical Care; Dose-Respons

2022
Randomized clinical trial to evaluate a routine full anticoagulation Strategy in Patients with Coronavirus Infection (SARS-CoV2) admitted to hospital: Rationale and design of the ACTION (AntiCoagulaTlon cOroNavirus)-Coalition IV trial.
    American heart journal, 2021, Volume: 238

    Topics: Administration, Oral; Anticoagulants; Brazil; COVID-19; Drug Administration Schedule; Enoxaparin; Fi

2021
Therapeutic versus prophylactic anticoagulation for patients admitted to hospital with COVID-19 and elevated D-dimer concentration (ACTION): an open-label, multicentre, randomised, controlled trial.
    Lancet (London, England), 2021, 06-12, Volume: 397, Issue:10291

    Topics: Adult; Aged; Anticoagulants; Blood Coagulation; Brazil; COVID-19; COVID-19 Drug Treatment; Endpoint

2021
Abelacimab for Prevention of Venous Thromboembolism.
    The New England journal of medicine, 2021, 08-12, Volume: 385, Issue:7

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Anticoagulants; Arthroplasty, Rep

2021
A RCT study of Rivaroxaban, low-molecular-weight heparin, and sequential medication regimens for the prevention of venous thrombosis after internal fixation of hip fracture.
    Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2017, Volume: 92

    Topics: Aged; Aged, 80 and over; China; Cost-Benefit Analysis; Double-Blind Method; Drug Administration Sche

2017
Comparison of Fatal or Irreversible Events With Extended-Duration Betrixaban Versus Standard Dose Enoxaparin in Acutely Ill Medical Patients: An APEX Trial Substudy.
    Journal of the American Heart Association, 2017, Jul-11, Volume: 6, Issue:7

    Topics: Acute Disease; Adult; Aged; Anticoagulants; Benzamides; Cardiovascular Diseases; Double-Blind Method

2017
Randomized phase III trial of low-molecular-weight heparin enoxaparin in addition to standard treatment in small-cell lung cancer: the RASTEN trial.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2018, 02-01, Volume: 29, Issue:2

    Topics: Aged; Anticoagulants; Antineoplastic Combined Chemotherapy Protocols; Enoxaparin; Female; Hemorrhage

2018
Targeting Coagulase Activity in Staphylococcus aureus Bacteraemia: A Randomized Controlled Single-Centre Trial of Staphylothrombin Inhibition.
    Thrombosis and haemostasis, 2018, Volume: 118, Issue:5

    Topics: Administration, Intravenous; Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Antithro

2018
Evaluation of prophylactic dosages of Enoxaparin in non-surgical elderly patients with renal impairment.
    BMC pharmacology & toxicology, 2019, 05-07, Volume: 20, Issue:1

    Topics: Aged; Aged, 80 and over; Anticoagulants; Enoxaparin; Factor Xa; Female; Hemorrhage; Humans; Male; Re

2019
Efficacy and Safety of Enoxaparin for Prophylaxis of Postoperative Venous Thromboembolism After Esophagectomy: A Single-center Prospective Randomized Controlled Phase II Study.
    Anticancer research, 2019, Volume: 39, Issue:5

    Topics: Aged; Enoxaparin; Esophageal Neoplasms; Esophagectomy; Female; Hemorrhage; Heparin, Low-Molecular-We

2019
Comparison of apixaban to rivaroxaban and enoxaparin in acute cancer-associated venous thromboembolism.
    American journal of hematology, 2019, Volume: 94, Issue:11

    Topics: Aged; Anticoagulants; Enoxaparin; Factor Xa Inhibitors; Female; Follow-Up Studies; Hemorrhage; Human

2019
Safety and efficacy of periprocedural anticoagulation with enoxaparin in patients undergoing peripheral endovascular revascularization.
    Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis, 2014, Volume: 20, Issue:5

    Topics: Aged; Anticoagulants; Endovascular Procedures; Enoxaparin; Female; Hemorrhage; Humans; Male; Middle

2014
Oral apixaban for the treatment of acute venous thromboembolism.
    The New England journal of medicine, 2013, Aug-29, Volume: 369, Issue:9

    Topics: Acute Disease; Administration, Oral; Adult; Aged; Anticoagulants; Double-Blind Method; Enoxaparin; F

2013
Oral apixaban for the treatment of acute venous thromboembolism.
    The New England journal of medicine, 2013, Aug-29, Volume: 369, Issue:9

    Topics: Acute Disease; Administration, Oral; Adult; Aged; Anticoagulants; Double-Blind Method; Enoxaparin; F

2013
Oral apixaban for the treatment of acute venous thromboembolism.
    The New England journal of medicine, 2013, Aug-29, Volume: 369, Issue:9

    Topics: Acute Disease; Administration, Oral; Adult; Aged; Anticoagulants; Double-Blind Method; Enoxaparin; F

2013
Oral apixaban for the treatment of acute venous thromboembolism.
    The New England journal of medicine, 2013, Aug-29, Volume: 369, Issue:9

    Topics: Acute Disease; Administration, Oral; Adult; Aged; Anticoagulants; Double-Blind Method; Enoxaparin; F

2013
Oral apixaban for the treatment of acute venous thromboembolism.
    The New England journal of medicine, 2013, Aug-29, Volume: 369, Issue:9

    Topics: Acute Disease; Administration, Oral; Adult; Aged; Anticoagulants; Double-Blind Method; Enoxaparin; F

2013
Oral apixaban for the treatment of acute venous thromboembolism.
    The New England journal of medicine, 2013, Aug-29, Volume: 369, Issue:9

    Topics: Acute Disease; Administration, Oral; Adult; Aged; Anticoagulants; Double-Blind Method; Enoxaparin; F

2013
Oral apixaban for the treatment of acute venous thromboembolism.
    The New England journal of medicine, 2013, Aug-29, Volume: 369, Issue:9

    Topics: Acute Disease; Administration, Oral; Adult; Aged; Anticoagulants; Double-Blind Method; Enoxaparin; F

2013
Oral apixaban for the treatment of acute venous thromboembolism.
    The New England journal of medicine, 2013, Aug-29, Volume: 369, Issue:9

    Topics: Acute Disease; Administration, Oral; Adult; Aged; Anticoagulants; Double-Blind Method; Enoxaparin; F

2013
Oral apixaban for the treatment of acute venous thromboembolism.
    The New England journal of medicine, 2013, Aug-29, Volume: 369, Issue:9

    Topics: Acute Disease; Administration, Oral; Adult; Aged; Anticoagulants; Double-Blind Method; Enoxaparin; F

2013
Oral apixaban for the treatment of acute venous thromboembolism.
    The New England journal of medicine, 2013, Aug-29, Volume: 369, Issue:9

    Topics: Acute Disease; Administration, Oral; Adult; Aged; Anticoagulants; Double-Blind Method; Enoxaparin; F

2013
Oral apixaban for the treatment of acute venous thromboembolism.
    The New England journal of medicine, 2013, Aug-29, Volume: 369, Issue:9

    Topics: Acute Disease; Administration, Oral; Adult; Aged; Anticoagulants; Double-Blind Method; Enoxaparin; F

2013
Oral apixaban for the treatment of acute venous thromboembolism.
    The New England journal of medicine, 2013, Aug-29, Volume: 369, Issue:9

    Topics: Acute Disease; Administration, Oral; Adult; Aged; Anticoagulants; Double-Blind Method; Enoxaparin; F

2013
Oral apixaban for the treatment of acute venous thromboembolism.
    The New England journal of medicine, 2013, Aug-29, Volume: 369, Issue:9

    Topics: Acute Disease; Administration, Oral; Adult; Aged; Anticoagulants; Double-Blind Method; Enoxaparin; F

2013
Oral apixaban for the treatment of acute venous thromboembolism.
    The New England journal of medicine, 2013, Aug-29, Volume: 369, Issue:9

    Topics: Acute Disease; Administration, Oral; Adult; Aged; Anticoagulants; Double-Blind Method; Enoxaparin; F

2013
Oral apixaban for the treatment of acute venous thromboembolism.
    The New England journal of medicine, 2013, Aug-29, Volume: 369, Issue:9

    Topics: Acute Disease; Administration, Oral; Adult; Aged; Anticoagulants; Double-Blind Method; Enoxaparin; F

2013
Oral apixaban for the treatment of acute venous thromboembolism.
    The New England journal of medicine, 2013, Aug-29, Volume: 369, Issue:9

    Topics: Acute Disease; Administration, Oral; Adult; Aged; Anticoagulants; Double-Blind Method; Enoxaparin; F

2013
Oral apixaban for the treatment of acute venous thromboembolism.
    The New England journal of medicine, 2013, Aug-29, Volume: 369, Issue:9

    Topics: Acute Disease; Administration, Oral; Adult; Aged; Anticoagulants; Double-Blind Method; Enoxaparin; F

2013
Oral apixaban for the treatment of acute venous thromboembolism.
    The New England journal of medicine, 2013, Aug-29, Volume: 369, Issue:9

    Topics: Acute Disease; Administration, Oral; Adult; Aged; Anticoagulants; Double-Blind Method; Enoxaparin; F

2013
Oral apixaban for the treatment of acute venous thromboembolism.
    The New England journal of medicine, 2013, Aug-29, Volume: 369, Issue:9

    Topics: Acute Disease; Administration, Oral; Adult; Aged; Anticoagulants; Double-Blind Method; Enoxaparin; F

2013
Oral apixaban for the treatment of acute venous thromboembolism.
    The New England journal of medicine, 2013, Aug-29, Volume: 369, Issue:9

    Topics: Acute Disease; Administration, Oral; Adult; Aged; Anticoagulants; Double-Blind Method; Enoxaparin; F

2013
Oral apixaban for the treatment of acute venous thromboembolism.
    The New England journal of medicine, 2013, Aug-29, Volume: 369, Issue:9

    Topics: Acute Disease; Administration, Oral; Adult; Aged; Anticoagulants; Double-Blind Method; Enoxaparin; F

2013
Oral apixaban for the treatment of acute venous thromboembolism.
    The New England journal of medicine, 2013, Aug-29, Volume: 369, Issue:9

    Topics: Acute Disease; Administration, Oral; Adult; Aged; Anticoagulants; Double-Blind Method; Enoxaparin; F

2013
Oral apixaban for the treatment of acute venous thromboembolism.
    The New England journal of medicine, 2013, Aug-29, Volume: 369, Issue:9

    Topics: Acute Disease; Administration, Oral; Adult; Aged; Anticoagulants; Double-Blind Method; Enoxaparin; F

2013
Oral apixaban for the treatment of acute venous thromboembolism.
    The New England journal of medicine, 2013, Aug-29, Volume: 369, Issue:9

    Topics: Acute Disease; Administration, Oral; Adult; Aged; Anticoagulants; Double-Blind Method; Enoxaparin; F

2013
Oral apixaban for the treatment of acute venous thromboembolism.
    The New England journal of medicine, 2013, Aug-29, Volume: 369, Issue:9

    Topics: Acute Disease; Administration, Oral; Adult; Aged; Anticoagulants; Double-Blind Method; Enoxaparin; F

2013
Oral apixaban for the treatment of acute venous thromboembolism.
    The New England journal of medicine, 2013, Aug-29, Volume: 369, Issue:9

    Topics: Acute Disease; Administration, Oral; Adult; Aged; Anticoagulants; Double-Blind Method; Enoxaparin; F

2013
Oral apixaban for the treatment of acute venous thromboembolism.
    The New England journal of medicine, 2013, Aug-29, Volume: 369, Issue:9

    Topics: Acute Disease; Administration, Oral; Adult; Aged; Anticoagulants; Double-Blind Method; Enoxaparin; F

2013
Oral apixaban for the treatment of acute venous thromboembolism.
    The New England journal of medicine, 2013, Aug-29, Volume: 369, Issue:9

    Topics: Acute Disease; Administration, Oral; Adult; Aged; Anticoagulants; Double-Blind Method; Enoxaparin; F

2013
Oral apixaban for the treatment of acute venous thromboembolism.
    The New England journal of medicine, 2013, Aug-29, Volume: 369, Issue:9

    Topics: Acute Disease; Administration, Oral; Adult; Aged; Anticoagulants; Double-Blind Method; Enoxaparin; F

2013
Oral apixaban for the treatment of acute venous thromboembolism.
    The New England journal of medicine, 2013, Aug-29, Volume: 369, Issue:9

    Topics: Acute Disease; Administration, Oral; Adult; Aged; Anticoagulants; Double-Blind Method; Enoxaparin; F

2013
Oral apixaban for the treatment of acute venous thromboembolism.
    The New England journal of medicine, 2013, Aug-29, Volume: 369, Issue:9

    Topics: Acute Disease; Administration, Oral; Adult; Aged; Anticoagulants; Double-Blind Method; Enoxaparin; F

2013
Oral apixaban for the treatment of acute venous thromboembolism.
    The New England journal of medicine, 2013, Aug-29, Volume: 369, Issue:9

    Topics: Acute Disease; Administration, Oral; Adult; Aged; Anticoagulants; Double-Blind Method; Enoxaparin; F

2013
Oral apixaban for the treatment of acute venous thromboembolism.
    The New England journal of medicine, 2013, Aug-29, Volume: 369, Issue:9

    Topics: Acute Disease; Administration, Oral; Adult; Aged; Anticoagulants; Double-Blind Method; Enoxaparin; F

2013
Oral apixaban for the treatment of acute venous thromboembolism.
    The New England journal of medicine, 2013, Aug-29, Volume: 369, Issue:9

    Topics: Acute Disease; Administration, Oral; Adult; Aged; Anticoagulants; Double-Blind Method; Enoxaparin; F

2013
Oral apixaban for the treatment of acute venous thromboembolism.
    The New England journal of medicine, 2013, Aug-29, Volume: 369, Issue:9

    Topics: Acute Disease; Administration, Oral; Adult; Aged; Anticoagulants; Double-Blind Method; Enoxaparin; F

2013
Oral apixaban for the treatment of acute venous thromboembolism.
    The New England journal of medicine, 2013, Aug-29, Volume: 369, Issue:9

    Topics: Acute Disease; Administration, Oral; Adult; Aged; Anticoagulants; Double-Blind Method; Enoxaparin; F

2013
Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism.
    The New England journal of medicine, 2013, Oct-10, Volume: 369, Issue:15

    Topics: Aged; Anticoagulants; Double-Blind Method; Drug Administration Schedule; Enoxaparin; Female; Hemorrh

2013
Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism.
    The New England journal of medicine, 2013, Oct-10, Volume: 369, Issue:15

    Topics: Aged; Anticoagulants; Double-Blind Method; Drug Administration Schedule; Enoxaparin; Female; Hemorrh

2013
Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism.
    The New England journal of medicine, 2013, Oct-10, Volume: 369, Issue:15

    Topics: Aged; Anticoagulants; Double-Blind Method; Drug Administration Schedule; Enoxaparin; Female; Hemorrh

2013
Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism.
    The New England journal of medicine, 2013, Oct-10, Volume: 369, Issue:15

    Topics: Aged; Anticoagulants; Double-Blind Method; Drug Administration Schedule; Enoxaparin; Female; Hemorrh

2013
Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism.
    The New England journal of medicine, 2013, Oct-10, Volume: 369, Issue:15

    Topics: Aged; Anticoagulants; Double-Blind Method; Drug Administration Schedule; Enoxaparin; Female; Hemorrh

2013
Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism.
    The New England journal of medicine, 2013, Oct-10, Volume: 369, Issue:15

    Topics: Aged; Anticoagulants; Double-Blind Method; Drug Administration Schedule; Enoxaparin; Female; Hemorrh

2013
Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism.
    The New England journal of medicine, 2013, Oct-10, Volume: 369, Issue:15

    Topics: Aged; Anticoagulants; Double-Blind Method; Drug Administration Schedule; Enoxaparin; Female; Hemorrh

2013
Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism.
    The New England journal of medicine, 2013, Oct-10, Volume: 369, Issue:15

    Topics: Aged; Anticoagulants; Double-Blind Method; Drug Administration Schedule; Enoxaparin; Female; Hemorrh

2013
Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism.
    The New England journal of medicine, 2013, Oct-10, Volume: 369, Issue:15

    Topics: Aged; Anticoagulants; Double-Blind Method; Drug Administration Schedule; Enoxaparin; Female; Hemorrh

2013
Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism.
    The New England journal of medicine, 2013, Oct-10, Volume: 369, Issue:15

    Topics: Aged; Anticoagulants; Double-Blind Method; Drug Administration Schedule; Enoxaparin; Female; Hemorrh

2013
Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism.
    The New England journal of medicine, 2013, Oct-10, Volume: 369, Issue:15

    Topics: Aged; Anticoagulants; Double-Blind Method; Drug Administration Schedule; Enoxaparin; Female; Hemorrh

2013
Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism.
    The New England journal of medicine, 2013, Oct-10, Volume: 369, Issue:15

    Topics: Aged; Anticoagulants; Double-Blind Method; Drug Administration Schedule; Enoxaparin; Female; Hemorrh

2013
Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism.
    The New England journal of medicine, 2013, Oct-10, Volume: 369, Issue:15

    Topics: Aged; Anticoagulants; Double-Blind Method; Drug Administration Schedule; Enoxaparin; Female; Hemorrh

2013
Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism.
    The New England journal of medicine, 2013, Oct-10, Volume: 369, Issue:15

    Topics: Aged; Anticoagulants; Double-Blind Method; Drug Administration Schedule; Enoxaparin; Female; Hemorrh

2013
Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism.
    The New England journal of medicine, 2013, Oct-10, Volume: 369, Issue:15

    Topics: Aged; Anticoagulants; Double-Blind Method; Drug Administration Schedule; Enoxaparin; Female; Hemorrh

2013
Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism.
    The New England journal of medicine, 2013, Oct-10, Volume: 369, Issue:15

    Topics: Aged; Anticoagulants; Double-Blind Method; Drug Administration Schedule; Enoxaparin; Female; Hemorrh

2013
Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism.
    The New England journal of medicine, 2013, Oct-10, Volume: 369, Issue:15

    Topics: Aged; Anticoagulants; Double-Blind Method; Drug Administration Schedule; Enoxaparin; Female; Hemorrh

2013
Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism.
    The New England journal of medicine, 2013, Oct-10, Volume: 369, Issue:15

    Topics: Aged; Anticoagulants; Double-Blind Method; Drug Administration Schedule; Enoxaparin; Female; Hemorrh

2013
Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism.
    The New England journal of medicine, 2013, Oct-10, Volume: 369, Issue:15

    Topics: Aged; Anticoagulants; Double-Blind Method; Drug Administration Schedule; Enoxaparin; Female; Hemorrh

2013
Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism.
    The New England journal of medicine, 2013, Oct-10, Volume: 369, Issue:15

    Topics: Aged; Anticoagulants; Double-Blind Method; Drug Administration Schedule; Enoxaparin; Female; Hemorrh

2013
Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism.
    The New England journal of medicine, 2013, Oct-10, Volume: 369, Issue:15

    Topics: Aged; Anticoagulants; Double-Blind Method; Drug Administration Schedule; Enoxaparin; Female; Hemorrh

2013
Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism.
    The New England journal of medicine, 2013, Oct-10, Volume: 369, Issue:15

    Topics: Aged; Anticoagulants; Double-Blind Method; Drug Administration Schedule; Enoxaparin; Female; Hemorrh

2013
Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism.
    The New England journal of medicine, 2013, Oct-10, Volume: 369, Issue:15

    Topics: Aged; Anticoagulants; Double-Blind Method; Drug Administration Schedule; Enoxaparin; Female; Hemorrh

2013
Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism.
    The New England journal of medicine, 2013, Oct-10, Volume: 369, Issue:15

    Topics: Aged; Anticoagulants; Double-Blind Method; Drug Administration Schedule; Enoxaparin; Female; Hemorrh

2013
Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism.
    The New England journal of medicine, 2013, Oct-10, Volume: 369, Issue:15

    Topics: Aged; Anticoagulants; Double-Blind Method; Drug Administration Schedule; Enoxaparin; Female; Hemorrh

2013
Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism.
    The New England journal of medicine, 2013, Oct-10, Volume: 369, Issue:15

    Topics: Aged; Anticoagulants; Double-Blind Method; Drug Administration Schedule; Enoxaparin; Female; Hemorrh

2013
Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism.
    The New England journal of medicine, 2013, Oct-10, Volume: 369, Issue:15

    Topics: Aged; Anticoagulants; Double-Blind Method; Drug Administration Schedule; Enoxaparin; Female; Hemorrh

2013
Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism.
    The New England journal of medicine, 2013, Oct-10, Volume: 369, Issue:15

    Topics: Aged; Anticoagulants; Double-Blind Method; Drug Administration Schedule; Enoxaparin; Female; Hemorrh

2013
Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism.
    The New England journal of medicine, 2013, Oct-10, Volume: 369, Issue:15

    Topics: Aged; Anticoagulants; Double-Blind Method; Drug Administration Schedule; Enoxaparin; Female; Hemorrh

2013
Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism.
    The New England journal of medicine, 2013, Oct-10, Volume: 369, Issue:15

    Topics: Aged; Anticoagulants; Double-Blind Method; Drug Administration Schedule; Enoxaparin; Female; Hemorrh

2013
Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism.
    The New England journal of medicine, 2013, Oct-10, Volume: 369, Issue:15

    Topics: Aged; Anticoagulants; Double-Blind Method; Drug Administration Schedule; Enoxaparin; Female; Hemorrh

2013
Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism.
    The New England journal of medicine, 2013, Oct-10, Volume: 369, Issue:15

    Topics: Aged; Anticoagulants; Double-Blind Method; Drug Administration Schedule; Enoxaparin; Female; Hemorrh

2013
Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism.
    The New England journal of medicine, 2013, Oct-10, Volume: 369, Issue:15

    Topics: Aged; Anticoagulants; Double-Blind Method; Drug Administration Schedule; Enoxaparin; Female; Hemorrh

2013
Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism.
    The New England journal of medicine, 2013, Oct-10, Volume: 369, Issue:15

    Topics: Aged; Anticoagulants; Double-Blind Method; Drug Administration Schedule; Enoxaparin; Female; Hemorrh

2013
Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism.
    The New England journal of medicine, 2013, Oct-10, Volume: 369, Issue:15

    Topics: Aged; Anticoagulants; Double-Blind Method; Drug Administration Schedule; Enoxaparin; Female; Hemorrh

2013
Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism.
    The New England journal of medicine, 2013, Oct-10, Volume: 369, Issue:15

    Topics: Aged; Anticoagulants; Double-Blind Method; Drug Administration Schedule; Enoxaparin; Female; Hemorrh

2013
Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism.
    The New England journal of medicine, 2013, Oct-10, Volume: 369, Issue:15

    Topics: Aged; Anticoagulants; Double-Blind Method; Drug Administration Schedule; Enoxaparin; Female; Hemorrh

2013
Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism.
    The New England journal of medicine, 2013, Oct-10, Volume: 369, Issue:15

    Topics: Aged; Anticoagulants; Double-Blind Method; Drug Administration Schedule; Enoxaparin; Female; Hemorrh

2013
Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism.
    The New England journal of medicine, 2013, Oct-10, Volume: 369, Issue:15

    Topics: Aged; Anticoagulants; Double-Blind Method; Drug Administration Schedule; Enoxaparin; Female; Hemorrh

2013
Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism.
    The New England journal of medicine, 2013, Oct-10, Volume: 369, Issue:15

    Topics: Aged; Anticoagulants; Double-Blind Method; Drug Administration Schedule; Enoxaparin; Female; Hemorrh

2013
Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism.
    The New England journal of medicine, 2013, Oct-10, Volume: 369, Issue:15

    Topics: Aged; Anticoagulants; Double-Blind Method; Drug Administration Schedule; Enoxaparin; Female; Hemorrh

2013
Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism.
    The New England journal of medicine, 2013, Oct-10, Volume: 369, Issue:15

    Topics: Aged; Anticoagulants; Double-Blind Method; Drug Administration Schedule; Enoxaparin; Female; Hemorrh

2013
Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism.
    The New England journal of medicine, 2013, Oct-10, Volume: 369, Issue:15

    Topics: Aged; Anticoagulants; Double-Blind Method; Drug Administration Schedule; Enoxaparin; Female; Hemorrh

2013
Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism.
    The New England journal of medicine, 2013, Oct-10, Volume: 369, Issue:15

    Topics: Aged; Anticoagulants; Double-Blind Method; Drug Administration Schedule; Enoxaparin; Female; Hemorrh

2013
Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism.
    The New England journal of medicine, 2013, Oct-10, Volume: 369, Issue:15

    Topics: Aged; Anticoagulants; Double-Blind Method; Drug Administration Schedule; Enoxaparin; Female; Hemorrh

2013
Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism.
    The New England journal of medicine, 2013, Oct-10, Volume: 369, Issue:15

    Topics: Aged; Anticoagulants; Double-Blind Method; Drug Administration Schedule; Enoxaparin; Female; Hemorrh

2013
Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism.
    The New England journal of medicine, 2013, Oct-10, Volume: 369, Issue:15

    Topics: Aged; Anticoagulants; Double-Blind Method; Drug Administration Schedule; Enoxaparin; Female; Hemorrh

2013
Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism.
    The New England journal of medicine, 2013, Oct-10, Volume: 369, Issue:15

    Topics: Aged; Anticoagulants; Double-Blind Method; Drug Administration Schedule; Enoxaparin; Female; Hemorrh

2013
Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism.
    The New England journal of medicine, 2013, Oct-10, Volume: 369, Issue:15

    Topics: Aged; Anticoagulants; Double-Blind Method; Drug Administration Schedule; Enoxaparin; Female; Hemorrh

2013
Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism.
    The New England journal of medicine, 2013, Oct-10, Volume: 369, Issue:15

    Topics: Aged; Anticoagulants; Double-Blind Method; Drug Administration Schedule; Enoxaparin; Female; Hemorrh

2013
Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism.
    The New England journal of medicine, 2013, Oct-10, Volume: 369, Issue:15

    Topics: Aged; Anticoagulants; Double-Blind Method; Drug Administration Schedule; Enoxaparin; Female; Hemorrh

2013
Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism.
    The New England journal of medicine, 2013, Oct-10, Volume: 369, Issue:15

    Topics: Aged; Anticoagulants; Double-Blind Method; Drug Administration Schedule; Enoxaparin; Female; Hemorrh

2013
Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism.
    The New England journal of medicine, 2013, Oct-10, Volume: 369, Issue:15

    Topics: Aged; Anticoagulants; Double-Blind Method; Drug Administration Schedule; Enoxaparin; Female; Hemorrh

2013
Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism.
    The New England journal of medicine, 2013, Oct-10, Volume: 369, Issue:15

    Topics: Aged; Anticoagulants; Double-Blind Method; Drug Administration Schedule; Enoxaparin; Female; Hemorrh

2013
Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism.
    The New England journal of medicine, 2013, Oct-10, Volume: 369, Issue:15

    Topics: Aged; Anticoagulants; Double-Blind Method; Drug Administration Schedule; Enoxaparin; Female; Hemorrh

2013
Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism.
    The New England journal of medicine, 2013, Oct-10, Volume: 369, Issue:15

    Topics: Aged; Anticoagulants; Double-Blind Method; Drug Administration Schedule; Enoxaparin; Female; Hemorrh

2013
Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism.
    The New England journal of medicine, 2013, Oct-10, Volume: 369, Issue:15

    Topics: Aged; Anticoagulants; Double-Blind Method; Drug Administration Schedule; Enoxaparin; Female; Hemorrh

2013
Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism.
    The New England journal of medicine, 2013, Oct-10, Volume: 369, Issue:15

    Topics: Aged; Anticoagulants; Double-Blind Method; Drug Administration Schedule; Enoxaparin; Female; Hemorrh

2013
Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism.
    The New England journal of medicine, 2013, Oct-10, Volume: 369, Issue:15

    Topics: Aged; Anticoagulants; Double-Blind Method; Drug Administration Schedule; Enoxaparin; Female; Hemorrh

2013
Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism.
    The New England journal of medicine, 2013, Oct-10, Volume: 369, Issue:15

    Topics: Aged; Anticoagulants; Double-Blind Method; Drug Administration Schedule; Enoxaparin; Female; Hemorrh

2013
Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism.
    The New England journal of medicine, 2013, Oct-10, Volume: 369, Issue:15

    Topics: Aged; Anticoagulants; Double-Blind Method; Drug Administration Schedule; Enoxaparin; Female; Hemorrh

2013
Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism.
    The New England journal of medicine, 2013, Oct-10, Volume: 369, Issue:15

    Topics: Aged; Anticoagulants; Double-Blind Method; Drug Administration Schedule; Enoxaparin; Female; Hemorrh

2013
Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism.
    The New England journal of medicine, 2013, Oct-10, Volume: 369, Issue:15

    Topics: Aged; Anticoagulants; Double-Blind Method; Drug Administration Schedule; Enoxaparin; Female; Hemorrh

2013
Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism.
    The New England journal of medicine, 2013, Oct-10, Volume: 369, Issue:15

    Topics: Aged; Anticoagulants; Double-Blind Method; Drug Administration Schedule; Enoxaparin; Female; Hemorrh

2013
Impact of age on the efficacy and safety of extended-duration thromboprophylaxis in medical patients. Subgroup analysis from the EXCLAIM randomised trial.
    Thrombosis and haemostasis, 2013, Volume: 110, Issue:6

    Topics: Age Factors; Aged; Anticoagulants; Canada; Enoxaparin; Europe; Female; Follow-Up Studies; Hemorrhage

2013
Darexaban (YM150) versus enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a randomised phase IIb dose confirmation study (ONYX-3).
    Thrombosis and haemostasis, 2014, Volume: 111, Issue:2

    Topics: Aged; Anticoagulants; Arthroplasty, Replacement, Hip; Australia; Azepines; Benzamides; Brazil; Canad

2014
A non-interventional comparison of rivaroxaban with standard of care for thromboprophylaxis after major orthopaedic surgery in 17,701 patients with propensity score adjustment.
    Thrombosis and haemostasis, 2014, Volume: 111, Issue:1

    Topics: Administration, Oral; Aged; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacemen

2014
D-dimer as a predictor of venous thromboembolism in acutely ill, hospitalized patients: a subanalysis of the randomized controlled MAGELLAN trial.
    Journal of thrombosis and haemostasis : JTH, 2014, Volume: 12, Issue:4

    Topics: Acute Disease; Adult; Aged; Anticoagulants; Enoxaparin; Female; Fibrin Fibrinogen Degradation Produc

2014
D-dimer as a predictor of venous thromboembolism in acutely ill, hospitalized patients: a subanalysis of the randomized controlled MAGELLAN trial.
    Journal of thrombosis and haemostasis : JTH, 2014, Volume: 12, Issue:4

    Topics: Acute Disease; Adult; Aged; Anticoagulants; Enoxaparin; Female; Fibrin Fibrinogen Degradation Produc

2014
D-dimer as a predictor of venous thromboembolism in acutely ill, hospitalized patients: a subanalysis of the randomized controlled MAGELLAN trial.
    Journal of thrombosis and haemostasis : JTH, 2014, Volume: 12, Issue:4

    Topics: Acute Disease; Adult; Aged; Anticoagulants; Enoxaparin; Female; Fibrin Fibrinogen Degradation Produc

2014
D-dimer as a predictor of venous thromboembolism in acutely ill, hospitalized patients: a subanalysis of the randomized controlled MAGELLAN trial.
    Journal of thrombosis and haemostasis : JTH, 2014, Volume: 12, Issue:4

    Topics: Acute Disease; Adult; Aged; Anticoagulants; Enoxaparin; Female; Fibrin Fibrinogen Degradation Produc

2014
A feasible strategy for preventing blood clots in critically ill patients with acute kidney injury (FBI): study protocol for a randomized controlled trial.
    Trials, 2014, Jun-13, Volume: 15

    Topics: Acute Kidney Injury; Acute-Phase Proteins; Adult; Anticoagulants; Critical Illness; Double-Blind Met

2014
Use of the CRUSADE bleeding risk score in the prediction of major bleeding for patients with acute coronary syndrome receiving enoxaparin in Thailand.
    Heart, lung & circulation, 2014, Volume: 23, Issue:11

    Topics: Acute Coronary Syndrome; Enoxaparin; Female; Fibrinolytic Agents; Hemorrhage; Humans; Male; Middle A

2014
Predicting the risk of venous thromboembolism in patients hospitalized with heart failure.
    Circulation, 2014, Jul-29, Volume: 130, Issue:5

    Topics: Aged; Aged, 80 and over; Anticoagulants; Double-Blind Method; Enoxaparin; Factor Xa Inhibitors; Fema

2014
Predicting the risk of venous thromboembolism in patients hospitalized with heart failure.
    Circulation, 2014, Jul-29, Volume: 130, Issue:5

    Topics: Aged; Aged, 80 and over; Anticoagulants; Double-Blind Method; Enoxaparin; Factor Xa Inhibitors; Fema

2014
Predicting the risk of venous thromboembolism in patients hospitalized with heart failure.
    Circulation, 2014, Jul-29, Volume: 130, Issue:5

    Topics: Aged; Aged, 80 and over; Anticoagulants; Double-Blind Method; Enoxaparin; Factor Xa Inhibitors; Fema

2014
Predicting the risk of venous thromboembolism in patients hospitalized with heart failure.
    Circulation, 2014, Jul-29, Volume: 130, Issue:5

    Topics: Aged; Aged, 80 and over; Anticoagulants; Double-Blind Method; Enoxaparin; Factor Xa Inhibitors; Fema

2014
Impact of fondaparinux versus enoxaparin on in-hospital bleeding and 1-year death in non-ST-segment elevation myocardial infarction. FAST-MI (French Registry of Acute ST-elevation and non-ST-elevation Myocardial Infarction) 2010.
    European heart journal. Acute cardiovascular care, 2015, Volume: 4, Issue:3

    Topics: Aged; Anticoagulants; Enoxaparin; Female; Fondaparinux; France; Heart Conduction System; Hemorrhage;

2015
Factor XI antisense oligonucleotide for prevention of venous thrombosis.
    The New England journal of medicine, 2015, Jan-15, Volume: 372, Issue:3

    Topics: Adult; Aged; Anticoagulants; Arthroplasty, Replacement, Knee; Blood Coagulation; Clinical Protocols;

2015
Use of prestudy heparin did not influence the efficacy and safety of rivaroxaban in patients treated for symptomatic venous thromboem-bolism in the EINSTEIN DVT and EINSTEIN PE studies.
    Academic emergency medicine : official journal of the Society for Academic Emergency Medicine, 2015, Volume: 22, Issue:2

    Topics: Adult; Aged; Anticoagulants; Enoxaparin; Female; Hemorrhage; Heparin; Humans; Male; Middle Aged; Mor

2015
Efficacy and safety of anticoagulation therapy with different doses of enoxaparin for portal vein thrombosis in cirrhotic patients with hepatitis B.
    European journal of gastroenterology & hepatology, 2015, Volume: 27, Issue:8

    Topics: Adult; China; Drug Administration Schedule; Enoxaparin; Female; Fibrinolytic Agents; Hemorrhage; Hep

2015
Comparison of switch-therapy modalities (enoxaparin to rivaroxaban/dabigatran) and enoxaparin monotherapy after hip and knee replacement.
    Acta orthopaedica et traumatologica turcica, 2015, Volume: 49, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replac

2015
Independent predictors of poor vitamin K antagonist control in venous thromboembolism patients. Data from the EINSTEIN-DVT and PE studies.
    Thrombosis and haemostasis, 2015, Nov-25, Volume: 114, Issue:6

    Topics: Acenocoumarol; Administration, Oral; Aged; Anticoagulants; Drug Therapy, Combination; Enoxaparin; Fe

2015
Impact of anticoagulation regimen prior to revascularization in patients with non-ST-segment elevation acute coronary syndromes: The ACUITY trial.
    Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions, 2016, Volume: 88, Issue:2

    Topics: Acute Coronary Syndrome; Aged; Anticoagulants; Antithrombins; Coronary Artery Bypass; Drug Therapy,

2016
Oral apixaban for the treatment of venous thromboembolism in cancer patients: results from the AMPLIFY trial.
    Journal of thrombosis and haemostasis : JTH, 2015, Volume: 13, Issue:12

    Topics: Aged; Anticoagulants; Chi-Square Distribution; Double-Blind Method; Enoxaparin; Factor Xa Inhibitors

2015
Risk of major bleeding in patients with venous thromboembolism treated with rivaroxaban or with heparin and vitamin K antagonists.
    Thrombosis and haemostasis, 2016, Volume: 115, Issue:2

    Topics: Administration, Oral; Aged; Anti-Inflammatory Agents, Non-Steroidal; Anticoagulants; Black or Africa

2016
A randomized controlled trial of differing doses of postcesarean enoxaparin thromboprophylaxis in obese women.
    Journal of perinatology : official journal of the California Perinatal Association, 2016, Volume: 36, Issue:2

    Topics: Adult; Blood Coagulation; Body Mass Index; Chemoprevention; Dose-Response Relationship, Drug; Drug A

2016
Early time courses of recurrent thromboembolism and bleeding during apixaban or enoxaparin/warfarin therapy. A sub-analysis of the AMPLIFY trial.
    Thrombosis and haemostasis, 2016, Volume: 115, Issue:4

    Topics: Adult; Aged; Enoxaparin; Female; Follow-Up Studies; Hemorrhage; Humans; Male; Middle Aged; Pyrazoles

2016
Effect of oral factor Xa inhibitor and low-molecular-weight heparin on surgical complications following total hip arthroplasty.
    Thrombosis and haemostasis, 2016, Volume: 115, Issue:3

    Topics: Aged; Anticoagulants; Arthroplasty, Replacement, Hip; Enoxaparin; Factor Xa Inhibitors; Female; Hemo

2016
Intravenous Enoxaparin Versus Unfractionated Heparin in Elderly Patients Undergoing Primary Percutaneous Coronary Intervention: An Analysis of the Randomized ATOLL Trial.
    Angiology, 2017, Volume: 68, Issue:1

    Topics: Aged; Aged, 80 and over; Anticoagulants; Enoxaparin; Female; Fibrinolytic Agents; Hemorrhage; Hepari

2017
Andexanet Alfa for Acute Major Bleeding Associated with Factor Xa Inhibitors.
    The New England journal of medicine, 2016, 09-22, Volume: 375, Issue:12

    Topics: Acute Disease; Aged; Aged, 80 and over; Cardiovascular Diseases; Enoxaparin; Factor Xa; Factor Xa In

2016
Andexanet Alfa for Acute Major Bleeding Associated with Factor Xa Inhibitors.
    The New England journal of medicine, 2016, 09-22, Volume: 375, Issue:12

    Topics: Acute Disease; Aged; Aged, 80 and over; Cardiovascular Diseases; Enoxaparin; Factor Xa; Factor Xa In

2016
Andexanet Alfa for Acute Major Bleeding Associated with Factor Xa Inhibitors.
    The New England journal of medicine, 2016, 09-22, Volume: 375, Issue:12

    Topics: Acute Disease; Aged; Aged, 80 and over; Cardiovascular Diseases; Enoxaparin; Factor Xa; Factor Xa In

2016
Andexanet Alfa for Acute Major Bleeding Associated with Factor Xa Inhibitors.
    The New England journal of medicine, 2016, 09-22, Volume: 375, Issue:12

    Topics: Acute Disease; Aged; Aged, 80 and over; Cardiovascular Diseases; Enoxaparin; Factor Xa; Factor Xa In

2016
Clinical presentation and course of bleeding events in patients with venous thromboembolism, treated with apixaban or enoxaparin and warfarin. Results from the AMPLIFY trial.
    Thrombosis and haemostasis, 2016, Nov-30, Volume: 116, Issue:6

    Topics: Anticoagulants; Enoxaparin; Hemorrhage; Humans; Pyrazoles; Pyridones; Venous Thromboembolism; Warfar

2016
Edoxaban versus enoxaparin-warfarin in patients undergoing cardioversion of atrial fibrillation (ENSURE-AF): a randomised, open-label, phase 3b trial.
    Lancet (London, England), 2016, Oct-22, Volume: 388, Issue:10055

    Topics: Aged; Anticoagulants; Atrial Fibrillation; Electric Countershock; Enoxaparin; Factor Xa Inhibitors;

2016
Comparison of Enoxaparin and Rivaroxaban in Balance of Anti-Fibrinolysis and Anticoagulation Following Primary Total Knee Replacement: A Pilot Study.
    Medical science monitor : international medical journal of experimental and clinical research, 2017, Feb-08, Volume: 23

    Topics: Aged; Anticoagulants; Arthroplasty, Replacement, Knee; Blood Coagulation; Drug Interactions; Enoxapa

2017
The safety and efficacy of full- versus reduced-dose betrixaban in the Acute Medically Ill VTE (Venous Thromboembolism) Prevention With Extended-Duration Betrixaban (APEX) trial.
    American heart journal, 2017, Volume: 185

    Topics: Aged; Aged, 80 and over; Anticoagulants; Benzamides; Double-Blind Method; Enoxaparin; Factor Xa Inhi

2017
Outcomes in elderly patients with acute coronary syndromes randomized to enoxaparin vs. unfractionated heparin: results from the SYNERGY trial.
    European heart journal, 2008, Volume: 29, Issue:15

    Topics: Acute Coronary Syndrome; Age Factors; Aged; Anticoagulants; Coronary Angiography; Cross-Over Studies

2008
Improving clinical outcomes by reducing bleeding in patients with non-ST-elevation acute coronary syndromes.
    European heart journal, 2009, Volume: 30, Issue:6

    Topics: Acute Coronary Syndrome; Aged; Anticoagulants; Enoxaparin; Female; Fondaparinux; Hemorrhage; Humans;

2009
Prevention of postoperative venous thromboembolism in Japanese patients undergoing total hip or knee arthroplasty: two randomized, double-blind, placebo-controlled studies with three dosage regimens of enoxaparin.
    Journal of orthopaedic science : official journal of the Japanese Orthopaedic Association, 2008, Volume: 13, Issue:5

    Topics: Aged; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Double-Blind

2008
Bleeding and outcome in acute coronary syndrome: insights from continuous electrocardiogram monitoring in the Integrilin and Enoxaparin Randomized Assessment of Acute Coronary Syndrome Treatment (INTERACT) Trial.
    American heart journal, 2008, Volume: 156, Issue:4

    Topics: Acute Coronary Syndrome; Aged; Anticoagulants; Electrocardiography, Ambulatory; Enoxaparin; Eptifiba

2008
Antithrombotic therapy with fondaparinux in relation to interventional management strategy in patients with ST- and non-ST-segment elevation acute coronary syndromes: an individual patient-level combined analysis of the Fifth and Sixth Organization to Ass
    Circulation, 2008, Nov-11, Volume: 118, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Anticoagulants; Double-Blind Method;

2008
The use of intravenous enoxaparin in elective percutaneous coronary intervention in patients with renal impairment: results from the SafeTy and Efficacy of Enoxaparin in PCI patients, an internationaL randomized Evaluation (STEEPLE) trial.
    American heart journal, 2009, Volume: 157, Issue:1

    Topics: Aged; Angioplasty, Balloon, Coronary; Anticoagulants; Elective Surgical Procedures; Enoxaparin; Fema

2009
A randomized evaluation of betrixaban, an oral factor Xa inhibitor, for prevention of thromboembolic events after total knee replacement (EXPERT).
    Thrombosis and haemostasis, 2009, Volume: 101, Issue:1

    Topics: Administration, Oral; Adult; Aged; Arthroplasty, Replacement, Knee; Canada; Dose-Response Relationsh

2009
[Outpatient treatment of deep vein thrombosis with low-molecular-weight heparins. Experience from an open, prospective study in daily practice].
    Medizinische Klinik (Munich, Germany : 1983), 2009, Jan-15, Volume: 104, Issue:1

    Topics: Adult; Aged; Ambulatory Care; Dose-Response Relationship, Drug; Drug Administration Schedule; Enoxap

2009
How useful is determination of anti-factor Xa activity to guide bridging therapy with enoxaparin? A pilot study.
    Thrombosis and haemostasis, 2009, Volume: 101, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Drug Administration Schedule; Drug Monitoring; Enoxa

2009
Impact of anticoagulation regimens on sheath management and bleeding in patients undergoing elective percutaneous coronary intervention in the STEEPLE trial.
    Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions, 2009, Feb-15, Volume: 73, Issue:3

    Topics: Aged; Angioplasty, Balloon, Coronary; Anticoagulants; Enoxaparin; Female; Hemorrhage; Humans; Inject

2009
Fondaparinux compared to enoxaparin in patients with acute coronary syndromes without ST-segment elevation: outcomes and treatment effect across different levels of risk.
    American heart journal, 2009, Volume: 157, Issue:3

    Topics: Acute Coronary Syndrome; Anticoagulants; Enoxaparin; Fondaparinux; Hemorrhage; Humans; Polysaccharid

2009
Enoxaparin dosing in the elderly using adjusted body weight.
    Journal of thrombosis and thrombolysis, 2009, Volume: 28, Issue:3

    Topics: Aged; Aged, 80 and over; Anticoagulants; Body Weight; Drug Dosage Calculations; Enoxaparin; Factor X

2009
Advanced age, antithrombotic strategy, and bleeding in non-ST-segment elevation acute coronary syndromes: results from the ACUITY (Acute Catheterization and Urgent Intervention Triage Strategy) trial.
    Journal of the American College of Cardiology, 2009, Mar-24, Volume: 53, Issue:12

    Topics: Acute Coronary Syndrome; Aged; Aging; Angioplasty, Balloon, Coronary; Anticoagulants; Coronary Arter

2009
Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial.
    Lancet (London, England), 2009, 05-16, Volume: 373, Issue:9676

    Topics: Administration, Oral; Aged; Analysis of Variance; Anticoagulants; Arthroplasty, Replacement, Knee; D

2009
Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial.
    Lancet (London, England), 2009, 05-16, Volume: 373, Issue:9676

    Topics: Administration, Oral; Aged; Analysis of Variance; Anticoagulants; Arthroplasty, Replacement, Knee; D

2009
Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial.
    Lancet (London, England), 2009, 05-16, Volume: 373, Issue:9676

    Topics: Administration, Oral; Aged; Analysis of Variance; Anticoagulants; Arthroplasty, Replacement, Knee; D

2009
Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial.
    Lancet (London, England), 2009, 05-16, Volume: 373, Issue:9676

    Topics: Administration, Oral; Aged; Analysis of Variance; Anticoagulants; Arthroplasty, Replacement, Knee; D

2009
Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial.
    Lancet (London, England), 2009, 05-16, Volume: 373, Issue:9676

    Topics: Administration, Oral; Aged; Analysis of Variance; Anticoagulants; Arthroplasty, Replacement, Knee; D

2009
Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial.
    Lancet (London, England), 2009, 05-16, Volume: 373, Issue:9676

    Topics: Administration, Oral; Aged; Analysis of Variance; Anticoagulants; Arthroplasty, Replacement, Knee; D

2009
Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial.
    Lancet (London, England), 2009, 05-16, Volume: 373, Issue:9676

    Topics: Administration, Oral; Aged; Analysis of Variance; Anticoagulants; Arthroplasty, Replacement, Knee; D

2009
Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial.
    Lancet (London, England), 2009, 05-16, Volume: 373, Issue:9676

    Topics: Administration, Oral; Aged; Analysis of Variance; Anticoagulants; Arthroplasty, Replacement, Knee; D

2009
Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial.
    Lancet (London, England), 2009, 05-16, Volume: 373, Issue:9676

    Topics: Administration, Oral; Aged; Analysis of Variance; Anticoagulants; Arthroplasty, Replacement, Knee; D

2009
Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial.
    Lancet (London, England), 2009, 05-16, Volume: 373, Issue:9676

    Topics: Administration, Oral; Aged; Analysis of Variance; Anticoagulants; Arthroplasty, Replacement, Knee; D

2009
Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial.
    Lancet (London, England), 2009, 05-16, Volume: 373, Issue:9676

    Topics: Administration, Oral; Aged; Analysis of Variance; Anticoagulants; Arthroplasty, Replacement, Knee; D

2009
Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial.
    Lancet (London, England), 2009, 05-16, Volume: 373, Issue:9676

    Topics: Administration, Oral; Aged; Analysis of Variance; Anticoagulants; Arthroplasty, Replacement, Knee; D

2009
Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial.
    Lancet (London, England), 2009, 05-16, Volume: 373, Issue:9676

    Topics: Administration, Oral; Aged; Analysis of Variance; Anticoagulants; Arthroplasty, Replacement, Knee; D

2009
Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial.
    Lancet (London, England), 2009, 05-16, Volume: 373, Issue:9676

    Topics: Administration, Oral; Aged; Analysis of Variance; Anticoagulants; Arthroplasty, Replacement, Knee; D

2009
Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial.
    Lancet (London, England), 2009, 05-16, Volume: 373, Issue:9676

    Topics: Administration, Oral; Aged; Analysis of Variance; Anticoagulants; Arthroplasty, Replacement, Knee; D

2009
Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial.
    Lancet (London, England), 2009, 05-16, Volume: 373, Issue:9676

    Topics: Administration, Oral; Aged; Analysis of Variance; Anticoagulants; Arthroplasty, Replacement, Knee; D

2009
Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial.
    Lancet (London, England), 2009, 05-16, Volume: 373, Issue:9676

    Topics: Administration, Oral; Aged; Analysis of Variance; Anticoagulants; Arthroplasty, Replacement, Knee; D

2009
Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial.
    Lancet (London, England), 2009, 05-16, Volume: 373, Issue:9676

    Topics: Administration, Oral; Aged; Analysis of Variance; Anticoagulants; Arthroplasty, Replacement, Knee; D

2009
Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial.
    Lancet (London, England), 2009, 05-16, Volume: 373, Issue:9676

    Topics: Administration, Oral; Aged; Analysis of Variance; Anticoagulants; Arthroplasty, Replacement, Knee; D

2009
Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial.
    Lancet (London, England), 2009, 05-16, Volume: 373, Issue:9676

    Topics: Administration, Oral; Aged; Analysis of Variance; Anticoagulants; Arthroplasty, Replacement, Knee; D

2009
Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial.
    Lancet (London, England), 2009, 05-16, Volume: 373, Issue:9676

    Topics: Administration, Oral; Aged; Analysis of Variance; Anticoagulants; Arthroplasty, Replacement, Knee; D

2009
Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial.
    Lancet (London, England), 2009, 05-16, Volume: 373, Issue:9676

    Topics: Administration, Oral; Aged; Analysis of Variance; Anticoagulants; Arthroplasty, Replacement, Knee; D

2009
Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial.
    Lancet (London, England), 2009, 05-16, Volume: 373, Issue:9676

    Topics: Administration, Oral; Aged; Analysis of Variance; Anticoagulants; Arthroplasty, Replacement, Knee; D

2009
Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial.
    Lancet (London, England), 2009, 05-16, Volume: 373, Issue:9676

    Topics: Administration, Oral; Aged; Analysis of Variance; Anticoagulants; Arthroplasty, Replacement, Knee; D

2009
Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial.
    Lancet (London, England), 2009, 05-16, Volume: 373, Issue:9676

    Topics: Administration, Oral; Aged; Analysis of Variance; Anticoagulants; Arthroplasty, Replacement, Knee; D

2009
Choice of arterial access site and outcomes in patients with acute coronary syndromes managed with an early invasive strategy: the ACUITY trial.
    EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology, 2009, Volume: 5, Issue:1

    Topics: Acute Coronary Syndrome; Adult; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Anticoagula

2009
Streptokinase and enoxaparin as an alternative to fibrin-specific lytic-based regimens: an ExTRACT-TIMI 25 analysis.
    Drugs, 2009, Jul-30, Volume: 69, Issue:11

    Topics: Adult; Aged; Angioplasty, Balloon, Coronary; Cohort Studies; Drug Therapy, Combination; Endpoint Det

2009
Apixaban or enoxaparin for thromboprophylaxis after knee replacement.
    The New England journal of medicine, 2009, Aug-06, Volume: 361, Issue:6

    Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Arthroplasty, Replacement, Knee; Double-Blind Method

2009
Relationship between baseline haemoglobin and major bleeding complications in acute coronary syndromes.
    European heart journal, 2010, Volume: 31, Issue:1

    Topics: Acute Coronary Syndrome; Aged; Analysis of Variance; Angioplasty, Balloon, Coronary; Anticoagulants;

2010
Relationship between baseline haemoglobin and major bleeding complications in acute coronary syndromes.
    European heart journal, 2010, Volume: 31, Issue:1

    Topics: Acute Coronary Syndrome; Aged; Analysis of Variance; Angioplasty, Balloon, Coronary; Anticoagulants;

2010
Relationship between baseline haemoglobin and major bleeding complications in acute coronary syndromes.
    European heart journal, 2010, Volume: 31, Issue:1

    Topics: Acute Coronary Syndrome; Aged; Analysis of Variance; Angioplasty, Balloon, Coronary; Anticoagulants;

2010
Relationship between baseline haemoglobin and major bleeding complications in acute coronary syndromes.
    European heart journal, 2010, Volume: 31, Issue:1

    Topics: Acute Coronary Syndrome; Aged; Analysis of Variance; Angioplasty, Balloon, Coronary; Anticoagulants;

2010
Low-molecular-weight heparin and unfractionated heparin in prophylaxis against deep vein thrombosis in critically ill patients undergoing major surgery.
    Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis, 2010, Volume: 21, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Critical Illness; Drug Administration Schedule; Elec

2010
Modelling the occurrence and severity of enoxaparin-induced bleeding and bruising events.
    British journal of clinical pharmacology, 2009, Volume: 68, Issue:5

    Topics: Anticoagulants; Dose-Response Relationship, Drug; Enoxaparin; Female; Hemorrhage; Humans; Kidney; Ki

2009
Efficacy and safety of enoxaparin in Japanese patients undergoing curative abdominal or pelvic cancer surgery: results from a multicenter, randomized, open-label study.
    Thrombosis research, 2010, Volume: 125, Issue:3

    Topics: Abdominal Neoplasms; Aged; Anticoagulants; Asian People; Drug Administration Schedule; Enoxaparin; F

2010
Enoxaparin versus unfractionated heparin in elective percutaneous coronary intervention 1-year results from the STEEPLE (SafeTy and efficacy of enoxaparin in percutaneous coronary intervention patients, an international randomized evaluation) trial.
    JACC. Cardiovascular interventions, 2009, Volume: 2, Issue:11

    Topics: Aged; Angioplasty, Balloon, Coronary; Anticoagulants; Australia; Canada; Enoxaparin; Europe; Female;

2009
Comparison of the anticoagulant intensities of fondaparinux and enoxaparin in the Organization to Assess Strategies in Acute Ischemic Syndromes (OASIS)-5 trial.
    Journal of thrombosis and haemostasis : JTH, 2010, Volume: 8, Issue:2

    Topics: Acute Coronary Syndrome; Aged; Anticoagulants; Blood Coagulation; Dose-Response Relationship, Drug;

2010
One-year outcomes after a strategy using enoxaparin vs. unfractionated heparin in patients undergoing fibrinolysis for ST-segment elevation myocardial infarction: 1-year results of the ExTRACT-TIMI 25 trial.
    European heart journal, 2010, Volume: 31, Issue:17

    Topics: Adult; Aged; Double-Blind Method; Drug Therapy, Combination; Enoxaparin; Female; Fibrinolytic Agents

2010
Relations between bleeding and outcomes in patients with ST-elevation myocardial infarction in the ExTRACT-TIMI 25 trial.
    European heart journal, 2010, Volume: 31, Issue:17

    Topics: Aged; Cause of Death; Drug Therapy, Combination; Enoxaparin; Female; Fibrinolytic Agents; Hemorrhage

2010
Extended-duration venous thromboembolism prophylaxis in acutely ill medical patients with recently reduced mobility: a randomized trial.
    Annals of internal medicine, 2010, Jul-06, Volume: 153, Issue:1

    Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Anticoagulants; Delayed-Action Preparations; Double-B

2010
Extended-duration venous thromboembolism prophylaxis in acutely ill medical patients with recently reduced mobility: a randomized trial.
    Annals of internal medicine, 2010, Jul-06, Volume: 153, Issue:1

    Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Anticoagulants; Delayed-Action Preparations; Double-B

2010
Extended-duration venous thromboembolism prophylaxis in acutely ill medical patients with recently reduced mobility: a randomized trial.
    Annals of internal medicine, 2010, Jul-06, Volume: 153, Issue:1

    Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Anticoagulants; Delayed-Action Preparations; Double-B

2010
Extended-duration venous thromboembolism prophylaxis in acutely ill medical patients with recently reduced mobility: a randomized trial.
    Annals of internal medicine, 2010, Jul-06, Volume: 153, Issue:1

    Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Anticoagulants; Delayed-Action Preparations; Double-B

2010
Long-term efficacy and safety of once-daily enoxaparin plus warfarin for the outpatient ambulatory treatment of lower-limb deep vein thrombosis in the TROMBOTEK trial.
    Journal of vascular surgery, 2010, Volume: 52, Issue:5

    Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Ambulatory Care; Anticoagulants; B

2010
Does ambulation modify venous thromboembolism risk in acutely ill medical patients?
    Thrombosis and haemostasis, 2010, Volume: 104, Issue:5

    Topics: Acute Disease; Anticoagulants; Drug Administration Schedule; Enoxaparin; Fibrinolytic Agents; Guidel

2010
A dose-finding study with TAK-442, an oral factor Xa inhibitor, in patients undergoing elective total knee replacement surgery.
    Thrombosis and haemostasis, 2010, Volume: 104, Issue:6

    Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Anticoagulants; Arthroplasty, Replacement, Kne

2010
Enoxaparin versus dabigatran or rivaroxaban for thromboprophylaxis after hip or knee arthroplasty: Results of separate pooled analyses of phase III multicenter randomized trials.
    Circulation. Cardiovascular quality and outcomes, 2010, Volume: 3, Issue:6

    Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Benzimidazoles; bet

2010
Oral rivaroxaban for symptomatic venous thromboembolism.
    The New England journal of medicine, 2010, Dec-23, Volume: 363, Issue:26

    Topics: Acenocoumarol; Acute Disease; Administration, Oral; Aged; Anticoagulants; Double-Blind Method; Enoxa

2010
Oral rivaroxaban for symptomatic venous thromboembolism.
    The New England journal of medicine, 2010, Dec-23, Volume: 363, Issue:26

    Topics: Acenocoumarol; Acute Disease; Administration, Oral; Aged; Anticoagulants; Double-Blind Method; Enoxa

2010
Oral rivaroxaban for symptomatic venous thromboembolism.
    The New England journal of medicine, 2010, Dec-23, Volume: 363, Issue:26

    Topics: Acenocoumarol; Acute Disease; Administration, Oral; Aged; Anticoagulants; Double-Blind Method; Enoxa

2010
Oral rivaroxaban for symptomatic venous thromboembolism.
    The New England journal of medicine, 2010, Dec-23, Volume: 363, Issue:26

    Topics: Acenocoumarol; Acute Disease; Administration, Oral; Aged; Anticoagulants; Double-Blind Method; Enoxa

2010
Oral rivaroxaban for symptomatic venous thromboembolism.
    The New England journal of medicine, 2010, Dec-23, Volume: 363, Issue:26

    Topics: Acenocoumarol; Acute Disease; Administration, Oral; Aged; Anticoagulants; Double-Blind Method; Enoxa

2010
Oral rivaroxaban for symptomatic venous thromboembolism.
    The New England journal of medicine, 2010, Dec-23, Volume: 363, Issue:26

    Topics: Acenocoumarol; Acute Disease; Administration, Oral; Aged; Anticoagulants; Double-Blind Method; Enoxa

2010
Oral rivaroxaban for symptomatic venous thromboembolism.
    The New England journal of medicine, 2010, Dec-23, Volume: 363, Issue:26

    Topics: Acenocoumarol; Acute Disease; Administration, Oral; Aged; Anticoagulants; Double-Blind Method; Enoxa

2010
Oral rivaroxaban for symptomatic venous thromboembolism.
    The New England journal of medicine, 2010, Dec-23, Volume: 363, Issue:26

    Topics: Acenocoumarol; Acute Disease; Administration, Oral; Aged; Anticoagulants; Double-Blind Method; Enoxa

2010
Oral rivaroxaban for symptomatic venous thromboembolism.
    The New England journal of medicine, 2010, Dec-23, Volume: 363, Issue:26

    Topics: Acenocoumarol; Acute Disease; Administration, Oral; Aged; Anticoagulants; Double-Blind Method; Enoxa

2010
Oral rivaroxaban for symptomatic venous thromboembolism.
    The New England journal of medicine, 2010, Dec-23, Volume: 363, Issue:26

    Topics: Acenocoumarol; Acute Disease; Administration, Oral; Aged; Anticoagulants; Double-Blind Method; Enoxa

2010
Oral rivaroxaban for symptomatic venous thromboembolism.
    The New England journal of medicine, 2010, Dec-23, Volume: 363, Issue:26

    Topics: Acenocoumarol; Acute Disease; Administration, Oral; Aged; Anticoagulants; Double-Blind Method; Enoxa

2010
Oral rivaroxaban for symptomatic venous thromboembolism.
    The New England journal of medicine, 2010, Dec-23, Volume: 363, Issue:26

    Topics: Acenocoumarol; Acute Disease; Administration, Oral; Aged; Anticoagulants; Double-Blind Method; Enoxa

2010
Oral rivaroxaban for symptomatic venous thromboembolism.
    The New England journal of medicine, 2010, Dec-23, Volume: 363, Issue:26

    Topics: Acenocoumarol; Acute Disease; Administration, Oral; Aged; Anticoagulants; Double-Blind Method; Enoxa

2010
Oral rivaroxaban for symptomatic venous thromboembolism.
    The New England journal of medicine, 2010, Dec-23, Volume: 363, Issue:26

    Topics: Acenocoumarol; Acute Disease; Administration, Oral; Aged; Anticoagulants; Double-Blind Method; Enoxa

2010
Oral rivaroxaban for symptomatic venous thromboembolism.
    The New England journal of medicine, 2010, Dec-23, Volume: 363, Issue:26

    Topics: Acenocoumarol; Acute Disease; Administration, Oral; Aged; Anticoagulants; Double-Blind Method; Enoxa

2010
Oral rivaroxaban for symptomatic venous thromboembolism.
    The New England journal of medicine, 2010, Dec-23, Volume: 363, Issue:26

    Topics: Acenocoumarol; Acute Disease; Administration, Oral; Aged; Anticoagulants; Double-Blind Method; Enoxa

2010
Oral rivaroxaban for symptomatic venous thromboembolism.
    The New England journal of medicine, 2010, Dec-23, Volume: 363, Issue:26

    Topics: Acenocoumarol; Acute Disease; Administration, Oral; Aged; Anticoagulants; Double-Blind Method; Enoxa

2010
Oral rivaroxaban for symptomatic venous thromboembolism.
    The New England journal of medicine, 2010, Dec-23, Volume: 363, Issue:26

    Topics: Acenocoumarol; Acute Disease; Administration, Oral; Aged; Anticoagulants; Double-Blind Method; Enoxa

2010
Oral rivaroxaban for symptomatic venous thromboembolism.
    The New England journal of medicine, 2010, Dec-23, Volume: 363, Issue:26

    Topics: Acenocoumarol; Acute Disease; Administration, Oral; Aged; Anticoagulants; Double-Blind Method; Enoxa

2010
Oral rivaroxaban for symptomatic venous thromboembolism.
    The New England journal of medicine, 2010, Dec-23, Volume: 363, Issue:26

    Topics: Acenocoumarol; Acute Disease; Administration, Oral; Aged; Anticoagulants; Double-Blind Method; Enoxa

2010
Oral rivaroxaban for symptomatic venous thromboembolism.
    The New England journal of medicine, 2010, Dec-23, Volume: 363, Issue:26

    Topics: Acenocoumarol; Acute Disease; Administration, Oral; Aged; Anticoagulants; Double-Blind Method; Enoxa

2010
Oral rivaroxaban for symptomatic venous thromboembolism.
    The New England journal of medicine, 2010, Dec-23, Volume: 363, Issue:26

    Topics: Acenocoumarol; Acute Disease; Administration, Oral; Aged; Anticoagulants; Double-Blind Method; Enoxa

2010
Oral rivaroxaban for symptomatic venous thromboembolism.
    The New England journal of medicine, 2010, Dec-23, Volume: 363, Issue:26

    Topics: Acenocoumarol; Acute Disease; Administration, Oral; Aged; Anticoagulants; Double-Blind Method; Enoxa

2010
Oral rivaroxaban for symptomatic venous thromboembolism.
    The New England journal of medicine, 2010, Dec-23, Volume: 363, Issue:26

    Topics: Acenocoumarol; Acute Disease; Administration, Oral; Aged; Anticoagulants; Double-Blind Method; Enoxa

2010
Oral rivaroxaban for symptomatic venous thromboembolism.
    The New England journal of medicine, 2010, Dec-23, Volume: 363, Issue:26

    Topics: Acenocoumarol; Acute Disease; Administration, Oral; Aged; Anticoagulants; Double-Blind Method; Enoxa

2010
Apixaban versus enoxaparin for thromboprophylaxis after hip replacement.
    The New England journal of medicine, 2010, Dec-23, Volume: 363, Issue:26

    Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Anticoagulants; Arthroplasty, Replacement, Hip

2010
Oral dabigatran versus enoxaparin for thromboprophylaxis after primary total hip arthroplasty (RE-NOVATE II*). A randomised, double-blind, non-inferiority trial.
    Thrombosis and haemostasis, 2011, Volume: 105, Issue:4

    Topics: Administration, Oral; Aged; Anticoagulants; Antithrombins; Arthroplasty, Replacement, Hip; Benzimida

2011
Enoxaparin versus unfractionated heparin in the management of recurrent abortion secondary to antiphospholipid syndrome.
    International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics, 2011, Volume: 112, Issue:3

    Topics: Abortion, Habitual; Adult; Antibodies, Antiphospholipid; Anticoagulants; Antiphospholipid Syndrome;

2011
Aspirin, warfarin, or enoxaparin thromboprophylaxis in patients with multiple myeloma treated with thalidomide: a phase III, open-label, randomized trial.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2011, Mar-10, Volume: 29, Issue:8

    Topics: Aged; Anticoagulants; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Aspirin

2011
Aspirin, warfarin, or enoxaparin thromboprophylaxis in patients with multiple myeloma treated with thalidomide: a phase III, open-label, randomized trial.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2011, Mar-10, Volume: 29, Issue:8

    Topics: Aged; Anticoagulants; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Aspirin

2011
Aspirin, warfarin, or enoxaparin thromboprophylaxis in patients with multiple myeloma treated with thalidomide: a phase III, open-label, randomized trial.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2011, Mar-10, Volume: 29, Issue:8

    Topics: Aged; Anticoagulants; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Aspirin

2011
Aspirin, warfarin, or enoxaparin thromboprophylaxis in patients with multiple myeloma treated with thalidomide: a phase III, open-label, randomized trial.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2011, Mar-10, Volume: 29, Issue:8

    Topics: Aged; Anticoagulants; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Aspirin

2011
The impact of postrandomization crossover of therapy in acute coronary syndromes care.
    Circulation. Cardiovascular quality and outcomes, 2011, Volume: 4, Issue:2

    Topics: Acute Coronary Syndrome; Aged; Anticoagulants; Cross-Over Studies; Enoxaparin; Female; Hemorrhage; H

2011
Evaluation of therapeutic anticoagulation with enoxaparin and associated anti-Xa monitoring in patients with morbid obesity: a case series.
    Journal of thrombosis and thrombolysis, 2011, Volume: 32, Issue:2

    Topics: Adult; Aged; Blood Coagulation Factor Inhibitors; Enoxaparin; Evaluation Studies as Topic; Factor Xa

2011
Outpatient versus inpatient treatment for patients with acute pulmonary embolism: an international, open-label, randomised, non-inferiority trial.
    Lancet (London, England), 2011, Jul-02, Volume: 378, Issue:9785

    Topics: Acute Disease; Administration, Oral; Ambulatory Care; Anticoagulants; Enoxaparin; Female; Health Res

2011
Outpatient versus inpatient treatment for patients with acute pulmonary embolism: an international, open-label, randomised, non-inferiority trial.
    Lancet (London, England), 2011, Jul-02, Volume: 378, Issue:9785

    Topics: Acute Disease; Administration, Oral; Ambulatory Care; Anticoagulants; Enoxaparin; Female; Health Res

2011
Outpatient versus inpatient treatment for patients with acute pulmonary embolism: an international, open-label, randomised, non-inferiority trial.
    Lancet (London, England), 2011, Jul-02, Volume: 378, Issue:9785

    Topics: Acute Disease; Administration, Oral; Ambulatory Care; Anticoagulants; Enoxaparin; Female; Health Res

2011
Outpatient versus inpatient treatment for patients with acute pulmonary embolism: an international, open-label, randomised, non-inferiority trial.
    Lancet (London, England), 2011, Jul-02, Volume: 378, Issue:9785

    Topics: Acute Disease; Administration, Oral; Ambulatory Care; Anticoagulants; Enoxaparin; Female; Health Res

2011
Comparison of enoxaparin and unfractionated heparin in endovascular interventions for the treatment of peripheral arterial occlusive disease: a randomized controlled trial.
    Journal of thrombosis and haemostasis : JTH, 2011, Volume: 9, Issue:11

    Topics: Aged; Arterial Occlusive Diseases; Aspirin; Drug Therapy, Combination; Endothelium, Vascular; Enoxap

2011
Apixaban versus enoxaparin for thromboprophylaxis in medically ill patients.
    The New England journal of medicine, 2011, Dec-08, Volume: 365, Issue:23

    Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Anticoagulants; Double-Blind Method; Drug Administrat

2011
Apixaban versus enoxaparin for thromboprophylaxis in medically ill patients.
    The New England journal of medicine, 2011, Dec-08, Volume: 365, Issue:23

    Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Anticoagulants; Double-Blind Method; Drug Administrat

2011
Apixaban versus enoxaparin for thromboprophylaxis in medically ill patients.
    The New England journal of medicine, 2011, Dec-08, Volume: 365, Issue:23

    Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Anticoagulants; Double-Blind Method; Drug Administrat

2011
Apixaban versus enoxaparin for thromboprophylaxis in medically ill patients.
    The New England journal of medicine, 2011, Dec-08, Volume: 365, Issue:23

    Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Anticoagulants; Double-Blind Method; Drug Administrat

2011
Apixaban versus enoxaparin for thromboprophylaxis in medically ill patients.
    The New England journal of medicine, 2011, Dec-08, Volume: 365, Issue:23

    Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Anticoagulants; Double-Blind Method; Drug Administrat

2011
Apixaban versus enoxaparin for thromboprophylaxis in medically ill patients.
    The New England journal of medicine, 2011, Dec-08, Volume: 365, Issue:23

    Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Anticoagulants; Double-Blind Method; Drug Administrat

2011
Apixaban versus enoxaparin for thromboprophylaxis in medically ill patients.
    The New England journal of medicine, 2011, Dec-08, Volume: 365, Issue:23

    Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Anticoagulants; Double-Blind Method; Drug Administrat

2011
Apixaban versus enoxaparin for thromboprophylaxis in medically ill patients.
    The New England journal of medicine, 2011, Dec-08, Volume: 365, Issue:23

    Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Anticoagulants; Double-Blind Method; Drug Administrat

2011
Apixaban versus enoxaparin for thromboprophylaxis in medically ill patients.
    The New England journal of medicine, 2011, Dec-08, Volume: 365, Issue:23

    Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Anticoagulants; Double-Blind Method; Drug Administrat

2011
Low-molecular-weight heparin and mortality in acutely ill medical patients.
    The New England journal of medicine, 2011, Dec-29, Volume: 365, Issue:26

    Topics: Acute Disease; Aged; Anticoagulants; Cause of Death; Combined Modality Therapy; Double-Blind Method;

2011
Low-molecular-weight heparin and mortality in acutely ill medical patients.
    The New England journal of medicine, 2011, Dec-29, Volume: 365, Issue:26

    Topics: Acute Disease; Aged; Anticoagulants; Cause of Death; Combined Modality Therapy; Double-Blind Method;

2011
Low-molecular-weight heparin and mortality in acutely ill medical patients.
    The New England journal of medicine, 2011, Dec-29, Volume: 365, Issue:26

    Topics: Acute Disease; Aged; Anticoagulants; Cause of Death; Combined Modality Therapy; Double-Blind Method;

2011
Low-molecular-weight heparin and mortality in acutely ill medical patients.
    The New England journal of medicine, 2011, Dec-29, Volume: 365, Issue:26

    Topics: Acute Disease; Aged; Anticoagulants; Cause of Death; Combined Modality Therapy; Double-Blind Method;

2011
Concomitant use of medication with antiplatelet effects in patients receiving either rivaroxaban or enoxaparin after total hip or knee arthroplasty.
    Thrombosis research, 2012, Volume: 130, Issue:2

    Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Anticoagulants; Arthroplasty, Replacement, Knee; Aspi

2012
Dabigatran, rivaroxaban and apixaban versus enoxaparin for thomboprophylaxis after total knee or hip arthroplasty: pool-analysis of phase III randomized clinical trials.
    Thrombosis research, 2012, Volume: 130, Issue:2

    Topics: Adult; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Benzimidazol

2012
Semuloparin for prevention of venous thromboembolism after major orthopedic surgery: results from three randomized clinical trials, SAVE-HIP1, SAVE-HIP2 and SAVE-KNEE.
    Journal of thrombosis and haemostasis : JTH, 2012, Volume: 10, Issue:5

    Topics: Adult; Aged; Aged, 80 and over; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Dou

2012
Semuloparin for prevention of venous thromboembolism after major orthopedic surgery: results from three randomized clinical trials, SAVE-HIP1, SAVE-HIP2 and SAVE-KNEE.
    Journal of thrombosis and haemostasis : JTH, 2012, Volume: 10, Issue:5

    Topics: Adult; Aged; Aged, 80 and over; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Dou

2012
Semuloparin for prevention of venous thromboembolism after major orthopedic surgery: results from three randomized clinical trials, SAVE-HIP1, SAVE-HIP2 and SAVE-KNEE.
    Journal of thrombosis and haemostasis : JTH, 2012, Volume: 10, Issue:5

    Topics: Adult; Aged; Aged, 80 and over; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Dou

2012
Semuloparin for prevention of venous thromboembolism after major orthopedic surgery: results from three randomized clinical trials, SAVE-HIP1, SAVE-HIP2 and SAVE-KNEE.
    Journal of thrombosis and haemostasis : JTH, 2012, Volume: 10, Issue:5

    Topics: Adult; Aged; Aged, 80 and over; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Dou

2012
Semuloparin for prevention of venous thromboembolism after major orthopedic surgery: results from three randomized clinical trials, SAVE-HIP1, SAVE-HIP2 and SAVE-KNEE.
    Journal of thrombosis and haemostasis : JTH, 2012, Volume: 10, Issue:5

    Topics: Adult; Aged; Aged, 80 and over; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Dou

2012
Semuloparin for prevention of venous thromboembolism after major orthopedic surgery: results from three randomized clinical trials, SAVE-HIP1, SAVE-HIP2 and SAVE-KNEE.
    Journal of thrombosis and haemostasis : JTH, 2012, Volume: 10, Issue:5

    Topics: Adult; Aged; Aged, 80 and over; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Dou

2012
Semuloparin for prevention of venous thromboembolism after major orthopedic surgery: results from three randomized clinical trials, SAVE-HIP1, SAVE-HIP2 and SAVE-KNEE.
    Journal of thrombosis and haemostasis : JTH, 2012, Volume: 10, Issue:5

    Topics: Adult; Aged; Aged, 80 and over; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Dou

2012
Semuloparin for prevention of venous thromboembolism after major orthopedic surgery: results from three randomized clinical trials, SAVE-HIP1, SAVE-HIP2 and SAVE-KNEE.
    Journal of thrombosis and haemostasis : JTH, 2012, Volume: 10, Issue:5

    Topics: Adult; Aged; Aged, 80 and over; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Dou

2012
Semuloparin for prevention of venous thromboembolism after major orthopedic surgery: results from three randomized clinical trials, SAVE-HIP1, SAVE-HIP2 and SAVE-KNEE.
    Journal of thrombosis and haemostasis : JTH, 2012, Volume: 10, Issue:5

    Topics: Adult; Aged; Aged, 80 and over; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Dou

2012
Oral rivaroxaban for the treatment of symptomatic pulmonary embolism.
    The New England journal of medicine, 2012, 04-05, Volume: 366, Issue:14

    Topics: Administration, Oral; Aged; Anticoagulants; Drug Therapy, Combination; Enoxaparin; Female; Follow-Up

2012
Oral rivaroxaban for the treatment of symptomatic pulmonary embolism.
    The New England journal of medicine, 2012, 04-05, Volume: 366, Issue:14

    Topics: Administration, Oral; Aged; Anticoagulants; Drug Therapy, Combination; Enoxaparin; Female; Follow-Up

2012
Oral rivaroxaban for the treatment of symptomatic pulmonary embolism.
    The New England journal of medicine, 2012, 04-05, Volume: 366, Issue:14

    Topics: Administration, Oral; Aged; Anticoagulants; Drug Therapy, Combination; Enoxaparin; Female; Follow-Up

2012
Oral rivaroxaban for the treatment of symptomatic pulmonary embolism.
    The New England journal of medicine, 2012, 04-05, Volume: 366, Issue:14

    Topics: Administration, Oral; Aged; Anticoagulants; Drug Therapy, Combination; Enoxaparin; Female; Follow-Up

2012
Oral rivaroxaban for the treatment of symptomatic pulmonary embolism.
    The New England journal of medicine, 2012, 04-05, Volume: 366, Issue:14

    Topics: Administration, Oral; Aged; Anticoagulants; Drug Therapy, Combination; Enoxaparin; Female; Follow-Up

2012
Oral rivaroxaban for the treatment of symptomatic pulmonary embolism.
    The New England journal of medicine, 2012, 04-05, Volume: 366, Issue:14

    Topics: Administration, Oral; Aged; Anticoagulants; Drug Therapy, Combination; Enoxaparin; Female; Follow-Up

2012
Oral rivaroxaban for the treatment of symptomatic pulmonary embolism.
    The New England journal of medicine, 2012, 04-05, Volume: 366, Issue:14

    Topics: Administration, Oral; Aged; Anticoagulants; Drug Therapy, Combination; Enoxaparin; Female; Follow-Up

2012
Oral rivaroxaban for the treatment of symptomatic pulmonary embolism.
    The New England journal of medicine, 2012, 04-05, Volume: 366, Issue:14

    Topics: Administration, Oral; Aged; Anticoagulants; Drug Therapy, Combination; Enoxaparin; Female; Follow-Up

2012
Oral rivaroxaban for the treatment of symptomatic pulmonary embolism.
    The New England journal of medicine, 2012, 04-05, Volume: 366, Issue:14

    Topics: Administration, Oral; Aged; Anticoagulants; Drug Therapy, Combination; Enoxaparin; Female; Follow-Up

2012
Oral rivaroxaban for the treatment of symptomatic pulmonary embolism.
    The New England journal of medicine, 2012, 04-05, Volume: 366, Issue:14

    Topics: Administration, Oral; Aged; Anticoagulants; Drug Therapy, Combination; Enoxaparin; Female; Follow-Up

2012
Oral rivaroxaban for the treatment of symptomatic pulmonary embolism.
    The New England journal of medicine, 2012, 04-05, Volume: 366, Issue:14

    Topics: Administration, Oral; Aged; Anticoagulants; Drug Therapy, Combination; Enoxaparin; Female; Follow-Up

2012
Oral rivaroxaban for the treatment of symptomatic pulmonary embolism.
    The New England journal of medicine, 2012, 04-05, Volume: 366, Issue:14

    Topics: Administration, Oral; Aged; Anticoagulants; Drug Therapy, Combination; Enoxaparin; Female; Follow-Up

2012
Oral rivaroxaban for the treatment of symptomatic pulmonary embolism.
    The New England journal of medicine, 2012, 04-05, Volume: 366, Issue:14

    Topics: Administration, Oral; Aged; Anticoagulants; Drug Therapy, Combination; Enoxaparin; Female; Follow-Up

2012
Oral rivaroxaban for the treatment of symptomatic pulmonary embolism.
    The New England journal of medicine, 2012, 04-05, Volume: 366, Issue:14

    Topics: Administration, Oral; Aged; Anticoagulants; Drug Therapy, Combination; Enoxaparin; Female; Follow-Up

2012
Oral rivaroxaban for the treatment of symptomatic pulmonary embolism.
    The New England journal of medicine, 2012, 04-05, Volume: 366, Issue:14

    Topics: Administration, Oral; Aged; Anticoagulants; Drug Therapy, Combination; Enoxaparin; Female; Follow-Up

2012
Oral rivaroxaban for the treatment of symptomatic pulmonary embolism.
    The New England journal of medicine, 2012, 04-05, Volume: 366, Issue:14

    Topics: Administration, Oral; Aged; Anticoagulants; Drug Therapy, Combination; Enoxaparin; Female; Follow-Up

2012
Oral rivaroxaban for the treatment of symptomatic pulmonary embolism.
    The New England journal of medicine, 2012, 04-05, Volume: 366, Issue:14

    Topics: Administration, Oral; Aged; Anticoagulants; Drug Therapy, Combination; Enoxaparin; Female; Follow-Up

2012
Oral rivaroxaban for the treatment of symptomatic pulmonary embolism.
    The New England journal of medicine, 2012, 04-05, Volume: 366, Issue:14

    Topics: Administration, Oral; Aged; Anticoagulants; Drug Therapy, Combination; Enoxaparin; Female; Follow-Up

2012
Oral rivaroxaban for the treatment of symptomatic pulmonary embolism.
    The New England journal of medicine, 2012, 04-05, Volume: 366, Issue:14

    Topics: Administration, Oral; Aged; Anticoagulants; Drug Therapy, Combination; Enoxaparin; Female; Follow-Up

2012
Oral rivaroxaban for the treatment of symptomatic pulmonary embolism.
    The New England journal of medicine, 2012, 04-05, Volume: 366, Issue:14

    Topics: Administration, Oral; Aged; Anticoagulants; Drug Therapy, Combination; Enoxaparin; Female; Follow-Up

2012
Oral rivaroxaban for the treatment of symptomatic pulmonary embolism.
    The New England journal of medicine, 2012, 04-05, Volume: 366, Issue:14

    Topics: Administration, Oral; Aged; Anticoagulants; Drug Therapy, Combination; Enoxaparin; Female; Follow-Up

2012
Oral rivaroxaban for the treatment of symptomatic pulmonary embolism.
    The New England journal of medicine, 2012, 04-05, Volume: 366, Issue:14

    Topics: Administration, Oral; Aged; Anticoagulants; Drug Therapy, Combination; Enoxaparin; Female; Follow-Up

2012
Oral rivaroxaban for the treatment of symptomatic pulmonary embolism.
    The New England journal of medicine, 2012, 04-05, Volume: 366, Issue:14

    Topics: Administration, Oral; Aged; Anticoagulants; Drug Therapy, Combination; Enoxaparin; Female; Follow-Up

2012
Oral rivaroxaban for the treatment of symptomatic pulmonary embolism.
    The New England journal of medicine, 2012, 04-05, Volume: 366, Issue:14

    Topics: Administration, Oral; Aged; Anticoagulants; Drug Therapy, Combination; Enoxaparin; Female; Follow-Up

2012
Oral rivaroxaban for the treatment of symptomatic pulmonary embolism.
    The New England journal of medicine, 2012, 04-05, Volume: 366, Issue:14

    Topics: Administration, Oral; Aged; Anticoagulants; Drug Therapy, Combination; Enoxaparin; Female; Follow-Up

2012
Oral rivaroxaban for the treatment of symptomatic pulmonary embolism.
    The New England journal of medicine, 2012, 04-05, Volume: 366, Issue:14

    Topics: Administration, Oral; Aged; Anticoagulants; Drug Therapy, Combination; Enoxaparin; Female; Follow-Up

2012
Oral rivaroxaban for the treatment of symptomatic pulmonary embolism.
    The New England journal of medicine, 2012, 04-05, Volume: 366, Issue:14

    Topics: Administration, Oral; Aged; Anticoagulants; Drug Therapy, Combination; Enoxaparin; Female; Follow-Up

2012
Oral rivaroxaban for the treatment of symptomatic pulmonary embolism.
    The New England journal of medicine, 2012, 04-05, Volume: 366, Issue:14

    Topics: Administration, Oral; Aged; Anticoagulants; Drug Therapy, Combination; Enoxaparin; Female; Follow-Up

2012
Oral rivaroxaban for the treatment of symptomatic pulmonary embolism.
    The New England journal of medicine, 2012, 04-05, Volume: 366, Issue:14

    Topics: Administration, Oral; Aged; Anticoagulants; Drug Therapy, Combination; Enoxaparin; Female; Follow-Up

2012
Oral rivaroxaban for the treatment of symptomatic pulmonary embolism.
    The New England journal of medicine, 2012, 04-05, Volume: 366, Issue:14

    Topics: Administration, Oral; Aged; Anticoagulants; Drug Therapy, Combination; Enoxaparin; Female; Follow-Up

2012
Oral rivaroxaban for the treatment of symptomatic pulmonary embolism.
    The New England journal of medicine, 2012, 04-05, Volume: 366, Issue:14

    Topics: Administration, Oral; Aged; Anticoagulants; Drug Therapy, Combination; Enoxaparin; Female; Follow-Up

2012
Oral rivaroxaban for the treatment of symptomatic pulmonary embolism.
    The New England journal of medicine, 2012, 04-05, Volume: 366, Issue:14

    Topics: Administration, Oral; Aged; Anticoagulants; Drug Therapy, Combination; Enoxaparin; Female; Follow-Up

2012
Oral rivaroxaban for the treatment of symptomatic pulmonary embolism.
    The New England journal of medicine, 2012, 04-05, Volume: 366, Issue:14

    Topics: Administration, Oral; Aged; Anticoagulants; Drug Therapy, Combination; Enoxaparin; Female; Follow-Up

2012
Oral rivaroxaban for the treatment of symptomatic pulmonary embolism.
    The New England journal of medicine, 2012, 04-05, Volume: 366, Issue:14

    Topics: Administration, Oral; Aged; Anticoagulants; Drug Therapy, Combination; Enoxaparin; Female; Follow-Up

2012
Oral rivaroxaban for the treatment of symptomatic pulmonary embolism.
    The New England journal of medicine, 2012, 04-05, Volume: 366, Issue:14

    Topics: Administration, Oral; Aged; Anticoagulants; Drug Therapy, Combination; Enoxaparin; Female; Follow-Up

2012
Oral rivaroxaban for the treatment of symptomatic pulmonary embolism.
    The New England journal of medicine, 2012, 04-05, Volume: 366, Issue:14

    Topics: Administration, Oral; Aged; Anticoagulants; Drug Therapy, Combination; Enoxaparin; Female; Follow-Up

2012
Oral rivaroxaban for the treatment of symptomatic pulmonary embolism.
    The New England journal of medicine, 2012, 04-05, Volume: 366, Issue:14

    Topics: Administration, Oral; Aged; Anticoagulants; Drug Therapy, Combination; Enoxaparin; Female; Follow-Up

2012
Oral rivaroxaban for the treatment of symptomatic pulmonary embolism.
    The New England journal of medicine, 2012, 04-05, Volume: 366, Issue:14

    Topics: Administration, Oral; Aged; Anticoagulants; Drug Therapy, Combination; Enoxaparin; Female; Follow-Up

2012
Oral rivaroxaban for the treatment of symptomatic pulmonary embolism.
    The New England journal of medicine, 2012, 04-05, Volume: 366, Issue:14

    Topics: Administration, Oral; Aged; Anticoagulants; Drug Therapy, Combination; Enoxaparin; Female; Follow-Up

2012
Oral rivaroxaban for the treatment of symptomatic pulmonary embolism.
    The New England journal of medicine, 2012, 04-05, Volume: 366, Issue:14

    Topics: Administration, Oral; Aged; Anticoagulants; Drug Therapy, Combination; Enoxaparin; Female; Follow-Up

2012
Oral rivaroxaban for the treatment of symptomatic pulmonary embolism.
    The New England journal of medicine, 2012, 04-05, Volume: 366, Issue:14

    Topics: Administration, Oral; Aged; Anticoagulants; Drug Therapy, Combination; Enoxaparin; Female; Follow-Up

2012
Oral rivaroxaban for the treatment of symptomatic pulmonary embolism.
    The New England journal of medicine, 2012, 04-05, Volume: 366, Issue:14

    Topics: Administration, Oral; Aged; Anticoagulants; Drug Therapy, Combination; Enoxaparin; Female; Follow-Up

2012
Oral rivaroxaban for the treatment of symptomatic pulmonary embolism.
    The New England journal of medicine, 2012, 04-05, Volume: 366, Issue:14

    Topics: Administration, Oral; Aged; Anticoagulants; Drug Therapy, Combination; Enoxaparin; Female; Follow-Up

2012
Oral rivaroxaban for the treatment of symptomatic pulmonary embolism.
    The New England journal of medicine, 2012, 04-05, Volume: 366, Issue:14

    Topics: Administration, Oral; Aged; Anticoagulants; Drug Therapy, Combination; Enoxaparin; Female; Follow-Up

2012
Oral rivaroxaban for the treatment of symptomatic pulmonary embolism.
    The New England journal of medicine, 2012, 04-05, Volume: 366, Issue:14

    Topics: Administration, Oral; Aged; Anticoagulants; Drug Therapy, Combination; Enoxaparin; Female; Follow-Up

2012
Oral rivaroxaban for the treatment of symptomatic pulmonary embolism.
    The New England journal of medicine, 2012, 04-05, Volume: 366, Issue:14

    Topics: Administration, Oral; Aged; Anticoagulants; Drug Therapy, Combination; Enoxaparin; Female; Follow-Up

2012
Oral rivaroxaban for the treatment of symptomatic pulmonary embolism.
    The New England journal of medicine, 2012, 04-05, Volume: 366, Issue:14

    Topics: Administration, Oral; Aged; Anticoagulants; Drug Therapy, Combination; Enoxaparin; Female; Follow-Up

2012
Oral rivaroxaban for the treatment of symptomatic pulmonary embolism.
    The New England journal of medicine, 2012, 04-05, Volume: 366, Issue:14

    Topics: Administration, Oral; Aged; Anticoagulants; Drug Therapy, Combination; Enoxaparin; Female; Follow-Up

2012
Oral rivaroxaban for the treatment of symptomatic pulmonary embolism.
    The New England journal of medicine, 2012, 04-05, Volume: 366, Issue:14

    Topics: Administration, Oral; Aged; Anticoagulants; Drug Therapy, Combination; Enoxaparin; Female; Follow-Up

2012
Oral rivaroxaban for the treatment of symptomatic pulmonary embolism.
    The New England journal of medicine, 2012, 04-05, Volume: 366, Issue:14

    Topics: Administration, Oral; Aged; Anticoagulants; Drug Therapy, Combination; Enoxaparin; Female; Follow-Up

2012
Oral rivaroxaban for the treatment of symptomatic pulmonary embolism.
    The New England journal of medicine, 2012, 04-05, Volume: 366, Issue:14

    Topics: Administration, Oral; Aged; Anticoagulants; Drug Therapy, Combination; Enoxaparin; Female; Follow-Up

2012
Oral rivaroxaban for the treatment of symptomatic pulmonary embolism.
    The New England journal of medicine, 2012, 04-05, Volume: 366, Issue:14

    Topics: Administration, Oral; Aged; Anticoagulants; Drug Therapy, Combination; Enoxaparin; Female; Follow-Up

2012
Oral rivaroxaban for the treatment of symptomatic pulmonary embolism.
    The New England journal of medicine, 2012, 04-05, Volume: 366, Issue:14

    Topics: Administration, Oral; Aged; Anticoagulants; Drug Therapy, Combination; Enoxaparin; Female; Follow-Up

2012
Oral rivaroxaban for the treatment of symptomatic pulmonary embolism.
    The New England journal of medicine, 2012, 04-05, Volume: 366, Issue:14

    Topics: Administration, Oral; Aged; Anticoagulants; Drug Therapy, Combination; Enoxaparin; Female; Follow-Up

2012
Oral rivaroxaban for the treatment of symptomatic pulmonary embolism.
    The New England journal of medicine, 2012, 04-05, Volume: 366, Issue:14

    Topics: Administration, Oral; Aged; Anticoagulants; Drug Therapy, Combination; Enoxaparin; Female; Follow-Up

2012
Oral rivaroxaban for the treatment of symptomatic pulmonary embolism.
    The New England journal of medicine, 2012, 04-05, Volume: 366, Issue:14

    Topics: Administration, Oral; Aged; Anticoagulants; Drug Therapy, Combination; Enoxaparin; Female; Follow-Up

2012
Oral rivaroxaban for the treatment of symptomatic pulmonary embolism.
    The New England journal of medicine, 2012, 04-05, Volume: 366, Issue:14

    Topics: Administration, Oral; Aged; Anticoagulants; Drug Therapy, Combination; Enoxaparin; Female; Follow-Up

2012
Oral rivaroxaban for the treatment of symptomatic pulmonary embolism.
    The New England journal of medicine, 2012, 04-05, Volume: 366, Issue:14

    Topics: Administration, Oral; Aged; Anticoagulants; Drug Therapy, Combination; Enoxaparin; Female; Follow-Up

2012
Oral rivaroxaban for the treatment of symptomatic pulmonary embolism.
    The New England journal of medicine, 2012, 04-05, Volume: 366, Issue:14

    Topics: Administration, Oral; Aged; Anticoagulants; Drug Therapy, Combination; Enoxaparin; Female; Follow-Up

2012
Oral rivaroxaban for the treatment of symptomatic pulmonary embolism.
    The New England journal of medicine, 2012, 04-05, Volume: 366, Issue:14

    Topics: Administration, Oral; Aged; Anticoagulants; Drug Therapy, Combination; Enoxaparin; Female; Follow-Up

2012
Oral rivaroxaban for the treatment of symptomatic pulmonary embolism.
    The New England journal of medicine, 2012, 04-05, Volume: 366, Issue:14

    Topics: Administration, Oral; Aged; Anticoagulants; Drug Therapy, Combination; Enoxaparin; Female; Follow-Up

2012
Oral rivaroxaban for the treatment of symptomatic pulmonary embolism.
    The New England journal of medicine, 2012, 04-05, Volume: 366, Issue:14

    Topics: Administration, Oral; Aged; Anticoagulants; Drug Therapy, Combination; Enoxaparin; Female; Follow-Up

2012
Oral rivaroxaban for the treatment of symptomatic pulmonary embolism.
    The New England journal of medicine, 2012, 04-05, Volume: 366, Issue:14

    Topics: Administration, Oral; Aged; Anticoagulants; Drug Therapy, Combination; Enoxaparin; Female; Follow-Up

2012
Oral rivaroxaban for the treatment of symptomatic pulmonary embolism.
    The New England journal of medicine, 2012, 04-05, Volume: 366, Issue:14

    Topics: Administration, Oral; Aged; Anticoagulants; Drug Therapy, Combination; Enoxaparin; Female; Follow-Up

2012
Therapeutic potential of apixaban in the prevention of venous thromboembolism in patients undergoing total knee replacement surgery.
    Journal of thrombosis and thrombolysis, 2012, Volume: 34, Issue:2

    Topics: Administration, Oral; Adult; Anticoagulants; Arthroplasty, Replacement, Knee; Enoxaparin; Factor Xa

2012
Comparison of antithrombotic and haemorrhagic effects of edoxaban, an oral direct factor Xa inhibitor, with warfarin and enoxaparin in rats.
    Thrombosis research, 2012, Volume: 130, Issue:3

    Topics: Administration, Oral; Animals; Anticoagulants; Enoxaparin; Factor Xa Inhibitors; Fibrinolytic Agents

2012
Rivaroxaban for thromboprophylaxis in acutely ill medical patients.
    The New England journal of medicine, 2013, Feb-07, Volume: 368, Issue:6

    Topics: Acute Disease; Administration, Oral; Adult; Aged; Anticoagulants; Double-Blind Method; Drug Administ

2013
Rivaroxaban for thromboprophylaxis in acutely ill medical patients.
    The New England journal of medicine, 2013, Feb-07, Volume: 368, Issue:6

    Topics: Acute Disease; Administration, Oral; Adult; Aged; Anticoagulants; Double-Blind Method; Drug Administ

2013
Rivaroxaban for thromboprophylaxis in acutely ill medical patients.
    The New England journal of medicine, 2013, Feb-07, Volume: 368, Issue:6

    Topics: Acute Disease; Administration, Oral; Adult; Aged; Anticoagulants; Double-Blind Method; Drug Administ

2013
Rivaroxaban for thromboprophylaxis in acutely ill medical patients.
    The New England journal of medicine, 2013, Feb-07, Volume: 368, Issue:6

    Topics: Acute Disease; Administration, Oral; Adult; Aged; Anticoagulants; Double-Blind Method; Drug Administ

2013
Rivaroxaban for thromboprophylaxis in acutely ill medical patients.
    The New England journal of medicine, 2013, Feb-07, Volume: 368, Issue:6

    Topics: Acute Disease; Administration, Oral; Adult; Aged; Anticoagulants; Double-Blind Method; Drug Administ

2013
Rivaroxaban for thromboprophylaxis in acutely ill medical patients.
    The New England journal of medicine, 2013, Feb-07, Volume: 368, Issue:6

    Topics: Acute Disease; Administration, Oral; Adult; Aged; Anticoagulants; Double-Blind Method; Drug Administ

2013
Rivaroxaban for thromboprophylaxis in acutely ill medical patients.
    The New England journal of medicine, 2013, Feb-07, Volume: 368, Issue:6

    Topics: Acute Disease; Administration, Oral; Adult; Aged; Anticoagulants; Double-Blind Method; Drug Administ

2013
Rivaroxaban for thromboprophylaxis in acutely ill medical patients.
    The New England journal of medicine, 2013, Feb-07, Volume: 368, Issue:6

    Topics: Acute Disease; Administration, Oral; Adult; Aged; Anticoagulants; Double-Blind Method; Drug Administ

2013
Rivaroxaban for thromboprophylaxis in acutely ill medical patients.
    The New England journal of medicine, 2013, Feb-07, Volume: 368, Issue:6

    Topics: Acute Disease; Administration, Oral; Adult; Aged; Anticoagulants; Double-Blind Method; Drug Administ

2013
Rivaroxaban for thromboprophylaxis in acutely ill medical patients.
    The New England journal of medicine, 2013, Feb-07, Volume: 368, Issue:6

    Topics: Acute Disease; Administration, Oral; Adult; Aged; Anticoagulants; Double-Blind Method; Drug Administ

2013
Rivaroxaban for thromboprophylaxis in acutely ill medical patients.
    The New England journal of medicine, 2013, Feb-07, Volume: 368, Issue:6

    Topics: Acute Disease; Administration, Oral; Adult; Aged; Anticoagulants; Double-Blind Method; Drug Administ

2013
Rivaroxaban for thromboprophylaxis in acutely ill medical patients.
    The New England journal of medicine, 2013, Feb-07, Volume: 368, Issue:6

    Topics: Acute Disease; Administration, Oral; Adult; Aged; Anticoagulants; Double-Blind Method; Drug Administ

2013
Rivaroxaban for thromboprophylaxis in acutely ill medical patients.
    The New England journal of medicine, 2013, Feb-07, Volume: 368, Issue:6

    Topics: Acute Disease; Administration, Oral; Adult; Aged; Anticoagulants; Double-Blind Method; Drug Administ

2013
Rivaroxaban for thromboprophylaxis in acutely ill medical patients.
    The New England journal of medicine, 2013, Feb-07, Volume: 368, Issue:6

    Topics: Acute Disease; Administration, Oral; Adult; Aged; Anticoagulants; Double-Blind Method; Drug Administ

2013
Rivaroxaban for thromboprophylaxis in acutely ill medical patients.
    The New England journal of medicine, 2013, Feb-07, Volume: 368, Issue:6

    Topics: Acute Disease; Administration, Oral; Adult; Aged; Anticoagulants; Double-Blind Method; Drug Administ

2013
Rivaroxaban for thromboprophylaxis in acutely ill medical patients.
    The New England journal of medicine, 2013, Feb-07, Volume: 368, Issue:6

    Topics: Acute Disease; Administration, Oral; Adult; Aged; Anticoagulants; Double-Blind Method; Drug Administ

2013
Comparison of enoxaparin versus unfractionated heparin in patients with unstable angina pectoris/non-ST-segment elevation acute myocardial infarction having subsequent percutaneous coronary intervention.
    The American journal of cardiology, 2002, Sep-01, Volume: 90, Issue:5

    Topics: Angina, Unstable; Angioplasty, Balloon, Coronary; Anticoagulants; Combined Modality Therapy; Electro

2002
Randomized double-blind safety study of enoxaparin versus unfractionated heparin in patients with non-ST-segment elevation acute coronary syndromes treated with tirofiban and aspirin: the ACUTE II study. The Antithrombotic Combination Using Tirofiban and
    American heart journal, 2002, Volume: 144, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Aspirin; Coronary Disease; Double-Blind Method; Drug Therapy, Combin

2002
Randomized evaluation of the safety and efficacy of enoxaparin versus unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes receiving the glycoprotein IIb/IIIa inhibitor eptifibatide.
    Circulation, 2003, Jan-21, Volume: 107, Issue:2

    Topics: Acute Disease; Aged; Aspirin; Coronary Disease; Electrocardiography; Enoxaparin; Eptifibatide; Femal

2003
Safety of concomitant therapy with eptifibatide and enoxaparin in patients undergoing percutaneous coronary intervention: results of the Coronary Revascularization Using Integrilin and Single bolus Enoxaparin Study.
    Journal of the American College of Cardiology, 2003, Jan-01, Volume: 41, Issue:1

    Topics: Adult; Angioplasty, Balloon, Coronary; Anticoagulants; Coronary Angiography; Drug Therapy, Combinati

2003
Direct thrombin inhibitor melagatran followed by oral ximelagatran in comparison with enoxaparin for prevention of venous thromboembolism after total hip or knee replacement.
    Thrombosis and haemostasis, 2003, Volume: 89, Issue:2

    Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Anticoagulants; Arthroplasty, Replacement, Hip

2003
Randomized comparison of enoxaparin with unfractionated heparin for the prevention of venous thromboembolism in medical patients with heart failure or severe respiratory disease.
    American heart journal, 2003, Volume: 145, Issue:4

    Topics: Aged; Anticoagulants; Drug Administration Schedule; Enoxaparin; Female; Heart Failure; Hemorrhage; H

2003
Prescribing patterns and outcomes of enoxaparin for anticoagulation of atrial fibrillation.
    Pharmacotherapy, 2003, Volume: 23, Issue:5

    Topics: Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Data Collection; Dose-Response Relatio

2003
Enoxaparin monotherapy without oral anticoagulation to treat acute symptomatic pulmonary embolism.
    Thrombosis and haemostasis, 2003, Volume: 89, Issue:6

    Topics: Acute Disease; Adult; Aged; Enoxaparin; Feasibility Studies; Female; Hemorrhage; Heparin; Humans; Le

2003
Prevention of venous thromboembolism in the rehabilitation phase after spinal cord injury: prophylaxis with low-dose heparin or enoxaparin.
    The Journal of trauma, 2003, Volume: 54, Issue:6

    Topics: Adult; Anticoagulants; Enoxaparin; Female; Hemorrhage; Heparin; Humans; Male; Prospective Studies; R

2003
Prevention of venous thromboembolism in the acute treatment phase after spinal cord injury: a randomized, multicenter trial comparing low-dose heparin plus intermittent pneumatic compression with enoxaparin.
    The Journal of trauma, 2003, Volume: 54, Issue:6

    Topics: Acute Disease; Adult; Anticoagulants; Bandages; Combined Modality Therapy; Enoxaparin; Female; Hemor

2003
Efficacy and safety of tenecteplase in combination with the low-molecular-weight heparin enoxaparin or unfractionated heparin in the prehospital setting: the Assessment of the Safety and Efficacy of a New Thrombolytic Regimen (ASSENT)-3 PLUS randomized tr
    Circulation, 2003, Jul-15, Volume: 108, Issue:2

    Topics: Aged; Cohort Studies; Drug Therapy, Combination; Emergency Medical Services; Enoxaparin; Female; Hem

2003
Efficacy and safety of tenecteplase in combination with the low-molecular-weight heparin enoxaparin or unfractionated heparin in the prehospital setting: the Assessment of the Safety and Efficacy of a New Thrombolytic Regimen (ASSENT)-3 PLUS randomized tr
    Circulation, 2003, Jul-15, Volume: 108, Issue:2

    Topics: Aged; Cohort Studies; Drug Therapy, Combination; Emergency Medical Services; Enoxaparin; Female; Hem

2003
Efficacy and safety of tenecteplase in combination with the low-molecular-weight heparin enoxaparin or unfractionated heparin in the prehospital setting: the Assessment of the Safety and Efficacy of a New Thrombolytic Regimen (ASSENT)-3 PLUS randomized tr
    Circulation, 2003, Jul-15, Volume: 108, Issue:2

    Topics: Aged; Cohort Studies; Drug Therapy, Combination; Emergency Medical Services; Enoxaparin; Female; Hem

2003
Efficacy and safety of tenecteplase in combination with the low-molecular-weight heparin enoxaparin or unfractionated heparin in the prehospital setting: the Assessment of the Safety and Efficacy of a New Thrombolytic Regimen (ASSENT)-3 PLUS randomized tr
    Circulation, 2003, Jul-15, Volume: 108, Issue:2

    Topics: Aged; Cohort Studies; Drug Therapy, Combination; Emergency Medical Services; Enoxaparin; Female; Hem

2003
[Multicenter, prospective study comparing enoxaparin with unfractionated heparin in the treatment of submassive pulmonary thromboembolism].
    Archivos de bronconeumologia, 2003, Volume: 39, Issue:8

    Topics: Aged; Anticoagulants; Enoxaparin; Female; Hemorrhage; Heparin; Humans; Male; Middle Aged; Prospectiv

2003
Venous thromboembolism prophylaxis conversion in nonsurgical inpatients.
    The Annals of pharmacotherapy, 2003, Volume: 37, Issue:9

    Topics: Anticoagulants; Cost-Benefit Analysis; Enoxaparin; Hemorrhage; Heparin; Hospitalization; Humans; Ris

2003
Comparison of dalteparin and enoxaparin for deep venous thrombosis prophylaxis in patients with spinal cord injury.
    American journal of physical medicine & rehabilitation, 2003, Volume: 82, Issue:9

    Topics: Adolescent; Adult; Aged; Dalteparin; Enoxaparin; Female; Fibrinolytic Agents; Health Status Indicato

2003
Population pharmacokinetics and pharmacodynamics of enoxaparin in unstable angina and non-ST-segment elevation myocardial infarction.
    British journal of clinical pharmacology, 2003, Volume: 56, Issue:4

    Topics: Angina, Unstable; Anticoagulants; Cohort Studies; Enoxaparin; Factor Xa Inhibitors; Female; Half-Lif

2003
Comparison of ximelagatran, an oral direct thrombin inhibitor, with enoxaparin for the prevention of venous thromboembolism following total hip replacement. A randomized, double-blind study.
    Journal of thrombosis and haemostasis : JTH, 2003, Volume: 1, Issue:10

    Topics: Administration, Oral; Aged; Anticoagulants; Arthroplasty, Replacement, Hip; Azetidines; Benzylamines

2003
Combining enoxaparin and glycoprotein IIb/IIIa antagonists for the treatment of acute coronary syndromes: final results of the National Investigators Collaborating on Enoxaparin-3 (NICE-3) study.
    American heart journal, 2003, Volume: 146, Issue:4

    Topics: Abciximab; Angina, Unstable; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Anticoagulants;

2003
The direct thrombin inhibitor melagatran followed by oral ximelagatran compared with enoxaparin for the prevention of venous thromboembolism after total hip or knee replacement: the EXPRESS study.
    Journal of thrombosis and haemostasis : JTH, 2003, Volume: 1, Issue:12

    Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replac

2003
Safety and efficacy of enoxaparin compared with unfractionated heparin and oral anticoagulants for prevention of thromboembolic complications in cardioversion of nonvalvular atrial fibrillation: the Anticoagulation in Cardioversion using Enoxaparin (ACE)
    Circulation, 2004, Mar-02, Volume: 109, Issue:8

    Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Cardiovascular Diseases; Drug Thera

2004
Treatment with anticoagulants in cerebral events (TRACE).
    Thrombosis and haemostasis, 2004, Volume: 91, Issue:4

    Topics: Aged; Anticoagulants; Constriction, Pathologic; Drug Monitoring; Embolism; Enoxaparin; Female; Hemor

2004
Facilitated percutaneous coronary intervention versus primary percutaneous coronary intervention: design and rationale of the Facilitated Intervention with Enhanced Reperfusion Speed to Stop Events (FINESSE) trial.
    American heart journal, 2004, Volume: 147, Issue:4

    Topics: Abciximab; Aged; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Anticoagulants; Combined Mo

2004
Fondaparinux or enoxaparin for the initial treatment of symptomatic deep venous thrombosis: a randomized trial.
    Annals of internal medicine, 2004, Jun-01, Volume: 140, Issue:11

    Topics: Aged; Body Weight; Cause of Death; Double-Blind Method; Drug Administration Schedule; Enoxaparin; Fe

2004
Fondaparinux or enoxaparin for the initial treatment of symptomatic deep venous thrombosis: a randomized trial.
    Annals of internal medicine, 2004, Jun-01, Volume: 140, Issue:11

    Topics: Aged; Body Weight; Cause of Death; Double-Blind Method; Drug Administration Schedule; Enoxaparin; Fe

2004
Fondaparinux or enoxaparin for the initial treatment of symptomatic deep venous thrombosis: a randomized trial.
    Annals of internal medicine, 2004, Jun-01, Volume: 140, Issue:11

    Topics: Aged; Body Weight; Cause of Death; Double-Blind Method; Drug Administration Schedule; Enoxaparin; Fe

2004
Fondaparinux or enoxaparin for the initial treatment of symptomatic deep venous thrombosis: a randomized trial.
    Annals of internal medicine, 2004, Jun-01, Volume: 140, Issue:11

    Topics: Aged; Body Weight; Cause of Death; Double-Blind Method; Drug Administration Schedule; Enoxaparin; Fe

2004
A dose-finding study of fondaparinux in patients with non-ST-segment elevation acute coronary syndromes: the Pentasaccharide in Unstable Angina (PENTUA) Study.
    Journal of the American College of Cardiology, 2004, Jun-16, Volume: 43, Issue:12

    Topics: Acute Disease; Adrenergic beta-Antagonists; Adult; Angioplasty, Balloon, Coronary; Angiotensin-Conve

2004
Safety and efficacy of enoxaparin vs unfractionated heparin in patients with non-ST-segment elevation acute coronary syndromes who receive tirofiban and aspirin: a randomized controlled trial.
    JAMA, 2004, Jul-07, Volume: 292, Issue:1

    Topics: Aged; Angina Pectoris; Aspirin; Enoxaparin; Female; Fibrinolytic Agents; Hemorrhage; Heparin; Humans

2004
Enoxaparin vs unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes managed with an intended early invasive strategy: primary results of the SYNERGY randomized trial.
    JAMA, 2004, Jul-07, Volume: 292, Issue:1

    Topics: Aged; Angina Pectoris; Angioplasty, Balloon, Coronary; Enoxaparin; Female; Fibrinolytic Agents; Hemo

2004
Anti-Xa activity relates to survival and efficacy in unselected acute coronary syndrome patients treated with enoxaparin.
    Circulation, 2004, Jul-27, Volume: 110, Issue:4

    Topics: Aged; Angina, Unstable; Angioplasty, Balloon, Coronary; Anticoagulants; Biomarkers; Cardiac Catheter

2004
Anti-Xa activity relates to survival and efficacy in unselected acute coronary syndrome patients treated with enoxaparin.
    Circulation, 2004, Jul-27, Volume: 110, Issue:4

    Topics: Aged; Angina, Unstable; Angioplasty, Balloon, Coronary; Anticoagulants; Biomarkers; Cardiac Catheter

2004
Anti-Xa activity relates to survival and efficacy in unselected acute coronary syndrome patients treated with enoxaparin.
    Circulation, 2004, Jul-27, Volume: 110, Issue:4

    Topics: Aged; Angina, Unstable; Angioplasty, Balloon, Coronary; Anticoagulants; Biomarkers; Cardiac Catheter

2004
Anti-Xa activity relates to survival and efficacy in unselected acute coronary syndrome patients treated with enoxaparin.
    Circulation, 2004, Jul-27, Volume: 110, Issue:4

    Topics: Aged; Angina, Unstable; Angioplasty, Balloon, Coronary; Anticoagulants; Biomarkers; Cardiac Catheter

2004
An open-label, comparative study of the efficacy and safety of once-daily dose of enoxaparin versus unfractionated heparin in the treatment of proximal lower limb deep-vein thrombosis.
    Thrombosis research, 2004, Volume: 114, Issue:3

    Topics: Adult; Ambulatory Care; Anticoagulants; Brazil; Causality; Comorbidity; Enoxaparin; Female; Hemorrha

2004
Venous thromboembolism prophylaxis after head and spinal trauma: intermittent pneumatic compression devices versus low molecular weight heparin.
    World journal of surgery, 2004, Volume: 28, Issue:8

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Brain Concussion; Cerebral Hemorrhage, Traumatic; Cervic

2004
Efficacy and safety of two doses of enoxaparin in women with thrombophilia and recurrent pregnancy loss: the LIVE-ENOX study.
    Journal of thrombosis and haemostasis : JTH, 2005, Volume: 3, Issue:2

    Topics: Abortion, Habitual; Dose-Response Relationship, Drug; Drug Hypersensitivity; Enoxaparin; Female; Hem

2005
Low-dose warfarin for prevention of symptomatic thromboembolism after orthopedic surgery.
    The Annals of pharmacotherapy, 2005, Volume: 39, Issue:6

    Topics: Angiography; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Cohort

2005
Once-daily enoxaparin in the outpatient setting versus unfractionated heparin in hospital for the treatment of symptomatic deep-vein thrombosis.
    Journal of thrombosis and thrombolysis, 2005, Volume: 19, Issue:3

    Topics: Adult; Aged; Ambulatory Care; Drug Administration Schedule; Enoxaparin; Female; Hemorrhage; Heparin;

2005
BAY 59-7939: an oral, direct factor Xa inhibitor for the prevention of venous thromboembolism in patients after total knee replacement. A phase II dose-ranging study.
    Journal of thrombosis and haemostasis : JTH, 2005, Volume: 3, Issue:11

    Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Anticoagulants; Antithrombin III; Arthroplasty

2005
Oral, direct Factor Xa inhibition with BAY 59-7939 for the prevention of venous thromboembolism after total hip replacement.
    Journal of thrombosis and haemostasis : JTH, 2006, Volume: 4, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Arthroplasty, Replacement, Hip; Dose-Response Relati

2006
Incidence of recurrent venous thromboembolism of patients after termination of treatment with ximelagatran.
    European journal of clinical pharmacology, 2006, Volume: 62, Issue:3

    Topics: Administration, Oral; Anticoagulants; Arteries; Azetidines; Benzylamines; Drug Therapy, Combination;

2006
Early ambulation and variability in anticoagulation during elective coronary stenting with a single intravenous bolus of low-dose, low-molecular weight heparin enoxaparin.
    The Journal of invasive cardiology, 2006, Volume: 18, Issue:2

    Topics: Aged; Anticoagulants; Coronary Disease; Device Removal; Early Ambulation; Enoxaparin; Factor Xa; Fac

2006
Comparison of fondaparinux and enoxaparin in acute coronary syndromes.
    The New England journal of medicine, 2006, Apr-06, Volume: 354, Issue:14

    Topics: Aged; Angina, Unstable; Angioplasty, Balloon, Coronary; Anticoagulants; Enoxaparin; Female; Fondapar

2006
Enoxaparin versus unfractionated heparin with fibrinolysis for ST-elevation myocardial infarction.
    The New England journal of medicine, 2006, Apr-06, Volume: 354, Issue:14

    Topics: Aged; Anticoagulants; Drug Therapy, Combination; Electrocardiography; Enoxaparin; Female; Fibrinolyt

2006
Switching from Enoxaparin to Bivalirudin in Patients with Acute Coronary Syndromes without ST-segment Elevation who Undergo Percutaneous Coronary Intervention. Results from SWITCH--a multicenter clinical trial.
    The Journal of invasive cardiology, 2006, Volume: 18, Issue:8

    Topics: Acute Disease; Aged; Angioplasty, Balloon, Coronary; Anticoagulants; Coronary Disease; Enoxaparin; F

2006
Enoxaparin versus unfractionated heparin in elective percutaneous coronary intervention.
    The New England journal of medicine, 2006, Sep-07, Volume: 355, Issue:10

    Topics: Aged; Angioplasty, Balloon, Coronary; Anticoagulants; Enoxaparin; Female; Hemorrhage; Heparin; Human

2006
Enoxaparin versus unfractionated heparin in elective percutaneous coronary intervention.
    The New England journal of medicine, 2006, Sep-07, Volume: 355, Issue:10

    Topics: Aged; Angioplasty, Balloon, Coronary; Anticoagulants; Enoxaparin; Female; Hemorrhage; Heparin; Human

2006
Enoxaparin versus unfractionated heparin in elective percutaneous coronary intervention.
    The New England journal of medicine, 2006, Sep-07, Volume: 355, Issue:10

    Topics: Aged; Angioplasty, Balloon, Coronary; Anticoagulants; Enoxaparin; Female; Hemorrhage; Heparin; Human

2006
Enoxaparin versus unfractionated heparin in elective percutaneous coronary intervention.
    The New England journal of medicine, 2006, Sep-07, Volume: 355, Issue:10

    Topics: Aged; Angioplasty, Balloon, Coronary; Anticoagulants; Enoxaparin; Female; Hemorrhage; Heparin; Human

2006
The use of enoxaparin compared with unfractionated heparin for short-term antithrombotic therapy in atrial fibrillation patients undergoing transoesophageal echocardiography-guided cardioversion: assessment of Cardioversion Using Transoesophageal Echocard
    European heart journal, 2006, Volume: 27, Issue:23

    Topics: Atrial Fibrillation; Echocardiography, Transesophageal; Electric Countershock; Enoxaparin; Feasibili

2006
Bivalirudin for patients with acute coronary syndromes.
    The New England journal of medicine, 2006, Nov-23, Volume: 355, Issue:21

    Topics: Adult; Aged; Aged, 80 and over; Angina, Unstable; Angioplasty, Balloon, Coronary; Anticoagulants; Co

2006
Bleeding complications in patients with acute coronary syndrome undergoing early invasive management can be reduced with radial access, smaller sheath sizes, and timely sheath removal.
    Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions, 2007, Volume: 69, Issue:1

    Topics: Aged; Angioplasty, Balloon, Coronary; Blood Transfusion; Chi-Square Distribution; Coronary Angiograp

2007
Efficacy and safety of enoxaparin compared with unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndrome undergoing percutaneous coronary intervention in the Superior Yield of the New Strategy of Enoxaparin, Revas
    American heart journal, 2006, Volume: 152, Issue:6

    Topics: Acute Disease; Aged; Angioplasty, Balloon, Coronary; Anticoagulants; Blood Transfusion; Coronary Dis

2006
Monotherapy with enoxaparin for the prevention of recurrent venous thromboembolism.
    Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis, 2007, Volume: 18, Issue:2

    Topics: Acenocoumarol; Aged; Aged, 80 and over; Enoxaparin; Female; Hemorrhage; Humans; In Vitro Techniques;

2007
Effect of obesity on outcomes after fondaparinux, enoxaparin, or heparin treatment for acute venous thromboembolism in the Matisse trials.
    Journal of thrombosis and haemostasis : JTH, 2007, Volume: 5, Issue:6

    Topics: Adult; Aged; Anticoagulants; Enoxaparin; Female; Fondaparinux; Hemorrhage; Heparin; Humans; Male; Mi

2007
Enoxaparin vs. unfractionated heparin with fibrinolysis for ST-elevation myocardial infarction in elderly and younger patients: results from ExTRACT-TIMI 25.
    European heart journal, 2007, Volume: 28, Issue:9

    Topics: Adult; Age Factors; Death, Sudden, Cardiac; Double-Blind Method; Enoxaparin; Female; Hemorrhage; Hep

2007
Extended-duration thromboprophylaxis with enoxaparin after arthroscopic surgery of the anterior cruciate ligament: a prospective, randomized, placebo-controlled study.
    Arthroscopy : the journal of arthroscopic & related surgery : official publication of the Arthroscopy Association of North America and the International Arthroscopy Association, 2007, Volume: 23, Issue:7

    Topics: Adult; Anterior Cruciate Ligament; Anticoagulants; Arthroscopy; Double-Blind Method; Drug Administra

2007
Bridging therapy in patients on long-term oral anticoagulants who require surgery: the Prospective Peri-operative Enoxaparin Cohort Trial (PROSPECT).
    Journal of thrombosis and haemostasis : JTH, 2007, Volume: 5, Issue:11

    Topics: Administration, Oral; Aged; Ambulatory Care; Anticoagulants; Atrial Fibrillation; Blood Loss, Surgic

2007
Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial.
    Journal of thrombosis and haemostasis : JTH, 2007, Volume: 5, Issue:11

    Topics: Acute Coronary Syndrome; Aged; Anticoagulants; Arthroplasty, Replacement, Knee; Benzimidazoles; Clin

2007
Influence of renal function on the efficacy and safety of fondaparinux relative to enoxaparin in non ST-segment elevation acute coronary syndromes.
    Annals of internal medicine, 2007, Sep-04, Volume: 147, Issue:5

    Topics: Aged; Aged, 80 and over; Angina Pectoris; Anticoagulants; Coronary Disease; Death, Sudden, Cardiac;

2007
The efficacy and safety of apixaban, an oral, direct factor Xa inhibitor, as thromboprophylaxis in patients following total knee replacement.
    Journal of thrombosis and haemostasis : JTH, 2007, Volume: 5, Issue:12

    Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Argentina; Arthroplasty, Replacement, Knee; Do

2007
Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial.
    Lancet (London, England), 2007, Sep-15, Volume: 370, Issue:9591

    Topics: Aged; Anticoagulants; Arthroplasty, Replacement, Hip; Benzimidazoles; Dabigatran; Double-Blind Metho

2007
Individualized compared with conventional dosing of enoxaparin.
    Clinical pharmacology and therapeutics, 2008, Volume: 83, Issue:6

    Topics: Adult; Aged; Body Weight; Dose-Response Relationship, Drug; Double-Blind Method; Enoxaparin; Female;

2008
Atrial fibrillation ablation in patients with therapeutic international normalized ratio: comparison of strategies of anticoagulation management in the periprocedural period.
    Circulation, 2007, Nov-27, Volume: 116, Issue:22

    Topics: Aged; Anticoagulants; Atrial Fibrillation; Catheter Ablation; Enoxaparin; Female; Hemorrhage; Humans

2007
Effect of enoxaparin versus unfractionated heparin in diabetic patients with ST-elevation myocardial infarction in the Enoxaparin and Thrombolysis Reperfusion for Acute Myocardial Infarction Treatment-Thrombolysis In Myocardial Infarction study 25 (ExTRAC
    American heart journal, 2007, Volume: 154, Issue:6

    Topics: Aged; Aspirin; Diabetes Complications; Drug Therapy, Combination; Electrocardiography; Enoxaparin; F

2007
Efficacy and safety of enoxaparin versus unfractionated heparin for prevention of deep venous thrombosis after elective knee arthroplasty. Enoxaparin Clinical Trial Group.
    Clinical orthopaedics and related research, 1995, Issue:321

    Topics: Aged; Anticoagulants; Enoxaparin; Female; Hemorrhage; Heparin; Humans; Knee Prosthesis; Male; Thromb

1995
Prevention of postoperative thromboembolism in general surgery with enoxaparin.
    The European journal of surgery. Supplement. : = Acta chirurgica. Supplement, 1994, Issue:571

    Topics: Adult; Aged; Blood Loss, Surgical; Enoxaparin; Hematologic Tests; Hemorrhage; Heparin; Humans; Middl

1994
Comparison of enoxaparin versus unfractionated heparin in general surgery. SURGEX-Study Group.
    The European journal of surgery. Supplement. : = Acta chirurgica. Supplement, 1994, Issue:571

    Topics: Blood Loss, Surgical; Double-Blind Method; Enoxaparin; Hemorrhage; Hemostasis; Heparin; Humans; Post

1994
Antithromboembolic efficacy and safety of enoxaparin in general surgery. German multicentre trial.
    The European journal of surgery. Supplement. : = Acta chirurgica. Supplement, 1994, Issue:571

    Topics: Adult; Aged; Enoxaparin; Female; Hematologic Tests; Hemorrhage; Humans; Incidence; Male; Middle Aged

1994
Low molecular weight heparin versus warfarin in the prevention of recurrences after deep vein thrombosis.
    Thrombosis and haemostasis, 1994, Volume: 72, Issue:2

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Cause of Death; Enoxaparin; Female; Fibrin Fibrinogen De

1994
Comparison of antithrombotic efficacy and haemorrhagic side-effects of Clivarin versus enoxaparin in patients undergoing total hip replacement surgery.
    Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis, 1993, Volume: 4 Suppl 1

    Topics: Aged; Enoxaparin; Factor Xa Inhibitors; Hemorrhage; Heparin, Low-Molecular-Weight; Hip Prosthesis; H

1993
Use of enoxaparin, a low-molecular-weight heparin, and unfractionated heparin for the prevention of deep venous thrombosis after elective hip replacement. A clinical trial comparing efficacy and safety. Enoxaparin Clinical Trial Group.
    The Journal of bone and joint surgery. American volume, 1994, Volume: 76, Issue:1

    Topics: Aged; Alanine Transaminase; Drug Administration Schedule; Enoxaparin; Female; Hemoglobins; Hemorrhag

1994
A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis.
    The New England journal of medicine, 1996, Mar-14, Volume: 334, Issue:11

    Topics: Aged; Anticoagulants; Enoxaparin; Female; Hemorrhage; Heparin; Home Nursing; Hospitalization; Humans

1996
A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis.
    The New England journal of medicine, 1996, Mar-14, Volume: 334, Issue:11

    Topics: Aged; Anticoagulants; Enoxaparin; Female; Hemorrhage; Heparin; Home Nursing; Hospitalization; Humans

1996
A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis.
    The New England journal of medicine, 1996, Mar-14, Volume: 334, Issue:11

    Topics: Aged; Anticoagulants; Enoxaparin; Female; Hemorrhage; Heparin; Home Nursing; Hospitalization; Humans

1996
A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis.
    The New England journal of medicine, 1996, Mar-14, Volume: 334, Issue:11

    Topics: Aged; Anticoagulants; Enoxaparin; Female; Hemorrhage; Heparin; Home Nursing; Hospitalization; Humans

1996
A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis.
    The New England journal of medicine, 1996, Mar-14, Volume: 334, Issue:11

    Topics: Aged; Anticoagulants; Enoxaparin; Female; Hemorrhage; Heparin; Home Nursing; Hospitalization; Humans

1996
A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis.
    The New England journal of medicine, 1996, Mar-14, Volume: 334, Issue:11

    Topics: Aged; Anticoagulants; Enoxaparin; Female; Hemorrhage; Heparin; Home Nursing; Hospitalization; Humans

1996
A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis.
    The New England journal of medicine, 1996, Mar-14, Volume: 334, Issue:11

    Topics: Aged; Anticoagulants; Enoxaparin; Female; Hemorrhage; Heparin; Home Nursing; Hospitalization; Humans

1996
A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis.
    The New England journal of medicine, 1996, Mar-14, Volume: 334, Issue:11

    Topics: Aged; Anticoagulants; Enoxaparin; Female; Hemorrhage; Heparin; Home Nursing; Hospitalization; Humans

1996
A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis.
    The New England journal of medicine, 1996, Mar-14, Volume: 334, Issue:11

    Topics: Aged; Anticoagulants; Enoxaparin; Female; Hemorrhage; Heparin; Home Nursing; Hospitalization; Humans

1996
Prevention of venous thromboembolism after knee arthroplasty. A randomized, double-blind trial comparing enoxaparin with warfarin.
    Annals of internal medicine, 1996, Apr-01, Volume: 124, Issue:7

    Topics: Aged; Anticoagulants; Double-Blind Method; Enoxaparin; Female; Follow-Up Studies; Hemorrhage; Humans

1996
Efficacy and safety of postdischarge administration of enoxaparin in the prevention of deep venous thrombosis after total hip replacement. A prospective randomised double-blind placebo-controlled trial.
    Drugs, 1996, Volume: 52 Suppl 7

    Topics: Aged; Anticoagulants; Double-Blind Method; Enoxaparin; Female; Hemorrhage; Hip Prosthesis; Humans; M

1996
Dose-ranging trial of enoxaparin for unstable angina: results of TIMI 11A. The Thrombolysis in Myocardial Infarction (TIMI) 11A Trial Investigators.
    Journal of the American College of Cardiology, 1997, Volume: 29, Issue:7

    Topics: Aged; Angina, Unstable; Anticoagulants; Enoxaparin; Female; Hemorrhage; Humans; Male; Middle Aged; M

1997
A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-Wave Coronary Events Study Group.
    The New England journal of medicine, 1997, Aug-14, Volume: 337, Issue:7

    Topics: Aged; Angina, Unstable; Aspirin; Double-Blind Method; Drug Therapy, Combination; Enoxaparin; Female;

1997
A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-Wave Coronary Events Study Group.
    The New England journal of medicine, 1997, Aug-14, Volume: 337, Issue:7

    Topics: Aged; Angina, Unstable; Aspirin; Double-Blind Method; Drug Therapy, Combination; Enoxaparin; Female;

1997
A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-Wave Coronary Events Study Group.
    The New England journal of medicine, 1997, Aug-14, Volume: 337, Issue:7

    Topics: Aged; Angina, Unstable; Aspirin; Double-Blind Method; Drug Therapy, Combination; Enoxaparin; Female;

1997
A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-Wave Coronary Events Study Group.
    The New England journal of medicine, 1997, Aug-14, Volume: 337, Issue:7

    Topics: Aged; Angina, Unstable; Aspirin; Double-Blind Method; Drug Therapy, Combination; Enoxaparin; Female;

1997
A clinical trial of vena caval filters in the prevention of pulmonary embolism in patients with proximal deep-vein thrombosis. Prévention du Risque d'Embolie Pulmonaire par Interruption Cave Study Group.
    The New England journal of medicine, 1998, Feb-12, Volume: 338, Issue:7

    Topics: Aged; Anticoagulants; Combined Modality Therapy; Enoxaparin; Female; Hemorrhage; Heparin; Humans; Ma

1998
A clinical trial of vena caval filters in the prevention of pulmonary embolism in patients with proximal deep-vein thrombosis. Prévention du Risque d'Embolie Pulmonaire par Interruption Cave Study Group.
    The New England journal of medicine, 1998, Feb-12, Volume: 338, Issue:7

    Topics: Aged; Anticoagulants; Combined Modality Therapy; Enoxaparin; Female; Hemorrhage; Heparin; Humans; Ma

1998
A clinical trial of vena caval filters in the prevention of pulmonary embolism in patients with proximal deep-vein thrombosis. Prévention du Risque d'Embolie Pulmonaire par Interruption Cave Study Group.
    The New England journal of medicine, 1998, Feb-12, Volume: 338, Issue:7

    Topics: Aged; Anticoagulants; Combined Modality Therapy; Enoxaparin; Female; Hemorrhage; Heparin; Humans; Ma

1998
A clinical trial of vena caval filters in the prevention of pulmonary embolism in patients with proximal deep-vein thrombosis. Prévention du Risque d'Embolie Pulmonaire par Interruption Cave Study Group.
    The New England journal of medicine, 1998, Feb-12, Volume: 338, Issue:7

    Topics: Aged; Anticoagulants; Combined Modality Therapy; Enoxaparin; Female; Hemorrhage; Heparin; Humans; Ma

1998
Comparison of two low-molecular-weight heparins for the prevention of postoperative venous thromboembolism after elective hip surgery. Reviparin Study Group.
    Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis, 1998, Volume: 9, Issue:6

    Topics: Adult; Aged; Anticoagulants; Arthroplasty, Replacement, Hip; Double-Blind Method; Enoxaparin; Factor

1998
Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q-wave myocardial infarction. Results of the thrombolysis in myocardial infarction (TIMI) 11B trial.
    Circulation, 1999, Oct-12, Volume: 100, Issue:15

    Topics: Acute Disease; Aged; Angina, Unstable; Anticoagulants; Creatine Kinase; Double-Blind Method; Electro

1999
Comparison of low-molecular-weight heparin (enoxaparin sodium) and standard unfractionated heparin for haemodialysis anticoagulation.
    Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 1999, Volume: 14, Issue:11

    Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Blood Coagulation; Cross-Over Studies; Drug Costs; E

1999
An equivalence study of two low-molecular-weight heparins in the prevention and treatment of deep-vein thrombosis after total hip replacement.
    Seminars in thrombosis and hemostasis, 2000, Volume: 26 Suppl 1

    Topics: Adult; Aged; Arthroplasty, Replacement, Hip; Double-Blind Method; Enoxaparin; Hemorrhage; Heparin, L

2000
Low molecular weight heparin (enoxaparin) versus oral anticoagulant therapy (acenocoumarol) in the long-term treatment of deep venous thrombosis in the elderly: a randomized trial.
    Thrombosis and haemostasis, 2000, Volume: 84, Issue:4

    Topics: Acenocoumarol; Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Enoxaparin; Female; He

2000
Subcutaneous enoxaparin once or twice daily compared with intravenous unfractionated heparin for treatment of venous thromboembolic disease.
    Annals of internal medicine, 2001, Feb-06, Volume: 134, Issue:3

    Topics: Administration, Cutaneous; Adolescent; Adult; Aged; Aged, 80 and over; Anticoagulants; Drug Administ

2001
A synthetic pentasaccharide for the prevention of deep-vein thrombosis after total hip replacement.
    The New England journal of medicine, 2001, Mar-01, Volume: 344, Issue:9

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticoagulants; Arthroplasty, Replacement, Hip; Dose-Res

2001
Prevention of venous thromboembolic disease following primary total knee arthroplasty. A randomized, multicenter, open-label, parallel-group comparison of enoxaparin and warfarin.
    The Journal of bone and joint surgery. American volume, 2001, Volume: 83, Issue:6

    Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Arthroplasty, Replacement, Knee; Enoxaparin; Female;

2001
Prospective comparison of hemorrhagic complications after treatment with enoxaparin versus unfractionated heparin for unstable angina pectoris or non-ST-segment elevation acute myocardial infarction.
    The American journal of cardiology, 2001, Dec-01, Volume: 88, Issue:11

    Topics: Aged; Angina, Unstable; Antifibrinolytic Agents; Double-Blind Method; Electrocardiography; Enoxapari

2001
Low molecular weight heparin and warfarin in the treatment of patients with antiphospholipid syndrome during pregnancy.
    Thrombosis and haemostasis, 2001, Volume: 86, Issue:6

    Topics: Abnormalities, Drug-Induced; Adult; Anticoagulants; Antiphospholipid Syndrome; Aspirin; Autoimmune D

2001
Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after hip-fracture surgery.
    The New England journal of medicine, 2001, Nov-01, Volume: 345, Issue:18

    Topics: Aged; Double-Blind Method; Enoxaparin; Female; Fibrinolytic Agents; Fondaparinux; Hemorrhage; Hip Fr

2001
Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after elective major knee surgery.
    The New England journal of medicine, 2001, Nov-01, Volume: 345, Issue:18

    Topics: Aged; Double-Blind Method; Drug Administration Schedule; Elective Surgical Procedures; Enoxaparin; F

2001
Enoxaparin as adjunctive antithrombin therapy for ST-elevation myocardial infarction: results of the ENTIRE-Thrombolysis in Myocardial Infarction (TIMI) 23 Trial.
    Circulation, 2002, Apr-09, Volume: 105, Issue:14

    Topics: Abciximab; Aged; Antibodies, Monoclonal; Anticoagulants; Blood Flow Velocity; Cohort Studies; Corona

2002
Randomized comparison of enoxaparin with unfractionated heparin following fibrinolytic therapy for acute myocardial infarction.
    European heart journal, 2002, Volume: 23, Issue:8

    Topics: Aged; Anticoagulants; Endpoint Determination; Enoxaparin; Female; Follow-Up Studies; Hemorrhage; Hep

2002
Out of hospital antithrombotic prophylaxis after total hip replacement: low-molecular-weight heparin, warfarin, aspirin or nothing? A cost-effectiveness analysis.
    Thrombosis and haemostasis, 2002, Volume: 87, Issue:4

    Topics: Ambulatory Care; Anticoagulants; Arthroplasty, Replacement, Hip; Aspirin; Cost-Benefit Analysis; Dal

2002
Enoxaparin vs heparin for prevention of deep-vein thrombosis in acute ischaemic stroke: a randomized, double-blind study.
    Acta neurologica Scandinavica, 2002, Volume: 106, Issue:2

    Topics: Acute Disease; Adolescent; Adult; Aged; Aged, 80 and over; Alanine Transaminase; Anticoagulants; Asp

2002
Low-molecular-weight heparin in arterial reconstructive surgery: a double-blind, randomized dose-finding trial.
    Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis, 2002, Volume: 8, Issue:4

    Topics: Aged; Anticoagulants; Arterial Occlusive Diseases; Blood Vessel Prosthesis Implantation; Dose-Respon

2002
Effects of reviparin, a low-molecular-weight heparin, on mortality, reinfarction, and strokes in patients with acute myocardial infarction presenting with ST-segment elevation.
    JAMA, 2005, Jan-26, Volume: 293, Issue:4

    Topics: Aged; Angina Pectoris, Variant; Anticoagulants; Bundle-Branch Block; Double-Blind Method; Female; He

2005
An international multicentre study: Clivarin in the prevention of venous thromboembolism in patients undergoing general surgery. Report of the International Clivarin Assessment Group.
    Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis, 1993, Volume: 4 Suppl 1

    Topics: Adult; Aged; Double-Blind Method; Female; Hemorrhage; Heparin, Low-Molecular-Weight; Humans; Inciden

1993
Low molecular weight heparin (reviparin) in percutaneous transluminal coronary angioplasty. Results of a randomized, double-blind, unfractionated heparin and placebo-controlled, multicenter trial (REDUCE trial). Reduction of Restenosis After PTCA, Early A
    Journal of the American College of Cardiology, 1996, Nov-15, Volume: 28, Issue:6

    Topics: Angioplasty, Balloon, Coronary; Anticoagulants; Coronary Angiography; Coronary Disease; Coronary Ves

1996
Efficacy and safety of a low-molecular-weight heparin and standard unfractionated heparin for prophylaxis of postoperative venous thromboembolism: European multicenter trial.
    World journal of surgery, 1997, Volume: 21, Issue:1

    Topics: Adult; Aged; Anticoagulants; Double-Blind Method; Female; Hemorrhage; Heparin; Heparin, Low-Molecula

1997
Low-molecular-weight heparin in the treatment of patients with venous thromboembolism.
    The New England journal of medicine, 1997, 09-04, Volume: 337, Issue:10

    Topics: Anticoagulants; Death, Sudden; Female; Hemorrhage; Heparin; Heparin, Low-Molecular-Weight; Humans; M

1997
Effects of a low-molecular-weight heparin on thrombus regression and recurrent thromboembolism in patients with deep-vein thrombosis.
    The New England journal of medicine, 2001, Mar-01, Volume: 344, Issue:9

    Topics: Acute Disease; Anticoagulants; Drug Administration Schedule; Female; Hemorrhage; Heparin; Heparin, L

2001
An open-label comparison of the efficacy and safety of certoparin versus unfractionated heparin for the prevention of thromboembolic complications in acutely ill medical patients: CERTAIN.
    Expert opinion on pharmacotherapy, 2010, Volume: 11, Issue:18

    Topics: Acute Disease; Aged; Aged, 80 and over; Anticoagulants; Female; Follow-Up Studies; Hemorrhage; Hepar

2010
CERTIFY: prophylaxis of venous thromboembolism in patients with severe renal insufficiency.
    Thrombosis and haemostasis, 2011, Volume: 105, Issue:6

    Topics: Acute Kidney Injury; Aged; Aged, 80 and over; Anticoagulants; Female; Germany; Hemorrhage; Heparin;

2011
Certoparin versus UFH to prevent venous thromboembolic events in the very elderly patient: an analysis of the CERTIFY study.
    Thrombosis research, 2011, Volume: 128, Issue:5

    Topics: Age Factors; Aged; Aged, 80 and over; Anticoagulants; Chemoprevention; Female; Hemorrhage; Heparin;

2011
Heparin based prophylaxis to prevent venous thromboembolic events and death in patients with cancer - a subgroup analysis of CERTIFY.
    BMC cancer, 2011, Jul-26, Volume: 11

    Topics: Aged; Aged, 80 and over; Anticoagulants; Double-Blind Method; Female; Hemorrhage; Heparin; Heparin,

2011
A multi-center, prospective, open-label, 8-week study of certoparin for anticoagulation during maintenance hemodialysis--the membrane study.
    BMC nephrology, 2012, Jun-28, Volume: 13

    Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Blood Coagulation Disorders; Female; Hemorrhage; Hep

2012
Fixed-dose, body weight-independent subcutaneous low molecular weight heparin Certoparin compared with adjusted-dose intravenous unfractionated heparin in patients with proximal deep venous thrombosis.
    Thrombosis and haemostasis, 2003, Volume: 90, Issue:2

    Topics: Aged; Body Weight; Dose-Response Relationship, Drug; Female; Hemorrhage; Heparin; Heparin, Low-Molec

2003
Comparison of six-month outcome of patients initially treated for acute deep vein thrombosis with a low molecular weight heparin Certoparin at a fixed, body-weight-independent dosage or unfractionated heparin.
    Haematologica, 2003, Volume: 88, Issue:10

    Topics: Anticoagulants; Body Weight; Drug Administration Schedule; Female; Hemorrhage; Heparin; Heparin, Low

2003
Fixed-dose, body weight-independent subcutaneous LMW heparin versus adjusted dose unfractionated intravenous heparin in the initial treatment of proximal venous thrombosis. EASTERN Investigators.
    Thrombosis and haemostasis, 2000, Volume: 83, Issue:5

    Topics: Acute Disease; Adult; Aged; Anticoagulants; Body Weight; Cohort Studies; Female; Hemorrhage; Heparin

2000
Treatment of acute ischemic stroke with the low-molecular-weight heparin certoparin: results of the TOPAS trial. Therapy of Patients With Acute Stroke (TOPAS) Investigators.
    Stroke, 2001, Volume: 32, Issue:1

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticoagulants; Brain Ischemia; Dose-Response Relationsh

2001
Reduction in thrombus extension and clinical end points in patients after initial treatment for deep vein thrombosis with the fixed-dose body weight-independent low molecular weight heparin certoparin.
    Seminars in thrombosis and hemostasis, 2001, Volume: 27, Issue:5

    Topics: Aged; Dose-Response Relationship, Drug; Female; Hemorrhage; Heparin, Low-Molecular-Weight; Humans; M

2001
Apixaban and Dalteparin for the Treatment of Venous Thromboembolism in Patients with Different Sites of Cancer.
    Thrombosis and haemostasis, 2022, Volume: 122, Issue:5

    Topics: Anticoagulants; Dalteparin; Hemorrhage; Humans; Neoplasms; Pyrazoles; Pyridones; Venous Thromboembol

2022
Rivaroxaban vs Dalteparin in Cancer-Associated Thromboembolism: A Randomized Trial.
    Chest, 2022, Volume: 161, Issue:3

    Topics: Aged; Anticoagulants; Dalteparin; Hemorrhage; Heparin, Low-Molecular-Weight; Humans; Neoplasms; Pulm

2022
A phase 2 pharmacodynamic dose-finding, safety, and efficacy study of dalteparin for pediatric venous thromboembolism treatment in children with and without cancer.
    Pediatric blood & cancer, 2022, Volume: 69, Issue:8

    Topics: Adolescent; Anticoagulants; Child; Dalteparin; Hemorrhage; Humans; Neoplasms; Prospective Studies; V

2022
Apixaban for the Treatment of Venous Thromboembolism Associated with Cancer.
    The New England journal of medicine, 2020, 04-23, Volume: 382, Issue:17

    Topics: Administration, Oral; Aged; Anticoagulants; Dalteparin; Female; Hemorrhage; Humans; Incidence; Injec

2020
Bleeding with Apixaban and Dalteparin in Patients with Cancer-Associated Venous Thromboembolism: Results from the Caravaggio Study.
    Thrombosis and haemostasis, 2021, Volume: 121, Issue:5

    Topics: Aged; Dalteparin; Drug-Related Side Effects and Adverse Reactions; Female; Fibrinolytic Agents; Gast

2021
Effects of concomitant administration of anticancer agents and apixaban or dalteparin on recurrence and bleeding in patients with cancer-associated venous thromboembolism.
    European journal of cancer (Oxford, England : 1990), 2021, Volume: 148

    Topics: Aged; Anticoagulants; Antineoplastic Combined Chemotherapy Protocols; Dalteparin; Drug Therapy, Comb

2021
Clinical characteristics and outcomes of incidental venous thromboembolism in cancer patients: Insights from the Caravaggio study.
    Journal of thrombosis and haemostasis : JTH, 2021, Volume: 19, Issue:11

    Topics: Anticoagulants; Dalteparin; Hemorrhage; Humans; Neoplasm Recurrence, Local; Neoplasms; Venous Thromb

2021
Renal function and clinical outcome of patients with cancer-associated venous thromboembolism randomized to receive apixaban or dalteparin. Results from the Caravaggio trial
    Haematologica, 2022, 07-01, Volume: 107, Issue:7

    Topics: Anticoagulants; Dalteparin; Hemorrhage; Humans; Kidney; Neoplasms; Pyrazoles; Pyridones; Venous Thro

2022
Apixaban and dalteparin in active malignancy associated venous thromboembolism. The ADAM VTE Trial.
    Thrombosis and haemostasis, 2017, 10-05, Volume: 117, Issue:10

    Topics: Anticoagulants; Canada; Dalteparin; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Male; Neoplasm

2017
Edoxaban for the Treatment of Cancer-Associated Venous Thromboembolism.
    The New England journal of medicine, 2018, Feb-15, Volume: 378, Issue:7

    Topics: Adult; Aged; Anticoagulants; Dalteparin; Follow-Up Studies; Hemorrhage; Heparin, Low-Molecular-Weigh

2018
Edoxaban for the Treatment of Cancer-Associated Venous Thromboembolism.
    The New England journal of medicine, 2018, Feb-15, Volume: 378, Issue:7

    Topics: Adult; Aged; Anticoagulants; Dalteparin; Follow-Up Studies; Hemorrhage; Heparin, Low-Molecular-Weigh

2018
Edoxaban for the Treatment of Cancer-Associated Venous Thromboembolism.
    The New England journal of medicine, 2018, Feb-15, Volume: 378, Issue:7

    Topics: Adult; Aged; Anticoagulants; Dalteparin; Follow-Up Studies; Hemorrhage; Heparin, Low-Molecular-Weigh

2018
Edoxaban for the Treatment of Cancer-Associated Venous Thromboembolism.
    The New England journal of medicine, 2018, Feb-15, Volume: 378, Issue:7

    Topics: Adult; Aged; Anticoagulants; Dalteparin; Follow-Up Studies; Hemorrhage; Heparin, Low-Molecular-Weigh

2018
Clinical Impact of Bleeding in Cancer-Associated Venous Thromboembolism: Results from the Hokusai VTE Cancer Study.
    Thrombosis and haemostasis, 2018, Volume: 118, Issue:8

    Topics: Aged; Anticoagulants; Clinical Decision-Making; Dalteparin; Factor Xa Inhibitors; Female; Hemorrhage

2018
Low-molecular-weight-heparin versus a coumarin for the prevention of recurrent venous thromboembolism in high- and low-risk patients with active cancer: a post hoc analysis of the CLOT Study.
    Journal of thrombosis and thrombolysis, 2019, Volume: 47, Issue:4

    Topics: Aged; Coumarins; Dalteparin; Disease-Free Survival; Female; Hemorrhage; Humans; Male; Middle Aged; N

2019
Extended treatment with edoxaban in cancer patients with venous thromboembolism: A post-hoc analysis of the Hokusai-VTE Cancer study.
    Journal of thrombosis and haemostasis : JTH, 2019, Volume: 17, Issue:11

    Topics: Aged; Blood Coagulation; Dalteparin; Drug Administration Schedule; Factor Xa Inhibitors; Female; Hem

2019
Aspirin versus low-molecular-weight heparin for extended venous thromboembolism prophylaxis after total hip arthroplasty: a randomized trial.
    Annals of internal medicine, 2013, Jun-04, Volume: 158, Issue:11

    Topics: Adult; Anticoagulants; Arthroplasty, Replacement, Hip; Aspirin; Dalteparin; Drug Administration Sche

2013
The effect of dalteparin versus unfractionated heparin on the levels of troponin I and creatine kinase isoenzyme MB in elective percutaneous coronary intervention: a multicenter study.
    Coronary artery disease, 2014, Volume: 25, Issue:6

    Topics: Aged; Anticoagulants; Biomarkers; China; Creatine Kinase, MB Form; Dalteparin; Female; Hemorrhage; H

2014
Antepartum dalteparin versus no antepartum dalteparin for the prevention of pregnancy complications in pregnant women with thrombophilia (TIPPS): a multinational open-label randomised trial.
    Lancet (London, England), 2014, Nov-08, Volume: 384, Issue:9955

    Topics: Adult; Dalteparin; Female; Fibrinolytic Agents; Hemorrhage; Humans; Pregnancy; Pregnancy Complicatio

2014
Multicenter dose-finding and efficacy and safety outcomes in neonates and children treated with dalteparin for acute venous thromboembolism.
    Journal of thrombosis and haemostasis : JTH, 2014, Volume: 12, Issue:11

    Topics: Acute Disease; Adolescent; Age Factors; Anticoagulants; Child; Child, Preschool; Dalteparin; Drug Ad

2014
Treatment of venous thromboembolism in cancer patients with dalteparin for up to 12 months: the DALTECAN Study.
    Journal of thrombosis and haemostasis : JTH, 2015, Volume: 13, Issue:6

    Topics: Aged; Anticoagulants; Canada; Dalteparin; Drug Administration Schedule; Europe; Female; Hemorrhage;

2015
Edoxaban for treatment of venous thromboembolism in patients with cancer. Rationale and design of the Hokusai VTE-cancer study.
    Thrombosis and haemostasis, 2015, Nov-25, Volume: 114, Issue:6

    Topics: Adult; Anticoagulants; Dalteparin; Double-Blind Method; Factor Xa Inhibitors; Hemorrhage; Humans; Ne

2015
Dalteparin thromboprophylaxis in cancer patients at high risk for venous thromboembolism: A randomized trial.
    Thrombosis research, 2017, Volume: 151

    Topics: Aged; Anticoagulants; Dalteparin; Female; Hemorrhage; Humans; Male; Middle Aged; Neoplasms; Treatmen

2017
Low molecular weight heparin significantly reduces embolisation after carotid endarterectomy--a randomised controlled trial.
    European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery, 2009, Volume: 37, Issue:6

    Topics: Adenosine Diphosphate; Aged; Anticoagulants; Arachidonic Acid; Aspirin; Carotid Artery Diseases; Dal

2009
Oral direct factor Xa inhibition with edoxaban for thromboprophylaxis after elective total hip replacement. A randomised double-blind dose-response study.
    Thrombosis and haemostasis, 2010, Volume: 104, Issue:3

    Topics: Administration, Oral; Aged; Anticoagulants; Arthroplasty, Replacement, Hip; Canada; Dalteparin; Doub

2010
Dalteparin versus unfractionated heparin in critically ill patients.
    The New England journal of medicine, 2011, Apr-07, Volume: 364, Issue:14

    Topics: Anticoagulants; Critical Illness; Dalteparin; Female; Hemorrhage; Heparin; Humans; Incidence; Inject

2011
Dalteparin versus unfractionated heparin in critically ill patients.
    The New England journal of medicine, 2011, Apr-07, Volume: 364, Issue:14

    Topics: Anticoagulants; Critical Illness; Dalteparin; Female; Hemorrhage; Heparin; Humans; Incidence; Inject

2011
Dalteparin versus unfractionated heparin in critically ill patients.
    The New England journal of medicine, 2011, Apr-07, Volume: 364, Issue:14

    Topics: Anticoagulants; Critical Illness; Dalteparin; Female; Hemorrhage; Heparin; Humans; Incidence; Inject

2011
Dalteparin versus unfractionated heparin in critically ill patients.
    The New England journal of medicine, 2011, Apr-07, Volume: 364, Issue:14

    Topics: Anticoagulants; Critical Illness; Dalteparin; Female; Hemorrhage; Heparin; Humans; Incidence; Inject

2011
Dalteparin versus unfractionated heparin in critically ill patients.
    The New England journal of medicine, 2011, Apr-07, Volume: 364, Issue:14

    Topics: Anticoagulants; Critical Illness; Dalteparin; Female; Hemorrhage; Heparin; Humans; Incidence; Inject

2011
Dalteparin versus unfractionated heparin in critically ill patients.
    The New England journal of medicine, 2011, Apr-07, Volume: 364, Issue:14

    Topics: Anticoagulants; Critical Illness; Dalteparin; Female; Hemorrhage; Heparin; Humans; Incidence; Inject

2011
Dalteparin versus unfractionated heparin in critically ill patients.
    The New England journal of medicine, 2011, Apr-07, Volume: 364, Issue:14

    Topics: Anticoagulants; Critical Illness; Dalteparin; Female; Hemorrhage; Heparin; Humans; Incidence; Inject

2011
Dalteparin versus unfractionated heparin in critically ill patients.
    The New England journal of medicine, 2011, Apr-07, Volume: 364, Issue:14

    Topics: Anticoagulants; Critical Illness; Dalteparin; Female; Hemorrhage; Heparin; Humans; Incidence; Inject

2011
Dalteparin versus unfractionated heparin in critically ill patients.
    The New England journal of medicine, 2011, Apr-07, Volume: 364, Issue:14

    Topics: Anticoagulants; Critical Illness; Dalteparin; Female; Hemorrhage; Heparin; Humans; Incidence; Inject

2011
A randomized trial of dalteparin compared with ibuprofen for the treatment of superficial thrombophlebitis.
    Journal of thrombosis and haemostasis : JTH, 2012, Volume: 10, Issue:5

    Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Dalte

2012
Benefits of extended treatment with dalteparin in patients with unstable coronary artery disease eligible for revascularization.
    European heart journal, 2002, Volume: 23, Issue:15

    Topics: Coronary Artery Disease; Dalteparin; Double-Blind Method; Female; Fibrinolytic Agents; Hemorrhage; H

2002
Safety and efficacy of abciximab combined with dalteparin in treatment of acute coronary syndromes.
    European heart journal, 2002, Volume: 23, Issue:19

    Topics: Abciximab; Acute Disease; Aged; Antibodies, Monoclonal; Anticoagulants; Cohort Studies; Coronary Dis

2002
Reporting the NAFT major bleeding rates in context: reviewers should include site investigator-classified rates.
    Archives of internal medicine, 2003, Feb-10, Volume: 163, Issue:3

    Topics: Anticoagulants; Dalteparin; Double-Blind Method; Hemorrhage; Humans; North America; Research Design;

2003
Low molecular weight heparin for the prevention of hepatic veno-occlusive disease (VOD) after hematopoietic stem cell transplantation: a prospective phase II study.
    Bone marrow transplantation, 2003, Volume: 31, Issue:12

    Topics: Adolescent; Adult; Dalteparin; Female; Hematopoietic Stem Cell Transplantation; Hemorrhage; Hepatic

2003
Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer.
    The New England journal of medicine, 2003, Jul-10, Volume: 349, Issue:2

    Topics: Acenocoumarol; Administration, Oral; Anticoagulants; Dalteparin; Drug Therapy, Combination; Female;

2003
Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer.
    The New England journal of medicine, 2003, Jul-10, Volume: 349, Issue:2

    Topics: Acenocoumarol; Administration, Oral; Anticoagulants; Dalteparin; Drug Therapy, Combination; Female;

2003
Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer.
    The New England journal of medicine, 2003, Jul-10, Volume: 349, Issue:2

    Topics: Acenocoumarol; Administration, Oral; Anticoagulants; Dalteparin; Drug Therapy, Combination; Female;

2003
Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer.
    The New England journal of medicine, 2003, Jul-10, Volume: 349, Issue:2

    Topics: Acenocoumarol; Administration, Oral; Anticoagulants; Dalteparin; Drug Therapy, Combination; Female;

2003
Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer.
    The New England journal of medicine, 2003, Jul-10, Volume: 349, Issue:2

    Topics: Acenocoumarol; Administration, Oral; Anticoagulants; Dalteparin; Drug Therapy, Combination; Female;

2003
Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer.
    The New England journal of medicine, 2003, Jul-10, Volume: 349, Issue:2

    Topics: Acenocoumarol; Administration, Oral; Anticoagulants; Dalteparin; Drug Therapy, Combination; Female;

2003
Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer.
    The New England journal of medicine, 2003, Jul-10, Volume: 349, Issue:2

    Topics: Acenocoumarol; Administration, Oral; Anticoagulants; Dalteparin; Drug Therapy, Combination; Female;

2003
Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer.
    The New England journal of medicine, 2003, Jul-10, Volume: 349, Issue:2

    Topics: Acenocoumarol; Administration, Oral; Anticoagulants; Dalteparin; Drug Therapy, Combination; Female;

2003
Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer.
    The New England journal of medicine, 2003, Jul-10, Volume: 349, Issue:2

    Topics: Acenocoumarol; Administration, Oral; Anticoagulants; Dalteparin; Drug Therapy, Combination; Female;

2003
Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer.
    The New England journal of medicine, 2003, Jul-10, Volume: 349, Issue:2

    Topics: Acenocoumarol; Administration, Oral; Anticoagulants; Dalteparin; Drug Therapy, Combination; Female;

2003
Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer.
    The New England journal of medicine, 2003, Jul-10, Volume: 349, Issue:2

    Topics: Acenocoumarol; Administration, Oral; Anticoagulants; Dalteparin; Drug Therapy, Combination; Female;

2003
Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer.
    The New England journal of medicine, 2003, Jul-10, Volume: 349, Issue:2

    Topics: Acenocoumarol; Administration, Oral; Anticoagulants; Dalteparin; Drug Therapy, Combination; Female;

2003
Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer.
    The New England journal of medicine, 2003, Jul-10, Volume: 349, Issue:2

    Topics: Acenocoumarol; Administration, Oral; Anticoagulants; Dalteparin; Drug Therapy, Combination; Female;

2003
Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer.
    The New England journal of medicine, 2003, Jul-10, Volume: 349, Issue:2

    Topics: Acenocoumarol; Administration, Oral; Anticoagulants; Dalteparin; Drug Therapy, Combination; Female;

2003
Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer.
    The New England journal of medicine, 2003, Jul-10, Volume: 349, Issue:2

    Topics: Acenocoumarol; Administration, Oral; Anticoagulants; Dalteparin; Drug Therapy, Combination; Female;

2003
Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer.
    The New England journal of medicine, 2003, Jul-10, Volume: 349, Issue:2

    Topics: Acenocoumarol; Administration, Oral; Anticoagulants; Dalteparin; Drug Therapy, Combination; Female;

2003
Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer.
    The New England journal of medicine, 2003, Jul-10, Volume: 349, Issue:2

    Topics: Acenocoumarol; Administration, Oral; Anticoagulants; Dalteparin; Drug Therapy, Combination; Female;

2003
Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer.
    The New England journal of medicine, 2003, Jul-10, Volume: 349, Issue:2

    Topics: Acenocoumarol; Administration, Oral; Anticoagulants; Dalteparin; Drug Therapy, Combination; Female;

2003
Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer.
    The New England journal of medicine, 2003, Jul-10, Volume: 349, Issue:2

    Topics: Acenocoumarol; Administration, Oral; Anticoagulants; Dalteparin; Drug Therapy, Combination; Female;

2003
Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer.
    The New England journal of medicine, 2003, Jul-10, Volume: 349, Issue:2

    Topics: Acenocoumarol; Administration, Oral; Anticoagulants; Dalteparin; Drug Therapy, Combination; Female;

2003
Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer.
    The New England journal of medicine, 2003, Jul-10, Volume: 349, Issue:2

    Topics: Acenocoumarol; Administration, Oral; Anticoagulants; Dalteparin; Drug Therapy, Combination; Female;

2003
Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer.
    The New England journal of medicine, 2003, Jul-10, Volume: 349, Issue:2

    Topics: Acenocoumarol; Administration, Oral; Anticoagulants; Dalteparin; Drug Therapy, Combination; Female;

2003
Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer.
    The New England journal of medicine, 2003, Jul-10, Volume: 349, Issue:2

    Topics: Acenocoumarol; Administration, Oral; Anticoagulants; Dalteparin; Drug Therapy, Combination; Female;

2003
Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer.
    The New England journal of medicine, 2003, Jul-10, Volume: 349, Issue:2

    Topics: Acenocoumarol; Administration, Oral; Anticoagulants; Dalteparin; Drug Therapy, Combination; Female;

2003
Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer.
    The New England journal of medicine, 2003, Jul-10, Volume: 349, Issue:2

    Topics: Acenocoumarol; Administration, Oral; Anticoagulants; Dalteparin; Drug Therapy, Combination; Female;

2003
Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer.
    The New England journal of medicine, 2003, Jul-10, Volume: 349, Issue:2

    Topics: Acenocoumarol; Administration, Oral; Anticoagulants; Dalteparin; Drug Therapy, Combination; Female;

2003
Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer.
    The New England journal of medicine, 2003, Jul-10, Volume: 349, Issue:2

    Topics: Acenocoumarol; Administration, Oral; Anticoagulants; Dalteparin; Drug Therapy, Combination; Female;

2003
Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer.
    The New England journal of medicine, 2003, Jul-10, Volume: 349, Issue:2

    Topics: Acenocoumarol; Administration, Oral; Anticoagulants; Dalteparin; Drug Therapy, Combination; Female;

2003
Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer.
    The New England journal of medicine, 2003, Jul-10, Volume: 349, Issue:2

    Topics: Acenocoumarol; Administration, Oral; Anticoagulants; Dalteparin; Drug Therapy, Combination; Female;

2003
Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer.
    The New England journal of medicine, 2003, Jul-10, Volume: 349, Issue:2

    Topics: Acenocoumarol; Administration, Oral; Anticoagulants; Dalteparin; Drug Therapy, Combination; Female;

2003
Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer.
    The New England journal of medicine, 2003, Jul-10, Volume: 349, Issue:2

    Topics: Acenocoumarol; Administration, Oral; Anticoagulants; Dalteparin; Drug Therapy, Combination; Female;

2003
Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer.
    The New England journal of medicine, 2003, Jul-10, Volume: 349, Issue:2

    Topics: Acenocoumarol; Administration, Oral; Anticoagulants; Dalteparin; Drug Therapy, Combination; Female;

2003
Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer.
    The New England journal of medicine, 2003, Jul-10, Volume: 349, Issue:2

    Topics: Acenocoumarol; Administration, Oral; Anticoagulants; Dalteparin; Drug Therapy, Combination; Female;

2003
Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer.
    The New England journal of medicine, 2003, Jul-10, Volume: 349, Issue:2

    Topics: Acenocoumarol; Administration, Oral; Anticoagulants; Dalteparin; Drug Therapy, Combination; Female;

2003
Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer.
    The New England journal of medicine, 2003, Jul-10, Volume: 349, Issue:2

    Topics: Acenocoumarol; Administration, Oral; Anticoagulants; Dalteparin; Drug Therapy, Combination; Female;

2003
Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer.
    The New England journal of medicine, 2003, Jul-10, Volume: 349, Issue:2

    Topics: Acenocoumarol; Administration, Oral; Anticoagulants; Dalteparin; Drug Therapy, Combination; Female;

2003
Randomized, placebo-controlled trial of dalteparin for the prevention of venous thromboembolism in acutely ill medical patients.
    Circulation, 2004, Aug-17, Volume: 110, Issue:7

    Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Anticoagulants; Dalteparin; Death, Sudden; Double-Bli

2004
Randomized, placebo-controlled trial of dalteparin for the prevention of venous thromboembolism in acutely ill medical patients.
    Circulation, 2004, Aug-17, Volume: 110, Issue:7

    Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Anticoagulants; Dalteparin; Death, Sudden; Double-Bli

2004
Randomized, placebo-controlled trial of dalteparin for the prevention of venous thromboembolism in acutely ill medical patients.
    Circulation, 2004, Aug-17, Volume: 110, Issue:7

    Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Anticoagulants; Dalteparin; Death, Sudden; Double-Bli

2004
Randomized, placebo-controlled trial of dalteparin for the prevention of venous thromboembolism in acutely ill medical patients.
    Circulation, 2004, Aug-17, Volume: 110, Issue:7

    Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Anticoagulants; Dalteparin; Death, Sudden; Double-Bli

2004
Long-term clinical outcomes of platelet glycoprotein IIb/IIIa inhibitor combined with low molecular weight heparin in patients with acute coronary syndrome.
    Circulation journal : official journal of the Japanese Circulation Society, 2005, Volume: 69, Issue:2

    Topics: Acute Disease; Aged; Coronary Disease; Dalteparin; Drug Therapy, Combination; Female; Hemorrhage; He

2005
Dalteparin thromboprophylaxis for critically ill medical-surgical patients with renal insufficiency.
    Journal of critical care, 2005, Volume: 20, Issue:4

    Topics: Anticoagulants; Creatinine; Dalteparin; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Intensive

2005
Safety of dalteparin for the prophylaxis of venous thromboembolism in elderly medical patients with renal insufficiency: a pilot study.
    Haematologica, 2006, Volume: 91, Issue:7

    Topics: Aged; Aged, 80 and over; Cohort Studies; Dalteparin; Female; Hemorrhage; Heparin, Low-Molecular-Weig

2006
Risk stratification and heparin prophylaxis to prevent venous thromboembolism in pregnant women.
    Thrombosis and haemostasis, 2007, Volume: 98, Issue:6

    Topics: Adult; Anticoagulants; Dalteparin; Dose-Response Relationship, Drug; Drug Administration Schedule; F

2007
Clinical evaluation of low-molecular-weight heparin (FR-860) on disseminated intravascular coagulation (DIC)--a multicenter co-operative double-blind trial in comparison with heparin.
    Thrombosis research, 1993, Dec-15, Volume: 72, Issue:6

    Topics: Adult; Aged; Blood Coagulation Tests; Dalteparin; Disseminated Intravascular Coagulation; Double-Bli

1993
Comparison of subcutaneous unfractionated heparin with a low molecular weight heparin (Fragmin) in patients with venous thromboembolism and contraindications to coumarin.
    Thrombosis and haemostasis, 1994, Volume: 71, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Contraindications; Coumarins; Dalteparin; Female; Fractures, Spontan

1994
Prevention of deep-vein thrombosis after total hip arthroplasty. Comparison of warfarin and dalteparin.
    The Journal of bone and joint surgery. American volume, 1997, Volume: 79, Issue:9

    Topics: Anticoagulants; Blood Loss, Surgical; Dalteparin; Female; Hemorrhage; Hip Prosthesis; Humans; Male;

1997
Randomized trial of low molecular weight heparin (dalteparin) in prevention of left ventricular thrombus formation and arterial embolism after acute anterior myocardial infarction: the Fragmin in Acute Myocardial Infarction (FRAMI) Study.
    Journal of the American College of Cardiology, 1997, Volume: 30, Issue:4

    Topics: Aged; Anticoagulants; Dalteparin; Double-Blind Method; Embolism; Female; Heart Diseases; Heart Ventr

1997
In-laboratory removal of femoral sheath following protamine administration in patients having intracoronary stent implantation.
    The American journal of cardiology, 1997, Nov-15, Volume: 80, Issue:10

    Topics: Anticoagulants; Coronary Disease; Dalteparin; Female; Femoral Artery; Hemorrhage; Heparin; Heparin A

1997
A controlled trial of low-molecular-weight heparin (dalteparin) versus unfractionated heparin as anticoagulant during continuous venovenous hemodialysis with filtration.
    Critical care medicine, 1999, Volume: 27, Issue:10

    Topics: Acute Kidney Injury; Adult; Anticoagulants; Cost-Benefit Analysis; Dalteparin; Hemofiltration; Hemog

1999
Thromboprophylaxis with low molecular weight heparin (dalteparin) in pregnancy.
    Thrombosis research, 1999, Nov-15, Volume: 96, Issue:4

    Topics: Adult; Dalteparin; Demography; Female; Fractures, Bone; Hemorrhage; Heparin; Heparin, Low-Molecular-

1999
Outpatient treatment of pulmonary embolism with dalteparin.
    Thrombosis and haemostasis, 2000, Volume: 83, Issue:2

    Topics: Adult; Aged; Ambulatory Care; Anticoagulants; Cohort Studies; Dalteparin; Disease-Free Survival; Fib

2000
Dalteparin as periprocedure anticoagulation for patients on warfarin and at high risk of thrombosis.
    The Annals of pharmacotherapy, 2001, Volume: 35, Issue:6

    Topics: Adult; Aged; Anticoagulants; Dalteparin; Feasibility Studies; Female; Hemorrhage; Hospitalization; H

2001
Clinically relevant bleeding in cancer patients treated for venous thromboembolism from the CATCH study.
    Journal of thrombosis and haemostasis : JTH, 2018, Volume: 16, Issue:6

    Topics: Aged; Anticoagulants; Drug Monitoring; Female; Hemorrhage; Humans; Incidence; International Normaliz

2018
Renal Impairment, Recurrent Venous Thromboembolism and Bleeding in Cancer Patients with Acute Venous Thromboembolism-Analysis of the CATCH Study.
    Thrombosis and haemostasis, 2018, Volume: 118, Issue:5

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Drug Administration Schedule; Female; Fibrinolytic Agent

2018
Tinzaparin vs Warfarin for Treatment of Acute Venous Thromboembolism in Patients With Active Cancer: A Randomized Clinical Trial.
    JAMA, 2015, Aug-18, Volume: 314, Issue:7

    Topics: Aged; Anticoagulants; Female; Hemorrhage; Heparin, Low-Molecular-Weight; Humans; International Norma

2015
[Effect of tinzaparin on survival in non-small-cell lung cancer after surgery. TILT: tinzaparin in lung tumours].
    Revue des maladies respiratoires, 2011, Volume: 28, Issue:5

    Topics: Carcinoma, Non-Small-Cell Lung; Clinical Protocols; Combined Modality Therapy; Follow-Up Studies; He

2011
A significant proportion of patients treated with citrate containing dialysate need additional anticoagulation.
    The International journal of artificial organs, 2013, Volume: 36, Issue:1

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticoagulants; Blood Coagulation; Citric Acid; Cross-Ov

2013
Intravenous and subcutaneous weight-based dosing of the low molecular weight heparin tinzaparin (Innohep) in end-stage renal disease patients undergoing chronic hemodialysis.
    American journal of kidney diseases : the official journal of the National Kidney Foundation, 2002, Volume: 40, Issue:3

    Topics: Adolescent; Adult; Aged; Antithrombin III; Biomarkers; Blood Coagulation; Cross-Over Studies; Dizzin

2002
Self-managed long-term low-molecular-weight heparin therapy: the balance of benefits and harms.
    The American journal of medicine, 2007, Volume: 120, Issue:1

    Topics: Anticoagulants; Cause of Death; Female; Fibrinolytic Agents; Hemorrhage; Heparin, Low-Molecular-Weig

2007
Reduction of painful vaso-occlusive crisis of sickle cell anaemia by tinzaparin in a double-blind randomized trial.
    Thrombosis and haemostasis, 2007, Volume: 98, Issue:2

    Topics: Adolescent; Adult; Anemia, Sickle Cell; Antisickling Agents; Double-Blind Method; Female; Fibrinolyt

2007
A comparison of low-molecular-weight heparin with unfractionated heparin for acute pulmonary embolism. The THESEE Study Group. Tinzaparine ou Heparine Standard: Evaluations dans l'Embolie Pulmonaire.
    The New England journal of medicine, 1997, Sep-04, Volume: 337, Issue:10

    Topics: Acute Disease; Aged; Anticoagulants; Cause of Death; Female; Fibrinolytic Agents; Hemorrhage; Hepari

1997
Dose relation in the prevention of proximal vein thrombosis with a low molecular weight heparin (tinzaparin) in elective hip arthroplasty.
    Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis, 2000, Volume: 6, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Arthroplasty, Replacement, Hip; Blood Transfusion; Double-Blind Meth

2000
Dosing in heavy-weight/obese patients with the LMWH, tinzaparin: a pharmacodynamic study.
    Thrombosis and haemostasis, 2002, Volume: 87, Issue:5

    Topics: Adult; Anticoagulants; Body Mass Index; Body Weight; Cross-Over Studies; Factor Xa Inhibitors; Femal

2002
Ardeparin (low-molecular-weight heparin) vs graduated compression stockings for the prevention of venous thromboembolism. A randomized trial in patients undergoing knee surgery.
    Archives of internal medicine, 1996, Apr-22, Volume: 156, Issue:8

    Topics: Aged; Anticoagulants; Bandages; Combined Modality Therapy; Double-Blind Method; Female; Hemorrhage;

1996
Abbreviated hospitalization for deep venous thrombosis with the use of ardeparin.
    Archives of internal medicine, 1998, Nov-23, Volume: 158, Issue:21

    Topics: Anticoagulants; Confidence Intervals; Drug Approval; Female; Follow-Up Studies; Hemorrhage; Heparin;

1998
Usefulness of subcutaneous low molecular weight heparin (ardeparin) for reduction of restenosis after percutaneous transluminal coronary angioplasty.
    The American journal of cardiology, 1999, Jun-01, Volume: 83, Issue:11

    Topics: Adult; Aged; Angiography; Angioplasty, Balloon, Coronary; Antibodies; Coronary Disease; Double-Blind

1999
Ardeparin sodium for extended out-of-hospital prophylaxis against venous thromboembolism after total hip or knee replacement. A randomized, double-blind, placebo-controlled trial.
    Annals of internal medicine, 2000, Jun-06, Volume: 132, Issue:11

    Topics: Adult; Aged; Ambulatory Care; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Cause

2000
[Low molecular weight heparin decreases thrombosis risk in patients receiving chemotherapy for cancer].
    Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al], 2013, Volume: 189, Issue:6

    Topics: Double-Blind Method; Fibrinolytic Agents; Follow-Up Studies; Hemorrhage; Heparin, Low-Molecular-Weig

2013
Semuloparin for thromboprophylaxis in patients receiving chemotherapy for cancer.
    The New England journal of medicine, 2012, Feb-16, Volume: 366, Issue:7

    Topics: Adult; Antineoplastic Agents; Double-Blind Method; Fibrinolytic Agents; Fibrinopeptide A; Hemorrhage

2012
Semuloparin for thromboprophylaxis in patients receiving chemotherapy for cancer.
    The New England journal of medicine, 2012, Feb-16, Volume: 366, Issue:7

    Topics: Adult; Antineoplastic Agents; Double-Blind Method; Fibrinolytic Agents; Fibrinopeptide A; Hemorrhage

2012
Semuloparin for thromboprophylaxis in patients receiving chemotherapy for cancer.
    The New England journal of medicine, 2012, Feb-16, Volume: 366, Issue:7

    Topics: Adult; Antineoplastic Agents; Double-Blind Method; Fibrinolytic Agents; Fibrinopeptide A; Hemorrhage

2012
Semuloparin for thromboprophylaxis in patients receiving chemotherapy for cancer.
    The New England journal of medicine, 2012, Feb-16, Volume: 366, Issue:7

    Topics: Adult; Antineoplastic Agents; Double-Blind Method; Fibrinolytic Agents; Fibrinopeptide A; Hemorrhage

2012
Semuloparin for thromboprophylaxis in patients receiving chemotherapy for cancer.
    The New England journal of medicine, 2012, Feb-16, Volume: 366, Issue:7

    Topics: Adult; Antineoplastic Agents; Double-Blind Method; Fibrinolytic Agents; Fibrinopeptide A; Hemorrhage

2012
Semuloparin for thromboprophylaxis in patients receiving chemotherapy for cancer.
    The New England journal of medicine, 2012, Feb-16, Volume: 366, Issue:7

    Topics: Adult; Antineoplastic Agents; Double-Blind Method; Fibrinolytic Agents; Fibrinopeptide A; Hemorrhage

2012
Semuloparin for thromboprophylaxis in patients receiving chemotherapy for cancer.
    The New England journal of medicine, 2012, Feb-16, Volume: 366, Issue:7

    Topics: Adult; Antineoplastic Agents; Double-Blind Method; Fibrinolytic Agents; Fibrinopeptide A; Hemorrhage

2012
Semuloparin for thromboprophylaxis in patients receiving chemotherapy for cancer.
    The New England journal of medicine, 2012, Feb-16, Volume: 366, Issue:7

    Topics: Adult; Antineoplastic Agents; Double-Blind Method; Fibrinolytic Agents; Fibrinopeptide A; Hemorrhage

2012
Semuloparin for thromboprophylaxis in patients receiving chemotherapy for cancer.
    The New England journal of medicine, 2012, Feb-16, Volume: 366, Issue:7

    Topics: Adult; Antineoplastic Agents; Double-Blind Method; Fibrinolytic Agents; Fibrinopeptide A; Hemorrhage

2012

Other Studies

374 other studies available for dalteparin and Hemorrhage

ArticleYear
The effect of renal impairment and obesity on anti-Xa peak and trough levels in patients receiving therapeutic doses of nadroparin: a comparison with control patients.
    European journal of clinical pharmacology, 2023, Volume: 79, Issue:11

    Topics: Anticoagulants; Factor Xa Inhibitors; Hemorrhage; Heparin, Low-Molecular-Weight; Humans; Nadroparin;

2023
Thromboembolic and bleeding complications in patients with oesophageal cancer.
    The British journal of surgery, 2020, Volume: 107, Issue:10

    Topics: Adenocarcinoma; Aged; Anticoagulants; Carcinoma, Squamous Cell; Chemoradiotherapy; Cohort Studies; E

2020
[Prevention of thrombohemorrhagic postoperative complications in patients with benign prostatic hyperplasia].
    Urologiia (Moscow, Russia : 1999), 2017, Issue:1

    Topics: Fibrinolytic Agents; Hemorrhage; Humans; Low-Level Light Therapy; Male; Nadroparin; Postoperative Co

2017
Major bleeding risks of different low-molecular-weight heparin agents: a cohort study in 12 934 patients treated for acute venous thrombosis.
    Journal of thrombosis and haemostasis : JTH, 2017, Volume: 15, Issue:7

    Topics: Acute Disease; Adult; Aged; Anticoagulants; Cohort Studies; Drug Administration Schedule; Female; He

2017
Fatal intrahepatic hemorrhage after nadroparin use for total hip arthroplasty.
    Forensic science, medicine, and pathology, 2014, Volume: 10, Issue:4

    Topics: Aged; Anticoagulants; Arthroplasty, Replacement, Hip; Autopsy; Cause of Death; Chemical and Drug Ind

2014
[Prophylaxis of thrombohemorrhagic complications in surgical treatment of chemoresistant pulmonary tuberculosis].
    Klinichna khirurhiia, 2014, Issue:10

    Topics: Adult; Anticoagulants; Antitubercular Agents; Female; Hemorrhage; Humans; Hydroxyethylrutoside; Indo

2014
Differences in the safety profiles of two low-molecular-weight heparins.
    Thrombosis and haemostasis, 2008, Volume: 99, Issue:6

    Topics: Anticoagulants; Drug Administration Schedule; Enoxaparin; Hemorrhage; Humans; Nadroparin; Orthopedic

2008
Bleeding complications after systematic switch of routine thromboprophylaxis for major orthopaedic surgery.
    Thrombosis and haemostasis, 2008, Volume: 99, Issue:6

    Topics: Anticoagulants; Drug Administration Schedule; Enoxaparin; Hemorrhage; Humans; Middle Aged; Nadropari

2008
The individually optimized bolus dose of nadroparin is safe and effective in diabetic and nondiabetic patients with bleeding risk on hemodialysis.
    Hemodialysis international. International Symposium on Home Hemodialysis, 2011, Volume: 15, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Blood Coagulation; Diabetes Mellitus; Female; Hemorr

2011
Postoperative nadroparin administration for prophylaxis of thromboembolic events is not associated with an increased risk of hemorrhage after spinal surgery.
    European spine journal : official publication of the European Spine Society, the European Spinal Deformity Society, and the European Section of the Cervical Spine Research Society, 2004, Volume: 13, Issue:1

    Topics: Adult; Aged; Anticoagulants; Bandages; Cohort Studies; Female; Hematoma; Hemorrhage; Humans; Laminec

2004
Prevention and treatment of experimental thrombosis in rabbits with rivaroxaban (BAY 597939)--an oral, direct factor Xa inhibitor.
    Thrombosis and haemostasis, 2007, Volume: 97, Issue:3

    Topics: Administration, Oral; Animals; Anticoagulants; Blood Coagulation Tests; Disease Models, Animal; Dose

2007
Pharmacological properties of CY 216 and of its ACLM and BCLM components in the rabbit.
    Thrombosis and haemostasis, 1994, Volume: 72, Issue:2

    Topics: Animals; Factor Xa Inhibitors; Hemorrhage; Infusions, Intravenous; Injections, Intravenous; Injectio

1994
[Comparative study of the efficacy of a low dose of antivitamin K and a preventive dose of low molecular weight heparin in the prevention of relapses of deep venous thrombosis after curative treatment in the aged subject].
    Journal des maladies vasculaires, 1994, Volume: 19, Issue:1

    Topics: 4-Hydroxycoumarins; Aged; Anticoagulants; Dose-Response Relationship, Drug; Hemorrhage; Humans; Inde

1994
Low-molecular-weight heparin and thromboembolism in pregnancy.
    Lancet (London, England), 1999, Mar-13, Volume: 353, Issue:9156

    Topics: Anticoagulants; Dose-Response Relationship, Drug; Female; Hemorrhage; Heparin, Low-Molecular-Weight;

1999
Home treatment of deep venous thrombosis with low molecular weight heparin: Long-term incidence of recurrent venous thromboembolism.
    American journal of hematology, 2001, Volume: 67, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Ambulatory Care; Cohort Studies; Disease-Free Survival; Female; Foll

2001
Eligibility for home treatment of deep vein thrombosis: a prospective study in 202 consecutive patients.
    Journal of vascular surgery, 2001, Volume: 34, Issue:6

    Topics: Adult; Aged; Aged, 80 and over; Ambulatory Care; Anticoagulants; Bandages; Combined Modality Therapy

2001
Monitoring anti-Xa levels in patients with cancer-associated venous thromboembolism treated with bemiparin.
    Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2020, Volume: 22, Issue:8

    Topics: Aged; Anticoagulants; Factor Xa Inhibitors; Female; Hemorrhage; Heparin, Low-Molecular-Weight; Human

2020
Thromboprophylaxis with the low-molecular-weight heparin bemiparin sodium in elderly medical patients in usual clinical practice: the ANCIANOS study.
    Clinical drug investigation, 2010, Volume: 30, Issue:5

    Topics: Aged; Aged, 80 and over; Cohort Studies; Female; Fibrinolytic Agents; Health Services for the Aged;

2010
Evaluation of the effectiveness and safety of bemiparin in a large population of orthopedic patients in a normal clinical practice.
    Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis, 2008, Volume: 14, Issue:1

    Topics: Adult; Aged; Chemoprevention; Dose-Response Relationship, Drug; Drug Evaluation; Female; Hemorrhage;

2008
Safety and Efficacy of Direct Oral Anticoagulants in Patients With Moderate to Severe Cirrhosis.
    The Annals of pharmacotherapy, 2022, Volume: 56, Issue:7

    Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Cohort Studies; Enoxaparin; Hemorrhage; H

2022
Enoxaparin titrated by anti-Xa levels reduces venous thromboembolism in trauma patients.
    The journal of trauma and acute care surgery, 2022, 01-01, Volume: 92, Issue:1

    Topics: Blood Coagulation Tests; Chemoprevention; Dose-Response Relationship, Drug; Drug Dosage Calculations

2022
Supraprophylactic Anti-Factor Xa Levels Are Associated with Major Bleeding in Neurosurgery Patients Receiving Prophylactic Enoxaparin.
    World neurosurgery, 2022, Volume: 157

    Topics: Adult; Aged; Anticoagulants; Drug Monitoring; Enoxaparin; Factor Xa Inhibitors; Female; Hemorrhage;

2022
Reversal Activity and Toxicity of Heparin-Binding Copolymer after Subcutaneous Administration of Enoxaparin in Mice.
    International journal of molecular sciences, 2021, Oct-15, Volume: 22, Issue:20

    Topics: Animals; Anticoagulants; Blood Coagulation Tests; Drug-Related Side Effects and Adverse Reactions; E

2021
A prospective cohort study of catheter-related thrombosis in cancer patients treated with 1 month of anticoagulation after catheter removal.
    Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis, 2022, Apr-01, Volume: 33, Issue:3

    Topics: Anticoagulants; Catheters; Enoxaparin; Hemorrhage; Humans; Neoplasms; Pilot Projects; Postthrombotic

2022
Effect of polypharmacy on bleeding with rivaroxaban versus vitamin K antagonist for treatment of venous thromboembolism.
    Journal of thrombosis and haemostasis : JTH, 2022, Volume: 20, Issue:6

    Topics: Anticoagulants; Cytochrome P-450 CYP3A; Enoxaparin; Factor Xa Inhibitors; Fibrinolytic Agents; Hemor

2022
Clinical use of low-dose parenteral anticoagulation, incidence of major bleeding and mortality: a multi-centre cohort study using the French national health data system.
    European journal of clinical pharmacology, 2022, Volume: 78, Issue:7

    Topics: Adult; Anticoagulants; Cohort Studies; Enoxaparin; Fondaparinux; Hemorrhage; Heparin; Heparin, Low-M

2022
Association of Bleeding Severity With Mortality in Extended Thromboprophylaxis of Medically Ill Patients in the MAGELLAN and MARINER Trials.
    Circulation, 2022, 05-10, Volume: 145, Issue:19

    Topics: Aftercare; Anticoagulants; Enoxaparin; Hemorrhage; Humans; Patient Discharge; Rivaroxaban; Venous Th

2022
Association of Bleeding Severity With Mortality in Extended Thromboprophylaxis of Medically Ill Patients in the MAGELLAN and MARINER Trials.
    Circulation, 2022, 05-10, Volume: 145, Issue:19

    Topics: Aftercare; Anticoagulants; Enoxaparin; Hemorrhage; Humans; Patient Discharge; Rivaroxaban; Venous Th

2022
Association of Bleeding Severity With Mortality in Extended Thromboprophylaxis of Medically Ill Patients in the MAGELLAN and MARINER Trials.
    Circulation, 2022, 05-10, Volume: 145, Issue:19

    Topics: Aftercare; Anticoagulants; Enoxaparin; Hemorrhage; Humans; Patient Discharge; Rivaroxaban; Venous Th

2022
Association of Bleeding Severity With Mortality in Extended Thromboprophylaxis of Medically Ill Patients in the MAGELLAN and MARINER Trials.
    Circulation, 2022, 05-10, Volume: 145, Issue:19

    Topics: Aftercare; Anticoagulants; Enoxaparin; Hemorrhage; Humans; Patient Discharge; Rivaroxaban; Venous Th

2022
Outcomes of Prophylactic Enoxaparin Against Venous Thromboembolism in Hospitalized Children.
    Hospital pediatrics, 2022, 06-01, Volume: 12, Issue:6

    Topics: Adolescent; Anticoagulants; Child; Child, Hospitalized; Enoxaparin; Factor Xa Inhibitors; Hemorrhage

2022
An Open-Label, Single-Arm, Pilot Intervention Study to Assess the Efficacy and Safety of Apixaban in Heparin-Induced Thrombocytopenia.
    Journal of clinical pharmacology, 2022, Volume: 62, Issue:11

    Topics: Anticoagulants; Enoxaparin; Factor Xa Inhibitors; Hemorrhage; Heparin; Humans; Pilot Projects; Pyraz

2022
Assessing the use of Extended Venous Thromboembolism Prophylaxis on the Rates of Venous Thromboembolism and Postpancreatectomy Hemorrhage Following Pancreatectomy for Malignancy.
    Annals of surgery, 2023, Jul-01, Volume: 278, Issue:1

    Topics: Aftercare; Anticoagulants; Enoxaparin; Hemorrhage; Humans; Neoplasms; Pancreatectomy; Patient Discha

2023
Impact of Increased Enoxaparin Dosing on Anti-Xa Levels for Venous Thromboembolism Prophylaxis in Trauma Patients.
    The American surgeon, 2022, Volume: 88, Issue:9

    Topics: Anticoagulants; Enoxaparin; Hemorrhage; Humans; Retrospective Studies; Venous Thromboembolism

2022
Safety and Efficacy of Direct Oral Anticoagulants for Treatment of Venous Thromboembolism in Pediatric Oncology Patients.
    Journal of pediatric hematology/oncology, 2023, 01-01, Volume: 45, Issue:1

    Topics: Administration, Oral; Adult; Anticoagulants; Child; Enoxaparin; Hemorrhage; Humans; Neoplasms; Venou

2023
Low-molecular-weight Heparin (enoxaparin) versus unfractionated heparin for venous thromboembolism prophylaxis in patients undergoing craniotomy.
    Clinical neurology and neurosurgery, 2022, Volume: 223

    Topics: Anticoagulants; Craniotomy; Enoxaparin; Hemorrhage; Heparin; Heparin, Low-Molecular-Weight; Humans;

2022
Features of Parenteral Anticoagulant Therapy in Patients With Myocardial Infarction According to the Russian Register of Acute Myocardial Infarction - REGION-IM.
    Kardiologiia, 2022, Oct-30, Volume: 62, Issue:10

    Topics: Anticoagulants; Enoxaparin; Fondaparinux; Hemorrhage; Heparin; Humans; Myocardial Infarction; Non-ST

2022
Features of Parenteral Anticoagulant Therapy in Patients With Myocardial Infarction According to the Russian Register of Acute Myocardial Infarction - REGION-IM.
    Kardiologiia, 2022, Oct-30, Volume: 62, Issue:10

    Topics: Anticoagulants; Enoxaparin; Fondaparinux; Hemorrhage; Heparin; Humans; Myocardial Infarction; Non-ST

2022
Features of Parenteral Anticoagulant Therapy in Patients With Myocardial Infarction According to the Russian Register of Acute Myocardial Infarction - REGION-IM.
    Kardiologiia, 2022, Oct-30, Volume: 62, Issue:10

    Topics: Anticoagulants; Enoxaparin; Fondaparinux; Hemorrhage; Heparin; Humans; Myocardial Infarction; Non-ST

2022
Features of Parenteral Anticoagulant Therapy in Patients With Myocardial Infarction According to the Russian Register of Acute Myocardial Infarction - REGION-IM.
    Kardiologiia, 2022, Oct-30, Volume: 62, Issue:10

    Topics: Anticoagulants; Enoxaparin; Fondaparinux; Hemorrhage; Heparin; Humans; Myocardial Infarction; Non-ST

2022
Features of Parenteral Anticoagulant Therapy in Patients With Myocardial Infarction According to the Russian Register of Acute Myocardial Infarction - REGION-IM.
    Kardiologiia, 2022, Oct-30, Volume: 62, Issue:10

    Topics: Anticoagulants; Enoxaparin; Fondaparinux; Hemorrhage; Heparin; Humans; Myocardial Infarction; Non-ST

2022
Features of Parenteral Anticoagulant Therapy in Patients With Myocardial Infarction According to the Russian Register of Acute Myocardial Infarction - REGION-IM.
    Kardiologiia, 2022, Oct-30, Volume: 62, Issue:10

    Topics: Anticoagulants; Enoxaparin; Fondaparinux; Hemorrhage; Heparin; Humans; Myocardial Infarction; Non-ST

2022
Features of Parenteral Anticoagulant Therapy in Patients With Myocardial Infarction According to the Russian Register of Acute Myocardial Infarction - REGION-IM.
    Kardiologiia, 2022, Oct-30, Volume: 62, Issue:10

    Topics: Anticoagulants; Enoxaparin; Fondaparinux; Hemorrhage; Heparin; Humans; Myocardial Infarction; Non-ST

2022
Features of Parenteral Anticoagulant Therapy in Patients With Myocardial Infarction According to the Russian Register of Acute Myocardial Infarction - REGION-IM.
    Kardiologiia, 2022, Oct-30, Volume: 62, Issue:10

    Topics: Anticoagulants; Enoxaparin; Fondaparinux; Hemorrhage; Heparin; Humans; Myocardial Infarction; Non-ST

2022
Features of Parenteral Anticoagulant Therapy in Patients With Myocardial Infarction According to the Russian Register of Acute Myocardial Infarction - REGION-IM.
    Kardiologiia, 2022, Oct-30, Volume: 62, Issue:10

    Topics: Anticoagulants; Enoxaparin; Fondaparinux; Hemorrhage; Heparin; Humans; Myocardial Infarction; Non-ST

2022
Clinical evaluation of the safety and efficacy of enoxaparin in patients with COVID-19.
    Blood transfusion = Trasfusione del sangue, 2022, Volume: 20, Issue:6

    Topics: Aged; Anticoagulants; COVID-19; COVID-19 Drug Treatment; Enoxaparin; Hemorrhage; Humans; Male; SARS-

2022
Clinical evaluation of the safety and efficacy of enoxaparin in patients with COVID-19.
    Blood transfusion = Trasfusione del sangue, 2022, Volume: 20, Issue:6

    Topics: Aged; Anticoagulants; COVID-19; COVID-19 Drug Treatment; Enoxaparin; Hemorrhage; Humans; Male; SARS-

2022
Clinical evaluation of the safety and efficacy of enoxaparin in patients with COVID-19.
    Blood transfusion = Trasfusione del sangue, 2022, Volume: 20, Issue:6

    Topics: Aged; Anticoagulants; COVID-19; COVID-19 Drug Treatment; Enoxaparin; Hemorrhage; Humans; Male; SARS-

2022
Clinical evaluation of the safety and efficacy of enoxaparin in patients with COVID-19.
    Blood transfusion = Trasfusione del sangue, 2022, Volume: 20, Issue:6

    Topics: Aged; Anticoagulants; COVID-19; COVID-19 Drug Treatment; Enoxaparin; Hemorrhage; Humans; Male; SARS-

2022
Rate of prophylactic anti-Xa achievement and impact on venous thromboembolism following oncologic hepato-pancreatico-biliary surgery: A prospective cohort study.
    American journal of surgery, 2023, Volume: 225, Issue:6

    Topics: Adult; Anticoagulants; Enoxaparin; Female; Hemorrhage; Heparin, Low-Molecular-Weight; Humans; Prospe

2023
Rate of prophylactic anti-Xa achievement and impact on venous thromboembolism following oncologic hepato-pancreatico-biliary surgery: A prospective cohort study.
    American journal of surgery, 2023, Volume: 225, Issue:6

    Topics: Adult; Anticoagulants; Enoxaparin; Female; Hemorrhage; Heparin, Low-Molecular-Weight; Humans; Prospe

2023
Rate of prophylactic anti-Xa achievement and impact on venous thromboembolism following oncologic hepato-pancreatico-biliary surgery: A prospective cohort study.
    American journal of surgery, 2023, Volume: 225, Issue:6

    Topics: Adult; Anticoagulants; Enoxaparin; Female; Hemorrhage; Heparin, Low-Molecular-Weight; Humans; Prospe

2023
Rate of prophylactic anti-Xa achievement and impact on venous thromboembolism following oncologic hepato-pancreatico-biliary surgery: A prospective cohort study.
    American journal of surgery, 2023, Volume: 225, Issue:6

    Topics: Adult; Anticoagulants; Enoxaparin; Female; Hemorrhage; Heparin, Low-Molecular-Weight; Humans; Prospe

2023
Management of venous thromboembolism in morbidly obese patients: a 10-year review.
    Journal of thrombosis and thrombolysis, 2023, Volume: 55, Issue:2

    Topics: Administration, Oral; Anticoagulants; Enoxaparin; Hemorrhage; Humans; Obesity, Morbid; Retrospective

2023
Management of venous thromboembolism in morbidly obese patients: a 10-year review.
    Journal of thrombosis and thrombolysis, 2023, Volume: 55, Issue:2

    Topics: Administration, Oral; Anticoagulants; Enoxaparin; Hemorrhage; Humans; Obesity, Morbid; Retrospective

2023
Management of venous thromboembolism in morbidly obese patients: a 10-year review.
    Journal of thrombosis and thrombolysis, 2023, Volume: 55, Issue:2

    Topics: Administration, Oral; Anticoagulants; Enoxaparin; Hemorrhage; Humans; Obesity, Morbid; Retrospective

2023
Management of venous thromboembolism in morbidly obese patients: a 10-year review.
    Journal of thrombosis and thrombolysis, 2023, Volume: 55, Issue:2

    Topics: Administration, Oral; Anticoagulants; Enoxaparin; Hemorrhage; Humans; Obesity, Morbid; Retrospective

2023
Management and outcomes of calf deep vein thrombosis in patients with contraindication to full anticoagulation due to bleeding.
    International angiology : a journal of the International Union of Angiology, 2023, Volume: 42, Issue:3

    Topics: Anticoagulants; Contraindications; Enoxaparin; Hemorrhage; Humans; Mesenteric Ischemia; Pulmonary Em

2023
Safety and Efficacy of Rivaroxaban in Primary Total Hip and Knee Arthroplasty.
    The Journal of arthroplasty, 2023, Volume: 38, Issue:8

    Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Aspirin; Enoxaparin

2023
Apixaban for extended postoperative thromboprophylaxis in gynecologic oncology patients undergoing laparotomy.
    Gynecologic oncology, 2023, Volume: 172

    Topics: Anticoagulants; Canada; Enoxaparin; Female; Genital Neoplasms, Female; Hemorrhage; Humans; Laparotom

2023
Effectiveness of Body Mass Index-Based Prophylactic Enoxaparin Dosing in Bariatric Surgery Patients.
    The Journal of surgical research, 2023, Volume: 287

    Topics: Adult; Anticoagulants; Bariatric Surgery; Body Mass Index; Enoxaparin; Female; Hemorrhage; Heparin,

2023
Intravenous enoxaparin as alternative ECMO anticoagulation over a period of 94 days: a case report.
    Journal of cardiothoracic surgery, 2023, Apr-11, Volume: 18, Issue:1

    Topics: Anticoagulants; Enoxaparin; Extracorporeal Membrane Oxygenation; Hemorrhage; Heparin; Heparin, Low-M

2023
Factors associated with bleeding events from enoxaparin used for patients with acute coronary syndrome.
    BMC cardiovascular disorders, 2023, 05-06, Volume: 23, Issue:1

    Topics: Acute Coronary Syndrome; Anticoagulants; Enoxaparin; Hemorrhage; Humans; Retrospective Studies; Thai

2023
Risk of venous thromboembolism or hemorrhage among individuals with chronic kidney disease on prophylactic anticoagulant after hip or knee arthroplasty.
    American journal of hematology, 2023, Volume: 98, Issue:9

    Topics: Adult; Aged; Anticoagulants; Arthroplasty, Replacement, Knee; Enoxaparin; Hemorrhage; Heparin, Low-M

2023
Clinical Impact of a Standardized Risk-Stratified Thromboprophylaxis Protocol for Multisystem Inflammatory Syndrome in Children.
    The Journal of pediatrics, 2023, Volume: 262

    Topics: Anticoagulants; Child; Enoxaparin; Hemorrhage; Humans; Retrospective Studies; Venous Thromboembolism

2023
Risk-Directed Ambulatory Thromboprophylaxis in Lung and Gastrointestinal Cancers: The TARGET-TP Randomized Clinical Trial.
    JAMA oncology, 2023, Nov-01, Volume: 9, Issue:11

    Topics: Adult; Aged; Anticoagulants; Biomarkers; Enoxaparin; Gastrointestinal Neoplasms; Hemorrhage; Humans;

2023
Enoxaparin-induced bullous haemorrhagic dermatosis.
    The Australasian journal of dermatology, 2020, Volume: 61, Issue:1

    Topics: Anticoagulants; Enoxaparin; Female; Hemorrhage; Humans; Middle Aged; Skin Diseases, Vesiculobullous

2020
Evaluation of the Efficacy of Enoxaparin in the Neonatal Intensive Care Unit.
    American journal of perinatology, 2021, Volume: 38, Issue:5

    Topics: Anticoagulants; Enoxaparin; Factor Xa; Female; Hemorrhage; Humans; Infant, Newborn; Intensive Care U

2021
New-onset seizure activity in a transplant patient on immunosuppressive therapy.
    Journal of the American Association of Nurse Practitioners, 2020, Volume: 32, Issue:12

    Topics: Cystic Fibrosis; Emergency Service, Hospital; Enoxaparin; Epilepsy; Female; Hemorrhage; Humans; Hype

2020
Heparin hemorrhagic bullae induced by enoxaparin.
    Medicina clinica, 2021, 01-08, Volume: 156, Issue:1

    Topics: Anticoagulants; Blister; Enoxaparin; Hemorrhage; Heparin; Humans

2021
Safety and Efficacy of High-Dose Unfractionated Heparin Versus High-Dose Enoxaparin for Venous Thromboembolism Prevention in Morbidly Obese Hospitalized Patients.
    The American journal of medicine, 2020, Volume: 133, Issue:6

    Topics: Adult; Aged; Anticoagulants; Dose-Response Relationship, Drug; Enoxaparin; Female; Hemorrhage; Hepar

2020
Bullous hemorrhagic dermatosis.
    CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne, 2020, 01-06, Volume: 192, Issue:1

    Topics: Anticoagulants; Diagnosis, Differential; Enoxaparin; Fatal Outcome; Female; Hemorrhage; Humans; Midd

2020
Safety and Pharmacokinetics of DS-1040 Drug-Drug Interactions With Aspirin, Clopidogrel, and Enoxaparin.
    Journal of clinical pharmacology, 2020, Volume: 60, Issue:6

    Topics: Administration, Oral; Adult; Area Under Curve; Aspirin; Clinical Trials as Topic; Clinical Trials, P

2020
Safety and Pharmacokinetics of DS-1040 Drug-Drug Interactions With Aspirin, Clopidogrel, and Enoxaparin.
    Journal of clinical pharmacology, 2020, Volume: 60, Issue:6

    Topics: Administration, Oral; Adult; Area Under Curve; Aspirin; Clinical Trials as Topic; Clinical Trials, P

2020
Safety and Pharmacokinetics of DS-1040 Drug-Drug Interactions With Aspirin, Clopidogrel, and Enoxaparin.
    Journal of clinical pharmacology, 2020, Volume: 60, Issue:6

    Topics: Administration, Oral; Adult; Area Under Curve; Aspirin; Clinical Trials as Topic; Clinical Trials, P

2020
Safety and Pharmacokinetics of DS-1040 Drug-Drug Interactions With Aspirin, Clopidogrel, and Enoxaparin.
    Journal of clinical pharmacology, 2020, Volume: 60, Issue:6

    Topics: Administration, Oral; Adult; Area Under Curve; Aspirin; Clinical Trials as Topic; Clinical Trials, P

2020
Primary prophylaxis of venous thromboembolism in extragonadal germ-cell tumour.
    Journal de medecine vasculaire, 2020, Volume: 45, Issue:2

    Topics: Anticoagulants; Antineoplastic Agents; Aspirin; Cisplatin; Enoxaparin; Hemorrhage; Humans; Male; Med

2020
Post-Procedural Anticoagulation After Primary Percutaneous Coronary Intervention for Anterior Acute Myocardial Infarction With Severe Left Ventricular Dysfunction.
    Circulation journal : official journal of the Japanese Circulation Society, 2020, 09-25, Volume: 84, Issue:10

    Topics: Aged; Anterior Wall Myocardial Infarction; Anticoagulants; Dual Anti-Platelet Therapy; Echocardiogra

2020
The hazard of fondaparinux in non-critically ill patients with COVID-19: Retrospective controlled study versus enoxaparin.
    Thrombosis research, 2020, Volume: 196

    Topics: Aged; Aged, 80 and over; Anticoagulants; COVID-19; COVID-19 Drug Treatment; Enoxaparin; Factor Xa In

2020
Fondaparinux Use in Patients With COVID-19: A Preliminary Multicenter Real-World Experience.
    Journal of cardiovascular pharmacology, 2020, Volume: 76, Issue:4

    Topics: Aged; Anticoagulants; Antithrombins; Coronavirus Infections; COVID-19; Enoxaparin; Factor Xa Inhibit

2020
Enoxaparin related spontaneous fatal retroperitoneal hemorrhage in a patient with atrial fibrillation.
    Reviews in cardiovascular medicine, 2020, Sep-30, Volume: 21, Issue:3

    Topics: Aged; Anticoagulants; Atrial Fibrillation; Drug Substitution; Enoxaparin; Fatal Outcome; Female; Hea

2020
Thromboprophylaxis in congenital nephrotic syndrome: 15-year experience from a national cohort.
    Pediatric nephrology (Berlin, Germany), 2021, Volume: 36, Issue:5

    Topics: Anticoagulants; Child; Enoxaparin; Hemorrhage; Humans; Nephrotic Syndrome; Thrombosis; Venous Thromb

2021
Multi-Criteria Model for Evaluating Drugs to Prevent Deep Venous Thrombosis Associated With Orthopedic Surgery: A Hospital-Based Case Study.
    Value in health regional issues, 2020, Volume: 23

    Topics: Anticoagulants; Brazil; Enoxaparin; Hemorrhage; Humans; Orthopedic Procedures; Pharmaceutical Prepar

2020
New-onset seizure activity in a transplant patient on immunosuppressive therapy.
    Journal of the American Association of Nurse Practitioners, 2020, Volume: 32, Issue:12

    Topics: Cystic Fibrosis; Emergency Service, Hospital; Enoxaparin; Epilepsy; Female; Hemorrhage; Humans; Hype

2020
Real-World Comparative Effectiveness and Cost Comparison of Thromboprophylactic Use of Enoxaparin versus Unfractionated Heparin in 376,858 Medically Ill Hospitalized US Patients.
    American journal of cardiovascular drugs : drugs, devices, and other interventions, 2021, Volume: 21, Issue:4

    Topics: Adult; Age Factors; Aged; Aged, 80 and over; Anticoagulants; Costs and Cost Analysis; Enoxaparin; Fe

2021
Early initiation of prophylactic anticoagulation for prevention of coronavirus disease 2019 mortality in patients admitted to hospital in the United States: cohort study.
    BMJ (Clinical research ed.), 2021, 02-11, Volume: 372

    Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; COVID-19; Enoxaparin; Female; Hemorrhage; Humans; Ma

2021
Thromboelastography-Guided Management of Anticoagulated COVID-19 Patients to Prevent Hemorrhage.
    Seminars in thrombosis and hemostasis, 2021, Volume: 47, Issue:4

    Topics: Adult; Aged; Aged, 80 and over; Algorithms; Anticoagulants; Blood Coagulation Tests; Blood Proteins;

2021
Anticoagulation and Transjugular Intrahepatic Portosystemic Shunt for the Management of Portal Vein Thrombosis in Cirrhosis: A Prospective Observational Study.
    The American journal of gastroenterology, 2021, 07-01, Volume: 116, Issue:7

    Topics: Adult; Aged; Algorithms; Anticoagulants; Combined Modality Therapy; Enoxaparin; Female; Hemorrhage;

2021
Enoxaparin versus unfractionated heparin for venous thromboembolism prophylaxis in renally impaired ICU patients.
    Pharmacotherapy, 2021, Volume: 41, Issue:5

    Topics: Anticoagulants; Enoxaparin; Hemorrhage; Heparin; Humans; Intensive Care Units; Renal Insufficiency;

2021
Enoxaparin Use and Adverse Events in Outpatients With a Continuous Flow Left Ventricular Assist Device at a Single Institution.
    Journal of pharmacy practice, 2022, Volume: 35, Issue:3

    Topics: Adolescent; Anticoagulants; Enoxaparin; Heart-Assist Devices; Hemorrhage; Humans; Outpatients; Prosp

2022
Comparison of Outcomes of Enoxaparin Bridge Therapy in HeartMate II versus HeartWare HVAD Recipients.
    Journal of cardiovascular pharmacology and therapeutics, 2021, Volume: 26, Issue:5

    Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Enoxaparin; Female; Heart Ventricles; Heart-Assist D

2021
Achievement of goal anti-Xa activity with weight-based enoxaparin dosing for venous thromboembolism prophylaxis in trauma patients.
    Pharmacotherapy, 2021, Volume: 41, Issue:6

    Topics: Adult; Anticoagulants; Enoxaparin; Factor Xa Inhibitors; Goals; Hemorrhage; Heparin, Low-Molecular-W

2021
Enoxaparin-induced distal haemorrhagic bullous dermatosis.
    Revista clinica espanola, 2021, Volume: 221, Issue:2

    Topics: Enoxaparin; Hemorrhage; Humans; Skin Diseases, Vesiculobullous

2021
Enoxaparin Reduces Catheter-associated Venous Thrombosis After Infant Cardiac Surgery.
    The Annals of thoracic surgery, 2022, Volume: 114, Issue:3

    Topics: Anticoagulants; Cardiac Surgical Procedures; Catheters; Child; Enoxaparin; Hemorrhage; Humans; Infan

2022
Direct Oral Anticoagulants for Venous Thromboembolism Prophylaxis Following Robot-assisted Radical Cystectomy: A Retrospective Feasibility Study at a Single Academic Medical Center.
    Urology, 2021, Volume: 156

    Topics: Anticoagulants; Antithrombins; Chemoprevention; Cystectomy; Enoxaparin; Female; Hemorrhage; Humans;

2021
Bleeding in Patients With Gastrointestinal Cancer Compared With Nongastrointestinal Cancer Treated With Apixaban, Rivaroxaban, or Enoxaparin for Acute Venous Thromboembolism.
    Mayo Clinic proceedings, 2021, Volume: 96, Issue:11

    Topics: Enoxaparin; Factor Xa Inhibitors; Female; Gastrointestinal Neoplasms; Hemorrhage; Humans; Liver Neop

2021
Relationship Between Arterial Access and Outcomes in ST-Elevation Myocardial Infarction With a Pharmacoinvasive Versus Primary Percutaneous Coronary Intervention Strategy: Insights From the STrategic Reperfusion Early After Myocardial Infarction (STREAM)
    Journal of the American Heart Association, 2016, 06-13, Volume: 5, Issue:6

    Topics: Aged; Aspirin; Catheterization, Peripheral; Clopidogrel; Coronary Angiography; Enoxaparin; Female; F

2016
Comparative Effectiveness and Safety of Drug Prophylaxis for Prevention of Venous Thromboembolism After Total Knee Arthroplasty.
    The Journal of arthroplasty, 2017, Volume: 32, Issue:11

    Topics: Aged; Anticoagulants; Arthroplasty, Replacement, Knee; Aspirin; Cohort Studies; Enoxaparin; Factor X

2017
Retrospective comparison of low molecular weight heparin vs. warfarin vs. oral Xa inhibitors for the prevention of recurrent venous thromboembolism in oncology patients: The Re-CLOT study.
    Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners, 2018, Volume: 24, Issue:7

    Topics: Aged; Aged, 80 and over; Anticoagulants; Enoxaparin; Factor Xa Inhibitors; Female; Hemorrhage; Hepar

2018
Effect of extended-duration thromboprophylaxis on venous thromboembolism and major bleeding among acutely ill hospitalized medical patients: a bivariate analysis.
    Journal of thrombosis and haemostasis : JTH, 2017, Volume: 15, Issue:10

    Topics: Acute Disease; Anticoagulants; Benzamides; Clinical Decision-Making; Clinical Trials, Phase III as T

2017
Effect of extended-duration thromboprophylaxis on venous thromboembolism and major bleeding among acutely ill hospitalized medical patients: a bivariate analysis.
    Journal of thrombosis and haemostasis : JTH, 2017, Volume: 15, Issue:10

    Topics: Acute Disease; Anticoagulants; Benzamides; Clinical Decision-Making; Clinical Trials, Phase III as T

2017
Effect of extended-duration thromboprophylaxis on venous thromboembolism and major bleeding among acutely ill hospitalized medical patients: a bivariate analysis.
    Journal of thrombosis and haemostasis : JTH, 2017, Volume: 15, Issue:10

    Topics: Acute Disease; Anticoagulants; Benzamides; Clinical Decision-Making; Clinical Trials, Phase III as T

2017
Effect of extended-duration thromboprophylaxis on venous thromboembolism and major bleeding among acutely ill hospitalized medical patients: a bivariate analysis.
    Journal of thrombosis and haemostasis : JTH, 2017, Volume: 15, Issue:10

    Topics: Acute Disease; Anticoagulants; Benzamides; Clinical Decision-Making; Clinical Trials, Phase III as T

2017
Effect of extended-duration thromboprophylaxis on venous thromboembolism and major bleeding among acutely ill hospitalized medical patients: a bivariate analysis.
    Journal of thrombosis and haemostasis : JTH, 2017, Volume: 15, Issue:10

    Topics: Acute Disease; Anticoagulants; Benzamides; Clinical Decision-Making; Clinical Trials, Phase III as T

2017
Effect of extended-duration thromboprophylaxis on venous thromboembolism and major bleeding among acutely ill hospitalized medical patients: a bivariate analysis.
    Journal of thrombosis and haemostasis : JTH, 2017, Volume: 15, Issue:10

    Topics: Acute Disease; Anticoagulants; Benzamides; Clinical Decision-Making; Clinical Trials, Phase III as T

2017
Effect of extended-duration thromboprophylaxis on venous thromboembolism and major bleeding among acutely ill hospitalized medical patients: a bivariate analysis.
    Journal of thrombosis and haemostasis : JTH, 2017, Volume: 15, Issue:10

    Topics: Acute Disease; Anticoagulants; Benzamides; Clinical Decision-Making; Clinical Trials, Phase III as T

2017
Effect of extended-duration thromboprophylaxis on venous thromboembolism and major bleeding among acutely ill hospitalized medical patients: a bivariate analysis.
    Journal of thrombosis and haemostasis : JTH, 2017, Volume: 15, Issue:10

    Topics: Acute Disease; Anticoagulants; Benzamides; Clinical Decision-Making; Clinical Trials, Phase III as T

2017
Effect of extended-duration thromboprophylaxis on venous thromboembolism and major bleeding among acutely ill hospitalized medical patients: a bivariate analysis.
    Journal of thrombosis and haemostasis : JTH, 2017, Volume: 15, Issue:10

    Topics: Acute Disease; Anticoagulants; Benzamides; Clinical Decision-Making; Clinical Trials, Phase III as T

2017
Effect of extended-duration thromboprophylaxis on venous thromboembolism and major bleeding among acutely ill hospitalized medical patients: a bivariate analysis.
    Journal of thrombosis and haemostasis : JTH, 2017, Volume: 15, Issue:10

    Topics: Acute Disease; Anticoagulants; Benzamides; Clinical Decision-Making; Clinical Trials, Phase III as T

2017
Effect of extended-duration thromboprophylaxis on venous thromboembolism and major bleeding among acutely ill hospitalized medical patients: a bivariate analysis.
    Journal of thrombosis and haemostasis : JTH, 2017, Volume: 15, Issue:10

    Topics: Acute Disease; Anticoagulants; Benzamides; Clinical Decision-Making; Clinical Trials, Phase III as T

2017
Effect of extended-duration thromboprophylaxis on venous thromboembolism and major bleeding among acutely ill hospitalized medical patients: a bivariate analysis.
    Journal of thrombosis and haemostasis : JTH, 2017, Volume: 15, Issue:10

    Topics: Acute Disease; Anticoagulants; Benzamides; Clinical Decision-Making; Clinical Trials, Phase III as T

2017
Effect of extended-duration thromboprophylaxis on venous thromboembolism and major bleeding among acutely ill hospitalized medical patients: a bivariate analysis.
    Journal of thrombosis and haemostasis : JTH, 2017, Volume: 15, Issue:10

    Topics: Acute Disease; Anticoagulants; Benzamides; Clinical Decision-Making; Clinical Trials, Phase III as T

2017
Effect of extended-duration thromboprophylaxis on venous thromboembolism and major bleeding among acutely ill hospitalized medical patients: a bivariate analysis.
    Journal of thrombosis and haemostasis : JTH, 2017, Volume: 15, Issue:10

    Topics: Acute Disease; Anticoagulants; Benzamides; Clinical Decision-Making; Clinical Trials, Phase III as T

2017
Effect of extended-duration thromboprophylaxis on venous thromboembolism and major bleeding among acutely ill hospitalized medical patients: a bivariate analysis.
    Journal of thrombosis and haemostasis : JTH, 2017, Volume: 15, Issue:10

    Topics: Acute Disease; Anticoagulants; Benzamides; Clinical Decision-Making; Clinical Trials, Phase III as T

2017
Effect of extended-duration thromboprophylaxis on venous thromboembolism and major bleeding among acutely ill hospitalized medical patients: a bivariate analysis.
    Journal of thrombosis and haemostasis : JTH, 2017, Volume: 15, Issue:10

    Topics: Acute Disease; Anticoagulants; Benzamides; Clinical Decision-Making; Clinical Trials, Phase III as T

2017
Antithrombotic treatment during coronary angioplasty after failed thrombolysis: strategies and prognostic implications. Results of the RESPIRE registry.
    BMC cardiovascular disorders, 2017, 08-01, Volume: 17, Issue:1

    Topics: Abciximab; Aged; Antibodies, Monoclonal; Chi-Square Distribution; Coronary Thrombosis; Drug Administ

2017
Can we reliably predict the level of anticoagulation after enoxaparin injection in elderly patients with renal failure?
    Aging clinical and experimental research, 2018, Volume: 30, Issue:6

    Topics: Aged; Aged, 80 and over; Anticoagulants; Enoxaparin; Female; Hemorrhage; Heparin, Low-Molecular-Weig

2018
Treatment of Cryptogenic Stroke with Active Cancer with a New Oral Anticoagulant.
    Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association, 2017, Volume: 26, Issue:12

    Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Blood Coagulation; Dabigatran; Daltep

2017
Once-Daily Versus Twice-Daily Enoxaparin for the Treatment of Acute Venous Thromboembolism in Cancer Patients.
    The Annals of pharmacotherapy, 2018, Volume: 52, Issue:3

    Topics: Acute Disease; Aged; Anticoagulants; Drug Administration Schedule; Enoxaparin; Female; Hemorrhage; H

2018
Anticoagulation prescribing patterns in patients with cancer.
    Journal of thrombosis and thrombolysis, 2018, Volume: 45, Issue:1

    Topics: Adult; Aged; Anticoagulants; Atrial Fibrillation; Dabigatran; Enoxaparin; Hemorrhage; Humans; Middle

2018
A 71-year-old man with a hemorrhagic vesicular eruption.
    International journal of dermatology, 2018, Volume: 57, Issue:2

    Topics: Aged; Anticoagulants; Drug Eruptions; Enoxaparin; Hemorrhage; Humans; Male; Skin Diseases, Vesiculob

2018
Evaluation of rivaroxaban use in patients with gynecologic malignancies at an academic medical center: A pilot study.
    Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners, 2019, Volume: 25, Issue:2

    Topics: Academic Medical Centers; Adult; Aged; Anticoagulants; Drug Substitution; Enoxaparin; Factor Xa Inhi

2019
Recurrence of malignancy-associated venous thromboembolism among patients treated with rivaroxaban compared to enoxaparin.
    Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners, 2018, Volume: 24, Issue:3

    Topics: Aged; Anticoagulants; Enoxaparin; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Male; Middle Age

2018
Suboptimal use of pharmacological venous thromboembolism prophylaxis in cirrhotic patients.
    Internal medicine journal, 2018, Volume: 48, Issue:9

    Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Enoxaparin; Female; Guideline Adherence; Hemorrhage;

2018
Rivaroxaban for thromboprophylaxis among patients recently hospitalized for acute infectious diseases: a subgroup analysis of the MAGELLAN study.
    Journal of thrombosis and haemostasis : JTH, 2018, Volume: 16, Issue:7

    Topics: Acute Disease; Aged; Aged, 80 and over; Anticoagulants; Blood Coagulation; Drug Administration Sched

2018
    Anasthesiologie, Intensivmedizin, Notfallmedizin, Schmerztherapie : AINS, 2018, Volume: 53, Issue:5

    Topics: Aged, 80 and over; Anesthesia, Spinal; Anticoagulants; Enoxaparin; Hemorrhage; Humans; Intraoperativ

2018
Incidence of symptomatic venous thromboembolism in 2372 knee and hip replacement patients after discharge: data from a thromboprophylaxis registry in Montreal, Canada.
    Vascular health and risk management, 2018, Volume: 14

    Topics: Aged; Anticoagulants; Antithrombins; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee

2018
Inability to predict subprophylactic anti-factor Xa levels in trauma patients receiving early low-molecular-weight heparin.
    The journal of trauma and acute care surgery, 2018, Volume: 85, Issue:5

    Topics: Adult; Anticoagulants; Enoxaparin; Factor Xa; Female; Hemorrhage; Humans; Information Storage and Re

2018
Differences in Reported Outcomes in Industry-Funded vs Nonfunded Studies Assessing Thromboprophylaxis After Total Joint Arthroplasty.
    The Journal of arthroplasty, 2018, Volume: 33, Issue:11

    Topics: Aged; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Aspirin; Conf

2018
Enoxaparin 20 mg for thromboprophylaxis in severe renal impairment.
    The Journal of international medical research, 2019, Volume: 47, Issue:1

    Topics: Adolescent; Aged; Aged, 80 and over; Anticoagulants; Creatinine; Drug Administration Schedule; Enoxa

2019
Successful angioembolization treatment in a patient with a mechanical heart valve with hemorrhagic corpus luteum.
    European journal of obstetrics, gynecology, and reproductive biology, 2019, Volume: 235

    Topics: Anticoagulants; Aortic Valve; Enoxaparin; Female; Heart Valve Prosthesis; Hemorrhage; Humans; Ovaria

2019
Fatal pulmonary embolism and pulmonary hemorrhage in lupus anticoagulant hypoprothrombinemia syndrome: a case report and review of literature.
    Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis, 2018, Volume: 29, Issue:8

    Topics: Aged; Anticoagulants; Antiphospholipid Syndrome; Enoxaparin; Fatal Outcome; Female; Gastrointestinal

2018
Utilization Patterns, Efficacy, and Complications of Venous Thromboembolism Prophylaxis Strategies in Primary Hip and Knee Arthroplasty as Reported by American Board of Orthopedic Surgery Part II Candidates.
    The Journal of arthroplasty, 2019, Volume: 34, Issue:4

    Topics: Aged; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Aspirin; Data

2019
Primary thromboprophylaxis in hospitalized children: A multi-center retrospective analysis.
    Thrombosis research, 2019, Volume: 176

    Topics: Adolescent; Anticoagulants; Child; Enoxaparin; Female; Hemorrhage; Humans; Male; Mechanical Thrombol

2019
Evaluation of weight based enoxaparin dosing on anti-Xa concentrations in patients with obesity.
    Journal of thrombosis and thrombolysis, 2019, Volume: 48, Issue:3

    Topics: Adult; Body Weight; Drug Dosage Calculations; Enoxaparin; Factor Xa Inhibitors; Female; Hemorrhage;

2019
Extended treatment with non-vitamin K antagonist oral anticoagulants versus low-molecular-weight heparins in cancer patients following venous thromboembolism. A pilot study.
    Vascular pharmacology, 2019, Volume: 120

    Topics: Administration, Oral; Aged; Anticoagulants; Antithrombins; Comparative Effectiveness Research; Dabig

2019
Comparison of Venous Thromboembolism Prophylactic Measures Post Coronary Artery Bypass Graft Surgery.
    American journal of cardiovascular drugs : drugs, devices, and other interventions, 2019, Volume: 19, Issue:6

    Topics: Aged; Anticoagulants; Coronary Artery Bypass; Enoxaparin; Female; Hemorrhage; Heparin; Humans; Lengt

2019
[Compliance of patients undergoing thromboprophylaxis with enoxaparin: the COMFORT study].
    Der Chirurg; Zeitschrift fur alle Gebiete der operativen Medizen, 2013, Volume: 84, Issue:3

    Topics: Anticoagulants; Dose-Response Relationship, Drug; Drug Administration Schedule; Enoxaparin; Female;

2013
Elective hip and knee arthroplasty and the effect of rivaroxaban and enoxaparin thromboprophylaxis on wound healing.
    European journal of orthopaedic surgery & traumatology : orthopedie traumatologie, 2013, Volume: 23, Issue:4

    Topics: Aged; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Chemopreventi

2013
A specific antidote for reversal of anticoagulation by direct and indirect inhibitors of coagulation factor Xa.
    Nature medicine, 2013, Volume: 19, Issue:4

    Topics: Animals; Anticoagulants; Antidotes; Benzamides; Dose-Response Relationship, Drug; Enoxaparin; Factor

2013
Impact of a venous thromboembolism prophylaxis "smart order set": Improved compliance, fewer events.
    American journal of hematology, 2013, Volume: 88, Issue:7

    Topics: Adult; Age Factors; Aged; Anticoagulants; Enoxaparin; Female; Guideline Adherence; Hemorrhage; Hepar

2013
Rivaroxaban for thromboprophylaxis in acutely ill medical patients.
    The New England journal of medicine, 2013, 05-16, Volume: 368, Issue:20

    Topics: Anticoagulants; Enoxaparin; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Male; Morpholines; Thi

2013
Rivaroxaban for thromboprophylaxis in acutely ill medical patients.
    The New England journal of medicine, 2013, 05-16, Volume: 368, Issue:20

    Topics: Anticoagulants; Enoxaparin; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Male; Morpholines; Thi

2013
Rivaroxaban for thromboprophylaxis in acutely ill medical patients.
    The New England journal of medicine, 2013, 05-16, Volume: 368, Issue:20

    Topics: Anticoagulants; Enoxaparin; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Male; Morpholines; Thi

2013
Rivaroxaban for thromboprophylaxis in acutely ill medical patients.
    The New England journal of medicine, 2013, 05-16, Volume: 368, Issue:20

    Topics: Anticoagulants; Enoxaparin; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Male; Morpholines; Thi

2013
Hemorrhagic bullae in a 73-year-old man. Bullous hemorrhagic dermatosis related to enoxaparin use.
    JAMA dermatology, 2013, Volume: 149, Issue:7

    Topics: Aged; Anticoagulants; Drug Eruptions; Enoxaparin; Hemorrhage; Humans; Male; Skin Diseases, Vesiculob

2013
No difference in bleeding risk between subcutaneous enoxaparin and heparin for thromboprophylaxis in end-stage renal disease.
    Kidney international, 2013, Volume: 84, Issue:3

    Topics: Aged; Aged, 80 and over; Anticoagulants; Dose-Response Relationship, Drug; Endpoint Determination; E

2013
Prognostic significance of bleeding location and severity among patients with acute coronary syndromes.
    JACC. Cardiovascular interventions, 2013, Volume: 6, Issue:7

    Topics: Acute Coronary Syndrome; Aged; Anticoagulants; Blood Loss, Surgical; Coronary Artery Bypass; Enoxapa

2013
Multidisciplinary approach in pregnancy-associated thrombotic thrombocytopenic purpura: a case report.
    Blood transfusion = Trasfusione del sangue, 2014, Volume: 12 Suppl 1

    Topics: Adult; Antibodies, Monoclonal, Murine-Derived; Anticoagulants; Cesarean Section; Combined Modality T

2014
Use of enoxaparin in end-stage renal disease.
    Kidney international, 2013, Volume: 84, Issue:3

    Topics: Enoxaparin; Female; Hemorrhage; Heparin; Humans; Kidney Failure, Chronic; Male; Venous Thromboemboli

2013
[Primary pharmacological prevention of thromboembolic events in ambulatory patients with advanced pancreatic cancer treated with chemotherapy?].
    Deutsche medizinische Wochenschrift (1946), 2013, Volume: 138, Issue:41

    Topics: Adenocarcinoma; Ambulatory Care; Anticoagulants; Dalteparin; Dose-Response Relationship, Drug; Enoxa

2013
Efficacy and safety of high-dose thromboprophylaxis in morbidly obese inpatients.
    Thrombosis and haemostasis, 2014, Volume: 111, Issue:1

    Topics: Aged; Anticoagulants; Body Mass Index; Enoxaparin; Female; Hemorrhage; Heparin; Humans; Male; Middle

2014
Assessment of bleeding events associated with short-duration therapeutic enoxaparin use in the morbidly obese.
    The Annals of pharmacotherapy, 2013, Volume: 47, Issue:12

    Topics: Academic Medical Centers; Adult; Anticoagulants; Enoxaparin; Female; Hemorrhage; Hospitalization; Hu

2013
Retrospective evaluation of antithrombin III supplementation in neonates and infants receiving enoxaparin for treatment of thrombosis.
    Pediatric blood & cancer, 2014, Volume: 61, Issue:6

    Topics: Age Factors; Anticoagulants; Antithrombin III; Critical Illness; Dose-Response Relationship, Drug; D

2014
[Bullous hemorrhagic dermatosis induced by heparin: description of 2 new cases].
    Medicina clinica, 2014, Dec-09, Volume: 143, Issue:11

    Topics: Aged; Anticoagulants; Aspirin; Brain Ischemia; Cerebral Hemorrhage; Drug Eruptions; Enoxaparin; Hemo

2014
Safety of postoperative thromboprophylaxis after major hepatobiliary-pancreatic surgery in Japanese patients.
    Surgery today, 2014, Volume: 44, Issue:9

    Topics: Aged; Anticoagulants; Asian People; Enoxaparin; Female; Fondaparinux; Hemorrhage; Hepatectomy; Human

2014
Benefit-risk assessment of rivaroxaban versus enoxaparin for the prevention of venous thromboembolism after total hip or knee arthroplasty.
    Vascular health and risk management, 2014, Volume: 10

    Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Enoxaparin; Hemorrh

2014
Bleeding risk of patients with acute venous thromboembolism taking nonsteroidal anti-inflammatory drugs or aspirin.
    JAMA internal medicine, 2014, Volume: 174, Issue:6

    Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Anticoagulants; Aspirin; Drug Therapy, Combina

2014
Lower extremity hemorrhage in patients with spinal cord injury receiving enoxaparin therapy.
    The journal of spinal cord medicine, 2015, Volume: 38, Issue:2

    Topics: Adult; Aged; Anticoagulants; Enoxaparin; Hemorrhage; Humans; Lower Extremity; Male; Middle Aged; Spi

2015
Early thromboembolic prophylaxis in patients with blunt solid abdominal organ injuries undergoing nonoperative management: is it safe?
    American journal of surgery, 2015, Volume: 209, Issue:1

    Topics: Abdominal Injuries; Adult; Aged; Anticoagulants; Drug Administration Schedule; Enoxaparin; Female; H

2015
Effects of enoxaparin and unfractionated heparin in prophylactic and therapeutic doses on the fertility of female Wistar rats.
    Acta cirurgica brasileira, 2014, Volume: 29, Issue:7

    Topics: Animals; Anticoagulants; Enoxaparin; Female; Fertility; Fetus; Hemorrhage; Heparin; Male; Placenta;

2014
Adverse outcomes of anticoagulant use among hospitalized patients with chronic kidney disease: a comparison of the rates of major bleeding events between unfractionated heparin and enoxaparin.
    PloS one, 2014, Volume: 9, Issue:9

    Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Cohort Studies; Enoxaparin; Female; Hemorrhage; Hepa

2014
Structural and functional analyses of biosimilar enoxaparins available in Brazil.
    Thrombosis and haemostasis, 2015, Volume: 113, Issue:1

    Topics: Animals; Anticoagulants; Biosimilar Pharmaceuticals; Blood Coagulation; Blood Coagulation Tests; Bra

2015
Chemoprophylaxis for venous thromboembolism in otolaryngology.
    JAMA otolaryngology-- head & neck surgery, 2014, Volume: 140, Issue:11

    Topics: Anticoagulants; Enoxaparin; Fondaparinux; Free Tissue Flaps; Hemorrhage; Heparin; Humans; Incidence;

2014
[Perioperative control of vitamin K antagonists in elective surgery].
    Medicina, 2014, Volume: 74, Issue:5

    Topics: Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Elective Surgical Procedures; Enoxapar

2014
Role of percutaneous transcatheter embolization (PTE) in the treatment of spontaneous bleeding associated with anticoagulant therapy.
    La Radiologia medica, 2015, Volume: 120, Issue:1

    Topics: Aged; Aged, 80 and over; Angiography, Digital Subtraction; Anticoagulants; Contrast Media; Embolizat

2015
Bullous hemorrhagic dermatosis distant from the site of heparin injection.
    Dermatology online journal, 2014, Oct-15, Volume: 20, Issue:10

    Topics: Enoxaparin; Female; Fibrinolytic Agents; Hemorrhage; Humans; Injections; Skin Diseases, Vesiculobull

2014
The economic implications of switching to rivaroxaban from enoxaparin plus vitamin K antagonist in the treatment of venous thromboembolism.
    Journal of medical economics, 2015, Volume: 18, Issue:5

    Topics: Anticoagulants; Computer Simulation; Cost-Benefit Analysis; Drug Therapy, Combination; Enoxaparin; H

2015
Rivaroxaban Versus Enoxaparin for Venous Thromboembolism Prophylaxis after Hip and Knee Arthroplasty.
    The Journal of arthroplasty, 2015, Volume: 30, Issue:7

    Topics: Aged; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Enoxaparin; F

2015
Enoxaparin-induced unilateral hemotympanum.
    Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis, 2015, Volume: 26, Issue:5

    Topics: Anticoagulants; Ear Diseases; Enoxaparin; Female; Hemorrhage; Humans; Middle Aged

2015
Variability in the international normalised ratio (INR) in patients with antiphospholipid syndrome and positive lupus anticoagulant: should the INR targets be higher?
    BMJ case reports, 2015, Apr-09, Volume: 2015

    Topics: Adult; Anticoagulants; Antiphospholipid Syndrome; Enoxaparin; Female; Hematuria; Hemorrhage; Humans;

2015
Bullous hemorrhagic dermatosis induced by enoxaparin.
    Cutaneous and ocular toxicology, 2016, Volume: 35, Issue:2

    Topics: Aged; Anticoagulants; Enoxaparin; Hemorrhage; Humans; Male; Skin; Skin Diseases, Vesiculobullous

2016
Should patients with chronic liver disease receive venous thromboembolism prophylaxis?
    JAAPA : official journal of the American Academy of Physician Assistants, 2015, Volume: 28, Issue:6

    Topics: Anticoagulants; Blood Coagulation Disorders; Enoxaparin; Hemorrhage; Heparin; Hospitalization; Human

2015
[Prevention with lower bleeding risk].
    MMW Fortschritte der Medizin, 2015, Apr-02, Volume: 157, Issue:6

    Topics: Adult; Enoxaparin; Hemorrhage; Humans; Pyrazoles; Pyridones; Thromboembolism

2015
Application of Adaptive DP-optimality to Design a Pilot Study for a Clotting Time Test for Enoxaparin.
    Pharmaceutical research, 2015, Volume: 32, Issue:10

    Topics: Adult; Anticoagulants; Blood Coagulation; Blood Coagulation Tests; Enoxaparin; Factor Xa Inhibitors;

2015
Perioperative Management of Antiplatelets and Anticoagulants Among Patients Undergoing Elective Transurethral Resection of the Prostate--A Single Institution Experience.
    Journal of endourology, 2015, Volume: 29, Issue:11

    Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Aspirin, Dipyridamole Drug Combination; Clopidogre

2015
Monitoring Enoxaparin with Antifactor Xa Levels in Obese Patients.
    Pharmacotherapy, 2015, Volume: 35, Issue:11

    Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Drug Monitoring; Enoxaparin; Factor Xa Inhibitors; F

2015
Emergent pediatric anticoagulation reversal using a 4-factor prothrombin complex concentrate.
    The American journal of emergency medicine, 2016, Volume: 34, Issue:6

    Topics: Anticoagulants; Blood Coagulation Factors; Child; Enoxaparin; Female; Headache; Hemorrhage; Heparin

2016
Cost-effectiveness of fondaparinux versus enoxaparin in non-ST-elevation acute coronary syndrome in Canada (OASIS-5).
    BMC cardiovascular disorders, 2015, Dec-29, Volume: 15

    Topics: Acute Coronary Syndrome; Anticoagulants; Canada; Cost-Benefit Analysis; Decision Support Techniques;

2015
Allosterism-based simultaneous, dual anticoagulant and antiplatelet action: allosteric inhibitor targeting the glycoprotein Ibα-binding and heparin-binding site of thrombin.
    Journal of thrombosis and haemostasis : JTH, 2016, Volume: 14, Issue:4

    Topics: Allosteric Site; Animals; Anticoagulants; Binding Sites; Bleeding Time; Blood Coagulation; Blood Coa

2016
Clinical and economic benefits of extended treatment with apixaban for the treatment and prevention of recurrent venous thromboembolism in Canada.
    Journal of medical economics, 2016, Volume: 19, Issue:6

    Topics: Anticoagulants; Canada; Cost-Benefit Analysis; Enoxaparin; Female; Hemorrhage; Humans; International

2016
Balancing Thromboprophylaxis and Bleeding in Total Joint Arthroplasty: Impact of Eliminating Enoxaparin and Predonation and Implementing Pneumatic Compression and Tranexamic Acid.
    The Journal of arthroplasty, 2016, Volume: 31, Issue:6

    Topics: Aged; Anticoagulants; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Arthroplasty, Replace

2016
Safety of anticoagulation in thrombocytopenic patients with hematologic malignancies: A case series.
    Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners, 2017, Volume: 23, Issue:3

    Topics: Aged; Anticoagulants; Enoxaparin; Female; Hematologic Neoplasms; Hemorrhage; Heparin, Low-Molecular-

2017
Comparing Length of Stay Between Patients Taking Rivaroxaban and Conventional Anticoagulants for Treatment of Venous Thromboembolism.
    Lung, 2016, Volume: 194, Issue:4

    Topics: Aged; Aged, 80 and over; Anticoagulants; Drug Therapy, Combination; Enoxaparin; Factor Xa Inhibitors

2016
Apixaban versus enoxaparin in the prevention of venous thromboembolism following total knee arthroplasty: a single-centre, single-surgeon, retrospective analysis.
    Internal medicine journal, 2016, Volume: 46, Issue:9

    Topics: Aged; Arthroplasty, Replacement, Knee; Australia; Enoxaparin; Factor Xa Inhibitors; Female; Hemorrha

2016
Venovenous Extracorporeal Membrane Oxygenation With Prophylactic Subcutaneous Anticoagulation Only: An Observational Study in More Than 60 Patients.
    Artificial organs, 2017, Volume: 41, Issue:2

    Topics: Adolescent; Adult; Aged; Anticoagulants; Blood Coagulation; Enoxaparin; Extracorporeal Membrane Oxyg

2017
Venovenous Extracorporeal Membrane Oxygenation With Prophylactic Subcutaneous Anticoagulation Only: An Observational Study in More Than 60 Patients.
    Artificial organs, 2017, Volume: 41, Issue:2

    Topics: Adolescent; Adult; Aged; Anticoagulants; Blood Coagulation; Enoxaparin; Extracorporeal Membrane Oxyg

2017
Venovenous Extracorporeal Membrane Oxygenation With Prophylactic Subcutaneous Anticoagulation Only: An Observational Study in More Than 60 Patients.
    Artificial organs, 2017, Volume: 41, Issue:2

    Topics: Adolescent; Adult; Aged; Anticoagulants; Blood Coagulation; Enoxaparin; Extracorporeal Membrane Oxyg

2017
Venovenous Extracorporeal Membrane Oxygenation With Prophylactic Subcutaneous Anticoagulation Only: An Observational Study in More Than 60 Patients.
    Artificial organs, 2017, Volume: 41, Issue:2

    Topics: Adolescent; Adult; Aged; Anticoagulants; Blood Coagulation; Enoxaparin; Extracorporeal Membrane Oxyg

2017
Evaluation of Enoxaparin Dosing as a Risk Factor for Bleeding in Lung Transplant Recipients.
    The Annals of pharmacotherapy, 2016, Volume: 50, Issue:10

    Topics: Adult; Aged; Anticoagulants; Blood Coagulation; Clinical Protocols; Dose-Response Relationship, Drug

2016
Association Between Enoxaparin Dosage Adjusted by Anti-Factor Xa Trough Level and Clinically Evident Venous Thromboembolism After Trauma.
    JAMA surgery, 2016, 11-01, Volume: 151, Issue:11

    Topics: Adult; Anticoagulants; Enoxaparin; Erythrocyte Transfusion; Factor Xa Inhibitors; Female; Hematocrit

2016
Letter to the Editor on "Balancing Thromboprophylaxis and Bleeding in Total Joint Arthroplasty: Impact of Eliminating Enoxaparin and Predonation and Implementing Pneumatic Compression and Tranexamic Acid".
    The Journal of arthroplasty, 2016, Volume: 31, Issue:11

    Topics: Anticoagulants; Arthroplasty; Arthroplasty, Replacement, Knee; Enoxaparin; Hemorrhage; Humans; Trane

2016
Fondaparinux versus Enoxaparin - Which is the Best Anticoagulant for Acute Coronary Syndrome? - Brazilian Registry Data.
    Arquivos brasileiros de cardiologia, 2016, Volume: 107, Issue:3

    Topics: Acute Coronary Syndrome; Aged; Anticoagulants; Brazil; Enoxaparin; Female; Fondaparinux; Hemorrhage;

2016
Response to Letter to the Editor on "Balancing Thromboprophylaxis and Bleeding in Total Joint Arthroplasty: Impact of Eliminating Enoxaparin and Predonation and Implementing Pneumatic Compression and Tranexamic Acid".
    The Journal of arthroplasty, 2016, Volume: 31, Issue:11

    Topics: Anticoagulants; Arthroplasty; Arthroplasty, Replacement, Knee; Enoxaparin; Hemorrhage; Humans; Trane

2016
Risk of Bleeding in Patients on Full-Dose Enoxaparin With Venous Thromboembolism and Selective Serotonin Reuptake Inhibitors.
    The Annals of pharmacotherapy, 2017, Volume: 51, Issue:3

    Topics: Aged; Anticoagulants; Dose-Response Relationship, Drug; Drug Interactions; Enoxaparin; Female; Hemor

2017
Oral Rivaroxaban for the Treatment of Symptomatic Venous Thromboembolism in 400 Patients With Active Cancer: A Single-Center Experience.
    Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis, 2017, Volume: 23, Issue:7

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Enoxaparin; Female; Hemorrhage; Humans; Male; Middle Age

2017
Retrospective Evaluation of Postoperative Adverse Drug Events in Patients Receiving Rivaroxaban After Major Orthopedic Surgery Compared with Standard Therapy in a Community Hospital.
    Pharmacotherapy, 2017, Volume: 37, Issue:2

    Topics: Aged; Anticoagulants; Dose-Response Relationship, Drug; Drug Therapy, Combination; Enoxaparin; Facto

2017
Letter to the Editor "Gender related aspects of bleeding with rivaroxaban in venous thromboembolism - Potential for pitfalls": A comment to "Impact of gender on safety and efficacy of rivaroxaban in adolescents & young adults with venous thromboembolism"
    Thrombosis research, 2016, Volume: 148

    Topics: Adult; Anticoagulants; Enoxaparin; Hemorrhage; Humans; Morpholines; Rivaroxaban; Thiophenes; Thrombo

2016
Once versus twice daily enoxaparin for the initial treatment of acute venous thromboembolism.
    Journal of thrombosis and haemostasis : JTH, 2017, Volume: 15, Issue:3

    Topics: Acute Disease; Aged; Anticoagulants; Drug Administration Schedule; Enoxaparin; Europe; Female; Hemor

2017
Effect of Plasmapheresis on the Anti-Factor Xa Activity of Enoxaparin in an Obese Adolescent Patient.
    Pharmacotherapy, 2017, Volume: 37, Issue:4

    Topics: Adolescent; Enoxaparin; Factor Xa; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Pediatric Obesi

2017
Enoxaparin dose reduction for thrombocytopenia in patients with cancer: a quality assessment study.
    Journal of thrombosis and thrombolysis, 2017, Volume: 43, Issue:4

    Topics: Adult; Anticoagulants; Enoxaparin; Female; Guideline Adherence; Hemorrhage; Humans; Male; Neoplasms;

2017
Safety and Effectiveness of Enoxaparin as Venous Thromboembolism Prophylaxis after Gastric Cancer Surgery in Japanese Patients.
    The American surgeon, 2016, Dec-01, Volume: 82, Issue:12

    Topics: Adult; Aged; Aged, 80 and over; Anastomosis, Surgical; Anticoagulants; Case-Control Studies; Enoxapa

2016
Appropriateness of direct oral anticoagulant dosing for venous thromboembolism treatment.
    Journal of thrombosis and thrombolysis, 2017, Volume: 43, Issue:4

    Topics: Administration, Oral; Anticoagulants; Cohort Studies; Enoxaparin; Female; Hemorrhage; Humans; Kidney

2017
Primary percutaneous coronary intervention for ST-elevation myocardial infarction using an intravenous and subcutaneous enoxaparin low molecular weight heparin regimen.
    Journal of thrombosis and thrombolysis, 2008, Volume: 26, Issue:2

    Topics: Aged; Angioplasty, Balloon, Coronary; Cardiovascular Diseases; Enoxaparin; Female; Fibrinolytic Agen

2008
Association of non-steroidal anti-inflammatory drugs with outcomes in patients with ST-segment elevation myocardial infarction treated with fibrinolytic therapy: an ExTRACT-TIMI 25 analysis.
    Journal of thrombosis and thrombolysis, 2009, Volume: 27, Issue:1

    Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Anticoagulants; Aspirin; Combined Modality Therapy; C

2009
Comparison of the two-year outcomes and costs of prophylaxis in medical patients at risk of venous thromboembolism.
    Thrombosis and haemostasis, 2008, Volume: 100, Issue:5

    Topics: Anticoagulants; Cost-Benefit Analysis; Direct Service Costs; Drug Costs; Enoxaparin; Health Care Cos

2008
Rivaroxaban for thromboprophylaxis.
    The New England journal of medicine, 2008, Nov-13, Volume: 359, Issue:20

    Topics: Anticoagulants; Arthroplasty, Replacement, Knee; Enoxaparin; Factor Xa Inhibitors; Hemorrhage; Human

2008
Obesity in patients with non-ST-segment elevation acute coronary syndromes: results from the SYNERGY trial.
    International journal of cardiology, 2010, Mar-04, Volume: 139, Issue:2

    Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Anticoagulants; Body Mass Index; Comorbidity; Data

2010
Bleeding events in patients receiving enoxaparin for the management of non-ST-elevation acute coronary syndrome (NSTEACS) at Dunedin Public Hospital, New Zealand.
    The New Zealand medical journal, 2008, Nov-07, Volume: 121, Issue:1285

    Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Case-Control Studies; Clinical Trials as Topic; Coro

2008
Efficacy and safety of optimized antithrombotic therapy with aspirin, clopidogrel and enoxaparin in patients with non-ST segment elevation acute coronary syndromes in clinical practice.
    Journal of thrombosis and thrombolysis, 2009, Volume: 28, Issue:3

    Topics: Acute Coronary Syndrome; Aged; Aspirin; Clopidogrel; Drug Evaluation; Drug Therapy, Combination; Dru

2009
Factors associated with bleeding in elderly hospitalized patients treated with enoxaparin sodium : a prospective, open-label, observational study.
    Drugs & aging, 2009, Volume: 26, Issue:1

    Topics: Aged; Aged, 80 and over; Anticoagulants; Body Weight; Clopidogrel; Creatinine; Dose-Response Relatio

2009
Dabigatran etexilate for prevention of venous thromboembolism.
    Thrombosis and haemostasis, 2009, Volume: 101, Issue:1

    Topics: Administration, Oral; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Kne

2009
Once daily enoxaparin for outpatient treatment of acute venous thromboembolism: a case-control study.
    Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis, 2010, Volume: 16, Issue:1

    Topics: Acute Disease; Adult; Aged; Anticoagulants; Case-Control Studies; Enoxaparin; Female; Follow-Up Stud

2010
[Summary and perspectives. Rivaroxaban].
    Annales francaises d'anesthesie et de reanimation, 2008, Volume: 27 Suppl 3

    Topics: Administration, Oral; Aged; Anticoagulants; Clinical Trials, Phase III as Topic; Comorbidity; Enoxap

2008
Clinical management of thrombosis in inherited factor VII deficiency: a description of two cases.
    Thrombosis and haemostasis, 2009, Volume: 101, Issue:2

    Topics: Acenocoumarol; Aged; Aged, 80 and over; Anticoagulants; Drug Monitoring; Enoxaparin; Factor VII Defi

2009
Economic evaluation of dabigatran etexilate for the prevention of venous thromboembolism after total knee and hip replacement surgery.
    Clinical therapeutics, 2009, Volume: 31, Issue:1

    Topics: Aged; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Benzimidazole

2009
The pain and the gain of treating patients with acute coronary syndromes-can the two be separated?
    American heart journal, 2009, Volume: 157, Issue:3

    Topics: Acute Coronary Syndrome; Anticoagulants; Enoxaparin; Fondaparinux; Hemorrhage; Humans; Myocardial Is

2009
Efficacy and safety of enoxaparin in combination with and without GP IIb/IIIa inhibitors in unselected patients with ST segment elevation myocardial infarction treated with primary percutaneous coronary intervention.
    EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology, 2009, Volume: 4, Issue:4

    Topics: Angioplasty, Balloon, Coronary; Cardiovascular Diseases; Drug Therapy, Combination; Enoxaparin; Fibr

2009
Enoxaparin attenuates endothelial damage with less bleeding compared with unfractionated heparin in endotoxemic rats.
    Shock (Augusta, Ga.), 2009, Volume: 32, Issue:5

    Topics: Animals; Anticoagulants; CD13 Antigens; Endothelium; Endotoxemia; Enoxaparin; Fibrinogen; Hemorrhage

2009
Fondaparinux in the treatment of acute coronary syndromes: evidence from OASIS 5 and 6.
    Expert review of cardiovascular therapy, 2009, Volume: 7, Issue:3

    Topics: Acute Coronary Syndrome; Anticoagulants; Double-Blind Method; Enoxaparin; Factor Xa Inhibitors; Fond

2009
Treatment of venous thromboembolism in patients with cancer: subgroup analysis of the Matisse clinical trials.
    Thrombosis and haemostasis, 2009, Volume: 101, Issue:4

    Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Double-Blind Method; Enoxaparin; Female; Fondaparinu

2009
Treatment of patients with dysfibrinogenemia and a history of abortions during pregnancy.
    Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis, 2009, Volume: 20, Issue:5

    Topics: Abortion, Habitual; Abruptio Placentae; Adult; Afibrinogenemia; Enoxaparin; Female; Fibrinogen; Fibr

2009
Retrospective evaluation of venous thromboembolism prophylaxis in the adult cancer population.
    Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners, 2010, Volume: 16, Issue:1

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticoagulants; Drug Therapy, Combination; Enoxaparin; F

2010
Safety of enoxaparin versus unfractionated heparin during percutaneous coronary intervention.
    Texas Heart Institute journal, 2009, Volume: 36, Issue:2

    Topics: Administration, Oral; Angioplasty, Balloon, Coronary; Anticoagulants; Biomarkers; Enoxaparin; Eptifi

2009
Weight-based dosing of enoxaparin in obese patients with non-ST-segment elevation acute coronary syndromes: results from the CRUSADE initiative.
    Pharmacotherapy, 2009, Volume: 29, Issue:6

    Topics: Acute Coronary Syndrome; Aged; Angina, Unstable; Anticoagulants; Body Weight; Cohort Studies; Enoxap

2009
Bridging of oral anticoagulation with low-molecular-weight heparin: experience in 373 patients with renal insufficiency undergoing invasive procedures.
    Thrombosis and haemostasis, 2009, Volume: 101, Issue:6

    Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Creatinine; Drug Dosage Calculations;

2009
Long term administration of LMWH - pharmacodynamic parameters under therapeutic or prophylactic regimen of enoxaparin or tinzaparin in neurological rehabilitation patients.
    Thrombosis research, 2009, Volume: 124, Issue:5

    Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Drug Administration Schedule; Enoxaparin; Female; Fi

2009
Dabigatran: new drug. Continue to use heparin, a better-known option.
    Prescrire international, 2009, Volume: 18, Issue:101

    Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Benzimidazoles; Dab

2009
The efficacy of Ankaferd Blood Stopper in antithrombotic drug-induced primary and secondary hemostatic abnormalities of a rat-bleeding model.
    Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis, 2009, Volume: 20, Issue:3

    Topics: Analysis of Variance; Animals; Anticoagulants; Aspirin; Disease Models, Animal; Enoxaparin; Female;

2009
[Prophylaxis of deep vein thrombosis with enoxaparin 40 mg in outpatients compared to hospitalized medically ill patients].
    Medizinische Klinik (Munich, Germany : 1983), 2009, Volume: 104, Issue:8

    Topics: Adult; Aged; Aged, 80 and over; Ambulatory Care; Anticoagulants; Cross-Sectional Studies; Enoxaparin

2009
Rivaroxaban versus enoxaparin after total knee arthroplasty.
    Lancet (London, England), 2009, Aug-29, Volume: 374, Issue:9691

    Topics: Anticoagulants; Arthroplasty, Replacement, Knee; Enoxaparin; Hemorrhage; Humans; Morpholines; Random

2009
Systemic bleeding in a patient with enoxaparin-induced thrombocytopenia.
    The American journal of emergency medicine, 2009, Volume: 27, Issue:6

    Topics: Aged, 80 and over; Anticoagulants; Enoxaparin; Fatal Outcome; Hemorrhage; Humans; Male; Thrombocytop

2009
Comparison of safety of subcutaneous enoxaparin as outpatient anticoagulation bridging therapy in patients with a mechanical heart valve versus patients with nonvalvular atrial fibrillation.
    The American journal of cardiology, 2009, Nov-15, Volume: 104, Issue:10

    Topics: Aged; Ambulatory Care; Anticoagulants; Atrial Fibrillation; Cohort Studies; Enoxaparin; Female; Hear

2009
Stroke prevention versus bleeding risk of vitamin-K antagonists: a double-edged sword in patients with atrial fibrillation who require surgery.
    Cardiovascular therapeutics, 2009,Winter, Volume: 27, Issue:4

    Topics: Anticoagulants; Atrial Fibrillation; Enoxaparin; Hemorrhage; Humans; Stroke; Vitamin K

2009
Bridging of chronic oral anticoagulation with enoxaparin in patients with atrial fibrillation: results from the prospective BRAVE registry.
    Cardiovascular therapeutics, 2009,Winter, Volume: 27, Issue:4

    Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Enoxaparin; Female; Hemorrhage; Hum

2009
Antithrombin therapy for elective percutaneous coronary intervention: which agent to use? Does it matter?
    JACC. Cardiovascular interventions, 2009, Volume: 2, Issue:11

    Topics: Angioplasty, Balloon, Coronary; Anticoagulants; Enoxaparin; Fibrinolytic Agents; Hemorrhage; Heparin

2009
Clinical and economic outcomes with appropriate or partial prophylaxis.
    Thrombosis research, 2010, Volume: 125, Issue:6

    Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Costs and Cost Analysis; Data Collection; Enoxaparin

2010
Contraindicated medication use in dialysis patients undergoing percutaneous coronary intervention.
    JAMA, 2009, Dec-09, Volume: 302, Issue:22

    Topics: Aged; Angioplasty, Balloon, Coronary; Cohort Studies; Contraindications; Drug Utilization; Enoxapari

2009
A life threatening complication of anticoagulation prophylaxis-bilateral adrenal hemorrhage.
    Journal of hospital medicine, 2009, Volume: 4, Issue:9

    Topics: Adrenal Gland Diseases; Anticoagulants; Arthroplasty, Replacement, Knee; Enoxaparin; Hemorrhage; Hum

2009
Economic evaluation of dabigatran etexilate for the prevention of venous thromboembolism in patients aged over 75 years or with moderate renal impairment undergoing total knee or hip replacement.
    Thrombosis and haemostasis, 2010, Volume: 103, Issue:2

    Topics: Aged; Aged, 80 and over; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement,

2010
Don't rule out retroperitoneal bleeding just because the angiogram was done from the radial artery.
    The Journal of invasive cardiology, 2010, Volume: 22, Issue:1

    Topics: Aged; Angiography; Anticoagulants; Cardiac Catheterization; Enoxaparin; Hematoma; Hemorrhage; Humans

2010
Current primary care practice in the diagnosis and management of patients with suspected venous thromboembolism and prescription of initiation dose of enoxaparin.
    International angiology : a journal of the International Union of Angiology, 2010, Volume: 29, Issue:1

    Topics: Aged; Aged, 80 and over; Anticoagulants; Belgium; Chi-Square Distribution; Cross-Sectional Studies;

2010
Enoxaparin and fibrinolysis: ExTRACTing prognosis from bleeding complications.
    European heart journal, 2010, Volume: 31, Issue:17

    Topics: Enoxaparin; Fibrinolytic Agents; Hemorrhage; Heparin; Humans; Myocardial Infarction

2010
Pooled analysis of trials may, in the presence of heterogeneity inadvertently lead to fragile conclusions due to the importance of clinically relevant variables being either hidden or lost when the findings are pooled.
    Thrombosis research, 2010, Volume: 126, Issue:3

    Topics: Administration, Oral; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Benzimidazole

2010
Prolonged thromboprophylaxis with enoxaparin in early neurological rehabilitation.
    Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis, 2011, Volume: 17, Issue:5

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticoagulants; Enoxaparin; Female; Hemorrhage; Humans;

2011
Heparin or enoxaparin anticoagulation for primary percutaneous coronary intervention.
    Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions, 2011, Feb-01, Volume: 77, Issue:2

    Topics: Aged; Analysis of Variance; Angioplasty, Balloon, Coronary; Anticoagulants; Chi-Square Distribution;

2011
Summaries for patients. Do the benefits of prolonged low-molecular-weight heparin treatment outweigh the harms in hospitalized patients who are bedbound?
    Annals of internal medicine, 2010, Jul-06, Volume: 153, Issue:1

    Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Anticoagulants; Delayed-Action Preparations; Drug Adm

2010
Quantification of apixaban's therapeutic utility in prevention of venous thromboembolism: selection of phase III trial dose.
    Clinical pharmacology and therapeutics, 2010, Volume: 88, Issue:3

    Topics: Aged; Area Under Curve; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Com

2010
Bridging with enoxaparin using a half-therapeutic dose regimen: safety and efficacy.
    VASA. Zeitschrift fur Gefasskrankheiten, 2010, Volume: 39, Issue:3

    Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Blood Coagulation; Blood Loss, Surgic

2010
Inference on treatment effects from a randomized clinical trial in the presence of premature treatment discontinuation: the SYNERGY trial.
    Biostatistics (Oxford, England), 2011, Volume: 12, Issue:2

    Topics: Acute Coronary Syndrome; Algorithms; Computer Simulation; Endpoint Determination; Enoxaparin; Hemorr

2011
Inhibition of the intrinsic coagulation pathway factor XI by antisense oligonucleotides: a novel antithrombotic strategy with lowered bleeding risk.
    Blood, 2010, Nov-25, Volume: 116, Issue:22

    Topics: Animals; Anticoagulants; Clopidogrel; Drug Combinations; Enoxaparin; Factor XI; Hemorrhage; Male; Mi

2010
Improve the results of phase II trials of thromboprophylaxis with the new oral anticoagulant drugs.
    Thrombosis and haemostasis, 2010, Volume: 104, Issue:6

    Topics: Administration, Oral; Anticoagulants; Arthroplasty, Replacement, Knee; Clinical Trials, Phase II as

2010
How should we define major bleeding events in thromboprophylaxis?
    The Journal of bone and joint surgery. American volume, 2010, Nov-03, Volume: 92, Issue:15

    Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Bandages; Enoxaparin; Hemorrhage; Heparin, Low-Molec

2010
Invited commentary.
    Journal of vascular surgery, 2010, Volume: 52, Issue:5

    Topics: Administration, Oral; Ambulatory Care; Anticoagulants; Blood Coagulation; Compression Bandages; Drug

2010
Extended-duration venous thromboembolism prophylaxis for medical patients.
    Annals of internal medicine, 2010, Nov-16, Volume: 153, Issue:10

    Topics: Anticoagulants; Drug Administration Schedule; Enoxaparin; Hemorrhage; Humans; Immobilization; Risk F

2010
Extended-duration venous thromboembolism prophylaxis for medical patients.
    Annals of internal medicine, 2010, Nov-16, Volume: 153, Issue:10

    Topics: Anticoagulants; Drug Administration Schedule; Enoxaparin; Hemorrhage; Humans; Immobilization; Risk F

2010
The ATOLL trial of enoxaparin in primary percutaneous coronary intervention.
    European heart journal, 2010, Volume: 31, Issue:23

    Topics: Angioplasty, Balloon, Coronary; Anticoagulants; Enoxaparin; Hemorrhage; Humans; Randomized Controlle

2010
Unfractionated versus low-molecular-weight heparin for primary angioplasty-More data suggesting to go low.
    Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions, 2011, Feb-01, Volume: 77, Issue:2

    Topics: Angioplasty, Balloon, Coronary; Anticoagulants; Enoxaparin; Evidence-Based Medicine; Hemorrhage; Hep

2011
Apixaban vs. enoxaparin after hip replacement.
    The New England journal of medicine, 2011, 03-24, Volume: 364, Issue:12

    Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Enoxaparin; Hemorrhage; Humans; Outcome Assessment,

2011
Oral rivaroxaban for symptomatic venous thromboembolism.
    The New England journal of medicine, 2011, 03-24, Volume: 364, Issue:12

    Topics: Acute Disease; Administration, Oral; Anticoagulants; Enoxaparin; Hemorrhage; Humans; Morpholines; Pu

2011
Effectiveness of dabigatran etexilate for thromboprophylaxis of mechanical heart valves.
    The Journal of thoracic and cardiovascular surgery, 2011, Volume: 141, Issue:6

    Topics: Administration, Oral; Animals; Anticoagulants; Antithrombins; Aortic Valve; Benzimidazoles; Blood Co

2011
Perioperative bridging of chronic oral anticoagulation in patients undergoing pacemaker implantation--a study in 200 patients.
    Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology, 2011, Volume: 13, Issue:9

    Topics: Aged; Aged, 80 and over; Anticoagulants; Cardiac Surgical Procedures; Enoxaparin; Female; Heart Fail

2011
Generic versions of enoxaparin available for clinical use in Brazil are similar to the original drug.
    Journal of thrombosis and haemostasis : JTH, 2011, Volume: 9, Issue:7

    Topics: Animals; Anticoagulants; Brazil; Drugs, Generic; Enoxaparin; Hemorrhage; Magnetic Resonance Spectros

2011
Heparin-induced thrombocytopenia: an increasingly common cause of bilateral adrenal hemorrhage.
    Journal of the American Geriatrics Society, 2011, Volume: 59, Issue:6

    Topics: Adrenal Gland Diseases; Adrenal Glands; Adrenal Insufficiency; Aged; Anticoagulants; Arthroplasty, R

2011
Razor blades, heparin and protamine--a potent mix.
    Irish medical journal, 2011, Volume: 104, Issue:4

    Topics: Adult; Enoxaparin; Female; Hemorrhage; Heparin Antagonists; Humans; Injections; Protamines; Suicide,

2011
An unusual case of massive subcutaneous chest wall haemorrhage with enoxaparin.
    Acute cardiac care, 2011, Volume: 13, Issue:3

    Topics: Aged; Anticoagulants; Diagnosis, Differential; Enoxaparin; Hemorrhage; Humans; Injections, Subcutane

2011
Effectiveness and safety of thromboprophylaxis with enoxaparin in medical inpatients.
    Thrombosis research, 2011, Volume: 128, Issue:5

    Topics: Aged; Comorbidity; Drug-Related Side Effects and Adverse Reactions; Emergency Medical Services; Enox

2011
Implementation of an enoxaparin protocol for venous thromboembolism prophylaxis in obese surgical intensive care unit patients.
    The Annals of pharmacotherapy, 2011, Volume: 45, Issue:11

    Topics: Adolescent; Adult; Aged; Anticoagulants; Body Mass Index; Drug Administration Schedule; Enoxaparin;

2011
Structure and haemostatic effects of generic versions of enoxaparin available for clinical use in Brazil: similarity to the original drug.
    Thrombosis and haemostasis, 2012, Volume: 107, Issue:2

    Topics: Animals; Anticoagulants; Blood Coagulation; Brazil; Disease Models, Animal; Drugs, Generic; Enoxapar

2012
Enoxaparin and fondaparinux attenuates endothelial damage in endotoxemic rats.
    The journal of trauma and acute care surgery, 2012, Volume: 72, Issue:1

    Topics: Animals; Anticoagulants; Endothelium, Vascular; Endotoxemia; Enoxaparin; Factor Xa Inhibitors; Fonda

2012
Initiative to improve thromboprophylactic enoxaparin exposure in hospitalized patients with renal impairment.
    American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 2012, Mar-01, Volume: 69, Issue:5

    Topics: Acute Disease; Aged; Aged, 80 and over; Anticoagulants; Chronic Disease; Cohort Studies; Creatinine;

2012
Anticoagulant for primary percutaneous coronary intervention - the last dance for unfractionated heparin?
    Archives of cardiovascular diseases, 2012, Volume: 105, Issue:5

    Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Anticoagulants; Coronary Thrombosis; Enoxap

2012
Management and adherence to VTE treatment guidelines in a national prospective cohort study in the Canadian outpatient setting. The Recovery Study.
    Thrombosis and haemostasis, 2012, Volume: 108, Issue:3

    Topics: Adult; Aged; Anticoagulants; Canada; Catheterization; Coumarins; Disease Management; Drug Utilizatio

2012
Glomerular filtration rate estimated by Cockcroft-Gault formula better predicts anti-Xa levels than modification of the diet in renal disease equation in older patients with prophylactic enoxaparin.
    The journal of nutrition, health & aging, 2012, Volume: 16, Issue:7

    Topics: Aged; Aged, 80 and over; Anticoagulants; Body Weight; Cohort Studies; Creatinine; Diet; Enoxaparin;

2012
The effects of rivaroxaban on the complications of surgery after total hip or knee replacement: results from the RECORD programme.
    The Journal of bone and joint surgery. British volume, 2012, Volume: 94, Issue:11

    Topics: Anticoagulants; Arthroplasty, Replacement, Ankle; Arthroplasty, Replacement, Knee; Clinical Trials,

2012
Are low-molecular-weight heparins appropriately dosed in patients with CKD stage 3 to 5?
    Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis, 2012, Volume: 23, Issue:8

    Topics: Aged; Aged, 80 and over; Anticoagulants; Biomarkers; Blood Coagulation Tests; Drug Dosage Calculatio

2012
Intentional low-molecular-weight heparin overdose: a case report and review.
    Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis, 2012, Volume: 23, Issue:8

    Topics: Adult; Anticoagulants; Blood Coagulation Tests; Drug Overdose; Enoxaparin; Factor VIIa; Factor Xa; F

2012
Apixaban after hip or knee arthroplasty versus enoxaparin: efficacy and safety in key clinical subgroups.
    Journal of thrombosis and haemostasis : JTH, 2013, Volume: 11, Issue:3

    Topics: Administration, Oral; Age Factors; Aged; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplast

2013
Apixaban after hip or knee arthroplasty versus enoxaparin: efficacy and safety in key clinical subgroups.
    Journal of thrombosis and haemostasis : JTH, 2013, Volume: 11, Issue:3

    Topics: Administration, Oral; Age Factors; Aged; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplast

2013
Apixaban after hip or knee arthroplasty versus enoxaparin: efficacy and safety in key clinical subgroups.
    Journal of thrombosis and haemostasis : JTH, 2013, Volume: 11, Issue:3

    Topics: Administration, Oral; Age Factors; Aged; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplast

2013
Apixaban after hip or knee arthroplasty versus enoxaparin: efficacy and safety in key clinical subgroups.
    Journal of thrombosis and haemostasis : JTH, 2013, Volume: 11, Issue:3

    Topics: Administration, Oral; Age Factors; Aged; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplast

2013
[Budgetary impact for the National Health System of apixaban prophylaxis of venous thromboembolism in patients undergoing total knee or hip replacement].
    Revista espanola de salud publica, 2012, Volume: 86, Issue:6

    Topics: Aged; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Benzimidazole

2012
Fondaparinux versus enoxaparin for prevention of venous.
    Lancet (London, England), 2002, Nov-16, Volume: 360, Issue:9345

    Topics: Arthroplasty, Replacement, Hip; Drug Administration Schedule; Enoxaparin; Fibrinolytic Agents; Fonda

2002
Enoxaparin or fondaparinux for thrombosis prevention after orthopaedic surgery.
    Lancet (London, England), 2002, Nov-23, Volume: 360, Issue:9346

    Topics: Arthroplasty; Enoxaparin; Fibrinolytic Agents; Fondaparinux; Hemorrhage; Humans; Polysaccharides; Po

2002
Enoxaparin or fondaparinux for thrombosis prevention after orthopaedic surgery.
    Lancet (London, England), 2002, Nov-23, Volume: 360, Issue:9346

    Topics: Arthroplasty; Enoxaparin; Fondaparinux; Hemorrhage; Heparin, Low-Molecular-Weight; Humans; Polysacch

2002
Enoxaparin in unstable angina patients who would have been excluded from randomized pivotal trials.
    Journal of the American College of Cardiology, 2003, Jan-01, Volume: 41, Issue:1

    Topics: Aged; Aged, 80 and over; Angina, Unstable; Anticoagulants; Aspirin; Creatinine; Drug Monitoring; Eno

2003
Utilisation and safety of low molecular weight heparins: prospective observational study in medical inpatients.
    Drug safety, 2003, Volume: 26, Issue:3

    Topics: Adolescent; Aged; Aged, 80 and over; Anticoagulants; Contraindications; Drug Prescriptions; Drug Uti

2003
[Venous thromboembolism prophylaxis with low molecular weight heparins in polytraumatized patients in intensive care unit (extended serie)].
    Ulusal travma ve acil cerrahi dergisi = Turkish journal of trauma & emergency surgery : TJTES, 2003, Volume: 9, Issue:1

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticoagulants; APACHE; Enoxaparin; Female; Hemorrhage;

2003
A safety analysis of thromboprophylaxis in acute medical illness.
    Thrombosis and haemostasis, 2003, Volume: 89, Issue:3

    Topics: Acute Disease; Anticoagulants; Enoxaparin; Hemorrhage; Heparin; Humans; Risk Factors; Safety; Thromb

2003
Experience with enoxaparin in patients with mechanical heart valves who must withhold acenocumarol.
    Heart (British Cardiac Society), 2003, Volume: 89, Issue:5

    Topics: Acenocoumarol; Anticoagulants; Blood Loss, Surgical; Cohort Studies; Contraindications; Enoxaparin;

2003
[Atraumatic retroperitoneal hemorrhage--interdisciplinary and differential diagnostic considerations based on a case report].
    Anaesthesiologie und Reanimation, 2003, Volume: 28, Issue:2

    Topics: Aged; Anticoagulants; Biopsy, Needle; Diagnosis, Differential; Enoxaparin; Female; Glomerulonephriti

2003
Use of low molecular mass heparin (enoxaparin) in newborn infants: a prospective cohort study of 62 patients.
    Archives of disease in childhood. Fetal and neonatal edition, 2003, Volume: 88, Issue:5

    Topics: Anticoagulants; Antithrombin III; Catheters, Indwelling; Cohort Studies; Coronary Disease; Dose-Resp

2003
[Spontaneous retroperitoneal hematoma induced by enoxiparin to therapeutic dose].
    Anales de medicina interna (Madrid, Spain : 1984), 2003, Volume: 20, Issue:7

    Topics: Aged; Anticoagulants; Enoxaparin; Female; Hematoma; Hemorrhage; Humans; Retroperitoneal Space; Tomog

2003
Dalteparin compared with an oral anticoagulant for thromboprophylaxis in patients with cancer.
    The New England journal of medicine, 2003, Oct-02, Volume: 349, Issue:14

    Topics: Age Factors; Aged; Anticoagulants; Dalteparin; Enoxaparin; Hemorrhage; Humans; Meta-Analysis as Topi

2003
Anticoagulation in hospitalized patients with renal insufficiency: a comparison of bleeding rates with unfractionated heparin vs enoxaparin.
    Chest, 2004, Volume: 125, Issue:3

    Topics: Aged; Anticoagulants; Enoxaparin; Female; Glomerular Filtration Rate; Hemorrhage; Heparin; Hospitali

2004
Life threatening haemorrhagic events associated with the administration of low-molecular-weight-heparin.
    Thrombosis and haemostasis, 2004, Volume: 91, Issue:4

    Topics: Adult; Aged; Aged, 80 and over; Critical Illness; Enoxaparin; Female; Hemorrhage; Heparin, Low-Molec

2004
Subcutaneous enoxaparin with early invasive strategy in patients with acute coronary syndromes.
    American heart journal, 2004, Volume: 147, Issue:4

    Topics: Analysis of Variance; Angina, Unstable; Angioplasty, Balloon, Coronary; Anticoagulants; Cardiac Cath

2004
Dosing practices and risk factors for bleeding in patients receiving enoxaparin for the treatment of an acute coronary syndrome.
    Chest, 2004, Volume: 125, Issue:5

    Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Angina, Unstable; Anticoagulants; Coronary Disease; E

2004
Summaries for patients. Fondaparinux or enoxaparin for deep venous thrombosis?
    Annals of internal medicine, 2004, Jun-01, Volume: 140, Issue:11

    Topics: Aged; Body Weight; Cause of Death; Double-Blind Method; Drug Administration Schedule; Enoxaparin; Fe

2004
Recombinant activated factor VII for treatment of enoxaparin-induced bleeding.
    Mayo Clinic proceedings, 2004, Volume: 79, Issue:6

    Topics: Aged; Enoxaparin; Factor VIIa; Fibrinolytic Agents; Hemorrhage; Humans; Male; Recombinant Proteins

2004
Low molecular weight heparin in the treatment of venous and arterial thromboses in the premature infant.
    Pediatrics, 2004, Volume: 114, Issue:3

    Topics: Anticoagulants; Dose-Response Relationship, Drug; Enoxaparin; Hemorrhage; Humans; Infant, Low Birth

2004
Advances in risk-benefit evaluation using probabilistic simulation methods: an application to the prophylaxis of deep vein thrombosis.
    Journal of clinical epidemiology, 2004, Volume: 57, Issue:8

    Topics: Anticoagulants; Decision Support Techniques; Enoxaparin; Hemorrhage; Heparin; Humans; Monte Carlo Me

2004
Large rectus muscle hematoma with intraperitoneal bleeding and fatal abdominal compartment syndrome complicating anticoagulant therapy.
    Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis, 2005, Volume: 11, Issue:1

    Topics: Anticoagulants; Compartment Syndromes; Enoxaparin; Fatal Outcome; Female; Hematoma; Hemorrhage; Huma

2005
Fatal retroperitoneal haemorrhage associated with enoxaparin and impaired renal function.
    International journal of cardiology, 2005, Feb-28, Volume: 98, Issue:3

    Topics: Aged; Angina, Unstable; Anticoagulants; Creatinine; Enoxaparin; Female; Hemorrhage; Humans; Kidney T

2005
The safety of low molecular weight heparin therapy during labor.
    The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians, 2005, Volume: 17, Issue:1

    Topics: Adult; Anticoagulants; Drug Administration Schedule; Enoxaparin; Female; Hemoglobins; Hemorrhage; He

2005
Safety of low-dose low-molecular-weight-heparins in thrombocytopenic stem cell transplantation patients: a case series and review of the literature.
    Bone marrow transplantation, 2005, Volume: 35, Issue:11

    Topics: Adult; Aged; Anticoagulants; Blood Platelets; Bone Marrow Transplantation; Cohort Studies; Enoxapari

2005
A protocol for the use of enoxaparin during pregnancy: results from 85 pregnancies including 13 multiple gestation pregnancies.
    Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis, 2005, Volume: 11, Issue:2

    Topics: Adult; Aspirin; Clinical Protocols; Dose-Response Relationship, Drug; Drug Monitoring; Enoxaparin; F

2005
On "Current role of antithrombotic agents in the treatment of acute coronary syndromes" (Semin Thromb Hemost 2004;30:627-632).
    Seminars in thrombosis and hemostasis, 2005, Volume: 31, Issue:2

    Topics: Cerebral Hemorrhage; Confounding Factors, Epidemiologic; Enoxaparin; Fibrinolytic Agents; Hemorrhage

2005
Life-threatening abdominal wall hematoma in a chronic renal failure patient after a single dose of enoxaparin.
    The American surgeon, 2005, Volume: 71, Issue:2

    Topics: Abdominal Injuries; Abdominal Wall; Accidents, Traffic; Adult; Anticoagulants; Enoxaparin; Epigastri

2005
Exploring the role of enoxaparin in the management of high-risk patients with non-ST-elevation acute coronary syndromes: the SYNERGY trial.
    American heart journal, 2005, Volume: 149, Issue:4 Suppl

    Topics: Aged; Anticoagulants; Aspirin; Cardiac Catheterization; Enoxaparin; Female; Hemorrhage; Heparin; Hum

2005
A perspective on trials comparing enoxaparin and unfractionated heparin in the treatment of non-ST-elevation acute coronary syndromes.
    American heart journal, 2005, Volume: 149, Issue:4 Suppl

    Topics: Aged; Anticoagulants; Coronary Disease; Enoxaparin; Female; Hemorrhage; Heparin; Humans; Male; Middl

2005
Low-molecular-weight-heparins as periprocedural anticoagulation for patients on long-term warfarin therapy: a standardized bridging therapy protocol.
    Journal of thrombosis and thrombolysis, 2005, Volume: 20, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Enoxaparin; Female; Heart Valve

2005
Blood thinner cuts risk of bleeding in half.
    Health news (Waltham, Mass.), 2006, Volume: 12, Issue:1

    Topics: Anticoagulants; Enoxaparin; Fondaparinux; Hemorrhage; Humans; Myocardial Infarction; Polysaccharides

2006
Therapy for patients with acute coronary syndromes--new opportunities.
    The New England journal of medicine, 2006, Apr-06, Volume: 354, Issue:14

    Topics: Angina, Unstable; Anticoagulants; Dose-Response Relationship, Drug; Enoxaparin; Fondaparinux; Hemorr

2006
Hemorrhagic complications in patients treated with anticoagulant doses of a low molecular weight heparin (enoxaparin) in routine hospital practice.
    Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis, 2006, Volume: 12, Issue:2

    Topics: Age Factors; Aged; Aged, 80 and over; Anticoagulants; Drug Evaluation; Enoxaparin; Female; Hemorrhag

2006
Cost effectiveness of enoxaparin as prophylaxis against venous thromboembolic complications in acutely ill medical inpatients: modelling study from the hospital perspective in Germany.
    PharmacoEconomics, 2006, Volume: 24, Issue:6

    Topics: Anticoagulants; Cost-Benefit Analysis; Drug Costs; Enoxaparin; Germany; Hemorrhage; Hospitals; Human

2006
Fondaparinux versus enoxaparin in acute coronary syndromes.
    The New England journal of medicine, 2006, Jun-29, Volume: 354, Issue:26

    Topics: Angina, Unstable; Angioplasty, Balloon, Coronary; Anticoagulants; Coronary Artery Bypass; Drug Thera

2006
Enoxaparin versus unfractionated heparin in ST-elevation myocardial infarction.
    The New England journal of medicine, 2006, Jun-29, Volume: 354, Issue:26

    Topics: Anticoagulants; Drug Administration Schedule; Enoxaparin; Hemorrhage; Heparin; Humans; Myocardial In

2006
Enoxaparin versus unfractionated heparin in ST-elevation myocardial infarction.
    The New England journal of medicine, 2006, Jun-29, Volume: 354, Issue:26

    Topics: Anticoagulants; Enoxaparin; Hemorrhage; Heparin; Humans; Myocardial Infarction

2006
Advances in antithrombotic therapy in acute myocardial infarction: the ExTRACT-TIMI 25 and OASIS-6 Trials.
    Current cardiology reports, 2006, Volume: 8, Issue:4

    Topics: Angioplasty, Balloon, Coronary; Anticoagulants; Clinical Trials, Phase III as Topic; Drug Therapy, C

2006
Risk of bleeding after elective percutaneous coronary intervention.
    The New England journal of medicine, 2006, Sep-07, Volume: 355, Issue:10

    Topics: Angioplasty, Balloon, Coronary; Anticoagulants; Cause of Death; Enoxaparin; Hemorrhage; Heparin; Hum

2006
Bleeding complications from femoral and sciatic nerve catheters in patients receiving low molecular weight heparin.
    Anesthesia and analgesia, 2006, Volume: 103, Issue:4

    Topics: Aged; Anticoagulants; Arthroplasty, Replacement, Knee; Catheterization, Peripheral; Catheters, Indwe

2006
Low-molecular-weight heparin and bleeding: how do we lower risk but maintain benefit?
    Annals of internal medicine, 2006, Nov-21, Volume: 145, Issue:10

    Topics: Anticoagulants; Enoxaparin; Hemorrhage; Humans; Renal Insufficiency; Risk Assessment

2006
Minimizing costs for treating deep vein thrombosis: the role for fondaparinux.
    Journal of thrombosis and thrombolysis, 2007, Volume: 23, Issue:3

    Topics: Body Weight; Costs and Cost Analysis; Enoxaparin; Fondaparinux; Hemorrhage; Heparin, Low-Molecular-W

2007
A simple venous thromboembolism prophylaxis protocol for patients undergoing bariatric surgery.
    Obesity (Silver Spring, Md.), 2006, Volume: 14, Issue:11

    Topics: Anticoagulants; Bariatric Surgery; Body Mass Index; Enoxaparin; Hemorrhage; Heparin; Humans; Obesity

2006
Long-term safety and efficacy data on childhood venous thrombosis treated with a low molecular weight heparin: an open-label pilot study of once-daily versus twice-daily enoxaparin administration.
    Haematologica, 2006, Volume: 91, Issue:12

    Topics: Adolescent; Child; Child, Preschool; Drug Administration Schedule; Enoxaparin; Female; Follow-Up Stu

2006
Enoxaparin in elective percutaneous coronary intervention.
    The New England journal of medicine, 2006, Dec-28, Volume: 355, Issue:26

    Topics: Angioplasty, Balloon, Coronary; Anticoagulants; Clinical Protocols; Enoxaparin; Hemorrhage; Heparin;

2006
Enoxaparin in elective percutaneous coronary intervention.
    The New England journal of medicine, 2006, Dec-28, Volume: 355, Issue:26

    Topics: Age Factors; Aged; Angioplasty, Balloon, Coronary; Anticoagulants; Enoxaparin; Hemorrhage; Heparin;

2006
Enoxaparin in elective percutaneous coronary intervention.
    The New England journal of medicine, 2006, Dec-28, Volume: 355, Issue:26

    Topics: Angioplasty, Balloon, Coronary; Anticoagulants; Enoxaparin; Hemorrhage; Heparin; Humans; Myocardial

2006
Enoxaparin in elective percutaneous coronary intervention.
    The New England journal of medicine, 2006, Dec-28, Volume: 355, Issue:26

    Topics: Angioplasty, Balloon, Coronary; Anticoagulants; Enoxaparin; Hemorrhage; Heparin; Humans; Myocardial

2006
Enoxaparin in elective percutaneous coronary intervention.
    The New England journal of medicine, 2006, Dec-28, Volume: 355, Issue:26

    Topics: Angioplasty, Balloon, Coronary; Anticoagulants; Enoxaparin; Hemorrhage; Heparin; Humans; Myocardial

2006
Atraumatic compartment syndrome of the dorsal compartment of the upper arm.
    American journal of orthopedics (Belle Mead, N.J.), 2006, Volume: 35, Issue:12

    Topics: Acute Disease; Aged; Arm; Aspirin; Compartment Syndromes; Diagnosis, Differential; Enoxaparin; Femal

2006
Summaries for patients. Safety of surgery during bridging anticoagulation therapy with low-molecular-weight heparin.
    Annals of internal medicine, 2007, Feb-06, Volume: 146, Issue:3

    Topics: Aged; Anticoagulants; Drug Administration Schedule; Enoxaparin; Factor Xa; Female; Hemorrhage; Human

2007
Brief communication: Preoperative anticoagulant activity after bridging low-molecular-weight heparin for temporary interruption of warfarin.
    Annals of internal medicine, 2007, Feb-06, Volume: 146, Issue:3

    Topics: Aged; Anticoagulants; Drug Administration Schedule; Enoxaparin; Factor Xa; Female; Hemorrhage; Human

2007
Fatal haemorrhage associated with enoxaparin.
    Internal medicine journal, 2007, Volume: 37, Issue:3

    Topics: Aged; Anticoagulants; Blood Transfusion; Enoxaparin; Fatal Outcome; Hemorrhage; Humans; Male; Muscul

2007
Peripheral nerve block catheters and low molecular weight heparin.
    Anesthesia and analgesia, 2007, Volume: 104, Issue:4

    Topics: Anticoagulants; Catheters, Indwelling; Device Removal; Drug Administration Schedule; Enoxaparin; Fem

2007
Continuous peripheral nerve catheters in patients receiving low molecular weight heparin.
    Anesthesia and analgesia, 2007, Volume: 104, Issue:4

    Topics: Anticoagulants; Catheters, Indwelling; Device Removal; Drug Administration Schedule; Enoxaparin; Fem

2007
Recombinant activated factor VII treatment of retroperitoneal hematoma in a patient with renal failure receiving enoxaparin and clopidogrel.
    Pharmacotherapy, 2007, Volume: 27, Issue:5

    Topics: Aged; Angiography; Anticoagulants; Blood Component Transfusion; Clopidogrel; Drug Interactions; Embo

2007
Enoxaparin as bridging anticoagulant treatment in cardiac surgery.
    Heart (British Cardiac Society), 2008, Volume: 94, Issue:2

    Topics: Aged; Anticoagulants; Cohort Studies; Enoxaparin; Female; Hemorrhage; Humans; Intraoperative Care; M

2008
Successful percutaneous retrieval of a swan-ganz catheter entrapped in an inferior vena cava filter.
    The Journal of trauma, 2007, Volume: 62, Issue:6

    Topics: Aged, 80 and over; Anticoagulants; Catheterization, Swan-Ganz; Catheters, Indwelling; Colonoscopy; D

2007
Periprocedural bridging therapy with low-molecular-weight heparin in chronically anticoagulated patients with prosthetic mechanical heart valves: experience in 116 patients from the prospective BRAVE registry.
    The Journal of heart valve disease, 2007, Volume: 16, Issue:3

    Topics: Aged; Anticoagulants; Aortic Valve; Enoxaparin; Feasibility Studies; Heart Valve Prosthesis; Heart V

2007
Enoxaparin dosing and associated risk of in-hospital bleeding and death in patients with non ST-segment elevation acute coronary syndromes.
    Archives of internal medicine, 2007, Jul-23, Volume: 167, Issue:14

    Topics: Aged; Coronary Disease; Electrocardiography; Enoxaparin; Female; Fibrinolytic Agents; Hemorrhage; Ho

2007
A probabilistic cost-effectiveness analysis of enoxaparin versus unfractionated heparin for the prophylaxis of deep-vein thrombosis following major trauma.
    The Canadian journal of clinical pharmacology = Journal canadien de pharmacologie clinique, 2007,Summer, Volume: 14, Issue:2

    Topics: Adult; Anticoagulants; Bayes Theorem; Canada; Cost-Benefit Analysis; Decision Support Techniques; De

2007
Enoxaparin use in the neonatal intensive care unit: experience over 8 years.
    Pharmacotherapy, 2007, Volume: 27, Issue:9

    Topics: Anticoagulants; Bone Diseases, Metabolic; Catheters, Indwelling; Dose-Response Relationship, Drug; E

2007
Bleeding during enoxaparin treatment more common with age over 75 years and severe renal insufficiency.
    Drugs & aging, 2007, Volume: 24, Issue:9

    Topics: Acute Disease; Age Factors; Aged; Aged, 80 and over; Anticoagulants; Endpoint Determination; Enoxapa

2007
[Perioperative Bridging with Enoxaparin. Results of the Prospective BRAVE Registry with 779 Patients].
    Medizinische Klinik (Munich, Germany : 1983), 2007, Oct-15, Volume: 102, Issue:10

    Topics: Aged; Aged, 80 and over; Anticoagulants; Dose-Response Relationship, Drug; Drug Administration Sched

2007
TIMI risk index and the benefit of enoxaparin in patients with ST-elevation myocardial infarction.
    The American journal of medicine, 2007, Volume: 120, Issue:11

    Topics: Adult; Aged; Arrhythmias, Cardiac; Cause of Death; Enoxaparin; Fibrinolytic Agents; Hemorrhage; Hepa

2007
Time to coronary angiography and outcomes among patients with high-risk non ST-segment elevation acute coronary syndromes: results from the SYNERGY trial.
    Circulation, 2007, Dec-04, Volume: 116, Issue:23

    Topics: Acute Coronary Syndrome; Aged; Blood Transfusion; Coronary Angiography; Enoxaparin; Female; Fibrinol

2007
[The safety of enoxaparine use in elderly with acute myocardial infarction].
    Vojnosanitetski pregled, 2007, Volume: 64, Issue:10

    Topics: Age Factors; Aged; Anticoagulants; Enoxaparin; Female; Hemorrhage; Heparin; Humans; Male; Myocardial

2007
Safety of enoxaparin bridge therapy in patients with mechanical heart valves.
    The Annals of pharmacotherapy, 2008, Volume: 42, Issue:1

    Topics: Aged; Aged, 80 and over; Anticoagulants; Enoxaparin; Heart Valve Prosthesis; Hemorrhage; Humans; Int

2008
Evaluating the optimal timing of angiography: landmark or off the mark?
    Circulation, 2007, Dec-04, Volume: 116, Issue:23

    Topics: Acute Coronary Syndrome; Aged; Blood Transfusion; Coronary Angiography; Enoxaparin; Female; Fibrinol

2007
Efficacy and safety of enoxaparin in unselected patients with ST-segment elevation myocardial infarction.
    Thrombosis and haemostasis, 2008, Volume: 99, Issue:1

    Topics: Aged; Angioplasty, Balloon, Coronary; Anticoagulants; Enoxaparin; Female; Germany; Hemorrhage; Hepar

2008
Cockcroft-Gault versus modification of diet in renal disease: importance of glomerular filtration rate formula for classification of chronic kidney disease in patients with non-ST-segment elevation acute coronary syndromes.
    Journal of the American College of Cardiology, 2008, Mar-11, Volume: 51, Issue:10

    Topics: Acute Coronary Syndrome; Age Factors; Aged; Creatinine; Enoxaparin; Female; Fibrinolytic Agents; Glo

2008
Bleeding effects of unfractionated heparin and low molecular weight heparins in an animal model.
    The European journal of surgery. Supplement. : = Acta chirurgica. Supplement, 1994, Issue:571

    Topics: Animals; Bleeding Time; Blood Pressure; Dalteparin; Dose-Response Relationship, Drug; Enoxaparin; Ga

1994
Managing the risk of thrombosis in the perioperative period in patients undergoing orthopedic and trauma surgery with low-molecular-weight heparin: enoxaparin.
    Orthopedics, 1997, Volume: 20 Suppl

    Topics: Anticoagulants; Bone and Bones; Enoxaparin; Hemorrhage; Hip Prosthesis; Humans; Joint Prosthesis; Kn

1997
Low-molecular-weight heparin for obstetric thromboprophylaxis: experience of sixty-nine pregnancies in sixty-one women at high risk.
    American journal of obstetrics and gynecology, 1997, Volume: 176, Issue:5

    Topics: Anticoagulants; Bone Density; Cohort Studies; Enoxaparin; Female; Hemorrhage; Heparin; Humans; Pregn

1997
An unexpected complication of DVT prophylaxis.
    Acta orthopaedica Belgica, 1997, Volume: 63, Issue:2

    Topics: Aged; Anticoagulants; Chemoprevention; Enoxaparin; Female; Hemorrhage; Hip Joint; Hip Prosthesis; Hu

1997
Comparison of enoxaparin, hirulog, and heparin as adjunctive antithrombotic therapy during thrombolysis with rtPA in the stenosed canine coronary artery.
    Thrombosis and haemostasis, 1997, Volume: 78, Issue:4

    Topics: Adenosine Diphosphate; Animals; Aspirin; Bleeding Time; Collagen; Coronary Thrombosis; Dogs; Drug Ev

1997
The incidence of symptomatic venous thromboembolism during and after prophylaxis with enoxaparin: a multi-institutional cohort study of patients who underwent hip or knee arthroplasty. Canadian Collaborative Group.
    Archives of internal medicine, 1998, Apr-27, Volume: 158, Issue:8

    Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replac

1998
Enoxaparin in neurosurgical patients.
    The New England journal of medicine, 1998, Nov-26, Volume: 339, Issue:22

    Topics: Anticoagulants; Bandages; Combined Modality Therapy; Enoxaparin; Hemorrhage; Heparin; Humans; Thromb

1998
[Hemorrhagic complications of spinal and epidural analgesia].
    Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke, 1999, Jan-30, Volume: 119, Issue:3

    Topics: Analgesia, Epidural; Anesthesia, Spinal; Anticoagulants; Enoxaparin; Fibrinolytic Agents; Hemorrhage

1999
Intrahepatic hemorrhage after use of low-molecular-weight heparin for total hip arthroplasty.
    The Journal of arthroplasty, 1999, Volume: 14, Issue:3

    Topics: Aged; Aged, 80 and over; Arthroplasty, Replacement, Hip; Chemical and Drug Induced Liver Injury; Eno

1999
Pursuing progress in acute coronary syndromes.
    Circulation, 1999, Oct-12, Volume: 100, Issue:15

    Topics: Acute Disease; Angina, Unstable; Anticoagulants; Clinical Trials as Topic; Coronary Disease; Enoxapa

1999
Enoxaparin for the prevention of venous thromboembolism.
    The New England journal of medicine, 2000, Jan-13, Volume: 342, Issue:2

    Topics: Anticoagulants; Enoxaparin; Hemorrhage; Heparin; Humans; Placebos; Thromboembolism

2000
Enoxaparin for the prevention of venous thromboembolism.
    The New England journal of medicine, 2000, Jan-13, Volume: 342, Issue:2

    Topics: Anticoagulants; Confidence Intervals; Enoxaparin; Hemorrhage; Humans; Pulmonary Embolism; Thromboemb

2000
Enoxaparin and bleeding complications: a review in patients with and without renal insufficiency.
    Pharmacotherapy, 2000, Volume: 20, Issue:7

    Topics: Aged; Anticoagulants; Enoxaparin; Female; Hemorrhage; Humans; Male; Middle Aged; Renal Dialysis; Ren

2000
Bleeding complications associated with low molecular weight heparin prophylaxis during pregnancy.
    Thrombosis and haemostasis, 2000, Volume: 84, Issue:1

    Topics: Anemia; Anticoagulants; Dalteparin; Delivery, Obstetric; Dextrans; Enoxaparin; Female; Hemorrhage; H

2000
Plasma tissue factor pathway inhibitor levels as a marker for postoperative bleeding after enoxaparin use in deep vein thrombosis prophylaxis in orthopedics and general surgery.
    Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis, 2000, Volume: 6, Issue:4

    Topics: Biomarkers; Double-Blind Method; Drug Monitoring; Enoxaparin; Factor Xa Inhibitors; Fibrinolytic Age

2000
Excessive anticoagulation in patients with mild renal insufficiency receiving long-term therapeutic enoxaparin.
    American journal of hematology, 2001, Volume: 67, Issue:1

    Topics: Adult; Anticoagulants; Creatine; Drug Monitoring; Enoxaparin; Female; Hemorrhage; Heparin, Low-Molec

2001
Low-molecular-weight heparin administration in patients with end-stage renal disease--a comment.
    Pharmacotherapy, 2001, Volume: 21, Issue:8

    Topics: Anticoagulants; Blood Transfusion; Enoxaparin; Hemorrhage; Humans; Kidney Diseases; Kidney Failure,

2001
Low molecular weight heparin and the risk of haemorrhage following percutaneous biopsy, despite a normal standard clotting screen.
    European radiology, 2001, Volume: 11, Issue:12

    Topics: Aged; Biopsy, Needle; Carcinoma, Endometrioid; Enoxaparin; Female; Hemorrhage; Humans; Iliac Vein; I

2001
Activated recombinant factor VII (rFVIIa) in bleeding management after therapy with IIb/IIIa-inhibitor tirofiban.
    Thrombosis and haemostasis, 2002, Volume: 87, Issue:2

    Topics: Anticoagulants; Coronary Stenosis; Drug Therapy, Combination; Enoxaparin; Factor VII; Hemorrhage; Hu

2002
Thromboprophylaxis with reviparin in a patient with acquired hemophilia.
    International journal of hematology, 2005, Volume: 81, Issue:2

    Topics: Aged; Anemia, Hemolytic, Autoimmune; Autoantibodies; Carcinoma, Renal Cell; Factor VIII; Hemophilia

2005
Biochemical and pharmacologic profile of low molecular weight heparin (LU 47311, Clivarin).
    Seminars in thrombosis and hemostasis, 1993, Volume: 19 Suppl 1

    Topics: Animals; Bleeding Time; Hemorrhage; Heparin, Low-Molecular-Weight; Humans; Male; Molecular Weight; P

1993
Porous balloon delivery of low molecular weight heparin in the dog coronary artery.
    European heart journal, 1996, Volume: 17, Issue:10

    Topics: Angioplasty, Balloon, Coronary; Animals; Catheterization; Coronary Thrombosis; Coronary Vessels; Dog

1996
[Possible effect low molecular weight heparin on survival time. New chances for cancer patients?].
    MMW Fortschritte der Medizin, 2003, May-08, Volume: 145, Issue:19

    Topics: Anticoagulants; Clinical Trials as Topic; Hemorrhage; Heparin, Low-Molecular-Weight; Humans; Injecti

2003
[Low-molecular-weight heparin in deep venous thrombosis. Dosage for all weight classes].
    MMW Fortschritte der Medizin, 2003, Jun-12, Volume: 145, Issue:24

    Topics: Anticoagulants; Body Weight; Clinical Trials as Topic; Fibrinolytic Agents; Hemorrhage; Heparin; Hep

2003
[Initial results of the PROTECT Study publicized. Stroke patients need effective thrombosis prevention].
    MMW Fortschritte der Medizin, 2005, Jun-02, Volume: 147, Issue:22

    Topics: Anticoagulants; Cerebral Infarction; Double-Blind Method; Hemorrhage; Heparin; Heparin, Low-Molecula

2005
Management of intentional overdose of low-molecular-weight heparin.
    CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne, 2022, 01-31, Volume: 194, Issue:4

    Topics: Administration, Intravenous; Adult; Anterior Compartment Syndrome; Anticoagulants; Dalteparin; Drug

2022
Recurrent venous thromboembolism and major bleeding in patients with localised, locally advanced or metastatic cancer: an analysis of the Caravaggio study.
    European journal of cancer (Oxford, England : 1990), 2022, Volume: 165

    Topics: Anticoagulants; Dalteparin; Hemorrhage; Humans; Neoplasms; Neoplasms, Second Primary; Venous Thrombo

2022
Prophylactic Dose of Dalteparin in Pregnant Women With History of Venous Thromboembolisms and/or Thrombophilia: Real-World Data.
    Angiology, 2023, Volume: 74, Issue:8

    Topics: Anticoagulants; Dalteparin; Female; Hemorrhage; Heparin, Low-Molecular-Weight; Humans; Pregnancy; Pr

2023
Comparison of rivaroxaban and dalteparin for the long-term treatment of venous thromboembolism in patients with gynecologic cancers.
    Journal of gynecologic oncology, 2020, Volume: 31, Issue:1

    Topics: Aged; Dalteparin; Factor Xa Inhibitors; Female; Genital Neoplasms, Female; Hemorrhage; Humans; Middl

2020
[Antithrombotic Treatment of Pulmonary Embolism].
    Deutsche medizinische Wochenschrift (1946), 2020, Volume: 145, Issue:14

    Topics: Acute Disease; Dalteparin; Dose-Response Relationship, Drug; Drug Administration Schedule; Fibrinoly

2020
[Toward the use of direct oral anticoagulants as a first line therapy in cancer-associated venous thromboembolism].
    La Revue de medecine interne, 2020, Volume: 41, Issue:9

    Topics: 4-Hydroxycoumarins; Administration, Oral; Anticoagulants; Clinical Trials as Topic; Dalteparin; Hemo

2020
Spontaneous Retroperitoneal Hemorrhage in Dermatomyositis.
    The American journal of medicine, 2021, Volume: 134, Issue:2

    Topics: Anti-Inflammatory Agents; Anticoagulants; Dalteparin; Dermatomyositis; Female; Hemorrhage; Humans; I

2021
In cancer-associated VTE, apixaban was noninferior to dalteparin for recurrence and did not increase major bleeding.
    Annals of internal medicine, 2020, 08-18, Volume: 173, Issue:4

    Topics: Anticoagulants; Dalteparin; Hemorrhage; Humans; Neoplasms; Pyrazoles; Pyridones; Recurrence; Venous

2020
Role of direct oral anticoagulants in the treatment of cancer-associated venous thromboembolism: guidance from the SSC of the ISTH.
    Journal of thrombosis and haemostasis : JTH, 2018, Volume: 16, Issue:9

    Topics: Administration, Oral; Anticoagulants; Antithrombins; Dabigatran; Dalteparin; Factor Xa Inhibitors; H

2018
Dalteparin anticoagulation in paediatric home haemodialysis.
    Pediatric nephrology (Berlin, Germany), 2018, Volume: 33, Issue:12

    Topics: Adolescent; Age Factors; Anticoagulants; Blood Coagulation; Child; Child, Preschool; Dalteparin; Dos

2018
[Treatment of cancer-associated venous thromboembolism].
    Giornale italiano di cardiologia (2006), 2018, Volume: 19, Issue:9 Suppl 1

    Topics: Anticoagulants; Dalteparin; Hemorrhage; Heparin, Low-Molecular-Weight; Humans; Neoplasms; Practice G

2018
Low molecular weight heparin in patients undergoing free tissue transfer following head and neck ablative surgery: review of efficacy and associated complications.
    The British journal of oral & maxillofacial surgery, 2013, Volume: 51, Issue:7

    Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Dalteparin; Dose-Response Relationship, Dru

2013
Risk factors and impact of major bleeding in critically ill patients receiving heparin thromboprophylaxis.
    Intensive care medicine, 2013, Volume: 39, Issue:12

    Topics: Adult; Aged; Anticoagulants; Critical Illness; Dalteparin; Female; Hemorrhage; Heparin; Hospital Mor

2013
The value of extended preoperative thromboprophylaxis with dalteparin in patients with ovarian cancer qualified to surgical treatment.
    International angiology : a journal of the International Union of Angiology, 2014, Volume: 33, Issue:4

    Topics: Adult; Anticoagulants; Biomarkers; Dalteparin; Drug Administration Schedule; Female; Fibrin Fibrinog

2014
Treatment with Dalteparin is Associated with a Lower Risk of Bleeding Compared to Treatment with Unfractionated Heparin in Patients with Renal Insufficiency.
    Journal of general internal medicine, 2016, Volume: 31, Issue:2

    Topics: Aged; Aged, 80 and over; Anticoagulants; Dalteparin; Female; Glomerular Filtration Rate; Hemorrhage;

2016
Evaluation of AR-H067637, the active metabolite of the new direct thrombin inhibitor AZD0837, in models of venous and arterial thrombosis and bleeding in anaesthetised rats.
    Thrombosis and haemostasis, 2010, Volume: 104, Issue:6

    Topics: Amidines; Animals; Antithrombin III; Antithrombins; Azetidines; Blood Coagulation; Chlorides; Daltep

2010
Treatment of upper-extremity deep vein thrombosis.
    Journal of thrombosis and haemostasis : JTH, 2011, Volume: 9, Issue:10

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticoagulants; Dalteparin; Drug Therapy, Combination; F

2011
Treatment of deep venous thrombosis with low-molecular-weight heparin during pregnancy.
    Thrombosis research, 2002, Apr-01, Volume: 106, Issue:1

    Topics: Adult; Dalteparin; Drug Evaluation; Female; Hemorrhage; Heparin; Heparin, Low-Molecular-Weight; Huma

2002
Should patients with deep vein thrombosis alone be treated as those with concomitant asymptomatic pulmonary embolism? A prospective study.
    Thrombosis and haemostasis, 2002, Volume: 88, Issue:6

    Topics: Anticoagulants; Cohort Studies; Dalteparin; Hemorrhage; Humans; Prospective Studies; Pulmonary Embol

2002
Safety of outpatient dalteparin therapy in veterans with mechanical heart valves.
    Pharmacotherapy, 2005, Volume: 25, Issue:11

    Topics: Aged; Aged, 80 and over; Anticoagulants; Dalteparin; Heart Valve Prosthesis; Hemorrhage; Humans; Mal

2005
The problem of risk assessment and prophylaxis of venous thromboembolism in pregnancy.
    Thrombosis and haemostasis, 2007, Volume: 98, Issue:6

    Topics: Anticoagulants; Dalteparin; Dose-Response Relationship, Drug; Drug Administration Schedule; Female;

2007
Venous thromboembolism and bleeding in critically ill patients with severe renal insufficiency receiving dalteparin thromboprophylaxis: prevalence, incidence and risk factors.
    Critical care (London, England), 2008, Volume: 12, Issue:2

    Topics: Aged; Anticoagulants; APACHE; Critical Illness; Dalteparin; Female; Hemorrhage; Humans; Incidence; I

2008
Anticoagulation with low molecular weight heparin (Fragmin) during continuous hemodialysis in the intensive care unit.
    Artificial organs, 1993, Volume: 17, Issue:8

    Topics: Acute Kidney Injury; Adult; Aged; Blood Coagulation; Critical Care; Dalteparin; Female; Fibrinopepti

1993
Management of unstable coronary-artery disease.
    Lancet (London, England), 2000, Feb-12, Volume: 355, Issue:9203

    Topics: Anticoagulants; Coronary Disease; Dalteparin; Hemorrhage; Humans; Troponin T

2000
Dalteparin-induced retroperitoneal bleeding.
    The Annals of pharmacotherapy, 2001, Volume: 35, Issue:2

    Topics: Animals; Anticoagulants; Dalteparin; Female; Hemorrhage; Humans; Retroperitoneal Space; Ultrasonogra

2001
Antithrombotic treatment in patients with unstable coronary artery disease undergoing CABG.
    The Annals of thoracic surgery, 2001, Volume: 71, Issue:5

    Topics: Angina, Unstable; Clinical Trials as Topic; Coronary Artery Bypass; Dalteparin; Drug Administration

2001
The antithrombotic efficacy of AT-1459, a novel, direct thrombin inhibitor, in rat models of venous and arterial thrombosis.
    Thrombosis and haemostasis, 2001, Volume: 86, Issue:6

    Topics: Administration, Oral; Amidines; Animals; Arginine; Azepines; Bleeding Time; Carotid Artery Thrombosi

2001
Safety and Efficacy of Tinzaparin Anticoagulation during Nocturnal Hemodialysis.
    American journal of nephrology, 2019, Volume: 50, Issue:4

    Topics: Adult; Aged; Anticoagulants; Blood Coagulation; Circadian Rhythm; Factor Xa; Female; Hemorrhage; Hep

2019
Compliance with current VTE prophylaxis guidelines and risk factors linked to complications of VTE prophylaxis in medical inpatients: a prospective cohort study in a Spanish internal medicine department.
    BMJ open, 2018, 05-14, Volume: 8, Issue:5

    Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Female; Guideline Adherence; Hemorrhage; Heparin, Lo

2018
Utility of global hemostatic assays in the management of anticoagulation in a haemophilia patient.
    Haemophilia : the official journal of the World Federation of Hemophilia, 2018, Volume: 24, Issue:4

    Topics: Anticoagulants; Coronary Angiography; Factor VIII; Hemophilia A; Hemorrhage; Humans; International N

2018
Weight-adjusted tinzaparin for the prevention of venous thromboembolism after bariatric surgery.
    Journal of thrombosis and haemostasis : JTH, 2018, Volume: 16, Issue:10

    Topics: Adult; Anticoagulants; Body Weight; Drug Administration Schedule; Drug Dosage Calculations; Female;

2018
Tinzaparin safety and efficacy in pregnancy.
    Irish journal of medical science, 2014, Volume: 183, Issue:2

    Topics: Abortion, Habitual; Adolescent; Adult; Drug Hypersensitivity; Female; Fibrinolytic Agents; Hemorrhag

2014
Tinzaparin and VKA use in patients with cancer associated venous thromboembolism: a retrospective cohort study.
    Thrombosis research, 2015, Volume: 135, Issue:1

    Topics: Anticoagulants; Female; Fibrinolytic Agents; Follow-Up Studies; Hemorrhage; Heparin, Low-Molecular-W

2015
Compartment syndrome of the thigh as a complication of anticoagulant therapy in a patient with a left ventricular assist device (Berlin Heart).
    General thoracic and cardiovascular surgery, 2010, Volume: 58, Issue:9

    Topics: Anticoagulants; Compartment Syndromes; Heart Failure; Heart-Assist Devices; Hemorrhage; Heparin, Low

2010
Severe bleeding associated with use of low molecular weight heparin and selective serotonin reuptake inhibitors.
    The American journal of medicine, 2002, Oct-15, Volume: 113, Issue:6

    Topics: Aged; Anticoagulants; Drug Interactions; Female; Fibrinolytic Agents; Fluoxetine; Hemorrhage; Hepari

2002
Assessment of recombinant factor VIIa as an antidote for bleeding induced in the rabbit by low molecular weight heparin.
    Journal of thrombosis and haemostasis : JTH, 2003, Volume: 1, Issue:4

    Topics: Animals; Antidotes; Bleeding Time; Drug Evaluation; Factor VII; Factor VIIa; Hemorrhage; Hemostasis;

2003
Tinzaparin in long-term treatment of deep venous thrombosis.
    European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery, 2007, Volume: 34, Issue:3

    Topics: Drug Administration Schedule; Fibrinolytic Agents; Hemorrhage; Heparin, Low-Molecular-Weight; Humans

2007
Recombinant human factor VIIa and a factor VIIa-analogue reduces heparin and low molecular weight heparin (LMWH)-induced bleeding in rats.
    Journal of thrombosis and haemostasis : JTH, 2008, Volume: 6, Issue:5

    Topics: Animals; Blood Coagulation; Drug Interactions; Factor VII; Factor VIIa; Hemorrhage; Heparin; Heparin

2008
Elderly patients treated with tinzaparin (Innohep) administered once daily (175 anti-Xa IU/kg): anti-Xa and anti-IIa activities over 10 days.
    Thrombosis and haemostasis, 2000, Volume: 84, Issue:5

    Topics: Age Factors; Aged; Aged, 80 and over; Factor Xa; Female; Fibrinolytic Agents; Hemorrhage; Heparin, L

2000
The outcome of ambulatory DVT management using a multidisciplinary approach.
    Clinical and laboratory haematology, 2001, Volume: 23, Issue:5

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Ambulatory Care; Disease Management; Drug Evaluation; Fe

2001